<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>PharmaSalts India 2026 â€“ Top 467 API Explorer</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
<style>
  body { font-family: 'Inter', sans-serif; background-color: #F1F5F9; color: #1E293B; }
  .chart-container { position:relative; width:100%; max-width:520px; margin:auto; height:280px; }
  @media(min-width:768px){ .chart-container{ height:320px; } }
  .custom-scrollbar::-webkit-scrollbar{width:5px}
  .custom-scrollbar::-webkit-scrollbar-track{background:#F1F5F9}
  .custom-scrollbar::-webkit-scrollbar-thumb{background:#CBD5E1;border-radius:4px}
  .card-hover{transition:all .2s ease}
  .card-hover:hover{transform:translateY(-3px);box-shadow:0 12px 24px -6px rgba(0,0,0,.12)}
  /* Schedule badge colours */
  .sch-OTC{background:#E2E8F0;color:#475569}
  .sch-C  {background:#CCFBF1;color:#0F766E}
  .sch-H  {background:#DBEAFE;color:#1D4ED8}
  .sch-H1 {background:#FED7AA;color:#C2410C}
  .sch-X  {background:#FEE2E2;color:#B91C1C}
  /* Section pill colours */
  .sec-1{background:#DBEAFE;color:#1D4ED8}
  .sec-2{background:#FEE2E2;color:#B91C1C}
  .sec-3{background:#DCFCE7;color:#15803D}
  .sec-4{background:#F3E8FF;color:#7E22CE}
  .sec-5{background:#FEF3C7;color:#B45309}
  .sec-6{background:#E0E7FF;color:#3730A3}
  .sec-7{background:#FFE4E6;color:#9F1239}
  .sec-8{background:#FDF4FF;color:#86198F}
  .sec-9{background:#E0F2FE;color:#0369A1}
  .sec-10{background:#ECFDF5;color:#047857}
  .sec-11{background:#FFFBEB;color:#92400E}
  .sec-12{background:#FFF7ED;color:#9A3412}
  .sec-13{background:#FDF2F8;color:#9D174D}
  .sec-14{background:#EFF6FF;color:#1E3A8A}
  .sec-15{background:#F0FDFA;color:#065F46}
  .sec-16{background:#F7FEE7;color:#365314}
  .sec-17{background:#F5F3FF;color:#4C1D95}
  .sec-18{background:#ECFEFF;color:#155E75}
  .sec-19{background:#FFF1F2;color:#881337}
  .filter-active{ring:2px solid currentColor;font-weight:600}
  input[type=text]:focus{outline:none}
</style>
</head>
<body class="min-h-screen flex flex-col">

<!-- â”€â”€ HEADER â”€â”€ -->
<header class="bg-white border-b border-slate-200 sticky top-0 z-30 shadow-sm">
  <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-3 flex flex-col md:flex-row md:items-center justify-between gap-3">
    <div>
      <h1 class="text-2xl font-bold text-teal-700 tracking-tight">
        Pharma Salts<span class="text-slate-500 font-light"> India 2026</span>
      </h1>
      <p class="text-xs text-slate-400 mt-0.5">Interactive Index Â· Top 467 Active Pharmaceutical Ingredients</p>
    </div>
    <div class="flex-1 max-w-xl w-full">
      <div class="relative">
        <span class="absolute inset-y-0 left-3 flex items-center text-slate-400 text-sm">ğŸ”</span>
        <input type="text" id="searchInput" placeholder="Search salt name, brand, uses, formationâ€¦"
          class="block w-full pl-9 pr-3 py-2 border border-slate-300 rounded-lg bg-slate-50 placeholder-slate-400
                 focus:bg-white focus:border-teal-500 focus:ring-1 focus:ring-teal-500 text-sm transition">
      </div>
    </div>
  </div>
</header>

<!-- â”€â”€ MAIN â”€â”€ -->
<main class="flex-grow max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-6 w-full">

  <!-- Intro -->
  <section class="mb-6">
    <p class="text-slate-600 max-w-3xl leading-relaxed text-sm">
      Complete ranked analysis of 467 pharmaceutical salts dominating the Indian market in 2026.
      Data from <strong>IQVIA/PharmaTrac</strong>, <strong>NLEM 2022</strong>, and hospital formularies.
      Each card shows <strong>brand names</strong>, drug <strong>schedule</strong>, section, dosing, and contraindications.
    </p>
  </section>

  <!-- Dashboard row -->
  <div class="grid grid-cols-1 lg:grid-cols-3 gap-5 mb-6">

    <!-- Chart -->
    <div class="bg-white p-5 rounded-2xl border border-slate-200 shadow-sm flex flex-col items-center">
      <h3 class="text-xs font-bold text-slate-400 uppercase tracking-widest mb-3 w-full text-center">Therapeutic Category Mix</h3>
      <div class="chart-container"><canvas id="categoryChart"></canvas></div>
      <p class="text-xs text-slate-400 text-center mt-3">Based on 467 indexed salts</p>
    </div>

    <!-- Filters panel -->
    <div class="bg-white p-5 rounded-2xl border border-slate-200 shadow-sm lg:col-span-2 flex flex-col gap-4">

      <!-- Safety row -->
      <div class="grid grid-cols-1 sm:grid-cols-3 gap-3">
        <div class="p-3 bg-rose-50 rounded-xl border border-rose-100">
          <div class="flex items-center justify-between mb-1">
            <span class="text-rose-700 font-semibold text-sm">Liver Safety</span>
            <span>âš ï¸</span>
          </div>
          <p class="text-xs text-rose-500 mb-2">Exclude hepatotoxic agents</p>
          <button id="btn-liver"
            class="w-full py-1.5 bg-white border border-rose-200 text-rose-700 rounded-lg text-xs font-medium hover:bg-rose-100 transition">
            Hide Hepatic-Risk
          </button>
        </div>
        <div class="p-3 bg-amber-50 rounded-xl border border-amber-100">
          <div class="flex items-center justify-between mb-1">
            <span class="text-amber-700 font-semibold text-sm">Renal Safety</span>
            <span>ğŸ«˜</span>
          </div>
          <p class="text-xs text-amber-500 mb-2">Exclude renally-contraindicated</p>
          <button id="btn-renal"
            class="w-full py-1.5 bg-white border border-amber-200 text-amber-700 rounded-lg text-xs font-medium hover:bg-amber-100 transition">
            Hide Renal-Risk
          </button>
        </div>
        <div class="p-3 bg-blue-50 rounded-xl border border-blue-100">
          <div class="flex items-center justify-between mb-1">
            <span class="text-blue-700 font-semibold text-sm">Pediatric Focus</span>
            <span>ğŸ‘¶</span>
          </div>
          <p class="text-xs text-blue-500 mb-2">Salts with defined child dosing</p>
          <button id="btn-pediatric"
            class="w-full py-1.5 bg-white border border-blue-200 text-blue-700 rounded-lg text-xs font-medium hover:bg-blue-100 transition">
            Pediatric Approved Only
          </button>
        </div>
      </div>

      <!-- Section pills -->
      <div>
        <p class="text-xs font-bold text-slate-400 uppercase tracking-widest mb-2">Book Section</p>
        <div class="flex flex-wrap gap-1.5" id="section-pills"></div>
      </div>

      <!-- Schedule pills -->
      <div>
        <p class="text-xs font-bold text-slate-400 uppercase tracking-widest mb-2">Drug Schedule (India)</p>
        <div class="flex flex-wrap gap-1.5" id="schedule-pills"></div>
      </div>

      <!-- Category pills -->
      <div>
        <p class="text-xs font-bold text-slate-400 uppercase tracking-widest mb-2">Therapeutic Category</p>
        <div class="flex flex-wrap gap-1.5" id="category-pills"></div>
      </div>

      <!-- Drug Class pills -->
      <div>
        <p class="text-xs font-bold text-slate-400 uppercase tracking-widest mb-2">Drug Class (by Suffix)</p>
        <div class="flex flex-wrap gap-1.5" id="drugclass-pills"></div>
      </div>

      <!-- Pregnancy pills -->
      <div>
        <p class="text-xs font-bold text-slate-400 uppercase tracking-widest mb-2">Pregnancy Category (FDA)</p>
        <div class="flex flex-wrap gap-1.5" id="pregnancy-pills"></div>
      </div>

    </div>
  </div>

  <!-- Toolbar -->
  <div class="flex flex-col sm:flex-row justify-between items-center mb-4 border-b border-slate-200 pb-3 gap-3">
    <h2 class="text-base font-bold text-slate-800 flex items-center gap-2">
      Salt Index
      <span id="count-badge" class="px-2.5 py-0.5 rounded-full bg-slate-100 text-slate-600 text-xs font-medium border border-slate-200">â€”</span>
    </h2>
    <div class="flex items-center gap-2 text-sm">
      <span class="text-slate-500">Sort:</span>
      <select id="sortSelect" class="border border-slate-300 rounded-lg px-2 py-1 bg-white focus:border-teal-500 outline-none text-sm">
        <option value="rank">Market Rank (1â€“467)</option>
        <option value="alpha">Name (Aâ€“Z)</option>
      </select>
      <button onclick="resetFilters()" class="ml-2 px-3 py-1 rounded-lg bg-slate-100 hover:bg-slate-200 text-slate-600 text-xs font-medium transition">
        Reset Filters
      </button>
    </div>
  </div>

  <!-- Grid -->
  <div id="saltGrid" class="grid grid-cols-1 gap-5 max-w-4xl mx-auto"></div>

  <!-- Empty state -->
  <div id="emptyState" class="hidden text-center py-20">
    <div class="text-5xl mb-4">ğŸ§ª</div>
    <h3 class="text-lg font-medium text-slate-800">No salts match your filters</h3>
    <p class="text-slate-500 text-sm mt-1">Try adjusting your search or filter criteria.</p>
    <button onclick="resetFilters()" class="mt-4 text-teal-600 hover:text-teal-800 font-medium text-sm">Reset All Filters</button>
  </div>

</main>

<footer class="bg-white border-t border-slate-200 py-6 mt-auto">
  <div class="max-w-7xl mx-auto px-4 text-center">
    <p class="text-sm text-slate-500">Â© 2026 Pharmacological Inventory of India Â· Data from IQVIA/PharmaTrac, NLEM 2022, CDSCO & NPPA</p>
    <p class="text-xs text-slate-400 mt-1">For educational & reference use only. Consult CDSCO/NLEM guidelines before clinical decisions.</p>
  </div>
</footer>

<script>
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  DATA
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
const saltsData = [
  {
    "rank": 1,
    "name": "Amoxicillin + Potassium Clavulanate",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Augmentin / Clavam / Moxikind-CV",
    "formation": "Penicillin derivative + beta-lactamase inhibitor",
    "uses": "Community-acquired pneumonia, sinusitis, soft tissue infections",
    "adult": "625 mg TID or 1 g Duo BID (based on severity)",
    "child": "25â€“45 mg/kg/day in divided doses",
    "avoid": "Penicillin hypersensitivity, history of cholestatic jaundice",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Skin rash",
      "Vomiting",
      "Candidal superinfection"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome",
      "Clostridioides difficile colitis",
      "Cholestatic jaundice (clavulanate)",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” reduce dose/frequency if CrCl <30 mL/min; avoid 875/125 mg tablet",
    "hepaticAdj": "Yes â€” use with caution; avoid if hepatic dysfunction due to clavulanate hepatotoxicity risk",
    "pregnancy": "Category B â€” generally considered safe; widely used in pregnancy",
    "lactation": "Safe â€” compatible with breastfeeding; monitor infant for diarrhoea",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect",
      "Methotrexate â€” reduced renal clearance, toxicity risk",
      "Oral contraceptives â€” potential reduced efficacy"
    ],
    "monitoring": [
      "Renal function",
      "LFT (if prolonged use)",
      "Signs of superinfection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Amoxicillin 4000 mg/day (Clavulanate 500 mg/day)",
    "clinicalPearl": "Take with food to reduce GI upset and improve clavulanate tolerance."
  },
  {
    "rank": 2,
    "name": "Metformin + Glimepiride",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Glycomet-GP / Glimestar-M",
    "formation": "Biguanide + third-generation sulfonylurea",
    "uses": "First-line management of Type 2 Diabetes Mellitus",
    "adult": "500 mg/1 mg to 1000 mg/2 mg BID (with meals)",
    "child": "Not recommended for standard diabetic use",
    "avoid": "Renal failure (eGFR < 30 mL/min), metabolic acidosis",
    "sideEffects": [
      "GI upset/nausea",
      "Hypoglycaemia (glimepiride)",
      "Dizziness",
      "Lactic acidosis risk (metformin, rare)",
      "Weight gain (glimepiride)"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia",
      "Lactic acidosis (metformin, rare)",
      "Agranulocytosis (rare, sulfonylurea)"
    ],
    "renalAdj": "Yes â€” contraindicated if eGFR <30 mL/min (metformin); reduce glimepiride dose in renal impairment",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment; risk of lactic acidosis and hypoglycaemia",
    "pregnancy": "Category C â€” avoid; insulin preferred in pregnancy",
    "lactation": "Avoid â€” both components not recommended during lactation",
    "drugInteractions": [
      "Alcohol â€” severe hypoglycaemia and lactic acidosis risk",
      "Fluoroquinolones â€” unpredictable glycaemia",
      "Beta-blockers â€” mask hypoglycaemia symptoms"
    ],
    "monitoring": [
      "Blood glucose (FBS/PPBS)",
      "HbA1c",
      "Renal function (eGFR)",
      "LFT"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Metformin 2000 mg + Glimepiride 8 mg per day",
    "clinicalPearl": "Take with first bite of meal to reduce hypoglycaemia and GI side effects."
  },
  {
    "rank": 3,
    "name": "Pantoprazole Sodium",
    "section": "Section 1: Foundational Molecules",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Pan / Pantodac / Pantop",
    "formation": "Substituted benzimidazole (Proton Pump Inhibitor)",
    "uses": "GERD, peptic ulcers, NSAID-induced ulcer prophylaxis",
    "adult": "40 mg OD, 30â€“60 minutes before breakfast",
    "child": "1 mg/kg/day (usage restricted under 5 years)",
    "avoid": "Hypersensitivity to benzimidazoles, severe hepatic impairment",
    "sideEffects": [
      "Headache",
      "Diarrhoea",
      "Nausea",
      "Flatulence",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "Hypomagnesaemia (long-term use)",
      "C. difficile colitis",
      "Bone fracture risk (prolonged use)",
      "Fundic gland polyps"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment (max 20 mg/day)",
    "pregnancy": "Category B â€” use only if clearly needed",
    "lactation": "Caution â€” excreted in breast milk; use briefly if essential",
    "drugInteractions": [
      "Clopidogrel â€” reduced antiplatelet effect (avoid combination)",
      "Atazanavir â€” reduced absorption, avoid",
      "Methotrexate â€” increased toxicity"
    ],
    "monitoring": [
      "Serum magnesium (long-term)",
      "Bone density (prolonged use)",
      "Symptom relief"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "80 mg/day",
    "clinicalPearl": "Give 30â€“60 minutes before meals for maximum acid suppression efficacy."
  },
  {
    "rank": 4,
    "name": "Telmisartan",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Telma / Telmikind",
    "formation": "Non-peptide angiotensin II receptor antagonist",
    "uses": "Hypertension, cardiovascular risk reduction",
    "adult": "40â€“80 mg OD",
    "child": "Not recommended",
    "avoid": "Pregnancy (2nd/3rd trimester), bilateral renal artery stenosis",
    "sideEffects": [
      "Dizziness",
      "Headache",
      "Hyperkalemia",
      "Upper respiratory infection",
      "Fatigue"
    ],
    "seriousRisks": [
      "Angioedema (rare)",
      "Severe hyperkalemia",
      "Acute kidney injury",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” monitor closely; reduce dose if eGFR <30 mL/min; avoid if eGFR <15",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category D â€” contraindicated (2nd and 3rd trimester); fetal renal toxicity",
    "lactation": "Avoid â€” insufficient data; use alternative ARB if needed",
    "drugInteractions": [
      "Potassium-sparing diuretics â€” hyperkalemia",
      "NSAIDs â€” reduced antihypertensive effect and renal risk",
      "Lithium â€” increased lithium toxicity"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function (creatinine/eGFR)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "80 mg/day",
    "clinicalPearl": "Telmisartan has the longest half-life among ARBs â€” once-daily dosing ideal for compliance."
  },
  {
    "rank": 5,
    "name": "Paracetamol (Acetaminophen)",
    "section": "Section 1: Foundational Molecules",
    "category": "Analgesics",
    "schedule": "OTC",
    "brand": "Dolo-650 / Calpol / Crocin",
    "formation": "p-aminophenol derivative",
    "uses": "Fever (antipyretic), mild-to-moderate pain (analgesic)",
    "adult": "500â€“1000 mg every 4â€“6 hrs (max 4 g/day)",
    "child": "10â€“15 mg/kg per dose (max 60 mg/kg/day)",
    "avoid": "Severe hepatic impairment, chronic heavy alcohol use",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Abdominal pain",
      "Rash",
      "Elevation of liver enzymes"
    ],
    "seriousRisks": [
      "Hepatotoxicity (overdose)",
      "Acute liver failure",
      "Stevens-Johnson syndrome (rare)",
      "Agranulocytosis (rare)"
    ],
    "renalAdj": "Yes â€” increase dosing interval to 6â€“8 hours if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” reduce dose/avoid in severe hepatic impairment; risk of accumulation",
    "pregnancy": "Category B â€” considered safe at recommended doses throughout pregnancy",
    "lactation": "Safe â€” compatible; low transfer into breast milk",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect with chronic use",
      "Alcohol â€” increased hepatotoxicity risk",
      "Isoniazid â€” increased hepatotoxicity"
    ],
    "monitoring": [
      "LFT (prolonged/high-dose use)",
      "Renal function",
      "Symptomatic relief (fever/pain)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (adults); 2000 mg/day in hepatic disease/alcoholism",
    "clinicalPearl": "Max safe dose 4 g/day; warn patients about hidden paracetamol in combination products."
  },
  {
    "rank": 6,
    "name": "Formoterol + Budesonide",
    "section": "Section 1: Foundational Molecules",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Foracort / Symbicort",
    "formation": "Long-acting beta2-agonist + inhaled corticosteroid",
    "uses": "Maintenance of Asthma and COPD symptoms",
    "adult": "12 mcg/400 mcg, 1â€“2 puffs BID",
    "child": "6/100 mcg or 6/200 mcg BID (Consult specialist)",
    "avoid": "Status asthmaticus, pulmonary tuberculosis",
    "sideEffects": [
      "Oral candidiasis",
      "Dysphonia (hoarseness)",
      "Tremor",
      "Palpitations",
      "Throat irritation"
    ],
    "seriousRisks": [
      "Paradoxical bronchospasm",
      "Adrenal suppression (high dose budesonide)",
      "Hypokalaemia (formoterol)",
      "Pneumonia (ICS-related)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment; budesonide metabolism affected",
    "pregnancy": "Category C â€” benefit usually outweighs risk in asthma/COPD; use lowest effective dose",
    "lactation": "Caution â€” inhaled corticosteroids at low doses generally acceptable; monitor infant",
    "drugInteractions": [
      "Beta-blockers â€” antagonise bronchodilation",
      "QT-prolonging drugs â€” additive QT risk (formoterol)",
      "Ketoconazole â€” increased budesonide levels"
    ],
    "monitoring": [
      "Peak flow/spirometry",
      "Oral cavity for candidiasis",
      "Growth in children (long-term ICS)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Formoterol 48 mcg + Budesonide 1600 mcg per day",
    "clinicalPearl": "Rinse mouth after each inhalation to prevent oral candidiasis."
  },
  {
    "rank": 7,
    "name": "Insulin Human (70/30)",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "C",
    "brand": "Mixtard / Huminsulin 30/70",
    "formation": "Biphasic mixture of Isophane (70%) and Soluble (30%) insulin",
    "uses": "Type 1 and Type 2 Diabetes Mellitus",
    "adult": "Individualized based on glucose (30 mins before meals)",
    "child": "Weight-based titration (0.5â€“1.0 units/kg/day)",
    "avoid": "During episodes of hypoglycemia",
    "sideEffects": [
      "Hypoglycaemia",
      "Injection site reactions",
      "Weight gain",
      "Lipodystrophy",
      "Oedema"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia",
      "Hypokalaemia",
      "Anaphylaxis (rare)",
      "Cerebral oedema (rapid correction of hyperglycaemia)"
    ],
    "renalAdj": "Yes â€” reduce dose; hypoglycaemia risk increases with renal impairment",
    "hepaticAdj": "Yes â€” lower doses may be needed; hepatic glucose production altered",
    "pregnancy": "Category B â€” insulin is drug of choice for diabetes in pregnancy",
    "lactation": "Safe â€” insulin does not pass significantly into breast milk",
    "drugInteractions": [
      "Beta-blockers â€” mask hypoglycaemia symptoms",
      "Alcohol â€” potentiate hypoglycaemia",
      "Corticosteroids â€” antagonise insulin effect"
    ],
    "monitoring": [
      "Blood glucose (FBS/PPBS/CBG)",
      "HbA1c",
      "Injection site",
      "Serum potassium"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualised; no fixed maximum â€” titrate to glycaemic targets",
    "clinicalPearl": "70/30 mix: 70% NPH + 30% Regular; administer 30 minutes before meals."
  },
  {
    "rank": 8,
    "name": "Tirzepatide",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Mounjaro",
    "formation": "Dual GIP and GLP-1 receptor agonist (Synthetic peptide)",
    "uses": "Advanced Type 2 Diabetes, weight management",
    "adult": "2.5 mg/week initial, titrate to 5â€“15 mg/week",
    "child": "Not recommended",
    "avoid": "History of Medullary Thyroid Carcinoma, MEN 2 syndrome",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Injection site reactions",
      "Decreased appetite"
    ],
    "seriousRisks": [
      "Pancreatitis",
      "Thyroid C-cell tumour risk (rodent data)",
      "Severe hypoglycaemia (with SU/insulin)",
      "Diabetic retinopathy worsening"
    ],
    "renalAdj": "No â€” standard dosing; use with caution in severe renal impairment (limited data)",
    "hepaticAdj": "No â€” standard dosing; limited data in severe hepatic impairment",
    "pregnancy": "Category X â€” contraindicated; discontinue 2 months before planned pregnancy",
    "lactation": "Avoid â€” no human data available",
    "drugInteractions": [
      "Insulin/sulfonylureas â€” additive hypoglycaemia risk",
      "Oral contraceptives â€” delayed absorption (take 1 hour before tirzepatide)",
      "Warfarin â€” monitor INR due to GI motility changes"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Pancreatic enzymes (if pain)",
      "Body weight",
      "Thyroid function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "15 mg/week (subcutaneous)",
    "clinicalPearl": "First dual GIP/GLP-1 agonist; superior weight loss compared to GLP-1 mono-agonists."
  },
  {
    "rank": 9,
    "name": "Pantoprazole + Domperidone",
    "section": "Section 1: Foundational Molecules",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Pan-D / Pantodac-D / Razo-D",
    "formation": "PPI + dopamine-receptor antagonist",
    "uses": "GERD with dyspepsia, acidity with nausea/vomiting",
    "adult": "40 mg/30 mg OD (30 mins before breakfast)",
    "child": "Not recommended",
    "avoid": "Prolactinoma, GI hemorrhage, cardiac conduction delays",
    "sideEffects": [
      "Headache",
      "Diarrhoea",
      "Nausea",
      "Dry mouth",
      "Flatulence"
    ],
    "seriousRisks": [
      "Hypomagnesaemia (long-term PPI)",
      "QT prolongation (domperidone)",
      "Tardive dyskinesia (rare, domperidone)",
      "C. difficile colitis"
    ],
    "renalAdj": "Yes â€” reduce domperidone dose; pantoprazole standard dosing",
    "hepaticAdj": "Yes â€” reduce pantoprazole dose in severe hepatic disease; avoid domperidone in hepatic impairment",
    "pregnancy": "Category C â€” avoid domperidone; use pantoprazole alone if PPI needed",
    "lactation": "Caution â€” domperidone increases prolactin; pantoprazole excreted in milk",
    "drugInteractions": [
      "Ketoconazole â€” reduced absorption (PPI raises gastric pH)",
      "Clopidogrel â€” reduced antiplatelet effect (pantoprazole)",
      "QT-prolonging drugs â€” additive risk (domperidone)"
    ],
    "monitoring": [
      "Serum magnesium (long-term)",
      "ECG (domperidone)",
      "GI symptom relief"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Pantoprazole 80 mg + Domperidone 30 mg per day",
    "clinicalPearl": "Domperidone does not cross BBB significantly â€” safer prokinetic than metoclopramide."
  },
  {
    "rank": 10,
    "name": "Levothyroxine Sodium",
    "section": "Section 1: Foundational Molecules",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Thyronorm / Eltroxin",
    "formation": "Synthetic levo-isomer of thyroxine (T4)",
    "uses": "Primary, secondary, and tertiary hypothyroidism",
    "adult": "12.5â€“200 mcg OD (on empty stomach, 1 hr before breakfast)",
    "child": "10â€“15 mcg/kg OD (titrate to euthyroid)",
    "avoid": "Uncorrected adrenal insufficiency, acute myocardial infarction",
    "sideEffects": [
      "Palpitations (if over-replaced)",
      "Insomnia",
      "Weight loss",
      "Tremor",
      "Heat intolerance"
    ],
    "seriousRisks": [
      "Angina/arrhythmias (over-replacement)",
      "Adrenal crisis if adrenal insufficiency not treated first",
      "Bone loss (long-term suppressive therapy)",
      "Thyrotoxicosis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing; monitor TSH",
    "pregnancy": "Category A â€” thyroid replacement is safe and essential in pregnancy; adjust dose (increases needed)",
    "lactation": "Safe â€” physiological replacement compatible with breastfeeding",
    "drugInteractions": [
      "Calcium/iron supplements â€” reduce absorption (give 4 hours apart)",
      "Cholestyramine â€” reduces levothyroxine absorption",
      "Warfarin â€” enhanced anticoagulant effect"
    ],
    "monitoring": [
      "TSH",
      "Free T4",
      "Heart rate",
      "Bone density (long-term)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mcg/day (hypothyroidism); suppressive therapy doses higher under specialist guidance",
    "clinicalPearl": "Take on empty stomach 30â€“60 minutes before breakfast; avoid concurrent calcium/iron."
  },
  {
    "rank": 11,
    "name": "Cilnidipine",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Cilacar / Clinidipine",
    "formation": "L-type and N-type calcium channel blocker",
    "uses": "Essential hypertension, hypertensive nephropathy",
    "adult": "5â€“20 mg OD",
    "child": "Not recommended",
    "avoid": "Unstable angina, cardiogenic shock",
    "sideEffects": [
      "Ankle oedema",
      "Flushing",
      "Headache",
      "Dizziness",
      "Palpitations"
    ],
    "seriousRisks": [
      "Reflex tachycardia (less than dihydropyridines)",
      "Severe hypotension",
      "Gingival hyperplasia (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; use safer alternatives (methyldopa, labetalol)",
    "lactation": "Caution â€” limited data; avoid if possible",
    "drugInteractions": [
      "CYP3A4 inhibitors (azoles, clarithromycin) â€” increased cilnidipine levels",
      "Beta-blockers â€” additive bradycardia caution",
      "Grapefruit juice â€” increased drug levels"
    ],
    "monitoring": [
      "BP",
      "Heart rate",
      "Ankle oedema"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day",
    "clinicalPearl": "Blocks both L- and N-type calcium channels; causes less reflex tachycardia and ankle oedema."
  },
  {
    "rank": 12,
    "name": "Azithromycin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Azithral / Azee / Zithromax",
    "formation": "Azalide subclass of macrolide antibiotics",
    "uses": "Upper/lower RTI, typhoid, skin infections",
    "adult": "500 mg OD for 3â€“5 days",
    "child": "10 mg/kg Day 1, then 5 mg/kg Day 2â€“5",
    "avoid": "History of cholestatic jaundice, QT prolongation",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Abdominal pain",
      "Headache"
    ],
    "seriousRisks": [
      "QT prolongation/torsades de pointes",
      "Hepatotoxicity",
      "Myasthenia gravis exacerbation",
      "C. difficile colitis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution; avoid in significant hepatic impairment",
    "pregnancy": "Category B â€” generally considered safe; avoid at term (kernicterus risk rare)",
    "lactation": "Caution â€” excreted in breast milk; use with caution",
    "drugInteractions": [
      "QT-prolonging drugs â€” additive QT risk (serious)",
      "Warfarin â€” increased INR",
      "Ergotamine â€” risk of acute ergot toxicity"
    ],
    "monitoring": [
      "ECG (QTc) if risk factors",
      "LFT",
      "GI tolerability"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "500 mg/day",
    "clinicalPearl": "Z-pack 3-day course (500 mg day 1, 250 mg days 2â€“5) widely used in community infections."
  },
  {
    "rank": 13,
    "name": "Atorvastatin",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Atorva / Storvas / Lipitor",
    "formation": "Synthetic HMG-CoA reductase inhibitor",
    "uses": "Primary hypercholesterolemia, prevention of CVD",
    "adult": "10â€“80 mg OD",
    "child": "Not recommended",
    "avoid": "Active liver disease, pregnancy, breastfeeding",
    "sideEffects": [
      "Myalgia",
      "Headache",
      "GI upset",
      "Elevated liver enzymes",
      "Insomnia"
    ],
    "seriousRisks": [
      "Rhabdomyolysis",
      "Severe myopathy",
      "Hepatotoxicity",
      "New-onset diabetes mellitus"
    ],
    "renalAdj": "Yes â€” reduce dose in severe renal impairment (CrCl <30); max 20 mg/day",
    "hepaticAdj": "Yes â€” contraindicated in active liver disease or unexplained persistent transaminase elevation",
    "pregnancy": "Category X â€” contraindicated; discontinue if pregnancy detected",
    "lactation": "Avoid â€” potential harm to infant; use alternative if essential",
    "drugInteractions": [
      "Gemfibrozil â€” increased myopathy/rhabdomyolysis risk",
      "Clarithromycin/azole antifungals â€” increased statin levels via CYP3A4",
      "Cyclosporine â€” markedly increased atorvastatin levels"
    ],
    "monitoring": [
      "LFT",
      "CK (if myalgia)",
      "Lipid profile",
      "Blood glucose"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "80 mg/day",
    "clinicalPearl": "Evening dosing preferred â€” cholesterol synthesis peaks at night; improves efficacy."
  },
  {
    "rank": 14,
    "name": "Cefixime",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Taxim-O / Zifi / Cefix",
    "formation": "Third-generation cephalosporin",
    "uses": "Typhoid fever, urinary tract infections, otitis media",
    "adult": "200â€“400 mg daily or BID",
    "child": "8â€“12 mg/kg/day in 2 divided doses",
    "avoid": "Cephalosporin/penicillin hypersensitivity",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Abdominal pain",
      "Headache",
      "Skin rash"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "Stevens-Johnson syndrome",
      "C. difficile colitis",
      "Seizures (high doses in renal failure)"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <20 mL/min; 200 mg every 48 hours",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” generally considered safe when needed",
    "lactation": "Safe â€” compatible with breastfeeding",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect",
      "Probenecid â€” increased cefixime levels",
      "Oral contraceptives â€” potential reduced efficacy"
    ],
    "monitoring": [
      "Renal function",
      "Signs of superinfection",
      "Symptom resolution"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg/day",
    "clinicalPearl": "Good oral bioavailability; drug of choice for uncomplicated gonorrhoea in India."
  },
  {
    "rank": 15,
    "name": "Metformin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Glycomet / Cetapin / Glucophage",
    "formation": "Biguanide (dimethylbiguanide)",
    "uses": "First-line Type 2 DM, PCOS management",
    "adult": "500â€“1000 mg BID (max 2550 mg/day)",
    "child": "500 mg BID (approved >10y for T2DM)",
    "avoid": "Severe renal impairment (eGFR < 30), metabolic acidosis",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Metallic taste",
      "Abdominal discomfort"
    ],
    "seriousRisks": [
      "Lactic acidosis (rare but fatal)",
      "Vitamin B12 deficiency (long-term)",
      "Acute kidney injury (contrast/dehydration)"
    ],
    "renalAdj": "Yes â€” contraindicated if eGFR <30; reduce dose if eGFR 30â€“45; use caution",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment; lactic acidosis risk",
    "pregnancy": "Category B â€” used off-label; insulin preferred; safe for gestational diabetes per FOGSI",
    "lactation": "Caution â€” small amount in breast milk; generally considered safe by most guidelines",
    "drugInteractions": [
      "Alcohol â€” potentiates lactic acidosis risk",
      "Contrast agents â€” hold 48 hours before/after iodinated contrast",
      "Cimetidine â€” increases metformin levels"
    ],
    "monitoring": [
      "eGFR/creatinine",
      "HbA1c",
      "Blood glucose",
      "Vitamin B12 (annually)",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "3000 mg/day (XR formulation); 2550 mg/day (IR)",
    "clinicalPearl": "Hold metformin 48 hours before iodinated contrast to prevent contrast-induced nephropathy."
  },
  {
    "rank": 16,
    "name": "Ursodeoxycholic Acid",
    "section": "Section 1: Foundational Molecules",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Udiliv / Ursocol",
    "formation": "Naturally occurring bile acid",
    "uses": "Dissolution of cholesterol gallstones, primary biliary cirrhosis",
    "adult": "300â€“600 mg daily in divided doses",
    "child": "10â€“15 mg/kg/day",
    "avoid": "Acute cholecystitis, complete biliary obstruction",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Abdominal discomfort",
      "Pruritus",
      "Headache"
    ],
    "seriousRisks": [
      "Hepatotoxicity (rare, paradoxical with high doses)",
      "Drug-induced liver injury",
      "Gallstone dissolution failure"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” contraindicated in acute cholangitis, biliary obstruction; use with caution in chronic liver disease",
    "pregnancy": "Category B â€” generally considered safe; used in obstetric cholestasis",
    "lactation": "Safe â€” limited data; low risk",
    "drugInteractions": [
      "Cholestyramine â€” reduces UDCA absorption",
      "Antacids (aluminium-containing) â€” reduce absorption",
      "Oral contraceptives â€” may increase biliary cholesterol (reduce UDCA efficacy)"
    ],
    "monitoring": [
      "LFT (ALT, AST, bilirubin)",
      "Bile duct ultrasound",
      "Lipid profile (PSC patients)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/kg/day (PBC/PSC); 15 mg/kg/day (gallstones)",
    "clinicalPearl": "Hydrophilic bile acid â€” replaces toxic bile acids; take with meals for best absorption."
  },
  {
    "rank": 17,
    "name": "Rosuvastatin",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Rosuvas / Rozavel / Crestor",
    "formation": "Hydrophilic HMG-CoA reductase inhibitor",
    "uses": "Severe hyperlipidemia, atherosclerosis stabilization",
    "adult": "5â€“40 mg OD",
    "child": "Not recommended",
    "avoid": "Active liver disease, severe renal impairment",
    "sideEffects": [
      "Myalgia",
      "Headache",
      "GI upset",
      "Elevated transaminases",
      "Dizziness"
    ],
    "seriousRisks": [
      "Rhabdomyolysis",
      "Severe myopathy",
      "Hepatotoxicity",
      "New-onset diabetes"
    ],
    "renalAdj": "Yes â€” max 10 mg/day if eGFR <30 mL/min",
    "hepaticAdj": "Yes â€” contraindicated in active liver disease",
    "pregnancy": "Category X â€” contraindicated",
    "lactation": "Avoid â€” potential harm to infant",
    "drugInteractions": [
      "Gemfibrozil â€” increased myopathy risk (avoid)",
      "Cyclosporine â€” markedly increased rosuvastatin levels; max 5 mg/day",
      "Antacids â€” reduce rosuvastatin absorption (give 2 hours apart)"
    ],
    "monitoring": [
      "LFT",
      "CK (if myalgia)",
      "Lipid profile",
      "Blood glucose"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day",
    "clinicalPearl": "Most potent LDL-lowering statin; does not require CYP3A4 metabolism â€” fewer interactions."
  },
  {
    "rank": 18,
    "name": "Ceftriaxone",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Monocef / Ceftriax / Rocephin",
    "formation": "Parenteral third-generation cephalosporin",
    "uses": "Meningitis, sepsis, gonorrhea, surgical prophylaxis",
    "adult": "1â€“2 g IV/IM daily",
    "child": "50â€“100 mg/kg/day (max 4 g/day)",
    "avoid": "Hyperbilirubinemic neonates, concomitant IV calcium",
    "sideEffects": [
      "Injection site pain/phlebitis",
      "Diarrhoea",
      "Rash",
      "Elevated liver enzymes",
      "Nausea"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "C. difficile colitis",
      "Stevens-Johnson syndrome",
      "Biliary sludge/gallstones (prolonged IV use)"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <10 mL/min; standard dosing for mild-moderate impairment",
    "hepaticAdj": "No â€” standard dosing; caution in severe hepatic impairment",
    "pregnancy": "Category B â€” commonly used for infections in pregnancy",
    "lactation": "Safe â€” compatible with breastfeeding",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect",
      "Calcium-containing IV solutions â€” do not mix (precipitation)",
      "Aminoglycosides â€” do not mix in same syringe"
    ],
    "monitoring": [
      "Renal function",
      "LFT",
      "CBC (prolonged use)",
      "Signs of superinfection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "4 g/day (meningitis/severe infection); 2 g/day standard",
    "clinicalPearl": "Never reconstitute with calcium-containing solutions â€” risk of fatal precipitation in neonates."
  },
  {
    "rank": 19,
    "name": "Amlodipine",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Amlodac / Stamlo / Norvasc",
    "formation": "Dihydropyridine calcium channel blocker",
    "uses": "Hypertension, chronic stable angina",
    "adult": "2.5â€“10 mg OD",
    "child": "0.1â€“0.6 mg/kg (usually 2.5 mg initial in teens)",
    "avoid": "Severe aortic stenosis, cardiogenic shock",
    "sideEffects": [
      "Peripheral oedema",
      "Flushing",
      "Headache",
      "Dizziness",
      "Palpitations"
    ],
    "seriousRisks": [
      "Severe hypotension",
      "Reflex tachycardia",
      "Gingival hyperplasia",
      "Exacerbation of heart failure (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment; prolonged half-life",
    "pregnancy": "Category C â€” avoid in 1st trimester; use if benefit outweighs risk",
    "lactation": "Caution â€” excreted in breast milk; limited data",
    "drugInteractions": [
      "CYP3A4 inhibitors â€” increased amlodipine levels",
      "Simvastatin â€” limit simvastatin to 20 mg/day",
      "Cyclosporine â€” increased cyclosporine levels"
    ],
    "monitoring": [
      "BP",
      "Heart rate",
      "Peripheral oedema",
      "ECG"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Long half-life (35â€“50 hours) allows once-daily dosing; oedema is position-dependent."
  },
  {
    "rank": 20,
    "name": "Aceclofenac + Paracetamol",
    "section": "Section 1: Foundational Molecules",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Zerodol-P / Aceclo-P",
    "formation": "Phenylacetic acid NSAID + p-aminophenol",
    "uses": "Acute musculoskeletal pain, osteoarthritis flares",
    "adult": "100 mg/325 mg BID",
    "child": "Not recommended (under 12 years)",
    "avoid": "Active GI ulcer, severe renal or cardiac failure",
    "sideEffects": [
      "GI upset/nausea",
      "Abdominal pain",
      "Dizziness",
      "Elevated liver enzymes",
      "Peripheral oedema"
    ],
    "seriousRisks": [
      "GI bleeding/ulceration",
      "Hepatotoxicity",
      "Acute kidney injury",
      "Cardiovascular events (aceclofenac)"
    ],
    "renalAdj": "Yes â€” avoid in eGFR <30; use with caution in mild-moderate impairment",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment",
    "pregnancy": "Category C/D â€” avoid (especially 3rd trimester); premature ductus closure risk",
    "lactation": "Caution â€” limited data; short-term use only",
    "drugInteractions": [
      "Warfarin â€” increased bleeding risk",
      "ACE inhibitors/ARBs â€” reduced antihypertensive effect and renal risk",
      "Methotrexate â€” reduced clearance, toxicity"
    ],
    "monitoring": [
      "Renal function",
      "LFT",
      "GI symptoms",
      "BP"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Aceclofenac 200 mg + Paracetamol 1000 mg per day",
    "clinicalPearl": "Always prescribe with a PPI to reduce GI risk in elderly or high-risk patients."
  },
  {
    "rank": 21,
    "name": "Glimepiride",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Amaryl / Glimpid / Glimy",
    "formation": "Third-generation sulfonylurea",
    "uses": "Glycemic control in Type 2 Diabetes",
    "adult": "1â€“4 mg OD",
    "child": "Not recommended",
    "avoid": "Type 1 DM, diabetic ketoacidosis",
    "sideEffects": [
      "Hypoglycaemia",
      "Weight gain",
      "Nausea",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia",
      "Agranulocytosis (rare)",
      "Haemolytic anaemia (rare, G6PD deficiency)"
    ],
    "renalAdj": "Yes â€” use with caution; start with lowest dose; avoid in severe renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; insulin preferred in pregnancy",
    "lactation": "Avoid â€” risk of neonatal hypoglycaemia",
    "drugInteractions": [
      "Fluconazole â€” increased glimepiride levels, hypoglycaemia",
      "Beta-blockers â€” mask hypoglycaemia",
      "Alcohol â€” potentiate hypoglycaemia"
    ],
    "monitoring": [
      "Blood glucose (FBS/PPBS)",
      "HbA1c",
      "Renal function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "8 mg/day",
    "clinicalPearl": "Take with first bite of meal â€” reduces hypoglycaemia and improves postprandial control."
  },
  {
    "rank": 22,
    "name": "Vitamin D3 (Cholecalciferol)",
    "section": "Section 1: Foundational Molecules",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Calcirol / D-3 60K / Uprise-D3",
    "formation": "Fat-soluble seco-steroid",
    "uses": "Vitamin D deficiency, osteoporosis, immune support",
    "adult": "60,000 IU once weekly for 8 weeks (deficiency)",
    "child": "400â€“1000 IU/day or 60,000 IU monthly",
    "avoid": "Hypercalcemia, hypervitaminosis D",
    "sideEffects": [
      "Hypercalcaemia (overdose)",
      "Nausea",
      "Constipation",
      "Polyuria",
      "Metallic taste"
    ],
    "seriousRisks": [
      "Vitamin D toxicity/hypercalcaemia",
      "Nephrocalcinosis (overdose)",
      "Nephrolithiasis"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; risk of hypercalcaemia; monitor calcium",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A (recommended doses)/C (high doses) â€” avoid megadoses",
    "lactation": "Safe â€” at recommended doses; avoid megadoses",
    "drugInteractions": [
      "Thiazide diuretics â€” hypercalcaemia risk",
      "Digoxin â€” hypercalcaemia potentiates toxicity",
      "Anticonvulsants â€” reduced vitamin D levels"
    ],
    "monitoring": [
      "Serum 25-OH Vitamin D",
      "Serum calcium",
      "Serum phosphorus",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 IU/day (maintenance); 60,000 IU/week pulse (deficiency therapy per Indian guidelines)",
    "clinicalPearl": "Measure 25-OH Vitamin D before starting; fat-soluble â€” take with fatty meal for absorption."
  },
  {
    "rank": 23,
    "name": "Diclofenac Sodium",
    "section": "Section 1: Foundational Molecules",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Voveran / Voltaren / Reactin",
    "formation": "Phenylacetic acid derivative",
    "uses": "Rheumatoid arthritis, acute trauma pain, spondylitis",
    "adult": "50â€“75 mg BID or 100 mg SR OD",
    "child": "1â€“3 mg/kg/day in divided doses",
    "avoid": "GI bleeding, aspirin-induced asthma, post-CABG pain",
    "sideEffects": [
      "GI upset/epigastric pain",
      "Nausea",
      "Headache",
      "Dizziness",
      "Oedema"
    ],
    "seriousRisks": [
      "GI bleeding/perforation",
      "Acute kidney injury",
      "Cardiovascular events",
      "Hepatotoxicity (rare)"
    ],
    "renalAdj": "Yes â€” avoid in eGFR <30; use caution in mild-moderate impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C (1st/2nd trimester)/D (3rd trimester) â€” avoid; risk of premature ductus closure",
    "lactation": "Caution â€” small amounts in breast milk; short-term use may be acceptable",
    "drugInteractions": [
      "Warfarin â€” increased bleeding risk",
      "ACE inhibitors â€” reduced antihypertensive effect and renal risk",
      "Lithium â€” reduced lithium clearance, toxicity"
    ],
    "monitoring": [
      "Renal function",
      "BP",
      "GI symptoms",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "150 mg/day (oral); 75 mg/day (SR formulation)",
    "clinicalPearl": "Topical diclofenac preferred over oral in elderly to reduce systemic GI/renal risk."
  },
  {
    "rank": 24,
    "name": "Levocetirizine",
    "section": "Section 1: Foundational Molecules",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "L-Cetzine / Levorid / Xyzal",
    "formation": "Third-generation piperazine antihistamine",
    "uses": "Allergic rhinitis, chronic idiopathic urticaria",
    "adult": "5 mg OD (bedtime)",
    "child": "1.25â€“2.5 mg OD (6moâ€“12y)",
    "avoid": "End-stage renal disease (CrCl < 10 mL/min)",
    "sideEffects": [
      "Somnolence/sedation",
      "Dry mouth",
      "Fatigue",
      "Headache",
      "Nausea"
    ],
    "seriousRisks": [
      "Paradoxical excitation in children",
      "Urinary retention",
      "QT prolongation (high doses)",
      "Seizures (rare)"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <50 mL/min; 5 mg/day for CrCl 10â€“50",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment",
    "pregnancy": "Category B â€” use only if clearly needed",
    "lactation": "Caution â€” excreted in breast milk; may cause sedation in infant",
    "drugInteractions": [
      "CNS depressants â€” additive sedation",
      "Alcohol â€” enhanced sedation",
      "Ritonavir â€” increased levocetirizine levels"
    ],
    "monitoring": [
      "CNS function (sedation)",
      "Renal function (long-term)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Less sedating than cetirizine; evening dosing reduces daytime drowsiness."
  },
  {
    "rank": 25,
    "name": "Montelukast + Levocetirizine",
    "section": "Section 1: Foundational Molecules",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Montair-LC / Telekast-L",
    "formation": "CysLT1 antagonist + antihistamine",
    "uses": "Chronic allergic rhinitis with bronchial asthma",
    "adult": "10 mg/5 mg OD",
    "child": "4 mg/2.5 mg OD",
    "avoid": "Acute asthma attack, neuropsychiatric events history",
    "sideEffects": [
      "Somnolence",
      "Dry mouth",
      "Headache",
      "Fatigue",
      "Nausea"
    ],
    "seriousRisks": [
      "Neuropsychiatric events (montelukast â€” suicidality)",
      "Churg-Strauss syndrome (montelukast)",
      "QT prolongation (rare)"
    ],
    "renalAdj": "Yes â€” levocetirizine dose reduction if CrCl <50; montelukast standard dosing",
    "hepaticAdj": "Yes â€” use caution; both drugs metabolised hepatically",
    "pregnancy": "Category B â€” limited data; use only if needed",
    "lactation": "Caution â€” both components may be present in breast milk",
    "drugInteractions": [
      "CNS depressants â€” additive sedation (levocetirizine)",
      "CYP3A4 inducers â€” reduced montelukast levels",
      "Phenobarbital â€” reduced montelukast AUC"
    ],
    "monitoring": [
      "Mood/behaviour (montelukast in children)",
      "Pulmonary function",
      "Symptom control"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Montelukast 10 mg + Levocetirizine 5 mg per day",
    "clinicalPearl": "FDA black box warning for montelukast â€” counsel for neuropsychiatric side effects."
  },
  {
    "rank": 26,
    "name": "Rabeprazole + Domperidone",
    "section": "Section 1: Foundational Molecules",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Cyra-D / Rabeloc-D / Razo-D",
    "formation": "PPI + prokinetic",
    "uses": "Dyspepsia, GERD with gastric stasis",
    "adult": "20 mg/30 mg OD (before breakfast)",
    "child": "Not recommended",
    "avoid": "Intestinal obstruction, cardiac arrhythmia history",
    "sideEffects": [
      "Headache",
      "Diarrhoea",
      "Nausea",
      "Dry mouth",
      "Dizziness"
    ],
    "seriousRisks": [
      "QT prolongation (domperidone)",
      "Hypomagnesaemia (long-term PPI)",
      "Tardive dyskinesia (rare)",
      "C. difficile colitis"
    ],
    "renalAdj": "Yes â€” reduce domperidone dose in renal impairment; rabeprazole standard dosing",
    "hepaticAdj": "Yes â€” avoid domperidone in hepatic impairment; reduce rabeprazole dose in severe disease",
    "pregnancy": "Category C â€” avoid domperidone; use with caution",
    "lactation": "Caution â€” domperidone excreted in milk; rabeprazole excreted in milk",
    "drugInteractions": [
      "Ketoconazole â€” reduced absorption (raised gastric pH)",
      "QT-prolonging drugs â€” additive risk with domperidone",
      "Clopidogrel â€” reduced antiplatelet effect (less with rabeprazole vs. omeprazole)"
    ],
    "monitoring": [
      "ECG (domperidone if risk)",
      "Serum magnesium (long-term PPI)",
      "GI symptom resolution"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Rabeprazole 40 mg + Domperidone 30 mg per day",
    "clinicalPearl": "Rabeprazole has least CYP2C19 interaction â€” safer with clopidogrel than omeprazole/pantoprazole."
  },
  {
    "rank": 27,
    "name": "Sitagliptin + Metformin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Janumet / Sitamet",
    "formation": "DPP-4 inhibitor + biguanide",
    "uses": "Type 2 DM uncontrolled on Metformin monotherapy",
    "adult": "50 mg/500 mg or 50 mg/1000 mg BID",
    "child": "Not recommended",
    "avoid": "Renal failure, risk of pancreatitis",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Headache",
      "Nasopharyngitis",
      "Hypoglycaemia (with SU)"
    ],
    "seriousRisks": [
      "Pancreatitis (rare)",
      "Lactic acidosis (metformin component)",
      "Acute kidney injury",
      "Angioedema"
    ],
    "renalAdj": "Yes â€” contraindicated if eGFR <30; sitagliptin dose reduction at eGFR 30â€“45 (50 mg/day)",
    "hepaticAdj": "Yes â€” avoid metformin in significant hepatic impairment",
    "pregnancy": "Category B â€” avoid; insulin preferred",
    "lactation": "Avoid â€” insufficient data for sitagliptin",
    "drugInteractions": [
      "Contrast agents â€” hold metformin",
      "Alcohol â€” lactic acidosis risk (metformin)",
      "Digoxin â€” sitagliptin slightly increases digoxin levels"
    ],
    "monitoring": [
      "eGFR",
      "HbA1c",
      "Blood glucose",
      "Lipase/amylase (if pain)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Sitagliptin 100 mg + Metformin 2000 mg per day",
    "clinicalPearl": "DPP-4 inhibitors are weight-neutral and rarely cause hypoglycaemia when used as monotherapy."
  },
  {
    "rank": 28,
    "name": "Teneligliptin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Tenglyn / Tengli / Tenepure",
    "formation": "Synthetic DPP-4 inhibitor",
    "uses": "Glycemic management in Type 2 Diabetes",
    "adult": "20 mg OD",
    "child": "Not recommended",
    "avoid": "Patients with heart failure, severe ketoacidosis",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Nausea",
      "Hypoglycaemia (with SU)",
      "Dizziness"
    ],
    "seriousRisks": [
      "Pancreatitis (rare)",
      "Angioedema (rare)",
      "Bullous pemphigoid"
    ],
    "renalAdj": "No â€” minimal renal dose adjustment required; advantage over other DPP-4 inhibitors",
    "hepaticAdj": "No â€” standard dosing; minor dose adjustment in severe disease",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Sulfonylureas â€” additive hypoglycaemia risk",
      "CYP3A4 inhibitors â€” minor interaction",
      "Digoxin â€” slight increase in digoxin exposure"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Renal function",
      "Pancreatic enzymes (if pain)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 mg/day (20 mg twice daily)",
    "clinicalPearl": "Indian-origin DPP-4 inhibitor; dual excretion (renal + hepatic) â€” minimal renal dose adjustment."
  },
  {
    "rank": 29,
    "name": "Salbutamol (Albuterol)",
    "section": "Section 1: Foundational Molecules",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Asthalin / Ventolin / Derihaler",
    "formation": "Selective beta2-adrenoceptor agonist",
    "uses": "Bronchospasm in asthma, COPD, and exercise-induced asthma",
    "adult": "200 mcg (2 puffs) every 4â€“6 hrs PRN",
    "child": "0.1â€“0.15 mg/kg per dose or 1â€“2 puffs",
    "avoid": "Severe cardiac disease, tachyarrhythmias",
    "sideEffects": [
      "Tremor",
      "Tachycardia",
      "Palpitations",
      "Headache",
      "Hypokalaemia"
    ],
    "seriousRisks": [
      "Paradoxical bronchospasm",
      "Severe hypokalaemia (high doses)",
      "Cardiac arrhythmias",
      "Lactic acidosis (parenteral, rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use for acute bronchospasm is acceptable; avoid prolonged high-dose use",
    "lactation": "Safe â€” inhaled doses are minimal systemic exposure",
    "drugInteractions": [
      "Beta-blockers â€” antagonise bronchodilation (avoid non-selective)",
      "MAO inhibitors â€” potentiate cardiovascular effects",
      "Loop diuretics â€” additive hypokalaemia"
    ],
    "monitoring": [
      "Peak expiratory flow/SpO2",
      "Heart rate",
      "Serum potassium (high doses)",
      "ECG (if IV)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1600 mcg/day (inhaled); 8 mg/day (oral)",
    "clinicalPearl": "Shake MDI before use; spacer devices improve drug delivery significantly."
  },
  {
    "rank": 30,
    "name": "Itraconazole",
    "section": "Section 1: Foundational Molecules",
    "category": "Antifungal",
    "schedule": "H",
    "brand": "Canditral / Sporanox / Itaspor",
    "formation": "Triazole antifungal",
    "uses": "Tinea infections, vulvovaginal candidiasis, blastomycosis",
    "adult": "100â€“200 mg OD or BID",
    "child": "3â€“5 mg/kg/day (under specialist guidance)",
    "avoid": "Congestive heart failure, drug-drug interactions with statins",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Abdominal pain",
      "Headache",
      "Rash"
    ],
    "seriousRisks": [
      "Hepatotoxicity",
      "QT prolongation (significant)",
      "Heart failure exacerbation",
      "Adrenal insufficiency (inhibits steroidogenesis)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” contraindicated in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid; teratogenic potential; use only if benefit outweighs risk",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "CYP3A4 substrates (statins, cisapride, terfenadine) â€” markedly increased levels (serious)",
      "Warfarin â€” increased INR",
      "Midazolam â€” prolonged sedation"
    ],
    "monitoring": [
      "LFT",
      "ECG (QTc)",
      "Symptom resolution",
      "Drug levels if needed"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg/day (pulse therapy); 200 mg/day (maintenance)",
    "clinicalPearl": "Take with food or cola drink â€” highly pH-dependent absorption; capsule better than tablet."
  },
  {
    "rank": 31,
    "name": "Iron + Folic Acid",
    "section": "Section 1: Foundational Molecules",
    "category": "Vitamins/Minerals",
    "schedule": "H",
    "brand": "Livogen / Fefol / Feronia-XT",
    "formation": "Ferrous salt + Vitamin B9",
    "uses": "Prevention and treatment of iron-deficiency anemia",
    "adult": "100 mg Fe/500 mcg FA OD",
    "child": "20 mg Fe/100 mcg FA (peds tablets/syrup)",
    "avoid": "Hemosiderosis, hemochromatosis",
    "sideEffects": [
      "GI upset/constipation",
      "Dark stools",
      "Nausea",
      "Abdominal cramps",
      "Heartburn"
    ],
    "seriousRisks": [
      "Iron overdose/toxicity in children (fatal)",
      "Haemosiderosis (chronic excess)",
      "Masking GI pathology"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment (iron overload risk)",
    "pregnancy": "Category A â€” recommended in pregnancy per NLEM/NHM guidelines (IFA supplementation)",
    "lactation": "Safe â€” standard supplementation doses are safe",
    "drugInteractions": [
      "Tetracyclines â€” chelation reduces absorption of both",
      "Fluoroquinolones â€” reduced antibiotic absorption",
      "Antacids â€” reduce iron absorption"
    ],
    "monitoring": [
      "Haemoglobin",
      "Serum ferritin",
      "Reticulocyte count",
      "GI tolerance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Elemental iron 200 mg + Folic acid 5 mg per day",
    "clinicalPearl": "Take on empty stomach with vitamin C (orange juice) to enhance iron absorption."
  },
  {
    "rank": 32,
    "name": "Dapagliflozin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Forxiga / Dapaglit",
    "formation": "SGLT2 inhibitor (glycoside)",
    "uses": "T2DM, heart failure (HFrEF/HFpEF), chronic kidney disease",
    "adult": "5â€“10 mg OD",
    "child": "Not recommended",
    "avoid": "Dialysis patients, history of ketoacidosis",
    "sideEffects": [
      "Genital mycotic infections",
      "Urinary tract infections",
      "Polyuria/increased urination",
      "Hypotension",
      "Nasopharyngitis"
    ],
    "seriousRisks": [
      "Diabetic ketoacidosis (euglycaemic DKA)",
      "Fournier's gangrene",
      "Urinary tract infections (serious)",
      "Acute kidney injury"
    ],
    "renalAdj": "Yes â€” avoid initiation if eGFR <45; contraindicated if eGFR <30",
    "hepaticAdj": "No â€” standard dosing; caution in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Diuretics â€” additive volume depletion risk",
      "Insulin/sulfonylureas â€” increased hypoglycaemia risk",
      "NSAIDs â€” increased renal risk"
    ],
    "monitoring": [
      "eGFR",
      "HbA1c",
      "Blood glucose",
      "Genital hygiene",
      "BP",
      "Urinalysis"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "10 mg/day",
    "clinicalPearl": "SGLT2 inhibitors have proven cardio-renal benefits; hold before major surgery or prolonged fasting."
  },
  {
    "rank": 33,
    "name": "Vildagliptin + Metformin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Galvus Met / Vildamet",
    "formation": "DPP-4 inhibitor + biguanide",
    "uses": "Combination therapy for Type 2 Diabetes",
    "adult": "50 mg/500 mg or 50 mg/1000 mg BID",
    "child": "Not recommended",
    "avoid": "Hepatic impairment, severe renal failure",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Headache",
      "Dizziness",
      "Nasopharyngitis"
    ],
    "seriousRisks": [
      "Lactic acidosis (metformin)",
      "Pancreatitis (rare, vildagliptin)",
      "Hepatotoxicity (vildagliptin â€” monitor LFT)",
      "Angioedema"
    ],
    "renalAdj": "Yes â€” metformin contraindicated if eGFR <30; vildagliptin dose reduction to 50 mg/day if eGFR <50",
    "hepaticAdj": "Yes â€” vildagliptin contraindicated in hepatic impairment (LFT >3x ULN); avoid metformin",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” insufficient safety data",
    "drugInteractions": [
      "Alcohol â€” lactic acidosis risk (metformin)",
      "Contrast agents â€” hold metformin",
      "ACE inhibitors â€” increased angioedema risk with vildagliptin"
    ],
    "monitoring": [
      "LFT (vildagliptin â€” every 3 months first year)",
      "eGFR",
      "HbA1c",
      "Blood glucose"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Vildagliptin 100 mg + Metformin 2000 mg per day",
    "clinicalPearl": "Monitor LFT every 3 months in the first year of vildagliptin â€” risk of hepatotoxicity."
  },
  {
    "rank": 34,
    "name": "Sildenafil",
    "section": "Section 1: Foundational Molecules",
    "category": "Urology",
    "schedule": "H",
    "brand": "Manforce / Penegra / Viagra",
    "formation": "Phosphodiesterase-5 (PDE5) inhibitor",
    "uses": "Erectile dysfunction, pulmonary arterial hypertension",
    "adult": "25â€“100 mg (ED) or 20 mg TID (PAH)",
    "child": "0.5â€“2 mg/kg/dose (PAH use only)",
    "avoid": "Nitrate use, severe hypotension, retinitis pigmentosa",
    "sideEffects": [
      "Headache",
      "Flushing",
      "Dyspepsia",
      "Nasal congestion",
      "Visual disturbances (bluish tinge)"
    ],
    "seriousRisks": [
      "Severe hypotension (with nitrates â€” life-threatening)",
      "Sudden hearing loss",
      "Priapism",
      "Vision loss (NAION)",
      "Cardiac events in underlying heart disease"
    ],
    "renalAdj": "Yes â€” start with 25 mg if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” start with 25 mg in hepatic impairment; avoid in severe disease",
    "pregnancy": "Category B â€” not indicated in women; used in pulmonary arterial hypertension",
    "lactation": "Caution â€” limited data in women; not applicable for ED indication",
    "drugInteractions": [
      "Nitrates â€” absolute contraindication (severe hypotension)",
      "Alpha-blockers â€” additive hypotension",
      "CYP3A4 inhibitors (ritonavir) â€” markedly increased sildenafil levels"
    ],
    "monitoring": [
      "BP",
      "Heart rate",
      "Symptom response",
      "Vision (prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg/dose (ED); 80 mg three times daily (PAH)",
    "clinicalPearl": "Absolutely contraindicated with nitrates â€” life-threatening hypotension; 24-hour washout required."
  },
  {
    "rank": 35,
    "name": "Calcium + Vitamin D3",
    "section": "Section 1: Foundational Molecules",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Shelcal / Calcimax / Calcitas",
    "formation": "Calcium carbonate + Cholecalciferol",
    "uses": "Hypocalcemia, osteoporosis, post-menopausal health",
    "adult": "500 mg/250 IU BID",
    "child": "250â€“500 mg daily",
    "avoid": "Nephrolithiasis (kidney stones), hypercalcemia",
    "sideEffects": [
      "Constipation",
      "GI upset/bloating",
      "Nausea",
      "Hypercalcaemia (overdose)",
      "Flatulence"
    ],
    "seriousRisks": [
      "Hypercalcaemia (renal stones, arrhythmias)",
      "Nephrolithiasis (calcium oxalate stones)",
      "Milk-alkali syndrome (calcium carbonate excess)"
    ],
    "renalAdj": "Yes â€” use with caution; avoid in severe renal impairment; hypercalcaemia risk",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” recommended supplement in pregnancy",
    "lactation": "Safe â€” required for maternal and infant health",
    "drugInteractions": [
      "Tetracyclines â€” calcium reduces absorption",
      "Fluoroquinolones â€” reduced absorption",
      "Bisphosphonates â€” calcium reduces absorption (give 2 hours apart)",
      "Thiazide diuretics â€” hypercalcaemia risk"
    ],
    "monitoring": [
      "Serum calcium",
      "Serum 25-OH Vitamin D",
      "Renal function",
      "Urinary calcium"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Calcium 2500 mg + Vitamin D3 2000 IU per day",
    "clinicalPearl": "Calcium carbonate requires stomach acid â€” take with meals; calcium citrate better for achlorhydria."
  },
  {
    "rank": 36,
    "name": "Gabapentin + Nortriptyline",
    "section": "Section 1: Foundational Molecules",
    "category": "CNS",
    "schedule": "H1",
    "brand": "Gabapin-NT / Gabantin-NT",
    "formation": "GABA analog + tricyclic antidepressant",
    "uses": "Diabetic neuropathic pain, post-herpetic neuralgia",
    "adult": "300 mg/10 mg BID or TID",
    "child": "Not recommended",
    "avoid": "Recent MI, glaucoma, urinary retention",
    "sideEffects": [
      "Sedation/somnolence",
      "Dizziness",
      "Dry mouth",
      "Constipation",
      "Weight gain"
    ],
    "seriousRisks": [
      "Suicidal ideation (nortriptyline)",
      "Cardiac arrhythmias (TCA â€” nortriptyline)",
      "Respiratory depression (overdose)",
      "Seizures"
    ],
    "renalAdj": "Yes â€” reduce gabapentin dose if eGFR <60; nortriptyline standard dosing",
    "hepaticAdj": "Yes â€” caution with nortriptyline in hepatic impairment; reduce dose",
    "pregnancy": "Category C â€” avoid; neuropathic pain management requires specialist guidance",
    "lactation": "Caution â€” both drugs excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "CNS depressants â€” additive sedation",
      "MAO inhibitors â€” potentially fatal with nortriptyline (contraindicated)",
      "Anticholinergic drugs â€” additive anticholinergic effects"
    ],
    "monitoring": [
      "Pain score (NRS)",
      "Sedation level",
      "ECG (nortriptyline baseline)",
      "Mood/suicidal ideation"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Gabapentin 3600 mg + Nortriptyline 150 mg per day",
    "clinicalPearl": "Start low and titrate slowly â€” sedation is dose-limiting; nighttime dosing reduces daytime impairment."
  },
  {
    "rank": 37,
    "name": "Clopidogrel",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Clopilet / Plavix / Deplatt",
    "formation": "P2Y12 platelet inhibitor",
    "uses": "Post-stent antiplatelet therapy, stroke prevention",
    "adult": "75 mg OD",
    "child": "0.2â€“1.0 mg/kg OD (Consult specialist)",
    "avoid": "Active pathological bleeding (e.g., peptic ulcer)",
    "sideEffects": [
      "Bleeding (bruising)",
      "GI upset",
      "Headache",
      "Dizziness",
      "Rash"
    ],
    "seriousRisks": [
      "Major bleeding (GI, intracranial)",
      "Thrombotic thrombocytopenic purpura (rare)",
      "Acquired haemophilia (rare)"
    ],
    "renalAdj": "No â€” standard dosing; use caution if significant bleeding risk",
    "hepaticAdj": "Yes â€” use with caution; increased bleeding risk in hepatic impairment",
    "pregnancy": "Category B â€” avoid if possible; use only if clearly indicated",
    "lactation": "Caution â€” limited data; avoid if possible",
    "drugInteractions": [
      "PPIs (omeprazole/esomeprazole) â€” reduced antiplatelet effect via CYP2C19 (prefer pantoprazole/rabeprazole)",
      "Warfarin â€” increased bleeding risk",
      "NSAIDs â€” additive bleeding risk"
    ],
    "monitoring": [
      "CBC (bleeding)",
      "Renal function",
      "Signs of bleeding",
      "CYP2C19 status if available"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "75 mg/day (antiplatelet); 300 mg loading dose",
    "clinicalPearl": "CYP2C19 poor metabolisers have reduced clopidogrel efficacy â€” consider prasugrel/ticagrelor."
  },
  {
    "rank": 38,
    "name": "Empagliflozin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Jardiance / Empa",
    "formation": "SGLT2 inhibitor",
    "uses": "T2DM, reduction of CV death risk",
    "adult": "10â€“25 mg OD",
    "child": "Not recommended",
    "avoid": "eGFR < 30 mL/min, during pregnancy",
    "sideEffects": [
      "Genital mycotic infections",
      "UTI",
      "Polyuria",
      "Hypotension",
      "Nasopharyngitis"
    ],
    "seriousRisks": [
      "Euglycaemic DKA",
      "Fournier's gangrene",
      "Acute kidney injury",
      "Lower limb amputation risk (less than canagliflozin)"
    ],
    "renalAdj": "Yes â€” contraindicated if eGFR <30; reduce to 10 mg if eGFR 30â€“45",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "Diuretics â€” additive volume depletion",
      "Insulin/SU â€” hypoglycaemia risk",
      "NSAIDs â€” additive renal risk"
    ],
    "monitoring": [
      "eGFR",
      "HbA1c",
      "BP",
      "Body weight",
      "Urinalysis",
      "Genital hygiene"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "25 mg/day",
    "clinicalPearl": "EMPA-REG trial showed CV mortality reduction â€” first-line in T2DM with established CVD."
  },
  {
    "rank": 39,
    "name": "Telmisartan + Amlodipine",
    "section": "Section 1: Foundational Molecules",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Telma-AM / Telmikind-AM",
    "formation": "ARB + Calcium channel blocker",
    "uses": "Moderate-to-severe hypertension",
    "adult": "40 mg/5 mg or 80 mg/5 mg OD",
    "child": "Not recommended",
    "avoid": "Cardiogenic shock, biliary obstruction",
    "sideEffects": [
      "Peripheral oedema (amlodipine)",
      "Dizziness",
      "Hyperkalemia (telmisartan)",
      "Flushing",
      "Headache"
    ],
    "seriousRisks": [
      "Angioedema (rare, telmisartan)",
      "Severe hypotension",
      "Acute kidney injury",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” monitor closely; avoid if eGFR <15; telmisartan preferred in mild-moderate renal impairment",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment; telmisartan caution",
    "pregnancy": "Category D â€” contraindicated",
    "lactation": "Avoid â€” both components not recommended",
    "drugInteractions": [
      "Potassium-sparing diuretics â€” hyperkalemia",
      "CYP3A4 inhibitors â€” increased amlodipine levels",
      "Simvastatin â€” limit to 20 mg with amlodipine"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function",
      "Peripheral oedema"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Telmisartan 80 mg + Amlodipine 10 mg per day",
    "clinicalPearl": "Single-pill combination improves adherence; ARB reduces amlodipine-induced oedema."
  },
  {
    "rank": 40,
    "name": "Ofloxacin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Oflox / Zanocin / Oflomac",
    "formation": "Second-generation fluoroquinolone",
    "uses": "Typhoid, chronic bronchitis flares, UTI",
    "adult": "200â€“400 mg BID",
    "child": "7.5â€“15 mg/kg/day (Restrict use <18y)",
    "avoid": "Tendinitis history, pregnancy, epilepsy",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Headache",
      "Insomnia",
      "GI upset"
    ],
    "seriousRisks": [
      "Tendon rupture (Achilles)",
      "QT prolongation",
      "C. difficile colitis",
      "Peripheral neuropathy",
      "Phototoxicity"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <20 mL/min",
    "hepaticAdj": "Yes â€” use with caution in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid (cartilage toxicity risk); use only if no safe alternative",
    "lactation": "Avoid â€” excreted in breast milk; cartilage toxicity concern",
    "drugInteractions": [
      "Antacids/iron/zinc â€” reduce ofloxacin absorption (give 2 hours apart)",
      "QT-prolonging drugs â€” additive risk",
      "Warfarin â€” increased INR"
    ],
    "monitoring": [
      "Renal function",
      "Tendon symptoms",
      "QTc (if risk factors)",
      "Blood glucose (in diabetics)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "800 mg/day",
    "clinicalPearl": "Avoid in children/pregnant women and elderly with tendon risk; take on empty stomach."
  },
  {
    "rank": 41,
    "name": "Povidone-Iodine",
    "section": "Section 1: Foundational Molecules",
    "category": "Topical",
    "schedule": "OTC",
    "brand": "Betadine / Wokadine",
    "formation": "Iodophor complex",
    "uses": "Topical antiseptic for wounds/surgery",
    "adult": "5â€“10% solution/ointment PRN",
    "child": "5% (Same as adult)",
    "avoid": "Iodine allergy, thyroid disease (extensive use)",
    "sideEffects": [
      "Skin irritation",
      "Burning sensation",
      "Contact dermatitis",
      "Iodine staining",
      "Dryness"
    ],
    "seriousRisks": [
      "Iodine absorption toxicity (large wounds/mucosae)",
      "Thyroid suppression (neonates)",
      "Anaphylaxis (rare)",
      "Metabolic acidosis (large area application)"
    ],
    "renalAdj": "No â€” topical; use with caution in extensive application",
    "hepaticAdj": "No â€” topical use",
    "pregnancy": "Category D â€” avoid large-area application; risk of fetal hypothyroidism",
    "lactation": "Caution â€” avoid large-area or prolonged use; iodine may appear in breast milk",
    "drugInteractions": [
      "Lithium â€” additive hypothyroid effect with systemic absorption",
      "Other antiseptics â€” avoid mixing (reduced efficacy)",
      "Thyroid medications â€” interference with thyroid function tests"
    ],
    "monitoring": [
      "Thyroid function (neonates/prolonged use)",
      "Wound healing",
      "Skin reaction"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Topical â€” as per wound size; 10% solution standard",
    "clinicalPearl": "Dilute 10% solution for use on mucous membranes; do not apply in deep puncture wounds."
  },
  {
    "rank": 42,
    "name": "Pregabalin",
    "section": "Section 1: Foundational Molecules",
    "category": "CNS",
    "schedule": "H1",
    "brand": "Maxgalin / Lyrica / Pregaba",
    "formation": "Gabapentinoid (GABA analog)",
    "uses": "Neuropathic pain, generalized anxiety disorder",
    "adult": "50â€“150 mg BID or TID (max 600 mg/day)",
    "child": "Not recommended (under 18 years)",
    "avoid": "Renal impairment (reduce dose), severe angioedema",
    "sideEffects": [
      "Dizziness",
      "Somnolence",
      "Weight gain",
      "Peripheral oedema",
      "Blurred vision"
    ],
    "seriousRisks": [
      "Suicidal ideation",
      "Respiratory depression (with CNS depressants)",
      "Angioedema",
      "Abuse/dependence potential"
    ],
    "renalAdj": "Yes â€” dose reduction required; CrCl 30â€“60: max 150 mg/day; CrCl 15â€“30: max 75 mg/day; CrCl <15: max 25 mg/day",
    "hepaticAdj": "No â€” standard dosing; no significant hepatic metabolism",
    "pregnancy": "Category C â€” avoid; limited safety data; neonatal withdrawal possible",
    "lactation": "Caution â€” excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "CNS depressants â€” additive sedation and respiratory depression",
      "Opioids â€” fatal respiratory depression risk (avoid)",
      "Alcohol â€” enhanced CNS depression"
    ],
    "monitoring": [
      "Pain score",
      "Sedation level",
      "Renal function",
      "Weight",
      "Mood changes"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "600 mg/day (neuropathic pain); 450 mg/day (anxiety)",
    "clinicalPearl": "Schedule H1 drug in India â€” controlled substance; taper dose slowly to avoid withdrawal."
  },
  {
    "rank": 43,
    "name": "Human Albumin",
    "section": "Section 1: Foundational Molecules",
    "category": "Biologicals",
    "schedule": "C",
    "brand": "Alburel / Albunorm",
    "formation": "Purified blood protein",
    "uses": "Hypovolemic shock, hypoalbuminemia",
    "adult": "20% solution, dose based on clinical response",
    "child": "0.5â€“1 g/kg (as 5% or 20% solution)",
    "avoid": "Severe anemia, congestive heart failure",
    "sideEffects": [
      "Fluid overload",
      "Chills/fever (infusion reaction)",
      "Nausea",
      "Hypertension (rapid infusion)",
      "Hypotension"
    ],
    "seriousRisks": [
      "Anaphylaxis/severe infusion reactions",
      "Pulmonary oedema (rapid infusion)",
      "Hypernatremia (if large volumes)",
      "Viral transmission (plasma-derived products)"
    ],
    "renalAdj": "Yes â€” use with caution; risk of fluid overload in renal failure",
    "hepaticAdj": "Yes â€” useful in hepatic disease (low albumin); monitor fluid balance",
    "pregnancy": "Category C â€” use in clinical necessity only",
    "lactation": "Safe â€” large molecule; minimal breast milk transfer",
    "drugInteractions": [
      "ACE inhibitors â€” risk of hypotension during albumin infusion",
      "Other blood products â€” do not mix in same line without consultation"
    ],
    "monitoring": [
      "Serum albumin",
      "Fluid balance/urine output",
      "BP",
      "Respiratory rate",
      "SpO2"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualised; typically 25 g/dose (100 mL of 25% solution)",
    "clinicalPearl": "20â€“25% albumin draws fluid from interstitium â€” use cautiously in pulmonary oedema."
  },
  {
    "rank": 44,
    "name": "Cefuroxime Axetil",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Pulmocef / Ceftin / Zinnat",
    "formation": "Second-generation cephalosporin ester",
    "uses": "Tonsillitis, skin infections, pneumonia",
    "adult": "250â€“500 mg BID",
    "child": "20â€“30 mg/kg/day in 2 divided doses",
    "avoid": "Cephalosporin allergy, phenylketonuria",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Headache",
      "Rash",
      "GI upset"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "Stevens-Johnson syndrome",
      "C. difficile colitis",
      "Seizures (rare, renal failure)"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <20 mL/min",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” generally considered safe",
    "lactation": "Safe â€” compatible with breastfeeding",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect",
      "Probenecid â€” increases cefuroxime levels",
      "Oral contraceptives â€” potential reduced efficacy"
    ],
    "monitoring": [
      "Renal function",
      "Signs of superinfection",
      "Symptom resolution"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1000 mg/day (oral axetil formulation)",
    "clinicalPearl": "Take with food to improve absorption of the axetil ester; film-coated tablets bitter if crushed."
  },
  {
    "rank": 45,
    "name": "Alpha Ketoanalogue",
    "section": "Section 1: Foundational Molecules",
    "category": "Nephrology",
    "schedule": "H",
    "brand": "Nefrosave / Ketosave",
    "formation": "Essential amino acid precursors",
    "uses": "Chronic Kidney Disease (with low protein diet)",
    "adult": "1 tablet per 5 kg body weight/day",
    "child": "Weight-adjusted (Consult nephrologist)",
    "avoid": "Hypercalcemia, disturbed amino acid metabolism",
    "sideEffects": [
      "Nausea",
      "GI discomfort",
      "Mild constipation",
      "Headache",
      "Diarrhoea (rare)"
    ],
    "seriousRisks": [
      "Hypercalcaemia (if excess calcium content in formulation)",
      "Masking of malnutrition",
      "Hyperphosphataemia worsening if used inappropriately"
    ],
    "renalAdj": "Yes â€” specifically used in CKD to reduce phosphate and retard progression; monitor calcium/phosphate balance",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” used under specialist guidance in CKD in pregnancy",
    "lactation": "Caution â€” limited data; use under specialist guidance",
    "drugInteractions": [
      "Phosphate binders â€” additive effect on serum phosphate",
      "Tetracyclines â€” chelation reduces absorption",
      "Other amino acid supplements â€” potential additive metabolic effects"
    ],
    "monitoring": [
      "Serum creatinine/eGFR",
      "Serum phosphate",
      "Serum calcium",
      "Serum bicarbonate",
      "Nutritional parameters"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Per body weight â€” typically 4â€“8 tablets/day (individualised by nephrologist)",
    "clinicalPearl": "Provides essential amino acid analogues without nitrogen load â€” reduces uraemic toxin generation in CKD."
  },
  {
    "rank": 46,
    "name": "Ipratropium + Salbutamol",
    "section": "Section 1: Foundational Molecules",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Duolin / Combivent",
    "formation": "Anticholinergic + SABA",
    "uses": "Acute bronchospasm in COPD and asthma",
    "adult": "250 mcg/100 mcg (Respules) every 6 hrs",
    "child": "0.15 mg/kg (Salbutamol) via nebulizer",
    "avoid": "Glaucoma, bladder neck obstruction",
    "sideEffects": [
      "Dry mouth",
      "Palpitations",
      "Tremor",
      "Headache",
      "Urinary retention"
    ],
    "seriousRisks": [
      "Paradoxical bronchospasm",
      "Acute urinary retention (BPH)",
      "Acute narrow-angle glaucoma",
      "Tachycardia"
    ],
    "renalAdj": "Yes â€” reduce dose in severe renal impairment (ipratropium clearance decreased)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” inhaled doses generally safe; use only if clearly needed",
    "lactation": "Caution â€” limited data; inhaled doses likely safe",
    "drugInteractions": [
      "Anticholinergic drugs â€” additive anticholinergic side effects",
      "Beta-blockers â€” antagonise salbutamol bronchodilation",
      "MAO inhibitors â€” potentiate cardiovascular effects of salbutamol"
    ],
    "monitoring": [
      "SpO2",
      "Peak expiratory flow",
      "Heart rate",
      "Serum potassium (high-dose salbutamol)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Ipratropium 2000 mcg/day + Salbutamol 1600 mcg/day (nebulised)",
    "clinicalPearl": "Combination synergistic in acute COPD exacerbation â€” ipratropium covers proximal, salbutamol distal airways."
  },
  {
    "rank": 47,
    "name": "Ciprofloxacin",
    "section": "Section 1: Foundational Molecules",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Ciplox / Ciprobid / Cifran",
    "formation": "Fluoroquinolone derivative",
    "uses": "UTI, gastroenteritis, bone/joint infections",
    "adult": "250â€“750 mg BID",
    "child": "10â€“20 mg/kg per dose (Restrict use)",
    "avoid": "Tendon disorders, concomitant tizanidine",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Headache",
      "GI upset",
      "Photosensitivity"
    ],
    "seriousRisks": [
      "Tendon rupture",
      "QT prolongation",
      "C. difficile colitis",
      "Peripheral neuropathy",
      "Aortic aneurysm/dissection"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <30 mL/min; 250â€“500 mg/12 hours",
    "hepaticAdj": "Yes â€” use with caution; avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; use safer alternatives",
    "lactation": "Avoid â€” present in breast milk",
    "drugInteractions": [
      "Antacids/iron/zinc â€” reduce ciprofloxacin absorption (give 2 hours apart)",
      "Warfarin â€” enhanced INR",
      "Theophylline â€” increased theophylline levels (toxic)"
    ],
    "monitoring": [
      "Renal function",
      "Tendon symptoms",
      "QTc",
      "Blood glucose"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1500 mg/day (oral); 800 mg/day (IV)",
    "clinicalPearl": "Avoid concurrent antacids/dairy â€” chelation reduces bioavailability; maintain hydration."
  },
  {
    "rank": 48,
    "name": "Semaglutide",
    "section": "Section 1: Foundational Molecules",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Rybelsus / Ozempic",
    "formation": "Human GLP-1 receptor agonist",
    "uses": "Type 2 Diabetes, chronic weight management",
    "adult": "3â€“14 mg OD (Oral) or 0.25â€“2.4 mg weekly (SC)",
    "child": "Not recommended",
    "avoid": "Family history of MTC, MEN 2 syndrome",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Injection site reactions",
      "Decreased appetite"
    ],
    "seriousRisks": [
      "Thyroid C-cell tumour (rodent data â€” black box warning)",
      "Pancreatitis",
      "Diabetic retinopathy worsening",
      "Severe hypoglycaemia (with SU/insulin)"
    ],
    "renalAdj": "No â€” standard dosing; no dose adjustment required",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category X â€” discontinue 2 months before planned pregnancy",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "Insulin/sulfonylureas â€” increased hypoglycaemia risk",
      "Oral medications (bioavailability) â€” semaglutide slows gastric emptying",
      "Warfarin â€” monitor INR"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Body weight",
      "Thyroid (symptom check)",
      "Pancreatic enzymes (if pain)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2.4 mg/week (obesity); 1 mg/week (diabetes â€” subcutaneous); 14 mg/day (oral semaglutide)",
    "clinicalPearl": "Oral semaglutide must be taken fasting with 120 mL plain water â€” 30 minutes before food."
  },
  {
    "rank": 49,
    "name": "B-Complex + Vitamin C",
    "section": "Section 1: Foundational Molecules",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Becosules / Polybion",
    "formation": "Water-soluble vitamin combination",
    "uses": "Vitamin deficiency, post-viral recovery",
    "adult": "1 capsule OD",
    "child": "2.5â€“5 ml OD (syrup form)",
    "avoid": "Megaloblastic anemia (with uncorrected B12)",
    "sideEffects": [
      "Nausea (large doses)",
      "Yellow discolouration of urine (B2)",
      "GI upset",
      "Skin flushing (B3, niacin)",
      "Headache"
    ],
    "seriousRisks": [
      "Hypersensitivity reactions (rare)",
      "Peripheral neuropathy (B6 excess)",
      "Masking B12 deficiency (folic acid)"
    ],
    "renalAdj": "No â€” standard dosing; water-soluble vitamins not significantly renally accumulated",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe and recommended",
    "lactation": "Safe â€” nutritional supplement; recommended in lactating women",
    "drugInteractions": [
      "Levodopa â€” B6 reduces levodopa efficacy (avoid high-dose B6 without carbidopa)",
      "Isoniazid â€” depletes B6 (supplement required)",
      "Metformin â€” depletes B12 (supplement recommended)"
    ],
    "monitoring": [
      "Nutritional status",
      "Neurological symptoms (B12 deficiency)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "As per RDA recommendations; no specific cap for combination supplements",
    "clinicalPearl": "B12 must be checked separately â€” B-complex supplements may not contain adequate B12."
  },
  {
    "rank": 50,
    "name": "Omeprazole",
    "section": "Section 1: Foundational Molecules",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Omez / Ocid / Prilosec",
    "formation": "Substituted benzimidazole (PPI)",
    "uses": "GERD, gastric ulcers, Zollinger-Ellison syndrome",
    "adult": "20â€“40 mg OD (30 mins before breakfast)",
    "child": "0.7â€“3 mg/kg/day",
    "avoid": "Concomitant use with nelfinavir",
    "sideEffects": [
      "Headache",
      "Diarrhoea",
      "Nausea",
      "Flatulence",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "Hypomagnesaemia",
      "C. difficile colitis",
      "Bone fracture risk (prolonged)",
      "Fundic gland polyps",
      "Subacute cutaneous lupus (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment; max 20 mg/day",
    "pregnancy": "Category C â€” use only if clearly needed",
    "lactation": "Caution â€” excreted in breast milk; short-term use if essential",
    "drugInteractions": [
      "Clopidogrel â€” reduced antiplatelet effect (omeprazole strongest CYP2C19 inhibitor â€” avoid)",
      "Atazanavir â€” decreased absorption, avoid",
      "Methotrexate â€” increased toxicity"
    ],
    "monitoring": [
      "Serum magnesium (long-term)",
      "Bone density (prolonged)",
      "Symptom relief"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 mg/day",
    "clinicalPearl": "Omeprazole has highest CYP2C19 inhibition among PPIs â€” avoid with clopidogrel; use rabeprazole/pantoprazole."
  },
  {
    "rank": 51,
    "name": "Losartan Potassium",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Losar / Cozaar / Losartan",
    "formation": "Biphenyl tetrazole derivative (ARB)",
    "uses": "Hypertension, diabetic nephropathy",
    "adult": "25â€“100 mg OD or BID",
    "child": "0.7 mg/kg initial (max 50 mg OD)",
    "avoid": "Pregnancy, severe hepatic impairment",
    "sideEffects": [
      "Dizziness",
      "Hyperkalemia",
      "Headache",
      "Back pain",
      "Upper respiratory infection"
    ],
    "seriousRisks": [
      "Angioedema (rare)",
      "Severe hyperkalemia",
      "Acute kidney injury",
      "Fetal toxicity (2nd/3rd trimester)"
    ],
    "renalAdj": "Yes â€” reduce dose in significant renal impairment; monitor closely",
    "hepaticAdj": "Yes â€” reduce initial dose in hepatic impairment; active metabolite E3174 responsible for effect",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester)",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Potassium-sparing diuretics/supplements â€” hyperkalemia",
      "NSAIDs â€” reduced effect and renal risk",
      "Lithium â€” increased lithium levels"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg/day",
    "clinicalPearl": "Losartan is the only ARB with uricosuric property â€” preferred in hypertension with gout."
  },
  {
    "rank": 52,
    "name": "Metoprolol Succinate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Metolar XL / Lopressor / Metpure XL",
    "formation": "Selective beta1-blocker (Extended-release)",
    "uses": "Hypertension, chronic heart failure, angina",
    "adult": "25â€“100 mg OD",
    "child": "1â€“2 mg/kg OD (Consult cardiology)",
    "avoid": "Severe bradycardia, second/third-degree AV block",
    "sideEffects": [
      "Fatigue",
      "Bradycardia",
      "Dizziness",
      "Cold extremities",
      "Headache"
    ],
    "seriousRisks": [
      "AV block",
      "Acute heart failure exacerbation",
      "Severe bradycardia",
      "Bronchospasm (rarely at high doses)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment; extensive hepatic metabolism",
    "pregnancy": "Category C â€” use with caution; may cause fetal bradycardia and IUGR",
    "lactation": "Caution â€” present in breast milk; monitor infant HR",
    "drugInteractions": [
      "Verapamil/diltiazem â€” severe bradycardia/AV block (avoid IV combination)",
      "Clonidine â€” rebound hypertension if clonidine stopped first",
      "Adrenaline â€” antagonism; possible hypertensive crisis"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG",
      "Signs of heart failure"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg/day",
    "clinicalPearl": "Succinate (CR) formulation preferred over tartrate in heart failure â€” once-daily dosing improves compliance."
  },
  {
    "rank": 53,
    "name": "Ramipril",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Cardace / Ramace / Altace",
    "formation": "ACE inhibitor (Pro-drug)",
    "uses": "Hypertension, heart failure post-MI",
    "adult": "2.5â€“10 mg OD",
    "child": "Not recommended",
    "avoid": "History of angioedema, pregnancy",
    "sideEffects": [
      "Dry cough",
      "Dizziness",
      "Hypotension",
      "Hyperkalemia",
      "Headache"
    ],
    "seriousRisks": [
      "Angioedema (1st dose or delayed)",
      "Severe hyperkalemia",
      "Acute renal failure (bilateral RAS)",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” reduce dose; start with 1.25 mg in significant renal impairment; avoid if eGFR <10",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment; ramiprilat accumulation",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester); 1st trimester Category C",
    "lactation": "Avoid â€” limited data",
    "drugInteractions": [
      "NSAIDs â€” reduced antihypertensive effect and renal risk",
      "Potassium-sparing diuretics â€” hyperkalemia",
      "Aliskiren â€” contraindicated in diabetes/renal impairment"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function",
      "Cough"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "10 mg/day",
    "clinicalPearl": "HOPE trial established ramipril for cardiovascular protection in high-risk patients beyond BP control."
  },
  {
    "rank": 54,
    "name": "Olmesartan Medoxomil",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Olsar / Olmy / Benicar",
    "formation": "Angiotensin II receptor antagonist",
    "uses": "Hypertension management",
    "adult": "20â€“40 mg OD",
    "child": "Not recommended",
    "avoid": "Biliary obstruction, severe renal failure",
    "sideEffects": [
      "Dizziness",
      "Hyperkalemia",
      "Headache",
      "Diarrhoea",
      "Back pain"
    ],
    "seriousRisks": [
      "Angioedema (rare)",
      "Severe hyperkalemia",
      "Acute kidney injury",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” no initial dose adjustment needed but monitor closely; reduce dose in severe impairment",
    "hepaticAdj": "Yes â€” use with caution; dosage adjustment in severe hepatic impairment",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester)",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Potassium-sparing diuretics â€” hyperkalemia",
      "NSAIDs â€” reduced antihypertensive effect",
      "Lithium â€” increased lithium toxicity"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function (creatinine/eGFR)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day",
    "clinicalPearl": "Olmesartan associated with sprue-like enteropathy (severe diarrhoea) on long-term use â€” often underdiagnosed."
  },
  {
    "rank": 55,
    "name": "Bisoprolol Fumarate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Concor / Biselect / Bisocor",
    "formation": "Beta1-selective adrenoceptor blocker",
    "uses": "Hypertension, stable chronic heart failure",
    "adult": "2.5â€“10 mg OD",
    "child": "Not recommended",
    "avoid": "Acute heart failure, bronchospastic diseases",
    "sideEffects": [
      "Fatigue",
      "Bradycardia",
      "Dizziness",
      "Cold extremities",
      "Headache"
    ],
    "seriousRisks": [
      "AV block",
      "Acute heart failure decompensation",
      "Severe bradycardia",
      "Bronchospasm (rare)"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <20 mL/min; metabolite accumulates",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” may cause fetal bradycardia/IUGR",
    "lactation": "Caution â€” present in breast milk; monitor infant",
    "drugInteractions": [
      "Verapamil/diltiazem â€” severe bradycardia/AV block",
      "Clonidine â€” rebound hypertension risk",
      "Antiarrhythmics â€” additive bradycardia"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG",
      "Signs of heart failure"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "20 mg/day",
    "clinicalPearl": "Highly selective beta-1 blocker â€” safest option in COPD patients requiring beta-blockade."
  },
  {
    "rank": 56,
    "name": "Furosemide",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Lasix / Frusemide",
    "formation": "Anthranilic acid derivative (Loop diuretic)",
    "uses": "Edema in CHF, renal disease, liver cirrhosis",
    "adult": "20â€“80 mg OD or BID",
    "child": "1â€“2 mg/kg per dose (max 6 mg/kg)",
    "avoid": "Anuria, hepatic coma, severe dehydration",
    "sideEffects": [
      "Hypokalaemia",
      "Dehydration/volume depletion",
      "Hyponatraemia",
      "Elevated creatinine",
      "Ototoxicity (high doses)"
    ],
    "seriousRisks": [
      "Severe electrolyte imbalance",
      "Ototoxicity (especially IV rapid infusion)",
      "Hyperuricaemia/gout",
      "Acute kidney injury"
    ],
    "renalAdj": "Yes â€” higher doses required in renal impairment for diuretic effect; can use up to 80â€“120 mg/day or more",
    "hepaticAdj": "Yes â€” use with caution; risk of electrolyte imbalance precipitating hepatic encephalopathy",
    "pregnancy": "Category C â€” use only if clearly needed; may cause fetal electrolyte disturbances",
    "lactation": "Caution â€” excreted in breast milk; may suppress lactation",
    "drugInteractions": [
      "Aminoglycosides â€” additive ototoxicity",
      "NSAIDs â€” reduced diuretic efficacy",
      "Digoxin â€” hypokalaemia potentiates digoxin toxicity"
    ],
    "monitoring": [
      "Serum electrolytes (K+, Na+)",
      "Renal function",
      "Fluid balance/weight",
      "BP",
      "Uric acid"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "600 mg/day",
    "clinicalPearl": "Infuse IV furosemide at â‰¤4 mg/min to prevent ototoxicity; supplement potassium in long-term therapy."
  },
  {
    "rank": 57,
    "name": "Spironolactone",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Aldactone / Spiromide",
    "formation": "Synthetic steroid (Aldosterone antagonist)",
    "uses": "Edema, primary hyperaldosteronism, CHF",
    "adult": "25â€“100 mg daily",
    "child": "1â€“3.3 mg/kg/day",
    "avoid": "Hyperkalemia, Addison's disease, acute renal failure",
    "sideEffects": [
      "Hyperkalaemia",
      "Gynaecomastia (men)",
      "Menstrual irregularities (women)",
      "Dizziness",
      "GI upset"
    ],
    "seriousRisks": [
      "Severe hyperkalaemia (life-threatening)",
      "Addisonian crisis (if adrenal insufficiency)",
      "Agranulocytosis (very rare)"
    ],
    "renalAdj": "Yes â€” contraindicated in significant renal impairment (eGFR <30); risk of fatal hyperkalaemia",
    "hepaticAdj": "Yes â€” dose adjustment in severe hepatic disease; used therapeutically in ascites",
    "pregnancy": "Category D â€” anti-androgenic effects on male fetus",
    "lactation": "Caution â€” metabolite canrenone present in breast milk",
    "drugInteractions": [
      "ACE inhibitors/ARBs â€” severe hyperkalaemia risk",
      "NSAIDs â€” reduced diuretic efficacy and increased hyperkalaemia",
      "Digoxin â€” spironolactone increases digoxin levels"
    ],
    "monitoring": [
      "Serum potassium",
      "Renal function",
      "BP",
      "Serum sodium"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg/day (primary hyperaldosteronism); 50 mg/day (heart failure)",
    "clinicalPearl": "RALES trial established 25â€“50 mg/day in heart failure; potassium monitoring mandatory."
  },
  {
    "rank": 58,
    "name": "Atorvastatin + Clopidogrel",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Deplatt-A / Atorva-CV",
    "formation": "Statin + P2Y12 inhibitor",
    "uses": "Secondary prevention of ischemic events",
    "adult": "10/75 mg or 20/75 mg OD",
    "child": "Not recommended",
    "avoid": "Active GI bleed, severe liver disease",
    "sideEffects": [
      "Myalgia",
      "GI upset",
      "Bleeding/bruising",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Rhabdomyolysis (atorvastatin)",
      "Major bleeding (clopidogrel)",
      "Hepatotoxicity",
      "TTP (clopidogrel, rare)"
    ],
    "renalAdj": "Yes â€” atorvastatin reduce dose in severe impairment; clopidogrel use with caution",
    "hepaticAdj": "Yes â€” atorvastatin contraindicated in active liver disease; clopidogrel caution in impairment",
    "pregnancy": "Category X â€” contraindicated (atorvastatin); Category B (clopidogrel) â€” avoid combination",
    "lactation": "Avoid â€” both components not recommended",
    "drugInteractions": [
      "Omeprazole/esomeprazole â€” reduce clopidogrel effect via CYP2C19",
      "CYP3A4 inhibitors â€” increase atorvastatin levels",
      "Warfarin â€” additive bleeding risk"
    ],
    "monitoring": [
      "Lipid profile",
      "LFT",
      "CK",
      "CBC",
      "Signs of bleeding"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Atorvastatin 80 mg + Clopidogrel 75 mg per day",
    "clinicalPearl": "Post-ACS combination; use rabeprazole/pantoprazole over omeprazole to preserve clopidogrel activity."
  },
  {
    "rank": 59,
    "name": "Rosuvastatin + Fenofibrate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Rosufeno / Rosuvas-F",
    "formation": "Statin + fibric acid derivative",
    "uses": "Mixed dyslipidemia (elevated LDL and TG)",
    "adult": "10 mg/160 mg OD",
    "child": "Not recommended",
    "avoid": "Severe renal impairment, gallbladder disease",
    "sideEffects": [
      "Myalgia",
      "GI upset",
      "Elevated liver enzymes",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Rhabdomyolysis",
      "Severe myopathy",
      "Hepatotoxicity",
      "Gallstones (fenofibrate)"
    ],
    "renalAdj": "Yes â€” rosuvastatin max 10 mg in eGFR <30; fenofibrate avoid in severe renal impairment",
    "hepaticAdj": "Yes â€” both agents contraindicated in active liver disease",
    "pregnancy": "Category X â€” contraindicated",
    "lactation": "Avoid â€” both components not recommended",
    "drugInteractions": [
      "Gemfibrozil â€” avoid (myopathy risk); fenofibrate safer",
      "Cyclosporine â€” increased rosuvastatin/fenofibrate levels",
      "Warfarin â€” fenofibrate enhances anticoagulant effect"
    ],
    "monitoring": [
      "Lipid profile (LDL + TG)",
      "LFT",
      "CK",
      "Renal function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Rosuvastatin 40 mg + Fenofibrate 160 mg per day",
    "clinicalPearl": "Fenofibrate + statin safer than gemfibrozil + statin for combined dyslipidaemia management."
  },
  {
    "rank": 60,
    "name": "Sacubitril + Valsartan",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Vymada / Entresto",
    "formation": "Neprilysin inhibitor + ARB (Crystal complex)",
    "uses": "Chronic heart failure (NYHA Class II-IV)",
    "adult": "50â€“200 mg BID (Individualized)",
    "child": "Consult specialist (Weight-based)",
    "avoid": "Concomitant ACE inhibitor use, history of angioedema",
    "sideEffects": [
      "Hypotension",
      "Hyperkalemia",
      "Dizziness",
      "Elevated creatinine",
      "Headache"
    ],
    "seriousRisks": [
      "Severe hypotension (first dose)",
      "Severe hyperkalemia",
      "Angioedema (valsartan component)",
      "Acute kidney injury"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30; use with caution if eGFR 30â€“60; reduce dose",
    "hepaticAdj": "Yes â€” dose reduction in moderate-severe hepatic impairment",
    "pregnancy": "Category D â€” contraindicated",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "ACE inhibitors â€” absolutely contraindicated (dual RAAS blockade risk)",
      "NSAIDs â€” reduced efficacy and renal risk",
      "Potassium-sparing diuretics â€” severe hyperkalemia"
    ],
    "monitoring": [
      "BP (especially first dose)",
      "Serum potassium",
      "Renal function",
      "BNP/NT-proBNP"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Sacubitril 194 mg + Valsartan 206 mg twice daily (total sacubitril/valsartan 400/412 mg/day)",
    "clinicalPearl": "36-hour washout required after ACE inhibitor before starting â€” prevents severe angioedema."
  },
  {
    "rank": 61,
    "name": "Chlorthalidone",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Hygroton / Thalitone",
    "formation": "Monosulfonamyl diuretic",
    "uses": "Hypertension, edema",
    "adult": "12.5â€“25 mg OD",
    "child": "2 mg/kg 3 times/week",
    "avoid": "Anuria, hypersensitivity to sulfonamides",
    "sideEffects": [
      "Hypokalaemia",
      "Hyperuricaemia",
      "Hyponatraemia",
      "Dizziness",
      "Fatigue"
    ],
    "seriousRisks": [
      "Severe electrolyte imbalance",
      "Gout precipitation",
      "Hyperglycaemia",
      "Hyponatraemia (SIADH-like)"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30 (ineffective); use with caution in mild-moderate impairment",
    "hepaticAdj": "Yes â€” use with caution; electrolyte imbalance risk in cirrhosis",
    "pregnancy": "Category B â€” avoid; may cause neonatal electrolyte disturbance",
    "lactation": "Caution â€” may suppress lactation; present in breast milk",
    "drugInteractions": [
      "Digoxin â€” hypokalaemia potentiates toxicity",
      "NSAIDs â€” reduced diuretic efficacy",
      "Lithium â€” reduced clearance, toxicity"
    ],
    "monitoring": [
      "Serum electrolytes",
      "Renal function",
      "BP",
      "Uric acid",
      "Blood glucose"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "50 mg/day",
    "clinicalPearl": "Long-acting diuretic â€” preferred over HCTZ in hypertension for 24-hour BP control."
  },
  {
    "rank": 62,
    "name": "Nebivolol",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Nebicard / Bystolic / Nebitop",
    "formation": "Beta1-selective blocker with vasodilatory effects",
    "uses": "Hypertension, chronic heart failure",
    "adult": "5 mg OD",
    "child": "Not recommended",
    "avoid": "Liver impairment, severe circulatory disorders",
    "sideEffects": [
      "Headache",
      "Dizziness",
      "Bradycardia",
      "Fatigue",
      "Peripheral oedema"
    ],
    "seriousRisks": [
      "Severe bradycardia",
      "AV block",
      "Hepatotoxicity (rare)",
      "Bronchospasm (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” present in breast milk; monitor infant",
    "drugInteractions": [
      "Verapamil/diltiazem â€” severe bradycardia",
      "CYP2D6 inhibitors (fluoxetine) â€” increased nebivolol levels",
      "Clonidine â€” rebound hypertension if clonidine discontinued first"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG",
      "LFT (if symptomatic)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Vasodilating beta-blocker (NO-mediated) â€” causes less peripheral vasoconstriction than older beta-blockers."
  },
  {
    "rank": 63,
    "name": "Atenolol",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Aten / Tenormin / Betacard",
    "formation": "Synthetic beta1-selective blocker",
    "uses": "Hypertension, angina pectoris, arrhythmias",
    "adult": "25â€“100 mg OD",
    "child": "0.5â€“1 mg/kg/dose BID",
    "avoid": "Sinus bradycardia, pulmonary hypertension",
    "sideEffects": [
      "Fatigue",
      "Bradycardia",
      "Cold extremities",
      "Dizziness",
      "Headache"
    ],
    "seriousRisks": [
      "Severe bradycardia",
      "AV block",
      "Acute heart failure",
      "Bronchospasm",
      "Peripheral arterial insufficiency worsening"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; atenolol renally excreted",
    "hepaticAdj": "No â€” standard dosing (renally cleared)",
    "pregnancy": "Category D â€” associated with IUGR and neonatal bradycardia; avoid if possible",
    "lactation": "Caution â€” excreted in breast milk; monitor infant HR",
    "drugInteractions": [
      "Verapamil/diltiazem â€” severe bradycardia and heart failure",
      "Clonidine â€” rebound hypertension",
      "NSAIDs â€” reduced antihypertensive efficacy"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG",
      "Signs of heart failure"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "200 mg/day",
    "clinicalPearl": "Hydrophilic beta-blocker â€” less CNS side effects; once-daily dosing due to long half-life."
  },
  {
    "rank": 64,
    "name": "Nifedipine (SR)",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Adalat Retard / Depin-E",
    "formation": "Dihydropyridine calcium channel blocker",
    "uses": "Angina, hypertension, preterm labor (off-label)",
    "adult": "30â€“60 mg OD (Extended-release)",
    "child": "0.25â€“0.5 mg/kg/dose",
    "avoid": "Cardiogenic shock, recent MI",
    "sideEffects": [
      "Flushing",
      "Headache",
      "Peripheral oedema",
      "Palpitations",
      "Dizziness"
    ],
    "seriousRisks": [
      "Reflex tachycardia",
      "Severe hypotension",
      "Myocardial ischaemia (rapid release formulations)",
      "Gingival hyperplasia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid in 1st trimester; oral SR used in hypertension in pregnancy as second-line",
    "lactation": "Caution â€” excreted in breast milk; limited data",
    "drugInteractions": [
      "Beta-blockers â€” additive hypotension; combination can cause reflex tachycardia control",
      "Grapefruit juice â€” increased nifedipine levels",
      "Rifampicin â€” reduced nifedipine levels"
    ],
    "monitoring": [
      "BP",
      "HR",
      "Ankle oedema"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "120 mg/day (SR formulation)",
    "clinicalPearl": "SR formulation avoids peak-trough fluctuations; immediate-release avoided (reflex tachycardia, MI risk)."
  },
  {
    "rank": 65,
    "name": "Valsartan",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Valzaar / Diovan",
    "formation": "Non-peptide tetrazole derivative (ARB)",
    "uses": "Hypertension, heart failure, post-MI",
    "adult": "80â€“160 mg OD",
    "child": "1.3 mg/kg OD (max 40 mg)",
    "avoid": "Pregnancy, concomitant use with Aliskiren",
    "sideEffects": [
      "Dizziness",
      "Headache",
      "Fatigue",
      "Hyperkalemia",
      "Nasopharyngitis"
    ],
    "seriousRisks": [
      "Angioedema (rare)",
      "Severe hyperkalemia",
      "Acute kidney injury",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; monitor potassium and creatinine",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic disease",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester)",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Potassium-sparing diuretics â€” hyperkalemia",
      "NSAIDs â€” reduced efficacy and renal risk",
      "Lithium â€” increased lithium toxicity"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "320 mg/day",
    "clinicalPearl": "Can be used in ACE inhibitor-intolerant patients (no ACE inhibitor cough); safe in heart failure."
  },
  {
    "rank": 66,
    "name": "Carvedilol",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "C-Vadin / Coreg / Carca",
    "formation": "Non-selective beta and alpha-1 blocker",
    "uses": "Congestive heart failure, post-MI",
    "adult": "3.125â€“25 mg BID",
    "child": "0.05â€“0.4 mg/kg BID",
    "avoid": "Bronchial asthma, severe hepatic failure",
    "sideEffects": [
      "Dizziness",
      "Fatigue",
      "Bradycardia",
      "Hypotension",
      "Weight gain"
    ],
    "seriousRisks": [
      "Severe bradycardia/AV block",
      "Acute heart failure exacerbation",
      "Bronchospasm",
      "Severe hypotension"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose significantly in hepatic impairment; extensively metabolised",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” present in breast milk",
    "drugInteractions": [
      "Verapamil/diltiazem â€” severe bradycardia and AV block (avoid IV)",
      "CYP2D6 inhibitors â€” increased carvedilol levels",
      "Clonidine â€” rebound hypertension risk"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG",
      "Signs of heart failure",
      "Blood glucose"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg/day (hypertension); 50 mg/day (heart failure)",
    "clinicalPearl": "Take with food to reduce orthostatic hypotension; antioxidant properties additional to beta-blockade."
  },
  {
    "rank": 67,
    "name": "Hydrochlorothiazide",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Esidrex / Aquazide",
    "formation": "Benzothiadiazine (Thiazide diuretic)",
    "uses": "Hypertension, edema",
    "adult": "12.5â€“25 mg OD",
    "child": "1â€“2 mg/kg/day",
    "avoid": "Sulfa allergy, anuria",
    "sideEffects": [
      "Hypokalaemia",
      "Hyponatraemia",
      "Hyperuricaemia",
      "Hyperglycaemia",
      "Dizziness"
    ],
    "seriousRisks": [
      "Severe electrolyte imbalance",
      "Gout",
      "Hyperglycaemia in diabetes",
      "Dyslipidaemia"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30 (ineffective and increases uraemia)",
    "hepaticAdj": "Yes â€” caution in cirrhosis; electrolyte disturbance can precipitate hepatic encephalopathy",
    "pregnancy": "Category B â€” use with caution; may cause neonatal electrolyte disturbance",
    "lactation": "Caution â€” excreted in breast milk; may suppress lactation",
    "drugInteractions": [
      "Digoxin â€” hypokalaemia potentiates toxicity",
      "NSAIDs â€” reduced diuretic efficacy",
      "Lithium â€” reduced excretion, toxicity"
    ],
    "monitoring": [
      "Serum electrolytes",
      "Renal function",
      "BP",
      "Uric acid",
      "Blood glucose"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "200 mg/day",
    "clinicalPearl": "Low-dose HCTZ (12.5 mg/day) for hypertension minimises metabolic side effects."
  },
  {
    "rank": 68,
    "name": "Clonidine HCl",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Arkamin / Catapres",
    "formation": "Imidazoline derivative (Alpha-2 agonist)",
    "uses": "Hypertension, ADHD (extended-release), pain",
    "adult": "0.1 mg BID (titrate based on response)",
    "child": "0.05â€“0.4 mg/day (ADHD use)",
    "avoid": "Severe bradyarrhythmia",
    "sideEffects": [
      "Dry mouth",
      "Sedation/drowsiness",
      "Dizziness",
      "Constipation",
      "Bradycardia"
    ],
    "seriousRisks": [
      "Rebound hypertension (abrupt withdrawal)",
      "Severe bradycardia",
      "AV block",
      "Hypotension"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; renally excreted",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” used in hypertension in pregnancy (second-line); monitor neonatal BP",
    "lactation": "Caution â€” excreted in breast milk; sedation risk in infant",
    "drugInteractions": [
      "Beta-blockers â€” additive bradycardia and AV block; rebound hypertension if clonidine stopped first",
      "TCAs â€” reduce clonidine antihypertensive effect",
      "CNS depressants â€” additive sedation"
    ],
    "monitoring": [
      "BP",
      "HR",
      "ECG",
      "Sedation level"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2.4 mg/day",
    "clinicalPearl": "Never stop abruptly â€” taper over 2â€“4 days to avoid rebound hypertensive crisis."
  },
  {
    "rank": 69,
    "name": "Enoxaparin Sodium",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "C",
    "brand": "Clexane / Lovenox",
    "formation": "Low molecular weight heparin (LMWH)",
    "uses": "DVT prophylaxis, unstable angina, MI",
    "adult": "40 mg SC OD or 1 mg/kg SC BID",
    "child": "1 mg/kg SC BID",
    "avoid": "Major active bleeding, heparin-induced thrombocytopenia",
    "sideEffects": [
      "Injection site haematoma",
      "Bleeding",
      "Elevated liver enzymes",
      "Thrombocytopenia (HIT)",
      "Pain at injection site"
    ],
    "seriousRisks": [
      "Heparin-induced thrombocytopenia (HIT)",
      "Major bleeding",
      "Spinal/epidural haematoma (neuraxial anaesthesia)",
      "Hyperkalaemia"
    ],
    "renalAdj": "Yes â€” reduce dose in CrCl <30; anti-Xa monitoring required; use UFH instead in severe impairment",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment (bleeding risk)",
    "pregnancy": "Category B â€” LMWH is preferred anticoagulant in pregnancy (does not cross placenta)",
    "lactation": "Safe â€” does not pass into breast milk significantly",
    "drugInteractions": [
      "Warfarin â€” additive anticoagulation (during bridging)",
      "Antiplatelet agents â€” additive bleeding risk",
      "NSAIDs â€” additive bleeding risk"
    ],
    "monitoring": [
      "Anti-Xa levels (therapeutic monitoring in renal impairment/extremes of weight)",
      "Platelet count (HIT)",
      "Haemoglobin/bleeding signs"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1.5 mg/kg/day (prophylaxis 40 mg/day; treatment 1 mg/kg twice daily)",
    "clinicalPearl": "Anti-Xa monitoring preferred over aPTT for LMWH; target 0.5â€“1.0 IU/mL for treatment dosing."
  },
  {
    "rank": 70,
    "name": "Rivaroxaban",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Xarelto / Relvus",
    "formation": "Factor Xa inhibitor",
    "uses": "Stroke prevention in AF, treatment of DVT/PE",
    "adult": "10â€“20 mg OD",
    "child": "Weight-adjusted (Consult pediatric hematology)",
    "avoid": "Active bleeding, severe renal/hepatic impairment",
    "sideEffects": [
      "Bleeding",
      "Bruising",
      "Anaemia",
      "Dizziness",
      "Nausea"
    ],
    "seriousRisks": [
      "Major bleeding (GI, intracranial)",
      "Spinal haematoma (neuraxial procedures)",
      "Wound complications post-surgery"
    ],
    "renalAdj": "Yes â€” contraindicated if CrCl <15; reduce dose for AF if CrCl 15â€“50 (15 mg/day with evening meal)",
    "hepaticAdj": "Yes â€” avoid in significant hepatic disease (Child-Pugh B/C) â€” coagulopathy risk",
    "pregnancy": "Category C â€” avoid; warfarin or LMWH preferred",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "CYP3A4 inhibitors (azoles, ritonavir) â€” increased rivaroxaban levels",
      "P-glycoprotein inhibitors â€” increased levels",
      "NSAIDs â€” additive bleeding risk"
    ],
    "monitoring": [
      "Renal function (at least annually)",
      "Signs of bleeding",
      "Haemoglobin"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "20 mg/day with evening meal (AF/VTE treatment)",
    "clinicalPearl": "Take with main meal â€” improves absorption; no routine INR monitoring required."
  },
  {
    "rank": 71,
    "name": "Apixaban",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Eliquis",
    "formation": "Selective Factor Xa inhibitor",
    "uses": "Prophylaxis of stroke and systemic embolism in AF",
    "adult": "2.5â€“5 mg BID",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment, significant bleeding risk",
    "sideEffects": [
      "Bleeding",
      "Bruising",
      "Nausea",
      "Anaemia",
      "Dizziness"
    ],
    "seriousRisks": [
      "Major bleeding (intracranial, GI)",
      "Spinal haematoma",
      "Thrombocytopenia (rare)"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <25 mL/min; reduce to 2.5 mg BD if 2 of 3 criteria met (age â‰¥80, weight â‰¤60 kg, creatinine â‰¥1.5 mg/dL)",
    "hepaticAdj": "Yes â€” avoid in significant hepatic disease",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "CYP3A4/P-gp inhibitors â€” increased apixaban levels",
      "CYP3A4 inducers (rifampicin, phenytoin) â€” reduced apixaban levels",
      "NSAIDs/antiplatelets â€” additive bleeding risk"
    ],
    "monitoring": [
      "Renal function",
      "Signs of bleeding",
      "Haemoglobin",
      "CBC"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "10 mg BD Ã— 7 days then 5 mg BD (VTE); 5 mg BD (AF)",
    "clinicalPearl": "Apixaban has lowest GI bleeding risk among DOACs â€” preferred in patients with GI bleed history."
  },
  {
    "rank": 72,
    "name": "Dabigatran Etexilate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Pradaxa",
    "formation": "Direct thrombin inhibitor",
    "uses": "AF stroke prevention, post-orthopedic DVT prophylaxis",
    "adult": "110â€“150 mg BID",
    "child": "Weight-based pellets (Consult specialist)",
    "avoid": "Mechanical prosthetic heart valve, active bleeding",
    "sideEffects": [
      "GI upset (dyspepsia)",
      "Bleeding",
      "Nausea",
      "Abdominal pain",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "Major GI bleeding (highest among DOACs)",
      "Intracranial haemorrhage",
      "Hepatotoxicity (rare)",
      "Myocardial infarction risk (marginal)"
    ],
    "renalAdj": "Yes â€” contraindicated if CrCl <30; reduce dose to 110 mg BD if CrCl 30â€“50 or age â‰¥75",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment (transaminase >2x ULN)",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "P-gp inhibitors (amiodarone, verapamil) â€” increased dabigatran levels",
      "P-gp inducers (rifampicin) â€” reduced levels",
      "NSAIDs â€” additive bleeding"
    ],
    "monitoring": [
      "Renal function (every 3â€“6 months)",
      "CBC",
      "Signs of bleeding",
      "ECG"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "300 mg/day (150 mg BD) for AF; 220 mg/day for VTE prophylaxis",
    "clinicalPearl": "Store in original blister pack â€” moisture degrades drug rapidly; take with/without food but avoid antacids."
  },
  {
    "rank": 73,
    "name": "Aspirin (Enteric Coated)",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "OTC",
    "brand": "Ecosprin / Aspirin / Disprin",
    "formation": "Salicylic acid derivative",
    "uses": "ACS prevention, analgesic, anti-inflammatory",
    "adult": "75â€“150 mg OD (Antiplatelet)",
    "child": "10â€“15 mg/kg (Analgesic)",
    "avoid": "Viral infection in kids (Reyeâ€™s), GI ulcer",
    "sideEffects": [
      "GI upset/nausea",
      "GI bleeding (minor)",
      "Tinnitus (high doses)",
      "Dyspepsia",
      "Heartburn"
    ],
    "seriousRisks": [
      "GI bleeding/ulceration",
      "Reye's syndrome (children with viral illness)",
      "Bronchoconstriction (aspirin-sensitive asthma)",
      "Haemorrhagic stroke"
    ],
    "renalAdj": "Yes â€” use with caution; avoid in severe renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic disease",
    "pregnancy": "Category D (3rd trimester) â€” avoid; premature ductus closure",
    "lactation": "Caution â€” avoid high doses; low-dose (75â€“100 mg) may be acceptable with monitoring",
    "drugInteractions": [
      "Warfarin â€” additive bleeding risk",
      "NSAIDs â€” additive GI toxicity and bleeding risk",
      "Methotrexate â€” reduced clearance, toxicity"
    ],
    "monitoring": [
      "Signs of bleeding",
      "GI symptoms",
      "Renal function",
      "Platelet function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "325 mg/day (antiplatelet); 4000 mg/day (analgesic â€” not recommended chronically)",
    "clinicalPearl": "Enteric coating reduces GI mucosal contact but does not eliminate systemic GI bleeding risk."
  },
  {
    "rank": 74,
    "name": "Propranolol HCl",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Inderal / Betacap / Ciplar",
    "formation": "Non-selective beta-adrenergic blocker",
    "uses": "Migraine prophylaxis, portal hypertension, anxiety",
    "adult": "20â€“40 mg BID or TID",
    "child": "0.5â€“1 mg/kg/day in divided doses",
    "avoid": "Bronchial asthma, cardiogenic shock",
    "sideEffects": [
      "Bradycardia",
      "Fatigue",
      "Cold extremities",
      "Dizziness",
      "Nightmares/insomnia"
    ],
    "seriousRisks": [
      "Severe bronchospasm",
      "Severe bradycardia/AV block",
      "Acute heart failure",
      "Masking of hypoglycaemia"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” use with caution; may cause neonatal bradycardia/hypoglycaemia",
    "lactation": "Caution â€” present in breast milk",
    "drugInteractions": [
      "Verapamil â€” severe bradycardia/cardiac arrest (avoid IV combination)",
      "Adrenaline â€” severe hypertension (propranolol blocks beta but not alpha response)",
      "Insulin â€” masks hypoglycaemia symptoms"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG",
      "Pulmonary function (COPD/asthma patients)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "640 mg/day (hypertension); 120 mg/day (portal hypertension)",
    "clinicalPearl": "Non-selective beta-blocker of choice for portal hypertension/variceal prophylaxis in cirrhosis."
  },
  {
    "rank": 75,
    "name": "Ezetimibe",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Ezetrol / Ezentia",
    "formation": "Cholesterol absorption inhibitor",
    "uses": "Primary hyperlipidemia (adjunct to statins)",
    "adult": "10 mg OD",
    "child": "10 mg OD (approved for >10y)",
    "avoid": "Moderate-to-severe hepatic impairment",
    "sideEffects": [
      "GI upset",
      "Diarrhoea",
      "Headache",
      "Myalgia (rare)",
      "Fatigue"
    ],
    "seriousRisks": [
      "Myopathy (rare, additive with statins)",
      "Hepatotoxicity (rare)",
      "Cholelithiasis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no safety data",
    "drugInteractions": [
      "Statins â€” additive muscle toxicity (monitor CK)",
      "Bile acid sequestrants â€” reduce ezetimibe absorption (give 2 hours apart)",
      "Cyclosporine â€” increased ezetimibe levels"
    ],
    "monitoring": [
      "Lipid profile",
      "LFT",
      "CK (if on statin combination)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Blocks NPC1L1 transporter in gut; adds 15â€“20% LDL reduction on top of statin therapy."
  },
  {
    "rank": 76,
    "name": "Fenofibrate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Tricor / Lipanthyl / Fenolip",
    "formation": "Fibric acid derivative",
    "uses": "Hypertriglyceridemia, mixed dyslipidemia",
    "adult": "145â€“160 mg OD",
    "child": "Not recommended",
    "avoid": "Severe renal disease, gallbladder disease",
    "sideEffects": [
      "GI upset",
      "Myalgia",
      "Elevated liver enzymes",
      "Headache",
      "Gallstones"
    ],
    "seriousRisks": [
      "Rhabdomyolysis (especially with statins â€” gemfibrozil risk)",
      "Cholelithiasis",
      "Hepatotoxicity",
      "Pulmonary embolism (rare)"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; avoid in severe renal failure",
    "hepaticAdj": "Yes â€” contraindicated in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no safety data",
    "drugInteractions": [
      "Statins (gemfibrozil â€” dangerous; fenofibrate safer) â€” myopathy risk",
      "Warfarin â€” significantly enhanced anticoagulant effect",
      "Cyclosporine â€” reduced cyclosporine levels"
    ],
    "monitoring": [
      "Lipid profile (LDL, TG, HDL)",
      "LFT",
      "CK",
      "Renal function",
      "Gallbladder symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "200 mg/day (micronised 160 mg/day)",
    "clinicalPearl": "Primarily lowers triglycerides and raises HDL â€” combine with statin for mixed dyslipidaemia."
  },
  {
    "rank": 77,
    "name": "Nicorandil",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Nicoril / Ikorel / Nicoloc",
    "formation": "Potassium channel opener + nitrate moiety",
    "uses": "Angina pectoris prophylaxis",
    "adult": "5â€“20 mg BID",
    "child": "Not recommended",
    "avoid": "Cardiogenic shock, severe hypotension",
    "sideEffects": [
      "Headache",
      "Flushing",
      "Palpitations",
      "Dizziness",
      "Hypotension"
    ],
    "seriousRisks": [
      "Severe hypotension (especially at high doses)",
      "Methemoglobinaemia (oral nitroglycerin-like risk)",
      "Reflex tachycardia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; limited data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "PDE5 inhibitors (sildenafil) â€” severe hypotension (contraindicated)",
      "Antihypertensives â€” additive hypotension",
      "Alcohol â€” enhanced hypotension"
    ],
    "monitoring": [
      "BP",
      "Heart rate",
      "Angina symptom relief",
      "ECG"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day",
    "clinicalPearl": "Dual mechanism â€” NO donor (like nitrate) + ATP-sensitive K+ channel opener; no nitrate tolerance."
  },
  {
    "rank": 78,
    "name": "Ivabradine",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Ivabrad / Corlanor / Bradia",
    "formation": "Hyperpolarization-activated cyclic nucleotide-gated inhibitor",
    "uses": "Chronic heart failure (to reduce hospitalizations)",
    "adult": "5â€“7.5 mg BID",
    "child": "Not recommended",
    "avoid": "Bradycardia (HR < 60), pacemaker dependence",
    "sideEffects": [
      "Bradycardia",
      "Phosphenes (visual brightness)",
      "Headache",
      "Dizziness",
      "Atrial fibrillation"
    ],
    "seriousRisks": [
      "Atrial fibrillation (increased risk)",
      "Severe bradycardia",
      "Visual disturbances",
      "Heart block"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in moderate hepatic impairment; contraindicated in severe hepatic impairment",
    "pregnancy": "Category D â€” teratogenic in animals; contraindicated",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "CYP3A4 inhibitors (diltiazem, verapamil, azoles) â€” markedly increased ivabradine levels â€” contraindicated",
      "CYP3A4 inducers â€” reduced ivabradine levels",
      "QT-prolonging drugs â€” additive risk"
    ],
    "monitoring": [
      "HR (maintain â‰¥50 bpm)",
      "ECG (PR, QTc)",
      "AF monitoring"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "15 mg/day (7.5 mg twice daily)",
    "clinicalPearl": "Pure heart rate reducer â€” lowers HR without reducing contractility; use only in sinus rhythm."
  },
  {
    "rank": 79,
    "name": "Digoxin",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Lanoxin / Digoxin",
    "formation": "Cardiac glycoside",
    "uses": "Atrial fibrillation rate control, heart failure",
    "adult": "0.125â€“0.25 mg OD",
    "child": "5â€“10 mcg/kg/day (titrate carefully)",
    "avoid": "Ventricular fibrillation, hypokalemia",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Anorexia",
      "Yellow-green vision disturbance",
      "Bradycardia"
    ],
    "seriousRisks": [
      "Digoxin toxicity (narrow therapeutic index)",
      "Life-threatening arrhythmias (VF/VT)",
      "AV block",
      "Hypokalaemia-induced toxicity"
    ],
    "renalAdj": "Yes â€” dose reduction critical in renal impairment; renally excreted",
    "hepaticAdj": "No â€” minimal hepatic metabolism; standard dosing",
    "pregnancy": "Category C â€” use with close monitoring; crosses placenta",
    "lactation": "Safe â€” compatible; monitor infant",
    "drugInteractions": [
      "Amiodarone â€” increases digoxin levels (halve digoxin dose)",
      "Hypokalaemia-inducing drugs (diuretics) â€” precipitate toxicity",
      "Verapamil/quinidine â€” increase digoxin levels"
    ],
    "monitoring": [
      "Digoxin serum levels (target 0.5â€“0.9 ng/mL)",
      "Serum potassium",
      "Renal function",
      "HR",
      "ECG"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "0.5 mg/day (loading); 0.25 mg/day (maintenance); reduce in elderly/renal impairment",
    "clinicalPearl": "Hypokalaemia is the most common precipitant of digoxin toxicity â€” always maintain K+ >4 mEq/L."
  },
  {
    "rank": 80,
    "name": "Hydralazine",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Nepresol / Apresoline",
    "formation": "Phthalazine derivative (Vasodilator)",
    "uses": "Essential hypertension, hypertensive crisis in pregnancy",
    "adult": "10â€“50 mg TID or QID",
    "child": "0.75 mg/kg/day (Consult specialist)",
    "avoid": "Idiopathic Systemic Lupus Erythematosus",
    "sideEffects": [
      "Reflex tachycardia",
      "Headache",
      "Palpitations",
      "Oedema",
      "Flushing"
    ],
    "seriousRisks": [
      "Drug-induced lupus erythematosus",
      "Peripheral neuropathy",
      "Severe reflex tachycardia",
      "Hypotension"
    ],
    "renalAdj": "Yes â€” reduce frequency in severe renal impairment",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” used in hypertension in pregnancy (IV form for severe hypertension)",
    "lactation": "Safe â€” small amounts in breast milk; acceptable",
    "drugInteractions": [
      "Beta-blockers â€” reduce reflex tachycardia (commonly co-prescribed)",
      "NSAIDs â€” reduced antihypertensive effect",
      "MAO inhibitors â€” additive hypotension"
    ],
    "monitoring": [
      "BP",
      "HR",
      "ANA/anti-dsDNA (lupus screen with long-term use)",
      "CBC"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg/day (oral); IV as per acute hypertension protocol",
    "clinicalPearl": "Drug-induced lupus more likely at doses >200 mg/day and slow acetylators â€” check ANA in long-term use."
  },
  {
    "rank": 81,
    "name": "Diltiazem HCl",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Dilzem / Cardizem / Dilcontin",
    "formation": "Benzothiazepine calcium channel blocker",
    "uses": "Angina, hypertension, AF rate control",
    "adult": "30â€“120 mg TID or 120â€“360 mg OD (SR)",
    "child": "1.5â€“2 mg/kg/day (Consult specialist)",
    "avoid": "Sick sinus syndrome, acute MI with lung congestion",
    "sideEffects": [
      "Bradycardia",
      "Hypotension",
      "Constipation",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Severe bradycardia/AV block",
      "Heart failure exacerbation",
      "Severe hypotension",
      "Toxic megacolon (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment; extensively metabolised",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” excreted in breast milk",
    "drugInteractions": [
      "Beta-blockers â€” complete heart block risk (avoid IV combination)",
      "Digoxin â€” additive bradycardia and AV block",
      "CYP3A4 inhibitors â€” increased diltiazem levels"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG (PR interval)",
      "Signs of heart failure"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "360 mg/day (SR formulation)",
    "clinicalPearl": "Non-dihydropyridine CCB â€” used in rate control of AF and Prinzmetal angina; avoid in HFrEF."
  },
  {
    "rank": 82,
    "name": "Verapamil HCl",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Calaptin / Isoptin / Verapress",
    "formation": "Phenylalkylamine calcium channel blocker",
    "uses": "Supraventricular tachycardia, hypertension, migraine prophy",
    "adult": "40â€“120 mg TID or 120â€“240 mg OD (SR)",
    "child": "4â€“8 mg/kg/day (Consult cardiology)",
    "avoid": "Heart block, severe left ventricular dysfunction",
    "sideEffects": [
      "Constipation",
      "Bradycardia",
      "Hypotension",
      "Dizziness",
      "Flushing"
    ],
    "seriousRisks": [
      "Severe bradycardia/AV block (more than diltiazem)",
      "Heart failure exacerbation",
      "Severe hypotension",
      "Paralytic ileus (overdose)"
    ],
    "renalAdj": "No â€” standard dosing; use caution",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” excreted in breast milk; monitor infant HR",
    "drugInteractions": [
      "Beta-blockers â€” severe bradycardia/AV block (IV combination contraindicated)",
      "Digoxin â€” increased digoxin levels and additive AV block",
      "CYP3A4 inhibitors â€” significantly increased verapamil levels"
    ],
    "monitoring": [
      "HR",
      "BP",
      "ECG (PR interval)",
      "Serum digoxin (if combined)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "480 mg/day",
    "clinicalPearl": "Most negatively chronotropic and inotropic CCB â€” avoid in HFrEF; useful in HOCM."
  },
  {
    "rank": 83,
    "name": "Torsemide",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Dytor / Torasemide / Demadex",
    "formation": "Pyridine-sulfonylurea loop diuretic",
    "uses": "Edema associated with CHF or renal disease",
    "adult": "10â€“20 mg OD",
    "child": "Not recommended",
    "avoid": "Anuria, hypersensitivity to sulfonylureas",
    "sideEffects": [
      "Hypokalaemia",
      "Dehydration",
      "Elevated creatinine",
      "Hyperuricaemia",
      "Headache"
    ],
    "seriousRisks": [
      "Severe electrolyte imbalance",
      "Ototoxicity (high doses)",
      "Acute kidney injury",
      "Gout"
    ],
    "renalAdj": "Yes â€” higher doses needed in renal impairment for diuretic efficacy",
    "hepaticAdj": "Yes â€” caution in cirrhosis; electrolyte imbalance may precipitate encephalopathy",
    "pregnancy": "Category B â€” use only if clearly needed",
    "lactation": "Caution â€” may suppress lactation",
    "drugInteractions": [
      "Aminoglycosides â€” additive ototoxicity",
      "Digoxin â€” hypokalaemia potentiates toxicity",
      "NSAIDs â€” reduced diuretic efficacy"
    ],
    "monitoring": [
      "Serum electrolytes",
      "Renal function",
      "Fluid balance/weight",
      "BP"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "200 mg/day",
    "clinicalPearl": "Better oral bioavailability than furosemide â€” more predictable diuresis; less ototoxic at equivalent doses."
  },
  {
    "rank": 84,
    "name": "Indapamide",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Natrilix / Lorvas",
    "formation": "Non-thiazide chlorobenzamide diuretic",
    "uses": "Essential hypertension",
    "adult": "1.5 mg OD (SR) or 2.5 mg OD",
    "child": "Not recommended",
    "avoid": "Severe renal failure, hepatic encephalopathy",
    "sideEffects": [
      "Hypokalaemia",
      "Hyponatraemia",
      "Headache",
      "Dizziness",
      "GI upset"
    ],
    "seriousRisks": [
      "Severe hyponatraemia (SIADH-like)",
      "Electrolyte imbalance",
      "Hyperuricaemia",
      "Hyperglycaemia"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30 (ineffective)",
    "hepaticAdj": "Yes â€” caution in cirrhosis",
    "pregnancy": "Category B â€” use with caution",
    "lactation": "Caution â€” may suppress lactation",
    "drugInteractions": [
      "Digoxin â€” hypokalaemia increases toxicity risk",
      "Lithium â€” reduced clearance",
      "NSAIDs â€” reduced diuretic effect"
    ],
    "monitoring": [
      "Serum electrolytes",
      "Renal function",
      "BP",
      "Uric acid"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "5 mg/day",
    "clinicalPearl": "Better antihypertensive than HCTZ at equipotent diuretic doses; sustained 24-hour BP control."
  },
  {
    "rank": 85,
    "name": "Perindopril Erbumine",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Coversyl / Acertil / Prexum",
    "formation": "ACE inhibitor (Long-acting)",
    "uses": "Hypertension, coronary artery disease",
    "adult": "4â€“8 mg OD",
    "child": "Not recommended",
    "avoid": "Bilateral renal artery stenosis, pregnancy",
    "sideEffects": [
      "Dry cough",
      "Dizziness",
      "Headache",
      "Hyperkalemia",
      "Hypotension"
    ],
    "seriousRisks": [
      "Angioedema",
      "Severe hyperkalemia",
      "Acute renal failure (bilateral RAS)",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; renally excreted active form",
    "hepaticAdj": "No â€” standard dosing (prodrug converted to perindoprilat extrahepatically)",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester)",
    "lactation": "Avoid â€” limited data",
    "drugInteractions": [
      "NSAIDs â€” reduced antihypertensive effect and AKI risk",
      "Potassium supplements/sparing diuretics â€” hyperkalemia",
      "Aliskiren â€” contraindicated combination"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function",
      "Cough"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "16 mg/day (erbumine salt); 10 mg/day (arginine salt)",
    "clinicalPearl": "EUROPA trial demonstrated perindopril's cardiovascular protection in stable coronary artery disease."
  },
  {
    "rank": 86,
    "name": "Enalapril Maleate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Enam / Vasotec / Envas",
    "formation": "ACE inhibitor pro-drug",
    "uses": "Hypertension, heart failure management",
    "adult": "5â€“40 mg OD or BID",
    "child": "0.08 mg/kg OD (max 5 mg)",
    "avoid": "Pregnancy, history of angioedema",
    "sideEffects": [
      "Dry cough",
      "Hypotension",
      "Dizziness",
      "Hyperkalemia",
      "Headache"
    ],
    "seriousRisks": [
      "Angioedema",
      "Severe hyperkalemia",
      "Acute renal failure",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <30; renally cleared",
    "hepaticAdj": "Yes â€” use with caution; prodrug (enalaprilat is active form)",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester)",
    "lactation": "Caution â€” small amounts in breast milk; relatively safer among ACEIs",
    "drugInteractions": [
      "Potassium-sparing diuretics â€” hyperkalemia",
      "NSAIDs â€” reduced antihypertensive effect and AKI",
      "Lithium â€” increased lithium toxicity"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "Renal function",
      "Cough"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day",
    "clinicalPearl": "CONSENSUS and SOLVD trials established enalapril as the evidence base for ACE inhibitors in heart failure."
  },
  {
    "rank": 87,
    "name": "Lisinopril",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Listril / Zestril / Cipril",
    "formation": "Lysine analog of enalaprilat (ACEI)",
    "uses": "Hypertension, heart failure, post-MI",
    "adult": "10â€“40 mg OD",
    "child": "0.07 mg/kg OD (max 5 mg)",
    "avoid": "Hereditary or idiopathic angioedema",
    "sideEffects": [
      "Dry cough",
      "Hypotension",
      "Dizziness",
      "Hyperkalemia",
      "Rash"
    ],
    "seriousRisks": [
      "Angioedema (higher incidence in Africans/Asians)",
      "Severe hyperkalemia",
      "Acute renal failure",
      "Fetal toxicity"
    ],
    "renalAdj": "Yes â€” adjust dose based on eGFR; renally excreted unchanged",
    "hepaticAdj": "No â€” not significantly metabolised hepatically; standard dosing",
    "pregnancy": "Category D â€” contraindicated (2nd/3rd trimester)",
    "lactation": "Caution â€” present in breast milk",
    "drugInteractions": [
      "NSAIDs â€” reduced efficacy and AKI",
      "Potassium-sparing diuretics â€” hyperkalemia",
      "Aliskiren â€” contraindicated"
    ],
    "monitoring": [
      "BP",
      "Serum potassium",
      "eGFR/creatinine",
      "Cough"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day",
    "clinicalPearl": "Not significantly metabolised â€” advantage in hepatic disease; renally cleared, so dose adjust carefully."
  },
  {
    "rank": 88,
    "name": "Labetalol HCl",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Normodyne / Trandate / Labetalol",
    "formation": "Combined alpha and beta blocker",
    "uses": "Hypertension in pregnancy, hypertensive emergency",
    "adult": "100â€“400 mg BID (Oral)",
    "child": "1â€“3 mg/kg/day",
    "avoid": "Bronchial asthma, heart block",
    "sideEffects": [
      "Dizziness",
      "Fatigue",
      "Hypotension (postural)",
      "Headache",
      "Nausea"
    ],
    "seriousRisks": [
      "Severe postural hypotension (especially first dose)",
      "Paradoxical hypertension (abrupt withdrawal)",
      "Neonatal hypoglycaemia/bradycardia",
      "Bronchospasm"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” drug of choice for acute severe hypertension in pregnancy (IV labetalol)",
    "lactation": "Caution â€” present in breast milk",
    "drugInteractions": [
      "Cimetidine â€” increases labetalol levels",
      "Halothane â€” additive hypotension",
      "TCAs â€” tremor enhancement"
    ],
    "monitoring": [
      "BP (supine and standing)",
      "HR",
      "ECG",
      "Blood glucose (mask hypoglycaemia)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2400 mg/day (oral); IV infusion titrated per protocol",
    "clinicalPearl": "IV labetalol drug of choice for hypertensive emergencies in pregnancy; do not use in asthma."
  },
  {
    "rank": 89,
    "name": "Isosorbide Mononitrate",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Imdur / Monotrate / Ismo",
    "formation": "Organic nitrate",
    "uses": "Prophylaxis of angina pectoris",
    "adult": "20 mg BID or 60 mg OD (SR)",
    "child": "Not recommended",
    "avoid": "Hypertrophic obstructive cardiomyopathy, nitrate allergy",
    "sideEffects": [
      "Headache",
      "Flushing",
      "Dizziness",
      "Hypotension",
      "Palpitations"
    ],
    "seriousRisks": [
      "Nitrate tolerance (with continuous dosing)",
      "Severe hypotension",
      "Methaemoglobinaemia (rare)",
      "Reflex tachycardia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category C â€” use only if clearly needed",
    "lactation": "Caution â€” limited data",
    "drugInteractions": [
      "PDE5 inhibitors (sildenafil, etc.) â€” severe hypotension (contraindicated)",
      "Antihypertensives â€” additive hypotension",
      "Alcohol â€” enhanced hypotension"
    ],
    "monitoring": [
      "BP",
      "HR",
      "Angina symptom control"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "240 mg/day (SR formulation)",
    "clinicalPearl": "Ensure 8â€“12 hour nitrate-free interval daily to prevent tolerance (patch-off at night)."
  },
  {
    "rank": 90,
    "name": "Nitroglycerin",
    "section": "Section 2: Cardiovascular",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Nitrostat / Sorbitrate / GTN",
    "formation": "Organic nitrate vasodilator",
    "uses": "Acute angina pectoris, heart failure in MI",
    "adult": "0.5 mg sublingual PRN",
    "child": "Not recommended for routine use",
    "avoid": "Severe anemia, increased intracranial pressure",
    "sideEffects": [
      "Headache",
      "Flushing",
      "Hypotension",
      "Dizziness",
      "Reflex tachycardia"
    ],
    "seriousRisks": [
      "Severe hypotension",
      "Methaemoglobinaemia (high doses)",
      "Nitrate tolerance",
      "Syncope"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category C â€” use only if clearly needed",
    "lactation": "Caution â€” limited data",
    "drugInteractions": [
      "PDE5 inhibitors â€” absolutely contraindicated (fatal hypotension)",
      "Antihypertensives â€” additive hypotension",
      "Heparin â€” sublingual nitroglycerin may decrease heparin efficacy (IV)"
    ],
    "monitoring": [
      "BP",
      "HR",
      "Angina symptom resolution"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Sublingual 1.5 mg per episode (0.5 mg/dose, repeat x3); IV infusion dose titrated",
    "clinicalPearl": "Sublingual nitroglycerin: onset 1â€“3 minutes; sit or lie down to avoid syncope on first dose."
  },
  {
    "rank": 91,
    "name": "Vildagliptin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Galvus / Jalra / Zomelis",
    "formation": "Synthetic DPP-4 inhibitor",
    "uses": "Type 2 Diabetes management",
    "adult": "50 mg OD or BID",
    "child": "Not recommended",
    "avoid": "Moderate-to-severe renal failure (dose adjustment)",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Nausea",
      "Dizziness",
      "Upper respiratory infection"
    ],
    "seriousRisks": [
      "Pancreatitis (rare)",
      "Hepatotoxicity (monitor LFT)",
      "Angioedema (rare)",
      "Bullous pemphigoid"
    ],
    "renalAdj": "Yes â€” reduce to 50 mg/day if eGFR 30â€“60; 50 mg/day for eGFR <30 also (review per product)",
    "hepaticAdj": "Yes â€” contraindicated if LFT >3x ULN",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "ACE inhibitors â€” increased angioedema risk",
      "Sulfonylureas â€” additive hypoglycaemia",
      "CYP3A4 inhibitors â€” minor interaction"
    ],
    "monitoring": [
      "LFT (every 3 months first year)",
      "HbA1c",
      "Blood glucose",
      "eGFR"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg/day (50 mg twice daily)",
    "clinicalPearl": "Monitor LFT every 3 months â€” vildagliptin has the highest hepatotoxicity signal among DPP-4 inhibitors."
  },
  {
    "rank": 92,
    "name": "Sitagliptin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Januvia / Istamet",
    "formation": "Selective DPP-4 inhibitor",
    "uses": "Type 2 Diabetes",
    "adult": "100 mg OD",
    "child": "Not recommended",
    "avoid": "History of pancreatitis, renal failure (titrate)",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Nausea",
      "Hypoglycaemia (with SU)",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "Pancreatitis (rare)",
      "Angioedema",
      "Acute renal failure (rare)",
      "Bullous pemphigoid"
    ],
    "renalAdj": "Yes â€” reduce dose: 50 mg/day if CrCl 30â€“50; 25 mg/day if CrCl <30",
    "hepaticAdj": "No â€” standard dosing; caution in severe disease",
    "pregnancy": "Category B â€” avoid; insulin preferred",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Digoxin â€” slight increase in digoxin exposure",
      "Sulfonylureas â€” additive hypoglycaemia",
      "Cyclosporine â€” increased sitagliptin AUC"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Renal function",
      "Lipase/amylase (if pain)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/day",
    "clinicalPearl": "Weight-neutral DPP-4 inhibitor; renal dose adjustment required â€” check eGFR before prescribing."
  },
  {
    "rank": 93,
    "name": "Linagliptin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Trajenta / Glyxambi",
    "formation": "Xanthine-based DPP-4 inhibitor",
    "uses": "Type 2 Diabetes (preferred in renal impairment)",
    "adult": "5 mg OD",
    "child": "Not recommended",
    "avoid": "Acute pancreatitis history",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Cough",
      "Diarrhoea",
      "UTI"
    ],
    "seriousRisks": [
      "Pancreatitis (rare)",
      "Angioedema",
      "Bullous pemphigoid",
      "Severe hypoglycaemia (with SU)"
    ],
    "renalAdj": "No â€” no dose adjustment required in renal impairment (advantage over other DPP-4 inhibitors)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” avoid; insulin preferred",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "P-glycoprotein inducers â€” reduced linagliptin levels",
      "Strong CYP3A4 inducers (rifampicin) â€” reduced efficacy",
      "Sulfonylureas â€” additive hypoglycaemia"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Pancreatic enzymes (if pain)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5 mg/day",
    "clinicalPearl": "Only DPP-4 inhibitor requiring no dose adjustment in renal or hepatic impairment â€” ideal in CKD."
  },
  {
    "rank": 94,
    "name": "Saxagliptin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Onglyza",
    "formation": "Cyclopropylglycine DPP-4 inhibitor",
    "uses": "Glycemic control in T2DM",
    "adult": "2.5â€“5 mg OD",
    "child": "Not recommended",
    "avoid": "Heart failure history (caution)",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Peripheral oedema",
      "UTI",
      "Sinusitis"
    ],
    "seriousRisks": [
      "Heart failure hospitalisation increase (FDA warning)",
      "Pancreatitis (rare)",
      "Angioedema",
      "Serious hypersensitivity reactions"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <45; no dose adjustment but use with caution",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” avoid; insulin preferred",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "CYP3A4/P-gp inducers â€” reduced saxagliptin levels",
      "Ketoconazole â€” increase saxagliptin exposure 2.5-fold (max 2.5 mg)",
      "Sulfonylureas â€” additive hypoglycaemia"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Signs of heart failure",
      "Renal function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "5 mg/day (2.5 mg/day with strong CYP3A4 inhibitors)",
    "clinicalPearl": "SAVOR-TIMI showed increased HF hospitalisation â€” avoid in patients with existing heart failure."
  },
  {
    "rank": 95,
    "name": "Pioglitazone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Pioz / Actos / Piosafe",
    "formation": "Thiazolidinedione (PPAR-gamma agonist)",
    "uses": "T2DM (specifically insulin resistance)",
    "adult": "15â€“45 mg OD",
    "child": "Not recommended",
    "avoid": "Bladder cancer, active heart failure",
    "sideEffects": [
      "Weight gain",
      "Peripheral oedema",
      "Upper respiratory infection",
      "Headache",
      "Myalgia"
    ],
    "seriousRisks": [
      "Bladder cancer risk (long-term use)",
      "Heart failure exacerbation (fluid retention)",
      "Macular oedema",
      "Osteoporosis/fractures"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in active hepatic disease or ALT >2.5x ULN",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "Insulin â€” additive fluid retention and oedema risk",
      "Gemfibrozil â€” increased pioglitazone exposure",
      "CYP2C8 inhibitors â€” increased pioglitazone levels"
    ],
    "monitoring": [
      "LFT",
      "Body weight/oedema",
      "HbA1c",
      "Bone density (long-term)",
      "Bladder symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "45 mg/day",
    "clinicalPearl": "Contraindicated in bladder cancer history; avoid in CHF â€” causes fluid retention and worsens oedema."
  },
  {
    "rank": 96,
    "name": "Voglibose",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Volix / Vocarb / Volibo",
    "formation": "Alpha-glucosidase inhibitor",
    "uses": "Postprandial hyperglycemia in T2DM",
    "adult": "0.2â€“0.3 mg TID (at start of meal)",
    "child": "Not recommended",
    "avoid": "Chronic intestinal disease, hernia",
    "sideEffects": [
      "Flatulence",
      "Abdominal bloating",
      "Diarrhoea",
      "GI discomfort",
      "Nausea"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia if combined with insulin/SU",
      "Hepatotoxicity (rare, especially at high doses)",
      "Ileus (rare)"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <25 mL/min",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment",
    "pregnancy": "Category B â€” generally considered safe; no significant teratogenicity data",
    "lactation": "Caution â€” limited data",
    "drugInteractions": [
      "Digestive enzyme preparations â€” reduce voglibose efficacy",
      "Cholestyramine â€” additive glucose-lowering (caution)",
      "Insulin/SU â€” additive hypoglycaemia (treat with glucose, not sucrose)"
    ],
    "monitoring": [
      "Blood glucose (1 hour post-meal preferred)",
      "HbA1c",
      "LFT (prolonged use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.9 mg/day (0.3 mg three times daily)",
    "clinicalPearl": "Hypoglycaemia from voglibose must be treated with glucose (dextrose), not sucrose â€” sucrase is blocked."
  },
  {
    "rank": 97,
    "name": "Insulin Glargine",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "C",
    "brand": "Lantus / Basalog / Glaritus",
    "formation": "Long-acting analog insulin (rDNA origin)",
    "uses": "Basal glycemic control in Type 1 and Type 2 DM",
    "adult": "Individualized (SC OD at bedtime)",
    "child": "Consult specialist (approved for >2y)",
    "avoid": "Acute hypoglycemia",
    "sideEffects": [
      "Hypoglycaemia (less than regular insulin)",
      "Injection site reactions",
      "Lipodystrophy",
      "Weight gain",
      "Oedema"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia (incorrect timing)",
      "Anaphylaxis (rare)",
      "Hypokalaemia"
    ],
    "renalAdj": "Yes â€” reduce dose; hypoglycaemia risk increases",
    "hepaticAdj": "Yes â€” lower doses may be needed",
    "pregnancy": "Category B â€” basal insulin is used in pregnancy; dose adjustment needed",
    "lactation": "Safe â€” does not significantly pass into breast milk",
    "drugInteractions": [
      "Corticosteroids â€” counteract insulin effect",
      "Beta-blockers â€” mask hypoglycaemia",
      "Alcohol â€” potentiate hypoglycaemia"
    ],
    "monitoring": [
      "Fasting blood glucose",
      "HbA1c",
      "Injection site",
      "Serum potassium"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualised; no set maximum â€” titrate to FBG target",
    "clinicalPearl": "Inject subcutaneously at same time each day â€” do not mix with other insulins in same syringe."
  },
  {
    "rank": 98,
    "name": "Insulin Aspart",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "C",
    "brand": "NovoRapid / NovoLog",
    "formation": "Rapid-acting analog insulin",
    "uses": "Prandial glycemic control",
    "adult": "Individualized (SC 5â€“10 mins before meals)",
    "child": "Weight-based titration",
    "avoid": "Hypoglycemia, severe insulin allergy",
    "sideEffects": [
      "Hypoglycaemia",
      "Injection site reactions",
      "Lipodystrophy",
      "Weight gain",
      "Rash"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia",
      "Anaphylaxis (rare)",
      "Hypokalaemia"
    ],
    "renalAdj": "Yes â€” reduce dose; hypoglycaemia risk elevated",
    "hepaticAdj": "Yes â€” lower dose may be needed",
    "pregnancy": "Category B â€” used in gestational diabetes; rapid-acting preferred prandially",
    "lactation": "Safe â€” does not pass significantly into breast milk",
    "drugInteractions": [
      "Corticosteroids â€” oppose insulin action",
      "Beta-blockers â€” mask hypoglycaemia symptoms",
      "Alcohol â€” enhance hypoglycaemia"
    ],
    "monitoring": [
      "Postprandial blood glucose",
      "HbA1c",
      "Injection site rotation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualised â€” no fixed maximum",
    "clinicalPearl": "Inject immediately before a meal (0â€“5 min before) â€” fastest onset of meal-time insulins."
  },
  {
    "rank": 99,
    "name": "Insulin Lispro",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "C",
    "brand": "Humalog / Rosulin-R",
    "formation": "Rapid-acting analog insulin",
    "uses": "Type 1 and Type 2 Diabetes",
    "adult": "Individualized based on carbohydrate intake",
    "child": "Weight-based",
    "avoid": "During hypoglycemic episodes",
    "sideEffects": [
      "Hypoglycaemia",
      "Injection site pain",
      "Lipodystrophy",
      "Weight gain",
      "Oedema"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia",
      "Anaphylaxis",
      "Hypokalaemia"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category B â€” used prandially in gestational/type 1 diabetes",
    "lactation": "Safe â€” minimal breast milk transfer",
    "drugInteractions": [
      "Corticosteroids â€” raise blood glucose",
      "Beta-blockers â€” mask hypoglycaemia",
      "Thiazolidinediones â€” additive oedema"
    ],
    "monitoring": [
      "Postprandial glucose",
      "HbA1c",
      "Injection site",
      "Serum K+"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualised",
    "clinicalPearl": "Can be injected up to 15 minutes before or after starting a meal â€” flexible dosing option."
  },
  {
    "rank": 100,
    "name": "Dulaglutide",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "C",
    "brand": "Trulicity",
    "formation": "GLP-1 receptor agonist (Injectable)",
    "uses": "T2DM management, CV risk reduction",
    "adult": "0.75â€“1.5 mg once weekly SC",
    "child": "Not recommended",
    "avoid": "Medullary thyroid carcinoma, MEN 2",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Injection site reactions",
      "Decreased appetite"
    ],
    "seriousRisks": [
      "Thyroid C-cell tumour (black box warning)",
      "Pancreatitis",
      "Retinopathy worsening",
      "Severe hypoglycaemia (with SU/insulin)"
    ],
    "renalAdj": "No â€” standard dosing; use with caution in severe renal impairment",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; discontinue 2 months before conception",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "Insulin/SU â€” additive hypoglycaemia",
      "Warfarin â€” monitor INR (GI motility change)",
      "Oral contraceptives â€” take 1 hour before injection to reduce absorption delay"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "Body weight",
      "Thyroid symptoms",
      "Pancreatic enzymes (if pain)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1.5 mg/week (subcutaneous injection)",
    "clinicalPearl": "Once-weekly injection (pre-filled pen) improves adherence; rotate injection sites each dose."
  },
  {
    "rank": 101,
    "name": "Metformin + Sitagliptin + Dapagliflozin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Tribet / Janumet-S",
    "formation": "Biguanide + DPP-4i + SGLT2i",
    "uses": "Triple therapy for refractory T2DM",
    "adult": "500/50/5 mg to 1000/50/10 mg OD/BID",
    "child": "Not recommended",
    "avoid": "Renal failure (CrCl < 30), metabolic acidosis",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Genital mycotic infections",
      "Headache",
      "UTI"
    ],
    "seriousRisks": [
      "Lactic acidosis (metformin)",
      "Euglycaemic DKA (dapagliflozin)",
      "Pancreatitis (sitagliptin)",
      "Fournier's gangrene"
    ],
    "renalAdj": "Yes â€” contraindicated if eGFR <45 (dapagliflozin + metformin); sitagliptin dose adjust at eGFR <50",
    "hepaticAdj": "Yes â€” avoid metformin; use with caution (triple combination)",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” all three components not recommended",
    "drugInteractions": [
      "Alcohol â€” lactic acidosis risk (metformin)",
      "Diuretics â€” additive volume depletion (dapagliflozin)",
      "CYP3A4 inhibitors â€” minor sitagliptin interaction"
    ],
    "monitoring": [
      "eGFR",
      "HbA1c",
      "Blood glucose",
      "LFT",
      "BP (volume status)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Per component maximums: Metformin 2000 mg + Sitagliptin 100 mg + Dapagliflozin 10 mg per day",
    "clinicalPearl": "Triple combination for uncontrolled T2DM â€” hold all components appropriately before surgery or contrast."
  },
  {
    "rank": 102,
    "name": "Metformin + Vildagliptin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Vildamet / Galvus Met",
    "formation": "Biguanide + DPP-4 inhibitor",
    "uses": "Combination management for Type 2 Diabetes",
    "adult": "500/50 mg to 1000/50 mg BID",
    "child": "Not recommended",
    "avoid": "Hepatic impairment, severe ketoacidosis",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Headache",
      "Nasopharyngitis",
      "Dizziness"
    ],
    "seriousRisks": [
      "Lactic acidosis (metformin)",
      "Hepatotoxicity (vildagliptin)",
      "Pancreatitis (rare)",
      "Angioedema"
    ],
    "renalAdj": "Yes â€” metformin CI if eGFR <30; vildagliptin 50 mg/day if eGFR <50",
    "hepaticAdj": "Yes â€” vildagliptin contraindicated if ALT/AST >3x ULN; avoid metformin",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid",
    "drugInteractions": [
      "ACE inhibitors â€” increased angioedema risk (vildagliptin)",
      "Alcohol â€” lactic acidosis (metformin)",
      "Contrast media â€” hold metformin"
    ],
    "monitoring": [
      "LFT (3 monthly first year)",
      "eGFR",
      "HbA1c",
      "Blood glucose"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Vildagliptin 100 mg + Metformin 2000 mg per day",
    "clinicalPearl": "Same as rank 33 â€” vildagliptin LFT monitoring is non-negotiable for patient safety."
  },
  {
    "rank": 103,
    "name": "Gliclazide",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Diamicron / Glizid MR",
    "formation": "Second-generation sulfonylurea",
    "uses": "Type 2 Diabetes",
    "adult": "30â€“120 mg OD (Modified release)",
    "child": "Not recommended",
    "avoid": "Type 1 DM, pregnancy, liver failure",
    "sideEffects": [
      "Hypoglycaemia",
      "Weight gain",
      "GI upset",
      "Headache",
      "Nausea"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia (less than glibenclamide)",
      "Agranulocytosis (rare)",
      "Haemolytic anaemia (G6PD deficiency)"
    ],
    "renalAdj": "Yes â€” use with caution in mild-moderate renal impairment; avoid severe impairment",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” neonatal hypoglycaemia risk",
    "drugInteractions": [
      "Fluconazole â€” increased gliclazide levels",
      "Beta-blockers â€” mask hypoglycaemia",
      "NSAIDs â€” enhanced hypoglycaemic effect"
    ],
    "monitoring": [
      "Blood glucose (FBS/PPBS)",
      "HbA1c",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "320 mg/day (standard); 120 mg/day (modified release)",
    "clinicalPearl": "MR formulation once-daily â€” lower hypoglycaemia risk than glibenclamide; preferred in elderly."
  },
  {
    "rank": 104,
    "name": "Remogliflozin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Remozen / Remo (Zydus)",
    "formation": "Selective SGLT2 inhibitor",
    "uses": "Glycemic control in T2DM",
    "adult": "100 mg BID",
    "child": "Not recommended",
    "avoid": "Dialysis, severe renal impairment",
    "sideEffects": [
      "Genital mycotic infections",
      "UTI",
      "Pollakiuria",
      "Nausea",
      "Hypotension"
    ],
    "seriousRisks": [
      "Euglycaemic DKA",
      "Fournier's gangrene",
      "UTI (complicated)",
      "Acute kidney injury"
    ],
    "renalAdj": "Yes â€” not recommended if eGFR <45; contraindicated if eGFR <30",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "Diuretics â€” additive volume depletion",
      "Insulin/SU â€” hypoglycaemia risk",
      "NSAIDs â€” renal risk"
    ],
    "monitoring": [
      "eGFR",
      "HbA1c",
      "BP",
      "Genital hygiene status"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg twice daily (100â€“200 mg/day)",
    "clinicalPearl": "Indian-developed SGLT2 inhibitor; primarily approved in India â€” efficacy comparable to other SGLT2 inhibitors."
  },
  {
    "rank": 105,
    "name": "Canagliflozin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Invokana",
    "formation": "SGLT2 inhibitor",
    "uses": "T2DM, diabetic nephropathy",
    "adult": "100â€“300 mg OD",
    "child": "Not recommended",
    "avoid": "eGFR < 30, prone to genital mycotic infections",
    "sideEffects": [
      "Genital mycotic infections",
      "UTI",
      "Pollakiuria",
      "Hypotension",
      "Constipation"
    ],
    "seriousRisks": [
      "Lower limb amputation risk (black box warning)",
      "Euglycaemic DKA",
      "Bone fractures",
      "Fournier's gangrene"
    ],
    "renalAdj": "Yes â€” contraindicated if eGFR <30; avoid initiation if eGFR <45",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” no human data",
    "drugInteractions": [
      "Diuretics â€” additive volume depletion",
      "Insulin/SU â€” hypoglycaemia",
      "UGT inducers â€” reduced canagliflozin levels"
    ],
    "monitoring": [
      "eGFR",
      "HbA1c",
      "BP",
      "Foot inspection (amputation risk)",
      "Bone density (long-term)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "300 mg/day",
    "clinicalPearl": "CANVAS trial showed increased amputation risk â€” inspect feet regularly; avoid in peripheral artery disease."
  },
  {
    "rank": 106,
    "name": "Teneligliptin + Metformin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Tengli-M / Zita-Met",
    "formation": "DPP-4i + Biguanide",
    "uses": "Type 2 Diabetes",
    "adult": "20 mg/500 mg OD or BID",
    "child": "Not recommended",
    "avoid": "Heart failure, renal acidosis",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Dizziness",
      "Hypoglycaemia (with SU)",
      "GI discomfort"
    ],
    "seriousRisks": [
      "Lactic acidosis (metformin)",
      "Pancreatitis (teneligliptin, rare)",
      "Angioedema"
    ],
    "renalAdj": "No â€” teneligliptin requires minimal adjustment; metformin contraindicated if eGFR <30",
    "hepaticAdj": "Yes â€” avoid metformin; use teneligliptin with caution in hepatic impairment",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid",
    "drugInteractions": [
      "Alcohol â€” lactic acidosis (metformin)",
      "QT-prolonging drugs â€” slight QT risk with teneligliptin",
      "Sulfonylureas â€” additive hypoglycaemia"
    ],
    "monitoring": [
      "HbA1c",
      "Blood glucose",
      "eGFR",
      "ECG (QTc)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Teneligliptin 40 mg + Metformin 2000 mg per day",
    "clinicalPearl": "Teneligliptin has dual excretion â€” uniquely suitable for CKD patients in India."
  },
  {
    "rank": 107,
    "name": "Glibenclamide (Glyburide)",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Daonil / Euglucon / Gliben",
    "formation": "Sulfonylurea derivative",
    "uses": "Type 2 Diabetes",
    "adult": "2.5â€“10 mg OD or BID",
    "child": "Not recommended",
    "avoid": "Severe elderly frailty (hypoglycemia risk)",
    "sideEffects": [
      "Hypoglycaemia (most potent)",
      "Weight gain",
      "GI upset",
      "Jaundice (rare, cholestatic)",
      "Headache"
    ],
    "seriousRisks": [
      "Severe prolonged hypoglycaemia (high potency)",
      "Agranulocytosis (rare)",
      "Haemolytic anaemia (G6PD deficiency)",
      "SIADH"
    ],
    "renalAdj": "Yes â€” avoid in renal impairment; high hypoglycaemia risk",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid; insulin preferred; neonatal hypoglycaemia risk",
    "lactation": "Avoid â€” neonatal hypoglycaemia risk",
    "drugInteractions": [
      "Fluconazole â€” severe hypoglycaemia",
      "Beta-blockers â€” mask and prolong hypoglycaemia",
      "Alcohol â€” disulfiram-like reaction and hypoglycaemia"
    ],
    "monitoring": [
      "Blood glucose",
      "HbA1c",
      "Renal function",
      "CBC"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "20 mg/day",
    "clinicalPearl": "Longest-acting sulfonylurea â€” not preferred in elderly or renal impairment due to severe hypoglycaemia risk."
  },
  {
    "rank": 108,
    "name": "Repaglinide",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Antidiabetic",
    "schedule": "H",
    "brand": "Novonorm / Repag",
    "formation": "Meglitinide derivative",
    "uses": "Type 2 Diabetes (post-prandial control)",
    "adult": "0.5â€“4 mg (15 mins before each meal)",
    "child": "Not recommended",
    "avoid": "Concomitant gemfibrozil use",
    "sideEffects": [
      "Hypoglycaemia",
      "Weight gain",
      "GI upset",
      "Nausea",
      "Headache"
    ],
    "seriousRisks": [
      "Severe hypoglycaemia",
      "Hepatotoxicity (rare)",
      "Cardiac adverse events"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; use with caution",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid; insulin preferred",
    "lactation": "Avoid â€” no adequate data",
    "drugInteractions": [
      "CYP2C8 inhibitors (gemfibrozil) â€” increased repaglinide levels (contraindicated)",
      "CYP3A4 inhibitors â€” increased levels",
      "Beta-blockers â€” mask hypoglycaemia"
    ],
    "monitoring": [
      "Blood glucose (pre- and post-prandial)",
      "HbA1c",
      "Renal function",
      "LFT"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "16 mg/day (4 mg before each meal, maximum 4 meals/day)",
    "clinicalPearl": "Take immediately before each meal; skip dose if meal skipped â€” flexible prandial dosing."
  },
  {
    "rank": 109,
    "name": "Alpha Lipoic Acid",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Thiocid / ALA-300 / Alphalipoic",
    "formation": "Naturally occurring antioxidant",
    "uses": "Diabetic neuropathy, cellular protection",
    "adult": "300â€“600 mg daily",
    "child": "Consult specialist",
    "avoid": "Hypoglycemia (additive effect with OADs)",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Headache",
      "Skin rash (rare)",
      "Fatigue"
    ],
    "seriousRisks": [
      "Hypoglycaemia (if combined with antidiabetics)",
      "Autoimmune reactions (very rare)",
      "Thiamine deficiency interference (theoretical)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; limited data",
    "lactation": "Caution â€” limited data; likely safe at therapeutic doses",
    "drugInteractions": [
      "Antidiabetics â€” enhanced glucose-lowering effect (monitor)",
      "Chemotherapy â€” may reduce efficacy (antioxidant paradox)",
      "Thyroid medications â€” may alter thyroid function (monitor)"
    ],
    "monitoring": [
      "Blood glucose (in diabetics)",
      "Neurological symptom response",
      "LFT"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day (neuropathy); 1800 mg/day (antioxidant therapy)",
    "clinicalPearl": "Both water- and fat-soluble antioxidant â€” scavenges free radicals in hydrophilic and lipophilic environments."
  },
  {
    "rank": 110,
    "name": "Myo-inositol",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Inofolic / Ovabless / Myo-Inositol",
    "formation": "Carbocyclic sugar (Vitamin-like)",
    "uses": "PCOD/PCOS, metabolic support",
    "adult": "2 g BID",
    "child": "Not recommended",
    "avoid": "Bipolar disorder (may trigger mania)",
    "sideEffects": [
      "GI discomfort",
      "Nausea",
      "Bloating",
      "Headache",
      "Diarrhoea (mild)"
    ],
    "seriousRisks": [
      "Hypoglycaemia (if combined with insulin/oral antidiabetics)",
      "Worsening of hypertriglyceridaemia (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” used in PCOS for ovulation induction; considered generally safe",
    "lactation": "Safe â€” limited data; generally considered safe",
    "drugInteractions": [
      "Insulin sensitisers â€” additive effect",
      "Oral contraceptives â€” may alter inositol efficacy in PCOS",
      "No significant CYP interactions known"
    ],
    "monitoring": [
      "Menstrual cycle regularity",
      "Hormonal profile (LH/FSH)",
      "Blood glucose (PCOS-related insulin resistance)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 g/day (myo-inositol)",
    "clinicalPearl": "Combination of myo-inositol + D-chiro-inositol (40:1 ratio) most studied for PCOS insulin resistance."
  },
  {
    "rank": 111,
    "name": "Progesterone (Micronized)",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Susten / Lutinus / Duphaston",
    "formation": "Natural steroid hormone",
    "uses": "Luteal phase support, prevention of preterm birth",
    "adult": "200â€“400 mg daily (Vaginal or Oral)",
    "child": "Not recommended",
    "avoid": "Undiagnosed vaginal bleeding, active liver disease",
    "sideEffects": [
      "Drowsiness",
      "Breast tenderness",
      "Nausea",
      "Dizziness",
      "Vaginal discharge"
    ],
    "seriousRisks": [
      "Thromboembolism (risk lower than synthetic progestogens)",
      "Breast cancer risk (long-term HRT)",
      "Depression exacerbation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic disease; micronised progesterone metabolised hepatically",
    "pregnancy": "Category B â€” used in luteal phase support and threatened abortion",
    "lactation": "Caution â€” excreted in breast milk; use for short duration only",
    "drugInteractions": [
      "CYP3A4 inhibitors â€” increased progesterone levels",
      "Enzyme inducers (rifampicin, phenytoin) â€” reduced progesterone levels",
      "Anticoagulants â€” progestins may antagonise anticoagulation"
    ],
    "monitoring": [
      "Hormonal levels (progesterone)",
      "Vaginal/uterine sonography",
      "Symptoms of thromboembolism"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "600 mg/day (vaginal/oral)",
    "clinicalPearl": "Micronised oral progesterone: take at bedtime â€” drowsiness is side effect; vaginal route avoids first-pass."
  },
  {
    "rank": 112,
    "name": "Estradiol",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Progynova / Estradot / Estradiol",
    "formation": "Principal endogenous human estrogen",
    "uses": "Menopause hormone replacement therapy (HRT)",
    "adult": "1â€“2 mg daily or 50 mcg/day (patch)",
    "child": "Titrate based on puberty induction needs",
    "avoid": "Estrogen-dependent tumors, history of DVT",
    "sideEffects": [
      "Nausea",
      "Breast tenderness",
      "Headache",
      "Vaginal bleeding (spotting)",
      "Fluid retention"
    ],
    "seriousRisks": [
      "Thromboembolism (DVT/PE)",
      "Breast cancer (long-term use)",
      "Endometrial cancer (unopposed oestrogen)",
      "Stroke"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” contraindicated in severe hepatic disease; avoid if history of hepatic tumours",
    "pregnancy": "Category X â€” contraindicated",
    "lactation": "Avoid â€” suppresses lactation",
    "drugInteractions": [
      "CYP3A4 inducers â€” reduced estradiol levels (reduced contraceptive/HRT efficacy)",
      "CYP3A4 inhibitors â€” increased estradiol levels",
      "Corticosteroids â€” reduced clearance, additive fluid retention"
    ],
    "monitoring": [
      "Breast examination",
      "Bone density (HRT)",
      "Endometrial thickness (transvaginal USG)",
      "BP",
      "Lipid profile"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "4 mg/day (oral); as per transdermal patch system",
    "clinicalPearl": "Always use with progestogen in non-hysterectomised women â€” unopposed oestrogen causes endometrial cancer."
  },
  {
    "rank": 113,
    "name": "Norethisterone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Primolut-N / Regestrone",
    "formation": "Synthetic progestational hormone",
    "uses": "Dysmenorrhea, heavy menstrual bleeding",
    "adult": "5 mg TID (for 10 days) or 10â€“20 mg/day",
    "child": "Not recommended",
    "avoid": "Porphyria, active thrombophlebitis",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Breast tenderness",
      "Irregular bleeding",
      "Weight gain"
    ],
    "seriousRisks": [
      "Thromboembolism",
      "Ectopic pregnancy risk (if fails as emergency contraceptive)",
      "Depression",
      "Stroke (with oestrogen)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic disease",
    "pregnancy": "Category X â€” contraindicated",
    "lactation": "Caution â€” excreted in breast milk; use with caution",
    "drugInteractions": [
      "Enzyme inducers (rifampicin, carbamazepine) â€” reduced norethisterone efficacy",
      "Anticoagulants â€” progestogen may antagonise effect",
      "CYP3A4 inhibitors â€” increased norethisterone levels"
    ],
    "monitoring": [
      "Menstrual cycle",
      "BP",
      "Liver function (if prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "15 mg/day (endometriosis); 5 mg/day (HRT); 5 mg TID (dysfunctional uterine bleeding)",
    "clinicalPearl": "Norethisterone 5 mg TID for 10 days can delay menstruation â€” commonly prescribed in India."
  },
  {
    "rank": 114,
    "name": "Levonorgestrel",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "i-Pill / Unwanted-72 / Eziday",
    "formation": "Second-generation synthetic progestogen",
    "uses": "Emergency contraception, long-term contraception",
    "adult": "1.5 mg single dose (within 72 hrs)",
    "child": "Same as adult post-menarche",
    "avoid": "Suspected pregnancy, severe hepatic disease",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Irregular bleeding",
      "Breast tenderness",
      "Fatigue"
    ],
    "seriousRisks": [
      "Ectopic pregnancy (if pregnancy occurs despite use)",
      "Thromboembolism (rare)",
      "Depression (long-term)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic disease",
    "pregnancy": "Category X â€” if taken inadvertently in pregnancy, no proven teratogenicity",
    "lactation": "Safe â€” progestogen-only pill considered compatible; small amount in milk",
    "drugInteractions": [
      "Enzyme inducers (rifampicin, carbamazepine, phenytoin) â€” reduced efficacy (use additional contraception)",
      "St John's Wort â€” reduced efficacy",
      "Antiretrovirals (HIV) â€” potential reduced efficacy"
    ],
    "monitoring": [
      "Menstrual pattern",
      "Pregnancy test if delayed menstruation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1.5 mg single dose (emergency contraception within 72 hours)",
    "clinicalPearl": "Emergency contraception â€” most effective within 72 hours of unprotected intercourse; efficacy decreases with time."
  },
  {
    "rank": 115,
    "name": "Finasteride",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Urology",
    "schedule": "H",
    "brand": "Finpecia / Propecia / Finast",
    "formation": "Type II 5-alpha-reductase inhibitor",
    "uses": "Benign Prostatic Hyperplasia (BPH), androgenic alopecia",
    "adult": "5 mg daily (BPH) or 1 mg daily (Alopecia)",
    "child": "Not recommended",
    "avoid": "Women of childbearing age, pediatric patients",
    "sideEffects": [
      "Decreased libido",
      "Erectile dysfunction",
      "Decreased ejaculate volume",
      "Gynecomastia",
      "Fatigue"
    ],
    "seriousRisks": [
      "Prostate cancer risk increase (debated)",
      "High-grade prostate cancer masking (lowers PSA)",
      "Depression/suicidal ideation (rare)",
      "Persistent sexual dysfunction post-discontinuation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; metabolised by CYP3A4",
    "pregnancy": "Category X â€” teratogenic (male fetal genital abnormalities); women should not handle crushed tablets",
    "lactation": "Not applicable â€” indicated only in males",
    "drugInteractions": [
      "CYP3A4 inhibitors â€” increased finasteride levels",
      "PSA interpretation â€” finasteride reduces PSA by ~50% (double PSA for interpretation)",
      "No significant drug-drug interactions otherwise"
    ],
    "monitoring": [
      "PSA (baseline and during â€” adjust interpretation)",
      "Urological symptoms (IPSS score)",
      "Sexual function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "5 mg/day (BPH); 1 mg/day (androgenetic alopecia)",
    "clinicalPearl": "PSA level must be doubled during finasteride therapy to get true PSA value for cancer screening."
  },
  {
    "rank": 116,
    "name": "Dutasteride",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Urology",
    "schedule": "H",
    "brand": "Dutas / Avodart",
    "formation": "Dual 5-alpha-reductase inhibitor",
    "uses": "Symptomatic BPH management",
    "adult": "0.5 mg OD",
    "child": "Not recommended",
    "avoid": "Hypersensitivity, severe hepatic impairment",
    "sideEffects": [
      "Decreased libido",
      "Erectile dysfunction",
      "Ejaculatory disorders",
      "Gynecomastia",
      "Dizziness"
    ],
    "seriousRisks": [
      "High-grade prostate cancer masking",
      "Persistent sexual dysfunction",
      "Serious cardiac failure (rare)",
      "Hepatotoxicity (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment; half-life extremely long (5 weeks)",
    "pregnancy": "Category X â€” teratogenic; women must not handle capsules",
    "lactation": "Not applicable",
    "drugInteractions": [
      "CYP3A4 inhibitors â€” increased dutasteride levels",
      "Verapamil/diltiazem â€” increased levels",
      "PSA reduced by ~50â€“90% â€” adjust cancer screening interpretation"
    ],
    "monitoring": [
      "PSA (adjust interpretation)",
      "IPSS score",
      "Sexual function",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "0.5 mg/day",
    "clinicalPearl": "Inhibits both type 1 and type 2 5-alpha reductase (vs. finasteride only type 2) â€” more complete DHT suppression."
  },
  {
    "rank": 117,
    "name": "Cabergoline",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Caberlin / Dostinex",
    "formation": "Ergot-derived dopamine receptor agonist",
    "uses": "Hyperprolactinemia, Parkinsonâ€™s disease adjunct",
    "adult": "0.25â€“0.5 mg twice weekly",
    "child": "Consult specialist",
    "avoid": "Uncontrolled hypertension, history of valvular heart disease",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Headache",
      "Postural hypotension",
      "Constipation"
    ],
    "seriousRisks": [
      "Cardiac valvulopathy (high-dose prolonged use)",
      "Pleuropulmonary fibrosis",
      "Retroperitoneal fibrosis",
      "Psychiatric effects (psychosis)"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category B â€” not recommended; may inhibit lactation; consult specialist",
    "lactation": "Avoid â€” suppresses prolactin (intended effect for hyperprolactinaemia); prevents lactation",
    "drugInteractions": [
      "Antipsychotics â€” antagonise dopamine receptor, reduce cabergoline efficacy",
      "Antihypertensives â€” additive hypotension",
      "Macrolide antibiotics â€” increased cabergoline levels"
    ],
    "monitoring": [
      "Serum prolactin",
      "MRI pituitary (tumour size)",
      "Echocardiogram (long-term high dose)",
      "Chest X-ray (fibrosis)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "4.5 mg/week (hyperprolactinaemia); higher doses in Parkinson's",
    "clinicalPearl": "Preferred over bromocriptine â€” better tolerability, once or twice weekly dosing, more potent prolactin suppression."
  },
  {
    "rank": 118,
    "name": "Bromocriptine",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Parlodel / Sicriptin",
    "formation": "Semisynthetic ergot alkaloid",
    "uses": "Hyperprolactinemia, acromegaly, T2DM (off-label)",
    "adult": "1.25â€“2.5 mg daily (titrate up)",
    "child": "Consult pediatric endocrinology",
    "avoid": "Preeclampsia, severe coronary artery disease",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Dizziness",
      "Postural hypotension",
      "Headache"
    ],
    "seriousRisks": [
      "Cardiac valvulopathy (Parkinson's doses)",
      "Pleuropulmonary fibrosis",
      "Psychiatric effects (hallucinations)",
      "Ergotism (high doses)"
    ],
    "renalAdj": "No â€” standard dosing; use with caution",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category B â€” limited use; consult specialist; may suppress lactation",
    "lactation": "Avoid â€” suppresses prolactin (used to suppress lactation post-partum in some cases)",
    "drugInteractions": [
      "Antipsychotics â€” pharmacodynamic antagonism",
      "Antihypertensives â€” additive hypotension",
      "Ergot alkaloids â€” additive vasospasm"
    ],
    "monitoring": [
      "Serum prolactin",
      "BP (postural)",
      "MRI pituitary",
      "Psychiatric symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg/day (Parkinson's); 7.5 mg/day (hyperprolactinaemia)",
    "clinicalPearl": "Start at low dose (1.25 mg at night) and titrate slowly to reduce nausea and postural hypotension."
  },
  {
    "rank": 119,
    "name": "Testosterone (Gel/Inj)",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Androgel / Cernos / Testogel",
    "formation": "Principal male sex hormone",
    "uses": "Male hypogonadism, delayed puberty",
    "adult": "50 mg OD (Gel) or 250 mg every 3 weeks (IM)",
    "child": "Consult pediatric endocrinology",
    "avoid": "Prostate or breast cancer in males",
    "sideEffects": [
      "Acne",
      "Erythrocytosis (polycythaemia)",
      "Application site reactions (gel)",
      "Oily skin/seborrhoea",
      "Mood changes"
    ],
    "seriousRisks": [
      "Polycythaemia/thromboembolic risk",
      "Hepatotoxicity (oral 17-alkylated forms only)",
      "Prostate cancer promotion",
      "Sleep apnoea exacerbation",
      "Infertility"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; oedema and fluid retention risk",
    "hepaticAdj": "Yes â€” avoid in hepatic disease; injectable/gel preferred over 17-alkylated oral forms",
    "pregnancy": "Category X â€” virilisation of female fetus; absolutely contraindicated",
    "lactation": "Avoid â€” contraindicated",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect",
      "Insulin â€” may reduce insulin requirements",
      "Corticosteroids â€” additive fluid retention"
    ],
    "monitoring": [
      "Haematocrit/Hb (polycythaemia)",
      "PSA (prostate cancer screening)",
      "Testosterone levels",
      "Lipid profile",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "250 mg/2â€“3 weeks (IM enanthate); gel: 50â€“100 mg/day applied to skin",
    "clinicalPearl": "Monitor haematocrit â€” if >54%, withhold therapy; donate blood or reduce dose to prevent thromboembolism."
  },
  {
    "rank": 120,
    "name": "Clomifene Citrate",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Siphene / Clomid / Fertomid",
    "formation": "Selective estrogen receptor modulator (SERM)",
    "uses": "Ovulation induction in infertile women",
    "adult": "50 mg daily for 5 days (starting day 3â€“5 of cycle)",
    "child": "Not recommended",
    "avoid": "Liver disease, ovarian cysts, pregnancy",
    "sideEffects": [
      "Ovarian cyst/ovarian hyperstimulation",
      "Hot flushes",
      "Visual disturbances",
      "Headache",
      "Mood changes"
    ],
    "seriousRisks": [
      "Ovarian hyperstimulation syndrome (OHSS)",
      "Multiple gestation (twins, etc.)",
      "Visual disturbances (discontinue if persistent)",
      "Ovarian cancer risk (prolonged use â€” limited evidence)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in hepatic disease; contraindicated in hepatic dysfunction",
    "pregnancy": "Category X â€” contraindicated after ovulation confirmed or if pregnancy occurs",
    "lactation": "Avoid â€” suppresses lactation",
    "drugInteractions": [
      "Gonadotropins â€” additive ovarian stimulation; careful monitoring",
      "No significant CYP interactions known"
    ],
    "monitoring": [
      "Ovarian ultrasound (follicle monitoring)",
      "Serum oestradiol",
      "LH surge/ovulation detection",
      "Pregnancy test"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "150 mg/day for 5 days (50â€“100 mg typical dose per cycle)",
    "clinicalPearl": "Administer from cycle day 2â€“5; limit to 6 ovulatory cycles to reduce long-term ovarian stimulation risk."
  },
  {
    "rank": 121,
    "name": "Letrozole",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Letoval / Femara / Letroz",
    "formation": "Nonsteroidal aromatase inhibitor",
    "uses": "Breast cancer, infertility (off-label ovulation induction)",
    "adult": "2.5 mg daily",
    "child": "Not recommended",
    "avoid": "Pre-menopausal status (unless for fertility), pregnancy",
    "sideEffects": [
      "Hot flushes",
      "Arthralgia",
      "Fatigue",
      "Headache",
      "Bone pain"
    ],
    "seriousRisks": [
      "Severe bone loss/osteoporosis",
      "Thromboembolic events (DVT/PE)",
      "Endometrial cancer (less than tamoxifen)",
      "Hypercholesterolaemia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category X â€” embryotoxic and fetotoxic",
    "lactation": "Avoid â€” contraindicated",
    "drugInteractions": [
      "Tamoxifen â€” not to be used concurrently (no benefit, increased risk)",
      "CYP3A4 inducers â€” reduced letrozole levels",
      "Estrogens â€” reduce efficacy (avoid)"
    ],
    "monitoring": [
      "Bone density (DEXA scan)",
      "Lipid profile",
      "Liver function",
      "Hormonal response"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "5 mg/day (oncology extended adjuvant); 2.5 mg/day (standard adjuvant/fertility)",
    "clinicalPearl": "Preferred over clomifene in PCOS ovulation induction (higher live birth rate per Indian/NICE guidelines)."
  },
  {
    "rank": 122,
    "name": "Human Growth Hormone (Somatropin)",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Biologicals",
    "schedule": "C",
    "brand": "Norditropin / Humatrope / Omnitrope",
    "formation": "rDNA-derived human growth hormone",
    "uses": "Growth failure in children, GHD in adults",
    "adult": "Individualized (usually 0.005â€“0.01 mg/kg SC)",
    "child": "0.16â€“0.24 mg/kg/week (divided daily doses)",
    "avoid": "Active malignancy, acute critical illness",
    "sideEffects": [
      "Injection site reactions",
      "Peripheral oedema",
      "Arthralgia/myalgia",
      "Headache",
      "Paraesthesia"
    ],
    "seriousRisks": [
      "Acromegaly features (excess dosing)",
      "Intracranial hypertension",
      "Slipped capital femoral epiphysis (children)",
      "Diabetes mellitus",
      "Malignancy (contraindicated in active cancer)"
    ],
    "renalAdj": "Yes â€” use with caution; lower starting dose in renal impairment",
    "hepaticAdj": "Yes â€” use with caution; hepatically metabolised",
    "pregnancy": "Category C â€” avoid unless clearly necessary for GH deficiency",
    "lactation": "Caution â€” limited data",
    "drugInteractions": [
      "Insulin/oral antidiabetics â€” GH induces insulin resistance; adjust antidiabetic doses",
      "Glucocorticoids â€” may reduce GH efficacy",
      "CYP3A4 substrates â€” GH may alter metabolism of drugs (sex steroids, anticonvulsants)"
    ],
    "monitoring": [
      "IGF-1 levels",
      "Blood glucose",
      "Bone age X-ray (children)",
      "Thyroid function",
      "BP"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Individualised (children: 0.025â€“0.05 mg/kg/day SC; adults: 0.15â€“0.3 mg/day SC)",
    "clinicalPearl": "Monitor IGF-1 to adjust dose â€” normalise to age-matched reference range; avoid in active neoplasms."
  },
  {
    "rank": 123,
    "name": "Desmopressin",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Minirin / Desmospray",
    "formation": "Synthetic analog of vasopressin",
    "uses": "Diabetes insipidus, primary nocturnal enuresis",
    "adult": "0.1â€“0.4 mg/day in divided doses",
    "child": "0.2 mg at bedtime (Enuresis)",
    "avoid": "Hyponatremia, moderate-to-severe renal failure",
    "sideEffects": [
      "Headache",
      "Nasal congestion (intranasal)",
      "Hyponatraemia",
      "Nausea",
      "Abdominal cramps"
    ],
    "seriousRisks": [
      "Severe hyponatraemia (water intoxication â€” especially in children)",
      "Seizures (hyponatraemia)",
      "Thromboembolism (high doses â€” haemostasis use)"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; risk of hyponatraemia increased",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” used in diabetes insipidus; monitor fluid balance",
    "lactation": "Caution â€” present in breast milk in small amounts",
    "drugInteractions": [
      "NSAIDs â€” may enhance antidiuretic effect and hyponatraemia risk",
      "Loop diuretics â€” reduce desmopressin efficacy",
      "Carbamazepine/chlorpropamide â€” enhance antidiuretic effect"
    ],
    "monitoring": [
      "Serum sodium",
      "Fluid balance/urine output",
      "BP",
      "Body weight"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mcg/day (intranasal); 0.6 mg/day (oral); 4 mcg/day (IV/SC)",
    "clinicalPearl": "Restrict fluid intake after dose to prevent dilutional hyponatraemia â€” most critical safety point."
  },
  {
    "rank": 124,
    "name": "Hydrocortisone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Cortef / Solu-Cortef / Efcortesol",
    "formation": "Synthetic glucocorticoid steroid",
    "uses": "Adrenal insufficiency, severe allergies, inflammation",
    "adult": "20â€“30 mg daily (divided) or 100 mg IV TID",
    "child": "0.5â€“2 mg/kg/dose (IV emergency)",
    "avoid": "Systemic fungal infections, live virus vaccines",
    "sideEffects": [
      "Hyperglycaemia",
      "Hypertension",
      "Weight gain",
      "Insomnia",
      "GI irritation"
    ],
    "seriousRisks": [
      "Adrenal suppression/crisis (abrupt withdrawal)",
      "Cushing's syndrome (long-term)",
      "Severe infections (immunosuppression)",
      "Osteoporosis",
      "Avascular necrosis"
    ],
    "renalAdj": "No â€” standard dosing; use with caution",
    "hepaticAdj": "No â€” standard dosing; use with caution in severe disease",
    "pregnancy": "Category C â€” use at lowest effective dose; may cause neonatal adrenal suppression",
    "lactation": "Caution â€” present in breast milk; use at low doses for short duration",
    "drugInteractions": [
      "NSAIDs â€” additive GI toxicity",
      "Antidiabetics â€” antagonised by corticosteroids",
      "CYP3A4 inducers (rifampicin) â€” reduced hydrocortisone levels"
    ],
    "monitoring": [
      "Blood glucose",
      "BP",
      "Serum electrolytes",
      "Bone density (long-term)",
      "Adrenal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "500 mg/day IV (stress dosing); 30 mg/day (physiological replacement); topical as per area",
    "clinicalPearl": "Drug of choice for physiological adrenal replacement â€” give 2/3 of dose morning, 1/3 afternoon."
  },
  {
    "rank": 125,
    "name": "Dexamethasone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Dexona / Decadron / Solurex",
    "formation": "High-potency synthetic glucocorticoid",
    "uses": "Cerebral edema, severe allergic states, COVID-19",
    "adult": "0.5â€“8 mg/day",
    "child": "0.02â€“0.3 mg/kg/day",
    "avoid": "Systemic fungal infections, active TB",
    "sideEffects": [
      "Hyperglycaemia",
      "Fluid retention",
      "Hypertension",
      "Insomnia",
      "Appetite stimulation"
    ],
    "seriousRisks": [
      "Adrenal suppression/crisis",
      "Severe immunosuppression",
      "Peptic ulcer (with NSAIDs)",
      "Psychosis (steroid-induced)",
      "Avascular necrosis of femur"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid prolonged use; risk of cleft palate (1st trimester data); given for fetal lung maturity at 24â€“34 weeks",
    "lactation": "Caution â€” excreted in breast milk; avoid high doses",
    "drugInteractions": [
      "NSAIDs â€” additive GI toxicity (peptic ulceration)",
      "Phenytoin/rifampicin â€” reduced dexamethasone effect",
      "Antidiabetics â€” raised blood glucose"
    ],
    "monitoring": [
      "Blood glucose",
      "BP",
      "Serum electrolytes",
      "Signs of infection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day (high-dose immunosuppression/oncology)",
    "clinicalPearl": "25â€“30x more potent than hydrocortisone; minimal mineralocorticoid activity â€” preferred for cerebral oedema."
  },
  {
    "rank": 126,
    "name": "Betamethasone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Betnesol / Celestone",
    "formation": "Synthetic fluorinated glucocorticoid",
    "uses": "Skin inflammation, fetal lung maturity (prenatal)",
    "adult": "12 mg IM (two doses 24 hrs apart for fetal lung)",
    "child": "Not recommended for systemic use",
    "avoid": "Hypersensitivity, idiopathic thrombocytopenic purpura",
    "sideEffects": [
      "Hyperglycaemia",
      "Skin atrophy (topical)",
      "Fluid retention",
      "Hypertension",
      "Mood changes"
    ],
    "seriousRisks": [
      "Adrenal suppression",
      "HPA axis suppression (topical extensive use)",
      "Cushing's syndrome",
      "Severe infections (immune suppression)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” used for fetal lung maturity (IM) at 24â€“34 weeks; avoid unnecessary systemic use",
    "lactation": "Caution â€” systemic betamethasone present in breast milk",
    "drugInteractions": [
      "NSAIDs â€” GI toxicity",
      "Antidiabetics â€” raised blood glucose",
      "Vaccines â€” reduced immune response"
    ],
    "monitoring": [
      "Blood glucose",
      "BP",
      "Skin condition (topical)",
      "Adrenal function (long-term systemic)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "IM 12 mg (antenatal â€” 2 doses 24 hours apart); systemic variable; topical as per area",
    "clinicalPearl": "Betamethasone 12 mg IM Ã— 2 doses 24 hours apart is gold standard for fetal lung maturity induction."
  },
  {
    "rank": 127,
    "name": "Methylprednisolone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Solu-Medrol / Medrol / Methpred",
    "formation": "Synthetic glucocorticoid",
    "uses": "Severe acute exacerbations of asthma/RA, organ transplant",
    "adult": "4â€“48 mg/day or high-dose pulse IV therapy",
    "child": "0.5â€“2 mg/kg/day",
    "avoid": "Intrathecal administration, systemic fungal infection",
    "sideEffects": [
      "Hyperglycaemia",
      "Fluid retention",
      "Hypertension",
      "Weight gain",
      "Mood changes/insomnia"
    ],
    "seriousRisks": [
      "Adrenal suppression",
      "Cushing's syndrome",
      "Avascular necrosis",
      "Severe infection",
      "Gastrointestinal bleeding"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use at lowest effective dose; neonatal adrenal suppression risk",
    "lactation": "Caution â€” present in breast milk; short-term use may be acceptable",
    "drugInteractions": [
      "NSAIDs â€” additive GI risk",
      "Anticoagulants (warfarin) â€” altered INR",
      "CYP3A4 inducers â€” reduced methylprednisolone efficacy"
    ],
    "monitoring": [
      "Blood glucose",
      "BP",
      "Serum electrolytes",
      "Weight",
      "Bone density (long-term)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1 g/day IV (pulse therapy); 64 mg/day (oral high dose)",
    "clinicalPearl": "IV pulse methylprednisolone 1 g/day Ã— 3 days used in autoimmune conditions and renal transplant rejection."
  },
  {
    "rank": 128,
    "name": "Prednisolone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Wysolone / Omnacortil / Deltacortril",
    "formation": "Synthetic glucocorticoid derivative",
    "uses": "Bronchial asthma, nephrotic syndrome, RA",
    "adult": "5â€“60 mg/day",
    "child": "1â€“2 mg/kg/day",
    "avoid": "Active TB, chickenpox/measles exposure",
    "sideEffects": [
      "Hyperglycaemia",
      "Weight gain",
      "Mood changes",
      "GI irritation",
      "Insomnia"
    ],
    "seriousRisks": [
      "Adrenal suppression",
      "Cushing's syndrome",
      "Osteoporosis",
      "Peptic ulcer",
      "Serious infections"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing; caution in severe disease",
    "pregnancy": "Category C â€” use at lowest effective dose; widely used in autoimmune conditions in pregnancy",
    "lactation": "Caution â€” present in breast milk; avoid doses >20 mg/day (breastfeed 4 hours after dose)",
    "drugInteractions": [
      "NSAIDs â€” additive GI toxicity",
      "Rifampicin â€” reduced prednisolone levels",
      "Cyclosporine â€” mutual interaction; increased toxicity"
    ],
    "monitoring": [
      "Blood glucose",
      "BP",
      "Bone density (long-term)",
      "Serum potassium",
      "Weight"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "80 mg/day (acute high dose); taper to maintenance doses (5â€“10 mg/day)",
    "clinicalPearl": "Single morning dose mimics cortisol diurnal rhythm â€” minimises HPA axis suppression."
  },
  {
    "rank": 129,
    "name": "Deflazacort",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Defcort / Calcort / Dezflam",
    "formation": "Oxazoline derivative of prednisolone",
    "uses": "Duchenne Muscular Dystrophy, RA, asthma",
    "adult": "6â€“90 mg/day",
    "child": "0.25â€“1.5 mg/kg/day",
    "avoid": "Hypersensitivity, live vaccine administration",
    "sideEffects": [
      "Hyperglycaemia (less than prednisolone)",
      "Insomnia",
      "Weight gain",
      "GI irritation",
      "Mood changes"
    ],
    "seriousRisks": [
      "Adrenal suppression",
      "Osteoporosis (less than prednisolone)",
      "Cushing's syndrome",
      "Infections",
      "Cataract/glaucoma"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” limited data; consider risks and benefits",
    "lactation": "Caution â€” limited data on excretion in breast milk",
    "drugInteractions": [
      "NSAIDs â€” additive GI effects",
      "Antidiabetics â€” glucose-raising effect",
      "Enzyme inducers â€” reduced deflazacort efficacy"
    ],
    "monitoring": [
      "Blood glucose",
      "Bone density",
      "BP",
      "Weight",
      "Eye examination (long-term)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "120 mg/day (acute); maintenance doses much lower",
    "clinicalPearl": "Oxazoline derivative of prednisolone â€” causes less glucose elevation and bone loss; preferred in children (DMD)."
  },
  {
    "rank": 130,
    "name": "Triamcinolone",
    "section": "Section 3: Metabolic & Endocrine",
    "category": "Hormonal",
    "schedule": "H",
    "brand": "Kenacort / Tricort",
    "formation": "Synthetic corticosteroid",
    "uses": "Oral ulcers, joint inflammation, skin conditions",
    "adult": "4 mg OD or intra-articular injection (40 mg)",
    "child": "0.1â€“0.5 mg/kg/day (systemic use restricted)",
    "avoid": "Extensive plaque psoriasis, systemic fungal infection",
    "sideEffects": [
      "Hyperglycaemia",
      "Skin atrophy (topical)",
      "Injection site reactions (intra-articular)",
      "Fluid retention",
      "Hypertension"
    ],
    "seriousRisks": [
      "Adrenal suppression (systemic use)",
      "Cushing's syndrome",
      "Septic arthritis (intra-articular injection)",
      "Tendon rupture (peri-tendinous injection)",
      "Anaphylaxis (IV)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” topical/intra-articular generally low systemic risk; avoid systemic high-dose",
    "lactation": "Caution â€” systemic doses present in breast milk; topical use safer",
    "drugInteractions": [
      "NSAIDs â€” additive GI toxicity (systemic triamcinolone)",
      "Antidiabetics â€” raised blood glucose",
      "CYP3A4 inhibitors â€” increased triamcinolone systemic exposure"
    ],
    "monitoring": [
      "Blood glucose",
      "BP",
      "Injection site (intra-articular â€” signs of infection)",
      "Skin thinning (topical)",
      "Eye pressure (ophthalmic use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "80 mg/dose (IM/intra-articular); topical as per body surface area",
    "clinicalPearl": "Intra-articular triamcinolone: do not inject same joint more than 3â€“4 times per year â€” avascular necrosis risk."
  },
  {
    "rank": 131,
    "name": "Cefpodoxime Proxetil",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Cepodem / Cefoprox / Vantin",
    "formation": "Oral third-generation cephalosporin ester",
    "uses": "Acute bronchitis, skin infections, tonsillitis",
    "adult": "200 mg BID",
    "child": "10 mg/kg/day in 2 divided doses",
    "avoid": "Hypersensitivity to beta-lactams",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Abdominal pain",
      "Headache",
      "Skin rash"
    ],
    "seriousRisks": [
      "C. difficile colitis",
      "Anaphylaxis",
      "Stevens-Johnson syndrome",
      "Severe hypersensitivity"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: dose every 24h; CrCl <10: every 48h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” generally considered safe; use only if clearly needed",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for GI effects",
    "drugInteractions": [
      "Antacids/H2 blockers â€” reduced absorption",
      "Probenecid â€” increased cefpodoxime levels",
      "Warfarin â€” enhanced anticoagulant effect"
    ],
    "monitoring": [
      "Renal function",
      "Signs of hypersensitivity",
      "Stool frequency"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (200 mg every 12h)",
    "clinicalPearl": "Take with food to improve bioavailability of this prodrug ester."
  },
  {
    "rank": 132,
    "name": "Levofloxacin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Levomac / Levoflox / Tavanic",
    "formation": "S-enantiomer of ofloxacin (Fluoroquinolone)",
    "uses": "Community-acquired pneumonia, acute pyelonephritis",
    "adult": "500 mg OD or BID",
    "child": "10â€“20 mg/kg/day (Restrict under 18y)",
    "avoid": "History of tendon rupture, myasthenia gravis",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Headache",
      "Insomnia",
      "Dizziness"
    ],
    "seriousRisks": [
      "Tendon rupture (Achilles)",
      "QT prolongation",
      "Peripheral neuropathy",
      "C. difficile colitis",
      "Aortic aneurysm/dissection"
    ],
    "renalAdj": "Yes â€” CrCl 20-49: 250-500 mg/24h; CrCl <20: 250 mg/24-48h; haemodialysis: 250 mg/48h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; risk of arthropathy in animal studies",
    "lactation": "Avoid â€” excreted in breast milk; risk of arthropathy in infant",
    "drugInteractions": [
      "Antacids/Iron â€” reduced absorption (separate by 2h)",
      "Class IA/III antiarrhythmics â€” additive QT prolongation",
      "NSAIDs â€” increased CNS stimulation/seizure risk"
    ],
    "monitoring": [
      "ECG (QTc)",
      "Renal function",
      "Tendon pain",
      "Blood glucose"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "750 mg/day",
    "clinicalPearl": "Avoid in elderly with corticosteroids â€” highest tendon rupture risk."
  },
  {
    "rank": 133,
    "name": "Metronidazole",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Flagyl / Metrogyl",
    "formation": "Nitroimidazole antibiotic/antiprotozoal",
    "uses": "Amoebiasis, giardiasis, anaerobic infections",
    "adult": "400 mg TID",
    "child": "30â€“50 mg/kg/day in 3 divided doses",
    "avoid": "First trimester of pregnancy, alcohol consumption",
    "sideEffects": [
      "Metallic taste",
      "Nausea",
      "Vomiting",
      "Headache",
      "Dark urine"
    ],
    "seriousRisks": [
      "Peripheral neuropathy (prolonged use)",
      "Seizures",
      "Encephalopathy",
      "Severe hepatotoxicity"
    ],
    "renalAdj": "No â€” standard dosing; caution in severe renal failure (metabolite accumulation)",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose by 50%; monitor closely",
    "pregnancy": "Category B â€” avoid in 1st trimester; safe in 2nd/3rd for bacterial vaginosis/trichomoniasis",
    "lactation": "Caution â€” excreted in breast milk; withhold feeding for 12-24h after high-dose therapy",
    "drugInteractions": [
      "Alcohol â€” disulfiram-like reaction (flushing, vomiting)",
      "Warfarin â€” potentiates anticoagulant effect",
      "Phenytoin â€” increased phenytoin levels"
    ],
    "monitoring": [
      "LFT",
      "Neurological symptoms",
      "CBC (prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (IV); 2000 mg/day (oral standard)",
    "clinicalPearl": "Strict alcohol avoidance mandatory â€” disulfiram reaction can occur up to 3 days post-dose."
  },
  {
    "rank": 134,
    "name": "Clindamycin HCl",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Dalacin-C / Clincin / Cleocin",
    "formation": "Lincosamide antibiotic",
    "uses": "Skin and soft tissue infections, MRSA, dental abscess",
    "adult": "150â€“450 mg TID or QID",
    "child": "10â€“30 mg/kg/day in 3â€“4 divided doses",
    "avoid": "History of Pseudomembranous colitis",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Abdominal cramps",
      "Rash",
      "Metallic taste"
    ],
    "seriousRisks": [
      "C. difficile-associated diarrhoea (high risk)",
      "Pseudomembranous colitis",
      "Anaphylaxis",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: use with caution, reduce dose",
    "pregnancy": "Category B â€” generally considered safe when benefit outweighs risk",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for GI effects/bloody stools",
    "drugInteractions": [
      "Neuromuscular blocking agents â€” enhanced blockade",
      "Erythromycin â€” antagonistic (same ribosomal binding site)",
      "Kaolin-pectin â€” reduced oral absorption"
    ],
    "monitoring": [
      "Stool frequency/consistency",
      "LFT",
      "Signs of superinfection"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4800 mg/day (IV); 1800 mg/day (oral)",
    "clinicalPearl": "Highest risk antibiotic for C. diff â€” stop immediately if significant diarrhoea develops."
  },
  {
    "rank": 135,
    "name": "Meropenem",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Meronem / Meromer / Merrem",
    "formation": "Parenteral carbapenem",
    "uses": "Complicated intra-abdominal infections, meningitis, sepsis",
    "adult": "500 mg to 1 g IV every 8 hrs",
    "child": "60â€“120 mg/kg/day in 3 divided doses",
    "avoid": "Anaphylactic reactions to beta-lactams",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Headache",
      "Injection site inflammation",
      "Rash"
    ],
    "seriousRisks": [
      "Seizures (especially renal impairment/high dose)",
      "C. difficile colitis",
      "Anaphylaxis",
      "Stevens-Johnson syndrome",
      "Thrombocytopenia"
    ],
    "renalAdj": "Yes â€” CrCl 26-50: standard dose every 12h; CrCl 10-25: half dose every 12h; CrCl <10: half dose every 24h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” use only if clearly needed; limited human data",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "Valproic acid â€” drastically reduced valproate levels (avoid combo)",
      "Probenecid â€” increased meropenem levels",
      "Warfarin â€” may potentiate anticoagulation"
    ],
    "monitoring": [
      "Renal function (creatinine)",
      "LFT",
      "CBC",
      "Seizure threshold"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "6000 mg/day (2g every 8h for meningitis/severe infections)",
    "clinicalPearl": "Always check valproate levels â€” meropenem can cause breakthrough seizures by dropping valproate >80%."
  },
  {
    "rank": 136,
    "name": "Piperacillin + Tazobactam",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Piptaz / Tazact / Zosyn",
    "formation": "Ureidopenicillin + beta-lactamase inhibitor",
    "uses": "Nosocomial pneumonia, neutropenic fever",
    "adult": "4.5 g IV every 6â€“8 hrs",
    "child": "240â€“300 mg/kg/day in divided doses",
    "avoid": "Hypersensitivity to penicillins",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Headache",
      "Insomnia",
      "Rash"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "C. difficile colitis",
      "Hypokalaemia",
      "Neutropenia (prolonged use)",
      "Haematological toxicity"
    ],
    "renalAdj": "Yes â€” CrCl 20-40: 2.25g every 6h; CrCl <20: 2.25g every 8h; haemodialysis: 2.25g every 8h + 0.75g after dialysis",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” generally considered safe when benefit outweighs risk",
    "lactation": "Caution â€” excreted in breast milk in small amounts; monitor infant",
    "drugInteractions": [
      "Aminoglycosides â€” synergistic antibacterial effect (do not mix in same line)",
      "Methotrexate â€” reduced methotrexate clearance, toxicity risk",
      "Vecuronium â€” prolonged neuromuscular blockade"
    ],
    "monitoring": [
      "Renal function",
      "Electrolytes (K+)",
      "CBC",
      "LFT"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "18g/2.25g per day (4.5g every 6h)",
    "clinicalPearl": "Extended infusion over 4h significantly improves PK/PD target attainment for MDR Gram-negatives."
  },
  {
    "rank": 137,
    "name": "Linezolid",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Linox / Zyvox / Lizolid",
    "formation": "Oxazolidinone subclass",
    "uses": "Vancomycin-resistant Enterococcus (VRE), pneumonia",
    "adult": "600 mg BID",
    "child": "10 mg/kg TID",
    "avoid": "Concomitant MAO inhibitor use",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Headache",
      "Insomnia",
      "Tongue discolouration"
    ],
    "seriousRisks": [
      "Myelosuppression (thrombocytopenia, anaemia)",
      "Serotonin syndrome (with SSRIs/MAOIs)",
      "Lactic acidosis",
      "Optic neuropathy (prolonged use)",
      "Peripheral neuropathy"
    ],
    "renalAdj": "No â€” standard dosing (metabolites accumulate but not clinically significant)",
    "hepaticAdj": "No â€” standard dosing (mild-moderate); caution in severe",
    "pregnancy": "Category C â€” avoid unless no alternative; limited human data",
    "lactation": "Avoid â€” excreted in breast milk; risk of myelosuppression in infant",
    "drugInteractions": [
      "SSRIs/MAOIs â€” serotonin syndrome (contraindicated)",
      "Sympathomimetics â€” hypertensive crisis",
      "Tyramine-rich foods â€” hypertensive reaction"
    ],
    "monitoring": [
      "CBC weekly (platelets, haemoglobin)",
      "LFT",
      "Vision (optic neuropathy)",
      "Lactic acid (prolonged use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1200 mg/day (600 mg every 12h)",
    "clinicalPearl": "Limit to 28 days â€” weekly CBC mandatory; avoid tyramine-rich foods throughout therapy."
  },
  {
    "rank": 138,
    "name": "Faropenem Sodium",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Farobact / Romenem",
    "formation": "Oral penem subclass",
    "uses": "RTI, UTI, gynecological infections",
    "adult": "200â€“300 mg TID",
    "child": "Not recommended",
    "avoid": "History of seizure disorders",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Headache",
      "Rash",
      "Elevated liver enzymes"
    ],
    "seriousRisks": [
      "C. difficile colitis",
      "Anaphylaxis (cross-reactivity with beta-lactams)",
      "Seizures (rare)",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: reduce dose and frequency; use with caution",
    "hepaticAdj": "Yes â€” moderate-severe impairment: reduce dose; monitor LFT",
    "pregnancy": "Category B â€” limited human data; use only if clearly indicated",
    "lactation": "Caution â€” limited data; avoid if possible",
    "drugInteractions": [
      "Valproic acid â€” may reduce valproate levels",
      "Probenecid â€” increased faropenem exposure",
      "Warfarin â€” may enhance anticoagulation"
    ],
    "monitoring": [
      "Renal function",
      "LFT",
      "Signs of hypersensitivity",
      "Stool consistency"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day (200 mg three times daily)",
    "clinicalPearl": "Oral penem â€” useful for community-acquired ESBL infections as step-down from IV carbapenems."
  },
  {
    "rank": 139,
    "name": "Nitrofurantoin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Macrobid / Furadantin / Niftran",
    "formation": "Nitrofuran derivative",
    "uses": "Uncomplicated urinary tract infections",
    "adult": "100 mg BID for 5 days",
    "child": "5â€“7 mg/kg/day in 4 divided doses",
    "avoid": "Renal impairment (CrCl < 30), near-term pregnancy",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Anorexia",
      "Headache",
      "Urine discolouration (brown)"
    ],
    "seriousRisks": [
      "Pulmonary toxicity (acute/chronic)",
      "Hepatotoxicity",
      "Peripheral neuropathy",
      "Haemolytic anaemia (G6PD deficiency)"
    ],
    "renalAdj": "Yes â€” contraindicated if CrCl <45 mL/min (ineffective + increased toxicity)",
    "hepaticAdj": "Yes â€” contraindicated in severe hepatic impairment",
    "pregnancy": "Category B â€” safe in 2nd trimester; avoid at term (38-42 weeks) â€” risk of neonatal haemolysis",
    "lactation": "Caution â€” avoid if infant <1 month or G6PD deficient",
    "drugInteractions": [
      "Antacids (magnesium trisilicate) â€” reduced absorption",
      "Fluoroquinolones â€” antagonistic effect (avoid combination)",
      "Probenecid â€” increased nitrofurantoin toxicity"
    ],
    "monitoring": [
      "Renal function (CrCl before initiating)",
      "Pulmonary symptoms",
      "LFT (prolonged use)",
      "CBC (G6PD status)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (100 mg four times daily standard; 100 mg BD modified-release)",
    "clinicalPearl": "Urine must reach adequate concentration â€” ineffective if CrCl <45; always take with food."
  },
  {
    "rank": 140,
    "name": "Norfloxacin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Norflox / Uroflox",
    "formation": "Fluoroquinolone derivative",
    "uses": "UTI, bacterial prostatitis, gastroenteritis",
    "adult": "400 mg BID",
    "child": "Not recommended (under 18 years)",
    "avoid": "Pregnancy, myasthenia gravis",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Headache",
      "Rash",
      "Abdominal discomfort"
    ],
    "seriousRisks": [
      "Tendon rupture",
      "QT prolongation",
      "C. difficile colitis",
      "Peripheral neuropathy",
      "Phototoxicity"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: 400 mg once daily",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; risk of arthropathy",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "Antacids/Iron â€” reduced absorption (separate by 2h)",
      "Warfarin â€” enhanced anticoagulant effect",
      "NSAIDs â€” increased CNS excitability/seizure risk"
    ],
    "monitoring": [
      "Renal function",
      "Tendon pain",
      "ECG if QT risk"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (400 mg every 12h)",
    "clinicalPearl": "Low systemic bioavailability â€” suitable only for urinary and GI tract infections, not systemic infections."
  },
  {
    "rank": 141,
    "name": "Ciprofloxacin Eye/Ear Drops",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Ciplox Eye/Ear / Ciproquin",
    "formation": "Fluoroquinolone",
    "uses": "Bacterial conjunctivitis, otitis externa",
    "adult": "1â€“2 drops every 4 hrs",
    "child": "Same as adult",
    "avoid": "Viral or fungal eye/ear infections",
    "sideEffects": [
      "Local burning/stinging",
      "Ocular discomfort",
      "Taste disturbance (ear drops)",
      "Transient blurred vision (eye drops)",
      "Eyelid margin crusting"
    ],
    "seriousRisks": [
      "Corneal perforation (if corneal ulcer mismanaged)",
      "Hypersensitivity reaction",
      "Superinfection with resistant organisms"
    ],
    "renalAdj": "No â€” topical use; systemic absorption negligible",
    "hepaticAdj": "No â€” topical use; systemic absorption negligible",
    "pregnancy": "Category C â€” topical; minimal systemic absorption; generally considered safe",
    "lactation": "Safe â€” minimal systemic absorption from topical use",
    "drugInteractions": [
      "Topical corticosteroids (combined) â€” mask infection signs",
      "Other topical eye drops â€” space by 5 minutes",
      "Systemic fluoroquinolones â€” additive (if used concurrently)"
    ],
    "monitoring": [
      "Clinical response at 48-72h",
      "Signs of superinfection",
      "Corneal healing (ulcers)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Eye: 2 drops every 2h (acute) then every 4h; Ear: 4 drops twice daily",
    "clinicalPearl": "Press lacrimal sac 1 min after eye drop instillation to minimise systemic absorption and bitter taste."
  },
  {
    "rank": 142,
    "name": "Tinidazole",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Tiniba / Fasigyn",
    "formation": "Nitroimidazole antiprotozoal",
    "uses": "Trichomoniasis, giardiasis, amoebiasis",
    "adult": "2 g single dose",
    "child": "50 mg/kg single dose",
    "avoid": "First trimester of pregnancy, blood dyscrasias",
    "sideEffects": [
      "Metallic taste",
      "Nausea",
      "Vomiting",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Peripheral neuropathy (prolonged use)",
      "Seizures",
      "Severe hypersensitivity",
      "Leucopenia"
    ],
    "renalAdj": "No â€” standard dosing; caution in severe renal failure",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose; monitor",
    "pregnancy": "Category C â€” avoid in 1st trimester; weigh risk-benefit in 2nd/3rd",
    "lactation": "Avoid â€” excreted in breast milk; withhold breastfeeding for 72h after dose",
    "drugInteractions": [
      "Alcohol â€” disulfiram-like reaction (contraindicated)",
      "Warfarin â€” potentiates anticoagulant effect",
      "Phenytoin â€” may increase phenytoin levels"
    ],
    "monitoring": [
      "Neurological symptoms",
      "CBC (prolonged use)",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2000 mg/day (single dose for giardiasis/trichomoniasis)",
    "clinicalPearl": "Better GI tolerability and longer half-life than metronidazole â€” single-dose regimen improves compliance."
  },
  {
    "rank": 143,
    "name": "Albendazole",
    "section": "Section 4: Anti-Infective",
    "category": "Antiparasitic",
    "schedule": "H",
    "brand": "Zentel / Noworm",
    "formation": "Benzimidazole anthelmintic",
    "uses": "Pinworm, hookworm, neurocysticercosis",
    "adult": "400 mg single dose or BID",
    "child": "200 mg (<2y) or 400 mg (>2y)",
    "avoid": "Pregnancy, severe liver disease",
    "sideEffects": [
      "Nausea",
      "Abdominal pain",
      "Headache",
      "Dizziness",
      "Elevated liver enzymes"
    ],
    "seriousRisks": [
      "Bone marrow suppression (agranulocytosis)",
      "Hepatotoxicity",
      "Stevens-Johnson syndrome",
      "Alopecia (prolonged use)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment; monitor LFT",
    "pregnancy": "Category D â€” teratogenic in animals; contraindicated in 1st trimester; avoid in pregnancy",
    "lactation": "Caution â€” limited data; avoid prolonged high-dose therapy during lactation",
    "drugInteractions": [
      "Dexamethasone â€” increases albendazole sulfoxide levels",
      "Cimetidine â€” increases albendazole sulfoxide levels",
      "Praziquantel â€” increased albendazole plasma levels"
    ],
    "monitoring": [
      "LFT (every 2 weeks for prolonged therapy)",
      "CBC",
      "Ophthalmic exam (neurocysticercosis)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (400 mg twice daily for tissue infections)",
    "clinicalPearl": "Take with fatty meal â€” fat increases bioavailability 5-fold; cycle therapy with steroid cover for neurocysticercosis."
  },
  {
    "rank": 144,
    "name": "Ivermectin",
    "section": "Section 4: Anti-Infective",
    "category": "Antiparasitic",
    "schedule": "H",
    "brand": "Stromectol / Ivercim",
    "formation": "Macrocyclic lactone",
    "uses": "Scabies, strongyloidiasis, onchocerciasis",
    "adult": "200 mcg/kg single dose",
    "child": "200 mcg/kg (Not recommended < 15 kg)",
    "avoid": "Pregnancy, disorders of the CNS",
    "sideEffects": [
      "Dizziness",
      "Nausea",
      "Pruritus",
      "Diarrhoea",
      "Mazzotti reaction (onchocerciasis)"
    ],
    "seriousRisks": [
      "Encephalopathy (in Loa loa co-infection)",
      "Severe allergic reaction",
      "Hypotension",
      "Neurological toxicity (high dose/CNS disorders)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid in 1st trimester; use only if essential",
    "lactation": "Caution â€” present in breast milk; avoid in infants <15 kg",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulant effect",
      "Barbiturates â€” may reduce ivermectin efficacy",
      "CYP3A4 inhibitors (e.g., ketoconazole) â€” increased ivermectin levels"
    ],
    "monitoring": [
      "Mazzotti reaction signs",
      "Neurological symptoms",
      "Response at 3 months (parasitological cure)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mcg/kg as single dose (repeated as needed)",
    "clinicalPearl": "Take on empty stomach with water â€” food increases absorption unpredictably and may cause toxicity."
  },
  {
    "rank": 145,
    "name": "Terbinafine HCl",
    "section": "Section 4: Anti-Infective",
    "category": "Antifungal",
    "schedule": "H",
    "brand": "Terbicip / Lamisil / Terbiforce",
    "formation": "Allylamine antifungal",
    "uses": "Onychomycosis, tinea capitis, tinea pedis",
    "adult": "250 mg OD for 6â€“12 weeks",
    "child": "62.5â€“250 mg OD (Weight-based)",
    "avoid": "Chronic or active liver disease",
    "sideEffects": [
      "GI disturbance",
      "Headache",
      "Rash",
      "Taste disturbance (dysgeusia)",
      "Elevated liver enzymes"
    ],
    "seriousRisks": [
      "Hepatotoxicity (severe, including liver failure)",
      "Stevens-Johnson syndrome",
      "Pancytopenia",
      "Severe taste loss (can be prolonged)"
    ],
    "renalAdj": "Yes â€” CrCl <50 mL/min: use with caution; half dose may be considered",
    "hepaticAdj": "Yes â€” contraindicated in active or chronic liver disease",
    "pregnancy": "Category B â€” avoid in 1st trimester; use only if essential",
    "lactation": "Avoid â€” excreted in breast milk; potential for hepatotoxicity in infant",
    "drugInteractions": [
      "Rifampicin â€” reduced terbinafine levels",
      "Cimetidine â€” increased terbinafine levels",
      "TCAs/SSRIs â€” terbinafine inhibits CYP2D6, increasing levels"
    ],
    "monitoring": [
      "LFT at baseline and 4-6 weeks",
      "CBC",
      "Taste sensation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "250 mg/day",
    "clinicalPearl": "Fungicidal (not fungistatic) â€” shorter treatment duration than azoles for onychomycosis."
  },
  {
    "rank": 146,
    "name": "Fluconazole",
    "section": "Section 4: Anti-Infective",
    "category": "Antifungal",
    "schedule": "OTC",
    "brand": "Forcan / Zocon / Diflucan",
    "formation": "Triazole antifungal",
    "uses": "Vaginal candidiasis, cryptococcal meningitis",
    "adult": "150 mg single dose or 100â€“400 mg daily",
    "child": "3â€“12 mg/kg/day",
    "avoid": "Concomitant QT-prolonging drugs",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Abdominal pain",
      "Diarrhoea",
      "Rash"
    ],
    "seriousRisks": [
      "Hepatotoxicity",
      "QT prolongation/Torsades de pointes",
      "Stevens-Johnson syndrome",
      "Adrenal insufficiency (high dose)",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” CrCl <50 mL/min: reduce dose by 50%; haemodialysis: full dose after each session",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; monitor LFT",
    "pregnancy": "Category D â€” avoid; associated with fetal abnormalities (high dose); single low dose may be acceptable",
    "lactation": "Avoid â€” excreted in breast milk in concentrations similar to plasma",
    "drugInteractions": [
      "Warfarin â€” markedly potentiates anticoagulation",
      "Terfenadine/cisapride â€” QT prolongation (contraindicated)",
      "Cyclosporin â€” increased cyclosporin levels"
    ],
    "monitoring": [
      "LFT",
      "ECG (QTc)",
      "Renal function",
      "Electrolytes (K+, Mg2+)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (loading dose for candidaemia)",
    "clinicalPearl": "Single 150 mg dose is first-line for uncomplicated vulvovaginal candidiasis â€” highly effective."
  },
  {
    "rank": 147,
    "name": "Griseofulvin",
    "section": "Section 4: Anti-Infective",
    "category": "Antifungal",
    "schedule": "OTC",
    "brand": "Grifulvin / Grisovin / Fulvicin",
    "formation": "Penicillium-derived antifungal",
    "uses": "Dermatophyte infections of skin/hair/nails",
    "adult": "500 mg to 1 g daily",
    "child": "10â€“20 mg/kg/day",
    "avoid": "Porphyria, hepatocellular failure, pregnancy",
    "sideEffects": [
      "Headache",
      "Nausea",
      "GI upset",
      "Photosensitivity",
      "Rash"
    ],
    "seriousRisks": [
      "Hepatotoxicity",
      "Leucopenia",
      "Lupus-like syndrome",
      "Stevens-Johnson syndrome",
      "Teratogenicity"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” contraindicated in hepatic failure; monitor LFT",
    "pregnancy": "Category X â€” teratogenic; absolutely contraindicated",
    "lactation": "Avoid â€” excreted in breast milk; potential carcinogenicity",
    "drugInteractions": [
      "Warfarin â€” reduced anticoagulant effect",
      "Oral contraceptives â€” reduced OCP efficacy (use barrier method)",
      "Alcohol â€” disulfiram-like reaction"
    ],
    "monitoring": [
      "LFT (prolonged therapy)",
      "CBC",
      "Renal function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1000 mg/day (ultramicrosize: 660-750 mg/day)",
    "clinicalPearl": "Fungistatic only â€” continue for 6-12 months for toenail; take with fatty meal for absorption."
  },
  {
    "rank": 148,
    "name": "Ketoconazole Topical",
    "section": "Section 4: Anti-Infective",
    "category": "Antifungal",
    "schedule": "H",
    "brand": "Nizoral / Ketozol / Ketoskin",
    "formation": "Imidazole antifungal",
    "uses": "Dandruff (seborrheic dermatitis), tinea versicolor",
    "adult": "2% cream/shampoo PRN",
    "child": "Same as adult",
    "avoid": "Hypersensitivity",
    "sideEffects": [
      "Local irritation",
      "Burning sensation",
      "Pruritus",
      "Contact dermatitis",
      "Dry skin"
    ],
    "seriousRisks": [
      "Systemic absorption (minimal but possible in large area use)",
      "Allergic contact dermatitis",
      "Adrenal suppression (large area/prolonged use â€” rare)"
    ],
    "renalAdj": "No â€” topical; systemic absorption negligible",
    "hepaticAdj": "No â€” topical; systemic absorption negligible",
    "pregnancy": "Category C â€” topical; avoid large-area application in 1st trimester",
    "lactation": "Safe â€” avoid applying to breast area",
    "drugInteractions": [
      "Topical corticosteroids â€” increased absorption with occlusion",
      "Oral ketoconazole â€” additive hepatotoxicity risk if used together",
      "Warfarin â€” negligible interaction from topical use"
    ],
    "monitoring": [
      "Clinical response at 2-4 weeks",
      "Skin integrity",
      "Signs of secondary infection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Shampoo: apply twice weekly; Cream: apply once or twice daily (area-dependent)",
    "clinicalPearl": "2% shampoo for seborrhoeic dermatitis â€” leave on 3-5 minutes before rinsing for maximum effect."
  },
  {
    "rank": 149,
    "name": "Clotrimazole",
    "section": "Section 4: Anti-Infective",
    "category": "Antifungal",
    "schedule": "OTC",
    "brand": "Canesten / Candid / Clotrimazole",
    "formation": "Imidazole derivative",
    "uses": "Candidiasis, tinea corporis, tinea cruris",
    "adult": "1% cream/powder BID",
    "child": "Same as adult",
    "avoid": "Hypersensitivity",
    "sideEffects": [
      "Local burning",
      "Itching",
      "Erythema",
      "Skin peeling",
      "Urethral burning (vaginal use)"
    ],
    "seriousRisks": [
      "Severe local allergic reaction",
      "Liver toxicity (oral troches only)",
      "Secondary bacterial infection"
    ],
    "renalAdj": "No â€” topical; systemic absorption minimal",
    "hepaticAdj": "No â€” topical; systemic absorption minimal",
    "pregnancy": "Category B â€” safe topically; vaginal tablet preferred over applicator in pregnancy",
    "lactation": "Safe â€” topical; avoid nipple area",
    "drugInteractions": [
      "Tacrolimus/cyclosporin â€” may increase levels if significant systemic absorption",
      "Warfarin â€” negligible from topical",
      "Latex condoms/diaphragms â€” may degrade with vaginal preparations"
    ],
    "monitoring": [
      "Clinical response at 1-2 weeks",
      "Signs of secondary bacterial infection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Topical: twice daily; Vaginal: 500 mg single dose or 200 mg for 3 days",
    "clinicalPearl": "Vaginal 500 mg single-dose pessary is as effective as 7-day regimen â€” maximises compliance."
  },
  {
    "rank": 150,
    "name": "Luliconazole",
    "section": "Section 4: Anti-Infective",
    "category": "Antifungal",
    "schedule": "H",
    "brand": "Lulifin / Lulican",
    "formation": "Imidazole-subclass antifungal",
    "uses": "Tinea pedis, tinea cruris, tinea corporis",
    "adult": "1% cream OD for 1â€“2 weeks",
    "child": "Not recommended (under 12 years)",
    "avoid": "Hypersensitivity",
    "sideEffects": [
      "Application site reactions",
      "Contact dermatitis",
      "Skin peeling",
      "Erythema",
      "Pruritus"
    ],
    "seriousRisks": [
      "Severe contact dermatitis",
      "Systemic absorption (minimal)",
      "Secondary infection"
    ],
    "renalAdj": "No â€” topical; negligible systemic absorption",
    "hepaticAdj": "No â€” topical; negligible systemic absorption",
    "pregnancy": "Category C â€” limited data; avoid in 1st trimester unless essential",
    "lactation": "Caution â€” limited data; avoid nipple area",
    "drugInteractions": [
      "CYP2C19/CYP3A4 substrates â€” potential interaction if significant systemic absorption",
      "Other topical antifungals â€” additive effect",
      "Topical corticosteroids â€” may mask clinical features"
    ],
    "monitoring": [
      "Clinical response at 1-2 weeks",
      "Application site reactions"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Once daily topical application for 1-2 weeks",
    "clinicalPearl": "Once-daily application for 1 week (tinea pedis 2 weeks) â€” superior patient compliance over older azoles."
  },
  {
    "rank": 151,
    "name": "Artesunate + Lumefantrine",
    "section": "Section 4: Anti-Infective",
    "category": "Antimalarial",
    "schedule": "H",
    "brand": "Riamet / Coartem",
    "formation": "Artemisinin derivative + fluorene",
    "uses": "Uncomplicated P. falciparum malaria",
    "adult": "80 mg/480 mg BID for 3 days",
    "child": "Weight-based dosing (Consult NCVBDC)",
    "avoid": "First trimester of pregnancy, severe malaria",
    "sideEffects": [
      "Headache",
      "Dizziness",
      "Nausea",
      "Vomiting",
      "Arthralgia"
    ],
    "seriousRisks": [
      "QT prolongation",
      "Neurotoxicity (high dose artesunate)",
      "Anaemia (haemolysis)",
      "Severe hypersensitivity",
      "Delayed haemolytic anaemia"
    ],
    "renalAdj": "No â€” standard dosing in mild-moderate renal impairment",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment; monitor LFT",
    "pregnancy": "Category C â€” 2nd/3rd trimester: acceptable for uncomplicated falciparum malaria; 1st trimester: use if benefit outweighs risk (IV artesunate preferred for severe)",
    "lactation": "Caution â€” lumefantrine excreted in breast milk; short-term use generally acceptable",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” reduced lumefantrine levels",
      "QT-prolonging drugs â€” additive QT prolongation (avoid)",
      "Grapefruit juice â€” increased lumefantrine levels"
    ],
    "monitoring": [
      "Parasite clearance (blood smear at 48h, day 3, day 28)",
      "ECG (QTc)",
      "Haemoglobin/PCV",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "As per weight-based dosing: standard adult 4 tablets (80/480 mg) twice daily for 3 days",
    "clinicalPearl": "Must take with fatty food â€” lumefantrine absorption increases 16-fold with fat; 6-dose regimen over 3 days is NLEM standard."
  },
  {
    "rank": 152,
    "name": "Chloroquine Phosphate",
    "section": "Section 4: Anti-Infective",
    "category": "Antimalarial",
    "schedule": "H",
    "brand": "Lariago / Resochin",
    "formation": "4-aminoquinoline derivative",
    "uses": "P. vivax malaria treatment and prophylaxis",
    "adult": "600 mg initial, then 300 mg at 6, 24, 48 hrs",
    "child": "10 mg/kg initial, then 5 mg/kg at 6, 24, 48 hrs",
    "avoid": "Psoriasis, retinal or visual field changes",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Headache",
      "Pruritus (especially in dark-skinned patients)",
      "Visual disturbances"
    ],
    "seriousRisks": [
      "Retinopathy (cumulative dose >3.5 mg/kg/day)",
      "QT prolongation/arrhythmia",
      "Cardiomyopathy",
      "Seizures",
      "Irreversible vision loss"
    ],
    "renalAdj": "Yes â€” CrCl <10 mL/min: dose every 48h; reduce dose in renal failure",
    "hepaticAdj": "Yes â€” use with caution in hepatic disease; monitor LFT",
    "pregnancy": "Category C â€” generally acceptable for malaria prophylaxis/treatment during pregnancy",
    "lactation": "Caution â€” excreted in breast milk; insufficient to protect infant; acceptable for short treatment courses",
    "drugInteractions": [
      "Antacids â€” reduced chloroquine absorption (separate by 4h)",
      "Amiodarone â€” increased risk of arrhythmia and QT prolongation",
      "Ciclosporin â€” increased ciclosporin levels"
    ],
    "monitoring": [
      "Ophthalmologic exam (baseline and annually for long-term use)",
      "ECG",
      "CBC",
      "Renal and hepatic function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg base (1000 mg phosphate) loading dose; 300 mg base/day maintenance",
    "clinicalPearl": "Annual ophthalmology review essential for long-term use (RA/lupus) â€” hydroxychloroquine safer alternative for chronic use."
  },
  {
    "rank": 153,
    "name": "Primaquine",
    "section": "Section 4: Anti-Infective",
    "category": "Antimalarial",
    "schedule": "H1",
    "brand": "Malirid / Primaquine",
    "formation": "8-aminoquinoline derivative",
    "uses": "Radical cure of P. vivax and P. ovale malaria",
    "adult": "15 mg OD for 14 days",
    "child": "0.25â€“0.5 mg/kg/day for 14 days",
    "avoid": "G6PD deficiency, pregnancy",
    "sideEffects": [
      "Nausea",
      "Abdominal cramps",
      "Headache",
      "Methaemoglobinaemia (mild)",
      "Dark urine"
    ],
    "seriousRisks": [
      "Haemolytic anaemia (G6PD deficiency â€” severe, life-threatening)",
      "Methaemoglobinaemia",
      "Agranulocytosis",
      "Severe GI symptoms"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” contraindicated; risk of haemolysis in G6PD-deficient fetus",
    "lactation": "Avoid â€” risk of haemolysis in G6PD-deficient infant",
    "drugInteractions": [
      "Other haemolytic agents â€” additive haemolysis risk",
      "Mepacrine/quinacrine â€” increased primaquine toxicity",
      "CYP2D6 inhibitors â€” may reduce active metabolite formation"
    ],
    "monitoring": [
      "G6PD level (mandatory before prescribing)",
      "Haemoglobin/PCV",
      "Methaemoglobin levels",
      "Urine colour"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "30 mg base/day (radical cure P. vivax); 0.75 mg/kg single dose for P. falciparum gametocytocidal",
    "clinicalPearl": "G6PD testing is mandatory before prescribing â€” haemolysis can be fatal in G6PD-deficient patients."
  },
  {
    "rank": 154,
    "name": "Doxycycline HCl",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Doxrid / Doxy-1 / Vibramycin",
    "formation": "Tetracycline antibiotic",
    "uses": "Acne, malaria prophylaxis, rickettsial infections",
    "adult": "100 mg OD or BID",
    "child": "2.2â€“4.4 mg/kg/day (Avoid <8y)",
    "avoid": "Children under 8y (tooth discoloration), pregnancy",
    "sideEffects": [
      "Nausea",
      "Oesophageal irritation",
      "Photosensitivity",
      "Diarrhoea",
      "Vaginal candidiasis"
    ],
    "seriousRisks": [
      "Oesophageal ulceration (if not swallowed with adequate water)",
      "Severe photosensitivity reactions",
      "Pseudotumour cerebri (intracranial hypertension)",
      "C. difficile colitis",
      "Hepatotoxicity"
    ],
    "renalAdj": "No â€” standard dosing (one of few antibiotics safe in renal failure)",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment; monitor LFT",
    "pregnancy": "Category D â€” avoid after 15 weeks; causes tooth discolouration and bone growth inhibition",
    "lactation": "Avoid â€” absorbed by infant; risk of tooth discolouration (short-term low-risk but caution)",
    "drugInteractions": [
      "Antacids/Iron/Calcium â€” significantly reduced absorption (separate by 2-3h)",
      "Retinoids â€” additive intracranial hypertension",
      "Oral contraceptives â€” may reduce OCP efficacy"
    ],
    "monitoring": [
      "LFT (prolonged use)",
      "Signs of photosensitivity",
      "Response to therapy"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg/day (100 mg every 12h)",
    "clinicalPearl": "Take sitting upright with full glass of water â€” avoid lying down for 30 min to prevent oesophageal ulceration."
  },
  {
    "rank": 155,
    "name": "Tenofovir Alafenamide (TAF)",
    "section": "Section 4: Anti-Infective",
    "category": "Antiviral",
    "schedule": "H1",
    "brand": "Vemlidy",
    "formation": "Nucleotide reverse transcriptase inhibitor",
    "uses": "Chronic Hepatitis B, HIV-1 infection",
    "adult": "25 mg OD",
    "child": "Weight-based (approved >35 kg)",
    "avoid": "End-stage renal disease (not on dialysis)",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Fatigue",
      "Diarrhoea",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "Lactic acidosis",
      "Severe hepatomegaly with steatosis",
      "HBV exacerbation on discontinuation",
      "Renal toxicity (less than TDF)",
      "Bone density loss"
    ],
    "renalAdj": "No â€” standard dosing; TAF preferred over TDF in renal impairment (eGFR>15); avoid if eGFR<15 (no ESRD data)",
    "hepaticAdj": "Yes â€” avoid in decompensated liver disease; use with caution in Child-Pugh B/C",
    "pregnancy": "Category B â€” preferred TDF alternative; TAF data emerging; use if clearly indicated",
    "lactation": "Avoid â€” HIV transmission risk; HBV: limited data",
    "drugInteractions": [
      "Rifampicin/rifabutin â€” reduced TAF levels (avoid)",
      "P-gp inhibitors â€” increased TAF exposure",
      "Anticonvulsants (carbamazepine, phenytoin) â€” reduced TAF levels"
    ],
    "monitoring": [
      "LFT",
      "HBV/HIV viral load",
      "Renal function (creatinine, phosphate)",
      "Bone density (long-term)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "25 mg/day (HIV, with pharmacokinetic booster); 25 mg/day (HBV standalone)",
    "clinicalPearl": "TAF has 90% lower plasma tenofovir than TDF â€” superior renal and bone safety profile."
  },
  {
    "rank": 156,
    "name": "Abacavir + Lamivudine",
    "section": "Section 4: Anti-Infective",
    "category": "Antiviral",
    "schedule": "H1",
    "brand": "Epzicom / Kivexa / Abamune-L",
    "formation": "NRTI + NRTI combination",
    "uses": "Treatment of HIV-1 infection",
    "adult": "600 mg/300 mg OD",
    "child": "Weight-based titration",
    "avoid": "HLA-B*5701 positive patients (hypersensitivity)",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Fatigue",
      "Diarrhoea",
      "Insomnia"
    ],
    "seriousRisks": [
      "Hypersensitivity reaction to abacavir (HLA-B*5701 positive â€” potentially fatal)",
      "Lactic acidosis",
      "Severe hepatomegaly with steatosis",
      "HBV exacerbation (lamivudine withdrawal)",
      "Immune reconstitution syndrome"
    ],
    "renalAdj": "Yes â€” CrCl <50 mL/min: use individual components to adjust lamivudine dose",
    "hepaticAdj": "Yes â€” abacavir contraindicated in moderate-severe hepatic impairment",
    "pregnancy": "Category C â€” widely used in PMTCT programs; generally considered safe",
    "lactation": "Avoid â€” HIV transmission risk via breast milk",
    "drugInteractions": [
      "Alcohol â€” increased abacavir plasma levels",
      "Ribavirin â€” antagonises lamivudine (HBV co-treatment)",
      "Methadone â€” abacavir increases methadone clearance"
    ],
    "monitoring": [
      "HLA-B*5701 (before starting abacavir)",
      "HIV viral load",
      "CD4 count",
      "LFT",
      "CBC"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Abacavir 600 mg + Lamivudine 300 mg once daily",
    "clinicalPearl": "HLA-B*5701 screening mandatory before abacavir â€” do not rechallenge after hypersensitivity reaction (fatal risk)."
  },
  {
    "rank": 157,
    "name": "Dolutegravir",
    "section": "Section 4: Anti-Infective",
    "category": "Antiviral",
    "schedule": "H",
    "brand": "Tivicay / Dovato",
    "formation": "HIV integrase strand transfer inhibitor",
    "uses": "HIV-1 infection (in combination therapy)",
    "adult": "50 mg OD",
    "child": "5 mg to 50 mg OD (Weight-based)",
    "avoid": "Concurrent dofetilide use",
    "sideEffects": [
      "Insomnia",
      "Headache",
      "Nausea",
      "Fatigue",
      "Dizziness"
    ],
    "seriousRisks": [
      "Neural tube defects (periconception use)",
      "Hypersensitivity reactions",
      "Immune reconstitution syndrome",
      "Hepatotoxicity (in HBV/HCV co-infection)",
      "Weight gain/metabolic syndrome"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment (Child-Pugh C); use with caution in Child-Pugh B",
    "pregnancy": "Category C â€” small risk of neural tube defects if used at conception; WHO now recommends use throughout pregnancy",
    "lactation": "Avoid â€” HIV transmission risk via breast milk",
    "drugInteractions": [
      "Divalent cations (antacids, iron, calcium) â€” reduced dolutegravir absorption (take 2h before or 6h after)",
      "Rifampicin â€” increased dolutegravir dose to 50 mg BD",
      "Metformin â€” dolutegravir increases metformin exposure (reduce metformin dose)"
    ],
    "monitoring": [
      "HIV viral load (at 3, 6, 12 months then annually)",
      "CD4 count",
      "LFT",
      "Creatinine",
      "Weight/metabolic parameters"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "50 mg/day (100 mg/day with rifampicin or integrase resistance mutations)",
    "clinicalPearl": "Take 2h before or 6h after calcium, iron, or antacids â€” chelation significantly reduces drug levels."
  },
  {
    "rank": 158,
    "name": "Sofosbuvir",
    "section": "Section 4: Anti-Infective",
    "category": "Antiviral",
    "schedule": "H",
    "brand": "Sovaldi / Hepcvir / Sofovir",
    "formation": "Nucleotide analog HCV NS5B polymerase inhibitor",
    "uses": "Chronic Hepatitis C (pangenotypic)",
    "adult": "400 mg OD",
    "child": "Weight-based (approved >3 years)",
    "avoid": "Concomitant use with amiodarone",
    "sideEffects": [
      "Fatigue",
      "Headache",
      "Nausea",
      "Insomnia",
      "Anaemia (with ribavirin)"
    ],
    "seriousRisks": [
      "Severe bradycardia (with amiodarone â€” contraindicated)",
      "Hepatitis B reactivation",
      "Severe anaemia (ribavirin combination)",
      "Symptomatic bradycardia and heart block"
    ],
    "renalAdj": "Yes â€” eGFR <30 mL/min: avoid sofosbuvir-based regimens (metabolite accumulation); use glecaprevir/pibrentasvir instead",
    "hepaticAdj": "Yes â€” Child-Pugh C: not recommended",
    "pregnancy": "Category B â€” limited data; defer treatment until post-partum if possible",
    "lactation": "Avoid â€” limited data; defer treatment",
    "drugInteractions": [
      "Amiodarone â€” severe bradycardia/heart block (contraindicated)",
      "P-gp inducers (rifampicin, carbamazepine) â€” reduced sofosbuvir levels (avoid)",
      "Proton pump inhibitors â€” reduced velpatasvir levels in combo regimens"
    ],
    "monitoring": [
      "HCV RNA (week 4, end of treatment, 12 weeks post-treatment)",
      "LFT",
      "Creatinine/eGFR",
      "Haemoglobin (with ribavirin)",
      "HBsAg/HBcAb before starting"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg/day (fixed)",
    "clinicalPearl": "Amiodarone co-administration is contraindicated â€” risk of fatal bradycardia; always screen for amiodarone use."
  },
  {
    "rank": 159,
    "name": "Acyclovir",
    "section": "Section 4: Anti-Infective",
    "category": "Antiviral",
    "schedule": "H",
    "brand": "Zovirax / Acivir / Herpex",
    "formation": "Synthetic purine nucleoside analog",
    "uses": "Herpes simplex, varicella-zoster (shingles)",
    "adult": "200â€“800 mg 5 times/day",
    "child": "20 mg/kg per dose QID",
    "avoid": "Renal impairment (dose reduction required)",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Diarrhoea",
      "Injection site phlebitis (IV)",
      "Crystalluria (IV high dose)"
    ],
    "seriousRisks": [
      "Nephrotoxicity (IV â€” crystalline nephropathy)",
      "Neurotoxicity (confusion, tremors â€” in renal failure)",
      "Thrombocytopenic purpura (TTP/HUS in immunocompromised)",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” CrCl 25-50: 5-10 mg/kg every 12h; CrCl 10-25: every 24h; CrCl <10: half dose every 24h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” safe; widely used for herpes zoster/HSV in pregnancy",
    "lactation": "Safe â€” excreted in breast milk but no adverse effects reported",
    "drugInteractions": [
      "Probenecid â€” increased acyclovir levels",
      "Nephrotoxic drugs â€” additive renal toxicity (IV use)",
      "Zidovudine â€” additive neurotoxicity"
    ],
    "monitoring": [
      "Renal function (especially IV use)",
      "Hydration status",
      "Neurological symptoms",
      "CBC"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day oral (800 mg five times daily for zoster); IV: 30 mg/kg/day (HSV encephalitis)",
    "clinicalPearl": "Adequate hydration essential with IV acyclovir â€” 1-2L/day prevents crystalline nephropathy."
  },
  {
    "rank": 160,
    "name": "Vancomycin HCl",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Vancocin / Vancomycin",
    "formation": "Tricyclic glycopeptide antibiotic",
    "uses": "MRSA, pseudomembranous colitis (Oral)",
    "adult": "500 mg to 1 g IV every 12 hrs",
    "child": "40 mg/kg/day in divided doses",
    "avoid": "Hypersensitivity, renal failure (titrate)",
    "sideEffects": [
      "Red man syndrome (rapid infusion)",
      "Nephrotoxicity",
      "Ototoxicity",
      "Phlebitis",
      "Fever"
    ],
    "seriousRisks": [
      "Severe nephrotoxicity",
      "Irreversible ototoxicity",
      "Anaphylaxis",
      "Neutropenia",
      "DRESS syndrome"
    ],
    "renalAdj": "Yes â€” dose and interval based on AUC-guided TDM or trough levels; CrCl <30: significant dose reduction required",
    "hepaticAdj": "No â€” renally eliminated; standard dosing in hepatic disease",
    "pregnancy": "Category C â€” use only if clearly indicated; monitor closely",
    "lactation": "Caution â€” excreted in breast milk; poor oral bioavailability in infant; caution for oral flora effects",
    "drugInteractions": [
      "Aminoglycosides â€” additive nephrotoxicity and ototoxicity",
      "Loop diuretics â€” additive ototoxicity",
      "Neuromuscular blocking agents â€” enhanced blockade"
    ],
    "monitoring": [
      "Vancomycin AUC/MIC ratio (target 400-600) or trough (15-20 mg/L for MRSA)",
      "Renal function (daily during loading)",
      "Audiology (prolonged use)",
      "CBC"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (weight and renal function dependent; individualised TDM)",
    "clinicalPearl": "Infuse over minimum 60 min (1h per gram) â€” Red man syndrome is rate-dependent, not a true allergy."
  },
  {
    "rank": 161,
    "name": "Amikacin Sulfate",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Amicin / Amikin",
    "formation": "Semisynthetic aminoglycoside",
    "uses": "Serious Gram-negative infections, MDR-TB",
    "adult": "15 mg/kg/day in divided doses",
    "child": "15â€“22.5 mg/kg/day",
    "avoid": "Myasthenia gravis, pregnancy",
    "sideEffects": [
      "Nephrotoxicity",
      "Ototoxicity (cochlear)",
      "Injection site pain",
      "Neuromuscular blockade (high dose)",
      "Fever"
    ],
    "seriousRisks": [
      "Irreversible sensorineural hearing loss",
      "Severe nephrotoxicity",
      "Respiratory paralysis (neuromuscular blockade)",
      "Vestibular toxicity"
    ],
    "renalAdj": "Yes â€” extend dosing interval based on CrCl; once-daily dosing preferred; TDM mandatory",
    "hepaticAdj": "No â€” renally eliminated",
    "pregnancy": "Category D â€” ototoxicity in fetus; avoid unless life-threatening infection with no alternative",
    "lactation": "Caution â€” poor oral bioavailability but caution in neonates",
    "drugInteractions": [
      "Vancomycin â€” additive nephrotoxicity",
      "Loop diuretics â€” additive ototoxicity",
      "Neuromuscular blocking agents â€” enhanced and prolonged blockade"
    ],
    "monitoring": [
      "Serum drug levels (peak 56-64 mg/L; trough <5 mg/L for once-daily)",
      "Serum creatinine (daily)",
      "Audiometry (prolonged use)",
      "Electrolytes"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "22.5 mg/kg/day (single daily dose protocol preferred)",
    "clinicalPearl": "Once-daily dosing exploits post-antibiotic effect â€” equally efficacious with less nephrotoxicity than divided doses."
  },
  {
    "rank": 162,
    "name": "Gentamicin Sulfate",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Garamycin / Genticin",
    "formation": "Aminoglycoside complex",
    "uses": "Sepsis, complicated UTI, endocarditis adjunct",
    "adult": "3â€“5 mg/kg/day IV/IM",
    "child": "2.5 mg/kg per dose every 8 hrs",
    "avoid": "Renal failure (titrate levels), ototoxicity history",
    "sideEffects": [
      "Nephrotoxicity",
      "Vestibular toxicity (dizziness, nystagmus)",
      "Injection site pain",
      "Fever",
      "Hypersensitivity rash"
    ],
    "seriousRisks": [
      "Irreversible vestibular damage",
      "Ototoxicity (cochlear)",
      "Severe nephrotoxicity",
      "Neuromuscular blockade",
      "Respiratory paralysis"
    ],
    "renalAdj": "Yes â€” extend interval based on CrCl; TDM mandatory; avoid if severe renal failure if possible",
    "hepaticAdj": "No â€” renally eliminated",
    "pregnancy": "Category D â€” vestibular toxicity in fetus; avoid unless essential",
    "lactation": "Caution â€” minimal oral absorption in infant; short-term considered acceptable",
    "drugInteractions": [
      "Vancomycin/amphotericin â€” additive nephrotoxicity",
      "Loop diuretics â€” additive ototoxicity",
      "Penicillins â€” synergistic antibacterial (do not mix in same syringe)"
    ],
    "monitoring": [
      "Serum drug levels (peak 5-10 mg/L; trough <2 mg/L)",
      "Renal function (daily)",
      "Vestibular function",
      "Audiometry"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "7 mg/kg/day (once-daily); 5 mg/kg/day in divided doses",
    "clinicalPearl": "Hartford nomogram-guided once-daily dosing reduces toxicity â€” mandatory TDM in all patients."
  },
  {
    "rank": 163,
    "name": "Erythromycin Stearate",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Erythrocin / Erymed",
    "formation": "Macrolide antibiotic salt",
    "uses": "Respiratory/skin infections (penicillin-allergic)",
    "adult": "250â€“500 mg QID",
    "child": "30â€“50 mg/kg/day in divided doses",
    "avoid": "Concomitant terfenadine or astemizole",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Abdominal cramps",
      "Diarrhoea",
      "Hepatotoxicity (estolate salt)"
    ],
    "seriousRisks": [
      "QT prolongation/Torsades de pointes",
      "Cholestatic hepatitis (especially estolate salt)",
      "Severe hypersensitivity",
      "Infantile hypertrophic pyloric stenosis (neonates)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; avoid estolate salt in liver disease",
    "pregnancy": "Category B â€” stearate salt acceptable; avoid estolate (hepatotoxicity); widely used for Chlamydia in pregnancy",
    "lactation": "Caution â€” excreted in breast milk; risk of infantile hypertrophic pyloric stenosis in neonates",
    "drugInteractions": [
      "Terfenadine/cisapride/pimozide â€” fatal QT prolongation (contraindicated)",
      "Statins â€” increased statin levels, rhabdomyolysis risk",
      "Theophylline â€” significantly increased theophylline levels"
    ],
    "monitoring": [
      "ECG (QTc)",
      "LFT",
      "GI symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (1g four times daily)",
    "clinicalPearl": "Avoid in neonates <6 weeks â€” significantly associated with infantile hypertrophic pyloric stenosis."
  },
  {
    "rank": 164,
    "name": "Clarithromycin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Claribid / Biaxin / Clarimac",
    "formation": "Semisynthetic macrolide",
    "uses": "H. pylori eradication, RTI, mycobacterial infections",
    "adult": "250â€“500 mg BID",
    "child": "7.5 mg/kg BID (max 1 g/day)",
    "avoid": "Concomitant colchicine in renal impairment",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Abdominal pain",
      "Abnormal taste (metallic)",
      "Headache"
    ],
    "seriousRisks": [
      "QT prolongation/Torsades de pointes",
      "Hepatotoxicity",
      "Clostridioides difficile colitis",
      "Cardiac death risk (post-treatment â€” cardiovascular patients)",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: reduce dose by 50% or double dosing interval",
    "hepaticAdj": "Yes â€” contraindicated in significant hepatic impairment without renal impairment",
    "pregnancy": "Category C â€” avoid; limited evidence of adverse fetal outcomes",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "Statins (simvastatin/lovastatin) â€” rhabdomyolysis (contraindicated)",
      "Warfarin â€” significantly increased INR",
      "Colchicine â€” fatal colchicine toxicity (avoid in renal/hepatic impairment)"
    ],
    "monitoring": [
      "ECG (QTc)",
      "LFT",
      "Renal function",
      "Drug levels of co-medications"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1000 mg/day (500 mg twice daily; 1g/day XL formulation)",
    "clinicalPearl": "Key component of H. pylori triple therapy â€” metallic taste is expected and improves with completion of course."
  },
  {
    "rank": 165,
    "name": "Roxithromycin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Rulide / Roxid / Surlid",
    "formation": "Semisynthetic macrolide antibiotic",
    "uses": "URTI, LRTI, skin and genital infections",
    "adult": "150 mg BID or 300 mg OD",
    "child": "5â€“8 mg/kg/day",
    "avoid": "Concomitant ergot alkaloid use",
    "sideEffects": [
      "Nausea",
      "Abdominal pain",
      "Diarrhoea",
      "Headache",
      "Abnormal taste"
    ],
    "seriousRisks": [
      "QT prolongation",
      "Hepatotoxicity (rare)",
      "Severe hypersensitivity",
      "Pseudomembranous colitis"
    ],
    "renalAdj": "No â€” standard dosing (mild-moderate renal impairment); caution in severe",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose to 150 mg once daily",
    "pregnancy": "Category B â€” limited data; generally considered safer macrolide option",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "Ergotamine â€” peripheral vasospasm (contraindicated)",
      "Warfarin â€” may increase INR",
      "Theophylline â€” mild increase in theophylline levels"
    ],
    "monitoring": [
      "LFT (prolonged use)",
      "ECG (QTc if at risk)",
      "Clinical response"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day (150 mg twice daily or 300 mg once daily)",
    "clinicalPearl": "Better GI tolerability than erythromycin and lower drug interaction profile â€” preferred macrolide for URTI/LRTI."
  },
  {
    "rank": 166,
    "name": "Cephalexin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Sporidex / Keflex",
    "formation": "First-generation cephalosporin",
    "uses": "Mild UTI, skin and soft tissue infections",
    "adult": "250â€“500 mg QID",
    "child": "25â€“50 mg/kg/day in 4 divided doses",
    "avoid": "Severe penicillin allergy (cross-reactivity)",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Abdominal pain",
      "Headache",
      "Skin rash"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "C. difficile colitis",
      "Stevens-Johnson syndrome",
      "Haemolytic anaemia",
      "Interstitial nephritis"
    ],
    "renalAdj": "Yes â€” CrCl 10-40: 500 mg every 8-12h; CrCl <10: 250-500 mg every 12-24h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” generally considered safe; widely used in pregnancy",
    "lactation": "Safe â€” low levels in breast milk; monitor infant for GI effects",
    "drugInteractions": [
      "Probenecid â€” increased cephalexin levels",
      "Warfarin â€” may potentiate anticoagulation",
      "Metformin â€” cephalexin may increase metformin levels"
    ],
    "monitoring": [
      "Renal function (prolonged use)",
      "Signs of hypersensitivity",
      "Stool consistency"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (1g four times daily)",
    "clinicalPearl": "First-line for uncomplicated skin/soft tissue infections and UTI in penicillin-tolerant patients."
  },
  {
    "rank": 167,
    "name": "Cefadroxil",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Droxyl / Duricef",
    "formation": "First-generation cephalosporin",
    "uses": "Pharyngitis, tonsillitis, UTI",
    "adult": "500 mg to 1 g BID",
    "child": "30 mg/kg/day in divided doses",
    "avoid": "Renal failure (adjust dose)",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Abdominal pain",
      "Rash",
      "Headache"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "C. difficile colitis",
      "Stevens-Johnson syndrome",
      "Haemolytic anaemia",
      "Renal toxicity"
    ],
    "renalAdj": "Yes â€” CrCl 10-25: 500 mg every 24h; CrCl <10: 500 mg every 36h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” generally safe; use when clearly indicated",
    "lactation": "Safe â€” excreted in small amounts; monitor infant",
    "drugInteractions": [
      "Probenecid â€” increased cefadroxil levels",
      "Warfarin â€” mild potentiation",
      "Antacids â€” minimal effect on absorption"
    ],
    "monitoring": [
      "Renal function",
      "Signs of hypersensitivity",
      "Clinical response"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2000 mg/day (1g twice daily for most infections)",
    "clinicalPearl": "Once or twice daily dosing improves compliance over cephalexin â€” preferred for streptococcal pharyngitis/tonsillitis."
  },
  {
    "rank": 168,
    "name": "Colistin (Polymyxin E)",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H1",
    "brand": "Colistin / Polymyxin E",
    "formation": "Polymyxin subclass antibiotic",
    "uses": "Multi-drug resistant Gram-negative infections",
    "adult": "2.5â€“5 mg/kg/day in 2â€“4 divided doses",
    "child": "2.5â€“5 mg/kg/day",
    "avoid": "Myasthenia gravis, renal failure",
    "sideEffects": [
      "Nephrotoxicity",
      "Neurotoxicity (paresthesia)",
      "Injection site pain",
      "Fever",
      "Rash"
    ],
    "seriousRisks": [
      "Severe nephrotoxicity (acute kidney injury)",
      "Neuromuscular blockade",
      "Respiratory paralysis",
      "Bronchospasm (inhaled)",
      "Severe hypersensitivity"
    ],
    "renalAdj": "Yes â€” dose based on CrCl; CrCl <30: maximum 3.5 million IU/day in divided doses; TDM recommended",
    "hepaticAdj": "No â€” renally eliminated",
    "pregnancy": "Category C â€” use only as last resort; nephrotoxicity risk",
    "lactation": "Avoid â€” insufficient data; theoretical toxicity risk",
    "drugInteractions": [
      "Aminoglycosides â€” additive nephrotoxicity and neuromuscular blockade",
      "Neuromuscular blocking agents â€” enhanced blockade",
      "Loop diuretics â€” additive nephrotoxicity"
    ],
    "monitoring": [
      "Renal function (daily creatinine)",
      "Drug levels (where available)",
      "Neurological symptoms",
      "Electrolytes",
      "Urine output"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "9 million IU/day (loading dose 9 million IU then 4.5 million IU every 12h â€” renally adjusted)",
    "clinicalPearl": "Last-resort antibiotic for XDR Gram-negatives â€” dose based on colistin base activity (CBA), not total colistimethate sodium."
  },
  {
    "rank": 169,
    "name": "Fusidic Acid",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Fucidin / Fusidate",
    "formation": "Steroidal antibiotic",
    "uses": "Impetigo, folliculitis, erythrasma",
    "adult": "2% cream TID",
    "child": "Same as adult",
    "avoid": "Extensive viral/fungal skin infections",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Abdominal pain",
      "Rash",
      "Jaundice (systemic)"
    ],
    "seriousRisks": [
      "Hepatotoxicity (systemic use)",
      "Jaundice/cholestasis",
      "Resistance development (monotherapy)",
      "Local sensitisation (topical)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; monitor LFT; avoid in severe impairment",
    "pregnancy": "Category C â€” limited data; avoid systemic use especially in 3rd trimester (neonatal jaundice risk)",
    "lactation": "Caution â€” systemic: excreted in breast milk; topical: generally safe",
    "drugInteractions": [
      "Statins â€” increased statin levels, rhabdomyolysis risk (avoid combination)",
      "Ciclosporin â€” increased fusidic acid levels and cyclosporin toxicity",
      "Rifampicin â€” synergistic for MRSA but monitoring essential"
    ],
    "monitoring": [
      "LFT (systemic use)",
      "Signs of jaundice",
      "Resistance development"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1500 mg/day systemic (500 mg three times daily)",
    "clinicalPearl": "Never use systemic fusidic acid as monotherapy â€” rapid resistance emergence; always combine with rifampicin for MRSA."
  },
  {
    "rank": 170,
    "name": "Mupirocin",
    "section": "Section 4: Anti-Infective",
    "category": "Antibiotics",
    "schedule": "H",
    "brand": "Bactroban / T-Bact",
    "formation": "Pseudomonic acid derivative",
    "uses": "Impetigo, eradication of nasal MRSA",
    "adult": "2% ointment TID",
    "child": "Same as adult",
    "avoid": "Large open wounds (polyethylene glycol risk)",
    "sideEffects": [
      "Local burning",
      "Stinging",
      "Pruritus",
      "Erythema",
      "Dry skin"
    ],
    "seriousRisks": [
      "Sensitisation/contact dermatitis",
      "Secondary infection",
      "Mupirocin resistance with prolonged use (especially nasal)"
    ],
    "renalAdj": "No â€” topical; systemic absorption negligible",
    "hepaticAdj": "No â€” topical; systemic absorption negligible",
    "pregnancy": "Category B â€” topical use generally considered safe",
    "lactation": "Safe â€” avoid applying to breast/nipple area",
    "drugInteractions": [
      "Polyethylene glycol base â€” avoid in large wounds/burns (PEG absorption/renal toxicity)",
      "Other topical agents â€” do not mix",
      "Nasal mupirocin â€” negligible systemic interactions"
    ],
    "monitoring": [
      "Clinical response at 3-5 days",
      "Signs of contact sensitisation",
      "MRSA decolonisation culture (nasal use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply 3 times daily for up to 10 days (skin); nasal: twice daily for 5 days",
    "clinicalPearl": "Nasal mupirocin is standard for MRSA decolonisation â€” limit to 5-day courses to minimise resistance."
  },
  {
    "rank": 171,
    "name": "Rabeprazole Sodium",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Razo / Rablet / Rabeloc",
    "formation": "PPI (substituted benzimidazole)",
    "uses": "Acid-peptic disorders, H. pylori eradication",
    "adult": "20 mg OD (30 mins before breakfast)",
    "child": "0.5â€“1 mg/kg/day",
    "avoid": "Hypersensitivity to benzimidazoles",
    "sideEffects": [
      "Headache",
      "Diarrhoea",
      "Nausea",
      "Abdominal pain",
      "Flatulence"
    ],
    "seriousRisks": [
      "Clostridium difficile infection (long-term use)",
      "Hypomagnesaemia (prolonged use)",
      "Bone fractures (prolonged use)",
      "Fundic gland polyps",
      "Vitamin B12 deficiency"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: use with caution; no dose adjustment needed for mild-moderate",
    "pregnancy": "Category B â€” generally considered safe when benefit outweighs risk",
    "lactation": "Caution â€” limited data; omeprazole preferred (more data)",
    "drugInteractions": [
      "Methotrexate â€” increased methotrexate toxicity (high-dose)",
      "Clopidogrel â€” minimal interaction vs omeprazole (CYP2C19 less affected)",
      "Atazanavir/nelfinavir â€” reduced antiviral absorption (avoid)"
    ],
    "monitoring": [
      "Magnesium (prolonged use >1 year)",
      "Vitamin B12 (prolonged use)",
      "Bone density (long-term)",
      "H. pylori eradication status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 mg/day (standard); 60 mg/day for Zollinger-Ellison",
    "clinicalPearl": "Least CYP2C19 interaction among PPIs â€” preferred when clopidogrel is co-prescribed."
  },
  {
    "rank": 172,
    "name": "Esomeprazole Magnesium",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Nexium / Raciper / Esomac",
    "formation": "S-isomer of omeprazole (PPI)",
    "uses": "Severe GERD, healing of erosive esophagitis",
    "adult": "20â€“40 mg OD",
    "child": "0.7â€“1 mg/kg/day",
    "avoid": "Concurrent use of clopidogrel (relative)",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Diarrhoea",
      "Abdominal pain",
      "Dry mouth"
    ],
    "seriousRisks": [
      "C. difficile colitis",
      "Hypomagnesaemia",
      "Bone fractures (prolonged use)",
      "Interstitial nephritis (rare)",
      "Subacute cutaneous lupus erythematosus"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: maximum 20 mg/day",
    "pregnancy": "Category B â€” generally considered safe",
    "lactation": "Caution â€” limited data; omeprazole preferred if PPI needed",
    "drugInteractions": [
      "Clopidogrel â€” CYP2C19 inhibition reduces clopidogrel efficacy (prefer rabeprazole)",
      "Methotrexate â€” increased methotrexate levels",
      "Atazanavir â€” reduced atazanavir absorption (contraindicated)"
    ],
    "monitoring": [
      "Magnesium (>1 year use)",
      "Vitamin B12",
      "Renal function (interstitial nephritis signs)",
      "H. pylori test and treat"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 mg/day (80 mg/day for Zollinger-Ellison)",
    "clinicalPearl": "S-isomer of omeprazole â€” take 30-60 minutes before first meal for maximum efficacy."
  },
  {
    "rank": 173,
    "name": "Lansoprazole",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Lanzol / Prevacid / Lancid",
    "formation": "Substituted benzimidazole (PPI)",
    "uses": "Duodenal ulcer, gastric ulcer, GERD",
    "adult": "15â€“30 mg OD",
    "child": "0.7â€“1.5 mg/kg/day",
    "avoid": "Severe hepatic impairment",
    "sideEffects": [
      "Diarrhoea",
      "Headache",
      "Nausea",
      "Abdominal pain",
      "Constipation"
    ],
    "seriousRisks": [
      "C. difficile colitis",
      "Hypomagnesaemia",
      "Bone fractures (prolonged use)",
      "Interstitial nephritis",
      "Subacute cutaneous lupus"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: maximum 15-30 mg/day; monitor LFT",
    "pregnancy": "Category B â€” generally considered safe",
    "lactation": "Caution â€” limited data; monitor infant",
    "drugInteractions": [
      "Clopidogrel â€” moderate CYP2C19 inhibition",
      "Methotrexate â€” increased toxicity risk",
      "Sucralfate â€” delayed lansoprazole absorption (take PPI first)"
    ],
    "monitoring": [
      "Magnesium (prolonged use)",
      "Vitamin B12",
      "Bone density (long-term)",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60 mg/day (30 mg twice daily for Zollinger-Ellison)",
    "clinicalPearl": "Available as disintegrating tablet (Fastab) â€” useful in patients with dysphagia or nasogastric tubes."
  },
  {
    "rank": 174,
    "name": "Ondansetron HCl",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Emeset / Zofran / Vomistop",
    "formation": "Selective 5-HT3 receptor antagonist",
    "uses": "Nausea and vomiting (chemo/radio/post-op)",
    "adult": "4â€“8 mg TID or before chemo",
    "child": "0.15 mg/kg per dose",
    "avoid": "Congenital long QT syndrome, apomorphine use",
    "sideEffects": [
      "Headache",
      "Constipation",
      "Dizziness",
      "Flushing",
      "Injection site reaction"
    ],
    "seriousRisks": [
      "QT prolongation/Torsades de pointes",
      "Serotonin syndrome (with serotonergic drugs)",
      "Anaphylaxis",
      "Bronchospasm",
      "Masking of progressive ileus"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: maximum 8 mg/day",
    "pregnancy": "Category B â€” 2nd/3rd trimester: generally considered safe; 1st trimester: small signal for cardiac defects â€” use with caution",
    "lactation": "Caution â€” excreted in breast milk; short-term use generally acceptable",
    "drugInteractions": [
      "Serotonergic drugs (SSRIs, tramadol) â€” serotonin syndrome risk",
      "QT-prolonging drugs (haloperidol, amiodarone) â€” additive QT prolongation",
      "Apomorphine â€” severe hypotension (contraindicated)"
    ],
    "monitoring": [
      "ECG (QTc) in at-risk patients",
      "Electrolytes (K+, Mg2+)",
      "Bowel sounds/constipation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "32 mg/day (8 mg three times daily); IV: maximum single dose 16 mg",
    "clinicalPearl": "IV single dose capped at 16 mg to reduce QTc risk â€” correct hypokalaemia and hypomagnesaemia before administration."
  },
  {
    "rank": 175,
    "name": "Metoclopramide HCl",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Perinorm / Reglan / Metoclopramide",
    "formation": "Substituted benzamide (D2 antagonist)",
    "uses": "Nausea, gastroparesis, GERD prokinetic",
    "adult": "5â€“10 mg TID",
    "child": "0.1 mg/kg per dose (Avoid in < 1y)",
    "avoid": "Pheochromocytoma, GI hemorrhage",
    "sideEffects": [
      "Drowsiness",
      "Fatigue",
      "Extrapyramidal symptoms (acute dystonia)",
      "Restlessness",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "Tardive dyskinesia (prolonged use â€” irreversible)",
      "Neuroleptic malignant syndrome",
      "Acute dystonic reactions",
      "QT prolongation",
      "Depression/suicidal ideation"
    ],
    "renalAdj": "Yes â€” CrCl <40 mL/min: reduce dose by 50%",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose",
    "pregnancy": "Category B â€” generally considered safe; widely used in hyperemesis gravidarum",
    "lactation": "Caution â€” excreted in breast milk; may increase prolactin/milk production; monitor infant for extrapyramidal symptoms",
    "drugInteractions": [
      "Antipsychotics â€” additive extrapyramidal effects and tardive dyskinesia risk",
      "MAOIs â€” hypertensive crisis",
      "Opioids â€” antagonise GI prokinetic effect"
    ],
    "monitoring": [
      "Extrapyramidal symptoms",
      "Mental status",
      "QTc if at risk"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day (10 mg three times daily); maximum 5 days continuous use",
    "clinicalPearl": "Limit to 5 days maximum â€” tardive dyskinesia risk increases dramatically with prolonged use."
  },
  {
    "rank": 176,
    "name": "Lactulose",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "OTC",
    "brand": "Duphalac / Lactoloss",
    "formation": "Synthetic disaccharide (Osmotic laxative)",
    "uses": "Constipation, hepatic encephalopathy",
    "adult": "15â€“30 ml OD or BID",
    "child": "2.5â€“10 ml/day",
    "avoid": "Galactosemia, intestinal obstruction",
    "sideEffects": [
      "Flatulence",
      "Abdominal bloating",
      "Nausea",
      "Cramps",
      "Diarrhoea (excessive dose)"
    ],
    "seriousRisks": [
      "Electrolyte imbalance (dehydration/hypokalaemia with excessive use)",
      "Bowel perforation (inappropriate use)",
      "Hypernatraemia",
      "Aspiration (in altered consciousness)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing; actually used for hepatic encephalopathy",
    "pregnancy": "Category B â€” generally considered safe throughout pregnancy",
    "lactation": "Safe â€” minimal systemic absorption",
    "drugInteractions": [
      "Antacids (non-absorbable) â€” may reduce lactulose efficacy",
      "Neomycin â€” additive for hepatic encephalopathy (but neomycin toxicity concern)",
      "Mesalamine enemas â€” concurrent rectal use compatibility"
    ],
    "monitoring": [
      "Stool frequency and consistency",
      "Serum ammonia (hepatic encephalopathy)",
      "Electrolytes (prolonged use)",
      "Clinical encephalopathy grade"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60-100 g/day for hepatic encephalopathy (titrate to 2-4 stools/day)",
    "clinicalPearl": "Target 2-3 soft stools per day for hepatic encephalopathy â€” not watery diarrhoea; titrate dose accordingly."
  },
  {
    "rank": 177,
    "name": "Bisacodyl",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "OTC",
    "brand": "Dulcolax / Conlax",
    "formation": "Diphenylmethane stimulant laxative",
    "uses": "Acute constipation, bowel prep for surgery",
    "adult": "5â€“10 mg (Oral) at bedtime or 10 mg (Rectal)",
    "child": "5 mg at bedtime",
    "avoid": "Appendicitis, severe abdominal pain",
    "sideEffects": [
      "Abdominal cramps",
      "Nausea",
      "Diarrhoea",
      "Rectal irritation (suppository)",
      "Electrolyte disturbance"
    ],
    "seriousRisks": [
      "Severe electrolyte imbalance (chronic use)",
      "Melanosis coli (chronic use)",
      "Abdominal colic/obstruction",
      "Dehydration"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid in 1st trimester; short-term use acceptable in 2nd/3rd trimester; suppositories preferred over oral",
    "lactation": "Caution â€” active metabolite detected in breast milk; short-term use generally acceptable",
    "drugInteractions": [
      "Antacids/milk â€” premature dissolution of enteric coating, causing gastric irritation (separate by 1h)",
      "Diuretics â€” additive electrolyte loss",
      "Other stimulant laxatives â€” excessive bowel stimulation"
    ],
    "monitoring": [
      "Electrolytes (K+, Na+ â€” prolonged use)",
      "Bowel habit frequency",
      "Signs of dependence"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day oral (10 mg for routine; up to 30 mg for bowel prep); Suppository: 10 mg",
    "clinicalPearl": "Do not crush or chew enteric-coated tablets and avoid with antacids/milk â€” gastric irritation and cramping results."
  },
  {
    "rank": 178,
    "name": "Polyethylene Glycol PEG 3350",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "OTC",
    "brand": "Peglec / Forlax / Moviprep",
    "formation": "Osmotic polymer",
    "uses": "Occasional constipation, bowel cleansing",
    "adult": "17 g powder in 240 ml liquid daily",
    "child": "0.2â€“0.8 g/kg/day",
    "avoid": "GI perforation, toxic megacolon",
    "sideEffects": [
      "Bloating",
      "Abdominal cramping",
      "Nausea",
      "Flatulence",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "Electrolyte disturbance (large-volume prep)",
      "Aspiration (altered consciousness)",
      "Allergic reactions (rare)",
      "Exacerbation of IBD"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment (electrolyte preparation); macrogol for constipation: generally safe",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” generally considered safe for constipation; bowel prep: avoid unless essential",
    "lactation": "Safe â€” minimal systemic absorption",
    "drugInteractions": [
      "Other oral medications â€” may alter absorption; take other drugs 1h before PEG",
      "Electrolyte solutions â€” monitor combined electrolyte load"
    ],
    "monitoring": [
      "Electrolytes (bowel prep doses)",
      "Hydration status",
      "Bowel frequency/consistency"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 litres/day for colonoscopy prep; 17 g/day for constipation",
    "clinicalPearl": "Osmotic laxative of choice in chronic constipation â€” non-habit-forming and safe for long-term use."
  },
  {
    "rank": 179,
    "name": "Liquid Paraffin",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Cremaffin / Liquid Paraffin",
    "formation": "Mineral oil (Lubricant laxative)",
    "uses": "Short-term management of constipation",
    "adult": "10â€“30 ml at bedtime",
    "child": "5â€“10 ml at bedtime",
    "avoid": "Patients with difficulty swallowing (aspiration risk)",
    "sideEffects": [
      "Anal seepage/soiling",
      "Pruritus ani",
      "Lipoid pneumonia (aspiration)",
      "Reduced fat-soluble vitamin absorption",
      "Nausea"
    ],
    "seriousRisks": [
      "Lipoid pneumonia (aspiration â€” especially in elderly/children)",
      "Fat-soluble vitamin deficiency (A, D, E, K)",
      "Aspiration in elderly/supine patients",
      "Intestinal obstruction (large doses)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; may reduce fat-soluble vitamin absorption; risk of neonatal coagulopathy",
    "lactation": "Caution â€” limited data; not preferred",
    "drugInteractions": [
      "Fat-soluble vitamins â€” reduced absorption of vitamins A, D, E, K",
      "Oral anticoagulants (warfarin) â€” may reduce vitamin K absorption, enhancing effect",
      "Docusate â€” increased paraffin absorption (avoid combination)"
    ],
    "monitoring": [
      "Bowel frequency",
      "Signs of lipoid pneumonia (cough, dyspnoea)",
      "Fat-soluble vitamin levels (prolonged use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "45 mL/day (15 mL three times daily)",
    "clinicalPearl": "Avoid in bedridden/elderly patients â€” aspiration risk causing lipoid pneumonia; safer alternatives exist."
  },
  {
    "rank": 180,
    "name": "Sucralfate",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "OTC",
    "brand": "Sucrafil / Carafate / Sucral",
    "formation": "Aluminum hydroxide + sulfated sucrose",
    "uses": "Duodenal ulcer, stress ulcer prophylaxis",
    "adult": "1 g QID (1 hr before meals)",
    "child": "40â€“80 mg/kg/day in 4 divided doses",
    "avoid": "Chronic renal failure (aluminum toxicity risk)",
    "sideEffects": [
      "Constipation",
      "Dry mouth",
      "Nausea",
      "Indigestion",
      "Aluminium accumulation (renal failure)"
    ],
    "seriousRisks": [
      "Aluminium toxicity (renal failure patients â€” prolonged use)",
      "Bezoar formation",
      "Hypo/hyperphosphataemia (rare)"
    ],
    "renalAdj": "Yes â€” avoid prolonged use in CrCl <30 mL/min (aluminium accumulation and toxicity)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” minimal systemic absorption; generally considered safe",
    "lactation": "Safe â€” minimal systemic absorption",
    "drugInteractions": [
      "Fluoroquinolones/tetracyclines â€” significantly reduced absorption (separate by 2h)",
      "Warfarin/digoxin/phenytoin â€” reduced absorption (take other drugs 2h before sucralfate)",
      "Antacids â€” reduced sucralfate efficacy (separate by 30 min)"
    ],
    "monitoring": [
      "Bowel frequency (constipation)",
      "Aluminium levels (renal failure patients)",
      "Phosphate levels"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (1g four times daily, 1h before meals and at bedtime)",
    "clinicalPearl": "Take on empty stomach â€” works by adhering to ulcer base; separate all other medications by 2 hours."
  },
  {
    "rank": 181,
    "name": "Megaldrate + Simethicone",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "OTC",
    "brand": "Mucaine / Antacid Plus",
    "formation": "Antacid + anti-foaming agent",
    "uses": "Hyperacidity, bloating, flatulence",
    "adult": "5â€“10 ml after meals",
    "child": "Consult specialist",
    "avoid": "Severe renal impairment",
    "sideEffects": [
      "Constipation",
      "Diarrhoea (dose-dependent)",
      "Nausea",
      "Chalky taste",
      "Aluminium accumulation (chronic use)"
    ],
    "seriousRisks": [
      "Aluminium toxicity (chronic use/renal impairment)",
      "Phosphate depletion (prolonged high-dose use)",
      "Milk-alkali syndrome (rare)"
    ],
    "renalAdj": "Yes â€” avoid prolonged aluminium-containing antacids in CrCl <30 mL/min",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” short-term use acceptable; avoid aluminium-containing antacids in large doses",
    "lactation": "Safe â€” minimal systemic absorption; short-term use acceptable",
    "drugInteractions": [
      "Fluoroquinolones/tetracyclines â€” reduced absorption (separate by 2h)",
      "Iron supplements â€” reduced iron absorption (separate by 2h)",
      "Azole antifungals â€” reduced absorption (separate by 2h)"
    ],
    "monitoring": [
      "Bowel habits",
      "Serum phosphate (prolonged use)",
      "Serum aluminium (renal impairment)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "As per formulation: typically 10-20 mL four times daily (1-3h after meals and at bedtime)",
    "clinicalPearl": "Shake suspension well before use â€” simethicone component provides rapid flatulence and bloating relief."
  },
  {
    "rank": 182,
    "name": "Aluminium + Magnesium Hydroxide",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Digene / Gelusil / Maalox",
    "formation": "Mixed metal hydroxide antacid",
    "uses": "Acid indigestion, heartburn, sour stomach",
    "adult": "5â€“10 ml QID",
    "child": "0.5 ml/kg QID",
    "avoid": "Hypophosphatemia",
    "sideEffects": [
      "Constipation (Al dominant)",
      "Diarrhoea (Mg dominant)",
      "Chalky/unpleasant taste",
      "Nausea",
      "Electrolyte disturbance (chronic)"
    ],
    "seriousRisks": [
      "Aluminium toxicity (chronic use â€” renal failure)",
      "Hypermagnesaemia (renal failure)",
      "Phosphate depletion (prolonged high-dose aluminium)",
      "Milk-alkali syndrome"
    ],
    "renalAdj": "Yes â€” avoid in severe renal failure; magnesium accumulation and aluminium toxicity risk",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” short-term use acceptable; avoid large doses of aluminium",
    "lactation": "Safe â€” short-term use; minimal systemic absorption",
    "drugInteractions": [
      "Fluoroquinolones/tetracyclines â€” chelation reduces antibiotic absorption (separate by 2-4h)",
      "Digoxin â€” reduced digoxin absorption",
      "Iron supplements â€” reduced iron absorption"
    ],
    "monitoring": [
      "Bowel habits",
      "Serum phosphate/magnesium (prolonged use)",
      "Electrolytes"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "80 mL/day (20 mL four times daily â€” 1h after meals and at bedtime)",
    "clinicalPearl": "Balanced Al/Mg ratio minimises constipation vs diarrhoea â€” separate from other oral medications by 2 hours."
  },
  {
    "rank": 183,
    "name": "Mesalamine (5-ASA)",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Mesacol / Asacol / Pentasa",
    "formation": "Salicylate derivative",
    "uses": "Ulcerative colitis, Crohnâ€™s disease",
    "adult": "800 mg TID or 2.4â€“4.8 g/day",
    "child": "30â€“50 mg/kg/day",
    "avoid": "Severe renal impairment, salicylate allergy",
    "sideEffects": [
      "Headache",
      "Abdominal pain",
      "Nausea",
      "Diarrhoea",
      "Flatulence"
    ],
    "seriousRisks": [
      "Mesalamine-induced nephrotoxicity (interstitial nephritis)",
      "Acute pancreatitis",
      "Hepatotoxicity",
      "Cardiac hypersensitivity (myocarditis â€” rare)",
      "Blood dyscrasias"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30 mL/min; monitor renal function closely in all patients",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category B â€” generally considered safe; preferred over sulfasalazine for IBD in pregnancy",
    "lactation": "Caution â€” minimal excretion in breast milk; monitor infant for diarrhoea",
    "drugInteractions": [
      "Azathioprine/6-mercaptopurine â€” mesalamine inhibits TPMT, increasing toxicity (monitor CBC)",
      "NSAIDs â€” additive nephrotoxicity",
      "Warfarin â€” may reduce anticoagulant effect"
    ],
    "monitoring": [
      "Renal function (at baseline, then every 6 months)",
      "CBC",
      "LFT",
      "Urinalysis (proteinuria/haematuria)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4800 mg/day oral (ulcerative colitis active disease)",
    "clinicalPearl": "Annual renal function monitoring is mandatory â€” mesalamine-induced nephropathy is insidious and irreversible if missed."
  },
  {
    "rank": 184,
    "name": "Silymarin",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Silybon / Legalon / Milk Thistle",
    "formation": "Flavonolignan complex (Milk thistle extract)",
    "uses": "Chronic inflammatory liver diseases, cirrhosis",
    "adult": "70â€“140 mg TID",
    "child": "Consult specialist",
    "avoid": "Hypersensitivity to Asteraceae plants",
    "sideEffects": [
      "Mild GI upset",
      "Diarrhoea",
      "Bloating",
      "Headache",
      "Allergic reactions (rare)"
    ],
    "seriousRisks": [
      "Anaphylaxis (rare â€” especially ragweed/Asteraceae allergy)",
      "Drug interactions via CYP modulation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” used for hepatic conditions; standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid unless clearly indicated",
    "lactation": "Caution â€” insufficient data; avoid",
    "drugInteractions": [
      "Glucuronidated drugs (e.g., irinotecan) â€” silymarin inhibits UGT1A, alters metabolism",
      "CYP3A4 substrates â€” silymarin may inhibit CYP3A4, increasing drug levels",
      "Antidiabetic drugs â€” may have additive glucose-lowering effect"
    ],
    "monitoring": [
      "LFT (response to therapy)",
      "Serum bilirubin",
      "Clinical symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "420 mg/day (140 mg three times daily)",
    "clinicalPearl": "Evidence strongest for Amanita phalloides (mushroom) poisoning hepatoprotection â€” efficacy in viral hepatitis is supplementary."
  },
  {
    "rank": 185,
    "name": "L-Ornithine L-Aspartate (LOLA)",
    "section": "Section 5: GI & Pain",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Hepa-Merz / Hepacare / LOLA",
    "formation": "Amino acid complex",
    "uses": "Hepatic encephalopathy, fatty liver",
    "adult": "3â€“6 g BID (Oral) or IV infusion",
    "child": "Not recommended",
    "avoid": "Severe renal impairment (CrCl < 3)",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Abdominal discomfort",
      "Diarrhoea",
      "Headache"
    ],
    "seriousRisks": [
      "Hyperammonaemia exacerbation (if inadequately dosed)",
      "Electrolyte imbalance (IV use)",
      "Worsening renal failure (high-dose IV in renal impairment)"
    ],
    "renalAdj": "Yes â€” reduce dose in significant renal impairment; avoid high-dose IV if creatinine elevated",
    "hepaticAdj": "No â€” used in hepatic encephalopathy; dose as per clinical status",
    "pregnancy": "Category C â€” limited data; avoid unless essential",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Lactulose â€” complementary/additive ammonia-lowering effect",
      "Rifaximin â€” additive hepatic encephalopathy benefit",
      "Neomycin â€” additive ammonia reduction (but neomycin toxicity)"
    ],
    "monitoring": [
      "Serum ammonia",
      "Encephalopathy grade (NCT grading)",
      "Renal function (IV use)",
      "Electrolytes"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20-40 g/day IV (infusion); 9-18 g/day oral (sachets)",
    "clinicalPearl": "LOLA provides ornithine and aspartate as substrates for urea cycle â€” adjunct to lactulose in hepatic encephalopathy."
  },
  {
    "rank": 186,
    "name": "Aceclofenac",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Zerodol / Hifenac / Aceclo",
    "formation": "Phenylacetic acid derivative (NSAID)",
    "uses": "Osteoarthritis, rheumatoid arthritis pain",
    "adult": "100 mg BID",
    "child": "Not recommended",
    "avoid": "Active peptic ulcer, third trimester pregnancy",
    "sideEffects": [
      "GI discomfort",
      "Nausea",
      "Dyspepsia",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "GI ulceration/bleeding",
      "Cardiovascular events (MI, stroke with long-term use)",
      "Acute kidney injury",
      "Hepatotoxicity",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "Yes â€” avoid in CrCl <30 mL/min; use with caution in mild-moderate renal impairment",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment; monitor LFT",
    "pregnancy": "Category C â€” avoid in 3rd trimester (premature closure of ductus arteriosus); caution 1st/2nd trimester",
    "lactation": "Caution â€” limited data; avoid if possible",
    "drugInteractions": [
      "Warfarin â€” increased bleeding risk (INR monitoring required)",
      "ACE inhibitors/ARBs â€” acute renal failure (triple whammy with diuretics)",
      "SSRIs â€” additive GI bleeding risk"
    ],
    "monitoring": [
      "Renal function",
      "LFT",
      "BP",
      "GI symptoms",
      "Haemoglobin (prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg/day (100 mg twice daily)",
    "clinicalPearl": "Partial COX-2 selectivity provides better GI tolerability than diclofenac â€” always add PPI for gastroprotection."
  },
  {
    "rank": 187,
    "name": "Ibuprofen",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Brufen / Advil / Ibugesic",
    "formation": "Propionic acid derivative (NSAID)",
    "uses": "Fever, mild pain, dysmenorrhea",
    "adult": "400 mg every 4â€“6 hrs",
    "child": "5â€“10 mg/kg/dose (max 40 mg/kg/day)",
    "avoid": "Aspirin triad, third trimester pregnancy",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Dyspepsia",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "GI ulceration/bleeding",
      "Acute kidney injury",
      "Cardiovascular events",
      "Anaphylaxis",
      "Hepatotoxicity (rare)"
    ],
    "renalAdj": "Yes â€” avoid in CrCl <30 mL/min; use minimum effective dose in mild-moderate impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester) â€” avoid after 28 weeks",
    "lactation": "Safe â€” low breast milk transfer; preferred NSAID in lactation",
    "drugInteractions": [
      "Warfarin/aspirin â€” increased bleeding risk",
      "ACE inhibitors/diuretics/ARBs â€” acute kidney injury (triple whammy)",
      "Lithium â€” increased lithium levels (toxicity)"
    ],
    "monitoring": [
      "Renal function",
      "BP",
      "GI symptoms",
      "CBC (prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3200 mg/day (prescribed); 1200 mg/day OTC",
    "clinicalPearl": "Most studied NSAID â€” ibuprofen 400 mg is the analgesic dose; 600-800 mg needed for anti-inflammatory effect."
  },
  {
    "rank": 188,
    "name": "Naproxen Sodium",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Naprosyn / Naprelan",
    "formation": "Propionic acid derivative (NSAID)",
    "uses": "RA, OA, acute gout, ankylosing spondylitis",
    "adult": "250â€“500 mg BID",
    "child": "10 mg/kg/day in 2 divided doses",
    "avoid": "Active GI bleed, severe heart failure",
    "sideEffects": [
      "GI upset",
      "Dyspepsia",
      "Nausea",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "GI ulceration/bleeding",
      "Cardiovascular events",
      "Acute kidney injury",
      "Anaphylaxis",
      "Hepatotoxicity"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <30 mL/min; caution in mild-moderate impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester)",
    "lactation": "Caution â€” excreted in breast milk; prolonged half-life; ibuprofen preferred",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulation",
      "ACE inhibitors/diuretics â€” acute renal failure",
      "SSRIs â€” additive GI bleeding risk"
    ],
    "monitoring": [
      "Renal function",
      "BP",
      "GI symptoms",
      "LFT (prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1375 mg/day (500 mg initial then 250 mg every 6-8h); 1500 mg/day as naproxen sodium",
    "clinicalPearl": "Lowest cardiovascular risk among traditional NSAIDs â€” preferred in patients at moderate CV risk."
  },
  {
    "rank": 189,
    "name": "Etoricoxib",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Arcoxia / Nucoxia",
    "formation": "Selective COX-2 inhibitor",
    "uses": "Gouty arthritis, dental pain, OA",
    "adult": "60â€“120 mg OD",
    "child": "Not recommended (under 16 years)",
    "avoid": "Uncontrolled hypertension (BP > 140/90), IHD",
    "sideEffects": [
      "Dyspepsia",
      "Headache",
      "Peripheral oedema",
      "Dizziness",
      "Elevated BP"
    ],
    "seriousRisks": [
      "Serious cardiovascular events (MI, stroke â€” dose-related)",
      "GI ulceration (lower risk than non-selective NSAIDs)",
      "Hepatotoxicity (including liver failure)",
      "Acute kidney injury",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” Child-Pugh A/B: maximum 60 mg/day; Child-Pugh C: contraindicated",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester) â€” avoid",
    "lactation": "Avoid â€” COX-2 inhibitors not recommended during lactation",
    "drugInteractions": [
      "Warfarin â€” INR monitoring required (significant interaction)",
      "ACE inhibitors/ARBs â€” acute renal failure",
      "Rifampicin â€” reduced etoricoxib levels by 65% (increase dose)"
    ],
    "monitoring": [
      "BP (at baseline and periodically)",
      "Renal function",
      "LFT",
      "Oedema",
      "Cardiovascular symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "120 mg/day (acute gout); 90 mg/day (ankylosing spondylitis); 60 mg/day (osteoarthritis)",
    "clinicalPearl": "Contraindicated in uncontrolled hypertension (>140/90 mmHg) â€” check BP before prescribing; significantly reduces gastric ulcer risk vs non-selective NSAIDs."
  },
  {
    "rank": 190,
    "name": "Celecoxib",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Celebrex / Celact",
    "formation": "Selective COX-2 inhibitor (Sulfonamide)",
    "uses": "OA, RA, acute pain",
    "adult": "100â€“200 mg BID",
    "child": "50â€“100 mg BID (approved for >2y JRA)",
    "avoid": "Sulfa allergy, post-CABG pain",
    "sideEffects": [
      "Dyspepsia",
      "Abdominal pain",
      "Diarrhoea",
      "Headache",
      "Peripheral oedema"
    ],
    "seriousRisks": [
      "Cardiovascular events (MI, stroke)",
      "Serious GI events (lower than non-selective)",
      "Acute kidney injury",
      "Hepatotoxicity",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <30 mL/min; caution in mild-moderate impairment",
    "hepaticAdj": "Yes â€” Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester)",
    "lactation": "Caution â€” excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulation (INR monitoring)",
      "Fluconazole â€” doubled celecoxib levels (reduce celecoxib dose)",
      "ACE inhibitors/diuretics â€” acute renal failure"
    ],
    "monitoring": [
      "BP",
      "Renal function",
      "LFT",
      "Cardiovascular symptoms",
      "Oedema"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (200 mg twice daily)",
    "clinicalPearl": "Sulfonamide allergy cross-reactivity possible â€” avoid in patients with sulfa allergy; superior GI safety over non-selective NSAIDs."
  },
  {
    "rank": 191,
    "name": "Mefenamic Acid",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Meftal / Ponstan",
    "formation": "Anthranilic acid derivative",
    "uses": "Dysmenorrhea, mild-to-moderate pain",
    "adult": "250â€“500 mg TID",
    "child": "6.5 mg/kg per dose",
    "avoid": "Inflammatory bowel disease, GI ulcer",
    "sideEffects": [
      "Diarrhoea",
      "GI upset",
      "Nausea",
      "Headache",
      "Drowsiness"
    ],
    "seriousRisks": [
      "GI ulceration/haemorrhage",
      "Haemolytic anaemia (Coombs-positive)",
      "Acute kidney injury",
      "Seizures (overdose/haematological)",
      "Severe allergic reactions"
    ],
    "renalAdj": "Yes â€” avoid in significant renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester)",
    "lactation": "Caution â€” small amounts in breast milk; short-term use acceptable",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulation",
      "Lithium â€” increased lithium toxicity",
      "ACE inhibitors/diuretics â€” acute renal failure"
    ],
    "monitoring": [
      "Renal function",
      "CBC (haemolytic anaemia risk)",
      "GI symptoms",
      "LFT"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1500 mg/day (500 mg three times daily); maximum 7 days use",
    "clinicalPearl": "Most effective for primary dysmenorrhoea â€” start 1-2 days before expected menstruation and continue for duration."
  },
  {
    "rank": 192,
    "name": "Serratiopeptidase",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Serapeptase / Serraflam / Sermion",
    "formation": "Proteolytic enzyme",
    "uses": "Reducing inflammation and edema",
    "adult": "10 mg TID",
    "child": "0.5 mg/kg/day (Consult pediatric surgeon)",
    "avoid": "Bleeding disorders, pregnancy",
    "sideEffects": [
      "Nausea",
      "Stomach upset",
      "Skin rash",
      "Decreased appetite",
      "Mild GI disturbance"
    ],
    "seriousRisks": [
      "Severe pneumonia interstitial lung disease (rare case reports)",
      "Bleeding risk (antiplatelet activity)",
      "Severe allergic reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid unless clearly necessary",
    "lactation": "Caution â€” insufficient data; avoid",
    "drugInteractions": [
      "Anticoagulants/antiplatelets â€” additive bleeding risk",
      "Fibrinolytics â€” additive effect",
      "NSAIDs â€” additive anti-inflammatory/bleeding risk"
    ],
    "monitoring": [
      "Bleeding symptoms",
      "Clinical response at 2 weeks"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day (10 mg three times daily)",
    "clinicalPearl": "Limited robust clinical trial evidence â€” used widely in India for post-operative inflammation and sinusitis as adjunct."
  },
  {
    "rank": 193,
    "name": "Chymotrypsin-Trypsin",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Chymoral / Wobenzym",
    "formation": "Proteolytic enzyme combination",
    "uses": "Trauma-related swelling, surgical wounds",
    "adult": "1â€“2 tablets TID",
    "child": "Consult specialist",
    "avoid": "Severe hepatic/renal disease, clotting issues",
    "sideEffects": [
      "Nausea",
      "Allergic reactions",
      "GI upset",
      "Rash",
      "Abdominal discomfort"
    ],
    "seriousRisks": [
      "Anaphylaxis (proteolytic enzyme allergy)",
      "Haemorrhage (anticoagulant properties)",
      "Systemic fibrinolysis (high dose parenteral)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid",
    "lactation": "Caution â€” insufficient data; avoid",
    "drugInteractions": [
      "Anticoagulants â€” additive bleeding risk (avoid combination)",
      "Fibrinolytics â€” additive effect",
      "Antibiotics â€” may enhance penetration to infection sites (theoretical benefit)"
    ],
    "monitoring": [
      "Signs of allergic reaction",
      "Bleeding symptoms",
      "Clinical response at 5-7 days"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "As per formulation: typically chymotrypsin 1.4 mg + trypsin 6 mg three to four times daily",
    "clinicalPearl": "Proteolytic enzymes for oedema/inflammation reduction â€” evidence remains limited; popular adjunct in dental and surgical settings."
  },
  {
    "rank": 194,
    "name": "Thiocolchicoside",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H1",
    "brand": "Myoril / Muscoril",
    "formation": "Semisynthetic sulfur-derivative colchicoside",
    "uses": "Skeletal muscle spasm, low back pain",
    "adult": "4â€“8 mg BID",
    "child": "Not approved for pediatric use",
    "avoid": "Pregnancy, breastfeeding, history of seizures",
    "sideEffects": [
      "Drowsiness",
      "Nausea",
      "Diarrhoea",
      "Rash",
      "Dizziness"
    ],
    "seriousRisks": [
      "Genotoxicity/clastogenicity (concerns from EMEA â€” restrict use)",
      "Seizures (rare, high dose)",
      "Liver toxicity (rare)",
      "Teratogenicity (animal data)"
    ],
    "renalAdj": "No â€” standard dosing; caution in renal impairment",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category D â€” contraindicated; genotoxic potential; avoid in women of childbearing age without contraception",
    "lactation": "Avoid â€” genotoxicity concerns",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive sedation",
      "Muscle relaxants â€” additive effect",
      "Benzodiazepines â€” enhanced sedation"
    ],
    "monitoring": [
      "Neurological symptoms",
      "LFT (prolonged use)",
      "Signs of genotoxicity concerns"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "16 mg/day (8 mg twice daily); maximum 7 days oral (EMEA restriction)",
    "clinicalPearl": "Restrict to maximum 7 days â€” EMEA raised clastogenicity concerns; European countries withdrew oral formulation."
  },
  {
    "rank": 195,
    "name": "Tramadol HCl",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "X",
    "brand": "Tramazac / Tramacip / Ultram",
    "formation": "Synthetic opioid (Centrally acting)",
    "uses": "Moderate-to-severe acute or chronic pain",
    "adult": "50â€“100 mg every 4â€“6 hrs",
    "child": "1â€“2 mg/kg per dose (Avoid in < 12y)",
    "avoid": "Severe respiratory depression, acute alcoholism",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Dizziness",
      "Constipation",
      "Headache"
    ],
    "seriousRisks": [
      "Seizures",
      "Serotonin syndrome",
      "Respiratory depression (overdose)",
      "Dependence/withdrawal",
      "Suicide risk (mental health patients)"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: 50-100 mg every 12h (maximum 200 mg/day)",
    "hepaticAdj": "Yes â€” severe hepatic impairment: 50 mg every 12h",
    "pregnancy": "Category C â€” avoid; neonatal withdrawal syndrome possible",
    "lactation": "Avoid â€” excreted in breast milk; neonatal sedation and respiratory depression",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome/seizures (contraindicated)",
      "SSRIs/SNRIs â€” serotonin syndrome",
      "Carbamazepine â€” reduced tramadol levels and reduced seizure threshold"
    ],
    "monitoring": [
      "Pain score",
      "Sedation level",
      "Respiratory rate",
      "Signs of serotonin syndrome",
      "Dependence signs"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (healthy adults); 300 mg/day (elderly >75 years)",
    "clinicalPearl": "CYP2D6 ultra-rapid metabolisers may experience respiratory depression at standard doses â€” be aware in diverse Indian populations."
  },
  {
    "rank": 196,
    "name": "Morphine Sulfate",
    "section": "Section 5: GI & Pain",
    "category": "Opioids",
    "schedule": "X",
    "brand": "Morphine / MSContin / Roxanol",
    "formation": "Phenanthrene alkaloid (Opioid)",
    "uses": "Severe pain, palliative care, dyspnea in CHF",
    "adult": "10â€“30 mg every 4 hrs or 30â€“60 mg SR BID",
    "child": "0.1â€“0.2 mg/kg IV or 0.2â€“0.5 mg/kg Oral",
    "avoid": "Paralytic ileus, severe respiratory insufficiency",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Constipation",
      "Drowsiness",
      "Pruritus"
    ],
    "seriousRisks": [
      "Respiratory depression",
      "Addiction/physical dependence",
      "Hypotension",
      "Increased intracranial pressure",
      "Urinary retention"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: reduce dose by 50% and increase interval; avoid M6G accumulation â€” use fentanyl instead",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose significantly; prolonged half-life",
    "pregnancy": "Category C â€” short-term use; neonatal respiratory depression and withdrawal; avoid at term",
    "lactation": "Caution â€” excreted in breast milk; monitor neonatal sedation; single doses generally acceptable",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive respiratory depression (contraindicated combination)",
      "MAOIs â€” severe CNS/respiratory depression (contraindicated)",
      "Rifampicin â€” significantly reduced morphine levels"
    ],
    "monitoring": [
      "Pain score",
      "Respiratory rate (>12/min)",
      "Sedation scale",
      "Bowel function",
      "Urine output"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "No absolute maximum (titrate to pain response); typical cancer pain: 100-200 mg/day oral",
    "clinicalPearl": "Always prescribe a laxative prophylactically â€” opioid-induced constipation is near-universal and does not develop tolerance."
  },
  {
    "rank": 197,
    "name": "Fentanyl Citrate",
    "section": "Section 5: GI & Pain",
    "category": "Opioids",
    "schedule": "H",
    "brand": "Duragesic / Fentanyl Patch",
    "formation": "Phenylpiperidine derivative (Opioid)",
    "uses": "Anesthesia, chronic severe pain (Patch)",
    "adult": "12.5â€“100 mcg/hr patch or 50â€“100 mcg IV",
    "child": "1â€“2 mcg/kg IV (Consult anesthesia)",
    "avoid": "Opioid-naive patients (for patch), acute pain",
    "sideEffects": [
      "Sedation",
      "Nausea",
      "Constipation",
      "Respiratory depression",
      "Pruritus"
    ],
    "seriousRisks": [
      "Severe respiratory depression/apnoea",
      "Chest wall rigidity (rapid IV injection)",
      "Addiction/dependence",
      "Bradycardia/hypotension",
      "Serotonin syndrome (with serotonergic drugs)"
    ],
    "renalAdj": "Yes â€” preferred opioid in renal failure (no active metabolite accumulation unlike morphine)",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose; prolonged half-life with patch",
    "pregnancy": "Category C â€” avoid; neonatal respiratory depression and withdrawal with prolonged use",
    "lactation": "Caution â€” excreted in breast milk; monitor neonatal sedation",
    "drugInteractions": [
      "CYP3A4 inhibitors (ketoconazole, ritonavir) â€” markedly increased fentanyl levels/toxicity",
      "CNS depressants â€” additive respiratory depression",
      "MAOIs â€” severe CNS depression"
    ],
    "monitoring": [
      "Respiratory rate",
      "Sedation level",
      "Pain score",
      "ECG (IV use)",
      "Patch site (transdermal)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Patch: 100 mcg/h (titrate from lower doses); IV: procedural doses as clinically indicated",
    "clinicalPearl": "Transdermal patch onset 12-24h â€” never use in opioid-naive patients for acute pain; preferred in renal failure."
  },
  {
    "rank": 198,
    "name": "Ketorolac Tromethamine",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Toradol / Ketanov / Ketrolac",
    "formation": "Pyrrolizine carboxylic acid derivative",
    "uses": "Short-term (max 5 days) severe pain",
    "adult": "10 mg every 4â€“6 hrs or 30 mg IV/IM",
    "child": "0.5â€“1 mg/kg IV (Restrict use)",
    "avoid": "Pre-operative use, renal impairment, GI bleed",
    "sideEffects": [
      "GI discomfort",
      "Nausea",
      "Headache",
      "Dizziness",
      "Injection site pain"
    ],
    "seriousRisks": [
      "Severe GI ulceration/bleeding (especially prolonged use)",
      "Acute kidney injury",
      "Cardiovascular events",
      "Operative site bleeding",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” avoid in moderate-severe renal impairment (CrCl <30); reduce dose if CrCl 30-60",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester) â€” avoid",
    "lactation": "Caution â€” excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "Warfarin â€” significantly enhanced anticoagulation (INR monitoring)",
      "ACE inhibitors/diuretics â€” acute renal failure",
      "Other NSAIDs/aspirin â€” additive GI toxicity (avoid combination)"
    ],
    "monitoring": [
      "Renal function",
      "GI symptoms/bleeding",
      "BP",
      "CBC (prolonged use)",
      "Surgical site for haemostasis"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "120 mg/day IM/IV; maximum treatment duration 5 days",
    "clinicalPearl": "Strictly limit to 5 days maximum â€” GI bleeding risk increases dramatically beyond 5 days of ketorolac use."
  },
  {
    "rank": 199,
    "name": "Nimesulide",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Nimulid / Nise",
    "formation": "Selective COX-2 inhibitor (Sulfonanilide)",
    "uses": "Acute pain, primary dysmenorrhea",
    "adult": "100 mg BID",
    "child": "Banned in India for children < 12 years",
    "avoid": "Liver disease, pregnancy, renal impairment",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Dyspepsia",
      "Headache",
      "Rash"
    ],
    "seriousRisks": [
      "Severe hepatotoxicity (including fatal liver failure)",
      "GI ulceration",
      "Acute kidney injury",
      "Anaphylaxis",
      "Reye's syndrome-like reaction (children)"
    ],
    "renalAdj": "Yes â€” avoid in significant renal impairment",
    "hepaticAdj": "Yes â€” contraindicated in any hepatic impairment",
    "pregnancy": "Category C â€” avoid; contraindicated in 3rd trimester",
    "lactation": "Avoid â€” insufficient data; hepatotoxicity concern",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulation",
      "ACE inhibitors/diuretics â€” acute renal failure",
      "Hepatotoxic drugs â€” additive hepatotoxicity (avoid)"
    ],
    "monitoring": [
      "LFT (at baseline and during treatment)",
      "Renal function",
      "GI symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "200 mg/day (100 mg twice daily); maximum 15 days use",
    "clinicalPearl": "Banned in children <12 years and in many countries due to hepatotoxicity â€” CDSCO limits use to maximum 15 days."
  },
  {
    "rank": 200,
    "name": "Piroxicam",
    "section": "Section 5: GI & Pain",
    "category": "Analgesics",
    "schedule": "H",
    "brand": "Dolonex / Feldene",
    "formation": "Enolic acid derivative (Oxicam NSAID)",
    "uses": "RA, OA, musculoskeletal pain",
    "adult": "20 mg OD",
    "child": "0.2â€“0.3 mg/kg OD (Consult specialist)",
    "avoid": "GI ulcers, elderly patients (high GI risk)",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Dyspepsia",
      "Dizziness",
      "Oedema"
    ],
    "seriousRisks": [
      "Serious GI ulceration/bleeding (long half-life increases GI risk)",
      "Acute kidney injury",
      "Cardiovascular events",
      "Severe skin reactions (Stevens-Johnson, TEN)",
      "Hepatotoxicity"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <30 mL/min; use minimum dose in mild-moderate impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C (1st/2nd trimester); Category D (3rd trimester)",
    "lactation": "Caution â€” excreted in breast milk; prolonged half-life â€” avoid",
    "drugInteractions": [
      "Warfarin â€” enhanced anticoagulation (significant)",
      "Lithium â€” increased lithium levels",
      "ACE inhibitors/diuretics â€” acute renal failure"
    ],
    "monitoring": [
      "Renal function",
      "GI symptoms",
      "LFT",
      "BP",
      "CBC"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day (single daily dose)",
    "clinicalPearl": "Once-daily convenience but highest GI bleeding risk among traditional NSAIDs due to 50h half-life â€” mandatory PPI cover."
  },
  {
    "rank": 201,
    "name": "Gabapentin",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H1",
    "brand": "Gabapin / Gabantin / Neurontin",
    "formation": "Cyclohexane derivative (GABA analog)",
    "uses": "Post-herpetic neuralgia, focal seizures",
    "adult": "300 mg initial, titrate to 900â€“1800 mg/day",
    "child": "10â€“30 mg/kg/day",
    "avoid": "Myasthenia gravis (caution), renal failure",
    "sideEffects": [
      "Drowsiness",
      "Dizziness",
      "Fatigue",
      "Peripheral oedema",
      "Weight gain"
    ],
    "seriousRisks": [
      "Respiratory depression (especially with opioids/CNS depressants)",
      "Suicidal ideation",
      "Drug dependence/abuse (growing concern)",
      "Severe hypersensitivity (DRESS)",
      "Falls in elderly"
    ],
    "renalAdj": "Yes â€” CrCl 30-59: maximum 1400 mg/day in divided doses; CrCl 15-29: maximum 700 mg/day; CrCl <15: 300 mg/day",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” limited human data; avoid if possible; risks include neonatal withdrawal",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for sedation",
    "drugInteractions": [
      "Opioids â€” significantly increased respiratory depression risk (black box)",
      "Alcohol/CNS depressants â€” additive sedation",
      "Antacids â€” reduced gabapentin absorption by 20% (separate by 2h)"
    ],
    "monitoring": [
      "Renal function (dose adjustment)",
      "Sedation/respiratory rate (if with opioids)",
      "Suicidal ideation",
      "Weight",
      "Peripheral oedema"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3600 mg/day (1200 mg three times daily)",
    "clinicalPearl": "Titrate slowly (start 100-300 mg at night) â€” abrupt discontinuation causes withdrawal seizures; taper over minimum 1 week."
  },
  {
    "rank": 202,
    "name": "Methylcobalamin",
    "section": "Section 5: GI & Pain",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Methylcobal / Mecobalamin / Neurobin",
    "formation": "Active form of Vitamin B12 (Organometallic)",
    "uses": "Peripheral neuropathy, B12 deficiency anemia",
    "adult": "500â€“1500 mcg OD",
    "child": "5â€“10 mcg/kg/day",
    "avoid": "Leberâ€™s optic atrophy",
    "sideEffects": [
      "Nausea (rare)",
      "Skin flushing (injection)",
      "Headache",
      "Mild GI disturbance",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "Hypokalaemia (during treatment of megaloblastic anaemia â€” monitor K+)",
      "Polycythaemia (rare)",
      "Anaphylaxis (injectable form â€” rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe; often recommended for vitamin B12 deficiency in pregnancy",
    "lactation": "Safe â€” essential vitamin; excreted in breast milk",
    "drugInteractions": [
      "Metformin â€” reduces B12 absorption (monitor B12 levels annually)",
      "PPIs/H2 blockers â€” reduce B12 absorption from food (supplement recommended)",
      "Chloramphenicol â€” impairs haematopoietic response to B12"
    ],
    "monitoring": [
      "Serum B12 level",
      "CBC (haematological response)",
      "Neurological improvement",
      "Potassium (initial treatment of severe deficiency)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1500 mcg/day oral; 1000 mcg IM daily (initial) then weekly",
    "clinicalPearl": "Preferred over cyanocobalamin for neuropathy â€” methylcobalamin is the active neurotropic form that crosses the blood-brain barrier."
  },
  {
    "rank": 203,
    "name": "Amitriptyline HCl",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Tryptomer / Elavil / Amitone",
    "formation": "Tricyclic antidepressant (Dibenzo-cycloheptene)",
    "uses": "Neuropathic pain, migraine prophy, depression",
    "adult": "10â€“75 mg OD (bedtime)",
    "child": "0.1 mg/kg/day (Restrict use)",
    "avoid": "Recent MI, glaucoma, concomitant MAOIs",
    "sideEffects": [
      "Dry mouth",
      "Constipation",
      "Drowsiness",
      "Blurred vision",
      "Weight gain"
    ],
    "seriousRisks": [
      "Cardiac arrhythmias/QT prolongation",
      "Suicidal ideation (initial treatment)",
      "Serotonin syndrome",
      "Urinary retention (prostatic hypertrophy)",
      "Seizures (overdose)"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; reduce dose",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment; reduce dose in mild-moderate",
    "pregnancy": "Category C â€” avoid in 1st trimester; risk of neonatal withdrawal/adaptation syndrome",
    "lactation": "Caution â€” excreted in breast milk; use lowest effective dose; monitor infant for sedation",
    "drugInteractions": [
      "MAOIs â€” hypertensive crisis/serotonin syndrome (contraindicated)",
      "CNS depressants/alcohol â€” additive sedation",
      "Antiarrhythmics (quinidine) â€” additive QT prolongation"
    ],
    "monitoring": [
      "ECG (QTc, prolonged PR)",
      "Suicidal ideation (first 4 weeks)",
      "BP (orthostatic hypotension)",
      "Weight",
      "Anticholinergic effects"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "150 mg/day (depression); 75 mg/day (neuropathic pain/migraine prophylaxis)",
    "clinicalPearl": "At night dosing exploits sedative side effect â€” start 10-25 mg nocte for neuropathic pain with minimal daytime drowsiness."
  },
  {
    "rank": 204,
    "name": "Duloxetine HCl",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Duvanta / Cymbalta / Duloxetine",
    "formation": "Serotonin-norepinephrine reuptake inhibitor",
    "uses": "Diabetic neuropathy, fibromyalgia, GAD",
    "adult": "30â€“60 mg OD",
    "child": "30 mg OD (approved for >7y GAD)",
    "avoid": "Chronic liver disease, severe renal failure",
    "sideEffects": [
      "Nausea",
      "Dry mouth",
      "Headache",
      "Insomnia",
      "Dizziness"
    ],
    "seriousRisks": [
      "Suicidal ideation (young adults)",
      "Serotonin syndrome",
      "Hepatotoxicity",
      "Hypertensive crisis (SNRI)",
      "Severe discontinuation syndrome"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: not recommended",
    "hepaticAdj": "Yes â€” contraindicated in significant hepatic impairment",
    "pregnancy": "Category C â€” avoid; neonatal discontinuation syndrome",
    "lactation": "Caution â€” excreted in breast milk in small amounts; monitor infant",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated; 14-day washout)",
      "Thioridazine â€” QT prolongation (contraindicated)",
      "CYP1A2 inhibitors (fluvoxamine) â€” 6-fold increase in duloxetine levels"
    ],
    "monitoring": [
      "BP",
      "LFT (at baseline)",
      "Suicidal ideation",
      "Pain/mood scores",
      "Discontinuation symptoms on stopping"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "120 mg/day (depression); 60 mg/day standard for neuropathic pain/fibromyalgia",
    "clinicalPearl": "Dual action on pain and mood makes it first-line for diabetic peripheral neuropathy â€” taper slowly to avoid discontinuation syndrome."
  },
  {
    "rank": 205,
    "name": "Sumatriptan Succinate",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Suminat / Imitrex",
    "formation": "Selective 5-HT1 receptor agonist",
    "uses": "Acute treatment of migraine attacks",
    "adult": "50â€“100 mg single dose (max 200 mg/day)",
    "child": "Nasal spray only (Consult pediatric neuro)",
    "avoid": "Ischemic heart disease, Prinzmetal's angina",
    "sideEffects": [
      "Tingling/flushing",
      "Heaviness in chest/throat",
      "Dizziness",
      "Nausea",
      "Injection site reactions"
    ],
    "seriousRisks": [
      "Coronary vasospasm/MI (contraindicated in CAD)",
      "Stroke (in patients with risk factors)",
      "Serotonin syndrome (with serotonergic drugs)",
      "Medication overuse headache (>10 days/month)",
      "Severe hypertension"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: avoid; mild-moderate: use with caution (maximum 50 mg)",
    "pregnancy": "Category C â€” avoid; use only if clearly needed for severe migraine",
    "lactation": "Caution â€” excreted in breast milk; express and discard milk for 12h post-dose",
    "drugInteractions": [
      "MAOIs â€” serotonin toxicity (contraindicated; 2-week washout)",
      "Ergotamine â€” additive vasospasm (contraindicated; separate by 24h)",
      "SSRIs/SNRIs â€” serotonin syndrome risk"
    ],
    "monitoring": [
      "Cardiovascular status before each treatment",
      "BP",
      "Headache diary (medication overuse)",
      "Response to dose"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "300 mg/day oral (100 mg per dose, may repeat once after 2h); 12 mg/day SC",
    "clinicalPearl": "Most effective taken at headache onset (not aura) â€” contraindicated in CAD, Prinzmetal angina, and stroke history."
  },
  {
    "rank": 206,
    "name": "Rimegepant",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Nurtec ODT",
    "formation": "CGRP receptor antagonist (Gepant)",
    "uses": "Acute and preventive treatment of migraine",
    "adult": "75 mg OD or every other day",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment",
    "sideEffects": [
      "Nausea",
      "Nasopharyngitis",
      "Fatigue",
      "Urinary tract infection",
      "Dizziness"
    ],
    "seriousRisks": [
      "Hepatotoxicity (rare)",
      "Severe hypersensitivity reactions",
      "Foetal harm (animal data)"
    ],
    "renalAdj": "Yes â€” severe renal impairment (eGFR <30): use with caution; no specific dose adjustment established",
    "hepaticAdj": "Yes â€” severe hepatic impairment: avoid",
    "pregnancy": "Category C â€” avoid; potential foetal harm based on animal data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Strong CYP3A4 inhibitors (ketoconazole) â€” significantly increased rimegepant levels; avoid",
      "Strong CYP3A4 inducers (rifampicin) â€” markedly reduced efficacy; avoid",
      "Moderate CYP3A4 inhibitors â€” use with caution"
    ],
    "monitoring": [
      "LFT (with prolonged prophylactic use)",
      "Headache frequency diary",
      "Signs of hypersensitivity"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "75 mg every 48h (maximum 75 mg/dose; not more than once every 48h for acute use)",
    "clinicalPearl": "CGRP antagonist â€” no vasoconstrictive effect; safe in cardiovascular disease where triptans are contraindicated."
  },
  {
    "rank": 207,
    "name": "Flunarizine",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Sibelium / Flunarin",
    "formation": "Difluorinated derivative of cinnarizine",
    "uses": "Prophylaxis of migraine, vertigo management",
    "adult": "5â€“10 mg OD (bedtime)",
    "child": "5 mg daily (Restrict use)",
    "avoid": "History of depression, Parkinsonâ€™s disease",
    "sideEffects": [
      "Sedation/drowsiness",
      "Weight gain",
      "Depression",
      "Extrapyramidal symptoms",
      "Fatigue"
    ],
    "seriousRisks": [
      "Parkinsonism (tardive â€” especially elderly women, prolonged use)",
      "Depression (including suicidal ideation)",
      "Drug-induced movement disorders",
      "QT prolongation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” avoid; animal teratogenicity data",
    "lactation": "Avoid â€” excreted in breast milk; risk of sedation and movement disorders in infant",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive sedation",
      "Antipsychotics â€” additive extrapyramidal effects",
      "Carbamazepine/phenytoin â€” may reduce flunarizine levels"
    ],
    "monitoring": [
      "Movement disorder signs (AIMS scale)",
      "Mood/depression screening",
      "Weight",
      "ECG (QTc)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day (nocte); 5 mg/day in elderly",
    "clinicalPearl": "Stop after 6 months and review â€” drug-induced parkinsonism is often missed; avoid in patients with personal/family history of movement disorders."
  },
  {
    "rank": 208,
    "name": "Escitalopram Oxalate",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Nexito / Cipralex / Escitalopram",
    "formation": "S-enantiomer of citalopram (SSRI)",
    "uses": "Generalized anxiety disorder, major depression",
    "adult": "10â€“20 mg OD",
    "child": "10 mg OD (approved >12y)",
    "avoid": "Concomitant QT-prolonging drugs, MAOIs",
    "sideEffects": [
      "Nausea",
      "Insomnia",
      "Headache",
      "Diarrhoea",
      "Dry mouth"
    ],
    "seriousRisks": [
      "Suicidal ideation (under-25 years, initial treatment)",
      "Serotonin syndrome",
      "QT prolongation (dose-dependent)",
      "Hyponatraemia (SIADH)",
      "Severe discontinuation syndrome"
    ],
    "renalAdj": "No â€” standard dosing in mild-moderate; caution in severe",
    "hepaticAdj": "Yes â€” severe hepatic impairment: maximum 5-10 mg/day",
    "pregnancy": "Category C â€” avoid in 1st trimester; neonatal adaptation syndrome (3rd trimester); persistent pulmonary hypertension",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for sedation/poor feeding",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated; 14-day washout)",
      "Serotonergic drugs (tramadol, triptans) â€” serotonin syndrome risk",
      "Pimozide/QT-prolonging drugs â€” additive QT prolongation (contraindicated)"
    ],
    "monitoring": [
      "Suicidal ideation (first 4 weeks)",
      "ECG (QTc â€” doses >20 mg)",
      "Sodium (SIADH)",
      "BP",
      "Mood/anxiety scores"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day",
    "clinicalPearl": "Most selective SSRI with fewest drug interactions â€” once-daily dosing; therapeutic response usually apparent by 4 weeks."
  },
  {
    "rank": 209,
    "name": "Sertraline HCl",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Serta / Zoloft / Lustral",
    "formation": "Naphthylamine-derivative SSRI",
    "uses": "Panic disorder, OCD, PTSD",
    "adult": "50â€“200 mg OD",
    "child": "25â€“50 mg OD (OCD use)",
    "avoid": "Concomitant use of pimozide",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Insomnia",
      "Dry mouth",
      "Ejaculatory delay (males)"
    ],
    "seriousRisks": [
      "Suicidal ideation (young adults)",
      "Serotonin syndrome",
      "Hyponatraemia (SIADH)",
      "Severe discontinuation syndrome",
      "Haemorrhagic events (antiplatelet effect)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: use lower dose and longer interval",
    "pregnancy": "Category C â€” SSRI of choice in pregnancy (most data); neonatal adaptation syndrome possible",
    "lactation": "Safe (relative) â€” low breast milk transfer; preferred SSRI during breastfeeding",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated)",
      "Pimozide â€” QT prolongation (contraindicated)",
      "Warfarin â€” increased bleeding risk (INR monitoring)"
    ],
    "monitoring": [
      "Suicidal ideation (first 4 weeks)",
      "Sodium (SIADH)",
      "Bleeding signs",
      "Mood/anxiety scores"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg/day",
    "clinicalPearl": "Most evidence-based SSRI for broadest range of indications â€” SSRI of choice in pregnancy and breastfeeding."
  },
  {
    "rank": 210,
    "name": "Fluoxetine HCl",
    "section": "Section 5: GI & Pain",
    "category": "CNS",
    "schedule": "H",
    "brand": "Fludac / Prozac / Fluoxetine",
    "formation": "Phenylpropylamine SSRI",
    "uses": "Bulimia nervosa, OCD, depression",
    "adult": "20â€“60 mg OD",
    "child": "10â€“20 mg OD (approved >8y)",
    "avoid": "Concomitant use with thioridazine",
    "sideEffects": [
      "Nausea",
      "Insomnia",
      "Headache",
      "Anxiety/agitation",
      "Decreased libido"
    ],
    "seriousRisks": [
      "Suicidal ideation (young adults)",
      "Serotonin syndrome",
      "Hyponatraemia (SIADH)",
      "Prolonged half-life causes persistent drug interactions even after stopping",
      "QT prolongation (high dose)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose/frequency (alternate-day dosing)",
    "pregnancy": "Category C â€” neonatal adaptation syndrome; avoid in 3rd trimester if possible",
    "lactation": "Caution â€” significant breast milk levels; prefer sertraline; monitor infant",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated; 5-week washout after stopping fluoxetine)",
      "Tamoxifen â€” inhibits CYP2D6, reduces tamoxifen efficacy (avoid in breast cancer)",
      "Pimozide â€” QT prolongation (contraindicated)"
    ],
    "monitoring": [
      "Suicidal ideation",
      "Sodium (SIADH)",
      "ECG (QTc)",
      "Mood scores",
      "Drug interactions (long washout period)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "80 mg/day",
    "clinicalPearl": "Longest half-life (4-6 days) â€” no discontinuation syndrome; but drug interactions persist 5 weeks after stopping."
  },
  {
    "rank": 211,
    "name": "Paroxetine HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Paxidep / Paxil / Paroxetine",
    "formation": "Phenylpiperidine SSRI",
    "uses": "Social anxiety disorder, panic disorder",
    "adult": "20â€“50 mg OD (CR)",
    "child": "Not recommended",
    "avoid": "Pregnancy (Category D), MAOI use",
    "sideEffects": [
      "Nausea",
      "Dry mouth",
      "Constipation",
      "Drowsiness",
      "Sexual dysfunction"
    ],
    "seriousRisks": [
      "Suicidal ideation (young adults)",
      "Serotonin syndrome",
      "Severe discontinuation syndrome (most potent withdrawal among SSRIs)",
      "Hyponatraemia (SIADH)",
      "Cardiac malformations (1st trimester)"
    ],
    "renalAdj": "Yes â€” CrCl <30 mL/min: maximum 20 mg/day",
    "hepaticAdj": "Yes â€” severe hepatic impairment: maximum 20 mg/day",
    "pregnancy": "Category D â€” avoid; associated with neonatal cardiac septal defects; persistent pulmonary hypertension",
    "lactation": "Caution â€” low breast milk transfer; sertraline preferred",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated)",
      "Tamoxifen â€” strong CYP2D6 inhibition reduces efficacy (contraindicated in breast cancer)",
      "Thioridazine â€” QT prolongation (contraindicated)"
    ],
    "monitoring": [
      "Suicidal ideation",
      "Sodium (SIADH)",
      "Discontinuation symptoms",
      "BP",
      "Mood scores"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60 mg/day (standard); 75 mg/day CR formulation",
    "clinicalPearl": "Worst SSRI for discontinuation syndrome â€” never stop abruptly; taper over minimum 4 weeks; avoid in pregnancy."
  },
  {
    "rank": 212,
    "name": "Venlafaxine HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Venlor / Effexor / Veniz XR",
    "formation": "Phenethylamine derivative (SNRI)",
    "uses": "Major depressive disorder, panic disorder",
    "adult": "75â€“225 mg daily (ER)",
    "child": "Not recommended",
    "avoid": "High risk of suicidal ideation in young adults",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Insomnia",
      "Dry mouth",
      "Hypertension"
    ],
    "seriousRisks": [
      "Suicidal ideation (young adults)",
      "Serotonin syndrome",
      "Severe discontinuation syndrome",
      "Hypertensive crisis (higher doses)",
      "Hyponatraemia (SIADH)"
    ],
    "renalAdj": "Yes â€” CrCl 10-70 mL/min: reduce daily dose by 25-50%",
    "hepaticAdj": "Yes â€” moderate impairment: reduce dose by 50%; severe: reduce by 50% and use with caution",
    "pregnancy": "Category C â€” neonatal adaptation syndrome; avoid in 3rd trimester",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for agitation",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated; 7-day washout)",
      "Triptans â€” serotonin syndrome risk",
      "CYP2D6 inhibitors (paroxetine) â€” increased venlafaxine levels"
    ],
    "monitoring": [
      "BP (dose-dependent increase â€” check weekly at start)",
      "Suicidal ideation",
      "Heart rate",
      "Sodium",
      "Discontinuation symptoms"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "375 mg/day (XR formulation â€” for inpatients only); typical maximum 225 mg/day outpatient",
    "clinicalPearl": "BP rises dose-dependently above 225 mg/day â€” monitor BP weekly when titrating; taper slowly to avoid withdrawal."
  },
  {
    "rank": 213,
    "name": "Desvenlafaxine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Divaa / Pristiq / Desnax",
    "formation": "O-desmethyl metabolite of venlafaxine (SNRI)",
    "uses": "Major depressive disorder",
    "adult": "50â€“100 mg OD",
    "child": "Not recommended",
    "avoid": "Concomitant use with linezolid",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Dizziness",
      "Dry mouth",
      "Hyperhidrosis"
    ],
    "seriousRisks": [
      "Suicidal ideation",
      "Serotonin syndrome",
      "Hypertension",
      "Severe discontinuation syndrome",
      "SIADH/Hyponatraemia"
    ],
    "renalAdj": "Yes â€” CrCl 30-50: maximum 50 mg/day; CrCl <30: 50 mg every other day",
    "hepaticAdj": "Yes â€” moderate-severe impairment: maximum 100 mg/day; dose >100 mg not recommended",
    "pregnancy": "Category C â€” avoid; neonatal adaptation syndrome",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated)",
      "Triptans/serotonergic agents â€” serotonin syndrome",
      "CYP3A4 inhibitors â€” modest increase in desvenlafaxine levels"
    ],
    "monitoring": [
      "BP",
      "Suicidal ideation",
      "Sodium (SIADH)",
      "Mood scores",
      "Discontinuation symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/day (50 mg/day standard therapeutic dose)",
    "clinicalPearl": "Active metabolite of venlafaxine â€” fewer drug interactions (less CYP2D6 inhibition); 50 mg is the standard effective dose."
  },
  {
    "rank": 214,
    "name": "Imipramine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Antideprin / Tofranil",
    "formation": "Dibenzazepine tricyclic antidepressant",
    "uses": "Depression, nocturnal enuresis in children",
    "adult": "75â€“150 mg/day",
    "child": "10â€“25 mg at bedtime (Enuresis)",
    "avoid": "Post-myocardial infarction, glaucoma",
    "sideEffects": [
      "Dry mouth",
      "Constipation",
      "Drowsiness",
      "Urinary retention",
      "Blurred vision"
    ],
    "seriousRisks": [
      "Cardiac arrhythmias/QT prolongation",
      "Suicidal ideation",
      "Serotonin syndrome (MAOIs)",
      "Seizures (overdose)",
      "Severe anticholinergic crisis"
    ],
    "renalAdj": "Yes â€” use with caution; reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment; reduce dose",
    "pregnancy": "Category C â€” avoid in 1st trimester; neonatal adaptation/withdrawal syndrome",
    "lactation": "Caution â€” excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "MAOIs â€” hypertensive crisis/serotonin syndrome (contraindicated)",
      "Cimetidine â€” increased imipramine levels",
      "Antiarrhythmics â€” additive QT prolongation"
    ],
    "monitoring": [
      "ECG (QTc, QRS widening)",
      "Suicidal ideation",
      "BP (orthostatic hypotension)",
      "Anticholinergic effects",
      "Urinary symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day (inpatient depression); 75 mg/day (nocturnal enuresis)",
    "clinicalPearl": "Drug of choice for childhood nocturnal enuresis (after behavioural therapy failure) â€” use at bedtime; ECG before starting."
  },
  {
    "rank": 215,
    "name": "Nortriptyline HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Sensival / Pamelor / Nortriptyline",
    "formation": "Secondary amine tricyclic antidepressant",
    "uses": "Major depression, adjuvant for chronic pain",
    "adult": "25â€“100 mg daily",
    "child": "Not recommended",
    "avoid": "Concomitant MAOI use, severe cardiac disease",
    "sideEffects": [
      "Dry mouth",
      "Constipation",
      "Drowsiness",
      "Blurred vision",
      "Weight gain"
    ],
    "seriousRisks": [
      "Cardiac arrhythmias",
      "Suicidal ideation",
      "Anticholinergic crisis",
      "QT prolongation",
      "Seizures (overdose)"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; neonatal withdrawal possible",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "MAOIs â€” hypertensive crisis (contraindicated)",
      "Fluconazole/CYP2D6 inhibitors â€” increased nortriptyline levels",
      "Antiarrhythmics â€” QT prolongation"
    ],
    "monitoring": [
      "ECG (QTc)",
      "Serum drug levels (therapeutic range 50-150 ng/mL)",
      "BP",
      "Suicidal ideation",
      "Anticholinergic symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "150 mg/day",
    "clinicalPearl": "Fewer anticholinergic and sedating side effects than amitriptyline â€” preferred TCA for elderly neuropathic pain patients."
  },
  {
    "rank": 216,
    "name": "Quetiapine Fumarate",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Qutipin / Seroquel / Quetiapine",
    "formation": "Dibenzothiazepine atypical antipsychotic",
    "uses": "Schizophrenia, bipolar mania, depression adjunct",
    "adult": "50â€“800 mg/day (titrate)",
    "child": "50â€“400 mg/day (Restrict use)",
    "avoid": "History of QT prolongation, dementia-related psychosis",
    "sideEffects": [
      "Sedation",
      "Dry mouth",
      "Weight gain",
      "Orthostatic hypotension",
      "Constipation"
    ],
    "seriousRisks": [
      "Metabolic syndrome (diabetes, dyslipidaemia)",
      "Tardive dyskinesia",
      "QT prolongation",
      "Neuroleptic malignant syndrome",
      "Suicidal ideation (young adults)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” start with lowest dose; titrate slowly in hepatic impairment",
    "pregnancy": "Category C â€” avoid; neonatal extrapyramidal symptoms and withdrawal",
    "lactation": "Avoid â€” excreted in breast milk; sedation and developmental concerns",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin, phenytoin) â€” 5-fold reduced quetiapine levels (increase quetiapine dose)",
      "CYP3A4 inhibitors (ketoconazole) â€” 7-fold increased levels (reduce quetiapine dose)",
      "QT-prolonging drugs â€” additive QT prolongation"
    ],
    "monitoring": [
      "Fasting glucose/HbA1c",
      "Lipid profile",
      "Weight/BMI",
      "ECG (QTc)",
      "Tardive dyskinesia (AIMS)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (schizophrenia/bipolar mania)",
    "clinicalPearl": "At low doses (25-100 mg), sedation predominates â€” widely used for insomnia in India, though not approved for this indication."
  },
  {
    "rank": 217,
    "name": "Risperidone",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Sizodon / Risperdal / Risperidone",
    "formation": "Benzisoxazole atypical antipsychotic",
    "uses": "Schizophrenia, irritability in autism",
    "adult": "2â€“6 mg daily",
    "child": "0.25â€“1 mg daily (Autism)",
    "avoid": "Elderly with dementia, cardiac disease",
    "sideEffects": [
      "Weight gain",
      "Hyperprolactinaemia",
      "Extrapyramidal symptoms",
      "Sedation",
      "Orthostatic hypotension"
    ],
    "seriousRisks": [
      "Tardive dyskinesia",
      "Neuroleptic malignant syndrome",
      "QT prolongation",
      "Metabolic syndrome",
      "Cerebrovascular events (elderly dementia patients)"
    ],
    "renalAdj": "Yes â€” start with 0.5 mg twice daily in renal impairment; titrate cautiously",
    "hepaticAdj": "Yes â€” start with 0.5 mg twice daily; titrate carefully",
    "pregnancy": "Category C â€” avoid; neonatal extrapyramidal and withdrawal symptoms",
    "lactation": "Avoid â€” high breast milk to plasma ratio",
    "drugInteractions": [
      "CYP2D6 inhibitors (fluoxetine, paroxetine) â€” increased risperidone levels (dose reduction)",
      "CYP3A4 inducers (carbamazepine) â€” significantly reduced risperidone levels (increase dose)",
      "QT-prolonging drugs â€” additive QT prolongation"
    ],
    "monitoring": [
      "Weight/BMI",
      "Fasting glucose/lipids",
      "Prolactin (if sexual side effects)",
      "AIMS (tardive dyskinesia)",
      "ECG (QTc)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "16 mg/day (schizophrenia); 6 mg/day elderly",
    "clinicalPearl": "Highest prolactin elevation among atypical antipsychotics â€” assess for sexual dysfunction, amenorrhoea, and galactorrhoea."
  },
  {
    "rank": 218,
    "name": "Olanzapine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Oleanz / Zyprexa / Olanzapine",
    "formation": "Thienobenzodiazepine atypical antipsychotic",
    "uses": "Schizophrenia, acute bipolar mania",
    "adult": "5â€“20 mg OD (bedtime)",
    "child": "2.5â€“10 mg OD (Restrict under 13y)",
    "avoid": "Severe metabolic syndrome, geriatric patients",
    "sideEffects": [
      "Weight gain (most among atypicals)",
      "Sedation",
      "Dry mouth",
      "Increased appetite",
      "Orthostatic hypotension"
    ],
    "seriousRisks": [
      "Metabolic syndrome (most severe among atypicals)",
      "Tardive dyskinesia",
      "Neuroleptic malignant syndrome",
      "Diabetic ketoacidosis",
      "Post-injection delirium/sedation syndrome (LAI)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution; start with lower dose in hepatic impairment",
    "pregnancy": "Category C â€” neonatal extrapyramidal and withdrawal; avoid unless clearly indicated",
    "lactation": "Avoid â€” excreted in breast milk; risk of infant sedation/hypotonia",
    "drugInteractions": [
      "CYP1A2 inducers (smoking, carbamazepine) â€” reduced olanzapine levels",
      "Fluvoxamine (CYP1A2 inhibitor) â€” increased olanzapine levels",
      "QT-prolonging drugs â€” additive effect"
    ],
    "monitoring": [
      "Fasting glucose/HbA1c (baseline and 3-monthly)",
      "Weight/waist circumference",
      "Lipid profile",
      "BP",
      "AIMS (tardive dyskinesia)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day",
    "clinicalPearl": "Greatest weight gain risk among atypicals â€” monitor for metabolic syndrome from day 1; smoking induces CYP1A2, significantly reducing levels."
  },
  {
    "rank": 219,
    "name": "Haloperidol",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Serenace / Haldol / Haloperidol",
    "formation": "Butyrophenone derivative antipsychotic",
    "uses": "Acute psychosis, Tourette's syndrome, hiccups",
    "adult": "0.5â€“5 mg BID or TID",
    "child": "0.05â€“0.15 mg/kg/day",
    "avoid": "Parkinsonâ€™s disease, CNS depression",
    "sideEffects": [
      "Extrapyramidal symptoms (EPS)",
      "Sedation",
      "Hyperprolactinaemia",
      "QT prolongation",
      "Anticholinergic effects (lower than others)"
    ],
    "seriousRisks": [
      "Tardive dyskinesia (high risk)",
      "Neuroleptic malignant syndrome",
      "QT prolongation/Torsades de pointes",
      "Acute dystonic reactions",
      "Cerebrovascular events (elderly)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; reduce dose",
    "pregnancy": "Category C â€” neonatal extrapyramidal symptoms; limb defects with high-dose 1st trimester (rare)",
    "lactation": "Avoid â€” excreted in breast milk; sedation and movement disorders in infant",
    "drugInteractions": [
      "QT-prolonging drugs â€” additive/synergistic QT prolongation",
      "CNS depressants â€” additive sedation",
      "Lithium â€” increased haloperidol neurotoxicity at high doses"
    ],
    "monitoring": [
      "ECG (QTc)",
      "AIMS (tardive dyskinesia)",
      "Extrapyramidal symptoms (ESRS)",
      "BP",
      "Electrolytes (K+, Mg2+)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day (acute psychosis); 20 mg/day maintenance",
    "clinicalPearl": "Highest EPS risk â€” always co-prescribe anticholinergic (trihexyphenidyl) prophylactically when starting at higher doses."
  },
  {
    "rank": 220,
    "name": "Aripiprazole",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Arip MT / Abilify / Aripiprazole",
    "formation": "Quinolinone atypical antipsychotic",
    "uses": "Schizophrenia, bipolar I disorder, Touretteâ€™s",
    "adult": "10â€“30 mg OD",
    "child": "2â€“10 mg OD (Weight-based)",
    "avoid": "Dementia-related psychosis, severe liver disease",
    "sideEffects": [
      "Insomnia",
      "Akathisia",
      "Nausea",
      "Headache",
      "Anxiety/restlessness"
    ],
    "seriousRisks": [
      "Tardive dyskinesia",
      "Neuroleptic malignant syndrome",
      "Suicidal ideation (young adults)",
      "Impulse control disorders (gambling, hypersexuality)",
      "Cerebrovascular events (elderly dementia)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (mild-moderate); caution in severe",
    "pregnancy": "Category C â€” neonatal extrapyramidal and withdrawal",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "Strong CYP2D6 inhibitors (fluoxetine, paroxetine) â€” double aripiprazole levels, reduce to half dose",
      "Strong CYP3A4 inducers (carbamazepine) â€” reduce aripiprazole levels; double dose",
      "QT-prolonging drugs â€” additive QT prolongation (minimal risk but monitor)"
    ],
    "monitoring": [
      "Akathisia assessment",
      "Impulse control behaviours",
      "Weight/metabolic parameters (less than others)",
      "AIMS",
      "Mental state"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day",
    "clinicalPearl": "Least weight gain and metabolic effects among atypicals; akathisia is the main limiting side effect â€” loprazolam or propranolol can help."
  },
  {
    "rank": 221,
    "name": "Clozapine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Sizopin / Clozaril / Leponex",
    "formation": "Dibenzodiazepine atypical antipsychotic",
    "uses": "Treatment-resistant schizophrenia",
    "adult": "12.5â€“450 mg/day (titrate slowly)",
    "child": "Not recommended",
    "avoid": "History of agranulocytosis, uncontrolled epilepsy",
    "sideEffects": [
      "Weight gain",
      "Hypersalivation (sialorrhoea)",
      "Sedation",
      "Constipation",
      "Tachycardia"
    ],
    "seriousRisks": [
      "Agranulocytosis (1-2% â€” potentially fatal)",
      "Myocarditis/Cardiomyopathy",
      "Seizures (dose-related)",
      "Metabolic syndrome",
      "Pulmonary embolism"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; reduce dose",
    "hepaticAdj": "Yes â€” severe hepatic impairment: contraindicated; moderate: reduce dose",
    "pregnancy": "Category C â€” use only for treatment-resistant schizophrenia where alternatives failed",
    "lactation": "Avoid â€” significant breast milk levels; agranulocytosis risk in infant",
    "drugInteractions": [
      "Benzodiazepines â€” severe respiratory depression/collapse (contraindicated in combination)",
      "CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) â€” markedly increased clozapine levels",
      "Smoking cessation â€” rapidly increases clozapine levels (50% dose reduction needed)"
    ],
    "monitoring": [
      "ANC (absolute neutrophil count) â€” mandatory protocol (weekly x 26 weeks, then fortnightly x 26 weeks, then monthly)",
      "ECG, troponin (myocarditis screening)",
      "Fasting glucose/lipids",
      "BP",
      "Seizure threshold"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "900 mg/day (reduce dose in seizure-prone: maximum 600 mg/day; ANC must be normal)",
    "clinicalPearl": "Only antipsychotic proven to reduce suicidality â€” mandatory clozapine patient monitoring system (CPMS/REMS) registration before dispensing."
  },
  {
    "rank": 222,
    "name": "Sodium Valproate",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Encorate / Depakote / Valprol",
    "formation": "Fatty acid derivative (Antiepileptic)",
    "uses": "Absence seizures, migraine prophylaxis, bipolar mania",
    "adult": "600â€“2000 mg/day in divided doses",
    "child": "20â€“30 mg/kg/day",
    "avoid": "Pregnancy (Category X for migraine), urea cycle disorders",
    "sideEffects": [
      "Weight gain",
      "Tremor",
      "Hair loss (alopecia)",
      "Nausea/GI upset",
      "Sedation"
    ],
    "seriousRisks": [
      "Teratogenicity (neural tube defects â€” highest among AEDs)",
      "Hepatotoxicity (fatal in children <2 years)",
      "Pancreatitis",
      "Thrombocytopenia",
      "Hyperammonaemic encephalopathy"
    ],
    "renalAdj": "No â€” standard dosing; monitor free valproate (protein binding reduced in renal failure)",
    "hepaticAdj": "Yes â€” contraindicated in hepatic disease; monitor LFT rigorously",
    "pregnancy": "Category D/X â€” avoid in women of childbearing age unless no alternative; highest risk of major congenital malformations (10-15%) and neurodevelopmental effects",
    "lactation": "Caution â€” low breast milk levels; generally acceptable if no alternative; monitor infant",
    "drugInteractions": [
      "Carbapenems â€” 50-90% reduction in valproate levels (avoid combination)",
      "Lamotrigine â€” valproate doubles lamotrigine levels (halve lamotrigine dose)",
      "Aspirin â€” displaces valproate from protein binding, increases free levels"
    ],
    "monitoring": [
      "LFT (every 6 months)",
      "Valproate levels (therapeutic: 50-100 mg/L)",
      "CBC/platelets",
      "Ammonia (encephalopathy)",
      "Weight"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "3000 mg/day (60 mg/kg/day â€” weight-based)",
    "clinicalPearl": "Mandatory pregnancy prevention programme for all women of childbearing potential â€” teratogenicity risk discussed at every visit."
  },
  {
    "rank": 223,
    "name": "Carbamazepine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Tegretol / Zen / Mazetol",
    "formation": "Dibenzazepine antiepileptic",
    "uses": "Trigeminal neuralgia, focal seizures",
    "adult": "200â€“800 mg/day in divided doses",
    "child": "10â€“20 mg/kg/day",
    "avoid": "Bone marrow depression, HLA-B*1502 positive",
    "sideEffects": [
      "Drowsiness",
      "Dizziness",
      "Diplopia/blurred vision",
      "Nausea",
      "Ataxia"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome/TEN (especially HLA-B*1502 positive â€” Asians)",
      "Aplastic anaemia/agranulocytosis",
      "Hyponatraemia (SIADH)",
      "Hepatotoxicity",
      "Teratogenicity (spina bifida)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” contraindicated in significant hepatic impairment",
    "pregnancy": "Category D â€” associated with neural tube defects (spina bifida), craniofacial abnormalities; supplement folate",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for sedation, hepatotoxicity, CBC",
    "drugInteractions": [
      "Enzyme inducer â€” reduces levels of OCP, warfarin, many drugs (>60 interactions)",
      "Valproate â€” mutual level changes; monitor both",
      "Erythromycin/clarithromycin â€” increased carbamazepine toxicity (inhibit CYP3A4)"
    ],
    "monitoring": [
      "CBC (baseline then monthly for 1 year, then annual)",
      "LFT",
      "Serum sodium (SIADH)",
      "Carbamazepine levels (therapeutic: 4-12 mg/L)",
      "HLA-B*1502 (before starting in Asian patients)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1600 mg/day (epilepsy); 1200 mg/day (trigeminal neuralgia)",
    "clinicalPearl": "Test HLA-B*1502 in South/Southeast Asian patients before prescribing â€” positive allele carries 10-fold higher SJS/TEN risk."
  },
  {
    "rank": 224,
    "name": "Phenytoin Sodium",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Eptoin / Dilantin / Phenytek",
    "formation": "Hydantoin derivative (Antiepileptic)",
    "uses": "Generalized tonic-clonic seizures, status epilepticus",
    "adult": "300â€“400 mg daily",
    "child": "5â€“8 mg/kg/day",
    "avoid": "Sinus bradycardia, SA block, second/third-degree AV block",
    "sideEffects": [
      "Gingival hyperplasia",
      "Hirsutism",
      "Ataxia",
      "Diplopia",
      "Nystagmus"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome/TEN",
      "Hepatotoxicity",
      "Aplastic anaemia",
      "Teratogenicity (fetal hydantoin syndrome)",
      "Purple glove syndrome (IV extravasation)"
    ],
    "renalAdj": "Yes â€” monitor free phenytoin levels in renal failure (reduced protein binding)",
    "hepaticAdj": "Yes â€” use with caution; hepatic metabolism affected; monitor levels",
    "pregnancy": "Category D â€” fetal hydantoin syndrome; cleft palate; avoid if possible; supplement folate",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for sedation",
    "drugInteractions": [
      "Warfarin â€” initially increases, then decreases INR (complex)",
      "Valproate â€” variable effect on phenytoin levels (monitor)",
      "OCP â€” reduces OCP efficacy (use alternative contraception)"
    ],
    "monitoring": [
      "Phenytoin levels (therapeutic: 10-20 mg/L; free: 1-2 mg/L)",
      "CBC",
      "LFT",
      "Calcium/vitamin D (long-term)",
      "Gingival assessment"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day (dose titrated to phenytoin levels); IV loading: 20 mg/kg",
    "clinicalPearl": "Narrow therapeutic index and non-linear kinetics â€” small dose increases can cause toxicity; always monitor levels."
  },
  {
    "rank": 225,
    "name": "Levetiracetam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Keppra / Levipil / Levetiracetam",
    "formation": "Pyrrolidine derivative antiepileptic",
    "uses": "Focal and myoclonic seizures",
    "adult": "500â€“1500 mg BID",
    "child": "20â€“60 mg/kg/day",
    "avoid": "Suicidal behavior history, renal failure (titrate)",
    "sideEffects": [
      "Somnolence",
      "Asthenia",
      "Dizziness",
      "Irritability/agitation",
      "Headache"
    ],
    "seriousRisks": [
      "Suicidal ideation",
      "Psychosis/severe behavioural disturbance",
      "Hypersensitivity (DRESS, SJS â€” rare)",
      "Aplastic anaemia (rare)"
    ],
    "renalAdj": "Yes â€” CrCl 30-50: maximum 1000 mg every 12h; CrCl <30: maximum 500 mg every 12h; haemodialysis: 500-1000 mg then 250-500 mg after each session",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” relatively safer among AEDs; UK Epilepsy and Pregnancy Register data reassuring",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for sedation",
    "drugInteractions": [
      "Very few drug-drug interactions (not CYP metabolised)",
      "Probenecid â€” increases levetiracetam levels slightly",
      "Methotrexate â€” levetiracetam may increase MTX toxicity"
    ],
    "monitoring": [
      "Renal function (dose adjustment)",
      "Suicidal ideation",
      "Behavioural changes",
      "Seizure frequency"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3000 mg/day (1500 mg twice daily)",
    "clinicalPearl": "Minimal drug interactions and no enzyme induction/inhibition â€” preferred AED in patients on polypharmacy or OCP."
  },
  {
    "rank": 226,
    "name": "Brivaracetam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Briviact",
    "formation": "Selective SV2A ligand (Antiepileptic)",
    "uses": "Focal-onset seizures",
    "adult": "50â€“100 mg BID",
    "child": "Weight-based (approved >4 years)",
    "avoid": "End-stage renal disease",
    "sideEffects": [
      "Somnolence",
      "Dizziness",
      "Fatigue",
      "Nausea",
      "Vomiting"
    ],
    "seriousRisks": [
      "Suicidal ideation",
      "Psychiatric disturbances (less than levetiracetam)",
      "Hypersensitivity reactions (SJS â€” rare)",
      "Haematological effects (rare)"
    ],
    "renalAdj": "No â€” standard dosing (mild-moderate); caution in severe renal impairment; avoid in end-stage renal disease",
    "hepaticAdj": "Yes â€” Child-Pugh A/B/C: maximum 150 mg/day",
    "pregnancy": "Category C â€” limited human data; avoid unless clearly necessary; folate supplementation",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Carbamazepine â€” increased carbamazepine-epoxide levels (may need carbamazepine dose reduction)",
      "Rifampicin â€” reduced brivaracetam levels (50% reduction)",
      "Phenytoin â€” increased phenytoin levels"
    ],
    "monitoring": [
      "Seizure frequency",
      "Suicidal ideation",
      "Psychiatric symptoms",
      "LFT (hepatic impairment)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg/day (100 mg twice daily)",
    "clinicalPearl": "10-fold higher affinity for SV2A than levetiracetam â€” fewer behavioural side effects; useful when levetiracetam causes psychiatric issues."
  },
  {
    "rank": 227,
    "name": "Lamotrigine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Lamictal / Lametec / Lamitor",
    "formation": "Phenyltriazine derivative antiepileptic",
    "uses": "Bipolar I maintenance, Lennox-Gastaut syndrome",
    "adult": "100â€“400 mg daily",
    "child": "1â€“5 mg/kg/day (with valproate) or higher alone",
    "avoid": "Severe skin rash (SJS/TEN risk), pregnancy",
    "sideEffects": [
      "Headache",
      "Dizziness",
      "Ataxia",
      "Diplopia",
      "Nausea"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome/TEN (especially if rapid titration or with valproate)",
      "DRESS",
      "Aseptic meningitis",
      "Blood dyscrasias",
      "Suicidal ideation"
    ],
    "renalAdj": "Yes â€” reduce maintenance dose in significant renal impairment",
    "hepaticAdj": "Yes â€” moderate impairment: reduce dose by 25-50%; severe: reduce by 50-75%",
    "pregnancy": "Category C â€” relatively safer AED; some risk of oral clefts at higher doses; use with folate",
    "lactation": "Caution â€” significant breast milk levels; monitor infant for sedation and rash",
    "drugInteractions": [
      "Valproate â€” doubles lamotrigine levels (must halve lamotrigine dose)",
      "Enzyme inducers (carbamazepine, phenytoin, rifampicin) â€” halve lamotrigine levels (must double dose)",
      "OCP â€” reduces lamotrigine levels by 50% (monitor on starting/stopping OCP)"
    ],
    "monitoring": [
      "Rash (first 8 weeks â€” most critical)",
      "Seizure frequency",
      "Suicidal ideation",
      "Mood (bipolar monitoring)",
      "Lamotrigine levels if altered drug interactions"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "500 mg/day (epilepsy â€” on enzyme inducer); 200 mg/day (on valproate)",
    "clinicalPearl": "Slow titration is mandatory â€” SJS risk is directly related to dose escalation speed; minimum 6-week titration from starting dose."
  },
  {
    "rank": 228,
    "name": "Clobazam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Frisium / Urban / Clobazam",
    "formation": "1,5-benzodiazepine antiepileptic",
    "uses": "Adjunct in LGS seizures, acute anxiety",
    "adult": "10â€“40 mg daily",
    "child": "5â€“20 mg/day (Weight-based)",
    "avoid": "Severe respiratory insufficiency, sleep apnea",
    "sideEffects": [
      "Sedation",
      "Ataxia",
      "Irritability",
      "Hypersalivation",
      "Aggression"
    ],
    "seriousRisks": [
      "Dependence/withdrawal (benzodiazepine class)",
      "Severe sedation/respiratory depression",
      "Stevens-Johnson syndrome/TEN (rare)",
      "Suicidal ideation"
    ],
    "renalAdj": "No â€” standard dosing; caution in severe renal impairment",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose; prolongs half-life",
    "pregnancy": "Category D â€” benzodiazepine class; neonatal withdrawal; avoid unless essential",
    "lactation": "Avoid â€” excreted in breast milk; neonatal sedation",
    "drugInteractions": [
      "CNS depressants/opioids â€” additive respiratory depression",
      "CYP2C19 inhibitors (fluoxetine, omeprazole) â€” increased active metabolite (N-desmethylclobazam) levels",
      "Valproate â€” may increase clobazam levels"
    ],
    "monitoring": [
      "Sedation level",
      "Seizure frequency",
      "Dependence signs",
      "Respiratory rate (if with opioids)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60 mg/day (epilepsy); 30 mg/day as adjunct in Lennox-Gastaut syndrome",
    "clinicalPearl": "Less sedating than other benzodiazepines (1,5-benzodiazepine) â€” intermittent use for catamenial epilepsy avoids tolerance."
  },
  {
    "rank": 229,
    "name": "Alprazolam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Alprax / Restyl / Xanax",
    "formation": "Triazolo-benzodiazepine (Anxiolytic)",
    "uses": "Anxiety, panic disorder",
    "adult": "0.25â€“1 mg TID",
    "child": "Not recommended",
    "avoid": "Concomitant use with opioids (fatal sedation risk)",
    "sideEffects": [
      "Sedation",
      "Cognitive impairment",
      "Anterograde amnesia",
      "Ataxia",
      "Dependence"
    ],
    "seriousRisks": [
      "Physical dependence and withdrawal seizures",
      "Respiratory depression (with opioids/CNS depressants)",
      "Paradoxical disinhibition",
      "Rebound anxiety",
      "Misuse/abuse potential"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; reduce dose",
    "hepaticAdj": "Yes â€” severe hepatic impairment: avoid; moderate: reduce dose significantly",
    "pregnancy": "Category D â€” neonatal withdrawal; cleft palate risk (1st trimester); floppy infant syndrome",
    "lactation": "Avoid â€” excreted in breast milk; neonatal sedation",
    "drugInteractions": [
      "Opioids â€” fatal respiratory depression (black box warning)",
      "CYP3A4 inhibitors (azoles, macrolides) â€” markedly increased alprazolam levels",
      "Alcohol â€” additive CNS/respiratory depression"
    ],
    "monitoring": [
      "Dependence/withdrawal signs",
      "Sedation level",
      "Cognitive function",
      "Anxiety scores (effectiveness)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 mg/day (panic disorder); 10 mg/day XR (extreme cases under supervision)",
    "clinicalPearl": "Most addictive benzodiazepine in India â€” Schedule H drug; limit to 4-week courses; never stop abruptly."
  },
  {
    "rank": 230,
    "name": "Clonazepam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Clonaz / Rivotril / Klonopin",
    "formation": "Nitro-benzodiazepine derivative",
    "uses": "Panic disorder, petit mal seizures",
    "adult": "0.25â€“2 mg daily (divided or bedtime)",
    "child": "0.01â€“0.03 mg/kg/day",
    "avoid": "Severe liver disease, acute narrow-angle glaucoma",
    "sideEffects": [
      "Sedation",
      "Ataxia",
      "Cognitive impairment",
      "Hypersalivation",
      "Anterograde amnesia"
    ],
    "seriousRisks": [
      "Physical dependence and withdrawal",
      "Respiratory depression",
      "Paradoxical disinhibition",
      "Suicidal ideation",
      "Tolerance to anticonvulsant effect"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: avoid or use minimum dose",
    "pregnancy": "Category D â€” neonatal withdrawal and floppy infant syndrome; avoid unless essential",
    "lactation": "Avoid â€” excreted in breast milk; neonatal sedation",
    "drugInteractions": [
      "Opioids â€” severe respiratory depression (black box warning)",
      "Valproate â€” clonazepam may precipitate absence status in patients with absence seizures (controversial)",
      "CYP3A4 inhibitors â€” increased clonazepam levels"
    ],
    "monitoring": [
      "Seizure frequency",
      "Sedation/cognitive effects",
      "Dependence signs",
      "Respiratory function (IV use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day (epilepsy â€” adults; dose titrated)",
    "clinicalPearl": "Anticonvulsant tolerance develops within weeks â€” effective for acute control and myoclonic/absence seizures; adjunct role best."
  },
  {
    "rank": 231,
    "name": "Lorazepam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Ativan / Calmpose / Lorazepam",
    "formation": "Benzodiazepine (Anxiolytic/Sedative)",
    "uses": "Acute anxiety, preoperative sedation, status epilepticus",
    "adult": "1â€“2 mg BID or TID",
    "child": "0.05 mg/kg per dose",
    "avoid": "Sleep apnea, severe respiratory insufficiency",
    "sideEffects": [
      "Sedation",
      "Ataxia",
      "Cognitive impairment",
      "Respiratory depression",
      "Amnesia"
    ],
    "seriousRisks": [
      "Severe respiratory depression/apnoea (especially IV)",
      "Physical dependence",
      "Propylene glycol toxicity (high-dose IV)",
      "Paradoxical agitation",
      "Withdrawal seizures"
    ],
    "renalAdj": "Yes â€” use with caution; IV formulation: propylene glycol accumulation in renal failure",
    "hepaticAdj": "Yes â€” severe hepatic impairment: avoid; glucuronidation impaired",
    "pregnancy": "Category D â€” neonatal withdrawal; floppy infant; avoid unless life-threatening seizures",
    "lactation": "Avoid â€” excreted in breast milk; neonatal sedation",
    "drugInteractions": [
      "Opioids â€” severe respiratory depression (black box warning)",
      "Valproate â€” increased lorazepam levels (reduce dose when given together)",
      "Alcohol/CNS depressants â€” additive sedation and respiratory depression"
    ],
    "monitoring": [
      "Respiratory rate (especially IV)",
      "Sedation level",
      "BP (hypotension)",
      "Seizure control",
      "Dependence signs"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day (acute anxiety/seizure; IV: 4 mg per episode, may repeat once)",
    "clinicalPearl": "First-line IV benzodiazepine for status epilepticus â€” shorter duration of action than diazepam; fewer paradoxical reactions."
  },
  {
    "rank": 232,
    "name": "Diazepam",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Valium / Calmpose / Diazepam",
    "formation": "Benzodiazepine (1,4-substituted)",
    "uses": "Muscle spasms, seizures, alcohol withdrawal",
    "adult": "2â€“10 mg 2â€“4 times/day",
    "child": "0.1â€“0.5 mg/kg/day",
    "avoid": "Severe hepatic insufficiency, myasthenia gravis",
    "sideEffects": [
      "Sedation",
      "Muscle relaxation",
      "Ataxia",
      "Anterograde amnesia",
      "Respiratory depression (IV)"
    ],
    "seriousRisks": [
      "Severe respiratory depression/apnoea (IV)",
      "Physical dependence",
      "Paradoxical agitation",
      "Withdrawal seizures (abrupt discontinuation)",
      "Phlebitis (IV)"
    ],
    "renalAdj": "No â€” standard dosing; active metabolites may accumulate",
    "hepaticAdj": "Yes â€” severe hepatic impairment: contraindicated; prolonged half-life",
    "pregnancy": "Category D â€” neonatal withdrawal; cleft palate; floppy infant syndrome",
    "lactation": "Avoid â€” excreted in breast milk; prolonged neonatal sedation (long half-life)",
    "drugInteractions": [
      "Opioids â€” potentially fatal respiratory depression",
      "CYP3A4/CYP2C19 inhibitors â€” increased diazepam levels",
      "Alcohol â€” additive CNS and respiratory depression"
    ],
    "monitoring": [
      "Respiratory rate",
      "Sedation level",
      "BP",
      "Dependence/withdrawal signs",
      "Seizure status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 mg/day oral; IV: 10-20 mg per status epilepticus episode",
    "clinicalPearl": "Rectal diazepam is first-line for paediatric seizure rescue in community settings â€” safe and effective without IV access."
  },
  {
    "rank": 233,
    "name": "Midazolam HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Dormicum / Versed / Midazolam",
    "formation": "Short-acting imidazole benzodiazepine",
    "uses": "Procedural sedation, induction of anesthesia",
    "adult": "1â€“5 mg IV/IM (titrate based on sedation)",
    "child": "0.1â€“0.5 mg/kg (Oral/IV)",
    "avoid": "Acute narrow-angle glaucoma, respiratory failure",
    "sideEffects": [
      "Sedation",
      "Respiratory depression",
      "Anterograde amnesia",
      "Hiccups (IV)",
      "Paradoxical agitation"
    ],
    "seriousRisks": [
      "Severe respiratory depression/apnoea (IV â€” black box)",
      "Cardiovascular depression",
      "Paradoxical reactions",
      "Dependence (prolonged use)",
      "Airway loss in oversedation"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; active glucuronide metabolite may accumulate",
    "hepaticAdj": "Yes â€” significantly prolonged action in hepatic impairment; reduce dose",
    "pregnancy": "Category D â€” avoid except for procedural sedation where benefit outweighs risk",
    "lactation": "Caution â€” single-dose procedural use generally acceptable; avoid repeated use",
    "drugInteractions": [
      "CYP3A4 inhibitors (azoles, macrolides, ritonavir) â€” markedly increased midazolam levels (contraindicated with oral midazolam)",
      "Opioids â€” synergistic respiratory depression",
      "CYP3A4 inducers (rifampicin) â€” severely reduced midazolam efficacy"
    ],
    "monitoring": [
      "SpO2/respiratory rate (continuous during procedure)",
      "BP and HR",
      "Sedation level (Ramsay scale)",
      "Airway patency"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "IV procedural sedation: 5-7.5 mg titrated; ICU sedation: per protocol infusion",
    "clinicalPearl": "IV midazolam must only be administered where resuscitation facilities are immediately available â€” black box warning."
  },
  {
    "rank": 234,
    "name": "Zolpidem Tartrate",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Zolfresh / Ambien / Stilnox",
    "formation": "Imidazopyridine non-benzodiazepine hypnotic",
    "uses": "Short-term treatment of insomnia",
    "adult": "5â€“10 mg at bedtime",
    "child": "Not recommended",
    "avoid": "Obstructive sleep apnea, complex sleep behaviors",
    "sideEffects": [
      "Drowsiness",
      "Headache",
      "Dizziness",
      "Anterograde amnesia",
      "Parasomnias (sleep-walking, sleep-driving)"
    ],
    "seriousRisks": [
      "Complex sleep behaviours (sleep-walking, sleep-driving, sleep-eating)",
      "Severe next-day impairment (especially women)",
      "Physical dependence/withdrawal",
      "Respiratory depression (with CNS depressants)",
      "Suicidal ideation (rare)"
    ],
    "renalAdj": "Yes â€” use with caution; reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” maximum 5 mg/day in hepatic impairment; significantly prolonged effect",
    "pregnancy": "Category C â€” avoid; neonatal withdrawal and respiratory depression",
    "lactation": "Avoid â€” excreted in breast milk; neonatal sedation",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive sedation and respiratory depression",
      "CYP3A4 inhibitors (azoles) â€” increased zolpidem levels",
      "Rifampicin â€” 73% reduction in zolpidem levels"
    ],
    "monitoring": [
      "Sleep quality and duration",
      "Complex sleep behaviours",
      "Daytime functioning/amnesia",
      "Dependence signs"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day (men); 5 mg/day (women and elderly)",
    "clinicalPearl": "Lower dose in women â€” slower elimination causes greater next-morning impairment; limit to 2-4 weeks to prevent dependence."
  },
  {
    "rank": 235,
    "name": "Melatonin",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "OTC",
    "brand": "Meloset / Melalong",
    "formation": "Endogenous indole hormone analog",
    "uses": "Jet lag, delayed sleep phase syndrome",
    "adult": "3â€“10 mg (bedtime)",
    "child": "1â€“3 mg (Consult specialist)",
    "avoid": "Autoimmune disorders, concomitant anticoagulant use",
    "sideEffects": [
      "Drowsiness",
      "Headache",
      "Dizziness",
      "Nausea",
      "Hypothermia (high dose)"
    ],
    "seriousRisks": [
      "Exacerbation of autoimmune conditions (theoretical)",
      "Hormonal effects with prolonged use (reproductive axis)",
      "Drug interactions with anticoagulants"
    ],
    "renalAdj": "No â€” standard dosing; caution in severe renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment (melatonin levels elevated)",
    "pregnancy": "Category C â€” insufficient data; avoid unless clearly necessary",
    "lactation": "Caution â€” naturally present in breast milk; supplement timing may affect infant circadian rhythm",
    "drugInteractions": [
      "Warfarin â€” may enhance anticoagulant effect (monitor INR)",
      "Fluvoxamine â€” significantly increases melatonin levels (CYP1A2 inhibition)",
      "Alcohol â€” additive sedation; impairs melatonin efficacy"
    ],
    "monitoring": [
      "Sleep diary (onset, duration, quality)",
      "Daytime functioning",
      "Mood in elderly"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day (extended-release); 5 mg standard for insomnia/jet lag",
    "clinicalPearl": "Take 30-60 minutes before bedtime at lowest effective dose (0.5-3 mg) â€” chronobiotic effect works best in the dark."
  },
  {
    "rank": 236,
    "name": "Donepezil HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Donecept / Aricept / Alzil",
    "formation": "Piperidine-based acetylcholinesterase inhibitor",
    "uses": "Mild-to-severe Alzheimer's dementia",
    "adult": "5â€“10 mg OD (bedtime)",
    "child": "Not recommended",
    "avoid": "Severe cardiac arrhythmias, obstructive lung disease",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Insomnia",
      "Vivid dreams/nightmares",
      "Muscle cramps"
    ],
    "seriousRisks": [
      "Bradycardia/syncope (vagotonic effect)",
      "GI bleeding (NSAID combination)",
      "Seizures (cholinergic excess)",
      "Worsening of peptic ulcer disease",
      "Rhabdomyolysis (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in moderate-severe hepatic impairment",
    "pregnancy": "Category C â€” not applicable (indication is elderly/dementia)",
    "lactation": "Not applicable",
    "drugInteractions": [
      "NSAIDs â€” additive GI bleeding risk",
      "Anticholinergics â€” pharmacodynamic antagonism (avoid)",
      "Succinylcholine â€” prolonged neuromuscular blockade (surgical caution)"
    ],
    "monitoring": [
      "MMSE/ADAS-Cog (cognitive function)",
      "ECG (bradycardia)",
      "GI symptoms",
      "Behavioural symptoms (BPSD)",
      "Weight"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "23 mg/day (moderate-severe Alzheimer's); 10 mg/day (mild-moderate)",
    "clinicalPearl": "Take at bedtime to reduce nausea and exploit insomnia side effect â€” nightmares indicate cholinergic excess; shift to morning dosing."
  },
  {
    "rank": 237,
    "name": "Memantine HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Admenta / Namenda / Ebixa",
    "formation": "Adamantane-derivative NMDA antagonist",
    "uses": "Moderate-to-severe Alzheimer's disease",
    "adult": "5â€“20 mg OD",
    "child": "Not recommended",
    "avoid": "Severe renal impairment (CrCl < 5), seizures",
    "sideEffects": [
      "Dizziness",
      "Headache",
      "Constipation",
      "Confusion",
      "Hypertension"
    ],
    "seriousRisks": [
      "Psychosis (rare â€” particularly at high doses)",
      "Seizures (rare)",
      "Serotonin syndrome (with serotonergic drugs)",
      "Falls (dizziness)"
    ],
    "renalAdj": "Yes â€” CrCl 5-29 mL/min: maximum 10 mg/day",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category B â€” not applicable (indication is elderly/dementia)",
    "lactation": "Not applicable",
    "drugInteractions": [
      "Amantadine/dextromethorphan â€” additive NMDA antagonism (avoid)",
      "Cimetidine/triamterene â€” compete for renal tubular secretion (monitor)",
      "Levodopa â€” may potentiate effects of levodopa"
    ],
    "monitoring": [
      "Renal function (dose adjustment)",
      "Cognitive function (MMSE)",
      "BP",
      "Behavioural symptoms",
      "Tolerability"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day (10 mg twice daily)",
    "clinicalPearl": "Complementary mechanism to cholinesterase inhibitors â€” evidence supports combination therapy in moderate-severe Alzheimer's disease."
  },
  {
    "rank": 238,
    "name": "Levodopa + Carbidopa",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Syndopa / Sinemet / Tidomet",
    "formation": "Dopamine precursor + decarboxylase inhibitor",
    "uses": "Parkinsonâ€™s disease, restless legs syndrome",
    "adult": "100 mg/25 mg TID (titrate based on mobility)",
    "child": "Not recommended",
    "avoid": "Concomitant non-selective MAOIs, narrow-angle glaucoma",
    "sideEffects": [
      "Nausea/vomiting",
      "Dyskinesias",
      "Orthostatic hypotension",
      "Hallucinations",
      "On-off fluctuations"
    ],
    "seriousRisks": [
      "Dyskinesias (dose-related, long-term)",
      "Psychosis/hallucinations",
      "Impulse control disorders",
      "Malignant hyperthermia-like syndrome (abrupt withdrawal)",
      "Sudden onset of sleep"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; dopaminergic effects on fetus",
    "lactation": "Avoid â€” inhibits prolactin/lactation; excreted in breast milk",
    "drugInteractions": [
      "MAOIs (non-selective) â€” hypertensive crisis (contraindicated)",
      "Antipsychotics (D2 antagonists) â€” pharmacodynamic antagonism; avoid typical antipsychotics",
      "Iron supplements â€” reduced levodopa absorption (separate by 2h)"
    ],
    "monitoring": [
      "Motor function (UPDRS scale)",
      "BP (orthostatic hypotension)",
      "Dyskinesia monitoring",
      "Neuropsychiatric symptoms",
      "Sleep quality"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2000 mg levodopa/day (in divided doses); individual titration required",
    "clinicalPearl": "Take 30 min before meals â€” protein in food competes with levodopa absorption; most effective anti-Parkinson drug available."
  },
  {
    "rank": 239,
    "name": "Pramipexole",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Pramipex / Mirapex",
    "formation": "Non-ergot dopamine receptor agonist",
    "uses": "Parkinsonâ€™s disease, restless legs syndrome",
    "adult": "0.125â€“1.5 mg TID",
    "child": "Not recommended",
    "avoid": "Severe renal impairment, sudden sleep onset history",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Somnolence",
      "Orthostatic hypotension",
      "Peripheral oedema"
    ],
    "seriousRisks": [
      "Impulse control disorders (gambling, hypersexuality â€” class effect)",
      "Sudden onset of sleep (driving caution)",
      "Hallucinations/psychosis",
      "Augmentation (restless legs syndrome)",
      "Pleuropulmonary fibrosis (rare)"
    ],
    "renalAdj": "Yes â€” CrCl 30-50: initial 0.088 mg twice daily, maximum 2.25 mg/day; CrCl <30: initial 0.088 mg once daily, maximum 1.5 mg/day",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” inhibits prolactin/lactation",
    "drugInteractions": [
      "Dopamine antagonists (metoclopramide, antipsychotics) â€” reduce efficacy",
      "Cimetidine â€” reduces pramipexole renal clearance (increase levels)",
      "CNS depressants â€” additive somnolence"
    ],
    "monitoring": [
      "Motor function/UPDRS",
      "Impulse control behaviours (screen at each visit)",
      "BP (orthostatic)",
      "Sleep attacks",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4.5 mg/day (Parkinson's disease; base equivalent)",
    "clinicalPearl": "Screen for impulse control disorders at every visit â€” patients often do not voluntarily report gambling or hypersexuality."
  },
  {
    "rank": 240,
    "name": "Ropinirole",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Ropitor / Requip",
    "formation": "Non-ergoline dopamine agonist",
    "uses": "Idiopathic Parkinsonâ€™s disease",
    "adult": "0.25â€“4 mg TID",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment, neuropsychiatric symptoms",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Somnolence",
      "Hallucinations",
      "Peripheral oedema"
    ],
    "seriousRisks": [
      "Impulse control disorders",
      "Sudden onset of sleep",
      "Psychosis/hallucinations",
      "Augmentation (restless legs)",
      "Fibrotic complications (rare)"
    ],
    "renalAdj": "Yes â€” severe renal impairment (CrCl <30): use with caution; dose titration needed",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; slower titration needed",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” inhibits prolactin secretion",
    "drugInteractions": [
      "Fluvoxamine/CYP1A2 inhibitors â€” increase ropinirole levels (reduce dose)",
      "Smoking cessation â€” increases ropinirole levels (reduce dose)",
      "Dopamine antagonists â€” pharmacodynamic antagonism"
    ],
    "monitoring": [
      "Motor function",
      "Impulse control behaviours",
      "BP (orthostatic)",
      "Sleep attacks",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "24 mg/day (Parkinson's disease)",
    "clinicalPearl": "Smoking cessation dramatically increases ropinirole levels (reduces CYP1A2 activity) â€” reduce dose when patient quits smoking."
  },
  {
    "rank": 241,
    "name": "Lithium Carbonate",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Licab / Eskalith / Lithosun",
    "formation": "Inorganic alkali metal salt",
    "uses": "Bipolar affective disorder, acute mania",
    "adult": "300 mg BID or TID (titrate to 0.6â€“1.2 mEq/L)",
    "child": "15â€“30 mg/kg/day (Restrict use <12y)",
    "avoid": "Severe renal disease, sodium depletion, dehydration",
    "sideEffects": [
      "Tremor",
      "Polyuria/polydipsia",
      "Weight gain",
      "Hypothyroidism",
      "GI upset (nausea, diarrhoea)"
    ],
    "seriousRisks": [
      "Lithium toxicity (narrow therapeutic index)",
      "Nephrogenic diabetes insipidus",
      "Chronic kidney disease (long-term)",
      "Teratogenicity (Ebstein's anomaly)",
      "Severe neurotoxicity (toxicity â€” ataxia, seizures, coma)"
    ],
    "renalAdj": "Yes â€” CrCl 20-50: reduce dose by 25-50%; CrCl <20: avoid",
    "hepaticAdj": "No â€” renally excreted; standard dosing",
    "pregnancy": "Category D â€” Ebstein's anomaly risk (0.05-0.1%); use only if essential with level monitoring",
    "lactation": "Avoid â€” high breast milk to plasma ratio; risk of neonatal toxicity (hypotonia, cyanosis)",
    "drugInteractions": [
      "NSAIDs â€” increase lithium levels (toxicity risk â€” except aspirin)",
      "ACE inhibitors/ARBs/Thiazides â€” increase lithium levels (serious toxicity risk)",
      "Sodium depletion (vomiting, diarrhoea, low-salt diet) â€” markedly increases lithium levels"
    ],
    "monitoring": [
      "Lithium levels (therapeutic: 0.6-1.0 mEq/L; toxic >1.5 mEq/L)",
      "Renal function (every 6 months)",
      "TFT (every 6 months)",
      "ECG (T-wave changes)",
      "eGFR"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Individualised to achieve therapeutic level (typically 900-1800 mg/day in divided doses)",
    "clinicalPearl": "Never use NSAIDs with lithium â€” can cause acute toxicity within 48h; counsel all patients at every visit about this interaction."
  },
  {
    "rank": 242,
    "name": "Methylphenidate HCl",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "X",
    "brand": "Ritalin / Concerta / Inspiral",
    "formation": "Piperidine-derivative CNS stimulant",
    "uses": "ADHD, narcolepsy",
    "adult": "10â€“60 mg/day (divided or extended-release)",
    "child": "5 mg BID initial (approved >6y)",
    "avoid": "Severe anxiety, motor tics, glaucoma",
    "sideEffects": [
      "Decreased appetite",
      "Insomnia",
      "Headache",
      "Increased BP/HR",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "Cardiovascular events (sudden death in patients with underlying cardiac disease)",
      "Psychosis/mania precipitation",
      "Growth suppression (children, long-term)",
      "Substance misuse potential",
      "Seizures (lower threshold)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; limited human data; neonatal withdrawal",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for agitation, reduced feeding",
    "drugInteractions": [
      "MAOIs â€” hypertensive crisis (contraindicated; 14-day washout)",
      "Antihypertensives â€” reduced effectiveness",
      "Warfarin/tricyclics/anticonvulsants â€” methylphenidate inhibits metabolism (monitor levels)"
    ],
    "monitoring": [
      "BP and HR (before each dose adjustment)",
      "Height/weight (children â€” growth monitoring)",
      "Appetite/weight",
      "Cardiovascular symptoms",
      "Mood (psychosis/mania signs)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60 mg/day (immediate-release); 72 mg/day (extended-release)",
    "clinicalPearl": "Cardiac screening before prescribing in children â€” ECG and family history of sudden cardiac death; drug holidays in summer for growth."
  },
  {
    "rank": 243,
    "name": "Modafinil",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Modalert / Provigil",
    "formation": "Benzhydryl sulfinyl acetamide (Wake-promoter)",
    "uses": "Narcolepsy, shift-work sleep disorder",
    "adult": "200 mg OD (morning)",
    "child": "Not recommended",
    "avoid": "Mitral valve prolapse, severe hypertension",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Nervousness",
      "Insomnia",
      "Dry mouth"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome/DRESS (rare but serious)",
      "Psychiatric symptoms (psychosis, mania)",
      "Severe allergic reactions",
      "Cardiovascular effects (increased BP/HR)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” severe hepatic impairment: reduce dose by 50%",
    "pregnancy": "Category C â€” avoid; potential for intrauterine growth restriction",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "OCP â€” CYP3A4 induction reduces OCP efficacy (use additional contraception)",
      "Warfarin â€” increased INR (INR monitoring required)",
      "CYP2C19 substrates (phenytoin, diazepam) â€” increased drug levels"
    ],
    "monitoring": [
      "BP and HR",
      "Rash/hypersensitivity (first month)",
      "Psychiatric symptoms",
      "Sleep quality/efficacy"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (Schedule X in India â€” controlled substance)",
    "clinicalPearl": "Schedule X controlled substance in India â€” warn patients on OCP to use additional contraception as modafinil induces CYP3A4."
  },
  {
    "rank": 244,
    "name": "Donepezil + Memantine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "CNS",
    "schedule": "H",
    "brand": "Donamem / Namzaric",
    "formation": "AChE inhibitor + NMDA antagonist",
    "uses": "Advanced Alzheimerâ€™s dementia",
    "adult": "10 mg/20 mg OD",
    "child": "Not recommended",
    "avoid": "Sick sinus syndrome, GI ulcer risk",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Dizziness",
      "Headache",
      "Vivid dreams (donepezil component)"
    ],
    "seriousRisks": [
      "Bradycardia (donepezil component)",
      "Psychosis (memantine component â€” rare)",
      "GI bleeding (cholinergic + NSAID use)",
      "Falls (dizziness/syncope)",
      "Seizures (rare)"
    ],
    "renalAdj": "Yes â€” memantine dose adjustment required if CrCl <30 mL/min; donepezil standard",
    "hepaticAdj": "Yes â€” use with caution; donepezil and memantine both affected",
    "pregnancy": "Not applicable",
    "lactation": "Not applicable",
    "drugInteractions": [
      "Anticholinergics â€” antagonise donepezil component (avoid)",
      "NMDA antagonists (dextromethorphan, amantadine) â€” additive with memantine component",
      "NSAIDs â€” GI bleeding risk (donepezil component)"
    ],
    "monitoring": [
      "Cognitive function (MMSE, ADAS-Cog)",
      "ECG (bradycardia)",
      "Renal function",
      "Behavioural symptoms (NPI)",
      "Weight"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Donepezil 10 mg + Memantine 20 mg per day (fixed-dose combination)",
    "clinicalPearl": "Combination therapy is evidence-based for moderate-to-severe Alzheimer's disease â€” complementary mechanisms provide additive cognitive benefit."
  },
  {
    "rank": 245,
    "name": "S-Adenosyl L-Methionine (SAMe)",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "Nutraceuticals",
    "schedule": "OTC",
    "brand": "Heptral / SAMe",
    "formation": "Naturally occurring cosubstrate",
    "uses": "Intrahepatic cholestasis, osteoarthritis",
    "adult": "400â€“800 mg daily",
    "child": "Consult specialist",
    "avoid": "Bipolar disorder (mania risk)",
    "sideEffects": [
      "Nausea",
      "GI upset",
      "Diarrhoea",
      "Insomnia",
      "Anxiety (activation)"
    ],
    "seriousRisks": [
      "Serotonin syndrome (with antidepressants)",
      "Mania precipitation (in bipolar disorder)",
      "Heavy metal contamination (supplement quality issues)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” used for hepatic conditions; monitor LFT for response",
    "pregnancy": "Category C â€” insufficient data; avoid unless clearly needed",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Antidepressants (SSRIs/MAOIs) â€” serotonin syndrome risk (avoid)",
      "Levodopa â€” may reduce efficacy of levodopa",
      "Tramadol â€” increased serotonin syndrome risk"
    ],
    "monitoring": [
      "LFT (hepatic indication)",
      "Mood (bipolar risk)",
      "Symptoms of serotonin syndrome"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1600 mg/day (depression/OA/liver); 800 mg/day oral standard",
    "clinicalPearl": "Methyl donor with hepatoprotective and mild antidepressant properties â€” avoid in bipolar disorder due to mania risk."
  },
  {
    "rank": 246,
    "name": "Coenzyme Q10",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "Nutraceuticals",
    "schedule": "OTC",
    "brand": "CoQ10 / Ubiquinol",
    "formation": "Fat-soluble benzoquinone compound",
    "uses": "Heart health, adjunct in mitochondrial disorders",
    "adult": "100â€“300 mg daily",
    "child": "1â€“3 mg/kg/day (Mitochondrial use)",
    "avoid": "Concurrent use with warfarin (may reduce effect)",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Decreased appetite",
      "Headache",
      "Insomnia"
    ],
    "seriousRisks": [
      "May reduce warfarin efficacy (anticoagulant antagonism)",
      "Hypoglycaemia (with antidiabetics)",
      "Drug interactions via CYP modulation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid unless clearly indicated",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Warfarin â€” may reduce anticoagulant effect (INR monitoring if combined)",
      "Antihypertensives â€” additive BP-lowering effect",
      "Statins â€” statins reduce CoQ10 levels; supplementation may mitigate statin myopathy"
    ],
    "monitoring": [
      "BP (if used for cardiovascular indication)",
      "INR (if on warfarin)",
      "Blood glucose (diabetic patients)",
      "Symptom response"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day (heart failure); 1200 mg/day (Parkinson's research doses)",
    "clinicalPearl": "Take with fat-containing meal â€” CoQ10 is fat-soluble; ubiquinol form has superior bioavailability over ubiquinone."
  },
  {
    "rank": 247,
    "name": "Omega-3 Fatty Acids (EPA/DHA)",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "Nutraceuticals",
    "schedule": "OTC",
    "brand": "Maxepa / Omacor / Omega-3",
    "formation": "Polyunsaturated fatty acids (Ethyl esters)",
    "uses": "Severe hypertriglyceridemia, CV protection",
    "adult": "1â€“4 g daily",
    "child": "500â€“1000 mg/day",
    "avoid": "Fish/shellfish allergy",
    "sideEffects": [
      "Fishy belching",
      "GI upset",
      "Diarrhoea",
      "Nausea",
      "Increased LDL cholesterol (high-dose EPA/DHA)"
    ],
    "seriousRisks": [
      "Increased bleeding risk (anti-platelet effect at high doses)",
      "Atrial fibrillation (high-dose prescription omega-3 â€” STRENGTH trial finding)",
      "Lipid peroxidation (rancid product)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” DHA supplementation generally recommended; EPA: use standard doses",
    "lactation": "Safe â€” DHA is recommended for infant neurodevelopment",
    "drugInteractions": [
      "Warfarin/antiplatelets â€” additive bleeding risk (monitor at high doses >3 g/day)",
      "Antihypertensives â€” additive BP-lowering effect",
      "Orlistat â€” may reduce absorption of omega-3s"
    ],
    "monitoring": [
      "Lipid profile (TG response)",
      "Bleeding symptoms (high dose)",
      "LFT (if used for NAFLD)",
      "BP"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 g/day EPA/DHA (prescription; triglyceride lowering); 1-2 g/day (supplement)",
    "clinicalPearl": "Prescription icosapentaenoic acid (EPA-only; Vascepa) reduces cardiovascular events â€” mixed EPA/DHA formulations show less benefit."
  },
  {
    "rank": 248,
    "name": "Chondroitin + Glucosamine",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "Nutraceuticals",
    "schedule": "OTC",
    "brand": "Glucosamine / JointFlex / Chondrogard",
    "formation": "Glycosaminoglycan + amino sugar salt",
    "uses": "Symptomatic relief in Osteoarthritis",
    "adult": "1200 mg/1500 mg daily (divided)",
    "child": "Not recommended",
    "avoid": "Shellfish allergy, asthma flares",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Diarrhoea",
      "Heartburn",
      "Headache"
    ],
    "seriousRisks": [
      "Hyperglycaemia (glucosamine â€” monitor in diabetics)",
      "Warfarin interaction (chondroitin)",
      "Shellfish allergy reaction (glucosamine from crustaceans)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Warfarin â€” chondroitin may enhance anticoagulant effect (INR monitoring)",
      "Antidiabetics â€” glucosamine may cause insulin resistance (monitor blood glucose)",
      "NSAIDs â€” may allow dose reduction (complementary)"
    ],
    "monitoring": [
      "Joint pain/function scores (WOMAC, VAS)",
      "Blood glucose (diabetic patients)",
      "INR (if on warfarin)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Glucosamine 1500 mg/day + Chondroitin 1200 mg/day",
    "clinicalPearl": "GAIT trial showed modest benefit only in moderate-severe OA knee â€” check shellfish allergy before prescribing glucosamine."
  },
  {
    "rank": 249,
    "name": "Ashwagandha (Withania somnifera)",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "Nutraceuticals",
    "schedule": "OTC",
    "brand": "KSM-66 / Himalaya Ashwagandha",
    "formation": "Natural withanolide glycosides",
    "uses": "Stress management, immunomodulation, energy",
    "adult": "300â€“600 mg daily (Standardized extract)",
    "child": "Consult specialist (Herbal guidelines)",
    "avoid": "Pregnancy (abortifacient risk), autoimmune disease",
    "sideEffects": [
      "GI upset",
      "Nausea",
      "Drowsiness",
      "Diarrhoea",
      "Headache"
    ],
    "seriousRisks": [
      "Hepatotoxicity (case reports of liver injury)",
      "Thyroid hormone elevation (may exacerbate hyperthyroidism)",
      "Abortion risk (uterine stimulant)",
      "Drug interactions with immunosuppressants"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution; hepatotoxicity cases reported",
    "pregnancy": "Avoid â€” uterine stimulant properties; teratogenicity not excluded",
    "lactation": "Caution â€” insufficient data; avoid",
    "drugInteractions": [
      "Thyroid medications â€” may increase thyroid hormone levels",
      "Immunosuppressants â€” may reduce efficacy (immune stimulation)",
      "CNS depressants â€” additive sedation"
    ],
    "monitoring": [
      "TFT (thyroid function)",
      "LFT (hepatotoxicity)",
      "Stress/anxiety scores",
      "Blood glucose (may lower glucose)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg root extract per day (standardised KSM-66 or Sensoril formulation)",
    "clinicalPearl": "Evidence supports cortisol reduction and stress relief â€” AYUSH-regulated product; verify hepatotoxicity risk at each follow-up."
  },
  {
    "rank": 250,
    "name": "Bacopa Monnieri (Brahmi)",
    "section": "Section 6: Neuro-Psychiatry & CNS",
    "category": "Nutraceuticals",
    "schedule": "OTC",
    "brand": "Himalaya Brahmi / Bacopa",
    "formation": "Natural saponin complex (Bacosides)",
    "uses": "Cognitive enhancement, memory improvement",
    "adult": "300â€“450 mg daily",
    "child": "100â€“200 mg daily (Restrict <12y)",
    "avoid": "Bradycardia, GI obstruction",
    "sideEffects": [
      "Nausea",
      "GI upset",
      "Diarrhoea",
      "Abdominal cramps",
      "Dry mouth"
    ],
    "seriousRisks": [
      "Drug interactions (theoretical â€” CYP modulation)",
      "Cholinergic excess (theoretical â€” combines with cholinesterase inhibitors)",
      "Heavy metal contamination (product quality)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Cholinesterase inhibitors (donepezil) â€” additive cholinergic effects",
      "Thyroid medications â€” may affect thyroid function",
      "CYP3A4/CYP2C9 substrates â€” theoretical interaction"
    ],
    "monitoring": [
      "Cognitive function testing",
      "GI tolerability",
      "Thyroid function (long-term use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day standardised extract (300 mg twice daily)",
    "clinicalPearl": "Take with food to minimise GI side effects; cognitive enhancement effects require minimum 8-12 weeks of consistent use."
  },
  {
    "rank": 251,
    "name": "Mometasone Furoate Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Elocon / Momoz / Mometasone Cream",
    "formation": "Mid-potency fluorinated topical corticosteroid",
    "uses": "Atopic dermatitis, psoriasis, seborrheic dermatitis",
    "adult": "Apply thin layer to affected area OD",
    "child": "Avoid <2y; thin layer OD (2â€“12y, short term)",
    "avoid": "Rosacea, acne, perioral dermatitis, skin infections",
    "sideEffects": [
      "Skin atrophy (prolonged use)",
      "Striae",
      "Telangiectasia",
      "Acneiform eruptions",
      "Skin depigmentation"
    ],
    "seriousRisks": [
      "HPA axis suppression (large area/prolonged/occlusive use)",
      "Cushing's syndrome (prolonged misuse)",
      "Glaucoma/cataracts (eyelid use)",
      "Secondary infection masking",
      "Adrenal suppression"
    ],
    "renalAdj": "No â€” topical; systemic absorption minimal with appropriate use",
    "hepaticAdj": "No â€” topical; systemic absorption minimal",
    "pregnancy": "Category C â€” avoid extensive use; topical steroids generally considered low-risk in limited use",
    "lactation": "Safe â€” limited application; avoid breast area",
    "drugInteractions": [
      "Topical antifungals â€” potential for combined preparation interactions",
      "Other topical corticosteroids â€” additive atrophy risk",
      "Occlusive dressings â€” increase systemic absorption"
    ],
    "monitoring": [
      "Skin integrity (atrophy, striae)",
      "Clinical response at 2-4 weeks",
      "Signs of secondary infection",
      "HPA axis (if large-area/prolonged)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply once daily (medium-potency steroid); limit continuous use to 3-4 weeks",
    "clinicalPearl": "Once-daily application is as effective as twice-daily â€” medium potency suitable for face and flexures; do not use continuously for >3 weeks."
  },
  {
    "rank": 252,
    "name": "Clobetasol Propionate Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Tenovate / Dermovate / Clobetasol",
    "formation": "Super-potent halogenated glucocorticoid",
    "uses": "Severe psoriasis, lichen planus, pemphigus vulgaris",
    "adult": "Apply thin layer BID (max 50 g/week, max 4 weeks)",
    "child": "Avoid <1y; restricted use <12y",
    "avoid": "Widespread plaque psoriasis, face/groin/axilla use",
    "sideEffects": [
      "Skin atrophy",
      "Striae",
      "Telangiectasia",
      "Purpura",
      "Skin burning"
    ],
    "seriousRisks": [
      "Severe HPA axis suppression (especially children/large areas)",
      "Cushing's syndrome (misuse)",
      "Glaucoma/posterior subcapsular cataract",
      "Adrenal crisis (abrupt withdrawal after prolonged use)",
      "Tinea incognito (masked infection)"
    ],
    "renalAdj": "No â€” topical; minimal systemic absorption with appropriate use",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” avoid; most potent topical steroid; fetal growth restriction risk with extensive use",
    "lactation": "Caution â€” avoid breast area; limit use",
    "drugInteractions": [
      "Topical antifungals â€” if combined prep, monitor for steroid-masked fungal infection",
      "Occlusive dressings â€” dramatically increase systemic absorption"
    ],
    "monitoring": [
      "Skin integrity (atrophy, striae)",
      "HPA axis (if >50g/week or large area/occlusion)",
      "Signs of infection masking",
      "Ophthalmic (if near eyes)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "50 g/week (maximum); apply twice daily; continuous use maximum 2 weeks",
    "clinicalPearl": "Class 1 (superpotent) steroid â€” never use on face, flexures, or genitals; strictly limit to 2 weeks; avoid in children."
  },
  {
    "rank": 253,
    "name": "Betamethasone + Clotrimazole Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Candid-B / Clotrasone / Betacot",
    "formation": "Fluorinated corticosteroid + azole antifungal",
    "uses": "Dermatophytosis with inflammation, intertrigo, tinea with eczema",
    "adult": "Apply BID for 2â€“4 weeks",
    "child": "Avoid prolonged use; consult dermatologist",
    "avoid": "Viral skin lesions, acne, perioral dermatitis, rosacea",
    "sideEffects": [
      "Skin atrophy",
      "Burning sensation",
      "Pruritus",
      "Telangiectasia",
      "Local irritation"
    ],
    "seriousRisks": [
      "HPA axis suppression (prolonged/large area use)",
      "Tinea incognito/masked fungal infection",
      "Skin thinning and secondary infection",
      "Cushing's syndrome (misuse)",
      "Increased risk of tinea recurrence with steroid component"
    ],
    "renalAdj": "No â€” topical",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” avoid prolonged/extensive use",
    "lactation": "Caution â€” avoid breast area; limited use acceptable",
    "drugInteractions": [
      "Other topical preparations â€” do not mix",
      "Occlusive dressings â€” increased systemic absorption of both components"
    ],
    "monitoring": [
      "Clinical response at 1-2 weeks (antifungal)",
      "Skin integrity (atrophy)",
      "Signs of masking/secondary infection",
      "HPA axis if large area prolonged use"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply twice daily; maximum 2-4 weeks; after fungal control wean to antifungal alone",
    "clinicalPearl": "Combination vastly overused in India for any skin condition â€” the steroid can mask and worsen fungal infection; restrict to 2 weeks maximum."
  },
  {
    "rank": 254,
    "name": "Tretinoin Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "A-Ret / Airol / Retino-A",
    "formation": "All-trans retinoic acid (Vitamin A derivative)",
    "uses": "Acne vulgaris, photoaging, fine wrinkles, keratosis pilaris",
    "adult": "0.025â€“0.1% Apply OD (bedtime)",
    "child": "Not recommended <12y",
    "avoid": "Pregnancy, sunburned skin, eczema, rosacea",
    "sideEffects": [
      "Erythema",
      "Peeling/dryness",
      "Photosensitivity",
      "Burning sensation",
      "Initial acne flare (first 2-6 weeks)"
    ],
    "seriousRisks": [
      "Teratogenicity (systemic absorption â€” although minimal topically)",
      "Severe photosensitivity",
      "Chemical burn with excessive use",
      "Skin sensitisation"
    ],
    "renalAdj": "No â€” topical",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” avoid; systemic tretinoin is Category X; topical absorption is minimal but caution advised",
    "lactation": "Caution â€” avoid nipple area; minimal systemic absorption",
    "drugInteractions": [
      "Benzoyl peroxide (simultaneous application) â€” inactivates tretinoin (apply at different times)",
      "Photosensitising agents (doxycycline, quinolones) â€” additive phototoxicity",
      "Keratolytic agents (salicylic acid) â€” additive irritation"
    ],
    "monitoring": [
      "Skin tolerance (erythema, peeling scale)",
      "Sun protection compliance",
      "Acne severity (at 8-12 weeks)",
      "Signs of skin barrier compromise"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply once daily at night (0.025%-0.1% cream/gel); quantity per facial application",
    "clinicalPearl": "Apply pea-sized amount at night only â€” photosensitiser; avoid in summer if sun protection not reliable; initial purging is normal."
  },
  {
    "rank": 255,
    "name": "Adapalene Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Deriva / Differin / Adaferin",
    "formation": "Third-generation synthetic naphthoic acid retinoid",
    "uses": "Mild-to-moderate acne vulgaris, comedonal acne",
    "adult": "Apply thin layer OD (bedtime) to affected area",
    "child": "0.1% approved â‰¥12y",
    "avoid": "Pregnancy, sunburned or eczematous skin",
    "sideEffects": [
      "Erythema",
      "Dryness",
      "Scaling",
      "Burning/stinging",
      "Initial acne flare"
    ],
    "seriousRisks": [
      "Severe skin irritation",
      "Teratogenicity concern (as retinoid class)",
      "Photosensitivity (less than tretinoin)",
      "Skin sensitisation"
    ],
    "renalAdj": "No â€” topical",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” avoid; retinoid class concern despite minimal absorption",
    "lactation": "Caution â€” avoid nipple area",
    "drugInteractions": [
      "Benzoyl peroxide â€” combine in fixed formulation (adapalene 0.1% + BPO 2.5% is approved); apply sequentially if separate",
      "Keratolytics â€” additive irritation",
      "Photosensitising drugs â€” additive phototoxicity"
    ],
    "monitoring": [
      "Skin tolerance",
      "Acne response at 8-12 weeks",
      "Sun protection compliance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply once daily at night (0.1% or 0.3% gel/cream)",
    "clinicalPearl": "Better tolerated than tretinoin â€” less retinoid-associated irritation; adapalene + benzoyl peroxide combination is superior to either alone."
  },
  {
    "rank": 256,
    "name": "Azelaic Acid Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Aziderm / Finacea / Azelaic cream",
    "formation": "Naturally occurring dicarboxylic acid (antibacterial + antikeratinizing)",
    "uses": "Acne vulgaris, rosacea, post-inflammatory hyperpigmentation",
    "adult": "15â€“20% Apply BID to clean skin",
    "child": "Avoid <12y",
    "avoid": "Known hypersensitivity to propylene glycol base",
    "sideEffects": [
      "Local burning/stinging",
      "Pruritus",
      "Dryness/scaling",
      "Erythema",
      "Transient skin discolouration (paradoxical hyperpigmentation â€” rare)"
    ],
    "seriousRisks": [
      "Severe local irritation",
      "Allergic contact dermatitis",
      "Exacerbation of rosacea (initial flare possible)"
    ],
    "renalAdj": "No â€” topical; negligible systemic absorption",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category B â€” generally considered safe; preferred acne treatment in pregnancy",
    "lactation": "Safe â€” minimal systemic absorption; avoid nipple area",
    "drugInteractions": [
      "Topical retinoids â€” additive irritation (stagger application times)",
      "Benzoyl peroxide â€” additive efficacy possible; additive irritation",
      "Topical corticosteroids (rosacea) â€” may be used sequentially"
    ],
    "monitoring": [
      "Clinical response at 4-8 weeks",
      "Skin tolerance",
      "Pigmentation change"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply twice daily (15% gel or 20% cream)",
    "clinicalPearl": "Dual benefit â€” antibacterial and depigmenting properties; safest acne and rosacea treatment in pregnancy."
  },
  {
    "rank": 257,
    "name": "Benzoyl Peroxide Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "OTC",
    "brand": "Persol / Benzac AC / BP gel",
    "formation": "Organic peroxide (bactericidal oxidizing agent)",
    "uses": "Acne vulgaris (comedonal and inflammatory)",
    "adult": "2.5â€“10% Apply OD or BID",
    "child": "Approved â‰¥12y",
    "avoid": "Sensitive or broken skin, concurrent retinoid use (bleaches fabric)",
    "sideEffects": [
      "Skin dryness",
      "Erythema",
      "Peeling",
      "Burning/stinging",
      "Contact dermatitis"
    ],
    "seriousRisks": [
      "Severe allergic contact dermatitis",
      "Bleaching of hair/clothing/bedding (cosmetic, not medical)",
      "Skin sensitisation (occasional)"
    ],
    "renalAdj": "No â€” topical",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” limited data; generally considered safe for topical acne treatment",
    "lactation": "Safe â€” avoid nipple area; minimal systemic absorption",
    "drugInteractions": [
      "Tretinoin/adapalene (simultaneous application) â€” inactivation (apply at different times of day)",
      "Other topical acne agents â€” additive irritation",
      "Keratolytics â€” additive drying effect"
    ],
    "monitoring": [
      "Skin tolerance (dryness, erythema)",
      "Acne response at 4-8 weeks",
      "Contact sensitisation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply once or twice daily (2.5%-10% cream/gel/wash)",
    "clinicalPearl": "Only topical acne agent with no antibiotic resistance risk â€” most effective against P. acnes; start with 2.5% to minimise irritation."
  },
  {
    "rank": 258,
    "name": "Salicylic Acid Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "OTC",
    "brand": "Acne-Aid / Salicylic Lotion / Keralyt",
    "formation": "Beta-hydroxy acid (keratolytic agent)",
    "uses": "Acne, dandruff, calluses, psoriasis, verrucae",
    "adult": "2â€“6% Apply daily as directed",
    "child": "Avoid large surface area <2y",
    "avoid": "Aspirin sensitivity, mucous membranes, inflamed skin",
    "sideEffects": [
      "Skin irritation",
      "Peeling/scaling",
      "Dryness",
      "Erythema",
      "Stinging"
    ],
    "seriousRisks": [
      "Salicylate toxicity (large area/prolonged use/children â€” salicylism)",
      "Severe skin irritation/chemical burn (high concentration)",
      "Systemic absorption in broken skin"
    ],
    "renalAdj": "No â€” topical; avoid large-area prolonged use in renal impairment",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” avoid extensive/prolonged use (systemic salicylate risk); limited spot use generally acceptable",
    "lactation": "Caution â€” avoid extensive use; systemic absorption and salicylate transfer",
    "drugInteractions": [
      "Topical retinoids â€” additive irritation (stagger application)",
      "Topical antibiotics â€” may enhance penetration",
      "Other keratolytics â€” additive peeling effect"
    ],
    "monitoring": [
      "Skin response at 2-4 weeks",
      "Signs of salicylate toxicity (large-area use)",
      "Wart/corn resolution"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2% for acne/scalp; up to 40% for warts/corns (localised only); avoid >2% on large body areas",
    "clinicalPearl": "Avoid in diabetics for foot wart/corn treatment â€” risk of ulceration; systemic salicylism possible in children with large-area use."
  },
  {
    "rank": 259,
    "name": "Hydroquinone + Tretinoin + Mometasone Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Tri-Luma / Melafree / HM Triple",
    "formation": "Depigmenting agent + retinoid + corticosteroid triple combination",
    "uses": "Moderate-to-severe melasma (facial hyperpigmentation)",
    "adult": "Apply thin layer OD (bedtime) for max 8 weeks",
    "child": "Not recommended",
    "avoid": "Pregnancy, active inflammatory acne, hypersensitivity to any component",
    "sideEffects": [
      "Erythema",
      "Skin irritation",
      "Ochronosis (prolonged hydroquinone use)",
      "Telangiectasia (steroid component)",
      "Photosensitivity"
    ],
    "seriousRisks": [
      "Exogenous ochronosis (irreversible blue-black pigmentation â€” prolonged hydroquinone)",
      "HPA axis suppression (steroid component, extensive use)",
      "Paradoxical hyperpigmentation on sun exposure",
      "Contact sensitisation to hydroquinone",
      "Tinea incognito (steroid component)"
    ],
    "renalAdj": "No â€” topical",
    "hepaticAdj": "No â€” topical",
    "pregnancy": "Category C â€” avoid; tretinoin and hydroquinone both have teratogenicity concerns",
    "lactation": "Avoid â€” multiple active components; avoid especially on breast",
    "drugInteractions": [
      "Other retinoids (oral isotretinoin) â€” additive irritation/retinoid effects",
      "Photosensitising agents â€” additive phototoxicity (tretinoin component)",
      "Other depigmenting agents â€” additive effects"
    ],
    "monitoring": [
      "Pigmentation response at 4-8 weeks",
      "Skin integrity (ochronosis monitoring)",
      "Sun protection compliance",
      "HPA axis (large area)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply once daily at night; maximum continuous use 8 weeks (cycle therapy)",
    "clinicalPearl": "Kligman's formula â€” use for maximum 8 weeks then cycle off; daily sunscreen is non-negotiable to prevent rebound hyperpigmentation."
  },
  {
    "rank": 260,
    "name": "Tacrolimus Topical",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Protopic / Tacroz / Tacromus Oint",
    "formation": "Macrolide calcineurin inhibitor (topical immunomodulator)",
    "uses": "Moderate-to-severe atopic dermatitis, vitiligo",
    "adult": "0.1% Apply BID (0.03% in elderly)",
    "child": "0.03% approved â‰¥2y",
    "avoid": "Netherton syndrome, active skin infections, immunocompromised state",
    "sideEffects": [
      "Local burning/stinging (first 1-2 weeks)",
      "Pruritus",
      "Skin flushing (with alcohol)",
      "Folliculitis",
      "Herpes simplex reactivation"
    ],
    "seriousRisks": [
      "Theoretical malignancy risk (lymphoma â€” FDA black box; not definitively proven)",
      "Serious skin infections (eczema herpeticum â€” herpes)",
      "Immunosuppression (theoretical systemic â€” minimal absorption)",
      "Lymphadenopathy"
    ],
    "renalAdj": "No â€” topical; systemic absorption negligible",
    "hepaticAdj": "No â€” topical; systemic absorption negligible",
    "pregnancy": "Category C â€” limited data; avoid unless clearly indicated; neonatal immunosuppression theoretical risk",
    "lactation": "Caution â€” avoid nipple area; minimal systemic absorption but precaution warranted",
    "drugInteractions": [
      "CYP3A4 inhibitors (systemic) â€” theoretical increase in tacrolimus absorption; monitor if significant skin barrier disruption",
      "Phototherapy (PUVA/UVB) â€” avoid concurrent use (immunosuppression + UV may increase skin cancer risk)",
      "Alcohol â€” causes flushing and irritation at application site"
    ],
    "monitoring": [
      "Eczema severity (EASI/SCORAD)",
      "Signs of skin infection (bacterial, herpes)",
      "Lymph nodes (lymphadenopathy)",
      "Skin cancer screening (long-term use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.03% (children â‰¥2 years); 0.1% (adults) â€” apply twice daily; no duration limit established",
    "clinicalPearl": "Steroid-sparing calcineurin inhibitor â€” no skin atrophy risk; FDA black box for lymphoma is theoretical; preferred for face and flexures in atopic dermatitis."
  },
  {
    "rank": 261,
    "name": "Pimecrolimus (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Elidel / Pimecrolimus cream",
    "formation": "Calcineurin inhibitor (ascomycin macrolactam derivative)",
    "uses": "Mild-to-moderate atopic eczema (non-steroid alternative)",
    "adult": "1% Apply BID",
    "child": "1% approved â‰¥2y",
    "avoid": "Immunocompromised patients, pre-malignant skin conditions",
    "drug": "Pimecrolimus Topical",
    "sideEffects": [
      "Burning sensation at application site",
      "Pruritus",
      "Erythema",
      "Skin infections",
      "Folliculitis"
    ],
    "seriousRisks": [
      "Lymphoma risk (theoretical/black box)",
      "Increased skin infection susceptibility",
      "Immunosuppression with extensive use"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid use; insufficient human data",
    "lactation": "Caution â€” avoid application on breast area; systemic absorption low",
    "drugInteractions": [
      "Immunosuppressants â€” additive immunosuppression",
      "CYP3A4 inhibitors (e.g., erythromycin) â€” increased systemic levels",
      "Live vaccines â€” reduced efficacy with systemic absorption"
    ],
    "monitoring": [
      "Skin infection signs",
      "Application area assessment",
      "Duration of therapy"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply thin layer twice daily (no systemic maximum defined)",
    "clinicalPearl": "Not for children under 2; use only when steroids fail or are inappropriate."
  },
  {
    "rank": 262,
    "name": "Isotretinoin (Oral)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Isotroin / Acutret / Sotret",
    "formation": "13-cis-retinoic acid (oral systemic retinoid)",
    "uses": "Severe nodular/cystic acne vulgaris unresponsive to antibiotics",
    "adult": "0.5â€“1 mg/kg/day in 2 divided doses for 4â€“6 months",
    "child": "Not recommended <12y; extreme caution in adolescents",
    "avoid": "Pregnancy (Category X â€“ teratogenic), hyperlipidemia, hepatic disease",
    "drug": "Isotretinoin Oral",
    "sideEffects": [
      "Cheilitis (dry lips)",
      "Dry skin and mucous membranes",
      "Elevated triglycerides",
      "Photosensitivity",
      "Myalgia"
    ],
    "seriousRisks": [
      "Teratogenicity (Category X)",
      "Severe depression/suicidal ideation",
      "Pancreatitis",
      "Pseudotumor cerebri",
      "Hepatotoxicity"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment; monitor LFT",
    "pregnancy": "Category X â€” absolutely contraindicated; mandatory pregnancy prevention program",
    "lactation": "Avoid â€” excreted in breast milk; teratogenic potential",
    "drugInteractions": [
      "Tetracyclines â€” increased pseudotumor cerebri risk",
      "Vitamin A supplements â€” additive toxicity",
      "Carbamazepine â€” reduced isotretinoin levels"
    ],
    "monitoring": [
      "LFT",
      "Lipid profile (triglycerides)",
      "Pregnancy test (monthly)",
      "Mood/psychiatric symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1 mg/kg/day (max 2 mg/kg/day in severe cases)",
    "clinicalPearl": "Schedule X drug; mandatory iPLEDGE-equivalent counselling and negative pregnancy test before prescribing."
  },
  {
    "rank": 263,
    "name": "Calcipotriol (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Daivonex / Calpotrex / Dovonex",
    "formation": "Synthetic Vitamin D3 analog (inhibits keratinocyte proliferation)",
    "uses": "Mild-to-moderate plaque psoriasis",
    "adult": "Apply BID to affected areas (max 100 g/week)",
    "child": "Avoid <6y; consult dermatologist 6â€“18y",
    "avoid": "Hypercalcemia, widespread pustular psoriasis, severe renal/hepatic disease",
    "drug": "Calcipotriol Topical",
    "sideEffects": [
      "Local skin irritation",
      "Burning",
      "Pruritus",
      "Erythema",
      "Dry skin"
    ],
    "seriousRisks": [
      "Hypercalcemia (with excessive use >100g/week)",
      "Hypercalciuria",
      "Facial/intertriginous skin irritation"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment; hypercalcemia risk",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use only if benefit outweighs risk; limit quantity",
    "lactation": "Caution â€” avoid application on breast; systemic absorption minimal at recommended doses",
    "drugInteractions": [
      "Calcium supplements â€” increased hypercalcemia risk",
      "Vitamin D supplements â€” additive hypercalcemia risk",
      "Thiazide diuretics â€” enhanced hypercalcemia risk"
    ],
    "monitoring": [
      "Serum calcium",
      "Urine calcium",
      "Skin response"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 g/week (adults)",
    "clinicalPearl": "Avoid face and flexures; limit to 100g/week to prevent hypercalcemia."
  },
  {
    "rank": 264,
    "name": "Minoxidil (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Mintop / Tugain / Regaine",
    "formation": "Pyrimidine derivative (potassium channel opener â€“ vasodilator)",
    "uses": "Androgenetic alopecia (male and female pattern hair loss)",
    "adult": "2â€“5% Apply BID to dry scalp",
    "child": "Not recommended",
    "avoid": "Scalp inflammation or infection, concurrent oral minoxidil",
    "drug": "Minoxidil Topical",
    "sideEffects": [
      "Scalp irritation/pruritus",
      "Contact dermatitis",
      "Hypertrichosis (unwanted facial hair)",
      "Dry scalp",
      "Initial hair shedding"
    ],
    "seriousRisks": [
      "Systemic absorption causing hypotension (rare)",
      "Tachycardia",
      "Fluid retention (rare with extensive application)"
    ],
    "renalAdj": "No â€” standard dosing (topical; minimal systemic absorption)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; animal teratogenicity data",
    "lactation": "Avoid â€” potential systemic absorption; insufficient safety data",
    "drugInteractions": [
      "Topical corticosteroids â€” enhanced percutaneous absorption",
      "Antihypertensives â€” additive hypotension risk",
      "Petrolatum â€” increased absorption"
    ],
    "monitoring": [
      "Scalp condition",
      "Hair regrowth assessment at 4-6 months",
      "BP (if large area application)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2 mL twice daily (5% solution for men; 2% for women)",
    "clinicalPearl": "Initial shedding in first 2-4 weeks is normal; reassure patients and continue therapy."
  },
  {
    "rank": 265,
    "name": "Dapsone",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Dapsone / DDS / Maloprim (combination)",
    "formation": "Sulfone derivative (antibacterial and anti-inflammatory)",
    "uses": "Leprosy (multibacillary and paucibacillary), dermatitis herpetiformis",
    "adult": "50â€“100 mg OD (leprosy, for 6â€“12 months+)",
    "child": "1â€“2 mg/kg/day",
    "avoid": "G6PD deficiency, severe anemia, sulfonamide hypersensitivity",
    "drug": "Dapsone",
    "sideEffects": [
      "Hemolytic anemia",
      "Methemoglobinemia",
      "Nausea",
      "Headache",
      "Peripheral neuropathy"
    ],
    "seriousRisks": [
      "G6PD deficiency-related severe hemolysis",
      "Dapsone hypersensitivity syndrome (DHS)",
      "Agranulocytosis",
      "Toxic hepatitis",
      "Severe methemoglobinemia"
    ],
    "renalAdj": "Yes â€” reduce dose in severe renal impairment; metabolite accumulation",
    "hepaticAdj": "Yes â€” use with caution; hepatotoxicity risk; monitor LFT",
    "pregnancy": "Category C â€” use with caution; neonatal hemolysis risk near term",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for hemolysis",
    "drugInteractions": [
      "Rifampicin â€” reduced dapsone levels (enzyme induction)",
      "Trimethoprim â€” increased dapsone levels; methemoglobinemia risk",
      "Probenecid â€” increased dapsone toxicity"
    ],
    "monitoring": [
      "CBC (hemoglobin, reticulocytes)",
      "Methemoglobin levels",
      "LFT",
      "G6PD screen before initiation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/day (leprosy); 300 mg/day (dermatitis herpetiformis)",
    "clinicalPearl": "Always screen for G6PD deficiency before starting; cornerstone of multidrug leprosy therapy."
  },
  {
    "rank": 266,
    "name": "Permethrin (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Scaboma / Kwellada-P / Permethrin lotion",
    "formation": "Synthetic pyrethroid (neurotoxic to ectoparasites)",
    "uses": "Scabies (Sarcoptes scabiei), head lice infestation",
    "adult": "5% cream apply overnight and wash; 1% for lice",
    "child": "1% lotion (lice â‰¥2 months); 5% cream (scabies â‰¥2 months)",
    "avoid": "Hypersensitivity to chrysanthemums or pyrethrins",
    "drug": "Permethrin Topical",
    "sideEffects": [
      "Burning/stinging at application",
      "Pruritus",
      "Erythema",
      "Numbness",
      "Rash"
    ],
    "seriousRisks": [
      "Severe allergic/contact dermatitis",
      "Neurotoxicity (rare, with extensive systemic absorption)"
    ],
    "renalAdj": "No â€” standard dosing (topical)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” considered safe; preferred treatment for scabies in pregnancy",
    "lactation": "Safe â€” minimal systemic absorption; preferred scabicide in lactation",
    "drugInteractions": [
      "No significant systemic drug interactions at topical doses"
    ],
    "monitoring": [
      "Resolution of pruritus (may persist 2-4 weeks post-treatment)",
      "Re-treatment need assessment at 1-2 weeks"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5% cream applied once (scabies); may repeat in 1-2 weeks",
    "clinicalPearl": "Treat all household contacts simultaneously; pruritus persisting after treatment does not indicate failure."
  },
  {
    "rank": 267,
    "name": "Silver Sulfadiazine (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Silverex / Silverskin / SSD Cream",
    "formation": "Silver salt of sulfonamide antibiotic",
    "uses": "Prophylaxis and treatment of infections in burns and skin grafts",
    "adult": "1% cream apply daily after cleansing",
    "child": "Avoid in neonates <2 months",
    "avoid": "Sulfonamide allergy, pregnancy near term, G6PD deficiency",
    "drug": "Silver Sulfadiazine Topical",
    "sideEffects": [
      "Local burning/pain",
      "Skin discoloration (grey)",
      "Pruritus",
      "Leukopenia (transient)",
      "Rash"
    ],
    "seriousRisks": [
      "Sulfonamide hypersensitivity",
      "Hemolytic anemia (G6PD deficiency)",
      "Systemic absorption toxicity in extensive burns",
      "Argyria (rare, chronic use)"
    ],
    "renalAdj": "Yes â€” use with caution in severe renal impairment; silver and sulfonamide accumulation",
    "hepaticAdj": "Yes â€” use with caution; sulfonamide hepatotoxicity risk",
    "pregnancy": "Category B/D (near term) â€” avoid at term; kernicterus risk in neonate",
    "lactation": "Avoid â€” sulfonamide excretion; risk to infant",
    "drugInteractions": [
      "Enzymatic wound debriders (collagenase) â€” silver inactivates enzyme",
      "Cimetidine â€” increased absorption risk",
      "Oral anticoagulants â€” enhanced anticoagulant effect"
    ],
    "monitoring": [
      "CBC (leukocyte count)",
      "Renal function (extensive burns)",
      "Wound healing",
      "Signs of infection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply 3-5 mm thick layer once or twice daily (topical; no systemic maximum)",
    "clinicalPearl": "Avoid in neonates and near-term pregnancy; transient leukopenia usually resolves without stopping."
  },
  {
    "rank": 268,
    "name": "Clindamycin + Benzoyl Peroxide (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Clindac BPO / Clindagel BPO / Acnesol-BP",
    "formation": "Lincosamide antibiotic + oxidizing bactericidal agent",
    "uses": "Moderate inflammatory acne, antibiotic-resistant acne vulgaris",
    "adult": "Apply OD to affected areas",
    "child": "Approved â‰¥12y",
    "avoid": "History of Clostridium difficile colitis, antibiotic-associated colitis",
    "drug": "Clindamycin + Benzoyl Peroxide Topical",
    "sideEffects": [
      "Dryness",
      "Peeling/desquamation",
      "Erythema",
      "Burning sensation",
      "Photosensitivity"
    ],
    "seriousRisks": [
      "Clostridium difficile colitis (with systemic absorption)",
      "Severe allergic contact dermatitis",
      "Bleaching of hair/fabrics (benzoyl peroxide)"
    ],
    "renalAdj": "No â€” standard dosing (topical)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; benzoyl peroxide limited data",
    "lactation": "Caution â€” avoid application on breast area; minimal systemic absorption",
    "drugInteractions": [
      "Erythromycin topical â€” antagonism of clindamycin",
      "Tretinoin topical â€” increased irritation",
      "Peeling agents â€” additive skin irritation"
    ],
    "monitoring": [
      "Skin tolerance and irritation",
      "Acne response at 6-8 weeks",
      "Signs of contact dermatitis"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Apply once daily to affected areas (topical; no systemic maximum)",
    "clinicalPearl": "Benzoyl peroxide component prevents clindamycin resistance; preferred fixed-dose combo for inflammatory acne."
  },
  {
    "rank": 269,
    "name": "Tazarotene (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Tazorac / Tazret / Tazarotene gel",
    "formation": "Synthetic receptor-selective acetylenic retinoid",
    "uses": "Plaque psoriasis, acne vulgaris, fine wrinkles",
    "adult": "0.05â€“0.1% Apply OD (bedtime)",
    "child": "Not recommended <12y",
    "avoid": "Pregnancy, sunburned or eczematous skin, concurrent phototherapy",
    "drug": "Tazarotene Topical",
    "sideEffects": [
      "Skin irritation/burning",
      "Pruritus",
      "Erythema",
      "Desquamation",
      "Photosensitivity"
    ],
    "seriousRisks": [
      "Teratogenicity (Category X)",
      "Severe local skin reactions",
      "Hyperpigmentation/hypopigmentation"
    ],
    "renalAdj": "No â€” standard dosing (topical)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category X â€” absolutely contraindicated; teratogenic (retinoid)",
    "lactation": "Avoid â€” potential systemic absorption; retinoid safety concerns",
    "drugInteractions": [
      "Photosensitizers (thiazides, tetracyclines) â€” increased photosensitivity",
      "Retinoids (systemic) â€” additive toxicity",
      "Peeling agents â€” excessive irritation"
    ],
    "monitoring": [
      "Skin tolerance",
      "Pregnancy test before initiation (women of childbearing age)",
      "Photoprotection compliance"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Apply thin layer once daily (0.05% or 0.1% gel/cream)",
    "clinicalPearl": "Most potent topical retinoid; mandatory contraception in women; apply at night to reduce photosensitivity."
  },
  {
    "rank": 270,
    "name": "Halobetasol Propionate (Topical)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Dermatology",
    "schedule": "H",
    "brand": "Ultravate / Haloderm / Halobetasol cream",
    "formation": "Super-high-potency halogenated glucocorticoid",
    "uses": "Severe dermatoses: recalcitrant psoriasis, lichen planus",
    "adult": "Apply thin film ODâ€“BID (max 2 weeks; max 50 g/week)",
    "child": "Not recommended <12y",
    "avoid": "Rosacea, perioral dermatitis, viral/fungal/bacterial skin infections",
    "drug": "Halobetasol Propionate Topical",
    "sideEffects": [
      "Skin atrophy",
      "Striae",
      "Telangiectasia",
      "Burning/stinging",
      "Folliculitis"
    ],
    "seriousRisks": [
      "HPA axis suppression (Cushing syndrome with extensive use)",
      "Glaucoma (periorbital use)",
      "Systemic corticosteroid effects",
      "Skin infections (masked)"
    ],
    "renalAdj": "No â€” standard dosing (topical)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid prolonged/extensive use; risk of fetal growth restriction",
    "lactation": "Caution â€” avoid extensive application; systemic absorption possible",
    "drugInteractions": [
      "Occlusive dressings â€” markedly increased systemic absorption",
      "CYP3A4 inhibitors â€” increased corticosteroid effect",
      "Antidiabetics â€” antagonism of glucose control"
    ],
    "monitoring": [
      "HPA axis function (with prolonged use)",
      "Skin atrophy signs",
      "IOP (if near eyes)",
      "Blood glucose"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "50 g/week; apply once or twice daily; limit to 2 consecutive weeks",
    "clinicalPearl": "Most potent (Class I) topical steroid; limit to 2 weeks maximum; never use on face or flexures."
  },
  {
    "rank": 271,
    "name": "Timolol Maleate (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Glucomol / Timoptic / Timoptol",
    "formation": "Non-selective beta-adrenergic blocker (ophthalmic)",
    "uses": "Elevated intraocular pressure (IOP), open-angle glaucoma",
    "adult": "0.25â€“0.5% one drop BID",
    "child": "0.25% (limited data; consult ophthalmologist)",
    "avoid": "Asthma, COPD, bradycardia, second/third-degree heart block",
    "drug": "Timolol Maleate Eye Drops",
    "sideEffects": [
      "Burning/stinging on instillation",
      "Bradycardia",
      "Bronchospasm",
      "Dry eye",
      "Blurred vision"
    ],
    "seriousRisks": [
      "Severe bronchospasm (asthma/COPD exacerbation)",
      "Cardiac conduction abnormalities",
      "Heart failure exacerbation",
      "Masking of hypoglycemia symptoms"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; neonatal bradycardia reported",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for bradycardia",
    "drugInteractions": [
      "Systemic beta-blockers â€” additive bradycardia/hypotension",
      "Calcium channel blockers (verapamil/diltiazem) â€” cardiac depression risk",
      "Antidiabetics â€” masking of hypoglycemia symptoms"
    ],
    "monitoring": [
      "HR and BP",
      "IOP",
      "Pulmonary function (asthma/COPD patients)",
      "Nasolacrimal occlusion post-instillation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "0.5% solution â€” 1 drop twice daily per eye",
    "clinicalPearl": "Contraindicated in asthma and COPD; apply nasolacrimal occlusion for 1 minute to reduce systemic absorption."
  },
  {
    "rank": 272,
    "name": "Latanoprost (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Latoprost / Xalatan / Latanoprost eye drops",
    "formation": "Prostaglandin F2Î± analog (increases uveoscleral outflow)",
    "uses": "Open-angle glaucoma, ocular hypertension",
    "adult": "0.005% one drop OD (bedtime)",
    "child": "Safety not established; use with caution",
    "avoid": "Active ocular inflammation, aphakic eyes",
    "drug": "Latanoprost Eye Drops",
    "sideEffects": [
      "Iris pigmentation change (irreversible)",
      "Eyelash growth/darkening",
      "Conjunctival hyperemia",
      "Punctate keratitis",
      "Periorbital skin darkening"
    ],
    "seriousRisks": [
      "Macular edema (aphakic/pseudophakic patients)",
      "Anterior uveitis exacerbation",
      "Herpes keratitis reactivation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; limited human data",
    "lactation": "Caution â€” insufficient data; use with care",
    "drugInteractions": [
      "Bimatoprost/travoprost â€” additive IOP lowering but precipitation if mixed",
      "Thimerosal-containing drops â€” precipitate formation",
      "NSAIDs ophthalmic â€” may reduce efficacy"
    ],
    "monitoring": [
      "IOP",
      "Iris color changes",
      "Macular edema (high-risk patients)",
      "Corneal status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.005% solution â€” 1 drop once daily (evening) per eye",
    "clinicalPearl": "Administer in the evening for maximum IOP reduction; warn patients about permanent iris color change."
  },
  {
    "rank": 273,
    "name": "Brimonidine Tartrate (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Alphagan P / Brimosun / Brimo eye drops",
    "formation": "Selective alpha-2 adrenergic agonist (reduces aqueous production)",
    "uses": "Reduction of IOP in glaucoma and ocular hypertension",
    "adult": "0.1â€“0.2% one drop TID (every 8 hrs)",
    "child": "Avoid <2y; caution <6y (CNS depression risk)",
    "avoid": "Concurrent MAOI therapy, neonates, severe cardiovascular disease",
    "drug": "Brimonidine Tartrate Eye Drops",
    "sideEffects": [
      "Ocular allergy/conjunctivitis",
      "Burning/stinging",
      "Dry mouth",
      "Drowsiness",
      "Eyelid retraction"
    ],
    "seriousRisks": [
      "CNS depression in neonates/infants (apnea, bradycardia)",
      "Systemic hypotension",
      "Severe ocular allergy"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” use with caution",
    "lactation": "Caution â€” avoid; CNS depression risk in infant",
    "drugInteractions": [
      "CNS depressants â€” additive sedation",
      "MAO inhibitors â€” hypertensive crisis risk",
      "Antihypertensives â€” additive hypotension"
    ],
    "monitoring": [
      "IOP",
      "BP",
      "CNS effects",
      "Ocular allergy signs"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "0.2% solution â€” 1 drop 2-3 times daily per eye",
    "clinicalPearl": "Absolutely contraindicated in children under 2 years; high rate of ocular allergic reactions (15-25%)."
  },
  {
    "rank": 274,
    "name": "Bimatoprost (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Careprost / Lumigan / Bimat",
    "formation": "Prostamide (prostaglandin analog) â€“ increases trabecular and uveoscleral outflow",
    "uses": "Open-angle glaucoma, ocular hypertension, eyelash hypotrichosis",
    "adult": "0.03% one drop OD (bedtime)",
    "child": "Safety not established",
    "avoid": "Active intraocular inflammation, cystoid macular edema risk",
    "drug": "Bimatoprost Eye Drops",
    "sideEffects": [
      "Conjunctival hyperemia",
      "Eyelash growth",
      "Iris pigmentation",
      "Pruritus",
      "Periorbital fat atrophy"
    ],
    "seriousRisks": [
      "Macular edema",
      "Uveitis exacerbation",
      "Herpetic keratitis reactivation",
      "Periorbital skin changes"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; limited data",
    "lactation": "Caution â€” insufficient safety data",
    "drugInteractions": [
      "Latanoprost â€” do not combine (no additive effect, precipitation risk)",
      "Corticosteroids ophthalmic â€” may reduce IOP-lowering effect",
      "Thimerosal eye drops â€” precipitate formation"
    ],
    "monitoring": [
      "IOP (target <18 mmHg)",
      "Iris pigmentation changes",
      "Periorbital changes",
      "Macular examination"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.01% or 0.03% â€” 1 drop once daily (evening) per eye",
    "clinicalPearl": "Most potent IOP-lowering prostaglandin; also approved for eyelash hypotrichosis (cosmetic use)."
  },
  {
    "rank": 275,
    "name": "Dorzolamide + Timolol (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Cosopt / Orzol-T / Dorzo-T",
    "formation": "Carbonic anhydrase inhibitor + non-selective beta-blocker (ophthalmic)",
    "uses": "Glaucoma requiring more than one hypotensive agent",
    "adult": "2%/0.5% one drop BID",
    "child": "Safety not established",
    "avoid": "Asthma, COPD, sulfonamide hypersensitivity, severe cardiac disease",
    "drug": "Dorzolamide + Timolol Eye Drops",
    "sideEffects": [
      "Burning/stinging",
      "Bitter taste",
      "Blurred vision",
      "Bradycardia",
      "Conjunctival hyperemia"
    ],
    "seriousRisks": [
      "Bronchospasm (timolol component)",
      "Sulfonamide hypersensitivity (dorzolamide)",
      "Cardiac conduction abnormalities",
      "Corneal decompensation"
    ],
    "renalAdj": "Yes â€” avoid dorzolamide component if CrCl <30 mL/min; sulfonamide accumulation",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; both components cross placenta",
    "lactation": "Avoid â€” beta-blocker excretion in milk; neonatal risk",
    "drugInteractions": [
      "Systemic CAIs (acetazolamide) â€” additive toxicity",
      "Systemic beta-blockers â€” additive bradycardia",
      "High-dose salicylates â€” metabolic acidosis (dorzolamide)"
    ],
    "monitoring": [
      "IOP",
      "HR and BP",
      "Renal function",
      "Corneal endothelium"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1 drop twice daily per eye (fixed-dose combination)",
    "clinicalPearl": "Convenient fixed-dose combo; contraindicated in asthma, COPD, and severe renal impairment."
  },
  {
    "rank": 276,
    "name": "Acetazolamide",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Diamox / Glaumox / Acetazolamide",
    "formation": "Carbonic anhydrase inhibitor (sulfonamide derivative, systemic/IV)",
    "uses": "Acute angle-closure glaucoma, altitude sickness, epilepsy adjunct",
    "adult": "250â€“1000 mg daily in divided doses; 125â€“250 mg OD (altitude)",
    "child": "5â€“10 mg/kg every 6 hrs",
    "avoid": "Sulfonamide allergy, severe renal/hepatic disease, hyponatremia",
    "drug": "Acetazolamide",
    "sideEffects": [
      "Paresthesia (tingling in extremities)",
      "Polyuria",
      "Taste disturbance",
      "Nausea",
      "Fatigue"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome",
      "Aplastic anemia",
      "Hypokalemia",
      "Metabolic acidosis",
      "Renal calculi (uric acid/calcium phosphate)"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <10 mL/min; risk of accumulation and acidosis",
    "hepaticAdj": "Yes â€” use with caution in cirrhosis; precipitate hepatic encephalopathy",
    "pregnancy": "Category C â€” avoid; teratogenic in animals; use only if clearly needed",
    "lactation": "Caution â€” excreted in breast milk in small amounts",
    "drugInteractions": [
      "Lithium â€” increased lithium excretion (reduced efficacy)",
      "Metformin â€” increased lactic acidosis risk",
      "Aspirin (high dose) â€” metabolic acidosis and toxicity"
    ],
    "monitoring": [
      "Serum electrolytes (K+, HCO3-)",
      "Renal function",
      "CBC (aplastic anemia risk)",
      "Urine pH"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1000 mg/day (glaucoma); 2500 mg/day (epilepsy)",
    "clinicalPearl": "Sulfonamide derivative; paresthesia is expected and indicates drug activity; supplement potassium."
  },
  {
    "rank": 277,
    "name": "Moxifloxacin (Ophthalmic)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Vigamox / Moxicip / Milflox",
    "formation": "Fourth-generation fluoroquinolone antibiotic (topical ophthalmic)",
    "uses": "Bacterial conjunctivitis, pre/post-operative ocular prophylaxis",
    "adult": "0.5% one drop TID for 7 days",
    "child": "Approved â‰¥1y (same dosing)",
    "avoid": "Hypersensitivity to fluoroquinolones",
    "drug": "Moxifloxacin Ophthalmic",
    "sideEffects": [
      "Burning/stinging on instillation",
      "Conjunctival hyperemia",
      "Dry eye",
      "Blurred vision",
      "Taste disturbance"
    ],
    "seriousRisks": [
      "Corneal perforation (rare, pre-existing ulcer)",
      "Severe allergic reaction",
      "Development of drug-resistant organisms"
    ],
    "renalAdj": "No â€” standard dosing (topical; negligible systemic absorption)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; limited ophthalmic data",
    "lactation": "Caution â€” systemic fluoroquinolone concerns; minimal ophthalmic absorption",
    "drugInteractions": [
      "Ophthalmic products with polyvalent cations â€” reduced absorption (administer separately)",
      "Systemic fluoroquinolones â€” additive effects (theoretical)"
    ],
    "monitoring": [
      "Clinical response at 3-5 days",
      "Signs of worsening infection",
      "Corneal integrity"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.5% solution â€” 1 drop 3 times daily for 7 days",
    "clinicalPearl": "Preservative-free formulation preferred; broad spectrum including Gram-positive; do not use contact lenses during treatment."
  },
  {
    "rank": 278,
    "name": "Prednisolone Acetate (Ophthalmic)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Pred Forte / Predforte / Ocumethyl",
    "formation": "Synthetic corticosteroid ophthalmic suspension",
    "uses": "Allergic and inflammatory ocular conditions, post-surgical inflammation",
    "adult": "1% one drop every 1â€“4 hrs initially, taper as inflammation resolves",
    "child": "Consult ophthalmologist",
    "avoid": "Herpes simplex keratitis, fungal/viral eye infections, glaucoma",
    "drug": "Prednisolone Acetate Ophthalmic",
    "sideEffects": [
      "Increased IOP",
      "Cataract (posterior subcapsular)",
      "Blurred vision",
      "Delayed wound healing",
      "Eye discomfort"
    ],
    "seriousRisks": [
      "Steroid-induced glaucoma",
      "Posterior subcapsular cataract",
      "Activation of herpes simplex keratitis",
      "Opportunistic ocular infections",
      "Corneal/scleral perforation"
    ],
    "renalAdj": "No â€” standard dosing (topical)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” brief use acceptable; avoid prolonged use",
    "lactation": "Caution â€” systemic absorption minimal at ophthalmic doses",
    "drugInteractions": [
      "Antifungals ophthalmic â€” antagonism (suppress immune response against fungi)",
      "Systemic corticosteroids â€” additive HPA suppression (negligible with eye drops)",
      "IOP-lowering agents â€” may need dose adjustment"
    ],
    "monitoring": [
      "IOP (at 2 weeks)",
      "Visual acuity",
      "Corneal integrity",
      "Cataract development (chronic use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1% suspension â€” 1-2 drops every 1-4 hours (acute phase); taper gradually",
    "clinicalPearl": "Always check IOP at 2-week mark; contraindicated in herpes simplex keratitis and fungal eye infections."
  },
  {
    "rank": 279,
    "name": "Nepafenac (Ophthalmic)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Nevanac / Ilevro / Nepafenac eye drops",
    "formation": "NSAID prodrug (converted to amfenac in ocular tissues)",
    "uses": "Post-cataract surgery pain, inflammation, and macular edema prevention",
    "adult": "0.1% one drop TID (day before to 2 weeks post-surgery)",
    "child": "Approved â‰¥10y",
    "avoid": "Aspirin hypersensitivity, active ocular infection",
    "drug": "Nepafenac Ophthalmic",
    "sideEffects": [
      "Burning/stinging",
      "Blurred vision",
      "Conjunctival hyperemia",
      "Corneal edema",
      "Headache"
    ],
    "seriousRisks": [
      "Corneal melt/perforation (rare)",
      "Keratitis",
      "Delayed corneal healing",
      "Severe ocular reactions in patients with pre-existing corneal disease"
    ],
    "renalAdj": "No â€” standard dosing (topical)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid in third trimester (NSAID closure of ductus arteriosus risk)",
    "lactation": "Caution â€” systemic NSAID concerns; minimal ophthalmic absorption",
    "drugInteractions": [
      "Topical corticosteroids â€” potential for corneal healing delay",
      "Anticoagulants â€” increased bleeding tendency (surgical setting)",
      "Other topical NSAIDs â€” additive effects"
    ],
    "monitoring": [
      "Corneal integrity",
      "Visual acuity",
      "IOP",
      "Wound healing (post-surgical)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.1% suspension â€” 1 drop 3 times daily",
    "clinicalPearl": "Prodrug converted to amfenac in eye; use for cataract surgery-related inflammation and macular edema prevention."
  },
  {
    "rank": 280,
    "name": "Olopatadine (Ophthalmic)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Patanol / Pataday / Olopatadine eye drops",
    "formation": "Selective H1-receptor antagonist + mast cell stabilizer (ophthalmic)",
    "uses": "Seasonal and perennial allergic conjunctivitis",
    "adult": "0.1% one drop BID; 0.2%/0.7% OD formulations available",
    "child": "Approved â‰¥3y",
    "avoid": "Contact lens wear during instillation",
    "drug": "Olopatadine Ophthalmic",
    "sideEffects": [
      "Burning/stinging",
      "Headache",
      "Dry eye",
      "Blurred vision",
      "Foreign body sensation"
    ],
    "seriousRisks": [
      "Severe allergic reactions (rare)",
      "Corneal toxicity with preservative (prolonged use)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” insufficient data; likely safe at ophthalmic doses",
    "drugInteractions": [
      "CNS depressants â€” minimal additive sedation (low systemic absorption)",
      "MAO inhibitors â€” theoretical interaction"
    ],
    "monitoring": [
      "Symptom relief (itching, redness)",
      "Conjunctival status",
      "Contact lens compliance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.1% â€” 1 drop twice daily; 0.2%/0.7% â€” 1 drop once daily",
    "clinicalPearl": "Dual antihistamine and mast cell stabilizer; wait 10 minutes before inserting contact lenses."
  },
  {
    "rank": 281,
    "name": "Cyclopentolate (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Cyclopentol / Cyclogyl / Cyclomydril",
    "formation": "Anticholinergic (muscarinic antagonist) ophthalmic cycloplegic",
    "uses": "Cycloplegia for refraction, mydriasis for diagnostic fundus examination",
    "adult": "1% one drop (repeat after 5â€“10 min if needed)",
    "child": "0.5% for infants; 1% for older children",
    "avoid": "Primary angle-closure glaucoma, narrow anterior chamber angle",
    "drug": "Cyclopentolate Eye Drops",
    "sideEffects": [
      "Photophobia",
      "Blurred vision",
      "Stinging on instillation",
      "Tachycardia",
      "Dry mouth"
    ],
    "seriousRisks": [
      "CNS toxicity in children (ataxia, hallucinations, seizures)",
      "Angle-closure glaucoma precipitation",
      "Systemic anticholinergic toxicity"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” systemic anticholinergic effects possible",
    "drugInteractions": [
      "Physostigmine â€” reverses cycloplegia/mydriasis",
      "Other anticholinergics â€” additive effects",
      "Cholinomimetics â€” antagonism"
    ],
    "monitoring": [
      "Pupil response",
      "IOP (pre-existing narrow angle)",
      "CNS status in children",
      "Duration of action"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1% solution â€” 1-2 drops; may repeat once in 5-10 minutes",
    "clinicalPearl": "Preferred cycloplegic for refraction in children; onset 30-60 min, duration 24 hours; watch for CNS toxicity in infants."
  },
  {
    "rank": 282,
    "name": "Tropicamide (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Tropicacyl / Mydracyl / Tropicamide drops",
    "formation": "Short-acting antimuscarinic mydriatic/cycloplegic",
    "uses": "Pupil dilation for fundus examination and refractive assessment",
    "adult": "0.5â€“1% one drop; repeat after 5 min",
    "child": "0.5% for children; consult specialist",
    "avoid": "Primary angle-closure glaucoma",
    "drug": "Tropicamide Eye Drops",
    "sideEffects": [
      "Photophobia",
      "Blurred vision",
      "Stinging",
      "Dry mouth",
      "Tachycardia"
    ],
    "seriousRisks": [
      "Angle-closure glaucoma precipitation",
      "CNS toxicity (rare, at high doses)",
      "Systemic anticholinergic syndrome"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” use minimum effective dose",
    "drugInteractions": [
      "Physostigmine â€” reversal of mydriasis",
      "Other anticholinergics â€” additive effects",
      "Cholinomimetics â€” antagonism"
    ],
    "monitoring": [
      "Pupil dilation (onset 15-30 min)",
      "IOP in at-risk patients",
      "Duration of effect (4-6 hours)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1% solution â€” 1-2 drops; may repeat once in 5 minutes",
    "clinicalPearl": "Shortest-acting mydriatic (4-6 hrs); preferred for fundus examination; inadequate for cycloplegia."
  },
  {
    "rank": 283,
    "name": "Ranibizumab (Intravitreal Injection)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Accentrix / Lucentis / Razumab",
    "formation": "Recombinant humanized anti-VEGF Fab fragment",
    "uses": "Wet age-related macular degeneration, diabetic macular edema, RVO",
    "adult": "0.5 mg monthly intravitreal injection",
    "child": "Not recommended",
    "avoid": "Ocular/periocular infections, active intraocular inflammation",
    "drug": "Ranibizumab Intravitreal",
    "sideEffects": [
      "Conjunctival hemorrhage",
      "Eye pain",
      "Increased IOP post-injection",
      "Vitreous floaters",
      "Retinal hemorrhage"
    ],
    "seriousRisks": [
      "Endophthalmitis",
      "Retinal detachment",
      "Arterial thromboembolic events (stroke, MI)",
      "Traumatic cataract from injection"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; anti-VEGF teratogenicity concerns",
    "lactation": "Avoid â€” insufficient safety data; anti-VEGF concerns",
    "drugInteractions": [
      "Bevacizumab â€” do not combine; same mechanism",
      "Photodynamic therapy â€” may use in combination for wet AMD",
      "Anticoagulants â€” increased ocular hemorrhage risk"
    ],
    "monitoring": [
      "Visual acuity",
      "IOP pre- and post-injection",
      "Retinal OCT",
      "Signs of endophthalmitis after injection"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "0.5 mg (0.05 mL) intravitreal injection monthly",
    "clinicalPearl": "Aseptic technique is critical; endophthalmitis is sight-threatening; always monitor IOP immediately post-injection."
  },
  {
    "rank": 284,
    "name": "Travoprost (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Travatan / Travoprost Z / TravAtan",
    "formation": "Synthetic prostaglandin F2Î± analog (selective FP receptor agonist)",
    "uses": "Open-angle glaucoma, elevated intraocular pressure",
    "adult": "0.004% one drop OD (evening)",
    "child": "Safety not established",
    "avoid": "Macular edema, uveitic glaucoma, contact lens wear during instillation",
    "drug": "Travoprost Eye Drops",
    "sideEffects": [
      "Conjunctival hyperemia",
      "Iris pigmentation change",
      "Eyelash growth",
      "Ocular pruritus",
      "Periorbital skin changes"
    ],
    "seriousRisks": [
      "Macular edema (aphakic/pseudophakic)",
      "Uveitis",
      "Herpetic keratitis reactivation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; animal embryotoxicity",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "NSAIDs ophthalmic â€” may reduce prostaglandin efficacy",
      "Other prostaglandin analogues â€” do not combine",
      "Thimerosal eye drops â€” precipitation"
    ],
    "monitoring": [
      "IOP",
      "Iris pigmentation",
      "Periorbital changes",
      "Macular status (high-risk patients)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.004% solution â€” 1 drop once daily (evening) per eye",
    "clinicalPearl": "Warn patients about potential permanent iris darkening; once-daily evening dosing improves adherence."
  },
  {
    "rank": 285,
    "name": "Carboxymethylcellulose (Eye Drops)",
    "section": "Section 7: Dermatology & Ophthalmology",
    "category": "Ophthalmology",
    "schedule": "OTC",
    "brand": "Refresh Tears / Systane / Lubrex",
    "formation": "Polymer lubricant (viscous ophthalmic solution)",
    "uses": "Dry eye syndrome, ocular lubrication, computer vision syndrome",
    "adult": "0.5â€“1% one drop PRN (up to 6 times daily)",
    "child": "Safe for all ages as directed",
    "avoid": "Known hypersensitivity to preservatives (use preservative-free if sensitive)",
    "drug": "Carboxymethylcellulose Eye Drops",
    "sideEffects": [
      "Mild transient burning/stinging",
      "Blurred vision (transient)",
      "Sticky feeling",
      "Eye discharge",
      "Hypersensitivity to preservatives"
    ],
    "seriousRisks": [
      "Preservative toxicity with chronic use (benzalkonium chloride)",
      "Corneal toxicity (with preserved formulations)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe; no systemic absorption",
    "lactation": "Safe â€” no systemic absorption",
    "drugInteractions": [
      "Other eye drops â€” wait 5 minutes between instillations",
      "Contact lenses â€” remove before instillation (preserved formulations)"
    ],
    "monitoring": [
      "Symptom relief",
      "Corneal status with chronic use",
      "Frequency of use (if >4 times/day, prefer preservative-free)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1-2 drops as needed (up to every 1-2 hours for severe dry eye)",
    "clinicalPearl": "Prefer preservative-free formulation for frequent use (>4x/day); compatible with most ophthalmic medications."
  },
  {
    "rank": 286,
    "name": "Imatinib Mesylate",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Gleevec / Veenat / Imatib",
    "formation": "BCR-ABL tyrosine kinase inhibitor (TKI)",
    "uses": "Chronic myeloid leukemia (CML), GIST, Ph+ ALL",
    "adult": "400â€“600 mg OD (CML-CP); 400 mg BID (blast phase)",
    "child": "260â€“340 mg/mÂ² OD",
    "avoid": "Severe hepatic impairment, concurrent strong CYP3A4 inducers",
    "drug": "Imatinib Mesylate",
    "sideEffects": [
      "Nausea",
      "Edema (periorbital/peripheral)",
      "Muscle cramps",
      "Diarrhea",
      "Fatigue"
    ],
    "seriousRisks": [
      "Severe fluid retention/pleural effusion",
      "Hepatotoxicity",
      "Cardiac toxicity (CHF)",
      "Severe cytopenias",
      "Stevens-Johnson syndrome"
    ],
    "renalAdj": "Yes â€” reduce dose by 50% if CrCl <20 mL/min; use with caution",
    "hepaticAdj": "Yes â€” reduce dose by 25-50% in moderate/severe hepatic impairment; monitor LFT",
    "pregnancy": "Category D â€” avoid; embryotoxic and teratogenic in animals",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "CYP3A4 inhibitors (ketoconazole) â€” increased imatinib levels",
      "CYP3A4 inducers (rifampicin) â€” reduced efficacy",
      "Warfarin â€” avoid; use LMWH instead"
    ],
    "monitoring": [
      "CBC (weekly x1 month, biweekly x1 month, then monthly)",
      "LFT",
      "Renal function",
      "Weight/edema",
      "BCR-ABL transcript level"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (CML accelerated phase); 400 mg/day (chronic phase CML)",
    "clinicalPearl": "Take with food and large glass of water to reduce GI side effects; monitor BCR-ABL for molecular response."
  },
  {
    "rank": 287,
    "name": "Hydroxyurea",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Hydrea / Droxia / Hydroxyurea",
    "formation": "Ribonucleoside diphosphate reductase inhibitor (antimetabolite)",
    "uses": "CML, polycythemia vera, sickle cell disease (crisis reduction)",
    "adult": "15â€“35 mg/kg/day or 500â€“1000 mg daily",
    "child": "10â€“20 mg/kg OD (sickle cell disease)",
    "avoid": "Severe bone marrow suppression, pregnancy, breastfeeding",
    "drug": "Hydroxyurea",
    "sideEffects": [
      "Myelosuppression",
      "Nausea/vomiting",
      "Mucositis",
      "Skin hyperpigmentation",
      "Leg ulcers"
    ],
    "seriousRisks": [
      "Severe bone marrow suppression",
      "Secondary leukemia (rare, long-term)",
      "Pulmonary toxicity",
      "Teratogenicity",
      "Severe cutaneous reactions"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; start with 50% dose if CrCl <60 mL/min",
    "hepaticAdj": "Yes â€” use with caution; monitor LFT",
    "pregnancy": "Category D â€” avoid; teratogenic",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "Antiretrovirals (didanosine, stavudine) â€” increased toxicity, pancreatitis risk",
      "Radiation therapy â€” enhanced myelosuppression",
      "5-Fluorouracil â€” additive toxicity"
    ],
    "monitoring": [
      "CBC (weekly initially)",
      "Renal function",
      "LFT",
      "HbF levels (sickle cell disease)",
      "Leg ulcer surveillance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "35 mg/kg/day (sickle cell); 80 mg/kg/day (solid tumors, short-term)",
    "clinicalPearl": "Increases HbF in sickle cell disease; patients need counseling on teratogenicity and contraception."
  },
  {
    "rank": 288,
    "name": "Methotrexate",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H1",
    "brand": "Folitrax / Mexate / Methotrexate",
    "formation": "Dihydrofolate reductase inhibitor (antimetabolite + DMARD)",
    "uses": "Leukemia, lymphoma, rheumatoid arthritis, psoriasis, ectopic pregnancy",
    "adult": "7.5â€“25 mg/week (RA); high-dose IV (cancer protocols)",
    "child": "7.5â€“30 mg/mÂ²/week (consult hematology)",
    "avoid": "Pregnancy, severe renal/hepatic disease, pleural effusion, immunodeficiency",
    "drug": "Methotrexate",
    "sideEffects": [
      "Nausea/vomiting",
      "Mucositis/stomatitis",
      "Hepatotoxicity",
      "Fatigue",
      "Bone marrow suppression"
    ],
    "seriousRisks": [
      "Severe myelosuppression",
      "Hepatic fibrosis/cirrhosis",
      "Pulmonary toxicity (MTX pneumonitis)",
      "Nephrotoxicity (high dose)",
      "Teratogenicity/embryotoxicity"
    ],
    "renalAdj": "Yes â€” reduce dose significantly; avoid if CrCl <30 mL/min (low-dose); MTX is renally cleared",
    "hepaticAdj": "Yes â€” avoid in significant hepatic impairment; cumulative dose hepatotoxicity risk",
    "pregnancy": "Category X â€” absolutely contraindicated; potent teratogen and abortifacient",
    "lactation": "Avoid â€” significant excretion in breast milk",
    "drugInteractions": [
      "NSAIDs â€” reduced MTX renal clearance; increased toxicity",
      "Co-trimoxazole/trimethoprim â€” additive antifolate toxicity",
      "Proton pump inhibitors â€” reduced renal MTX elimination"
    ],
    "monitoring": [
      "CBC (with differential)",
      "LFT",
      "Renal function (creatinine)",
      "Pulmonary symptoms",
      "Folic acid supplementation compliance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "25 mg/week (RA/psoriasis oral); variable for oncology (IV protocols)",
    "clinicalPearl": "Give folic acid 5 mg/week (not on same day) to reduce mucosal and hematologic toxicity without losing efficacy."
  },
  {
    "rank": 289,
    "name": "Capecitabine",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Xeloda / Capecita / Xabine",
    "formation": "Oral fluoropyrimidine carbamate (prodrug of 5-FU)",
    "uses": "Metastatic colorectal cancer, breast cancer, gastric cancer",
    "adult": "1000â€“1250 mg/mÂ² BID for 14 days (21-day cycles)",
    "child": "Not recommended",
    "avoid": "DPD enzyme deficiency, severe renal impairment (CrCl <30)",
    "drug": "Capecitabine",
    "sideEffects": [
      "Hand-foot syndrome (palmar-plantar erythrodysesthesia)",
      "Diarrhea",
      "Nausea",
      "Fatigue",
      "Mucositis"
    ],
    "seriousRisks": [
      "Severe diarrhea (grade 3-4)",
      "Severe hand-foot syndrome",
      "Cardiotoxicity (angina, MI)",
      "DPD deficiency â€” life-threatening toxicity",
      "Myelosuppression"
    ],
    "renalAdj": "Yes â€” reduce to 75% dose if CrCl 30-50 mL/min; contraindicated if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” use with caution; monitor LFT; dose reduction in severe impairment",
    "pregnancy": "Category D â€” avoid; teratogenic (fluorouracil prodrug)",
    "lactation": "Avoid â€” potential excretion and toxicity to infant",
    "drugInteractions": [
      "Warfarin â€” markedly enhanced anticoagulant effect (INR monitoring essential)",
      "Phenytoin â€” increased phenytoin levels",
      "Antacids (aluminum/magnesium) â€” increased capecitabine absorption"
    ],
    "monitoring": [
      "CBC",
      "LFT",
      "Renal function",
      "INR (if on warfarin)",
      "Hand-foot syndrome grading"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2500 mg/mÂ²/day in 2 divided doses for 14 days (21-day cycle)",
    "clinicalPearl": "DPD enzyme deficiency screening before initiation prevents fatal toxicity; hand-foot syndrome managed with urea creams."
  },
  {
    "rank": 290,
    "name": "Tamoxifen Citrate",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Tamodex / Nolvadex / Tamoxifen",
    "formation": "Non-steroidal selective estrogen receptor modulator (SERM)",
    "uses": "Hormone receptor-positive breast cancer, breast cancer prevention",
    "adult": "20 mg OD for 5â€“10 years",
    "child": "Not recommended",
    "avoid": "History of DVT, pulmonary embolism, or stroke; anticoagulant use",
    "drug": "Tamoxifen Citrate",
    "sideEffects": [
      "Hot flushes",
      "Vaginal discharge/dryness",
      "Menstrual irregularities",
      "Nausea",
      "Fatigue"
    ],
    "seriousRisks": [
      "Endometrial carcinoma",
      "Thromboembolic events (DVT, PE)",
      "Stroke",
      "Cataracts",
      "Uterine sarcoma (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (use with caution in severe hepatic impairment)",
    "pregnancy": "Category D â€” avoid; teratogenic; effective contraception mandatory",
    "lactation": "Avoid â€” excreted in breast milk; growth inhibition concerns",
    "drugInteractions": [
      "CYP2D6 inhibitors (fluoxetine, paroxetine) â€” reduced active metabolite (endoxifen); avoid",
      "Warfarin â€” enhanced anticoagulant effect",
      "Rifampicin â€” reduced tamoxifen efficacy"
    ],
    "monitoring": [
      "Annual gynecological examination/endometrial monitoring",
      "LFT",
      "Lipid profile",
      "Bone density",
      "Signs of DVT/PE"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg/day",
    "clinicalPearl": "Avoid CYP2D6 inhibitor antidepressants (fluoxetine, paroxetine); use venlafaxine for hot flushes instead."
  },
  {
    "rank": 291,
    "name": "Anastrozole",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Arimidex / Anastrol / Anabrez",
    "formation": "Non-steroidal aromatase inhibitor (third-generation)",
    "uses": "Post-menopausal hormone receptor-positive breast cancer",
    "adult": "1 mg OD",
    "child": "Not recommended",
    "avoid": "Pre-menopausal women, osteoporosis (monitor BMD), pregnancy",
    "drug": "Anastrozole",
    "sideEffects": [
      "Hot flushes",
      "Arthralgia/joint stiffness",
      "Osteoporosis/fractures",
      "Fatigue",
      "Headache"
    ],
    "seriousRisks": [
      "Severe osteoporosis and fractures",
      "Cardiovascular events",
      "Severe arthralgia leading to discontinuation",
      "Endometrial thickening (less than tamoxifen)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (mild-moderate); avoid in severe hepatic impairment",
    "pregnancy": "Category X â€” absolutely contraindicated",
    "lactation": "Avoid â€” insufficient safety data",
    "drugInteractions": [
      "Tamoxifen â€” do not combine; antagonism",
      "Estrogen-containing preparations â€” antagonism; contraindicated",
      "Warfarin â€” modest enhancement of anticoagulation"
    ],
    "monitoring": [
      "Bone mineral density (DEXA scan)",
      "Lipid profile",
      "Joint symptoms",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1 mg/day",
    "clinicalPearl": "For postmenopausal ER+ breast cancer; ensure adequate calcium/vitamin D and bone protection from start."
  },
  {
    "rank": 292,
    "name": "Erlotinib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Tarceva / Erlonat / Erlotinib",
    "formation": "First-generation EGFR tyrosine kinase inhibitor",
    "uses": "EGFR-mutated NSCLC (exon 19 del / exon 21 L858R), pancreatic cancer",
    "adult": "150 mg OD (NSCLC); 100 mg OD (Pancreatic, with gemcitabine)",
    "child": "Not recommended",
    "avoid": "Interstitial lung disease, severe renal/hepatic impairment",
    "drug": "Erlotinib",
    "sideEffects": [
      "Acneiform rash",
      "Diarrhea",
      "Fatigue",
      "Anorexia",
      "Mucositis"
    ],
    "seriousRisks": [
      "Interstitial lung disease/pneumonitis",
      "Hepatotoxicity",
      "Severe skin reactions (SJS)",
      "GI perforation",
      "Keratitis/corneal ulceration"
    ],
    "renalAdj": "No â€” standard dosing (minimal renal elimination)",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment; monitor LFT closely",
    "pregnancy": "Category D â€” avoid; embryotoxic",
    "lactation": "Avoid â€” potential harm to infant",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” significantly reduced erlotinib levels",
      "CYP3A4 inhibitors (ketoconazole) â€” increased erlotinib toxicity",
      "Proton pump inhibitors â€” reduced absorption (separate by 2 hours; use H2 blockers instead)"
    ],
    "monitoring": [
      "LFT",
      "Pulmonary symptoms (ILD)",
      "Skin rash severity",
      "EGFR mutation status before initiation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "150 mg/day (NSCLC); 100 mg/day (pancreatic cancer)",
    "clinicalPearl": "Paradoxically, skin rash correlates with clinical benefit; avoid PPIs (take 2 hrs before/10 hrs after PPI if needed)."
  },
  {
    "rank": 293,
    "name": "Gefitinib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Iressa / Geftinat / Geftinib",
    "formation": "Selective EGFR-TKI (quinazoline derivative)",
    "uses": "EGFR-mutation positive NSCLC (first-line)",
    "adult": "250 mg OD",
    "child": "Not recommended",
    "avoid": "Interstitial lung disease, severe hepatic impairment",
    "drug": "Gefitinib",
    "sideEffects": [
      "Acneiform rash",
      "Diarrhea",
      "Nausea",
      "Anorexia",
      "Dry skin"
    ],
    "seriousRisks": [
      "Interstitial lung disease",
      "Hepatotoxicity (severe)",
      "GI perforation",
      "Severe skin reactions",
      "Ocular toxicity"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution; reduce dose in severe hepatic impairment; frequent LFT monitoring",
    "pregnancy": "Category D â€” avoid; teratogenic",
    "lactation": "Avoid â€” excretion in breast milk likely",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” markedly reduced gefitinib levels",
      "Warfarin â€” enhanced anticoagulation; monitor INR",
      "Proton pump inhibitors â€” reduced absorption"
    ],
    "monitoring": [
      "LFT (monthly)",
      "EGFR mutation status (exon 19/21)",
      "Pulmonary function/ILD signs",
      "INR (if on warfarin)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "250 mg/day",
    "clinicalPearl": "Only for EGFR mutation-positive NSCLC; first EGFR TKI approved in India; test EGFR before prescribing."
  },
  {
    "rank": 294,
    "name": "Lenalidomide",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Revlimid / Lenalid / Lenalidomide",
    "formation": "Thalidomide analog â€“ immunomodulatory drug (IMiD)",
    "uses": "Multiple myeloma, myelodysplastic syndrome (del 5q), mantle cell lymphoma",
    "adult": "25 mg OD days 1â€“21 of 28-day cycle",
    "child": "Not recommended",
    "avoid": "Pregnancy (Category X â€“ highly teratogenic), DVT risk, severe renal failure",
    "drug": "Lenalidomide",
    "sideEffects": [
      "Myelosuppression (neutropenia, thrombocytopenia)",
      "DVT/PE",
      "Fatigue",
      "Diarrhea",
      "Peripheral neuropathy"
    ],
    "seriousRisks": [
      "Severe thromboembolism",
      "Severe myelosuppression",
      "Teratogenicity (Category X)",
      "Second primary malignancies",
      "Tumor lysis syndrome"
    ],
    "renalAdj": "Yes â€” significant dose reduction based on CrCl; primarily renally excreted",
    "hepaticAdj": "No â€” standard dosing (limited hepatic metabolism)",
    "pregnancy": "Category X â€” absolutely contraindicated; mandatory REMS program equivalent",
    "lactation": "Avoid â€” potential harm to infant",
    "drugInteractions": [
      "Erythropoietin â€” increased thromboembolic risk",
      "Digoxin â€” increased digoxin levels (monitor)",
      "Dexamethasone â€” enhanced thromboembolic risk in combination"
    ],
    "monitoring": [
      "CBC (weekly for first 8 weeks, monthly thereafter)",
      "Renal function",
      "DVT/PE symptoms",
      "Pregnancy test (monthly in women)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "25 mg/day for 21 days of 28-day cycle (myeloma)",
    "clinicalPearl": "Mandatory thromboprophylaxis (aspirin or LMWH) required; absolute teratogen â€” dual contraception mandatory."
  },
  {
    "rank": 295,
    "name": "Bortezomib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Velcade / Bortecad / Bortenat",
    "formation": "Dipeptidyl boronic acid proteasome inhibitor",
    "uses": "Multiple myeloma, mantle cell lymphoma",
    "adult": "1.3 mg/mÂ² IV/SC (twice weekly Ã— 2 weeks in 21-day cycle)",
    "child": "Not established",
    "avoid": "Severe peripheral neuropathy, severe hepatic impairment",
    "drug": "Bortezomib",
    "sideEffects": [
      "Peripheral neuropathy",
      "Thrombocytopenia",
      "Fatigue",
      "Nausea",
      "Diarrhea"
    ],
    "seriousRisks": [
      "Severe peripheral neuropathy",
      "Severe thrombocytopenia",
      "Cardiac toxicity (CHF)",
      "Posterior reversible encephalopathy syndrome",
      "Herpes zoster reactivation"
    ],
    "renalAdj": "No â€” standard dosing (minimal renal clearance)",
    "hepaticAdj": "Yes â€” reduce dose in moderate-severe hepatic impairment; primarily hepatically metabolized",
    "pregnancy": "Category D â€” avoid; embryotoxic",
    "lactation": "Avoid â€” insufficient safety data",
    "drugInteractions": [
      "CYP3A4 inhibitors (ketoconazole) â€” increased bortezomib exposure",
      "Antidiabetics â€” hypoglycemia or hyperglycemia (dysglycemia)",
      "Antihypertensives â€” additive hypotension"
    ],
    "monitoring": [
      "CBC",
      "Peripheral neuropathy assessment",
      "Blood glucose",
      "LFT",
      "Cardiac function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1.3 mg/mÂ² per dose (per protocol; IV or SC)",
    "clinicalPearl": "Subcutaneous administration reduces peripheral neuropathy risk vs. IV; use antiviral prophylaxis against herpes zoster."
  },
  {
    "rank": 296,
    "name": "Irinotecan HCl",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Campto / Irinotel / Irinotecan",
    "formation": "Topoisomerase I inhibitor (semisynthetic camptothecin)",
    "uses": "Metastatic colorectal cancer (FOLFIRI regimen), small cell lung cancer",
    "adult": "125 mg/mÂ² weekly Ã— 4 or 350 mg/mÂ² every 3 weeks",
    "child": "Protocol-based dosing under specialist guidance",
    "avoid": "Chronic inflammatory bowel disease, severe biliary obstruction, UGT1A1 deficiency",
    "drug": "Irinotecan HCl",
    "sideEffects": [
      "Diarrhea (early and late)",
      "Nausea/vomiting",
      "Myelosuppression",
      "Alopecia",
      "Abdominal cramping"
    ],
    "seriousRisks": [
      "Severe late-onset diarrhea (life-threatening)",
      "Severe neutropenia/sepsis",
      "Cholinergic syndrome (early)",
      "UGT1A1 polymorphism â€” severe toxicity in poor metabolizers"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment; primarily hepatically metabolized (UGT1A1)",
    "pregnancy": "Category D â€” avoid; embryotoxic",
    "lactation": "Avoid â€” potential harm to infant",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin, phenytoin) â€” reduced SN-38 levels; avoid",
      "St. John's Wort â€” reduced efficacy",
      "Fluorouracil â€” synergistic cytotoxicity"
    ],
    "monitoring": [
      "CBC",
      "Diarrhea severity (grade)",
      "LFT",
      "UGT1A1 genotyping (before initiation if possible)",
      "Hydration status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "350 mg/mÂ² IV every 3 weeks (monotherapy)",
    "clinicalPearl": "Early diarrhea (within 24h): use atropine; late diarrhea (>24h): high-dose loperamide â€” do not confuse management."
  },
  {
    "rank": 297,
    "name": "Oxaliplatin",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Eloxatin / Oxalidem / Oxaliplatin",
    "formation": "Third-generation platinum complex (DNA cross-linking agent)",
    "uses": "Colorectal cancer (FOLFOX regimen), pancreatic cancer",
    "adult": "85 mg/mÂ² every 2 weeks or 130 mg/mÂ² every 3 weeks",
    "child": "Not recommended for routine use",
    "avoid": "Baseline peripheral sensory neuropathy, severe renal impairment",
    "drug": "Oxaliplatin",
    "sideEffects": [
      "Peripheral neuropathy (cumulative)",
      "Nausea/vomiting",
      "Neutropenia",
      "Cold-induced dysesthesia",
      "Fatigue"
    ],
    "seriousRisks": [
      "Severe sensory peripheral neuropathy",
      "Anaphylactic reactions",
      "Severe myelosuppression",
      "Hepatotoxicity (CASH â€” chemotherapy-associated steatohepatitis)",
      "QT prolongation"
    ],
    "renalAdj": "Yes â€” reduce dose if CrCl <30 mL/min; monitor renal function",
    "hepaticAdj": "Yes â€” use with caution; hepatotoxicity risk; monitor LFT",
    "pregnancy": "Category D â€” avoid; platinum compound teratogenicity",
    "lactation": "Avoid",
    "drugInteractions": [
      "5-Fluorouracil â€” synergistic (FOLFOX regimen)",
      "Nephrotoxic drugs â€” additive renal toxicity",
      "QT-prolonging drugs â€” additive risk"
    ],
    "monitoring": [
      "CBC",
      "Neuropathy assessment",
      "Renal function",
      "LFT",
      "QTc interval"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "130 mg/mÂ² IV every 3 weeks (CAPOX); 85 mg/mÂ² every 2 weeks (FOLFOX)",
    "clinicalPearl": "Cold-triggered dysesthesia is hallmark; advise patients to avoid cold drinks and cold exposure during/after infusion."
  },
  {
    "rank": 298,
    "name": "Paclitaxel",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Taxol / Intaxel / Paclitaxel",
    "formation": "Taxane antimicrotubule agent (diterpene from Taxus brevifolia)",
    "uses": "Breast cancer, ovarian cancer, NSCLC, Kaposi's sarcoma",
    "adult": "135â€“175 mg/mÂ² IV every 3 weeks or 80 mg/mÂ²/week",
    "child": "Consult oncology (limited data)",
    "avoid": "Neutrophil count <1500 cells/mmÂ³, severe neuropathy, hypersensitivity to Cremophor EL",
    "drug": "Paclitaxel",
    "sideEffects": [
      "Peripheral neuropathy",
      "Alopecia",
      "Myelosuppression",
      "Arthralgia/myalgia",
      "Nausea"
    ],
    "seriousRisks": [
      "Severe hypersensitivity reactions (Cremophor EL vehicle)",
      "Severe neutropenia/febrile neutropenia",
      "Cardiac conduction abnormalities",
      "Severe neuropathy",
      "Extravasation injury"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment; primarily hepatically metabolized",
    "pregnancy": "Category D â€” avoid; teratogenic",
    "lactation": "Avoid",
    "drugInteractions": [
      "Cisplatin â€” sequence matters; give paclitaxel before cisplatin to reduce myelosuppression",
      "CYP3A4/CYP2C8 inhibitors â€” increased paclitaxel levels",
      "Anthracyclines â€” additive cardiotoxicity"
    ],
    "monitoring": [
      "CBC (especially neutrophils)",
      "Peripheral neuropathy assessment",
      "Cardiac monitoring (ECG)",
      "LFT",
      "Signs of hypersensitivity during infusion"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "175 mg/mÂ² IV over 3 hours every 3 weeks",
    "clinicalPearl": "Mandatory premedication with dexamethasone, diphenhydramine, H2 blocker 30 minutes before infusion to prevent hypersensitivity."
  },
  {
    "rank": 299,
    "name": "Docetaxel",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Taxotere / Docefrez / Docepar",
    "formation": "Semi-synthetic taxane (antimitotic â€“ stabilizes microtubules)",
    "uses": "Breast cancer, prostate cancer, NSCLC, gastric cancer, HNSCC",
    "adult": "60â€“100 mg/mÂ² IV every 3 weeks",
    "child": "Not established",
    "avoid": "Neutrophil count <1500/mmÂ³, severe hepatic dysfunction",
    "drug": "Docetaxel",
    "sideEffects": [
      "Alopecia",
      "Fluid retention/edema",
      "Myelosuppression",
      "Peripheral neuropathy",
      "Nail changes"
    ],
    "seriousRisks": [
      "Severe fluid retention (pleural effusion, ascites)",
      "Severe neutropenia/febrile neutropenia",
      "Hepatotoxicity",
      "Severe hypersensitivity reactions",
      "Severe skin reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” contraindicated in severe hepatic impairment (AST/ALT >3.5x ULN with alkaline phosphatase >6x ULN); reduce dose in moderate impairment",
    "pregnancy": "Category D â€” avoid; teratogenic",
    "lactation": "Avoid",
    "drugInteractions": [
      "CYP3A4 inhibitors (ketoconazole) â€” increased docetaxel toxicity",
      "CYP3A4 inducers (rifampicin) â€” reduced efficacy",
      "Anthracyclines â€” additive cardiotoxicity"
    ],
    "monitoring": [
      "CBC",
      "LFT (before each cycle)",
      "Edema/weight monitoring",
      "Peripheral neuropathy",
      "Signs of hypersensitivity"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/mÂ² IV every 3 weeks (monotherapy)",
    "clinicalPearl": "Dexamethasone premedication (8 mg BD x 3 days) is mandatory to reduce fluid retention and hypersensitivity."
  },
  {
    "rank": 300,
    "name": "Gemcitabine HCl",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Gemita / Gemtero / Gemcitabine",
    "formation": "Nucleoside analog (pyrimidine antimetabolite, pro-drug)",
    "uses": "Pancreatic cancer, NSCLC, breast cancer, ovarian cancer, bladder cancer",
    "adult": "1000â€“1250 mg/mÂ² IV over 30 min weekly",
    "child": "Not established",
    "avoid": "Concurrent radiation therapy (radiosensitization risk), severe renal failure",
    "drug": "Gemcitabine HCl",
    "sideEffects": [
      "Myelosuppression",
      "Nausea/vomiting",
      "Flu-like syndrome",
      "Elevated transaminases",
      "Rash"
    ],
    "seriousRisks": [
      "Severe myelosuppression (thrombocytopenia)",
      "Pulmonary toxicity (pneumonitis)",
      "Hemolytic uremic syndrome",
      "Capillary leak syndrome",
      "Hepatotoxicity"
    ],
    "renalAdj": "Yes â€” use with caution; dose reduction may be needed in severe renal impairment",
    "hepaticAdj": "Yes â€” use with caution; elevated transaminases common; withhold for severe hepatic impairment",
    "pregnancy": "Category D â€” avoid; teratogenic nucleoside analogue",
    "lactation": "Avoid",
    "drugInteractions": [
      "Cisplatin â€” synergistic combination (sequence: gemcitabine before cisplatin)",
      "Warfarin â€” enhanced anticoagulant effect",
      "Bleomycin â€” additive pulmonary toxicity"
    ],
    "monitoring": [
      "CBC (before each cycle)",
      "LFT",
      "Renal function",
      "Pulmonary symptoms",
      "Blood pressure (HUS monitoring)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1250 mg/mÂ² IV days 1 and 8 of 21-day cycle",
    "clinicalPearl": "Flu-like syndrome (fever, myalgia) occurs within 6-12 hours of infusion; manage with paracetamol; not infection."
  },
  {
    "rank": 301,
    "name": "Sorafenib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Nexavar / Sorafenib / Sorafnat",
    "formation": "Multi-kinase inhibitor (Raf/VEGFR/PDGFR/c-KIT inhibitor)",
    "uses": "Hepatocellular carcinoma (HCC), renal cell carcinoma, differentiated thyroid cancer",
    "adult": "400 mg BID on empty stomach",
    "child": "Not recommended",
    "avoid": "Squamous cell lung cancer, severe hepatic impairment (Child-Pugh C)",
    "drug": "Sorafenib",
    "sideEffects": [
      "Hand-foot skin reaction",
      "Diarrhea",
      "Fatigue",
      "Hypertension",
      "Alopecia"
    ],
    "seriousRisks": [
      "Severe hand-foot syndrome",
      "Cardiac ischemia/infarction",
      "Hemorrhage",
      "GI perforation",
      "QT prolongation"
    ],
    "renalAdj": "No â€” standard dosing (mild-moderate); use with caution in severe impairment",
    "hepaticAdj": "Yes â€” reduce dose in Child-Pugh B/C; primarily hepatically metabolized",
    "pregnancy": "Category D â€” avoid; embryotoxic",
    "lactation": "Avoid",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” reduced sorafenib levels",
      "Warfarin â€” increased bleeding risk; monitor INR",
      "QT-prolonging drugs â€” additive QT risk"
    ],
    "monitoring": [
      "BP (weekly initially)",
      "LFT",
      "Renal function",
      "Hand-foot skin reaction grading",
      "ECG (QTc)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (400 mg twice daily)",
    "clinicalPearl": "Hand-foot reaction correlates with efficacy; manage with urea creams and dose reduction; control BP aggressively."
  },
  {
    "rank": 302,
    "name": "Sunitinib Malate",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Sutent / Sunitinib / Suni-50",
    "formation": "Multi-targeted receptor tyrosine kinase inhibitor (VEGFR/PDGFR/FLT3/c-KIT)",
    "uses": "Renal cell carcinoma, imatinib-resistant GIST, pNET",
    "adult": "50 mg OD (4 weeks on, 2 weeks off) or 37.5 mg OD continuous",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment, concurrent strong CYP3A4 inhibitors/inducers",
    "drug": "Sunitinib Malate",
    "sideEffects": [
      "Fatigue",
      "Diarrhea",
      "Mucositis/stomatitis",
      "Hypertension",
      "Yellow skin discoloration"
    ],
    "seriousRisks": [
      "Cardiac toxicity (cardiomyopathy, CHF)",
      "Hepatotoxicity",
      "Severe hypertension",
      "Hypothyroidism",
      "Hemorrhage"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment; monitor LFT",
    "pregnancy": "Category D â€” avoid; embryotoxic",
    "lactation": "Avoid",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” reduced efficacy; increase dose",
      "CYP3A4 inhibitors (ketoconazole) â€” increased toxicity; reduce dose",
      "QT-prolonging drugs â€” additive risk"
    ],
    "monitoring": [
      "CBC",
      "LFT",
      "Thyroid function (TSH)",
      "Cardiac function (ECHO/MUGA)",
      "BP",
      "Urinalysis"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "50 mg/day (4 weeks on, 2 weeks off cycle)",
    "clinicalPearl": "Yellow/orange skin discoloration due to drug color â€” benign; monitor thyroid function every 3 months."
  },
  {
    "rank": 303,
    "name": "Bevacizumab (IV)",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Avastin / Bevatas / Bevacizumab",
    "formation": "Recombinant humanized anti-VEGF monoclonal antibody (IgG1)",
    "uses": "Metastatic colorectal cancer, NSCLC, glioblastoma, renal cell carcinoma",
    "adult": "5â€“15 mg/kg IV every 2â€“3 weeks (protocol-dependent)",
    "child": "Not established",
    "avoid": "Untreated brain metastases, uncontrolled hypertension, recent GI perforation, surgery within 28 days",
    "drug": "Bevacizumab IV",
    "sideEffects": [
      "Hypertension",
      "Proteinuria",
      "Fatigue",
      "Bleeding/hemorrhage",
      "Impaired wound healing"
    ],
    "seriousRisks": [
      "GI perforation",
      "Arterial thromboembolic events (stroke, MI)",
      "Severe hemorrhage",
      "Posterior reversible encephalopathy syndrome",
      "Nephrotic syndrome"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C/D â€” avoid; anti-VEGF teratogenicity",
    "lactation": "Avoid",
    "drugInteractions": [
      "Anthracyclines â€” additive cardiotoxicity",
      "Sunitinib â€” increased microangiopathic hemolytic anemia risk",
      "NSAIDs â€” increased hemorrhage risk"
    ],
    "monitoring": [
      "BP (every 2-3 weeks)",
      "Urinalysis/proteinuria (24h urine protein)",
      "CBC",
      "Signs of perforation/fistula",
      "Wound healing status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "10-15 mg/kg IV every 2-3 weeks (indication-dependent)",
    "clinicalPearl": "Withhold at least 28 days before/after elective surgery; discontinue if GI perforation or severe hemorrhage occurs."
  },
  {
    "rank": 304,
    "name": "Rituximab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Mabthera / Ristova / Rituximab",
    "formation": "Chimeric anti-CD20 monoclonal antibody (IgG1)",
    "uses": "Non-Hodgkin's lymphoma, CLL, RA, ANCA-associated vasculitis",
    "adult": "375 mg/mÂ² IV weekly Ã— 4 (NHL); 500â€“1000 mg IV (RA/vasculitis)",
    "child": "375 mg/mÂ² (mature B-cell NHL; specialist supervision)",
    "avoid": "Active severe infections, live virus vaccines, hepatitis B reactivation risk",
    "drug": "Rituximab",
    "sideEffects": [
      "Infusion reactions (fever, chills, rigors)",
      "Fatigue",
      "Nausea",
      "Infections",
      "Cytopenias"
    ],
    "seriousRisks": [
      "Progressive multifocal leukoencephalopathy (JC virus)",
      "Severe infusion reactions",
      "Hepatitis B reactivation",
      "Severe infections",
      "Cardiac arrhythmias"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (use with caution in hepatic impairment)",
    "pregnancy": "Category C â€” avoid; B-cell depletion in neonate",
    "lactation": "Avoid â€” potential immunosuppression in infant",
    "drugInteractions": [
      "Live vaccines â€” avoid during and 12 months after treatment",
      "Hepatitis B antivirals â€” screen and prophylax before initiation",
      "Nephrotoxic drugs â€” additive renal risk"
    ],
    "monitoring": [
      "CBC (B-cell counts)",
      "Hepatitis B serology (HBsAg, HBcAb)",
      "Immunoglobulin levels",
      "Signs of infection/PML",
      "Infusion reactions during administration"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "375 mg/mÂ² IV per dose (per protocol)",
    "clinicalPearl": "Screen all patients for hepatitis B before initiation; premedicate with paracetamol and antihistamine to reduce infusion reactions."
  },
  {
    "rank": 305,
    "name": "Trastuzumab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Herceptin / Hertraz / Trastumab",
    "formation": "Recombinant humanized anti-HER2 monoclonal antibody (IgG1)",
    "uses": "HER2-positive early and metastatic breast cancer, HER2-positive gastric cancer",
    "adult": "8 mg/kg IV loading, then 6 mg/kg every 3 weeks",
    "child": "Not recommended",
    "avoid": "Severe cardiac dysfunction, baseline LVEF <50%, severe dyspnea",
    "drug": "Trastuzumab",
    "sideEffects": [
      "Infusion reactions",
      "Fatigue",
      "Cardiac dysfunction (LVEF reduction)",
      "Diarrhea",
      "Nausea"
    ],
    "seriousRisks": [
      "Cardiotoxicity (cardiomyopathy, CHF)",
      "Severe infusion reactions/anaphylaxis",
      "Pulmonary toxicity",
      "Fetal harm (embryotoxicity)",
      "Severe cytopenias"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category D â€” avoid; oligohydramnios and fetal renal failure reported",
    "lactation": "Avoid â€” insufficient safety data",
    "drugInteractions": [
      "Anthracyclines â€” additive cardiotoxicity (do not use concurrently)",
      "Paclitaxel â€” synergistic; sequence carefully",
      "Pertuzumab â€” used in combination per protocol"
    ],
    "monitoring": [
      "LVEF (ECHO or MUGA) baseline and every 3 months",
      "CBC",
      "Signs of cardiac dysfunction (dyspnea, edema)",
      "HER2 status before initiation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "8 mg/kg loading dose then 6 mg/kg IV every 3 weeks",
    "clinicalPearl": "Only for HER2-overexpressing cancers (IHC 3+ or FISH amplified); avoid concurrent anthracyclines due to cardiotoxicity."
  },
  {
    "rank": 306,
    "name": "Osimertinib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Tagrisso / Osimertinib",
    "formation": "Third-generation EGFR-TKI (T790M-selective, irreversible)",
    "uses": "EGFR T790M mutation-positive NSCLC (1st and 2nd line); adjuvant use",
    "adult": "80 mg OD",
    "child": "Not recommended",
    "avoid": "QTc interval >470 ms, concurrent QT-prolonging drugs, severe hepatic impairment",
    "drug": "Osimertinib",
    "sideEffects": [
      "Diarrhea",
      "Rash",
      "Dry skin",
      "Paronychia",
      "Fatigue"
    ],
    "seriousRisks": [
      "Interstitial lung disease/pneumonitis",
      "QT prolongation",
      "Cardiomyopathy",
      "Keratitis",
      "Severe skin reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in severe hepatic impairment; monitor LFT",
    "pregnancy": "Category D â€” avoid; embryotoxic",
    "lactation": "Avoid",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” significantly reduce osimertinib levels; avoid",
      "QT-prolonging drugs â€” additive risk",
      "CYP3A4 substrates with narrow therapeutic index â€” increased levels"
    ],
    "monitoring": [
      "EGFR T790M mutation status",
      "LFT",
      "ECG (QTc)",
      "Pulmonary symptoms/ILD",
      "LVEF"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "80 mg/day (first-line); 160 mg/day may be used in selected cases with T790M",
    "clinicalPearl": "Third-generation EGFR TKI; active against T790M resistance mutation; penetrates CNS â€” preferred for brain metastases."
  },
  {
    "rank": 307,
    "name": "Pembrolizumab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Keytruda / Pembrolizumab",
    "formation": "Anti-PD-1 humanized monoclonal antibody (immune checkpoint inhibitor)",
    "uses": "Melanoma, NSCLC, HNSCC, MSI-H solid tumors, classical Hodgkin lymphoma",
    "adult": "200 mg IV every 3 weeks or 400 mg every 6 weeks",
    "child": "2 mg/kg (â‰¥6y, max 200 mg) for classical Hodgkin lymphoma",
    "avoid": "Active autoimmune disease, organ transplant recipients, systemic immunosuppressants",
    "drug": "Pembrolizumab",
    "sideEffects": [
      "Fatigue",
      "Rash/pruritus",
      "Diarrhea",
      "Nausea",
      "Arthralgia"
    ],
    "seriousRisks": [
      "Immune-mediated pneumonitis",
      "Immune-mediated colitis",
      "Immune-mediated hepatitis",
      "Immune-mediated endocrinopathies",
      "Severe infusion reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (mild-moderate); withhold for immune-mediated hepatitis",
    "pregnancy": "Category D â€” avoid; potential fetal harm (PD-L1 role in fetal tolerance)",
    "lactation": "Avoid",
    "drugInteractions": [
      "Systemic corticosteroids â€” may reduce efficacy (avoid prophylactic steroids; use only for irAE management)",
      "Immunosuppressants â€” reduce immune-mediated toxicity management",
      "Live vaccines â€” avoid"
    ],
    "monitoring": [
      "LFT",
      "Thyroid function (TSH)",
      "Adrenal function (cortisol)",
      "Creatinine",
      "Blood glucose",
      "Pulmonary symptoms"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg IV every 3 weeks (fixed dose) or 400 mg every 6 weeks",
    "clinicalPearl": "Immune-related AEs can affect any organ; early corticosteroid use for grade 2+ irAEs is critical to prevent progression."
  },
  {
    "rank": 308,
    "name": "Nivolumab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Opdivo / Nivolumab",
    "formation": "Human anti-PD-1 IgG4 monoclonal antibody",
    "uses": "Melanoma, NSCLC, RCC, urothelial carcinoma, HNSCC, ESCC",
    "adult": "240 mg IV every 2 weeks or 480 mg every 4 weeks",
    "child": "3 mg/kg IV every 2 weeks (specific malignancies; specialist guidance)",
    "avoid": "Active autoimmune disease, organ transplant, severe immune-mediated reactions",
    "drug": "Nivolumab",
    "sideEffects": [
      "Fatigue",
      "Rash",
      "Diarrhea",
      "Nausea",
      "Pruritus"
    ],
    "seriousRisks": [
      "Immune-mediated pneumonitis",
      "Immune-mediated colitis",
      "Immune-mediated hepatitis",
      "Myocarditis",
      "Hypophysitis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (withhold for immune-mediated hepatitis)",
    "pregnancy": "Category D â€” avoid",
    "lactation": "Avoid",
    "drugInteractions": [
      "Systemic corticosteroids â€” reduce for irAE management only; high-dose may blunt anti-tumor effect",
      "Immunosuppressants â€” reduce immune-related toxicity control",
      "Live vaccines â€” avoid"
    ],
    "monitoring": [
      "LFT",
      "TSH/free T4",
      "Creatinine",
      "CBC",
      "Cortisol/ACTH",
      "Pulmonary symptoms"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "240 mg IV every 2 weeks or 480 mg every 4 weeks",
    "clinicalPearl": "Can cause immune-mediated myocarditis (rare but fatal); any new cardiac symptoms need urgent ECG and troponin."
  },
  {
    "rank": 309,
    "name": "Carboplatin",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Paraplatin / Kemocarb / Carbosynt",
    "formation": "Second-generation platinum complex (DNA cross-linking agent)",
    "uses": "Ovarian cancer, NSCLC, SCLC, head and neck cancer",
    "adult": "AUC 5â€“6 IV (Calvert formula) every 4 weeks",
    "child": "175â€“400 mg/mÂ² (protocol-based dosing)",
    "avoid": "Severe renal impairment, severe thrombocytopenia, hearing loss (ototoxicity risk)",
    "drug": "Carboplatin",
    "sideEffects": [
      "Myelosuppression (thrombocytopenia)",
      "Nausea/vomiting",
      "Nephrotoxicity (less than cisplatin)",
      "Peripheral neuropathy (less than cisplatin)",
      "Alopecia"
    ],
    "seriousRisks": [
      "Severe thrombocytopenia",
      "Anaphylactic reactions (especially after 6+ cycles)",
      "Ototoxicity (less than cisplatin)",
      "Severe myelosuppression"
    ],
    "renalAdj": "Yes â€” dose calculated by Calvert formula based on GFR/CrCl; critical dose adjustment",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category D â€” avoid; platinum compound teratogenicity",
    "lactation": "Avoid",
    "drugInteractions": [
      "Nephrotoxic agents â€” additive renal toxicity",
      "Aminoglycosides â€” additive ototoxicity and nephrotoxicity",
      "Paclitaxel â€” sequence matters (paclitaxel first)"
    ],
    "monitoring": [
      "CBC (platelet nadir day 21)",
      "Renal function (GFR)",
      "Electrolytes (Mg, Ca, K)",
      "Audiometry (cumulative ototoxicity)",
      "Allergic reactions during infusion"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Calvert formula: AUC x (GFR + 25) mg; typically AUC 5-6 per cycle",
    "clinicalPearl": "Use Calvert formula for dosing (not BSA); thrombocytopenia is dose-limiting toxicity (unlike cisplatin which is nephrotoxicity)."
  },
  {
    "rank": 310,
    "name": "Cyclophosphamide",
    "section": "Section 8: Oncology & Immunology",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Cycloxan / Endoxan / Cytoxan",
    "formation": "Nitrogen mustard alkylating agent (prodrug activated by CYP450)",
    "uses": "Breast cancer, lymphomas, leukemia, nephrotic syndrome, SLE",
    "adult": "50â€“100 mg/day (oral) or 500â€“1500 mg/mÂ² IV cyclical",
    "child": "1â€“5 mg/kg/day or protocol-based",
    "avoid": "Severe myelosuppression, urinary tract obstruction, active hemorrhagic cystitis",
    "drug": "Cyclophosphamide",
    "sideEffects": [
      "Hemorrhagic cystitis",
      "Nausea/vomiting",
      "Alopecia",
      "Myelosuppression",
      "Gonadal toxicity"
    ],
    "seriousRisks": [
      "Hemorrhagic cystitis",
      "Secondary malignancies (bladder cancer, AML)",
      "Severe myelosuppression",
      "Cardiotoxicity (high dose)",
      "Pulmonary toxicity"
    ],
    "renalAdj": "Yes â€” reduce dose in severe renal impairment; metabolite accumulation",
    "hepaticAdj": "Yes â€” use with caution; prodrug requiring hepatic activation",
    "pregnancy": "Category D â€” avoid; alkylating agent teratogenicity",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "Allopurinol â€” increased myelosuppression",
      "CYP2B6 inducers â€” altered activation to acrolein/active metabolites",
      "Succinylcholine â€” prolonged neuromuscular blockade"
    ],
    "monitoring": [
      "CBC",
      "Urinalysis (hematuria)",
      "Renal function",
      "LFT",
      "Cardiac function (high dose)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "50 mg/kg/day IV (high dose); 1-5 mg/kg/day oral (low dose immunosuppression)",
    "clinicalPearl": "MESNA co-administration mandatory at IV doses to prevent hemorrhagic cystitis; force fluids and frequent voiding."
  },
  {
    "rank": 311,
    "name": "Hydroxychloroquine Sulfate",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Hcqs / Plaquenil / Hydroxychloroquine",
    "formation": "4-aminoquinoline antimalarial and immunomodulatory agent",
    "uses": "Rheumatoid arthritis, SLE, Sjogren's syndrome, malaria prophylaxis",
    "adult": "200â€“400 mg/day (max 5 mg/kg/day ideal body weight)",
    "child": "3â€“5 mg/kg/day for juvenile RA",
    "avoid": "Pre-existing retinal disease, G6PD deficiency, QT prolongation history",
    "drug": "Hydroxychloroquine Sulfate",
    "sideEffects": [
      "Nausea/GI upset",
      "Headache",
      "Skin rash",
      "Retinopathy (long-term)",
      "Pruritus"
    ],
    "seriousRisks": [
      "Irreversible retinal toxicity (bull's eye maculopathy)",
      "QT prolongation/arrhythmia",
      "Cardiomyopathy (rare)",
      "Severe hypoglycemia (in diabetics)",
      "G6PD hemolysis"
    ],
    "renalAdj": "Yes â€” reduce dose in severe renal impairment; dose based on ideal body weight",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” considered relatively safe; used in SLE pregnancies",
    "lactation": "Caution â€” excreted in breast milk; low amounts; generally considered compatible",
    "drugInteractions": [
      "QT-prolonging drugs â€” additive QT prolongation",
      "Digoxin â€” increased digoxin levels",
      "Insulin/oral antidiabetics â€” enhanced hypoglycemia"
    ],
    "monitoring": [
      "Annual ophthalmic examination (baseline + annually after 5 years)",
      "ECG (QTc)",
      "CBC",
      "LFT",
      "Renal function",
      "G6PD status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (do not exceed 5 mg/kg/day based on ideal body weight â€” retinopathy risk)",
    "clinicalPearl": "Annual ophthalmology review mandatory; dose based on ideal body weight (not actual) to minimize retinopathy risk."
  },
  {
    "rank": 312,
    "name": "Sulfasalazine",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Saaz / Salazopyrin / Azulfidine",
    "formation": "Azo compound prodrug (5-ASA + sulfapyridine) â€“ DMARD",
    "uses": "Rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease",
    "adult": "500â€“1000 mg BIDâ€“TID (titrate to 2â€“3 g/day)",
    "child": "30â€“50 mg/kg/day in divided doses (JIA, UC)",
    "avoid": "Sulfonamide/salicylate hypersensitivity, G6PD deficiency, porphyria",
    "drug": "Sulfasalazine",
    "sideEffects": [
      "Nausea/vomiting",
      "Anorexia",
      "Headache",
      "Oligospermia (reversible)",
      "Skin rash/photosensitivity"
    ],
    "seriousRisks": [
      "Severe sulfonamide hypersensitivity (SJS/TEN)",
      "Agranulocytosis",
      "Hepatotoxicity",
      "Hemolytic anemia (G6PD)",
      "Pulmonary toxicity"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; sulfonamide metabolite accumulation",
    "hepaticAdj": "Yes â€” use with caution; monitor LFT; avoid in severe impairment",
    "pregnancy": "Category B â€” generally considered safe; add folic acid 5 mg/day",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for jaundice; avoid in G6PD-deficient infants",
    "drugInteractions": [
      "Folic acid â€” reduced folate absorption; supplement mandatory",
      "Methotrexate â€” additive hematologic toxicity",
      "Warfarin â€” enhanced anticoagulation; monitor INR"
    ],
    "monitoring": [
      "CBC (first 3 months: every 2-4 weeks)",
      "LFT",
      "Urinalysis",
      "Folate levels",
      "G6PD status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 g/day (RA/IBD)",
    "clinicalPearl": "Always co-prescribe folic acid; enteric-coated tablets reduce GI side effects; start low and titrate up."
  },
  {
    "rank": 313,
    "name": "Leflunomide",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Arava / Lefno / Leflunomide",
    "formation": "Isoxazole immunosuppressant (DHODH inhibitor â€“ DMARD)",
    "uses": "Active rheumatoid arthritis, psoriatic arthritis",
    "adult": "100 mg OD loading Ã— 3 days, then 20 mg OD maintenance",
    "child": "Consult rheumatologist (limited evidence base)",
    "avoid": "Pregnancy (washout protocol required), severe hepatic impairment, immunodeficiency",
    "drug": "Leflunomide",
    "sideEffects": [
      "Diarrhea",
      "Nausea",
      "Alopecia",
      "Elevated liver enzymes",
      "Hypertension"
    ],
    "seriousRisks": [
      "Hepatotoxicity (severe including failure)",
      "Teratogenicity (Category X)",
      "Severe infections",
      "Peripheral neuropathy",
      "Interstitial lung disease"
    ],
    "renalAdj": "No â€” standard dosing (mild); use with caution in moderate-severe impairment",
    "hepaticAdj": "Yes â€” contraindicated in significant hepatic impairment; monitor LFT monthly",
    "pregnancy": "Category X â€” absolutely contraindicated; cholestyramine washout procedure required before conception",
    "lactation": "Avoid â€” excreted in breast milk; cholestyramine washout required",
    "drugInteractions": [
      "Methotrexate â€” additive hepatotoxicity; use only in specialist settings",
      "Warfarin â€” enhanced anticoagulation; monitor INR",
      "Cholestyramine â€” accelerated leflunomide elimination (washout procedure)"
    ],
    "monitoring": [
      "LFT (monthly for 6 months, then 6-8 weekly)",
      "CBC",
      "BP",
      "Pregnancy test before initiation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "20 mg/day (after 100 mg loading dose for 3 days)",
    "clinicalPearl": "Long drug half-life due to enterohepatic recirculation; cholestyramine 8g TDS x 11 days needed for rapid washout if toxicity or pregnancy."
  },
  {
    "rank": 314,
    "name": "Mycophenolate Mofetil",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Cellcept / Mycophenol / Mofetil",
    "formation": "Prodrug of mycophenolic acid (IMPDH inhibitor)",
    "uses": "Prevention of organ transplant rejection, lupus nephritis, autoimmune diseases",
    "adult": "1â€“1.5 g BID",
    "child": "600 mg/mÂ² BID (renal transplant; â‰¥3 months)",
    "avoid": "Pregnancy (Category D), active serious GI disorders, live vaccines",
    "drug": "Mycophenolate Mofetil",
    "sideEffects": [
      "GI upset (nausea, diarrhea, vomiting)",
      "Leukopenia",
      "Increased infection risk",
      "Fatigue",
      "Headache"
    ],
    "seriousRisks": [
      "Progressive multifocal leukoencephalopathy (rare)",
      "Severe infections",
      "Pure red cell aplasia",
      "Malignancies (lymphoma)",
      "Teratogenicity"
    ],
    "renalAdj": "Yes â€” avoid doses >1g BD if CrCl <25 mL/min in non-transplant patients",
    "hepaticAdj": "No â€” standard dosing (mild-moderate impairment)",
    "pregnancy": "Category D â€” avoid; teratogenic; effective contraception mandatory",
    "lactation": "Avoid â€” potential neonatal immunosuppression",
    "drugInteractions": [
      "Antacids/proton pump inhibitors â€” reduced MMF absorption",
      "Cholestyramine â€” reduced MMF enterohepatic recirculation",
      "Live vaccines â€” avoid (immunosuppression)"
    ],
    "monitoring": [
      "CBC (monthly for 6 months, then 3 monthly)",
      "Renal function",
      "LFT",
      "Signs of infection",
      "Pregnancy test"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "3 g/day (transplant: 1.5 g BD); 2 g/day (lupus nephritis)",
    "clinicalPearl": "Take on empty stomach for better absorption; MPA (active form) therapeutic drug monitoring may be used in transplant."
  },
  {
    "rank": 315,
    "name": "Tacrolimus (Systemic)",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Prograf / Tacromus / Pangraf",
    "formation": "Macrolide calcineurin inhibitor (FK506) â€“ systemic immunosuppressant",
    "uses": "Organ transplant rejection prevention, refractory nephrotic syndrome",
    "adult": "0.1â€“0.2 mg/kg/day in 2 divided doses (target trough 5â€“20 ng/mL)",
    "child": "0.15â€“0.3 mg/kg/day (higher clearance in pediatrics)",
    "avoid": "Concurrent ciclosporin, hypersensitivity to polyoxyl 60 hydrogenated castor oil",
    "drug": "Tacrolimus Systemic",
    "sideEffects": [
      "Nephrotoxicity",
      "Neurotoxicity (tremor, headache)",
      "Hypertension",
      "Hyperglycemia/diabetes",
      "GI disturbances"
    ],
    "seriousRisks": [
      "Nephrotoxicity (acute and chronic)",
      "New-onset diabetes after transplant (NODAT)",
      "Serious infections",
      "Posterior reversible encephalopathy syndrome",
      "Malignancies (lymphoma)"
    ],
    "renalAdj": "Yes â€” reduce dose and monitor trough levels closely in renal impairment",
    "hepaticAdj": "Yes â€” significantly reduce dose in hepatic impairment; primary hepatic metabolism",
    "pregnancy": "Category C â€” avoid unless essential; neonatal renal impairment reported",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "CYP3A4 inhibitors (fluconazole, erythromycin) â€” markedly increased tacrolimus levels",
      "CYP3A4 inducers (rifampicin) â€” significantly reduced tacrolimus levels",
      "Nephrotoxic agents (aminoglycosides, NSAIDs) â€” additive nephrotoxicity"
    ],
    "monitoring": [
      "Tacrolimus trough levels (C0)",
      "Renal function (creatinine, eGFR)",
      "Blood glucose",
      "BP",
      "LFT",
      "Electrolytes (K+, Mg++)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualized by trough levels (target 5-20 ng/mL depending on organ and time post-transplant)",
    "clinicalPearl": "Narrow therapeutic index; trough level monitoring essential; grapefruit juice inhibits CYP3A4 â€” avoid completely."
  },
  {
    "rank": 316,
    "name": "Cyclosporine (Systemic)",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Sandimmun / Neoral / Panimun",
    "formation": "Cyclic undecapeptide calcineurin inhibitor",
    "uses": "Organ transplantation, psoriasis, RA, uveitis, nephrotic syndrome",
    "adult": "2.5â€“5 mg/kg/day in 2 divided doses (monitor renal function)",
    "child": "Weight-based dosing (similar to adult)",
    "avoid": "Uncontrolled hypertension, active infection, concurrent nephrotoxins",
    "drug": "Cyclosporine Systemic",
    "sideEffects": [
      "Nephrotoxicity",
      "Hypertension",
      "Hirsutism",
      "Gingival hyperplasia",
      "Tremor"
    ],
    "seriousRisks": [
      "Nephrotoxicity (dose-dependent)",
      "Hepatotoxicity",
      "Hypertensive crisis",
      "Serious infections",
      "Lymphoma/skin malignancy"
    ],
    "renalAdj": "Yes â€” significant dose reduction; monitor cyclosporine levels and creatinine closely",
    "hepaticAdj": "Yes â€” reduce dose; primarily hepatically metabolized (CYP3A4)",
    "pregnancy": "Category C â€” use only if essential; premature birth and low birth weight risk",
    "lactation": "Avoid â€” excreted in breast milk; neonatal immunosuppression",
    "drugInteractions": [
      "CYP3A4 inhibitors (diltiazem, verapamil, fluconazole) â€” increased cyclosporine levels and nephrotoxicity",
      "NSAIDs â€” additive nephrotoxicity",
      "Statins (except pravastatin) â€” increased myopathy and rhabdomyolysis risk"
    ],
    "monitoring": [
      "Cyclosporine trough levels (C0) or 2-hour post-dose (C2) levels",
      "Renal function (creatinine)",
      "BP",
      "LFT",
      "Lipid profile",
      "Gingival status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5 mg/kg/day (RA/psoriasis); higher doses for transplant per protocol",
    "clinicalPearl": "Grapefruit juice inhibits CYP3A4 â€” strictly avoid; pravastatin is the safest statin to use with cyclosporine."
  },
  {
    "rank": 317,
    "name": "Azathioprine",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Imuran / Azoran / Azathio",
    "formation": "Thiopurine immunosuppressant (6-mercaptopurine prodrug)",
    "uses": "RA, IBD, SLE, organ transplant rejection, autoimmune hepatitis",
    "adult": "1â€“3 mg/kg/day",
    "child": "1â€“2.5 mg/kg/day",
    "avoid": "TPMT enzyme deficiency, severe myelosuppression, pregnancy (relative)",
    "drug": "Azathioprine",
    "sideEffects": [
      "Nausea/vomiting",
      "Myelosuppression",
      "Hepatotoxicity",
      "Increased infection risk",
      "GI disturbances"
    ],
    "seriousRisks": [
      "Severe myelosuppression (especially TPMT-deficient patients)",
      "Hepatotoxicity (veno-occlusive disease)",
      "Opportunistic infections",
      "Lymphoma",
      "Pancreatitis"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment; metabolite accumulation",
    "hepaticAdj": "Yes â€” use with caution; hepatotoxicity risk; monitor LFT",
    "pregnancy": "Category D â€” avoid if possible; considered relatively safer among immunosuppressants when benefit outweighs risk",
    "lactation": "Caution â€” low amounts in breast milk; generally considered acceptable in stable patients",
    "drugInteractions": [
      "Allopurinol â€” life-threatening myelosuppression (xanthine oxidase inhibition blocks 6-MP metabolism); reduce AZA dose by 75%",
      "Co-trimoxazole â€” additive myelosuppression",
      "ACE inhibitors â€” enhanced leukopenia"
    ],
    "monitoring": [
      "CBC (weekly for 8 weeks, then 3 monthly)",
      "LFT",
      "TPMT genotyping before initiation",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2.5 mg/kg/day",
    "clinicalPearl": "TPMT genotyping before initiation identifies poor metabolizers at risk for fatal myelosuppression; avoid allopurinol co-prescription."
  },
  {
    "rank": 318,
    "name": "Tofacitinib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Xeljanz / Tofacinat / Jakvinus",
    "formation": "Selective JAK1/JAK3 inhibitor (oral targeted DMARD)",
    "uses": "Rheumatoid arthritis, ulcerative colitis, psoriatic arthritis",
    "adult": "5 mg BID or 11 mg ER OD",
    "child": "Not approved for most indications",
    "avoid": "Active serious infection, malignancy history, thromboembolism risk",
    "drug": "Tofacitinib",
    "sideEffects": [
      "Upper respiratory tract infections",
      "Nausea",
      "Headache",
      "Diarrhea",
      "Elevated cholesterol"
    ],
    "seriousRisks": [
      "Serious infections (bacterial, fungal, viral)",
      "Herpes zoster reactivation",
      "MACE (cardiovascular events)",
      "Venous thromboembolism",
      "Malignancies"
    ],
    "renalAdj": "Yes â€” reduce to 5 mg once daily if CrCl 15-60 mL/min; avoid if CrCl <15 mL/min",
    "hepaticAdj": "Yes â€” reduce to 5 mg once daily in moderate hepatic impairment; avoid in severe",
    "pregnancy": "Category C â€” avoid; animal embryotoxicity",
    "lactation": "Avoid",
    "drugInteractions": [
      "CYP3A4 inhibitors (fluconazole, clarithromycin) â€” increased tofacitinib levels; reduce dose",
      "CYP3A4 inducers (rifampicin) â€” reduced efficacy",
      "Potent immunosuppressants â€” additive immunosuppression"
    ],
    "monitoring": [
      "CBC (lymphocytes, neutrophils)",
      "Lipid profile",
      "LFT",
      "Creatinine",
      "TB screening before initiation",
      "Signs of infection/VTE"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg twice daily (RA); 10 mg twice daily for induction in UC (then 5 mg BD maintenance)",
    "clinicalPearl": "Screen for TB, hepatitis B/C and latent infections before initiation; vaccinate (especially for herpes zoster) before starting."
  },
  {
    "rank": 319,
    "name": "Baricitinib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Olumiant / Barinat / Baricitinib",
    "formation": "Selective JAK1/JAK2 inhibitor (oral small molecule)",
    "uses": "Moderate-to-severe RA, atopic dermatitis, severe COVID-19 (adjunct)",
    "adult": "2â€“4 mg OD",
    "child": "2 mg OD (atopic dermatitis â‰¥2y); not approved for RA",
    "avoid": "Active TB, severe infection, thrombosis history",
    "drug": "Baricitinib",
    "sideEffects": [
      "Upper respiratory infections",
      "Nasopharyngitis",
      "Nausea",
      "Elevated creatinine",
      "Headache"
    ],
    "seriousRisks": [
      "Serious bacterial/opportunistic infections",
      "Herpes zoster",
      "VTE (DVT, PE)",
      "MACE",
      "Lymphopenia"
    ],
    "renalAdj": "Yes â€” 1 mg/day if CrCl 30-60 mL/min; avoid if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; embryotoxic in animals",
    "lactation": "Avoid",
    "drugInteractions": [
      "OAT3 inhibitors (probenecid) â€” increased baricitinib AUC; reduce dose to 1 mg/day",
      "Strong immunosuppressants â€” additive immunosuppression; avoid",
      "Live vaccines â€” avoid"
    ],
    "monitoring": [
      "CBC (lymphocytes)",
      "Lipid profile",
      "Renal function",
      "LFT",
      "TB and viral hepatitis screening",
      "VTE symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 mg/day (RA); 4 mg/day for severe COVID-19",
    "clinicalPearl": "Probenecid raises baricitinib levels significantly â€” reduce dose when used together; once-daily dosing improves adherence."
  },
  {
    "rank": 320,
    "name": "Upadacitinib",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Rinvoq / Upadacitinib",
    "formation": "Selective JAK1 inhibitor (oral DMARD)",
    "uses": "Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis",
    "adult": "15â€“30 mg OD (indication-dependent)",
    "child": "Not approved",
    "avoid": "Active serious infection, thromboembolism risk, malignancy",
    "drug": "Upadacitinib",
    "sideEffects": [
      "Upper respiratory infections",
      "Nausea",
      "Acne",
      "Elevated creatine kinase",
      "Herpes zoster"
    ],
    "seriousRisks": [
      "Serious infections",
      "VTE",
      "MACE",
      "Malignancies",
      "Myelosuppression"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment (CrCl <15 mL/min)",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid; embryotoxic",
    "lactation": "Avoid",
    "drugInteractions": [
      "CYP3A4 inhibitors â€” increased upadacitinib exposure; reduce dose",
      "CYP3A4 inducers (rifampicin) â€” reduced efficacy",
      "Biologic DMARDs â€” avoid combination (additive immunosuppression)"
    ],
    "monitoring": [
      "CBC",
      "Lipid profile",
      "LFT",
      "Renal function",
      "TB screening",
      "VTE symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day (RA induction for UC/CD); 15 mg/day (RA maintenance)",
    "clinicalPearl": "Most selective JAK1 inhibitor; associated with acne in young patients; VTE risk mandates thromboprophylaxis in high-risk patients."
  },
  {
    "rank": 321,
    "name": "Secukinumab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Cosentyx / Secukinumab",
    "formation": "Fully human anti-IL-17A monoclonal antibody (IgG1/Îº)",
    "uses": "Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, nr-axSpA",
    "adult": "300 mg SC (psoriasis) / 150 mg SC (PsA/AS) monthly after loading",
    "child": "75â€“150 mg SC (psoriasis â‰¥6y)",
    "avoid": "Active Crohn's disease, active serious infection, live vaccines",
    "drug": "Secukinumab",
    "sideEffects": [
      "Nasopharyngitis",
      "Upper respiratory infections",
      "Diarrhea",
      "Headache",
      "Injection site reactions"
    ],
    "seriousRisks": [
      "Serious infections",
      "Inflammatory bowel disease exacerbation",
      "Candidal infections",
      "Hypersensitivity reactions",
      "Neutropenia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” limited data; use with caution",
    "lactation": "Caution â€” insufficient data; use only if benefit outweighs risk",
    "drugInteractions": [
      "Live vaccines â€” avoid during and 3 months after treatment",
      "Other biologics â€” avoid combination (additive immunosuppression)",
      "CYP450 substrates â€” may normalize CYP450 levels after initiation; monitor drugs with narrow TI"
    ],
    "monitoring": [
      "Signs of infection (especially candidiasis)",
      "IBD symptoms",
      "CBC (neutrophils)",
      "TB screening before initiation"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg SC weekly for 5 weeks then monthly (psoriasis); 150 mg for AS",
    "clinicalPearl": "Contraindicated or use with extreme caution in active IBD; superior to anti-TNF for ankylosing spondylitis."
  },
  {
    "rank": 322,
    "name": "Adalimumab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Humira / Exemptia / Adalimumab",
    "formation": "Fully human anti-TNF-Î± monoclonal antibody",
    "uses": "RA, Crohn's disease, plaque psoriasis, ankylosing spondylitis, JIA",
    "adult": "40 mg SC every 2 weeks (RA/PsA); 80 then 40 mg biweekly (Crohn's)",
    "child": "24 mg/mÂ² (max 40 mg) SC every 2 weeks (JIA â‰¥2y)",
    "avoid": "Active TB/serious infections, demyelinating disease, CHF (NYHA III/IV)",
    "drug": "Adalimumab",
    "sideEffects": [
      "Injection site reactions",
      "Upper respiratory infections",
      "Headache",
      "Rash",
      "Nausea"
    ],
    "seriousRisks": [
      "Serious infections (TB reactivation)",
      "Demyelinating disorders",
      "CHF exacerbation",
      "Malignancies (lymphoma)",
      "Lupus-like syndrome"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” avoid in third trimester; neonatal immunosuppression (crosses placenta after week 20)",
    "lactation": "Caution â€” low concentrations in breast milk; generally considered acceptable",
    "drugInteractions": [
      "Live vaccines â€” absolutely contraindicated during therapy",
      "Anakinra â€” increased serious infection risk; avoid",
      "Methotrexate â€” reduces adalimumab immunogenicity; used concomitantly"
    ],
    "monitoring": [
      "TB screening (TST/IGRA) and CXR before initiation",
      "Hepatitis B serology",
      "CBC",
      "Signs of infection",
      "ANA and anti-dsDNA (lupus-like syndrome)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "40 mg SC every 2 weeks (RA/psoriasis); 160/80/40 mg induction for CD",
    "clinicalPearl": "Screen for latent TB with TST/IGRA before initiation; complete 9 months INH prophylaxis before starting if LTBI positive."
  },
  {
    "rank": 323,
    "name": "Etanercept",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Enbrel / Etacept / Etanercept",
    "formation": "Dimeric fusion protein (TNF receptor + IgG1 Fc â€“ soluble TNF decoy)",
    "uses": "RA, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis",
    "adult": "25 mg SC twice weekly or 50 mg once weekly",
    "child": "0.4â€“0.8 mg/kg (max 50 mg) SC weekly (JIA â‰¥2y)",
    "avoid": "Active serious infection, sepsis, demyelinating disease",
    "drug": "Etanercept",
    "sideEffects": [
      "Injection site reactions",
      "Upper respiratory infections",
      "Headache",
      "Dizziness",
      "Rash"
    ],
    "seriousRisks": [
      "Serious infections (TB reactivation)",
      "Demyelinating disorders",
      "Lupus-like syndrome",
      "CHF exacerbation",
      "Malignancies"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” avoid in third trimester; less placental transfer vs adalimumab",
    "lactation": "Caution â€” low levels in breast milk; generally considered acceptable",
    "drugInteractions": [
      "Live vaccines â€” contraindicated",
      "Anakinra â€” increased infection risk; avoid",
      "Abatacept â€” do not combine; increased infections"
    ],
    "monitoring": [
      "TB screening before initiation",
      "CBC",
      "Signs of infection",
      "ANA (lupus-like reaction)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "50 mg SC once weekly (adult RA/psoriasis)",
    "clinicalPearl": "Lower TB reactivation risk vs infliximab/adalimumab (does not bind membrane TNF); still screen for latent TB before starting."
  },
  {
    "rank": 324,
    "name": "Infliximab",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Remicade / Infimab / Inflectra",
    "formation": "Chimeric anti-TNF-Î± monoclonal antibody (IgG1 â€“ 25% murine)",
    "uses": "RA, Crohn's disease, UC, psoriasis, ankylosing spondylitis",
    "adult": "3â€“10 mg/kg IV infusion at 0, 2, 6 weeks; then every 8 weeks",
    "child": "5 mg/kg IV (Crohn's, UC; â‰¥6y)",
    "avoid": "Active infection, CHF (NYHA III/IV), demyelinating disorders",
    "drug": "Infliximab",
    "sideEffects": [
      "Infusion reactions",
      "Upper respiratory infections",
      "Headache",
      "Nausea",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "TB reactivation (highest risk among TNF inhibitors)",
      "Serious bacterial infections",
      "Hepatotoxicity",
      "Demyelinating disorders",
      "Malignancies (lymphoma)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution; hepatotoxicity risk; monitor LFT",
    "pregnancy": "Category B â€” avoid in third trimester; significant placental transfer",
    "lactation": "Caution â€” low levels in breast milk; generally considered safe",
    "drugInteractions": [
      "Live vaccines â€” absolutely contraindicated",
      "Azathioprine/6-MP â€” increased hepatosplenic T-cell lymphoma risk",
      "Other biologics â€” avoid combination"
    ],
    "monitoring": [
      "TB screening (TST/IGRA + CXR) before initiation",
      "Hepatitis B serology",
      "CBC",
      "LFT",
      "CRP/ESR",
      "Infusion reaction monitoring"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "10 mg/kg IV per dose (IBD); 5 mg/kg per dose (RA) at weeks 0, 2, 6 then every 8 weeks",
    "clinicalPearl": "Highest TB reactivation risk among TNF-inhibitors; mandatory TB and hepatitis B screening and prophylaxis before initiation."
  },
  {
    "rank": 325,
    "name": "Abatacept",
    "section": "Section 8: Oncology & Immunology",
    "category": "Immunology",
    "schedule": "H",
    "brand": "Orencia / Abatacept",
    "formation": "Selective T-cell co-stimulation modulator (CTLA4-Ig fusion protein)",
    "uses": "Moderate-to-severe RA (inadequate response to MTX or TNF inhibitors)",
    "adult": "<60 kg: 500 mg; 60â€“100 kg: 750 mg; >100 kg: 1000 mg IV monthly",
    "child": "10 mg/kg IV (JIA â‰¥6y, max 1000 mg)",
    "avoid": "Active serious infection, COPD (worsens), live vaccines within 3 months",
    "drug": "Abatacept",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Nausea",
      "Injection/infusion site reactions",
      "Upper respiratory infections"
    ],
    "seriousRisks": [
      "Serious infections",
      "Malignancies (lung cancer â€” higher in COPD patients)",
      "Anaphylaxis",
      "COPD exacerbation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; limited human data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "TNF inhibitors â€” do not combine; increased infections without added efficacy",
      "Live vaccines â€” avoid during and 3 months after treatment",
      "Other biologics â€” avoid combination"
    ],
    "monitoring": [
      "Signs of infection",
      "CBC",
      "TB screening before initiation",
      "Pulmonary symptoms (COPD patients)",
      "Blood glucose (contains maltose â€” interfere with point-of-care glucose monitors if IV formulation)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "125 mg SC weekly (or IV weight-based: <60 kg=500 mg; 60-100 kg=750 mg; >100 kg=1000 mg)",
    "clinicalPearl": "IV formulation contains maltose â€” use only glucose-specific monitors; preferred in seropositive RA as CTLA-4Ig mechanism."
  },
  {
    "rank": 326,
    "name": "Tiotropium Bromide",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Spiriva / Tiova / Tiotropium",
    "formation": "Long-acting muscarinic antagonist (LAMA) anticholinergic inhaler",
    "uses": "COPD maintenance, reduction of exacerbation frequency",
    "adult": "18 mcg OD (HandiHaler) or 5 mcg OD (Respimat)",
    "child": "Not recommended",
    "avoid": "Narrow-angle glaucoma, urinary retention, severe renal impairment",
    "drug": "Tiotropium Bromide",
    "sideEffects": [
      "Dry mouth",
      "Constipation",
      "Urinary retention",
      "Blurred vision",
      "Pharyngitis"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma (if powder enters eyes)",
      "Urinary retention (BPH patients)",
      "Bronchospasm (paradoxical)",
      "Anaphylaxis (rare)"
    ],
    "renalAdj": "Yes â€” use with caution in moderate-severe renal impairment (CrCl <50 mL/min); monitor for anticholinergic toxicity",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; inhaled route minimizes systemic exposure",
    "lactation": "Caution â€” limited data; inhaled route preferred",
    "drugInteractions": [
      "Other anticholinergics (ipratropium) â€” additive effects; avoid combination",
      "Amantadine â€” enhanced anticholinergic adverse effects"
    ],
    "monitoring": [
      "FEV1/FVC (spirometry)",
      "Exercise tolerance",
      "Exacerbation frequency",
      "Urinary symptoms",
      "Dry mouth/vision"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "18 mcg/day (HandiHaler) or 5 mcg/day (Respimat) â€” once daily",
    "clinicalPearl": "Do not swallow capsule; use only in HandiHaler device; shake inhaler before use to ensure consistent dose."
  },
  {
    "rank": 327,
    "name": "Salmeterol + Fluticasone Propionate",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Seroflo / Advair / Foxair",
    "formation": "LABA (long-acting beta2-agonist) + ICS (inhaled corticosteroid)",
    "uses": "Asthma maintenance, symptomatic COPD",
    "adult": "50/100â€“500 mcg BID via inhaler",
    "child": "50/100 mcg BID (approved â‰¥4y)",
    "avoid": "Acute severe asthma attacks, LABA monotherapy in uncontrolled asthma",
    "drug": "Salmeterol + Fluticasone Propionate",
    "sideEffects": [
      "Oral candidiasis",
      "Hoarseness/dysphonia",
      "Headache",
      "Tremor",
      "Palpitations"
    ],
    "seriousRisks": [
      "Paradoxical bronchospasm",
      "Adrenal suppression (high dose)",
      "Growth retardation (children, high dose)",
      "Increased pneumonia risk in COPD",
      "Salmeterol monotherapy LABA risk (never use LABA without ICS in asthma)"
    ],
    "renalAdj": "No â€” standard dosing (inhaled; minimal systemic absorption)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” inhaled corticosteroids preferred in pregnancy; budesonide has more safety data",
    "lactation": "Caution â€” low systemic absorption; considered generally safe",
    "drugInteractions": [
      "Beta-blockers â€” antagonism of salmeterol bronchodilator effect",
      "CYP3A4 inhibitors (ritonavir, ketoconazole) â€” increased fluticasone levels; adrenal suppression",
      "Diuretics â€” increased hypokalemia risk with salmeterol"
    ],
    "monitoring": [
      "PEF/FEV1",
      "Oral cavity (candidiasis)",
      "Growth in children",
      "Potassium (high dose)",
      "Adrenal function (very high dose chronic use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Salmeterol 100 mcg/day + Fluticasone 2000 mcg/day (divided doses)",
    "clinicalPearl": "Rinse mouth after every use to prevent candidiasis; never use LABA alone in asthma â€” always combine with ICS."
  },
  {
    "rank": 328,
    "name": "Umeclidinium + Vilanterol",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Anoro Ellipta / Umeclidinium-Vilanterol",
    "formation": "LAMA + LABA dual bronchodilator (fixed-dose inhaler)",
    "uses": "COPD maintenance therapy (no ICS component)",
    "adult": "62.5/25 mcg OD via Ellipta inhaler",
    "child": "Not recommended",
    "avoid": "Narrow-angle glaucoma, urinary retention, asthma without ICS",
    "drug": "Umeclidinium + Vilanterol",
    "sideEffects": [
      "Nasopharyngitis",
      "Upper respiratory infections",
      "Headache",
      "Dry mouth",
      "Cough"
    ],
    "seriousRisks": [
      "Paradoxical bronchospasm",
      "Acute angle-closure glaucoma (anticholinergic component)",
      "Urinary retention",
      "Cardiovascular effects (vilanterol)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment",
    "pregnancy": "Category C â€” limited data; inhaled route minimizes systemic exposure",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Other anticholinergics â€” additive anticholinergic adverse effects; avoid",
      "Other LABAs â€” additive cardiovascular effects; avoid",
      "MAO inhibitors/TCAs â€” increased cardiovascular effects from vilanterol"
    ],
    "monitoring": [
      "Spirometry (FEV1)",
      "Exacerbation frequency",
      "Urinary symptoms",
      "CV status (arrhythmia)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Umeclidinium 62.5 mcg + Vilanterol 25 mcg once daily",
    "clinicalPearl": "Once-daily LAMA+LABA combination; superior to monotherapy for COPD; use Ellipta inhaler with correct technique."
  },
  {
    "rank": 329,
    "name": "Indacaterol + Glycopyrronium",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Ultibro Breezhaler / QVA149",
    "formation": "LABA + LAMA fixed-dose combination bronchodilator",
    "uses": "COPD maintenance (GOLD grade 2â€“4)",
    "adult": "110/50 mcg OD via Breezhaler capsule",
    "child": "Not recommended",
    "avoid": "Severe heart disease, narrow-angle glaucoma, urinary retention",
    "drug": "Indacaterol + Glycopyrronium",
    "sideEffects": [
      "Nasopharyngitis",
      "Headache",
      "Urinary tract infection",
      "Dry mouth",
      "Dizziness"
    ],
    "seriousRisks": [
      "Paradoxical bronchospasm",
      "Urinary retention (glycopyrronium component)",
      "Cardiovascular effects",
      "Acute angle-closure glaucoma"
    ],
    "renalAdj": "Yes â€” use with caution in severe renal impairment; glycopyrronium renally excreted",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Other LABAs â€” additive cardiovascular risk; avoid",
      "Other anticholinergics â€” additive effects; avoid",
      "Beta-blockers â€” reduced LABA bronchodilator effect"
    ],
    "monitoring": [
      "FEV1/PEF",
      "Exacerbation rate",
      "Urinary symptoms",
      "HR and rhythm"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Indacaterol 110 mcg + Glycopyrronium 50 mcg once daily (Ultibro Breezhaler)",
    "clinicalPearl": "Once-daily Breezhaler device â€” insert capsule and pierce before inhalation; do not swallow the capsule."
  },
  {
    "rank": 330,
    "name": "Beclomethasone Dipropionate (Inhaled)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Beclate / Becotide / Clenil",
    "formation": "Second-generation halogenated inhaled corticosteroid (MDI)",
    "uses": "Prophylaxis of asthma, inhaled maintenance anti-inflammatory therapy",
    "adult": "100â€“400 mcg BID via MDI",
    "child": "50â€“200 mcg BID (approved â‰¥5y)",
    "avoid": "Status asthmaticus, acute asthma attack, active pulmonary tuberculosis",
    "drug": "Beclomethasone Dipropionate Inhaled",
    "sideEffects": [
      "Oral candidiasis",
      "Dysphonia",
      "Throat irritation",
      "Cough",
      "Headache"
    ],
    "seriousRisks": [
      "Adrenal suppression (high dose, long-term)",
      "Growth retardation (children)",
      "Osteoporosis (high dose, long-term)",
      "Paradoxical bronchospasm"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” considered safe at lowest effective dose; budesonide preferred",
    "lactation": "Caution â€” minimal systemic absorption; generally considered safe",
    "drugInteractions": [
      "CYP3A4 inhibitors (ritonavir) â€” increased systemic corticosteroid exposure",
      "Other corticosteroids â€” additive adrenal suppression"
    ],
    "monitoring": [
      "PEF/spirometry",
      "Oral cavity (candidiasis)",
      "Growth in children",
      "Bone density (long-term high dose)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mcg/day (adults); 400 mcg/day (children)",
    "clinicalPearl": "Extra-fine particle formulations (HFA pMDI) deposit in small airways; always rinse mouth after use to prevent oral candidiasis."
  },
  {
    "rank": 331,
    "name": "Ciclesonide (Inhaled)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Alvesco / Omnaris / Ciclesonide inhaler",
    "formation": "Prodrug ICS (activated to des-ciclesonide in the airways)",
    "uses": "Asthma prophylaxis, mild-to-moderate COVID-19 early treatment (investigational)",
    "adult": "80â€“320 mcg ODâ€“BID via MDI",
    "child": "80 mcg BID (approved â‰¥6y)",
    "avoid": "Acute asthma attacks, active or latent pulmonary tuberculosis",
    "drug": "Ciclesonide Inhaled",
    "sideEffects": [
      "Headache",
      "Nasopharyngitis",
      "Sinusitis",
      "Arthralgia",
      "Minimal oral candidiasis (prodrug advantage)"
    ],
    "seriousRisks": [
      "Adrenal suppression (high dose)",
      "Growth retardation (children, high dose)",
      "Paradoxical bronchospasm",
      "Osteoporosis (chronic high dose)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” minimal systemic absorption; generally considered safe",
    "drugInteractions": [
      "CYP3A4 inhibitors â€” increased active metabolite exposure",
      "Other corticosteroids â€” additive suppression"
    ],
    "monitoring": [
      "PEF/FEV1",
      "Exacerbation frequency",
      "Growth in children"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "320 mcg twice daily (640 mcg/day)",
    "clinicalPearl": "Prodrug activated in lungs â€” lower oropharyngeal deposition and candidiasis risk; once or twice daily dosing."
  },
  {
    "rank": 332,
    "name": "Theophylline",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Theo-Asthalin / Elixophyllin / Uniphyllin",
    "formation": "Methylxanthine bronchodilator (phosphodiesterase inhibitor)",
    "uses": "Asthma (add-on therapy), COPD, neonatal apnea of prematurity",
    "adult": "300â€“600 mg/day ER; target serum level 8â€“12 mcg/mL",
    "child": "5â€“10 mg/kg/day divided (neonatal apnea: 1â€“2 mg/kg BID)",
    "avoid": "Concurrent quinolone/macrolide antibiotics (toxicity risk), active peptic ulcer, seizure disorder",
    "drug": "Theophylline",
    "sideEffects": [
      "Nausea/vomiting",
      "Headache",
      "Palpitations/tachycardia",
      "Insomnia",
      "Tremor"
    ],
    "seriousRisks": [
      "Theophylline toxicity/seizures",
      "Cardiac arrhythmias (VT, VF)",
      "Theophylline toxicity at narrow therapeutic window",
      "Status epilepticus"
    ],
    "renalAdj": "No â€” standard dosing (hepatically metabolized)",
    "hepaticAdj": "Yes â€” significantly reduce dose; hepatic dysfunction prolongs half-life markedly",
    "pregnancy": "Category C â€” use with caution; crosses placenta; neonatal theophylline toxicity possible",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for irritability and tachycardia",
    "drugInteractions": [
      "Fluoroquinolones (ciprofloxacin, enoxacin) â€” markedly increased theophylline levels; toxicity risk",
      "Rifampicin â€” reduced theophylline levels",
      "Erythromycin/clarithromycin â€” increased theophylline levels"
    ],
    "monitoring": [
      "Serum theophylline levels (target 10-20 mcg/mL)",
      "HR and ECG",
      "LFT",
      "Seizure history"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "900 mg/day (immediate-release); guided by serum levels",
    "clinicalPearl": "Narrow therapeutic index (10-20 mcg/mL); toxicity signs (nausea, tachycardia, tremor) = check level immediately."
  },
  {
    "rank": 333,
    "name": "Doxofylline",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Xanthium / Doxovent / Doxofyllin",
    "formation": "7-(1,3-dioxolan-2-ylmethyl)theophylline (methylxanthine with fewer side effects)",
    "uses": "Mild-to-moderate asthma, COPD (better GI and cardiac tolerability than theophylline)",
    "adult": "400 mg BID or TID",
    "child": "6â€“8 mg/kg BID",
    "avoid": "Acute MI, active peptic ulcer, severe hypotension",
    "drug": "Doxofylline",
    "sideEffects": [
      "Nausea",
      "Headache",
      "Palpitations",
      "Gastric discomfort",
      "Insomnia"
    ],
    "seriousRisks": [
      "Cardiac arrhythmias (lower risk than theophylline)",
      "Seizures (lower risk than theophylline)",
      "GI bleeding"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; reduce dose",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” insufficient data; avoid if possible",
    "drugInteractions": [
      "Fluoroquinolones â€” increased doxofylline levels (less than theophylline interaction)",
      "Erythromycin â€” increased levels",
      "Cimetidine â€” increased levels"
    ],
    "monitoring": [
      "HR",
      "Pulmonary function",
      "GI symptoms",
      "Plasma levels if available"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1200 mg/day (400 mg three times daily)",
    "clinicalPearl": "Preferred over theophylline in India for better GI and cardiac tolerability; fewer drug interactions; widely used in COPD/asthma."
  },
  {
    "rank": 334,
    "name": "Aminophylline",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Aminophylline Inj / Aminophylline",
    "formation": "Theophylline ethylenediamine complex (IV bronchodilator)",
    "uses": "Acute severe asthma, acute COPD exacerbation (IV use)",
    "adult": "5 mg/kg IV loading over 30 min, then 0.5â€“1 mg/kg/hr maintenance",
    "child": "5 mg/kg IV loading, then 0.7â€“1 mg/kg/hr",
    "avoid": "Concurrent oral theophylline therapy, severe cardiac arrhythmia",
    "drug": "Aminophylline",
    "sideEffects": [
      "Nausea/vomiting",
      "Tachycardia",
      "Headache",
      "Restlessness",
      "Tremor"
    ],
    "seriousRisks": [
      "Cardiac arrhythmias",
      "Seizures (at toxic levels)",
      "Severe hypotension (rapid IV)",
      "Theophylline toxicity"
    ],
    "renalAdj": "No â€” standard dosing (hepatically metabolized; adjust for toxicity signs)",
    "hepaticAdj": "Yes â€” significantly reduce dose; prolonged half-life in hepatic failure",
    "pregnancy": "Category C â€” use only for acute severe asthma when benefit outweighs risk",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "Fluoroquinolones (ciprofloxacin) â€” severely increased theophylline levels",
      "Erythromycin/clarithromycin â€” increased levels",
      "Phenytoin/rifampicin â€” reduced aminophylline levels"
    ],
    "monitoring": [
      "Serum theophylline levels (10-20 mcg/mL)",
      "HR and ECG (continuous during IV)",
      "BP",
      "Respiratory rate"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "500 mg IV loading dose; 0.5 mg/kg/hour infusion (adjust per levels)",
    "clinicalPearl": "IV must be given slowly (over minimum 20-30 minutes); rapid IV injection causes fatal arrhythmias."
  },
  {
    "rank": 335,
    "name": "Roflumilast",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Daxas / Libertas / Roflumilast",
    "formation": "Selective PDE4 inhibitor (oral anti-inflammatory for COPD)",
    "uses": "COPD (GOLD D) with chronic bronchitis and frequent exacerbations",
    "adult": "500 mcg OD (with food to reduce GI effects)",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment (Child-Pugh B/C), depression/suicidal history",
    "drug": "Roflumilast",
    "sideEffects": [
      "Diarrhea",
      "Nausea",
      "Headache",
      "Weight loss",
      "Insomnia"
    ],
    "seriousRisks": [
      "Psychiatric side effects (depression, suicidal ideation)",
      "Significant weight loss",
      "Insomnia and anxiety"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in moderate-severe hepatic impairment (Child-Pugh B/C)",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "CYP3A4/CYP1A2 inducers (rifampicin) â€” reduced roflumilast levels; avoid",
      "CYP3A4 inhibitors (erythromycin, ketoconazole) â€” increased levels",
      "Theophylline â€” avoid combination (additive PDE4 inhibition)"
    ],
    "monitoring": [
      "Body weight (monthly)",
      "Psychiatric symptoms (depression, mood)",
      "LFT",
      "FEV1"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "500 mcg once daily",
    "clinicalPearl": "Add-on for severe COPD with frequent exacerbations and chronic bronchitis phenotype; monitor weight and mood monthly."
  },
  {
    "rank": 336,
    "name": "N-Acetylcysteine (NAC)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Fluimucil / Mucomyst / Acetylcysteine",
    "formation": "Cysteine derivative (glutathione precursor and mucolytic)",
    "uses": "COPD mucolytic, paracetamol overdose antidote, contrast nephropathy prevention",
    "adult": "600 mg ODâ€“BID (mucolytic); 150 mg/kg IV (paracetamol overdose antidote)",
    "child": "100 mg BID (mucolytic); weight-based IV protocol (overdose antidote)",
    "avoid": "Active bronchospasm (may worsen asthma), known hypersensitivity",
    "drug": "N-Acetylcysteine (NAC)",
    "sideEffects": [
      "Nausea/vomiting",
      "Rash",
      "Anaphylactoid reactions (IV)",
      "Flushing",
      "Bronchospasm (inhaled)"
    ],
    "seriousRisks": [
      "Anaphylactoid reactions (IV â€” especially with rapid infusion)",
      "Severe bronchospasm (inhaled formulation in asthmatics)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing (used to protect liver in paracetamol overdose)",
    "pregnancy": "Category B â€” safe; used in paracetamol overdose in pregnancy",
    "lactation": "Safe â€” used in short-term treatment",
    "drugInteractions": [
      "Nitroglycerin â€” enhanced hypotension and headache",
      "Activated charcoal â€” reduces oral NAC absorption (separate by 2 hours)",
      "Carbamazepine â€” NAC may reduce metabolism"
    ],
    "monitoring": [
      "LFT and INR (paracetamol overdose)",
      "Serum paracetamol levels",
      "Anaphylactoid reaction signs during IV infusion",
      "Respiratory status (inhaled)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Mucolytic: 600 mg/day oral; Paracetamol antidote: 300 mg/kg IV over 21 hours (Prescott protocol)",
    "clinicalPearl": "For paracetamol overdose: start IV NAC within 8-10 hours for maximum benefit; slow down infusion to manage anaphylactoid reactions."
  },
  {
    "rank": 337,
    "name": "Ambroxol HCl",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Ambrodil / Mucosolvan / Ambrox",
    "formation": "Active metabolite of bromhexine (mucokinetic secretolytic agent)",
    "uses": "Acute and chronic bronchopulmonary diseases with viscous mucus hypersecretion",
    "adult": "30 mg TID or 75 mg SR OD",
    "child": "1.2â€“1.6 mg/kg/day in 2â€“3 divided doses",
    "avoid": "Rare hereditary galactose intolerance (formulation-specific)",
    "drug": "Ambroxol HCl",
    "sideEffects": [
      "Nausea",
      "Diarrhea",
      "Dry mouth",
      "Dyspepsia",
      "Skin reactions (rare)"
    ],
    "seriousRisks": [
      "Severe skin reactions (SJS/TEN â€” rare)",
      "Anaphylaxis (rare)"
    ],
    "renalAdj": "Yes â€” use with caution in severe renal impairment; reduce frequency",
    "hepaticAdj": "Yes â€” use with caution; reduce dose in hepatic impairment",
    "pregnancy": "Category B â€” avoid in first trimester; use only in second/third trimesters if needed",
    "lactation": "Caution â€” excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "Antibiotics (amoxicillin, erythromycin, cefuroxime) â€” enhanced antibiotic penetration into bronchial secretions",
      "Antitussives â€” avoid combination; impairs expectoration"
    ],
    "monitoring": [
      "Sputum consistency/volume",
      "Respiratory symptoms",
      "Skin (SJS monitoring)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "90 mg/day (30 mg three times daily)",
    "clinicalPearl": "Increases surfactant production; combined with antibiotics improves antibiotic concentration in lung tissue."
  },
  {
    "rank": 338,
    "name": "Bromhexine HCl",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Bisolvon / Bisolvin / Bromhexine",
    "formation": "Synthetic derivative of vasicine (mucolytic expectorant)",
    "uses": "Productive cough with viscous mucus, chronic bronchitis, bronchiectasis",
    "adult": "8â€“16 mg TID",
    "child": "4 mg TID (6â€“12y); 2 mg TID (<6y)",
    "avoid": "Active peptic ulcer, hereditary fructose intolerance",
    "drug": "Bromhexine HCl",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhea",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Severe skin reactions (rare)",
      "Anaphylaxis (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category B â€” avoid in first trimester",
    "lactation": "Caution â€” insufficient data; avoid if possible",
    "drugInteractions": [
      "Antibiotics â€” may enhance antibiotic penetration into respiratory secretions",
      "Antitussives â€” avoid; combination impairs sputum clearance"
    ],
    "monitoring": [
      "Sputum characteristics",
      "Respiratory symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "48 mg/day (8 mg three times daily orally; 16 mg TDS in severe cases)",
    "clinicalPearl": "Prodrug of ambroxol; widely used in India for productive cough; encourage adequate hydration for mucolytic effect."
  },
  {
    "rank": 339,
    "name": "Levosalbutamol (Levalbuterol)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Levolin / Asthavent-L / Levalbuterol",
    "formation": "R-enantiomer of salbutamol (selective beta2-agonist with less cardiac stimulation)",
    "uses": "Bronchospasm in asthma and COPD (fewer cardiac side effects than racemic salbutamol)",
    "adult": "45â€“90 mcg (0.63â€“1.25 mg) via nebulizer TIDâ€“QID PRN",
    "child": "0.31â€“0.63 mg nebulized TID",
    "avoid": "Cardiac arrhythmias, tachycardia, severe hypertension",
    "drug": "Levosalbutamol (Levalbuterol)",
    "sideEffects": [
      "Tremor",
      "Tachycardia",
      "Palpitations",
      "Headache",
      "Hypokalemia"
    ],
    "seriousRisks": [
      "Severe paradoxical bronchospasm",
      "Significant hypokalemia",
      "Cardiac arrhythmias (high dose)",
      "Lactic acidosis (high dose IV equivalent â€” rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use only if benefit outweighs risk; premature labor inhibition effect",
    "lactation": "Caution â€” excreted in breast milk; use minimum effective dose",
    "drugInteractions": [
      "Beta-blockers â€” antagonism; avoid non-selective beta-blockers",
      "MAO inhibitors/TCAs â€” enhanced cardiovascular effects",
      "Diuretics â€” additive hypokalemia"
    ],
    "monitoring": [
      "HR and rhythm",
      "Serum potassium",
      "Respiratory response",
      "Blood pressure"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.63-1.25 mg per nebulization, every 4-8 hours",
    "clinicalPearl": "R-isomer of salbutamol â€” claimed fewer cardiac side effects at equivalent bronchodilator doses; widely used in India."
  },
  {
    "rank": 340,
    "name": "Guaifenesin",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "OTC",
    "brand": "Mucinex / Grilinctus-SF / Robitussin",
    "formation": "Glycerol guaiacolate (expectorant â€“ reduces mucus viscosity)",
    "uses": "Productive cough, chest congestion in upper and lower respiratory tract infections",
    "adult": "200â€“400 mg every 4 hrs (max 2400 mg/day)",
    "child": "50â€“100 mg every 4 hrs (2â€“12y)",
    "avoid": "Persistent or chronic cough without diagnosis, cough with haemoptysis",
    "drug": "Guaifenesin",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Dizziness",
      "Headache",
      "Diarrhea (high dose)"
    ],
    "seriousRisks": [
      "Kidney stones (high dose, inadequate hydration)",
      "Allergic reactions (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” limited data; generally considered low risk",
    "lactation": "Caution â€” insufficient data; avoid prolonged use",
    "drugInteractions": [
      "Antitussives â€” avoid combination; suppressing cough with accumulated secretions is harmful"
    ],
    "monitoring": [
      "Sputum consistency",
      "Fluid intake adequacy",
      "Respiratory symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2400 mg/day (extended release: 1200 mg twice daily)",
    "clinicalPearl": "Adequate hydration (â‰¥8 glasses of water/day) is essential for guaifenesin's mucolytic action to be effective."
  },
  {
    "rank": 341,
    "name": "Xylometazoline HCl",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "ENT",
    "schedule": "OTC",
    "brand": "Otrivin / Nasivion / Xylomist",
    "formation": "Imidazoline alpha-adrenergic agonist (topical nasal decongestant)",
    "uses": "Nasal congestion due to rhinitis, sinusitis, common cold",
    "adult": "0.1% spray: 2â€“3 drops/sprays each nostril TID (max 5 days)",
    "child": "0.05% (2â€“12y); 0.025% (<2y, under medical guidance)",
    "avoid": "Atrophic rhinitis, concurrent MAOI use, >5 days use (rebound congestion)",
    "drug": "Xylometazoline HCl",
    "sideEffects": [
      "Nasal burning/stinging",
      "Dryness",
      "Sneezing",
      "Rhinitis medicamentosa (rebound congestion)",
      "Headache"
    ],
    "seriousRisks": [
      "Rhinitis medicamentosa (rebound congestion with >3-5 days use)",
      "CNS stimulation/hypertension (systemic absorption)",
      "Cardiac arrhythmias (in children with overdose)"
    ],
    "renalAdj": "No â€” standard dosing (topical; minimal absorption)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid in first trimester; use sparingly",
    "lactation": "Caution â€” avoid prolonged use; systemic absorption",
    "drugInteractions": [
      "MAO inhibitors â€” severe hypertensive crisis",
      "TCAs â€” enhanced sympathomimetic effects",
      "Other sympathomimetics â€” additive cardiovascular effects"
    ],
    "monitoring": [
      "Nasal symptoms",
      "Duration of use (limit to 3-5 days)",
      "BP (especially in hypertensive patients)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.1% â€” 2-3 drops/sprays per nostril every 8-10 hours (maximum 3-5 days total)",
    "clinicalPearl": "Never exceed 5 days of use â€” rebound congestion (rhinitis medicamentosa) is worse than original congestion."
  },
  {
    "rank": 342,
    "name": "Oxymetazoline HCl",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "ENT",
    "schedule": "OTC",
    "brand": "Nasivion / Afrin / Nasifit",
    "formation": "Imidazoline sympathomimetic amine (long-acting nasal decongestant)",
    "uses": "Nasal and sinus congestion, allergic rhinitis, sinusitis",
    "adult": "0.05% two sprays per nostril BID (12-hr; max 3 days)",
    "child": "0.025% (2â€“5y); 0.05% (â‰¥6y)",
    "avoid": "Atrophic rhinitis, hypertension, MAOI use (14-day washout required)",
    "drug": "Oxymetazoline HCl",
    "sideEffects": [
      "Nasal stinging/burning",
      "Rebound congestion",
      "Dryness",
      "Sneezing",
      "Headache"
    ],
    "seriousRisks": [
      "Rhinitis medicamentosa (>3-5 days use)",
      "Hypertension",
      "CNS effects (restlessness, insomnia)",
      "Bradycardia (reflex, rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use sparingly; avoid prolonged use",
    "lactation": "Caution â€” avoid prolonged use",
    "drugInteractions": [
      "MAO inhibitors â€” severe hypertensive crisis; contraindicated",
      "Antihypertensives â€” reduced antihypertensive effect",
      "TCAs â€” enhanced pressor effect"
    ],
    "monitoring": [
      "Nasal symptom duration",
      "BP",
      "Duration of use (max 3-5 days)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.05% â€” 2-3 drops/sprays per nostril every 12 hours (maximum 3-5 days)",
    "clinicalPearl": "Longest-acting topical decongestant (12 hours); strictly limit to 3-5 days; contraindicated with MAO inhibitors."
  },
  {
    "rank": 343,
    "name": "Budesonide (Nasal Spray)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "ENT",
    "schedule": "H",
    "brand": "Rhinocort / Rhinobudez / Budesonide Nasal",
    "formation": "Non-halogenated topical glucocorticoid (nasal formulation)",
    "uses": "Seasonal and perennial allergic rhinitis, nasal polyps",
    "adult": "64â€“256 mcg (2â€“4 sprays) ODâ€“BID per nostril",
    "child": "32â€“64 mcg (1â€“2 sprays) OD (â‰¥6y)",
    "avoid": "Nasal septum perforation, active epistaxis, untreated nasal infections",
    "drug": "Budesonide Nasal Spray",
    "sideEffects": [
      "Nasal burning/stinging",
      "Epistaxis",
      "Nasal dryness",
      "Headache",
      "Throat irritation"
    ],
    "seriousRisks": [
      "Nasal septal perforation (rare)",
      "Adrenal suppression (high dose, long-term)",
      "Growth retardation (children, high dose)",
      "Glaucoma/cataracts (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” most safety data among intranasal steroids; preferred in pregnancy",
    "lactation": "Safe â€” minimal systemic absorption; most studied ICS in lactation",
    "drugInteractions": [
      "CYP3A4 inhibitors (ritonavir) â€” increased systemic budesonide levels",
      "Other corticosteroids â€” additive adrenal suppression"
    ],
    "monitoring": [
      "Nasal symptom control",
      "Epistaxis frequency",
      "Growth in children",
      "IOP (long-term use in glaucoma patients)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "256 mcg/day (2 sprays each nostril twice daily)",
    "clinicalPearl": "Most pregnancy-safe intranasal steroid; spray toward outer wall of nose (not septum) to reduce epistaxis risk."
  },
  {
    "rank": 344,
    "name": "Fluticasone Propionate (Nasal Spray)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "ENT",
    "schedule": "H",
    "brand": "Flixonase / Nasoflo / Flutinose",
    "formation": "Synthetic trifluorinated corticosteroid (nasal spray)",
    "uses": "Seasonal and perennial allergic rhinitis, chronic sinusitis",
    "adult": "100 mcg (2 sprays) per nostril OD (or 50 mcg each nostril BID)",
    "child": "50 mcg (1 spray) per nostril OD (â‰¥4y)",
    "avoid": "Recent nasal surgery, nasal septum deviation/perforation",
    "drug": "Fluticasone Propionate Nasal Spray",
    "sideEffects": [
      "Epistaxis",
      "Nasal dryness",
      "Headache",
      "Nasal irritation",
      "Unpleasant taste"
    ],
    "seriousRisks": [
      "Nasal septum perforation",
      "Adrenal suppression (systemic, rare)",
      "Growth retardation (children)",
      "Glaucoma/cataracts (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; budesonide preferred",
    "lactation": "Caution â€” minimal systemic absorption; considered safe",
    "drugInteractions": [
      "CYP3A4 inhibitors (ritonavir) â€” markedly increased systemic exposure; avoid combination",
      "Other corticosteroids â€” additive suppression"
    ],
    "monitoring": [
      "Nasal symptoms",
      "Epistaxis",
      "Growth in children",
      "Vision (chronic use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mcg/day (2 sprays per nostril once daily)",
    "clinicalPearl": "Avoid in patients on ritonavir; shake bottle well before use; onset of action 12-24 hours, maximum effect at 1-2 weeks."
  },
  {
    "rank": 345,
    "name": "Azelastine HCl (Nasal Spray)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "ENT",
    "schedule": "H",
    "brand": "Astelin / Azep / Azelastin nasal",
    "formation": "Phthalazinone H1-receptor antagonist (topical nasal antihistamine)",
    "uses": "Seasonal and perennial allergic rhinitis, vasomotor rhinitis",
    "adult": "1â€“2 sprays per nostril BID",
    "child": "1 spray per nostril BID (5â€“11y); 2 sprays (â‰¥12y)",
    "avoid": "Hypersensitivity to azelastine, avoid driving after intranasal use (drowsiness)",
    "drug": "Azelastine HCl Nasal Spray",
    "sideEffects": [
      "Bitter taste",
      "Somnolence/drowsiness",
      "Nasal burning/stinging",
      "Headache",
      "Epistaxis"
    ],
    "seriousRisks": [
      "CNS depression (significant sedation with systemic absorption)",
      "Psychomotor impairment (driving risk)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive sedation",
      "Cimetidine â€” increased azelastine levels",
      "Other antihistamines â€” additive sedation"
    ],
    "monitoring": [
      "Nasal symptom control",
      "Sedation level",
      "Driving ability assessment"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.15% â€” 2 sprays per nostril twice daily (548 mcg/day)",
    "clinicalPearl": "Fastest onset intranasal antihistamine (15 minutes); bitter taste managed by downward head tilt after spraying."
  },
  {
    "rank": 346,
    "name": "Ipratropium Bromide (Nasal Spray)",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "ENT",
    "schedule": "H",
    "brand": "Ipravent Nasal / Atrovent Nasal",
    "formation": "Quaternary ammonium anticholinergic (nasal anticholinergic)",
    "uses": "Rhinorrhea in perennial rhinitis, post-infectious rhinitis",
    "adult": "0.03% two sprays per nostril BIDâ€“TID",
    "child": "0.03% (â‰¥5y); same dosing",
    "avoid": "Narrow-angle glaucoma, urinary retention, soy/peanut allergy (CFC-free)",
    "drug": "Ipratropium Bromide Nasal Spray",
    "sideEffects": [
      "Nasal dryness",
      "Epistaxis",
      "Dry mouth",
      "Headache",
      "Nasal irritation"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma (accidental eye contact)",
      "Urinary retention (systemic absorption)",
      "Paradoxical bronchospasm (rare)"
    ],
    "renalAdj": "No â€” standard dosing (minimal systemic absorption)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” considered safe at recommended doses",
    "lactation": "Caution â€” minimal systemic absorption; likely safe",
    "drugInteractions": [
      "Other anticholinergics â€” additive anticholinergic effects",
      "Amantadine â€” additive anticholinergic toxicity"
    ],
    "monitoring": [
      "Nasal symptom relief",
      "Rhinorrhea",
      "Urinary symptoms (elderly)",
      "Eye symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.03% â€” 2 sprays per nostril 2-3 times daily (84 mcg per nostril per dose)",
    "clinicalPearl": "Specifically effective for cholinergic rhinorrhea (watery discharge); avoid spraying into eyes â€” risk of acute glaucoma."
  },
  {
    "rank": 347,
    "name": "Cetirizine HCl",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Cetzine / Zyrtec / Alerid",
    "formation": "Racemic piperazine carboxylate H1-antihistamine (second-generation)",
    "uses": "Perennial and seasonal allergic rhinitis, chronic idiopathic urticaria",
    "adult": "10 mg OD",
    "child": "5 mg OD (6â€“11y); 2.5 mg OD (2â€“5y)",
    "avoid": "End-stage renal disease (CrCl <10 mL/min), concurrent CNS depressants",
    "drug": "Cetirizine HCl",
    "sideEffects": [
      "Somnolence/drowsiness",
      "Dry mouth",
      "Fatigue",
      "Headache",
      "Dizziness"
    ],
    "seriousRisks": [
      "Severe somnolence impairing psychomotor function",
      "QT prolongation (rare, high dose or cardiac patients)",
      "Urinary retention (anticholinergic)"
    ],
    "renalAdj": "Yes â€” 5 mg/day if CrCl 11-31 mL/min; 5 mg every other day if CrCl <10 mL/min",
    "hepaticAdj": "Yes â€” 5 mg/day in hepatic impairment",
    "pregnancy": "Category B â€” considered safe; one of preferred antihistamines in pregnancy",
    "lactation": "Caution â€” excreted in breast milk; may cause drowsiness in infant",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive sedation",
      "Theophylline â€” slightly reduced cetirizine clearance",
      "Ritonavir â€” increased cetirizine levels"
    ],
    "monitoring": [
      "Symptom control (itching, urticaria, rhinitis)",
      "Sedation level",
      "Renal function (dose adjustment)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "More sedating than fexofenadine or loratadine; advise patients not to drive; avoid alcohol during use."
  },
  {
    "rank": 348,
    "name": "Fexofenadine HCl",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Allegra / Fexova / Telfast",
    "formation": "Carboxylate active metabolite of terfenadine (H1-antihistamine)",
    "uses": "Seasonal allergic rhinitis, chronic idiopathic urticaria",
    "adult": "120â€“180 mg OD",
    "child": "30 mg BID (2â€“11y); 60 mg BID (â‰¥12y)",
    "avoid": "Severe renal impairment (dose reduction needed), concurrent antacids (Al/Mg)",
    "drug": "Fexofenadine HCl",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Dizziness",
      "Drowsiness (mild)",
      "Back pain"
    ],
    "seriousRisks": [
      "QT prolongation (rare, in cardiac patients)",
      "Severe allergic reactions (rare)"
    ],
    "renalAdj": "Yes â€” 60 mg once daily in moderate-severe renal impairment",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution; limited data",
    "lactation": "Caution â€” excreted in breast milk; low levels",
    "drugInteractions": [
      "Fruit juices (grapefruit, orange, apple) â€” reduce fexofenadine absorption by up to 36%; take with water only",
      "Antacids (Al/Mg hydroxide) â€” reduced fexofenadine absorption; separate by 2 hours",
      "Erythromycin/ketoconazole â€” increased fexofenadine levels"
    ],
    "monitoring": [
      "Allergy symptom control",
      "Renal function (dose adjustment)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "180 mg/day (120 mg for allergic rhinitis variants)",
    "clinicalPearl": "Least sedating antihistamine; no CYP450 metabolism; avoid fruit juices â€” they significantly reduce bioavailability."
  },
  {
    "rank": 349,
    "name": "Loratadine",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "OTC",
    "brand": "Lorfast / Clarityn / Loratadine",
    "formation": "Piperidine-type long-acting non-sedating antihistamine (H1-blocker)",
    "uses": "Allergic rhinitis, urticaria",
    "adult": "10 mg OD",
    "child": "5 mg OD (2â€“12y, <30 kg); 10 mg OD (>30 kg)",
    "avoid": "Severe hepatic impairment (dose adjustment or avoid)",
    "drug": "Loratadine",
    "sideEffects": [
      "Headache",
      "Dry mouth",
      "Fatigue",
      "Somnolence (low)",
      "Nausea"
    ],
    "seriousRisks": [
      "QT prolongation (rare, when combined with QT-prolonging drugs)",
      "Severe allergic reactions (rare)"
    ],
    "renalAdj": "Yes â€” 10 mg every other day if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” 10 mg every other day in hepatic impairment",
    "pregnancy": "Category B â€” considered safe; commonly used in pregnancy",
    "lactation": "Caution â€” excreted in breast milk; use with caution",
    "drugInteractions": [
      "CYP3A4/CYP2D6 inhibitors (ketoconazole, erythromycin) â€” increased loratadine levels",
      "CNS depressants â€” minimal additive sedation",
      "QT-prolonging drugs â€” additive QT risk (rare at standard doses)"
    ],
    "monitoring": [
      "Symptom control",
      "Renal and hepatic function (dose adjustment)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Non-sedating; convert to desloratadine (active metabolite) for potentially lower drug interactions and once-daily convenience."
  },
  {
    "rank": 350,
    "name": "Desloratadine",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Neoclarityn / Deslor / Desloratadine",
    "formation": "Active metabolite of loratadine (non-sedating H1-antagonist)",
    "uses": "Seasonal and perennial allergic rhinitis, chronic idiopathic urticaria",
    "adult": "5 mg OD",
    "child": "1.25 mg OD (1â€“5y); 2.5 mg OD (6â€“11y)",
    "avoid": "Severe renal impairment, galactose intolerance",
    "drug": "Desloratadine",
    "sideEffects": [
      "Headache",
      "Dry mouth",
      "Fatigue",
      "Pharyngitis",
      "Myalgia"
    ],
    "seriousRisks": [
      "Severe hypersensitivity (rare)",
      "QT prolongation (very rare)"
    ],
    "renalAdj": "Yes â€” 5 mg every other day in severe renal impairment",
    "hepaticAdj": "Yes â€” 5 mg every other day in hepatic impairment",
    "pregnancy": "Category C â€” use with caution; limited data",
    "lactation": "Caution â€” excreted in breast milk; avoid if possible",
    "drugInteractions": [
      "No significant CYP450-mediated interactions",
      "CNS depressants â€” minimal additive sedation"
    ],
    "monitoring": [
      "Symptom control",
      "Renal/hepatic function (for dose adjustment)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5 mg/day",
    "clinicalPearl": "Active metabolite of loratadine; no CYP450 metabolism â€” fewer drug interactions; safe in patients on multiple medications."
  },
  {
    "rank": 351,
    "name": "Chlorpheniramine Maleate",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "OTC",
    "brand": "Piriton / Allercet / Chlor-Trimeton",
    "formation": "Propylamine-type first-generation H1-antihistamine",
    "uses": "Allergic rhinitis, urticaria, common cold, anaphylaxis (adjunct)",
    "adult": "4 mg every 4â€“6 hrs (max 24 mg/day)",
    "child": "0.1 mg/kg/dose every 6 hrs (â‰¥2y)",
    "avoid": "Narrow-angle glaucoma, urinary retention, concurrent CNS depressants",
    "drug": "Chlorpheniramine Maleate",
    "sideEffects": [
      "Sedation/drowsiness",
      "Dry mouth",
      "Urinary retention",
      "Constipation",
      "Blurred vision"
    ],
    "seriousRisks": [
      "Severe CNS depression",
      "Paradoxical excitation (in children)",
      "Urinary retention (BPH)",
      "Acute angle-closure glaucoma"
    ],
    "renalAdj": "Yes â€” use with caution; reduce dose in renal impairment",
    "hepaticAdj": "Yes â€” use with caution; reduce dose in hepatic impairment",
    "pregnancy": "Category B â€” used cautiously; avoid at term (neonatal withdrawal)",
    "lactation": "Caution â€” excreted in breast milk; anticholinergic effects in infant; avoid prolonged use",
    "drugInteractions": [
      "CNS depressants/alcohol â€” profound additive sedation",
      "MAO inhibitors â€” prolonged anticholinergic effects; avoid",
      "Anticholinergics â€” additive anticholinergic toxicity"
    ],
    "monitoring": [
      "Sedation level",
      "Urinary symptoms",
      "Vision (glaucoma risk)",
      "CIOMS in children"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "24 mg/day (4 mg every 4-6 hours)",
    "clinicalPearl": "First-generation; potent sedation â€” advise not to drive; paradoxical excitation in young children requires monitoring."
  },
  {
    "rank": 352,
    "name": "Montelukast",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Montair / Singulair / Montek",
    "formation": "Cysteinyl leukotriene receptor (CysLT1) antagonist",
    "uses": "Seasonal allergic rhinitis, mild persistent asthma prophylaxis",
    "adult": "10 mg OD (bedtime)",
    "child": "4 mg (2â€“5y); 5 mg (6â€“14y); 10 mg (â‰¥15y)",
    "avoid": "Acute asthma attacks, neuropsychiatric adverse events (monitor closely)",
    "drug": "Montelukast",
    "sideEffects": [
      "Headache",
      "GI discomfort",
      "Elevated transaminases",
      "Dizziness",
      "Rash"
    ],
    "seriousRisks": [
      "Neuropsychiatric events (depression, suicidal ideation, aggression â€” black box warning)",
      "Churg-Strauss syndrome (eosinophilic granulomatosis)",
      "Severe allergic reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in moderate-severe hepatic impairment",
    "pregnancy": "Category B â€” generally considered safe for asthma management in pregnancy",
    "lactation": "Caution â€” excreted in breast milk; insufficient data on infant safety",
    "drugInteractions": [
      "CYP2C8/CYP3A4 inducers (rifampicin) â€” reduced montelukast levels",
      "Gemfibrozil (CYP2C8 inhibitor) â€” increased montelukast levels",
      "Warfarin â€” monitor INR (rare interaction reports)"
    ],
    "monitoring": [
      "Asthma symptom control",
      "Neuropsychiatric symptoms (mood, behavior changes)",
      "LFT"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day (adults); 5 mg/day (6-14 years)",
    "clinicalPearl": "FDA black box warning for neuropsychiatric effects; monitor mood and behavior in all patients, especially children."
  },
  {
    "rank": 353,
    "name": "Ketotifen",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Zaditen / Ketotifen / Kelast",
    "formation": "Benzocycloheptathiophene (mast cell stabilizer + H1-receptor antagonist)",
    "uses": "Prophylaxis of asthma, allergic rhinitis, atopic dermatitis",
    "adult": "1â€“2 mg BID",
    "child": "0.5â€“1 mg BID (â‰¥3y)",
    "avoid": "Concurrent oral hypoglycemic drugs (thrombocytopenia risk), drowsiness warning",
    "drug": "Ketotifen",
    "sideEffects": [
      "Sedation/drowsiness",
      "Dry mouth",
      "Weight gain",
      "Dizziness",
      "Headache"
    ],
    "seriousRisks": [
      "CNS depression",
      "Seizure threshold reduction (in patients with epilepsy)",
      "Thrombocytopenia (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” use with caution; limited data",
    "lactation": "Avoid â€” insufficient safety data; sedation risk in infant",
    "drugInteractions": [
      "CNS depressants/alcohol â€” additive sedation",
      "Oral antidiabetics â€” reversible thrombocytopenia reported; monitor",
      "Antihistamines â€” additive sedation"
    ],
    "monitoring": [
      "Asthma symptom control",
      "Weight",
      "Sedation level",
      "CBC (if on oral antidiabetics)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2 mg/day (1 mg twice daily)",
    "clinicalPearl": "Mast cell stabilizer + H1 blocker; start low (0.5 mg/day) to minimize sedation; eye drop form also used for allergic conjunctivitis."
  },
  {
    "rank": 354,
    "name": "Rupatadine",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Rupanex / Rupatadine / Pafinur",
    "formation": "Dual H1 and PAF (platelet-activating factor) receptor antagonist",
    "uses": "Seasonal and perennial allergic rhinitis, chronic urticaria",
    "adult": "10 mg OD",
    "child": "2.5â€“5 mg OD (â‰¥2y)",
    "avoid": "Severe hepatic/renal impairment, concurrent CYP3A4 inhibitors",
    "drug": "Rupatadine",
    "sideEffects": [
      "Somnolence",
      "Headache",
      "Dizziness",
      "Fatigue",
      "Dry mouth"
    ],
    "seriousRisks": [
      "QT prolongation (at supratherapeutic doses)",
      "CNS depression (higher doses)"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment; primarily hepatically metabolized",
    "pregnancy": "Category C â€” avoid; limited data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "CYP3A4 inhibitors (ketoconazole, erythromycin) â€” increased rupatadine levels and QT prolongation risk",
      "CNS depressants/alcohol â€” additive sedation",
      "QT-prolonging drugs â€” additive risk"
    ],
    "monitoring": [
      "Allergy symptom control",
      "ECG (QTc) in high-risk patients",
      "Sedation level"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Unique dual action: H1 antihistamine + platelet-activating factor (PAF) antagonist; avoid with CYP3A4 inhibitors."
  },
  {
    "rank": 355,
    "name": "Bilastine",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Bilistin / Bilaxten / Bilastine",
    "formation": "Piperidine non-sedating H1-antihistamine (benzimidazole derivative)",
    "uses": "Allergic rhinoconjunctivitis, chronic urticaria",
    "adult": "20 mg OD (on empty stomach)",
    "child": "10 mg OD (4â€“11y, weight >20 kg); 20 mg (â‰¥12y)",
    "avoid": "Severe renal impairment (reduce dose), concurrent P-gp inhibitors",
    "drug": "Bilastine",
    "sideEffects": [
      "Headache",
      "Somnolence (minimal)",
      "Dizziness",
      "Fatigue",
      "Nausea"
    ],
    "seriousRisks": [
      "QT prolongation (at high doses)",
      "Severe hypersensitivity (rare)"
    ],
    "renalAdj": "Yes â€” use with caution in severe renal impairment",
    "hepaticAdj": "No â€” standard dosing (not hepatically metabolized)",
    "pregnancy": "Category C â€” avoid; limited data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Fruit juices (grapefruit, apple, orange) â€” significantly reduce bilastine absorption; take with water only",
      "P-glycoprotein inhibitors (ketoconazole) â€” increased bilastine levels",
      "Erythromycin â€” increased bilastine exposure"
    ],
    "monitoring": [
      "Allergy symptom control",
      "QTc (in high-risk patients)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day",
    "clinicalPearl": "Minimal sedation and no CYP450 metabolism; must be taken on empty stomach (food/fruit juice reduces absorption by 30%)."
  },
  {
    "rank": 356,
    "name": "Omalizumab",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Antiallergic",
    "schedule": "H",
    "brand": "Xolair / Omab / Omalizumab",
    "formation": "Recombinant humanized anti-IgE monoclonal antibody",
    "uses": "Moderate-to-severe allergic asthma (uncontrolled), chronic urticaria",
    "adult": "150â€“375 mg SC every 2â€“4 weeks (dose based on serum IgE level and weight)",
    "child": "â‰¥6y (asthma): 75â€“375 mg SC every 2â€“4 weeks",
    "avoid": "Acute asthma exacerbation, anaphylaxis history (observe post-injection)",
    "drug": "Omalizumab",
    "sideEffects": [
      "Injection site reactions",
      "Headache",
      "Nasopharyngitis",
      "Upper respiratory infections",
      "Arthralgia"
    ],
    "seriousRisks": [
      "Anaphylaxis (0.1-0.2% risk, even after multiple doses)",
      "Malignancies (marginal signal)",
      "Helminth infections (IgE role in parasite defense)",
      "Serum sickness-like reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” limited data; generally considered safe when needed",
    "lactation": "Caution â€” limited data; IgG antibodies detected in breast milk",
    "drugInteractions": [
      "Live vaccines â€” use with caution during immunosuppressive regimens"
    ],
    "monitoring": [
      "FEV1/PEF",
      "Asthma exacerbation rate",
      "Total serum IgE (for dosing)",
      "Anaphylaxis monitoring post-injection (30-60 minutes)",
      "Eosinophil count"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg SC every 2-4 weeks (based on body weight and total IgE level)",
    "clinicalPearl": "Must observe patient 30-60 minutes post-injection; anaphylaxis can occur even after many successful doses."
  },
  {
    "rank": 357,
    "name": "Pirfenidone",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Esbriet / Pirfenidone / Pirespa",
    "formation": "Pyridinone antifibrotic agent (TGF-Î², TNF-Î±, and PDGF inhibitor)",
    "uses": "Idiopathic pulmonary fibrosis (IPF) â€“ slows disease progression",
    "adult": "267 mg TID (wk 1â€“2), 534 mg TID (wk 3â€“4), 801 mg TID (wk â‰¥5)",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment, concurrent fluvoxamine, photosensitivity (sunscreen essential)",
    "drug": "Pirfenidone",
    "sideEffects": [
      "Nausea",
      "Rash/photosensitivity",
      "Fatigue",
      "Anorexia",
      "Dizziness"
    ],
    "seriousRisks": [
      "Hepatotoxicity (elevated liver enzymes)",
      "Severe photosensitivity",
      "Severe GI adverse events"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment (CrCl <30 mL/min) or ESRD",
    "hepaticAdj": "Yes â€” avoid in moderate-severe hepatic impairment; monitor LFT",
    "pregnancy": "Category C â€” avoid; insufficient data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) â€” markedly increased pirfenidone levels; avoid",
      "CYP1A2 inducers (smoking) â€” reduced pirfenidone levels; counsel smoking cessation",
      "Omeprazole â€” mild increase in pirfenidone levels"
    ],
    "monitoring": [
      "LFT (monthly for 6 months, then 3 monthly)",
      "Pulmonary function (FVC)",
      "Photosensitivity/skin status",
      "GI tolerance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2403 mg/day (801 mg three times daily)",
    "clinicalPearl": "Always take with food to reduce GI adverse effects; strict sun protection mandatory â€” use SPF 50+ sunscreen daily."
  },
  {
    "rank": 358,
    "name": "Nintedanib Esylate",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Ofev / Nintedanib / Vargatef",
    "formation": "Triple kinase inhibitor (VEGFR, FGFR, PDGFR) â€“ antifibrotic",
    "uses": "Idiopathic pulmonary fibrosis (IPF), systemic sclerosis-ILD, other fibrosing ILDs",
    "adult": "150 mg BID (with food)",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment (Child-Pugh B/C), concurrent anticoagulants (bleeding risk)",
    "drug": "Nintedanib Esylate",
    "sideEffects": [
      "Diarrhea",
      "Nausea",
      "Vomiting",
      "Abdominal pain",
      "Elevated liver enzymes"
    ],
    "seriousRisks": [
      "Hepatotoxicity",
      "Bleeding/hemorrhage",
      "GI perforation",
      "Arterial thromboembolism",
      "Fetal harm (Category D)"
    ],
    "renalAdj": "No â€” standard dosing in mild-moderate renal impairment",
    "hepaticAdj": "Yes â€” contraindicated in moderate-severe hepatic impairment (Child-Pugh B/C); 100 mg BD in mild impairment",
    "pregnancy": "Category D â€” absolutely contraindicated; embryotoxic (anti-VEGF mechanism)",
    "lactation": "Avoid â€” potential harm to infant",
    "drugInteractions": [
      "P-glycoprotein inhibitors (ketoconazole) â€” increased nintedanib levels",
      "P-glycoprotein inducers (rifampicin, carbamazepine) â€” significantly reduced efficacy",
      "Anticoagulants â€” additive bleeding risk"
    ],
    "monitoring": [
      "LFT (monthly for 3 months, then 3 monthly)",
      "FVC/DLCO",
      "Signs of bleeding",
      "GI symptoms",
      "Pregnancy test"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "300 mg/day (150 mg twice daily)",
    "clinicalPearl": "Take with food at same time each day; diarrhea in majority of patients â€” proactive antidiarrheal management reduces discontinuation."
  },
  {
    "rank": 359,
    "name": "Erdosteine",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Erdotin / Erdos / Orcerin",
    "formation": "Thiol derivative mucolytic agent (indirect mucokinetic)",
    "uses": "Chronic obstructive pulmonary disease, chronic bronchitis",
    "adult": "300 mg BIDâ€“TID",
    "child": "Consult specialist (limited data)",
    "avoid": "Cystinuria, homocystinuria, active peptic ulcer",
    "drug": "Erdosteine",
    "sideEffects": [
      "Nausea",
      "GI discomfort",
      "Headache",
      "Diarrhea",
      "Allergic reactions (rare)"
    ],
    "seriousRisks": [
      "Severe allergic reactions (rare)",
      "Liver function test abnormalities"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment (CrCl <25 mL/min)",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid in first trimester; use only when necessary",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Antibiotics â€” may enhance antibiotic penetration into bronchial secretions",
      "Antitussives â€” avoid combination"
    ],
    "monitoring": [
      "Sputum characteristics",
      "Respiratory symptoms",
      "LFT (if prolonged use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "900 mg/day (300 mg three times daily)",
    "clinicalPearl": "Antioxidant mucolytic with free radical scavenging; useful in COPD exacerbations; reduces exacerbation frequency."
  },
  {
    "rank": 360,
    "name": "Carbocisteine",
    "section": "Section 9: Respiratory, Allergy & ENT",
    "category": "Respiratory",
    "schedule": "H",
    "brand": "Solmux / Mucodyne / Carbocisteine",
    "formation": "S-carboxymethylcysteine (mucoregulatory agent â€“ modifies mucus glycoproteins)",
    "uses": "Respiratory tract hypersecretion, COPD, chronic bronchitis",
    "adult": "750 mg TID initially, reduce to 500 mg TID",
    "child": "62.5â€“125 mg TID (2â€“12y)",
    "avoid": "Active peptic ulceration, first trimester of pregnancy",
    "drug": "Carbocisteine",
    "sideEffects": [
      "Nausea",
      "Gastric irritation",
      "Diarrhea",
      "Skin rash",
      "Headache"
    ],
    "seriousRisks": [
      "GI hemorrhage (with peptic ulcer disease)",
      "Severe allergic reactions (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” avoid in first trimester",
    "lactation": "Caution â€” insufficient data; avoid if possible",
    "drugInteractions": [
      "Antitussives â€” avoid combination (impairs mucus clearance)",
      "NSAIDs â€” additive GI irritation"
    ],
    "monitoring": [
      "Sputum volume and consistency",
      "GI symptoms",
      "Respiratory function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2250 mg/day (750 mg three times daily)",
    "clinicalPearl": "Contraindicated in active peptic ulcer disease; modifies mucus structure â€” not just viscosity; useful in COPD and bronchiectasis."
  },
  {
    "rank": 361,
    "name": "Tamsulosin HCl",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Urimax / Flomax / Tamsulosin",
    "formation": "Selective alpha1A/1D-adrenergic receptor blocker (uroselective)",
    "uses": "Benign prostatic hyperplasia (BPH), ureteral calculi expulsion (medical expulsion therapy)",
    "adult": "0.4 mg OD (30 min after breakfast)",
    "child": "Not recommended",
    "avoid": "Orthostatic hypotension, concurrent PDE5 inhibitors, sulfa drug allergy",
    "drug": "Tamsulosin HCl",
    "sideEffects": [
      "Ejaculatory dysfunction/retrograde ejaculation",
      "Dizziness/orthostatic hypotension",
      "Headache",
      "Rhinitis",
      "Asthenia"
    ],
    "seriousRisks": [
      "Intraoperative Floppy Iris Syndrome (IFIS â€” cataract surgery)",
      "Orthostatic hypotension/syncope",
      "Priapism (rare)"
    ],
    "renalAdj": "No â€” standard dosing in mild-moderate impairment; use with caution in severe impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Not indicated in women",
    "lactation": "Not applicable",
    "drugInteractions": [
      "PDE5 inhibitors (sildenafil, tadalafil) â€” severe hypotension; use with extreme caution",
      "Strong CYP3A4 inhibitors (ketoconazole) â€” increased tamsulosin levels",
      "Antihypertensives â€” additive hypotension"
    ],
    "monitoring": [
      "BP (orthostatic)",
      "Urinary flow rate and symptom scores (IPSS)",
      "IFIS risk (inform ophthalmologist before cataract surgery)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.4 mg/day",
    "clinicalPearl": "Inform ophthalmologist before any ocular surgery â€” IFIS risk persists even after stopping tamsulosin; take 30 min after same meal daily."
  },
  {
    "rank": 362,
    "name": "Alfuzosin HCl",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Xatral / Alfoo / Alfuzosin",
    "formation": "Quinazolinamine selective alpha1-adrenergic receptor blocker",
    "uses": "Symptomatic BPH, ureteral stone passage",
    "adult": "2.5 mg TID or 10 mg XR OD (after dinner)",
    "child": "Not recommended",
    "avoid": "Severe hepatic impairment, orthostatic hypotension, QT prolongation",
    "drug": "Alfuzosin HCl",
    "sideEffects": [
      "Dizziness",
      "Headache",
      "Fatigue",
      "Hypotension",
      "GI discomfort"
    ],
    "seriousRisks": [
      "Orthostatic hypotension/syncope",
      "QT prolongation",
      "IFIS (cataract surgery)",
      "Priapism (rare)"
    ],
    "renalAdj": "Yes â€” use with caution in moderate renal impairment; avoid in severe impairment",
    "hepaticAdj": "Yes â€” contraindicated in moderate-severe hepatic impairment",
    "pregnancy": "Not indicated in women",
    "lactation": "Not applicable",
    "drugInteractions": [
      "PDE5 inhibitors â€” additive severe hypotension",
      "CYP3A4 inhibitors (ketoconazole, itraconazole) â€” significantly increased alfuzosin levels; contraindicated",
      "Antihypertensives â€” additive hypotension"
    ],
    "monitoring": [
      "BP (orthostatic)",
      "IPSS symptom score",
      "QTc (in cardiac patients)",
      "ECG if QT risk"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day (extended release)",
    "clinicalPearl": "Uro-selective; less ejaculatory dysfunction vs tamsulosin; contraindicated with potent CYP3A4 inhibitors."
  },
  {
    "rank": 363,
    "name": "Solifenacin Succinate",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Vesicare / Soliflow / Urifit",
    "formation": "Selective M3 muscarinic receptor antagonist",
    "uses": "Overactive bladder (urgency urinary incontinence, frequency)",
    "adult": "5â€“10 mg OD",
    "child": "Not recommended",
    "avoid": "Urinary retention, narrow-angle glaucoma, severe GI motility disorder",
    "drug": "Solifenacin Succinate",
    "sideEffects": [
      "Dry mouth",
      "Constipation",
      "Blurred vision",
      "Urinary retention",
      "Somnolence"
    ],
    "seriousRisks": [
      "Urinary retention (in patients with BPO/BPH)",
      "Acute angle-closure glaucoma",
      "QT prolongation",
      "CNS effects (cognitive impairment in elderly)"
    ],
    "renalAdj": "Yes â€” maximum 5 mg/day if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” maximum 5 mg/day in moderate hepatic impairment; avoid in severe impairment",
    "pregnancy": "Category C â€” avoid; anticholinergic risks",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Strong CYP3A4 inhibitors (ketoconazole) â€” doubled solifenacin exposure; reduce dose to 5 mg",
      "QT-prolonging drugs â€” additive QT risk",
      "Other anticholinergics â€” additive adverse effects"
    ],
    "monitoring": [
      "Urinary symptoms/flow",
      "Post-void residual volume",
      "QTc",
      "Signs of urinary retention",
      "Cognitive status in elderly"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day",
    "clinicalPearl": "Contraindicated in uncontrolled narrow-angle glaucoma and urinary retention; assess post-void residual urine before prescribing."
  },
  {
    "rank": 364,
    "name": "Oxybutynin Chloride",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Ditropan / Oxytrol / Cyspas",
    "formation": "Tertiary amine anticholinergic + smooth muscle relaxant",
    "uses": "Overactive bladder, neurogenic bladder, nocturnal enuresis",
    "adult": "5 mg BIDâ€“TID or 5â€“15 mg/day (ER)",
    "child": "0.2 mg/kg BIDâ€“TID (â‰¥5y)",
    "avoid": "Urinary retention, GI obstruction, myasthenia gravis, uncontrolled glaucoma",
    "drug": "Oxybutynin Chloride",
    "sideEffects": [
      "Dry mouth (most common)",
      "Constipation",
      "Blurred vision",
      "Urinary retention",
      "Tachycardia"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma",
      "Urinary retention",
      "Heat stroke (anticholinergic)",
      "Cognitive impairment/dementia risk (elderly)",
      "QT prolongation"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” use with caution",
    "lactation": "Caution â€” anticholinergic effects in infant; may reduce milk production",
    "drugInteractions": [
      "Anticholinergics â€” additive adverse effects (avoid combination)",
      "CNS depressants â€” additive sedation",
      "Ketoconazole/CYP3A4 inhibitors â€” increased oxybutynin levels"
    ],
    "monitoring": [
      "Urinary symptoms",
      "Post-void residual",
      "Cognitive status (elderly)",
      "IOP",
      "Heart rate"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "20 mg/day (5 mg four times daily); extended release: 30 mg/day",
    "clinicalPearl": "Most anticholinergic adverse effects among OAB agents; transdermal formulation reduces dry mouth; avoid in elderly (Beers criteria)."
  },
  {
    "rank": 365,
    "name": "Mirabegron",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Betmiga / Myrbetriq / Mirabegron",
    "formation": "Beta-3 adrenergic receptor agonist (non-antimuscarinic OAB agent)",
    "uses": "Overactive bladder (urgency, incontinence) â€“ alternative when antimuscarinics are not tolerated",
    "adult": "25â€“50 mg OD",
    "child": "Not approved for adults <18y",
    "avoid": "Severe uncontrolled hypertension (SBP â‰¥180 mmHg), severe renal impairment (25 mg only)",
    "drug": "Mirabegron",
    "sideEffects": [
      "Hypertension",
      "Nasopharyngitis",
      "Urinary tract infection",
      "Tachycardia",
      "Headache"
    ],
    "seriousRisks": [
      "Severe hypertension",
      "Urinary retention (in BOO/BPH)",
      "Angioedema (rare)",
      "Atrial fibrillation (rare)"
    ],
    "renalAdj": "Yes â€” maximum 25 mg/day if CrCl 15-29 mL/min; avoid if CrCl <15 mL/min",
    "hepaticAdj": "Yes â€” maximum 25 mg/day in moderate hepatic impairment; avoid in severe impairment",
    "pregnancy": "Category C â€” avoid; limited data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "CYP2D6 substrates (metoprolol, desipramine) â€” inhibits CYP2D6; may increase substrate levels",
      "Digoxin â€” increased digoxin levels; use lowest digoxin dose and monitor",
      "Warfarin â€” modest INR increase; monitor"
    ],
    "monitoring": [
      "BP (before and during therapy)",
      "Urinary symptoms/flow",
      "Post-void residual",
      "HR (tachycardia)",
      "Digoxin levels (if co-administered)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "50 mg/day",
    "clinicalPearl": "Non-anticholinergic OAB treatment â€” preferred in elderly and patients with cognitive impairment or glaucoma; monitor BP at initiation."
  },
  {
    "rank": 366,
    "name": "Tolterodine Tartrate",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Detrol / Tolterol / Tolterodine",
    "formation": "Muscarinic receptor antagonist (bladder-selective profile)",
    "uses": "Overactive bladder (OAB) with urge incontinence",
    "adult": "2 mg BID or 4 mg ER OD",
    "child": "Not recommended",
    "avoid": "Urinary retention, gastric retention, narrow-angle glaucoma",
    "drug": "Tolterodine Tartrate",
    "sideEffects": [
      "Dry mouth",
      "Headache",
      "Constipation",
      "Abdominal pain",
      "Dizziness"
    ],
    "seriousRisks": [
      "Urinary retention",
      "Acute angle-closure glaucoma",
      "QT prolongation",
      "Cognitive impairment (elderly)"
    ],
    "renalAdj": "Yes â€” 1 mg twice daily in severe renal impairment",
    "hepaticAdj": "Yes â€” 1 mg twice daily in hepatic impairment; avoid severe impairment",
    "pregnancy": "Category C â€” avoid; anticholinergic",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "CYP3A4 inhibitors (ketoconazole, clarithromycin) â€” increased tolterodine levels; reduce dose",
      "QT-prolonging drugs â€” additive risk",
      "Other anticholinergics â€” additive effects"
    ],
    "monitoring": [
      "Urinary symptoms (urgency, frequency)",
      "Post-void residual",
      "QTc",
      "Cognitive status (elderly)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 mg/day (2 mg twice daily); ER formulation: 4 mg once daily",
    "clinicalPearl": "More bladder-selective than oxybutynin; less dry mouth; extended-release formulation improves tolerability and compliance."
  },
  {
    "rank": 367,
    "name": "Tadalafil",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Megalis / Cialis / Forzest",
    "formation": "Long-acting phosphodiesterase-5 (PDE5) inhibitor",
    "uses": "Erectile dysfunction, BPH symptoms, pulmonary arterial hypertension",
    "adult": "10â€“20 mg PRN (ED); 5 mg OD (BPH/daily ED); 40 mg OD (PAH)",
    "child": "Not recommended",
    "avoid": "Concurrent nitrate use, severe hypotension, LVOT obstruction, severe renal/hepatic disease",
    "drug": "Tadalafil",
    "sideEffects": [
      "Headache",
      "Dyspepsia",
      "Back pain",
      "Myalgia",
      "Flushing"
    ],
    "seriousRisks": [
      "Severe hypotension (with nitrates â€” absolute contraindication)",
      "Non-arteritic anterior ischemic optic neuropathy (NAION)",
      "Priapism",
      "Sudden hearing loss"
    ],
    "renalAdj": "Yes â€” 10 mg max every 48 hours if CrCl 30-50 mL/min; 5 mg max if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” maximum 10 mg in mild-moderate impairment; avoid in severe impairment",
    "pregnancy": "Category B â€” not indicated in women (approved for PAH in women)",
    "lactation": "Caution â€” insufficient data for PAH use in lactating women",
    "drugInteractions": [
      "Nitrates (isosorbide, GTN) â€” severe, potentially fatal hypotension; absolutely contraindicated",
      "Alpha-blockers â€” severe hypotension; start at lowest dose",
      "CYP3A4 inhibitors (ritonavir) â€” increased tadalafil levels; dose reduction required"
    ],
    "monitoring": [
      "BP and HR",
      "Cardiac status",
      "Visual symptoms",
      "Renal/hepatic function (for dosing)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "20 mg/day (ED, as-needed); 5 mg/day (BPH/daily dosing ED); 40 mg/day (PAH)",
    "clinicalPearl": "Longest acting PDE5 inhibitor (36 hours); absolutely contraindicated with all nitrates; also approved for BPH and PAH."
  },
  {
    "rank": 368,
    "name": "Dutasteride + Tamsulosin",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Duodart / Combodart / Dynapress",
    "formation": "Dual 5-alpha-reductase inhibitor + uroselective alpha1-blocker combination",
    "uses": "Moderate-to-severe symptomatic BPH requiring combination therapy",
    "adult": "Dutasteride 0.5 mg + Tamsulosin 0.4 mg OD",
    "child": "Not recommended",
    "avoid": "Women (especially pregnant), severe hepatic impairment, severe orthostatic hypotension",
    "drug": "Dutasteride + Tamsulosin",
    "sideEffects": [
      "Erectile dysfunction",
      "Ejaculatory dysfunction",
      "Decreased libido",
      "Dizziness",
      "Breast tenderness/gynecomastia"
    ],
    "seriousRisks": [
      "High-grade prostate cancer (dutasteride component â€” black box warning)",
      "IFIS during cataract surgery (tamsulosin component)",
      "Orthostatic hypotension"
    ],
    "renalAdj": "No â€” standard dosing for dutasteride; tamsulosin caution in severe impairment",
    "hepaticAdj": "Yes â€” dutasteride contraindicated in severe hepatic impairment",
    "pregnancy": "Absolutely contraindicated in women â€” dutasteride is teratogenic; pregnant women should not handle capsules",
    "lactation": "Not indicated in women",
    "drugInteractions": [
      "PDE5 inhibitors â€” additive hypotension (tamsulosin component)",
      "CYP3A4 inhibitors â€” increased dutasteride/tamsulosin levels",
      "Warfarin â€” dutasteride may slightly reduce warfarin clearance"
    ],
    "monitoring": [
      "PSA (baseline, 3-6 months, then yearly â€” dutasteride halves PSA)",
      "IPSS symptom score",
      "Urinary flow rate",
      "BP (orthostatic)",
      "IFIS risk (inform ophthalmologist)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Dutasteride 0.5 mg + Tamsulosin 0.4 mg once daily",
    "clinicalPearl": "Dutasteride halves PSA â€” multiply PSA by 2 for true baseline; warn about sexual side effects at treatment initiation."
  },
  {
    "rank": 369,
    "name": "Phenazopyridine HCl",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Pyridium / Uristat / Phenazopyridine",
    "formation": "Azo dye (urinary tract analgesic â€“ not an antibiotic)",
    "uses": "Symptomatic relief of burning, urgency, and pain in UTI (adjunct to antibiotic)",
    "adult": "200 mg TID after meals (max 2 days)",
    "child": "4 mg/kg TID (â‰¥6y)",
    "avoid": "Hepatic impairment, renal failure (orange/red urine discoloration â€“ inform patient)",
    "drug": "Phenazopyridine HCl",
    "sideEffects": [
      "Orange-red urine/bodily fluids",
      "GI upset",
      "Headache",
      "Dizziness",
      "Skin discoloration"
    ],
    "seriousRisks": [
      "Methemoglobinemia (especially with renal impairment)",
      "Hemolytic anemia (G6PD deficiency)",
      "Hepatotoxicity (prolonged use)",
      "Masking of UTI symptoms"
    ],
    "renalAdj": "Yes â€” avoid in renal impairment (CrCl <50 mL/min); toxic metabolite accumulation",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment",
    "pregnancy": "Category B â€” use with caution; avoid near term",
    "lactation": "Avoid â€” insufficient safety data",
    "drugInteractions": [
      "Urinary alkalinizers â€” altered drug distribution",
      "G6PD-stressing drugs â€” additive hemolysis risk"
    ],
    "monitoring": [
      "Urine color (normal orange-red expected)",
      "Renal function",
      "CBC (hemolysis signs)",
      "Urinary symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day (200 mg three times daily) â€” maximum 2 days",
    "clinicalPearl": "Analgesic only â€” not an antibiotic; warn patients urine will turn orange-red; use maximum 2 days until antibiotic takes effect."
  },
  {
    "rank": 370,
    "name": "Bethanechol Chloride",
    "section": "Section 10: Specialty & Emerging",
    "category": "Urology",
    "schedule": "H",
    "brand": "Myotonine / Urecholine / Bethacol",
    "formation": "Synthetic carbamate choline ester (direct muscarinic cholinergic agonist)",
    "uses": "Neurogenic bladder, postoperative urinary retention, GERD adjunct",
    "adult": "10â€“50 mg TIDâ€“QID",
    "child": "0.3â€“0.6 mg/kg/day in 3â€“4 divided doses",
    "avoid": "Asthma, bradycardia, hypotension, GI/bladder obstruction, peptic ulcer",
    "drug": "Bethanechol Chloride",
    "sideEffects": [
      "Sweating",
      "Flushing",
      "Nausea/vomiting",
      "Abdominal cramps",
      "Bradycardia"
    ],
    "seriousRisks": [
      "Severe bronchospasm (asthma patients)",
      "Cardiac arrest (rapid absorption)",
      "Severe hypotension",
      "Cholinergic crisis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” use with caution",
    "lactation": "Caution â€” cholinergic effects possible in infant",
    "drugInteractions": [
      "Anticholinergics (atropine) â€” antagonism; used to treat bethanechol toxicity",
      "Ganglionic blockers â€” severe hypotension",
      "Cholinesterase inhibitors â€” additive cholinergic effects"
    ],
    "monitoring": [
      "Urinary output/flow",
      "BP and HR",
      "Bowel sounds",
      "Signs of cholinergic excess (sweating, bronchospasm)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "200 mg/day (25-50 mg four times daily orally)",
    "clinicalPearl": "Never give IV (cardiac arrest risk); atropine must be available as antidote; contraindicated in asthma and mechanical urinary obstruction."
  },
  {
    "rank": 371,
    "name": "Alendronate Sodium",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Osteofos / Fosamax / Alendromax",
    "formation": "Aminobisphosphonate (nitrogen-containing â€“ osteoclast inhibitor)",
    "uses": "Osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease of bone",
    "adult": "10 mg OD or 70 mg once weekly (fasting, plain water, upright 30 min)",
    "child": "Not recommended",
    "avoid": "Hypocalcemia, esophageal abnormalities, inability to sit or stand upright for 30 min",
    "drug": "Alendronate Sodium",
    "sideEffects": [
      "Esophageal irritation/esophagitis",
      "Abdominal pain",
      "Musculoskeletal pain",
      "Nausea",
      "Diarrhea"
    ],
    "seriousRisks": [
      "Osteonecrosis of the jaw (ONJ)",
      "Atypical femoral fractures",
      "Severe esophageal reactions (stricture, ulcer)",
      "Hypocalcemia"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <35 mL/min; risk of renal accumulation",
    "hepaticAdj": "No â€” standard dosing (not hepatically metabolized)",
    "pregnancy": "Category C â€” avoid; potential fetal harm (skeletal mineralization effects)",
    "lactation": "Caution â€” minimal absorption in infant; avoid prolonged use",
    "drugInteractions": [
      "Calcium supplements/antacids â€” reduce alendronate absorption by >60%; separate by 2+ hours",
      "NSAIDs â€” additive GI irritation",
      "Aspirin â€” increased GI side effects"
    ],
    "monitoring": [
      "Bone mineral density (DEXA scan â€” annually)",
      "Serum calcium and phosphate",
      "Renal function",
      "Oral examination (ONJ)",
      "Musculoskeletal pain"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "70 mg once weekly (osteoporosis) or 10 mg/day",
    "clinicalPearl": "Take with plain water on empty stomach; remain upright for 30 minutes after; do not take with food, coffee, or other medications."
  },
  {
    "rank": 372,
    "name": "Zoledronic Acid",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Zometa / Aclasta / Zoledronate",
    "formation": "Imidazole bisphosphonate (intravenous â€“ most potent bisphosphonate)",
    "uses": "Osteoporosis, hypercalcemia of malignancy, Paget's disease, bone metastases",
    "adult": "4 mg IV once (oncology) or 5 mg IV once yearly (osteoporosis)",
    "child": "0.025â€“0.05 mg/kg IV (osteogenesis imperfecta; specialist supervised)",
    "avoid": "Severe renal impairment (CrCl <35 mL/min), hypocalcemia, osteonecrosis of jaw risk",
    "drug": "Zoledronic Acid",
    "sideEffects": [
      "Flu-like syndrome (post-infusion)",
      "Hypocalcemia",
      "Musculoskeletal pain",
      "Fatigue",
      "Nausea"
    ],
    "seriousRisks": [
      "Osteonecrosis of the jaw (ONJ)",
      "Atypical femoral fractures",
      "Nephrotoxicity (renal impairment)",
      "Severe hypocalcemia",
      "Uveitis/scleritis"
    ],
    "renalAdj": "Yes â€” adjust dose based on CrCl; avoid if CrCl <35 mL/min (osteoporosis indication); dose reduction in oncology use for CrCl 30-60 mL/min",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category D â€” avoid; embryotoxic bisphosphonate",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Nephrotoxic agents (aminoglycosides, NSAIDs) â€” additive nephrotoxicity",
      "Calcium supplements â€” may reduce zoledronic acid efficacy if taken too close to infusion",
      "Thalidomide â€” increased nephrotoxicity risk in myeloma"
    ],
    "monitoring": [
      "Renal function (creatinine before each dose)",
      "Serum calcium (and correct before infusion)",
      "Phosphate and magnesium",
      "Dental examination before initiation (ONJ)",
      "CBC"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "4 mg IV over 15+ minutes every 3-4 weeks (oncology); 5 mg IV once yearly (osteoporosis)",
    "clinicalPearl": "Dental check mandatory before starting; maintain adequate calcium/Vitamin D supplementation; infuse over minimum 15 minutes to reduce nephrotoxicity."
  },
  {
    "rank": 373,
    "name": "Teriparatide",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Forsteo / Osteoace / Teribone",
    "formation": "Recombinant human PTH 1â€“34 (anabolic bone-forming agent)",
    "uses": "Severe osteoporosis at high fracture risk, glucocorticoid-induced osteoporosis",
    "adult": "20 mcg SC OD (maximum 2 years lifetime use)",
    "child": "Not recommended",
    "avoid": "Prior radiation to skeleton, Paget's disease, bone malignancy, hypercalcemia",
    "drug": "Teriparatide",
    "sideEffects": [
      "Nausea",
      "Dizziness",
      "Leg cramps",
      "Hypercalcemia (transient)",
      "Injection site reactions"
    ],
    "seriousRisks": [
      "Osteosarcoma risk (black box â€” seen in rat studies at high doses)",
      "Hypercalcemia",
      "Hypotension (orthostatic)",
      "Urolithiasis"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment (CrCl <30 mL/min); hypercalcemia risk",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Digoxin â€” hypercalcemia increases digoxin toxicity risk",
      "Thiazide diuretics â€” additive hypercalcemia",
      "Calcium supplements â€” may worsen hypercalcemia; monitor levels"
    ],
    "monitoring": [
      "Serum calcium and phosphate",
      "Renal function",
      "Urinary calcium (24h collection)",
      "Bone turnover markers",
      "Bone density (DEXA) at 18-24 months"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "20 mcg SC once daily (maximum treatment duration 24 months)",
    "clinicalPearl": "Only anabolic (bone-forming) osteoporosis treatment; limited to 24 months lifetime use; refrigerate pen â€” allow to warm before injection."
  },
  {
    "rank": 374,
    "name": "Denosumab",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Prolia / Xgeva / Denosumab",
    "formation": "Human anti-RANKL monoclonal antibody (bone resorption inhibitor)",
    "uses": "Postmenopausal osteoporosis, bone metastases (solid tumors), GCTB",
    "adult": "60 mg SC every 6 months (Prolia); 120 mg SC every 4 weeks (Xgeva)",
    "child": "Consult specialist for Xgeva; Prolia not for pediatrics",
    "avoid": "Hypocalcemia, osteonecrosis of jaw risk (dental check prior to treatment)",
    "drug": "Denosumab",
    "sideEffects": [
      "Hypocalcemia",
      "Infections (UTI, URTI)",
      "Back pain",
      "Musculoskeletal pain",
      "Injection site reactions"
    ],
    "seriousRisks": [
      "Severe hypocalcemia (potentially fatal if calcium not corrected first)",
      "Osteonecrosis of the jaw",
      "Atypical femoral fractures",
      "Rebound vertebral fractures (on discontinuation)",
      "Serious infections"
    ],
    "renalAdj": "Yes â€” severe risk of hypocalcemia in CKD/ESRD patients; requires careful calcium monitoring and supplementation",
    "hepaticAdj": "No â€” standard dosing (not hepatically metabolized)",
    "pregnancy": "Category X â€” contraindicated; fetal bone development risk",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Calcium/Vitamin D supplements â€” required co-administration to prevent hypocalcemia",
      "Immunosuppressants â€” additive infection risk",
      "Other bisphosphonates â€” do not combine"
    ],
    "monitoring": [
      "Serum calcium (before each dose and regularly)",
      "Renal function",
      "Oral dental examination (ONJ)",
      "Signs of infection",
      "Bone density (DEXA)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "60 mg SC every 6 months (osteoporosis); 120 mg SC every 4 weeks (bone metastases)",
    "clinicalPearl": "Correct hypocalcemia BEFORE initiation; rebound fractures can occur on discontinuation â€” transition to bisphosphonate when stopping."
  },
  {
    "rank": 375,
    "name": "Colchicine",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Colchicine / Colmibe / Zycolchine",
    "formation": "Alkaloid from Colchicum autumnale (anti-tubulin, anti-inflammatory)",
    "uses": "Acute gout attack, FMF (Familial Mediterranean Fever) prophylaxis, pericarditis",
    "adult": "1â€“1.2 mg stat, then 0.5â€“0.6 mg every 1â€“2 hrs (acute gout, max 6 mg/course)",
    "child": "0.3â€“1.8 mg/day (FMF â‰¥5y)",
    "avoid": "Severe renal/hepatic impairment, concurrent strong CYP3A4 inhibitors (clarithromycin etc.)",
    "drug": "Colchicine",
    "sideEffects": [
      "Diarrhea",
      "Nausea/vomiting",
      "Abdominal cramps",
      "Myopathy (long-term)",
      "Leukopenia"
    ],
    "seriousRisks": [
      "Severe myelosuppression",
      "Multi-organ failure (overdose)",
      "Neuromyopathy (especially with CsA/statins)",
      "Rhabdomyolysis",
      "Life-threatening toxicity in overdose"
    ],
    "renalAdj": "Yes â€” reduce dose significantly in renal impairment; toxic metabolite accumulation; dialysis patients: 0.3 mg 2-3 times/week",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” use with caution in FMF; human data shows relative safety at therapeutic doses",
    "lactation": "Caution â€” excreted in breast milk; use lowest effective dose",
    "drugInteractions": [
      "CYP3A4 inhibitors (clarithromycin, cyclosporine) â€” potentially fatal colchicine toxicity; dose reduce or avoid",
      "P-glycoprotein inhibitors â€” increased colchicine levels",
      "Statins â€” additive myopathy risk"
    ],
    "monitoring": [
      "CBC",
      "Renal function",
      "LFT",
      "Muscle symptoms (CK if myopathy suspected)",
      "GI tolerance"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1.8 mg on day 1 (for acute gout); 1.2 mg/day for prophylaxis",
    "clinicalPearl": "Narrow therapeutic-to-toxic window; clarithromycin co-administration has caused deaths â€” reduce dose to 0.3 mg BID max."
  },
  {
    "rank": 376,
    "name": "Allopurinol",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Zyloric / Lopurin / Allopurinol",
    "formation": "Hypoxanthine analog (xanthine oxidase inhibitor â€“ urate-lowering agent)",
    "uses": "Chronic gout and hyperuricemia, tumor lysis syndrome prevention",
    "adult": "100â€“300 mg OD (after meals; titrate to serum urate <6 mg/dL)",
    "child": "100â€“300 mg/day (tumor lysis syndrome)",
    "avoid": "Allopurinol hypersensitivity syndrome, azathioprine/6-MP without dose reduction",
    "drug": "Allopurinol",
    "sideEffects": [
      "Rash",
      "Nausea",
      "Diarrhea",
      "Elevated liver enzymes",
      "Drowsiness"
    ],
    "seriousRisks": [
      "Allopurinol hypersensitivity syndrome (AHS) â€” life-threatening SJS/TEN/DRESS",
      "HLA-B*5801 associated severe reactions (especially in Han Chinese, Thai, Korean)",
      "Aplastic anemia",
      "Hepatic necrosis",
      "Allopurinol-induced vasculitis"
    ],
    "renalAdj": "Yes â€” start low (50-100 mg/day) and titrate up; reduce dose based on CrCl; 100 mg every 3 days if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” use only if essential; some human data available",
    "lactation": "Caution â€” excreted in breast milk; use lowest effective dose",
    "drugInteractions": [
      "Azathioprine/6-MP â€” life-threatening myelosuppression (reduce AZA/6-MP dose by 75%)",
      "Warfarin â€” enhanced anticoagulation; monitor INR",
      "Ampicillin/amoxicillin â€” increased rash incidence"
    ],
    "monitoring": [
      "Serum uric acid (target <6 mg/dL, <5 mg/dL in tophi)",
      "Renal function",
      "LFT",
      "CBC",
      "Skin (rash â€” early sign of AHS)",
      "HLA-B*5801 testing in high-risk populations"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "800 mg/day (titrate slowly starting from 100 mg/day)",
    "clinicalPearl": "HLA-B*5801 screening before use in Southeast Asian populations prevents life-threatening hypersensitivity syndrome."
  },
  {
    "rank": 377,
    "name": "Febuxostat",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Febustat / Zurig / Fequin",
    "formation": "Non-purine selective xanthine oxidase inhibitor",
    "uses": "Hyperuricemia in gout (when allopurinol is contraindicated or not tolerated)",
    "adult": "40â€“80 mg OD",
    "child": "Not recommended",
    "avoid": "Cardiovascular disease (higher CV risk vs allopurinol), concurrent azathioprine/6-MP",
    "drug": "Febuxostat",
    "sideEffects": [
      "Liver enzyme elevation",
      "Nausea",
      "Arthralgia",
      "Rash",
      "Edema"
    ],
    "seriousRisks": [
      "Cardiovascular mortality risk (vs allopurinol â€” FDA warning)",
      "Severe rash (SJS/TEN)",
      "Hepatotoxicity",
      "Acute gout flare on initiation"
    ],
    "renalAdj": "No â€” standard dosing up to severe CKD (advantage over allopurinol); no dose adjustment needed if CrCl >15 mL/min",
    "hepaticAdj": "Yes â€” avoid in moderate-severe hepatic impairment; monitor LFT",
    "pregnancy": "Category C â€” avoid; limited data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Azathioprine/6-MP/theophylline â€” inhibits xanthine oxidase; increased levels of these drugs (fatal toxicity risk)",
      "Warfarin â€” monitor INR",
      "Didanosine â€” increased didanosine exposure"
    ],
    "monitoring": [
      "Serum uric acid (target <6 mg/dL)",
      "LFT (at baseline, 2 months, 4 months)",
      "Cardiovascular status",
      "Colchicine/NSAID prophylaxis compliance for first 6 months"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "120 mg/day",
    "clinicalPearl": "Preferred in renal impairment over allopurinol; avoid in established cardiovascular disease (FDA warning); do not use with azathioprine."
  },
  {
    "rank": 378,
    "name": "Indomethacin",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Indocap / Indocin / Indomethacin",
    "formation": "Indole acetic acid derivative (potent non-selective NSAID/COX inhibitor)",
    "uses": "Acute gout attack, ankylosing spondylitis, pericarditis, PDA closure (neonatal)",
    "adult": "25â€“50 mg TID or 75â€“100 mg SR OD",
    "child": "0.5â€“1 mg/kg BIDâ€“QID (PDA closure or JIA; specialist use)",
    "avoid": "Active GI ulceration, severe renal impairment, aspirin hypersensitivity, cerebrovascular disease",
    "drug": "Indomethacin",
    "sideEffects": [
      "GI upset/peptic ulceration",
      "Headache",
      "Dizziness",
      "Fluid retention",
      "Elevated blood pressure"
    ],
    "seriousRisks": [
      "GI perforation/bleeding",
      "Renal failure (acute)",
      "Cardiovascular events (MI, stroke)",
      "CNS effects (psychosis, depression â€” higher than other NSAIDs)",
      "Premature closure of ductus arteriosus (pregnancy)"
    ],
    "renalAdj": "Yes â€” reduce dose; avoid in severe renal impairment (GFR <30)",
    "hepaticAdj": "Yes â€” use with caution; hepatotoxicity risk",
    "pregnancy": "Category C/D (third trimester â€” avoid) â€” premature ductus arteriosus closure",
    "lactation": "Caution â€” excreted in breast milk; avoid in first month postpartum",
    "drugInteractions": [
      "Lithium â€” reduced lithium renal clearance; lithium toxicity",
      "Anticoagulants â€” additive bleeding risk",
      "Antihypertensives â€” reduced efficacy and increased renal toxicity"
    ],
    "monitoring": [
      "Renal function",
      "GI symptoms",
      "BP",
      "CBC",
      "CNS symptoms"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "200 mg/day (50 mg three times daily or SR 75 mg twice daily)",
    "clinicalPearl": "Most potent anti-inflammatory NSAID; also used to close patent ductus arteriosus in neonates; highest CNS side effect risk among NSAIDs."
  },
  {
    "rank": 379,
    "name": "Benzbromarone",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Normalurate / Urinorm / Benzbromarone",
    "formation": "Benzofuranyl ketone uricosuric agent (URAT1 inhibitor)",
    "uses": "Hyperuricemia and gout (renal under-excretion type), when xanthine oxidase inhibitors fail",
    "adult": "50â€“200 mg OD (with food)",
    "child": "Not recommended",
    "avoid": "Uric acid nephrolithiasis, severe renal impairment, hepatotoxicity risk (monitor LFT)",
    "drug": "Benzbromarone",
    "sideEffects": [
      "GI upset",
      "Liver enzyme elevation",
      "Diarrhea",
      "Urolithiasis (uric acid stones)",
      "Rash"
    ],
    "seriousRisks": [
      "Hepatotoxicity (including fulminant hepatic failure â€” withdrawn in EU)",
      "Uric acid urolithiasis",
      "Renal calculi"
    ],
    "renalAdj": "Yes â€” contraindicated if CrCl <25 mL/min; uricosuric effect lost in severe renal impairment",
    "hepaticAdj": "Yes â€” contraindicated in hepatic impairment; hepatotoxicity risk",
    "pregnancy": "Category C â€” avoid",
    "lactation": "Avoid",
    "drugInteractions": [
      "Warfarin â€” increased anticoagulant effect; monitor INR closely",
      "Salicylates (aspirin) â€” antagonism of uricosuric effect",
      "Pyrazinamide â€” antagonism of uricosuric action"
    ],
    "monitoring": [
      "Serum uric acid",
      "LFT (mandatory â€” monthly initially)",
      "Urinary uric acid",
      "Renal function",
      "Urinary pH (alkalinize to prevent stones)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100-200 mg/day",
    "clinicalPearl": "Potent uricosuric; urinary alkalinization and high fluid intake (2L/day) essential to prevent uric acid stone formation during therapy."
  },
  {
    "rank": 380,
    "name": "Strontium Ranelate",
    "section": "Section 10: Specialty & Emerging",
    "category": "Rheumatology",
    "schedule": "H",
    "brand": "Protelos / Osseor / Strontium Ranelate",
    "formation": "Strontium salt of ranelic acid (dual-action bone agent â€“ inhibits resorption and stimulates formation)",
    "uses": "Postmenopausal osteoporosis at high fracture risk (when bisphosphonates are contraindicated)",
    "adult": "2 g/day sachet in water at bedtime (>2 hrs after food and calcium)",
    "child": "Not recommended",
    "avoid": "Ischemic heart disease, peripheral arterial disease, uncontrolled hypertension, DVT history",
    "drug": "Strontium Ranelate",
    "sideEffects": [
      "Nausea",
      "Diarrhea",
      "Headache",
      "Eczema",
      "Memory and consciousness disturbance"
    ],
    "seriousRisks": [
      "DRESS syndrome",
      "Cardiovascular events (MI, thromboembolism â€” restricted use in EU)",
      "Venous thromboembolism",
      "Severe allergic reactions"
    ],
    "renalAdj": "Yes â€” avoid if CrCl <30 mL/min",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” avoid; insufficient data",
    "lactation": "Avoid â€” excreted in breast milk",
    "drugInteractions": [
      "Calcium-rich food/supplements/milk â€” reduce strontium ranelate absorption (separate by 2 hours)",
      "Antacids (Al/Mg) â€” reduced absorption; separate by 2 hours",
      "Tetracyclines â€” chelation reduces absorption of both"
    ],
    "monitoring": [
      "Bone mineral density (DEXA)",
      "Cardiovascular assessment (before and annually)",
      "Renal function",
      "Skin (DRESS surveillance)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2 g/day (sachet dissolved in water, taken at bedtime)",
    "clinicalPearl": "Restricted use due to cardiovascular risk â€” only for severe osteoporosis when other options are not tolerated; cardiovascular screen mandatory."
  },
  {
    "rank": 381,
    "name": "Folic Acid",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Folvite / Folinine / Folirich",
    "formation": "Vitamin B9 (pteroylmonoglutamic acid â€“ essential for one-carbon metabolism)",
    "uses": "Megaloblastic anemia, neural tube defect prevention in pregnancy, methotrexate-induced deficiency",
    "adult": "5 mg OD (anemia treatment); 0.4â€“5 mg/day (pre-conception and pregnancy)",
    "child": "50â€“200 mcg OD (deficiency); 5 mg OD (megaloblastic anemia)",
    "avoid": "Undiagnosed Vitamin B12 deficiency (may mask macrocytosis, unmask subacute combined degeneration)",
    "drug": "Folic Acid",
    "sideEffects": [
      "Rarely causes side effects at recommended doses",
      "Nausea (high dose)",
      "Bloating",
      "Bitter taste",
      "Allergic reactions (rare)"
    ],
    "seriousRisks": [
      "Masking of Vitamin B12 deficiency (megaloblastic anemia â€” treats anemia but not neurological damage)",
      "Seizure threshold reduction (very high doses in epilepsy patients)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” essential; 400 mcg/day pre-conception and first trimester (5 mg/day for high-risk women); prevents neural tube defects",
    "lactation": "Safe â€” essential; 500 mcg/day during lactation",
    "drugInteractions": [
      "Methotrexate â€” folate antagonist; supplement folic acid (not folinic acid) on non-MTX days",
      "Anticonvulsants (phenytoin, valproate, carbamazepine) â€” reduce folate levels; supplement needed",
      "Sulfasalazine â€” impairs folate absorption"
    ],
    "monitoring": [
      "Serum folate and homocysteine",
      "CBC (MCV)",
      "Vitamin B12 levels (rule out B12 deficiency before folic acid alone)",
      "Neural tube defect prevention in pregnancy"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5 mg/day (prophylaxis); 15 mg/day (therapeutic)",
    "clinicalPearl": "Always rule out B12 deficiency before prescribing folic acid alone â€” corrects anemia but worsens subacute combined degeneration."
  },
  {
    "rank": 382,
    "name": "Pyridoxine HCl (Vitamin B6)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Becadex / B6 / Pyridoxine",
    "formation": "Water-soluble B-vitamin (coenzyme for aminotransferases and decarboxylases)",
    "uses": "Vitamin B6 deficiency, hyperemesis gravidarum, INH-induced peripheral neuropathy prophylaxis",
    "adult": "10â€“50 mg daily (deficiency); 25 mg TID (morning sickness)",
    "child": "5â€“25 mg/day",
    "avoid": "High-dose >200 mg/day prolonged use (sensory neuropathy risk)",
    "drug": "Pyridoxine HCl (Vitamin B6)",
    "sideEffects": [
      "GI discomfort (high dose)",
      "Photosensitivity",
      "Nausea",
      "Headache",
      "Peripheral neuropathy (paradoxically at very high doses)"
    ],
    "seriousRisks": [
      "Peripheral sensory neuropathy (doses >200 mg/day chronically)",
      "Photosensitivity dermatitis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe and often prescribed for nausea in pregnancy (B6 + doxylamine combo)",
    "lactation": "Safe â€” present in breast milk; may reduce milk production at high doses",
    "drugInteractions": [
      "Isoniazid (INH) â€” INH depletes B6; always supplement B6 with INH therapy",
      "Levodopa â€” reduces levodopa efficacy (do not use high-dose B6 with levodopa without carbidopa)",
      "Phenobarbital/phenytoin â€” B6 reduces their levels"
    ],
    "monitoring": [
      "Neurological symptoms (neuropathy at high dose)",
      "Response to deficiency symptoms",
      "Serum B6 levels if available"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/day (therapeutic); 200 mg/day upper limit (avoid chronic high-dose â€” neuropathy risk)",
    "clinicalPearl": "Always prescribe B6 25-50 mg/day with isoniazid therapy to prevent INH-induced peripheral neuropathy."
  },
  {
    "rank": 383,
    "name": "Cyanocobalamin (Vitamin B12)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "H",
    "brand": "Neurobion / Cobadex / Cyanocobalamin",
    "formation": "Cyano form of cobalamin (synthetic Vitamin B12)",
    "uses": "Pernicious anemia, strict vegetarian B12 deficiency, peripheral neuropathy",
    "adult": "1000 mcg IM/SC monthly (pernicious anemia); 25â€“250 mcg oral daily (prophylaxis)",
    "child": "0.5â€“1 mcg/day (infant); 1â€“2 mcg/day (child)",
    "avoid": "Leber's hereditary optic neuropathy (can cause acute optic atrophy)",
    "drug": "Cyanocobalamin (Vitamin B12)",
    "sideEffects": [
      "Mild diarrhea",
      "Itching",
      "Rash (rare)",
      "Polycythemia vera unmasking (rare)",
      "Hypokalemia (on initiation in severe deficiency)"
    ],
    "seriousRisks": [
      "Hypokalemia (treatment of severe megaloblastic anemia)",
      "Anaphylaxis (injectable form â€” very rare)",
      "Thrombosis (polycythemia activation â€” rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” essential during pregnancy; deficiency causes neural tube defects",
    "lactation": "Safe â€” required for infant neurological development; supplement if vegetarian/vegan",
    "drugInteractions": [
      "Proton pump inhibitors â€” reduce B12 absorption from food (not from supplements)",
      "Metformin â€” long-term use reduces B12 levels; supplement annually",
      "Colchicine â€” reduces B12 absorption"
    ],
    "monitoring": [
      "Serum B12 levels",
      "CBC and MCV",
      "Neurological symptoms (subacute combined degeneration)",
      "Serum potassium (on initiation of treatment)",
      "Folate levels"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1000 mcg/day oral or IM (1 mg)",
    "clinicalPearl": "Correct potassium before B12 replacement in severe deficiency â€” rapid treatment causes cellular uptake of K+ leading to fatal hypokalemia."
  },
  {
    "rank": 384,
    "name": "Thiamine HCl (Vitamin B1)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "H",
    "brand": "Bevitex / Beplex / Thiamine inj",
    "formation": "Water-soluble vitamin (cocarboxylase precursor â€“ essential for carbohydrate metabolism)",
    "uses": "Wernicke's encephalopathy, beriberi, alcoholic neuropathy",
    "adult": "100â€“500 mg IV/IM (Wernicke's emergency); 10â€“25 mg OD oral (deficiency)",
    "child": "10â€“50 mg OD (deficiency)",
    "avoid": "Known hypersensitivity (rare anaphylaxis with parenteral use â€“ always have resuscitation available)",
    "drug": "Thiamine HCl (Vitamin B1)",
    "sideEffects": [
      "Mild GI discomfort (oral)",
      "Injection site reactions (IM/IV)",
      "Anaphylaxis (IV, rare)",
      "Flushing",
      "Pruritus"
    ],
    "seriousRisks": [
      "Anaphylaxis (IV formulation â€” rare)",
      "Wernicke's encephalopathy (if inadequate dosing in deficient patients)",
      "Respiratory failure (Wernicke's â€” if untreated)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe; essential for fetal neurological development",
    "lactation": "Safe â€” present in breast milk; supplementation required in deficiency",
    "drugInteractions": [
      "Alcohol â€” chronic alcohol consumption severely depletes thiamine (Wernicke-Korsakoff risk)",
      "Furosemide â€” increased renal thiamine excretion; supplement with long-term use",
      "Dextrose (IV glucose) â€” giving glucose to thiamine-deficient patient precipitates Wernicke's encephalopathy"
    ],
    "monitoring": [
      "Neurological status (Wernicke's triad: confusion, ataxia, ophthalmoplegia)",
      "Nutritional assessment",
      "Response to supplementation"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day IV (Wernicke's prophylaxis/treatment); 100 mg/day oral supplementation",
    "clinicalPearl": "Always give thiamine BEFORE IV dextrose in malnourished/alcoholic patients â€” glucose alone precipitates fatal Wernicke's encephalopathy."
  },
  {
    "rank": 385,
    "name": "Ascorbic Acid (Vitamin C)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Limcee / Cevit / Ester-C",
    "formation": "L-ascorbic acid (reducing agent, antioxidant, collagen synthesis cofactor)",
    "uses": "Scurvy prevention and treatment, immune support, enhanced iron absorption",
    "adult": "70â€“500 mg/day (preventive); 1â€“2 g/day (therapeutic scurvy)",
    "child": "30â€“45 mg/day (RDA); 100â€“400 mg/day (therapeutic)",
    "avoid": "High-dose >2 g/day chronically (oxalate kidney stones risk), G6PD deficiency",
    "drug": "Ascorbic Acid (Vitamin C)",
    "sideEffects": [
      "GI upset",
      "Diarrhea (high dose)",
      "Nausea",
      "Kidney stones (oxalate â€” high dose)",
      "Hemolysis (G6PD deficiency â€” high dose)"
    ],
    "seriousRisks": [
      "Oxalate renal stones (doses >2g/day)",
      "Hemolytic anemia (high dose in G6PD deficiency)",
      "Iron overload exacerbation (hemochromatosis)",
      "Rebound scurvy (abrupt stopping of high dose)"
    ],
    "renalAdj": "Yes â€” avoid high doses in renal impairment; oxalate stone risk",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe at RDA; avoid megadoses (>2g/day); rebound scurvy in neonate possible",
    "lactation": "Safe â€” RDA doses; breast milk concentration increases with supplementation",
    "drugInteractions": [
      "Warfarin â€” high dose may reduce INR; monitor",
      "Iron supplements â€” enhances non-heme iron absorption (beneficial interaction)",
      "Deferoxamine â€” vitamin C enhances iron release from tissues"
    ],
    "monitoring": [
      "Urinary oxalate/kidney stones (high dose)",
      "Serum iron (if iron overload concern)",
      "CBC (G6PD-deficient patients at high dose)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2000 mg/day (tolerable upper intake level); 1000 mg/day commonly used therapeutically",
    "clinicalPearl": "Take iron supplements with vitamin C to enhance non-heme iron absorption by 2-3 fold; avoid megadoses in renal impairment."
  },
  {
    "rank": 386,
    "name": "Biotin (Vitamin B7)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Biotax / Biotimax / Bioten",
    "formation": "Water-soluble sulfur-containing vitamin (coenzyme for carboxylases)",
    "uses": "Biotin deficiency, brittle nails and hair loss, biotinidase deficiency",
    "adult": "2.5â€“5 mg OD (hair/nail); 5â€“10 mg OD (deficiency)",
    "child": "5â€“20 mcg/kg/day (biotinidase deficiency)",
    "avoid": "Interferes with thyroid immunoassays (stop biotin 48 hrs before TSH testing)",
    "drug": "Biotin (Vitamin B7)",
    "sideEffects": [
      "Generally well tolerated",
      "Rare skin reactions",
      "GI discomfort (high dose)",
      "Interference with laboratory assays"
    ],
    "seriousRisks": [
      "False laboratory results (major concern) â€” biotin interferes with biotin-streptavidin immunoassays (troponin, thyroid function, drug levels)",
      "Misleading diagnosis due to assay interference"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe at recommended doses",
    "lactation": "Safe â€” adequate intake during lactation important",
    "drugInteractions": [
      "Anticonvulsants (carbamazepine, valproate, phenobarbital) â€” reduce biotin levels",
      "Raw egg whites (avidin) â€” impairs biotin absorption (prolonged consumption)",
      "Alpha-lipoic acid â€” may interfere with biotin transport"
    ],
    "monitoring": [
      "Lab test interference awareness (inform lab of biotin supplement use)",
      "Hair and nail growth response",
      "Biotinidase deficiency screening in neonates"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "No established upper limit; clinical use 2.5-10 mg/day for hair/nails; 100-300 mg/day for biotinidase deficiency",
    "clinicalPearl": "Biotin supplements falsely lower troponin and TSH results in immunoassays â€” inform lab and stop biotin 2-3 days before cardiac/thyroid testing."
  },
  {
    "rank": 387,
    "name": "Zinc Sulfate",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Zincovit / Zinconia / Zinc",
    "formation": "Inorganic zinc salt (essential trace element for enzyme function and immunity)",
    "uses": "Zinc deficiency, diarrhea (WHO ORS protocol), wound healing support",
    "adult": "220 mg (50 mg elemental zinc) ODâ€“TID",
    "child": "10â€“20 mg elemental zinc OD (diarrhea WHO protocol)",
    "avoid": "Concurrent high-dose copper/iron (competitive absorption), IV zinc without dilution",
    "drug": "Zinc Sulfate",
    "sideEffects": [
      "Nausea/vomiting",
      "Metallic taste",
      "Gastric irritation",
      "Diarrhea",
      "Abdominal cramps"
    ],
    "seriousRisks": [
      "Copper deficiency (with high-dose/long-term use â€” anemia, neuropathy)",
      "Sideroblastic anemia",
      "Immunosuppression (excess zinc)"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment; excretion reduced",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe at recommended doses; excess zinc causes copper deficiency in fetus",
    "lactation": "Safe â€” RDA doses; breast milk zinc content important for infant",
    "drugInteractions": [
      "Tetracyclines/fluoroquinolones â€” zinc chelates antibiotics; separate administration by 2 hours",
      "Iron supplements â€” competitive absorption; separate by 2 hours",
      "Copper supplements â€” high zinc reduces copper absorption"
    ],
    "monitoring": [
      "Serum zinc and copper levels (long-term high dose)",
      "CBC (copper-deficiency anemia)",
      "Growth in children"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 mg/day elemental zinc (upper tolerable limit); therapeutic doses vary by indication",
    "clinicalPearl": "Take between meals for better absorption but with food if GI side effects occur; excess zinc depletes copper â€” monitor long-term."
  },
  {
    "rank": 388,
    "name": "Magnesium Hydroxide",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "OTC",
    "brand": "Milk of Magnesia / Gelusil / MOM",
    "formation": "Inorganic magnesium salt (antacid and osmotic laxative)",
    "uses": "Constipation (osmotic laxative), mild heartburn and hyperacidity (antacid), hypomagnesemia",
    "adult": "30â€“60 mL OD (laxative); 5â€“15 mL QID (antacid)",
    "child": "0.5 mL/kg ODâ€“BID (laxative)",
    "avoid": "Renal failure (hypermagnesemia risk), intestinal obstruction, appendicitis",
    "drug": "Magnesium Hydroxide",
    "sideEffects": [
      "Diarrhea (laxative action)",
      "Nausea",
      "Abdominal cramping",
      "Hypermagnesemia (in renal impairment)",
      "Chalky taste"
    ],
    "seriousRisks": [
      "Hypermagnesemia (in renal failure â€” respiratory depression, cardiac arrest)",
      "Severe diarrhea and electrolyte imbalance",
      "Milk-alkali syndrome (with calcium co-ingestion)"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment; risk of hypermagnesemia accumulation",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe for occasional use; avoid prolonged use",
    "lactation": "Safe â€” minimal systemic absorption",
    "drugInteractions": [
      "Tetracyclines/fluoroquinolones â€” chelation reduces antibiotic absorption; separate by 2 hours",
      "Iron supplements â€” reduced iron absorption; separate by 2 hours",
      "Bisphosphonates â€” significantly reduced absorption; do not co-administer"
    ],
    "monitoring": [
      "Serum magnesium (renal patients)",
      "Bowel movements",
      "Electrolytes (prolonged use)",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4 g/day (antacid); 8-16 g/day (laxative â€” short term only)",
    "clinicalPearl": "Contraindicated in renal failure due to hypermagnesemia risk; antacid effect provides relief within 30 minutes; take 1-2 hours after other medications."
  },
  {
    "rank": 389,
    "name": "Potassium Chloride (Oral)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "H",
    "brand": "Slow K / KCl / Potrate",
    "formation": "Inorganic potassium salt (electrolyte replenisher)",
    "uses": "Hypokalemia (mild-to-moderate), diuretic-induced potassium depletion prevention",
    "adult": "40â€“100 mEq/day in divided doses (with food and adequate water)",
    "child": "2â€“4 mEq/kg/day (supplementation)",
    "avoid": "Hyperkalemia, renal failure, concurrent potassium-sparing diuretics",
    "drug": "Potassium Chloride Oral",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "GI ulceration (solid tablets)",
      "Diarrhea",
      "Abdominal discomfort"
    ],
    "seriousRisks": [
      "Hyperkalemia (especially in renal impairment â€” cardiac arrest risk)",
      "GI ulceration/perforation (wax-matrix tablets)",
      "Cardiac arrhythmias (rapid IV equivalent, or large oral doses in renal impairment)"
    ],
    "renalAdj": "Yes â€” use with extreme caution; frequent serum K+ monitoring mandatory; significant hyperkalemia risk",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category A â€” safe when used correctly; essential for maternal and fetal health",
    "lactation": "Safe â€” required electrolyte",
    "drugInteractions": [
      "ACE inhibitors/ARBs â€” severe hyperkalemia risk; monitor K+ closely",
      "Potassium-sparing diuretics (spironolactone, amiloride) â€” additive hyperkalemia; avoid or monitor closely",
      "NSAIDs â€” impaired renal K+ excretion; hyperkalemia"
    ],
    "monitoring": [
      "Serum potassium (before and after initiation)",
      "ECG (hyperkalemia â€” peaked T waves)",
      "Renal function",
      "GI symptoms",
      "Acid-base status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100-200 mEq/day (divided doses; maximum 40 mEq per dose)",
    "clinicalPearl": "Always give with food or after meals to prevent GI ulceration; use liquid formulation in patients with esophageal motility disorders."
  },
  {
    "rank": 390,
    "name": "Ferric Carboxymaltose (IV)",
    "section": "Section 10: Specialty & Emerging",
    "category": "Vitamins/Minerals",
    "schedule": "H",
    "brand": "Ferinject / FCM Inj / Jectofer",
    "formation": "Non-dextran iron(III) complex (IV iron preparation)",
    "uses": "Iron deficiency anemia when oral iron is insufficient, intolerable, or ineffective",
    "adult": "500â€“1000 mg IV per dose (based on hemoglobin and body weight)",
    "child": "750 mg/dose (>50 kg); 15 mg/kg (<50 kg)",
    "avoid": "Iron overload, anemia not due to iron deficiency, hypersensitivity to parenteral iron",
    "drug": "Ferric Carboxymaltose IV",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Flushing",
      "Injection site reactions",
      "Dizziness"
    ],
    "seriousRisks": [
      "Hypersensitivity/anaphylaxis reactions",
      "Hypophosphatemia (significant, especially with repeated doses)",
      "Hypertension (during infusion)",
      "Iron overload"
    ],
    "renalAdj": "No â€” standard dosing (preferred IV iron in CKD â€” no dextran-related reactions)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” avoid first trimester; considered safer than iron dextran for IV iron in 2nd/3rd trimester",
    "lactation": "Safe â€” iron supplementation generally safe during lactation",
    "drugInteractions": [
      "Oral iron â€” avoid simultaneous use; IV iron reduces absorption of oral iron",
      "ACE inhibitors â€” may increase risk of hypersensitivity reactions",
      "Calcium supplements â€” not relevant for IV formulation"
    ],
    "monitoring": [
      "Hemoglobin and ferritin (at 4-8 weeks post-infusion)",
      "Serum phosphate (especially repeated doses â€” hypophosphatemia risk)",
      "Signs of anaphylaxis during infusion (first 30 minutes)",
      "Iron saturation (TSAT)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1000 mg iron per single dose (maximum per infusion); can repeat after 7+ days",
    "clinicalPearl": "No test dose required; can give 1000 mg in single infusion â€” much higher than iron sucrose; monitor phosphate on repeat dosing."
  },
  {
    "rank": 391,
    "name": "Rifaximin",
    "section": "Section 10: Specialty & Emerging",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Xifaxan / Rcifax / Rifaximin",
    "formation": "Rifamycin-derived minimally-absorbed oral broad-spectrum antibiotic",
    "uses": "Traveler's diarrhea, hepatic encephalopathy (prophylaxis/reduction), IBS-D",
    "adult": "200 mg TID Ã— 3 days (traveler's diarrhea); 550 mg BID (hepatic encephalopathy)",
    "child": "12 mg/kg/day (â‰¥12y for traveler's diarrhea)",
    "avoid": "Active intestinal obstruction, systemic infection requiring absorbable antibiotic",
    "drug": "Rifaximin",
    "sideEffects": [
      "Flatulence",
      "Nausea",
      "Abdominal pain",
      "Headache",
      "Peripheral oedema"
    ],
    "seriousRisks": [
      "Clostridium difficile-associated diarrhea",
      "Severe hypersensitivity reactions"
    ],
    "renalAdj": "No â€” standard dosing (minimal systemic absorption)",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment (Child-Pugh C)",
    "pregnancy": "Category C â€” limited data; avoid unless clearly needed",
    "lactation": "Caution â€” minimal absorption but data lacking; use with caution",
    "drugInteractions": [
      "Warfarin â€” may increase INR (rare)",
      "P-glycoprotein substrates â€” altered levels",
      "Cyclosporine â€” increased rifaximin exposure"
    ],
    "monitoring": [
      "Stool frequency",
      "Serum ammonia (HE use)",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1200 mg/day (HE); 1650 mg/day (IBS-D)",
    "clinicalPearl": "Non-absorbable antibiotic; ideal for traveler's diarrhea without systemic toxicity."
  },
  {
    "rank": 392,
    "name": "Domperidone",
    "section": "Section 10: Specialty & Emerging",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Domstal / Vomistop / Motilium",
    "formation": "Peripheral dopamine D2-receptor antagonist (prokinetic antiemetic)",
    "uses": "Nausea, vomiting, gastroparesis, functional dyspepsia",
    "adult": "10 mg TID (before meals, short-term use only; max 30 mg/day)",
    "child": "0.25 mg/kg TID (avoid in <12 kg or <1y)",
    "avoid": "Cardiac arrhythmia (QT prolongation risk), severe hepatic impairment, pheochromocytoma",
    "drug": "Domperidone",
    "sideEffects": [
      "Dry mouth",
      "Headache",
      "Galactorrhoea",
      "Amenorrhoea",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "QT prolongation",
      "Cardiac arrhythmia (especially at high doses)",
      "Sudden cardiac death"
    ],
    "renalAdj": "Yes â€” reduce dose frequency in severe renal impairment; avoid prolonged use",
    "hepaticAdj": "Yes â€” avoid in moderate-to-severe hepatic impairment",
    "pregnancy": "Category C â€” avoid in first trimester; limited safety data",
    "lactation": "Caution â€” excreted in breast milk; cardiac risk in neonates",
    "drugInteractions": [
      "Ketoconazole â€” QT prolongation risk increased",
      "Erythromycin â€” additive QT prolongation",
      "Antacids/H2 blockers â€” reduced domperidone absorption"
    ],
    "monitoring": [
      "ECG (QTc interval)",
      "Prolactin levels",
      "Cardiac symptoms"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "30 mg/day (10 mg TDS)",
    "clinicalPearl": "Peripheral D2 antagonist â€” no CNS side effects; avoid with QT-prolonging drugs."
  },
  {
    "rank": 393,
    "name": "Drotaverine HCl",
    "section": "Section 10: Specialty & Emerging",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "No-Spa / Drotin / Spasmofen",
    "formation": "Isoquinoline derivative (selective smooth muscle PDE4 inhibitor â€“ spasmolytic)",
    "uses": "Renal, biliary and gastrointestinal smooth muscle colic, spasm, dysmenorrhea",
    "adult": "40â€“80 mg TID",
    "child": "20 mg BIDâ€“TID (â‰¥6y)",
    "avoid": "Heart failure, severe hepatic/renal failure, hypotension",
    "drug": "Drotaverine HCl",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Dizziness",
      "Hypotension",
      "Flushing"
    ],
    "seriousRisks": [
      "Severe hypotension",
      "Hypersensitivity reactions"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” widely used in Indian obstetric practice for cervical dilation; limited controlled data",
    "lactation": "Caution â€” limited data; short-term use generally considered acceptable",
    "drugInteractions": [
      "Levodopa â€” may reduce antiparkinsonian effect",
      "Other antispasmodics â€” additive effect",
      "Antihypertensives â€” additive hypotension"
    ],
    "monitoring": [
      "BP",
      "Pain relief response",
      "Uterine activity (obstetric use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "240 mg/day (80 mg TDS)",
    "clinicalPearl": "PDE inhibitor antispasmodic â€” no anticholinergic side effects; safe in glaucoma/BPH."
  },
  {
    "rank": 394,
    "name": "Hyoscine Butylbromide",
    "section": "Section 10: Specialty & Emerging",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Buscopan / Hyoscine / Spancopal",
    "formation": "Quaternary ammonium anticholinergic (does not cross blood-brain barrier)",
    "uses": "Abdominal spasm, irritable bowel syndrome, renal colic, biliary colic",
    "adult": "20 mg TIDâ€“QID (oral) or 20 mg IV (acute spasm)",
    "child": "0.5â€“1 mg/kg/dose TID (â‰¥6y)",
    "avoid": "Myasthenia gravis, narrow-angle glaucoma, obstructive GI disease, tachyarrhythmia",
    "drug": "Hyoscine Butylbromide",
    "sideEffects": [
      "Dry mouth",
      "Tachycardia",
      "Urinary retention",
      "Constipation",
      "Blurred vision"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma",
      "Urinary retention in BPH",
      "Paralytic ileus"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” quaternary ammonium; limited placental transfer; use with caution",
    "lactation": "Caution â€” limited data; anticholinergic effects possible in infant",
    "drugInteractions": [
      "Antihistamines â€” additive anticholinergic effects",
      "Tricyclic antidepressants â€” additive anticholinergic toxicity",
      "Metoclopramide â€” opposing GI motility effects"
    ],
    "monitoring": [
      "Heart rate",
      "Urinary output",
      "Pain relief"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/day oral; 100 mg/day IM/IV",
    "clinicalPearl": "Quaternary ammonium compound â€” does not cross BBB; no CNS anticholinergic effects."
  },
  {
    "rank": 395,
    "name": "Mosapride Citrate",
    "section": "Section 10: Specialty & Emerging",
    "category": "Gastrointestinal",
    "schedule": "H",
    "brand": "Mosaride / Mosarex / Gastropride",
    "formation": "Substituted benzamide â€“ selective serotonin 5-HT4 receptor agonist (prokinetic)",
    "uses": "Gastroparesis, GERD (acid regurgitation), functional dyspepsia",
    "adult": "5 mg TID (30 min before meals)",
    "child": "Consult specialist",
    "avoid": "Severe hepatic disease, GI obstruction or hemorrhage",
    "drug": "Mosapride Citrate",
    "sideEffects": [
      "Diarrhoea",
      "Abdominal pain",
      "Dry mouth",
      "Headache",
      "Nausea"
    ],
    "seriousRisks": [
      "QT prolongation (rare)",
      "Hypersensitivity reactions"
    ],
    "renalAdj": "Yes â€” reduce dose in severe renal impairment",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” insufficient human data; avoid unless necessary",
    "lactation": "Caution â€” insufficient data; avoid if possible",
    "drugInteractions": [
      "Erythromycin â€” QT prolongation risk",
      "Antifungals (azoles) â€” increased mosapride levels",
      "Anticholinergics â€” opposing prokinetic effect"
    ],
    "monitoring": [
      "ECG (QTc)",
      "GI symptoms",
      "LFT (long-term)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "15 mg/day (5 mg TDS)",
    "clinicalPearl": "5-HT4 agonist â€” selective GI prokinetic; no dopamine blockade, hence no hyperprolactinaemia."
  },
  {
    "rank": 396,
    "name": "Topiramate",
    "section": "Section 10: Specialty & Emerging",
    "category": "CNS",
    "schedule": "H",
    "brand": "Topamax / Topamac / Topirol",
    "formation": "Sulfamate-substituted monosaccharide (multiple antiepileptic mechanisms)",
    "uses": "Epilepsy (focal and generalized), migraine prophylaxis, weight management adjunct",
    "adult": "25â€“400 mg/day in 2 divided doses (titrate slowly over 6â€“8 weeks)",
    "child": "5â€“9 mg/kg/day in 2 divided doses (epilepsy â‰¥2y)",
    "avoid": "Metabolic acidosis, kidney stones (risk increased), acute myopia/glaucoma",
    "drug": "Topiramate",
    "sideEffects": [
      "Cognitive slowing (word-finding difficulty)",
      "Fatigue",
      "Weight loss",
      "Paresthesias",
      "Nausea"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma",
      "Kidney stones",
      "Metabolic acidosis",
      "Suicidal ideation",
      "Oligohidrosis/hyperthermia"
    ],
    "renalAdj": "Yes â€” reduce dose by 50% if CrCl <70 mL/min",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment; clearance reduced",
    "pregnancy": "Category D â€” increased risk of oral clefts; avoid in first trimester",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for drowsiness",
    "drugInteractions": [
      "Valproate â€” hyperammonaemia risk",
      "Oral contraceptives â€” reduced OCP efficacy",
      "Carbonic anhydrase inhibitors â€” increased nephrolithiasis risk"
    ],
    "monitoring": [
      "Serum bicarbonate",
      "Renal function",
      "Eye pressure (acute)",
      "Weight",
      "Cognitive function"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (epilepsy); 100 mg/day (migraine prophylaxis)",
    "clinicalPearl": "The 'dopamax' â€” causes cognitive slowing and word-finding difficulty; also causes weight loss."
  },
  {
    "rank": 397,
    "name": "Oxcarbazepine",
    "section": "Section 10: Specialty & Emerging",
    "category": "CNS",
    "schedule": "H",
    "brand": "Trileptal / Oxrate / Oxcarb",
    "formation": "Dibenzazepine ketone (active keto-analog of carbamazepine â€“ Na+ channel blocker)",
    "uses": "Focal (partial) seizures, generalized tonic-clonic seizures",
    "adult": "300â€“1200 mg BID",
    "child": "8â€“10 mg/kg/day in 2 divided doses (â‰¥2y)",
    "avoid": "Hyponatremia (significant risk), carbamazepine hypersensitivity (cross-reactivity in ~25%)",
    "drug": "Oxcarbazepine",
    "sideEffects": [
      "Dizziness",
      "Hyponatraemia",
      "Diplopia",
      "Nausea",
      "Headache"
    ],
    "seriousRisks": [
      "Severe hyponatraemia",
      "Stevens-Johnson syndrome",
      "Multi-organ hypersensitivity",
      "Suicidal ideation"
    ],
    "renalAdj": "Yes â€” reduce dose by 50% if CrCl <30 mL/min",
    "hepaticAdj": "No â€” standard dosing in mild-moderate impairment; caution in severe",
    "pregnancy": "Category C â€” teratogenic risk; use with adequate folate supplementation",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "Oral contraceptives â€” reduced efficacy (enzyme induction)",
      "Phenytoin â€” increased phenytoin levels",
      "Carbamazepine â€” cross-hypersensitivity in 25-30%"
    ],
    "monitoring": [
      "Serum sodium",
      "LFT",
      "CBC",
      "Drug levels (if available)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2400 mg/day",
    "clinicalPearl": "10-keto analogue of carbamazepine â€” fewer drug interactions but hyponatraemia is key concern."
  },
  {
    "rank": 398,
    "name": "Lacosamide",
    "section": "Section 10: Specialty & Emerging",
    "category": "CNS",
    "schedule": "H",
    "brand": "Vimpat / Lacosam / Lacoset",
    "formation": "Functionalized amino acid â€“ selective slow inactivation enhancer of sodium channels",
    "uses": "Focal-onset (partial) seizures, adjunct in generalized tonic-clonic seizures",
    "adult": "50 mg BID initial; titrate to 100â€“400 mg BID (target)",
    "child": "2 mg/kg/day BID initial (â‰¥4y; weight-based titration)",
    "avoid": "Second/third-degree AV block, severe cardiac conduction abnormalities",
    "drug": "Lacosamide",
    "sideEffects": [
      "Dizziness",
      "Diplopia",
      "Nausea",
      "Headache",
      "Fatigue"
    ],
    "seriousRisks": [
      "PR interval prolongation/cardiac arrhythmia",
      "Suicidal ideation",
      "Multiorgan hypersensitivity",
      "Drug reaction with eosinophilia"
    ],
    "renalAdj": "Yes â€” max 250 mg/day if CrCl <30 mL/min or ESRD",
    "hepaticAdj": "Yes â€” max 250 mg/day in mild-moderate impairment; avoid in severe",
    "pregnancy": "Category C â€” insufficient human data; animal studies show teratogenicity",
    "lactation": "Caution â€” excreted in breast milk; monitor infant",
    "drugInteractions": [
      "PR-prolonging drugs (beta-blockers, digoxin) â€” additive cardiac conduction slowing",
      "Sodium channel blockers â€” additive effects",
      "Carbamazepine â€” may increase lacosamide clearance"
    ],
    "monitoring": [
      "ECG (PR interval)",
      "LFT",
      "Seizure frequency"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day",
    "clinicalPearl": "Slow inactivation of sodium channels â€” unique MOA; check ECG before initiating in cardiac patients."
  },
  {
    "rank": 399,
    "name": "Clomipramine HCl",
    "section": "Section 10: Specialty & Emerging",
    "category": "CNS",
    "schedule": "H",
    "brand": "Anafranil / Clonil / Clomipramine",
    "formation": "Chloro-substituted imipramine (TCA with potent serotonin reuptake inhibition)",
    "uses": "Obsessive-compulsive disorder (OCD), depression, panic disorder, cataplexy",
    "adult": "25â€“250 mg/day (divided or single nocturnal dose; titrate over weeks)",
    "child": "25â€“200 mg/day (OCD â‰¥10y; titrate carefully)",
    "avoid": "Acute MI, closed-angle glaucoma, urinary retention, concurrent MAOI use (14-day washout)",
    "drug": "Clomipramine HCl",
    "sideEffects": [
      "Dry mouth",
      "Sedation",
      "Constipation",
      "Weight gain",
      "Sexual dysfunction"
    ],
    "seriousRisks": [
      "Cardiac arrhythmia/QT prolongation",
      "Seizures (dose-dependent)",
      "Suicidal ideation",
      "Serotonin syndrome",
      "Urinary retention"
    ],
    "renalAdj": "No â€” standard dosing with caution",
    "hepaticAdj": "Yes â€” use with caution; reduce dose in hepatic impairment",
    "pregnancy": "Category C â€” neonatal withdrawal syndrome risk; avoid near term",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for sedation",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated)",
      "SSRIs â€” serotonin syndrome risk",
      "Antiarrhythmics â€” additive QT prolongation"
    ],
    "monitoring": [
      "ECG",
      "LFT",
      "CBC",
      "Seizure threshold monitoring",
      "Blood pressure"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "250 mg/day",
    "clinicalPearl": "Gold standard TCA for OCD â€” highest serotonergic activity among TCAs."
  },
  {
    "rank": 400,
    "name": "Mirtazapine",
    "section": "Section 10: Specialty & Emerging",
    "category": "CNS",
    "schedule": "H",
    "brand": "Mirtaz / Remeron / Mirteron",
    "formation": "Tetracyclic antidepressant (NaSSA â€“ noradrenergic and specific serotonergic antidepressant)",
    "uses": "Major depressive disorder, anxiety, appetite stimulation, insomnia adjunct",
    "adult": "15â€“45 mg OD (bedtime; higher doses are less sedating)",
    "child": "Not recommended",
    "avoid": "Concurrent MAOI use (14-day washout), narrow-angle glaucoma, agranulocytosis history",
    "drug": "Mirtazapine",
    "sideEffects": [
      "Sedation",
      "Weight gain",
      "Increased appetite",
      "Dry mouth",
      "Dizziness"
    ],
    "seriousRisks": [
      "Agranulocytosis (rare)",
      "Suicidal ideation",
      "Serotonin syndrome",
      "Severe hypersensitivity"
    ],
    "renalAdj": "Yes â€” use with caution; clearance reduced in renal impairment",
    "hepaticAdj": "Yes â€” use with caution; clearance reduced in hepatic impairment",
    "pregnancy": "Category C â€” limited data; potential neonatal withdrawal; use if benefits outweigh risks",
    "lactation": "Caution â€” present in breast milk; monitor infant",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated)",
      "CNS depressants/alcohol â€” additive sedation",
      "CYP1A2 inhibitors (fluvoxamine) â€” increased mirtazapine levels"
    ],
    "monitoring": [
      "CBC (agranulocytosis)",
      "Weight",
      "LFT",
      "Mood/suicidality"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "45 mg/day",
    "clinicalPearl": "Paradoxically, lower doses (7.5 mg) are more sedating than higher doses due to H1 blockade dominance."
  },
  {
    "rank": 401,
    "name": "Rifampicin",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Rifacin / Rimactane / R-Cin",
    "formation": "Rifamycin antibiotic; inhibits bacterial DNA-dependent RNA polymerase",
    "uses": "Tuberculosis (all forms), leprosy, prophylaxis of meningococcal meningitis",
    "adult": "10 mg/kg/day OD (max 600 mg) fasting; or 3Ã— weekly DOTS",
    "child": "10â€“20 mg/kg/day OD (max 600 mg) fasting",
    "avoid": "Hepatic failure, concurrent saquinavir/ritonavir; potent CYP inducer â€“ check all co-medications",
    "drug": "Rifampicin",
    "sideEffects": [
      "Orange-red discoloration of urine/secretions",
      "Nausea",
      "Hepatotoxicity",
      "Flu-like syndrome",
      "Rash"
    ],
    "seriousRisks": [
      "Drug-induced hepatitis (fulminant)",
      "Thrombocytopenia",
      "Haemolytic anaemia",
      "Acute renal failure (intermittent regimen)",
      "Drug interactions (potent CYP inducer)"
    ],
    "renalAdj": "No â€” standard dosing; dose adjustment only in severe renal failure",
    "hepaticAdj": "Yes â€” avoid or use with extreme caution in active hepatic disease; max 8 mg/kg/day",
    "pregnancy": "Category C â€” potential for neonatal haemorrhage; give vitamin K at delivery",
    "lactation": "Safe â€” excreted in small amounts; considered compatible with breastfeeding",
    "drugInteractions": [
      "Oral contraceptives â€” reduced OCP efficacy (potent CYP3A4 inducer)",
      "Warfarin â€” dramatically reduced anticoagulant effect",
      "Antiretrovirals (PIs/NNRTIs) â€” significantly reduced drug levels"
    ],
    "monitoring": [
      "LFT (baseline + monthly)",
      "CBC",
      "Serum bilirubin",
      "Visual acuity (combination use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day",
    "clinicalPearl": "Potent CYP inducer â€” always counsel patients about orange urine and drug interactions before starting."
  },
  {
    "rank": 402,
    "name": "Isoniazid",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Isokin / INH / Stanozide",
    "formation": "Nicotinic acid hydrazide; inhibits mycolic acid synthesis (InhA enzyme)",
    "uses": "Tuberculosis (all forms), latent TB prophylaxis",
    "adult": "5 mg/kg/day OD (max 300 mg) or 10 mg/kg 3Ã— weekly DOTS; co-prescribe pyridoxine 10 mg/day",
    "child": "10 mg/kg/day OD (max 300 mg) with pyridoxine",
    "avoid": "Active hepatitis, previous INH hepatotoxicity; monitor LFTs; peripheral neuropathy risk â€“ supplement B6",
    "drug": "Isoniazid",
    "sideEffects": [
      "Peripheral neuropathy",
      "Hepatotoxicity",
      "Nausea",
      "Rash",
      "Fever"
    ],
    "seriousRisks": [
      "Drug-induced hepatitis (severe/fatal)",
      "Pellagra-like syndrome",
      "Psychosis",
      "Seizures",
      "Lupus-like syndrome"
    ],
    "renalAdj": "Yes â€” reduce dose or increase interval in severe renal impairment; pyridoxine supplementation essential",
    "hepaticAdj": "Yes â€” avoid in active hepatic disease; use with caution and close monitoring in hepatic impairment",
    "pregnancy": "Category C â€” benefit outweighs risk in active TB; give pyridoxine supplement",
    "lactation": "Safe â€” compatible with breastfeeding; supplement infant with pyridoxine",
    "drugInteractions": [
      "Rifampicin â€” increased hepatotoxicity risk",
      "Phenytoin â€” increased phenytoin toxicity (CYP2C9 inhibition)",
      "Antacids/aluminum salts â€” reduced isoniazid absorption"
    ],
    "monitoring": [
      "LFT (baseline + monthly)",
      "Neurological assessment",
      "Pyridoxine levels",
      "Sputum culture"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day (5 mg/kg)",
    "clinicalPearl": "Always co-prescribe pyridoxine (B6) 10-25 mg/day to prevent INH-induced peripheral neuropathy."
  },
  {
    "rank": 403,
    "name": "Pyrazinamide",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Pyrafat / Tisamid / Pyzina",
    "formation": "Pyrazine analogue pro-drug; active in acidic intracellular macrophage environment against TB",
    "uses": "Tuberculosis (initial 2-month intensive phase)",
    "adult": "25 mg/kg/day OD (max 2 g); or weight-banded DOTS regimen",
    "child": "35 mg/kg/day OD (max 2 g)",
    "avoid": "Severe hepatic disease, acute gout; causes hyperuricaemia â€“ monitor uric acid and LFTs",
    "drug": "Pyrazinamide",
    "sideEffects": [
      "Hepatotoxicity",
      "Hyperuricaemia",
      "Arthralgia",
      "Nausea",
      "Anorexia"
    ],
    "seriousRisks": [
      "Severe drug-induced hepatitis",
      "Gout exacerbation",
      "Photosensitivity",
      "Sideroblastic anaemia"
    ],
    "renalAdj": "Yes â€” extend dosing interval to 3 times/week in CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” avoid in pre-existing hepatic disease; most hepatotoxic first-line anti-TB drug",
    "pregnancy": "Category C â€” generally used in Indian/WHO TB regimens despite limited data",
    "lactation": "Safe â€” small amounts in breast milk; generally considered compatible",
    "drugInteractions": [
      "Allopurinol â€” reduced uricosuric effect",
      "Cyclosporine â€” reduced cyclosporine levels",
      "Probenecid â€” reduced uricosuric effect"
    ],
    "monitoring": [
      "LFT (baseline + monthly)",
      "Serum uric acid",
      "Joints (arthralgia)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2000 mg/day (25-35 mg/kg/day)",
    "clinicalPearl": "Only active against TB in acidic intracellular environment â€” most effective in first 2 months of therapy."
  },
  {
    "rank": 404,
    "name": "Ethambutol",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Myambutol / Combutol / Servambutol",
    "formation": "Synthetic bacteriostatic; inhibits arabinosyltransferases required for mycobacterial cell wall synthesis",
    "uses": "Tuberculosis (combination regimen), non-tuberculous mycobacterial infections",
    "adult": "15â€“20 mg/kg/day OD (max 1.6 g) with food",
    "child": "15â€“20 mg/kg/day OD; avoid <5y (unable to monitor vision)",
    "avoid": "Optic neuritis, pre-existing visual impairment; monitor visual acuity and colour vision monthly",
    "drug": "Ethambutol",
    "sideEffects": [
      "Optic neuritis",
      "Visual field defects",
      "Colour vision loss (red-green)",
      "Hyperuricaemia",
      "Peripheral neuropathy"
    ],
    "seriousRisks": [
      "Irreversible optic nerve damage",
      "Severe visual loss",
      "Retrobulbar neuritis"
    ],
    "renalAdj": "Yes â€” dose every 24-36 hours if CrCl 10-50 mL/min; every 48 hours if CrCl <10 mL/min",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” considered safe; monitor visual acuity",
    "lactation": "Safe â€” small amounts in breast milk; compatible with breastfeeding",
    "drugInteractions": [
      "Antacids (aluminum) â€” reduced ethambutol absorption",
      "Other optic neurotoxic drugs â€” additive risk",
      "Zinc/magnesium supplements â€” chelation reduces absorption"
    ],
    "monitoring": [
      "Visual acuity (monthly)",
      "Red-green colour discrimination",
      "Renal function",
      "Serum uric acid"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1600 mg/day (25 mg/kg/day in intensive phase)",
    "clinicalPearl": "Stop immediately if patient reports any visual change â€” optic neuritis is dose-dependent and reversible if caught early."
  },
  {
    "rank": 405,
    "name": "4-FDC Anti-TB (RHZE)",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Forecox / Rimcure / 4FDC Tablet",
    "formation": "Fixed-dose combination: Rifampicin 150mg + Isoniazid 75mg + Pyrazinamide 400mg + Ethambutol 275mg",
    "uses": "New smear-positive pulmonary TB and new smear-negative pulmonary TB (intensive phase 2 months)",
    "adult": "Weight-banded: 30â€“37 kg = 2 tabs; 38â€“54 kg = 3 tabs; 55â€“70 kg = 4 tabs; >70 kg = 5 tabs OD fasting",
    "child": "Paediatric FDC tablets (dispersible) as per weight; avoid crushing adult tabs",
    "avoid": "Jaundice, hypersensitivity to any component; DO NOT split or crush â€“ leads to sub-therapeutic levels",
    "drug": "4-FDC Anti-TB (RHZE)",
    "sideEffects": [
      "Hepatotoxicity",
      "Orange discoloration of urine",
      "Peripheral neuropathy",
      "Visual disturbance",
      "Hyperuricaemia"
    ],
    "seriousRisks": [
      "Drug-induced hepatitis",
      "Optic neuritis",
      "Severe cutaneous reactions",
      "Thrombocytopenia",
      "Haemolytic anaemia"
    ],
    "renalAdj": "Yes â€” individual dose adjustment required based on renal function; avoid FDC in severe renal impairment",
    "hepaticAdj": "Yes â€” avoid in active hepatic disease; monitor LFT closely",
    "pregnancy": "Category C â€” use under RNTCP guidelines; add pyridoxine supplementation",
    "lactation": "Safe â€” compatible with breastfeeding under RNTCP guidelines",
    "drugInteractions": [
      "Antiretrovirals â€” multiple interactions via rifampicin CYP induction",
      "Oral contraceptives â€” reduced efficacy due to rifampicin",
      "Warfarin â€” reduced anticoagulant effect due to rifampicin"
    ],
    "monitoring": [
      "LFT (baseline + monthly)",
      "Visual acuity",
      "CBC",
      "Serum uric acid",
      "Sputum culture at 2 months"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Per weight-band dosing as per RNTCP/NTEP guidelines",
    "clinicalPearl": "NTEP weight-band dosing ensures optimal drug exposure â€” always use weight-based FDC selection."
  },
  {
    "rank": 406,
    "name": "Streptomycin",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Streptomycin Sulphate IP / Cipstren",
    "formation": "Aminoglycoside; inhibits 30S ribosomal subunit protein synthesis; bactericidal against TB",
    "uses": "Drug-resistant TB (as injectable second-line), plague, tularaemia, brucellosis",
    "adult": "15 mg/kg IM/IV OD (max 1 g); reduce to 750 mg in >60y; 2â€“3Ã— weekly DOTS after 2 months",
    "child": "20â€“40 mg/kg/day IM (max 1 g)",
    "avoid": "Ototoxicity (irreversible hearing loss), nephrotoxicity; avoid in pregnancy (VIII nerve toxicity in fetus); monitor creatinine",
    "drug": "Streptomycin",
    "sideEffects": [
      "Ototoxicity (vestibular)",
      "Nephrotoxicity",
      "Rash",
      "Injection site pain",
      "Paresthesias"
    ],
    "seriousRisks": [
      "Irreversible vestibular damage/deafness",
      "Acute renal failure",
      "Neuromuscular blockade",
      "Severe hypersensitivity"
    ],
    "renalAdj": "Yes â€” extend interval: CrCl 50-90: every 24-72h; CrCl 10-50: every 24-72h; avoid if possible in CrCl <10",
    "hepaticAdj": "No â€” standard dosing (renally eliminated)",
    "pregnancy": "Category D â€” causes fetal ototoxicity; contraindicated",
    "lactation": "Caution â€” poorly absorbed orally by infant; risk considered low",
    "drugInteractions": [
      "Loop diuretics (furosemide) â€” additive ototoxicity and nephrotoxicity",
      "Other aminoglycosides â€” additive toxicity",
      "Neuromuscular blockers â€” enhanced blockade"
    ],
    "monitoring": [
      "Renal function (SCr/BUN)",
      "Audiometry",
      "Vestibular function",
      "Drug levels (if available)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "1000 mg/day IM (15 mg/kg/day)",
    "clinicalPearl": "Preferentially causes vestibular toxicity (not cochlear) â€” watch for gait disturbance before hearing loss."
  },
  {
    "rank": 407,
    "name": "Bedaquiline",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H1",
    "brand": "Sirturo / Bedaquiline (DOTS-Plus)",
    "formation": "Diarylquinoline; inhibits mycobacterial ATP synthase â€“ novel mechanism; MDR-TB agent",
    "uses": "Multidrug-resistant TB (MDR-TB) and pre-XDR-TB as part of combination regimen",
    "adult": "400 mg OD Ã— 2 weeks, then 200 mg 3Ã— weekly Ã— 22 weeks (total 24 weeks); under DOTS-Plus",
    "child": "5â€“<12y: weight-banded; approved down to 5 years (>15 kg)",
    "avoid": "QTc >500 ms, concurrent QT-prolonging drugs; monitor ECG and LFTs; only prescribed at PMDT centres",
    "drug": "Bedaquiline",
    "sideEffects": [
      "Nausea",
      "Arthralgia",
      "Headache",
      "Haemoptysis",
      "Chest pain"
    ],
    "seriousRisks": [
      "QT prolongation",
      "Hepatotoxicity",
      "Increased mortality signal (mechanism unclear)",
      "Severe arrhythmia"
    ],
    "renalAdj": "No â€” standard dosing (mild-moderate); avoid in severe renal impairment",
    "hepaticAdj": "Yes â€” avoid in moderate-severe hepatic impairment; use with caution in mild",
    "pregnancy": "Category B â€” animal data reassuring; insufficient human data; use in MDR-TB only if no alternative",
    "lactation": "Avoid â€” excreted in breast milk; long half-life (5 months)",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” significantly reduced bedaquiline levels",
      "QT-prolonging drugs (clofazimine, moxifloxacin) â€” additive QT prolongation",
      "CYP3A4 inhibitors (azoles) â€” increased bedaquiline exposure"
    ],
    "monitoring": [
      "ECG (QTc â€” baseline, 2, 12, 24 weeks)",
      "LFT (monthly)",
      "Electrolytes (K+, Mg2+)",
      "Sputum culture"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day for 2 weeks, then 200 mg three times/week for 22 weeks",
    "clinicalPearl": "First new anti-TB drug in 40 years â€” used only for MDR-TB; QT monitoring is mandatory."
  },
  {
    "rank": 408,
    "name": "Clofazimine",
    "section": "Section 11: Anti-Tuberculosis & Leprosy",
    "category": "Anti-TB",
    "schedule": "H",
    "brand": "Clofaz / Lamprene",
    "formation": "Riminophenazine dye; binds mycobacterial DNA and generates reactive oxygen species; bactericidal",
    "uses": "Leprosy (multibacillary â€“ part of MDT), MDR-TB regimen (BPaLM), Mycobacterium avium complex",
    "adult": "Leprosy: 50 mg OD + 300 mg supervised once monthly; MDR-TB: 100 mg OD",
    "child": "1 mg/kg/day; paediatric MDT packs available",
    "avoid": "Causes reversible reddish-brown skin discolouration and ichthyosis; counsel patient; avoid severe hepatic disease",
    "drug": "Clofazimine",
    "sideEffects": [
      "Skin discoloration (red-brown/black)",
      "GI intolerance",
      "Ichthyosis",
      "Photosensitivity",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "QT prolongation",
      "Crystal deposition in GI tract",
      "Splenic infarction",
      "Severe GI toxicity"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” skin discoloration in neonate; use only if essential (leprosy/MDR-TB)",
    "lactation": "Caution â€” excreted in breast milk; may cause skin discoloration in infant",
    "drugInteractions": [
      "Bedaquiline â€” additive QT prolongation (critical)",
      "Moxifloxacin â€” additive QT prolongation",
      "Rifampicin â€” may reduce clofazimine levels"
    ],
    "monitoring": [
      "ECG (QTc)",
      "Skin pigmentation",
      "LFT",
      "Electrolytes"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day (leprosy reactional states)",
    "clinicalPearl": "Pink-red skin discoloration is dose-dependent and reversible but may persist for years after stopping."
  },
  {
    "rank": 409,
    "name": "Epinephrine (Adrenaline)",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H",
    "brand": "Adrenaline IP / EpiPen / Anapen",
    "formation": "Endogenous catecholamine; Î±1+Î²1+Î²2 agonist; primary vasopressor and cardiac stimulant",
    "uses": "Anaphylaxis (first-line), cardiac arrest (ACLS), severe bronchospasm, croup (nebulised)",
    "adult": "Anaphylaxis: 0.5 mg (0.5 mL of 1:1000) IM anterolateral thigh; repeat every 5â€“15 min PRN; ACLS: 1 mg IV every 3â€“5 min",
    "child": "Anaphylaxis: 0.01 mg/kg IM (max 0.5 mg); ACLS: 0.01 mg/kg IV every 3â€“5 min",
    "avoid": "No absolute contraindication in anaphylaxis or cardiac arrest; use with caution in hypertensive/ischaemic heart disease",
    "drug": "Epinephrine (Adrenaline)",
    "sideEffects": [
      "Tachycardia",
      "Anxiety/tremor",
      "Hypertension",
      "Headache",
      "Pallor"
    ],
    "seriousRisks": [
      "Ventricular arrhythmia",
      "Acute myocardial infarction",
      "Hypertensive crisis",
      "Pulmonary oedema",
      "Cerebral haemorrhage"
    ],
    "renalAdj": "No â€” standard dosing (emergency use)",
    "hepaticAdj": "No â€” standard dosing (emergency use)",
    "pregnancy": "Category C â€” essential for anaphylaxis; benefits outweigh risks; may cause fetal tachycardia",
    "lactation": "Safe â€” poorly absorbed orally; emergency use justified",
    "drugInteractions": [
      "Beta-blockers â€” paradoxical hypertension (unopposed alpha effect)",
      "MAOIs â€” severe hypertensive crisis",
      "Halogenated anaesthetics â€” ventricular sensitization"
    ],
    "monitoring": [
      "Heart rate",
      "Blood pressure",
      "ECG",
      "Oxygen saturation",
      "Respiratory response"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Anaphylaxis: 0.5 mg IM (1:1000); infusion: titrated to response",
    "clinicalPearl": "Drug of choice for anaphylaxis â€” give IM into outer thigh; never delay for IV access."
  },
  {
    "rank": 410,
    "name": "Atropine Sulphate",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H",
    "brand": "Atropine Sulphate IP / Atropair",
    "formation": "Anticholinergic (muscarinic antagonist); blocks parasympathetic tone on heart, secretions, and smooth muscle",
    "uses": "Symptomatic bradycardia, organophosphate poisoning, pre-anaesthetic drying agent, ophthalmology (mydriasis)",
    "adult": "Bradycardia: 0.5â€“1 mg IV every 3â€“5 min (max 3 mg); OP poisoning: 2â€“4 mg IV every 5â€“10 min until secretions dry",
    "child": "0.02 mg/kg IV (min 0.1 mg, max 0.5 mg per dose); OP poisoning: 0.05 mg/kg IV titrated",
    "avoid": "Angle-closure glaucoma, myasthenia gravis, obstructive uropathy; use caution in febrile children (impairs sweating)",
    "drug": "Atropine Sulphate",
    "sideEffects": [
      "Dry mouth",
      "Tachycardia",
      "Urinary retention",
      "Constipation",
      "Blurred vision"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma",
      "Paralytic ileus",
      "Toxic psychosis (high doses)",
      "Hyperthermia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” crosses placenta; may cause fetal tachycardia; use in emergency",
    "lactation": "Caution â€” excreted in breast milk; monitor infant for anticholinergic effects",
    "drugInteractions": [
      "Anticholinergic drugs â€” additive toxicity",
      "Digoxin â€” reduced tachycardia reversal in digoxin toxicity",
      "Metoclopramide â€” opposing GI effects"
    ],
    "monitoring": [
      "Heart rate",
      "BP",
      "Pupil size (organophosphate poisoning)",
      "Urinary output"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3 mg (single IV bolus for bradycardia); organophosphate poisoning: titrate until secretions dry",
    "clinicalPearl": "In organophosphate poisoning, titrate atropine to drying of secretions (NOT heart rate) â€” use large doses."
  },
  {
    "rank": 411,
    "name": "Norepinephrine (Noradrenaline)",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H",
    "brand": "Levophed / Noradrenaline Bitartrate IP",
    "formation": "Endogenous catecholamine; primarily Î±1-adrenergic agonist causing vasoconstriction; mild Î²1 inotropic effect",
    "uses": "Septic shock (vasopressor of choice), cardiogenic shock, other distributive shock states",
    "adult": "0.01â€“3 mcg/kg/min IV infusion; titrate to MAP â‰¥65 mmHg; via central venous catheter preferred",
    "child": "0.01â€“2 mcg/kg/min IV infusion, titrated",
    "avoid": "Hypovolaemia (correct before starting), mesenteric/peripheral vascular thrombosis; avoid peripheral IV if possible (extravasation necrosis)",
    "drug": "Norepinephrine (Noradrenaline)",
    "sideEffects": [
      "Hypertension",
      "Bradycardia (reflex)",
      "Peripheral vasoconstriction",
      "Headache",
      "Extravasation necrosis"
    ],
    "seriousRisks": [
      "Peripheral ischaemia/gangrene",
      "Organ hypoperfusion",
      "Tissue necrosis (extravasation)",
      "Severe hypertension"
    ],
    "renalAdj": "No â€” standard dosing (titrated to MAP in ICU)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” may reduce uterine blood flow; use only in life-threatening shock",
    "lactation": "Safe â€” emergency use justified; poor oral absorption",
    "drugInteractions": [
      "MAOIs â€” severe hypertensive crisis",
      "Tricyclic antidepressants â€” enhanced pressor response",
      "Halogenated anaesthetics â€” arrhythmia sensitization"
    ],
    "monitoring": [
      "MAP (target 65-70 mmHg)",
      "Urine output",
      "Lactate",
      "Peripheral perfusion",
      "ECG"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Titrated to response (typically 0.01-3 mcg/kg/min); no fixed max",
    "clinicalPearl": "First-line vasopressor in septic shock per SSC guidelines â€” always give via central line to prevent necrosis."
  },
  {
    "rank": 412,
    "name": "Dopamine",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H",
    "brand": "Intropin / Dopamine HCl IP / Revimine",
    "formation": "Catecholamine; dose-dependent: low-dose = DA1 renal vasodilation; medium = Î²1 inotropic; high-dose = Î±1 vasoconstriction",
    "uses": "Cardiogenic shock, bradycardia refractory to atropine, acute decompensated heart failure with hypotension",
    "adult": "2â€“20 mcg/kg/min IV infusion via central line; titrate to response",
    "child": "2â€“20 mcg/kg/min IV infusion, titrated",
    "avoid": "Uncorrected tachyarrhythmias, phaeochromocytoma, VF; 'renal-dose dopamine' no longer recommended for renal protection",
    "drug": "Dopamine",
    "sideEffects": [
      "Tachycardia",
      "Nausea/vomiting",
      "Hypertension",
      "Arrhythmia",
      "Headache"
    ],
    "seriousRisks": [
      "Ventricular arrhythmias",
      "Tissue necrosis (extravasation)",
      "Peripheral gangrene (high dose)",
      "Myocardial ischaemia"
    ],
    "renalAdj": "No â€” standard dosing (titrated by effect)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” may reduce uteroplacental perfusion; use only in life-threatening situations",
    "lactation": "Safe â€” emergency ICU use justified",
    "drugInteractions": [
      "MAOIs â€” severe hypertension (contraindicated)",
      "Halogenated anaesthetics â€” arrhythmia risk",
      "Beta-blockers â€” cardiac effects antagonised"
    ],
    "monitoring": [
      "Heart rate",
      "BP (MAP)",
      "ECG",
      "Urine output",
      "Lactate"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Titrated: 2-20 mcg/kg/min (no absolute max; effect-guided)",
    "clinicalPearl": "Dose-dependent effects: low (renal/DA), medium (beta-1/cardiac), high (alpha/vasopressor) â€” NE preferred in sepsis."
  },
  {
    "rank": 413,
    "name": "Dobutamine",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H",
    "brand": "Dobutrex / Dobutamine HCl IP",
    "formation": "Synthetic catecholamine; Î²1-selective inotropic agent; increases cardiac contractility and CO",
    "uses": "Acute decompensated heart failure with low cardiac output (cardiogenic shock adjunct), cardiac stress testing",
    "adult": "2â€“20 mcg/kg/min IV infusion, titrated to haemodynamics; stress test: 5â€“40 mcg/kg/min incremental",
    "child": "2â€“20 mcg/kg/min IV infusion",
    "avoid": "HOCM (outflow tract obstruction worsens), atrial fibrillation with rapid rate (increases ventricular response); not a vasopressor",
    "drug": "Dobutamine",
    "sideEffects": [
      "Tachycardia",
      "Hypertension",
      "Palpitations",
      "Headache",
      "Nausea"
    ],
    "seriousRisks": [
      "Ventricular arrhythmias",
      "Myocardial ischaemia (increased O2 demand)",
      "Hypotension (vasodilation)",
      "Hypokalaemia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” limited data; use in cardiogenic shock if essential",
    "lactation": "Safe â€” emergency use justified",
    "drugInteractions": [
      "Beta-blockers â€” attenuate inotropic effect",
      "MAOIs â€” exaggerated pressor response",
      "Nitrates â€” synergistic in cardiogenic shock (caution hypotension)"
    ],
    "monitoring": [
      "Heart rate",
      "BP",
      "ECG",
      "Cardiac output (if available)",
      "Urine output"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Titrated: 2-40 mcg/kg/min",
    "clinicalPearl": "Preferred inotrope in cardiogenic shock â€” increases contractility with less chronotropy than adrenaline."
  },
  {
    "rank": 414,
    "name": "Ketamine",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H1",
    "brand": "Ketalar / Aneket / Ketoject",
    "formation": "Phencyclidine-class NMDA receptor antagonist; dissociative anaesthetic with bronchodilation and sympathomimetic properties",
    "uses": "Induction of anaesthesia, procedural sedation in ED, RSI in haemodynamically unstable patients, ketamine infusion for pain",
    "adult": "IV induction: 1â€“2 mg/kg; IM: 4â€“6 mg/kg; procedural sedation: 0.5â€“1 mg/kg IV; analgesic: 0.1â€“0.5 mg/kg IV",
    "child": "IV induction: 1â€“2 mg/kg; IM: 4â€“6 mg/kg (excellent IM bioavailability, useful in paediatric emergencies)",
    "avoid": "Ischaemic heart disease, uncontrolled hypertension, conditions where raised ICP is a concern (use cautiously â€“ evidence evolving); pre-medicate with benzodiazepine to reduce emergence phenomena",
    "drug": "Ketamine",
    "sideEffects": [
      "Emergence reactions (hallucinations)",
      "Increased secretions",
      "Tachycardia",
      "Hypertension",
      "Nausea"
    ],
    "seriousRisks": [
      "Laryngospasm",
      "Respiratory depression (high doses)",
      "Raised ICP/IOP",
      "Severe emergence delirium",
      "Cystitis (chronic use)"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment (norketamine accumulation)",
    "hepaticAdj": "Yes â€” use with caution; hepatically metabolised",
    "pregnancy": "Category B â€” used for emergency anaesthesia; may increase uterine tone at term",
    "lactation": "Caution â€” excreted in milk; single use generally acceptable",
    "drugInteractions": [
      "Benzodiazepines â€” attenuate emergence reactions (beneficial combination)",
      "Theophylline â€” lowered seizure threshold",
      "Lithium â€” prolonged anaesthesia"
    ],
    "monitoring": [
      "HR",
      "BP",
      "SpO2",
      "Emergence reaction assessment",
      "ICP (TBI patients)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2 mg/kg IV bolus (anaesthesia); infusion titrated to effect",
    "clinicalPearl": "Dissociative anaesthetic that preserves airway reflexes and BP â€” ideal for emergency/field anaesthesia."
  },
  {
    "rank": 415,
    "name": "Propofol",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Emergency",
    "schedule": "H",
    "brand": "Diprivan / Propofol-Lipuro / Fresofol",
    "formation": "Alkylphenol; GABA-A potentiator; ultra-short acting IV anaesthetic and sedative",
    "uses": "Induction and maintenance of anaesthesia, ICU sedation, procedural sedation, status epilepticus (refractory)",
    "adult": "Induction: 1â€“2.5 mg/kg IV (1â€“1.5 mg/kg in elderly); ICU sedation: 0.3â€“4 mg/kg/h infusion",
    "child": "Induction: 2.5â€“3.5 mg/kg IV; NOT recommended for long-term ICU sedation in children (propofol infusion syndrome risk)",
    "avoid": "Propofol infusion syndrome (PRIS) risk with prolonged high-dose infusion (>4 mg/kg/h >48h); soya/egg allergy; avoid in paediatric ICU sedation",
    "drug": "Propofol",
    "sideEffects": [
      "Hypotension",
      "Apnoea/respiratory depression",
      "Injection site pain",
      "Bradycardia",
      "Hypertriglyceridaemia"
    ],
    "seriousRisks": [
      "Propofol infusion syndrome (PRIS) â€” fatal",
      "Severe respiratory depression",
      "Anaphylaxis",
      "Bacterial contamination (lipid emulsion)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” used for procedural sedation; crosses placenta; neonatal CNS depression possible",
    "lactation": "Caution â€” present in milk; discard milk for 24 hours after use",
    "drugInteractions": [
      "CNS depressants/opioids â€” additive respiratory depression",
      "Midazolam â€” synergistic sedation (dose-reduce both)",
      "Fentanyl â€” potentiation (standard combination)"
    ],
    "monitoring": [
      "SpO2",
      "BP",
      "Heart rate",
      "Triglycerides (prolonged ICU use)",
      "Urinalysis (PRIS: acidosis, rhabdomyolysis)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "ICU sedation: 4 mg/kg/hour (max); anaesthesia induction: 1.5-2.5 mg/kg",
    "clinicalPearl": "Propofol infusion syndrome occurs at doses >4 mg/kg/h for >48h â€” monitor for metabolic acidosis and rhabdomyolysis."
  },
  {
    "rank": 416,
    "name": "Warfarin",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Haematology",
    "schedule": "H",
    "brand": "Warf / Warfarin Sodium IP / Coumadin",
    "formation": "Vitamin K antagonist; inhibits hepatic synthesis of clotting factors II, VII, IX, X and proteins C and S",
    "uses": "AF (non-valvular and valvular), DVT/PE treatment and prevention, mechanical prosthetic heart valves, thrombophilia",
    "adult": "Individualised dose targeting INR 2â€“3 (AF/DVT) or 2.5â€“3.5 (mechanical mitral valve); loading 5â€“10 mg OD, maintenance 2â€“10 mg OD",
    "child": "0.1â€“0.2 mg/kg OD under haematology guidance; target INR per indication",
    "avoid": "Active bleeding, pregnancy (teratogenic â€“ Category X; use heparin), uncontrolled hypertension; numerous drug and food (vit K) interactions â€“ check every co-medication",
    "drug": "Warfarin",
    "sideEffects": [
      "Bleeding (minor)",
      "Bruising",
      "Nausea",
      "Alopecia",
      "Skin necrosis (rare)"
    ],
    "seriousRisks": [
      "Major haemorrhage (intracranial, GI)",
      "Warfarin skin necrosis (protein C deficiency)",
      "Purple toe syndrome",
      "Fetal warfarin syndrome (embryopathy)"
    ],
    "renalAdj": "Yes â€” use with caution; increased bleeding risk; more frequent INR monitoring",
    "hepaticAdj": "Yes â€” avoid or use with extreme caution; severely impairs clotting factor synthesis",
    "pregnancy": "Category X â€” absolute contraindication (1st trimester): embryopathy; use LMWH instead",
    "lactation": "Safe â€” does not transfer significantly into breast milk; compatible",
    "drugInteractions": [
      "NSAIDs/aspirin â€” increased bleeding risk",
      "Rifampicin â€” markedly reduced warfarin effect (CYP induction)",
      "Azole antifungals/metronidazole â€” markedly increased INR"
    ],
    "monitoring": [
      "INR (target 2-3 for most indications; 2.5-3.5 for mechanical valves)",
      "CBC",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Individualised by INR (no fixed max dose)",
    "clinicalPearl": "Hundreds of drug and food interactions â€” consistent vitamin K intake is as important as the dose itself."
  },
  {
    "rank": 417,
    "name": "Heparin (Unfractionated)",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Haematology",
    "schedule": "H",
    "brand": "Heparin Sodium IP / Uniparin / Heplean",
    "formation": "Sulphated polysaccharide; potentiates antithrombin III; inhibits thrombin (IIa) and Xa; immediate onset IV",
    "uses": "Acute DVT/PE anticoagulation, STEMI/ACS adjunct, CABG and cardiac catheterisation, haemodialysis circuit, bridging anticoagulation",
    "adult": "ACS: 60â€“70 IU/kg IV bolus (max 5000 IU), then 12â€“15 IU/kg/h infusion; target aPTT 60â€“100 s; DVT/PE: 80 IU/kg bolus then 18 IU/kg/h",
    "child": "75 IU/kg IV bolus, then 28 IU/kg/h (<1y) or 20 IU/kg/h (>1y); titrate to aPTT",
    "avoid": "Active haemorrhage, HIT (heparin-induced thrombocytopenia â€“ monitor platelets), severe thrombocytopenia; protamine sulphate reverses toxicity",
    "drug": "Heparin Unfractionated",
    "sideEffects": [
      "Bleeding",
      "Injection site haematoma",
      "Thrombocytopenia (HIT)",
      "Hyperkalaemia",
      "Transient transaminase elevation"
    ],
    "seriousRisks": [
      "Heparin-induced thrombocytopenia (HIT) â€” paradoxical thrombosis",
      "Major haemorrhage",
      "Osteoporosis (long-term)",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” use with caution; increased bleeding risk in renal failure; aPTT monitoring essential",
    "hepaticAdj": "Yes â€” use with caution; hepatic impairment increases bleeding risk",
    "pregnancy": "Category C â€” drug of choice parenteral anticoagulant in pregnancy (does not cross placenta)",
    "lactation": "Safe â€” does not transfer into breast milk",
    "drugInteractions": [
      "NSAIDs/antiplatelet agents â€” additive bleeding risk",
      "Nitroglycerin IV â€” heparin resistance",
      "Protamine â€” reversal agent (1 mg per 100 IU heparin)"
    ],
    "monitoring": [
      "aPTT (target 60-100 sec, or 1.5-2.5x control)",
      "Platelet count (HIT screening)",
      "Anti-Xa level (if available)",
      "CBC"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Continuous infusion: 35,000 IU/24h (weight-adjusted protocol)",
    "clinicalPearl": "Monitor platelets day 5-10 for HIT â€” any platelet drop >50% with thrombosis warrants immediate cessation."
  },
  {
    "rank": 418,
    "name": "Tranexamic Acid",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Haematology",
    "schedule": "H",
    "brand": "Traxyl / Trenaxa / Cyclokapron / TXA",
    "formation": "Lysine analogue antifibrinolytic; blocks plasminogenâ€“fibrin binding; prevents clot lysis",
    "uses": "Trauma haemorrhage (CRASH-2 evidence â€“ give within 3h), PPH, menorrhagia, surgical bleeding, haemophilia haemarthrosis",
    "adult": "Trauma/PPH: 1 g IV over 10 min, repeat 1 g over 8h; menorrhagia: 1â€“1.5 g TDS for 3â€“4 days PO",
    "child": "10â€“15 mg/kg IV TDS (max 1 g/dose); or 15â€“25 mg/kg PO TDS",
    "avoid": "Active thromboembolic disease, subarachnoid haemorrhage (cerebral oedema risk), haematuria (upper urinary tract â€“ risk of ureteral clot)",
    "drug": "Tranexamic Acid",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Abdominal pain",
      "Visual disturbances",
      "Headache"
    ],
    "seriousRisks": [
      "Thromboembolic events (DVT, PE)",
      "Seizures (high IV doses)",
      "Cortical venous thrombosis",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” reduce dose significantly in renal impairment (accumulation risk); CrCl <10: 250 mg BD",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” widely used in PPH; WOMAN trial supports use; considered safe",
    "lactation": "Safe â€” excreted in breast milk at low concentrations; compatible with breastfeeding",
    "drugInteractions": [
      "Procoagulant agents â€” additive thrombotic risk",
      "THAM (tromethamine) â€” incompatible in solution",
      "Factor IX complex â€” increased thrombosis risk"
    ],
    "monitoring": [
      "Renal function",
      "Visual acuity (prolonged use)",
      "Signs of thrombosis",
      "Haemoglobin"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "4000 mg/day (IV); 6000 mg/day (oral â€” menorrhagia)",
    "clinicalPearl": "Must be given within 3 hours of trauma/PPH onset â€” efficacy drops sharply after 3 hours (CRASH-2 trial)."
  },
  {
    "rank": 419,
    "name": "Streptokinase",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Haematology",
    "schedule": "H",
    "brand": "Streptokinase IP / Streptase / Kabikinase",
    "formation": "Bacterial protein thrombolytic; forms complex with plasminogen to activate plasmin; lysing established thrombi",
    "uses": "STEMI (thrombolysis when primary PCI unavailable, within 12h), massive PE, acute peripheral arterial occlusion",
    "adult": "STEMI: 1.5 million IU IV over 60 min (single dose); PE: 250,000 IU loading over 30 min, then 100,000 IU/h Ã— 24h",
    "child": "3500â€“4000 IU/kg over 30 min loading, then 1000â€“1500 IU/kg/h; specialist guidance essential",
    "avoid": "Recent stroke (<6m), active internal bleeding, recent major surgery/trauma (<2w), uncontrolled hypertension, pregnancy, previous SK therapy within 6â€“12m (antibody resistance)",
    "drug": "Streptokinase",
    "sideEffects": [
      "Bleeding",
      "Fever",
      "Allergic reactions",
      "Hypotension",
      "Nausea"
    ],
    "seriousRisks": [
      "Intracranial haemorrhage",
      "Major systemic bleeding",
      "Anaphylaxis/anaphylactoid reactions",
      "Reperfusion arrhythmia"
    ],
    "renalAdj": "No â€” standard dosing (use with caution; increased bleeding risk)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” teratogenic potential not established; risk of placental abruption; use only if life-threatening",
    "lactation": "Avoid â€” insufficient data; large molecular weight makes transfer unlikely but avoid for 24 hours",
    "drugInteractions": [
      "Anticoagulants (heparin/warfarin) â€” markedly increased haemorrhage risk",
      "Antiplatelet drugs â€” additive bleeding",
      "ACE inhibitors â€” increased anaphylactoid reaction risk"
    ],
    "monitoring": [
      "Neurological status",
      "BP",
      "aPTT/PT",
      "CBC/Hb",
      "ECG (post-MI use)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "1,500,000 IU over 60 minutes (STEMI); 250,000 IU loading + 100,000 IU/hour (DVT/PE)",
    "clinicalPearl": "Antigenic â€” cannot be re-used within 6 months to 1 year due to neutralising antibodies from prior streptococcal infection."
  },
  {
    "rank": 420,
    "name": "Alteplase (tPA)",
    "section": "Section 12: Emergency, Critical Care & Haematology",
    "category": "Haematology",
    "schedule": "H",
    "brand": "Actilyse / Alteplase IP",
    "formation": "Recombinant tissue plasminogen activator (rt-PA); clot-selective fibrinolytic; cleaves plasminogen to plasmin",
    "uses": "Acute ischaemic stroke (within 4.5h), massive PE, STEMI (accelerated regimen), central venous catheter occlusion",
    "adult": "Stroke: 0.9 mg/kg IV (max 90 mg); 10% bolus, 90% over 60 min; PE: 100 mg over 2h; STEMI: 15 mg bolus + 0.75 mg/kg over 30 min + 0.5 mg/kg over 60 min",
    "child": "Stroke <18y: 0.9 mg/kg (max 90 mg) â€“ limited data; CVC occlusion: 0.5â€“2 mg instilled into catheter",
    "avoid": "Same as streptokinase plus: blood glucose <50 or >400 mg/dL for stroke; haemorrhagic transformation risk; anticoagulants at full dose; time-window strict",
    "drug": "Alteplase (tPA)",
    "sideEffects": [
      "Bleeding at puncture sites",
      "Nausea/vomiting",
      "Hypotension",
      "Fever",
      "Hypersensitivity"
    ],
    "seriousRisks": [
      "Intracranial haemorrhage (stroke use: 6% risk)",
      "Major systemic haemorrhage",
      "Angioedema",
      "Reperfusion arrhythmia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in severe hepatic impairment (increased bleeding risk)",
    "pregnancy": "Category C â€” limited data; risk of placental haemorrhage; use only in life-threatening conditions",
    "lactation": "Caution â€” short half-life (5 min); discard breast milk for 24 hours after use",
    "drugInteractions": [
      "Anticoagulants â€” major increased haemorrhage risk",
      "Antiplatelet drugs â€” additive bleeding",
      "Nitroglycerin IV â€” may reduce alteplase efficacy"
    ],
    "monitoring": [
      "Neurological status (stroke)",
      "BP (strict <180/105 in stroke)",
      "CBC",
      "PT/aPTT",
      "ECG"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg total (STEMI/PE); 0.9 mg/kg max 90 mg (ischaemic stroke)",
    "clinicalPearl": "In ischaemic stroke: 4.5-hour treatment window â€” BP must be <185/110 before giving; check all contraindications."
  },
  {
    "rank": 421,
    "name": "Oxytocin",
    "section": "Section 13: Obstetrics & Gynaecology",
    "category": "Obstetrics",
    "schedule": "H",
    "brand": "Syntocinon / Pitocin / Oxyto",
    "formation": "Synthetic hypothalamic nonapeptide; stimulates myometrial OT receptors causing uterine contractions",
    "uses": "Induction of labour, augmentation of labour, active management of third stage (PPH prevention and treatment)",
    "adult": "Labour induction: 1â€“2 mIU/min IV infusion, titrate by 1â€“2 mIU every 30 min; PPH: 10 IU IM stat or 40 IU in 500 mL NS over 4h IV",
    "child": "Not applicable",
    "avoid": "Cephalopelvic disproportion, abnormal foetal presentation, previous classical CS, foetal distress, hypertonic uterine contractions; water intoxication at high doses",
    "drug": "Oxytocin",
    "sideEffects": [
      "Uterine hyperstimulation",
      "Nausea/vomiting",
      "Water intoxication/hyponatraemia",
      "Hypotension",
      "Fetal bradycardia"
    ],
    "seriousRisks": [
      "Uterine rupture",
      "Fetal distress/asphyxia",
      "Severe hyponatraemia (antidiuretic effect)",
      "Amniotic fluid embolism",
      "Placental abruption"
    ],
    "renalAdj": "Yes â€” monitor fluid balance carefully; risk of water retention",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category â€” used for induction/augmentation; administer with continuous fetal monitoring only",
    "lactation": "Safe â€” used to promote milk let-down; compatible",
    "drugInteractions": [
      "Prostaglandins â€” additive uterotonic effect (increased hyperstimulation risk)",
      "Ergometrine â€” additive uterotonic effect",
      "Sympathomimetics â€” may reduce oxytocin effect"
    ],
    "monitoring": [
      "Uterine contractions (frequency/duration/intensity)",
      "Fetal heart rate (CTG)",
      "Maternal BP",
      "Fluid balance/urine output"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "40 IU/500 mL (PPH); induction: 20 milliunits/min (titrated)",
    "clinicalPearl": "Rapid IV bolus causes severe hypotension â€” always give as slow IV infusion, especially in PPH management."
  },
  {
    "rank": 422,
    "name": "Mifepristone",
    "section": "Section 13: Obstetrics & Gynaecology",
    "category": "Obstetrics",
    "schedule": "X",
    "brand": "Mifeprin / Mifegest / Korlym",
    "formation": "Synthetic antiprogestogen and antiglucocorticoid; competitive PR antagonist; sensitises uterus to prostaglandins",
    "uses": "Medical termination of pregnancy (MTP) â‰¤9 weeks (with misoprostol), cervical priming before surgical termination",
    "adult": "MTP: 200 mg PO single dose, followed by misoprostol 24â€“48h later; cervical priming: 200 mg 36h before procedure",
    "child": "Not applicable",
    "avoid": "Ectopic pregnancy (must be excluded), IUD in situ, chronic adrenal failure (glucocorticoid-dependent), haemorrhagic disorders, long-term corticosteroid therapy",
    "drug": "Mifepristone",
    "sideEffects": [
      "Abdominal cramps",
      "Nausea",
      "Vomiting",
      "Headache",
      "Vaginal bleeding"
    ],
    "seriousRisks": [
      "Serious bacterial infection (Clostridium sordellii)",
      "Fatal sepsis (rare)",
      "Heavy haemorrhage requiring transfusion",
      "Incomplete abortion requiring surgery"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment (hepatically metabolised)",
    "pregnancy": "Category â€” used for medical termination; acts as anti-progestogen",
    "lactation": "Avoid â€” excreted in breast milk; withhold breastfeeding for 3-4 days",
    "drugInteractions": [
      "Corticosteroids â€” mifepristone reduces glucocorticoid efficacy",
      "Anticoagulants â€” increased bleeding risk",
      "NSAIDs â€” may reduce prostaglandin-mediated effects (avoid for 8-12 days after)"
    ],
    "monitoring": [
      "Haemoglobin (post-procedure)",
      "Confirmation of complete expulsion (ultrasound)",
      "Signs of infection",
      "Vital signs"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "600 mg single dose (MTP); 200 mg (standard WHO regimen with misoprostol)",
    "clinicalPearl": "Always combine with misoprostol 24-48 hours later â€” mifepristone alone has only 60-70% efficacy for complete abortion."
  },
  {
    "rank": 423,
    "name": "Misoprostol",
    "section": "Section 13: Obstetrics & Gynaecology",
    "category": "Obstetrics",
    "schedule": "H",
    "brand": "Cytolog / Misoprost / Cytotec",
    "formation": "Synthetic PGE1 analogue; stimulates myometrial EP1/EP3 receptors; causes uterine contractions and cervical ripening",
    "uses": "PPH prevention/treatment, medical MTP (with mifepristone), labour induction (cervical ripening), missed miscarriage",
    "adult": "PPH: 600 mcg sublingual/buccal or 800 mcg rectal; MTP: 800 mcg vaginal/sublingual 48h after mifepristone; labour induction: 25 mcg PV every 6h",
    "child": "Not applicable",
    "avoid": "Previous CS or uterine scar (increased uterine rupture risk with labour induction doses), allergy to prostaglandins; teratogenic if pregnancy continues after failed MTP",
    "drug": "Misoprostol",
    "sideEffects": [
      "Uterine cramping",
      "Diarrhoea",
      "Nausea",
      "Fever/chills",
      "Vomiting"
    ],
    "seriousRisks": [
      "Uterine hyperstimulation/rupture (especially VBAC)",
      "Amniotic fluid embolism",
      "Severe haemorrhage",
      "Fetal distress"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category X (1st trimester) â€” used for MTP and PPH; MÃ¶bius syndrome risk if fails; contraindicated for GI use in pregnancy",
    "lactation": "Caution â€” present in small amounts in breast milk; single dose generally safe",
    "drugInteractions": [
      "Oxytocin â€” additive uterotonic (enhanced effect and risk)",
      "Mifepristone â€” synergistic for MTP (standard combination)",
      "NSAIDs â€” may reduce misoprostol GI protection effect"
    ],
    "monitoring": [
      "Uterine contractions",
      "Vaginal bleeding",
      "Fetal heart rate (obstetric use)",
      "Complete expulsion (MTP)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "800 mcg (MTP); 600 mcg (PPH prophylaxis â€” sublingual/rectal); 200 mcg (ulcer treatment)",
    "clinicalPearl": "Sublingual route has fastest onset and highest bioavailability for PPH â€” buccal route preferred in WHO PPH protocol."
  },
  {
    "rank": 424,
    "name": "Methylergometrine",
    "section": "Section 13: Obstetrics & Gynaecology",
    "category": "Obstetrics",
    "schedule": "H",
    "brand": "Methergin / Methylergot / Ergocal",
    "formation": "Ergot alkaloid; agonist at Î±-adrenergic and serotonin receptors in uterine smooth muscle; causes sustained tetanic contraction",
    "uses": "PPH treatment (second-line after oxytocin), subinvolution of uterus",
    "adult": "0.2 mg IM/IV (slow) stat; may repeat every 2â€“4h; oral 0.125â€“0.25 mg TDS Ã— 2â€“7 days",
    "child": "Not applicable",
    "avoid": "Hypertension, pre-eclampsia/eclampsia, Raynaud's phenomenon, peripheral vascular disease, cardiac disease; IV use only in life-threatening haemorrhage (hypertensive crisis risk)",
    "drug": "Methylergometrine",
    "sideEffects": [
      "Nausea/vomiting",
      "Uterine cramping",
      "Hypertension",
      "Dizziness",
      "Headache"
    ],
    "seriousRisks": [
      "Severe hypertension (contraindicated in PIH)",
      "Coronary vasospasm/MI",
      "Stroke",
      "Ergotism with prolonged use",
      "Severe vasoconstriction"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment",
    "pregnancy": "Category â€” used only for 3rd stage of labour/PPH; absolute contraindication before delivery of placenta",
    "lactation": "Caution â€” ergot alkaloids suppress lactation; avoid prolonged use in breastfeeding mothers",
    "drugInteractions": [
      "Vasopressors â€” severe hypertension (additive vasoconstriction)",
      "CYP3A4 inhibitors (azoles, macrolides) â€” increased ergotism risk",
      "Oxytocin â€” additive uterotonic (used sequentially)"
    ],
    "monitoring": [
      "BP (especially in PIH)",
      "Uterine tone",
      "Lochia",
      "Peripheral vasoconstriction signs"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "0.2 mg IM/IV; oral 0.2 mg TDS (3 days max postpartum)",
    "clinicalPearl": "Absolutely contraindicated in hypertension/PIH â€” causes severe vasospasm; give oxytocin/misoprostol instead."
  },
  {
    "rank": 425,
    "name": "Medroxyprogesterone Acetate",
    "section": "Section 13: Obstetrics & Gynaecology",
    "category": "Obstetrics",
    "schedule": "H",
    "brand": "Depo-Provera / Provera / Modus",
    "formation": "Synthetic progestin; agonist at PR; suppresses LH surge (contraception), stabilises endometrium",
    "uses": "Contraception (DMPA 3-monthly injection), endometriosis, dysfunctional uterine bleeding, hormone replacement therapy, endometrial cancer",
    "adult": "Contraception: 150 mg IM every 3 months; DUB: 10 mg OD Ã— 10 days/cycle; cancer: 500â€“1000 mg IM/week",
    "child": "Not for contraception <16y; may be used for specific gynaecological indications under specialist care",
    "avoid": "Undiagnosed vaginal bleeding, active thromboembolic disease, liver disease, known/suspected breast cancer; bone density loss with prolonged contraceptive use â€“ counsel",
    "drug": "Medroxyprogesterone Acetate",
    "sideEffects": [
      "Irregular menstrual bleeding",
      "Weight gain",
      "Depression/mood changes",
      "Decreased libido",
      "Breast tenderness"
    ],
    "seriousRisks": [
      "VTE/pulmonary embolism",
      "Stroke (high-dose)",
      "Loss of bone mineral density (DMPA)",
      "Breast cancer risk (long-term HRT)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in active hepatic disease or hepatic tumours",
    "pregnancy": "Category X â€” absolutely contraindicated; congenital heart defects and virilisation risk",
    "lactation": "Safe â€” low-dose (DMPA) considered compatible with breastfeeding per WHO",
    "drugInteractions": [
      "CYP3A4 inducers (rifampicin) â€” reduced progestogen efficacy",
      "Anticoagulants â€” may reduce anticoagulant requirement",
      "Aminoglutethimide â€” reduced MPA levels"
    ],
    "monitoring": [
      "BP",
      "Bone density (DMPA long-term)",
      "Blood glucose (diabetics)",
      "Menstrual pattern"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10 mg/day oral (HRT/DUB); 150 mg IM every 3 months (contraception)",
    "clinicalPearl": "DMPA (150 mg IM) is 99.7% effective contraception but causes bone density loss â€” calcium/vitamin D supplementation recommended."
  },
  {
    "rank": 426,
    "name": "Amiodarone",
    "section": "Section 14: Cardiovascular Extended",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Cordarone / Amiodar / Tachyra",
    "formation": "Class III antiarrhythmic (Vaughan-Williams); also has Class I, II, IV actions; prolongs action potential and ERP in all cardiac tissues",
    "uses": "VF/pulseless VT (ACLS), AF/flutter (rate/rhythm control), sustained VT, refractory SVT",
    "adult": "Cardiac arrest: 300 mg IV bolus; AF cardioversion: 5 mg/kg IV over 20â€“60 min then 50 mg/h; maintenance: 100â€“200 mg OD PO",
    "child": "Cardiac arrest: 5 mg/kg IV bolus; AF/VT: 5 mg/kg IV over 20â€“60 min; oral 5â€“10 mg/kg/day",
    "avoid": "Iodine allergy (contains iodine), thyroid dysfunction, severe sinus node dysfunction, pulmonary toxicity history; multiple interactions; photosensitivity; routine PFT/TFT/LFT monitoring",
    "drug": "Amiodarone",
    "sideEffects": [
      "Thyroid dysfunction (hypo/hyperthyroidism)",
      "Photosensitivity",
      "Corneal microdeposits",
      "Peripheral neuropathy",
      "Nausea"
    ],
    "seriousRisks": [
      "Pulmonary toxicity (pulmonary fibrosis)",
      "Severe hepatotoxicity",
      "Torsades de pointes/QT prolongation",
      "Optic neuropathy/visual loss",
      "Fatal thyroid storm (hyperthyroidism)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment; hepatotoxicity risk",
    "pregnancy": "Category D â€” neonatal hypothyroidism, bradycardia; use only in life-threatening arrhythmia",
    "lactation": "Avoid â€” excreted in breast milk; neonatal thyroid suppression",
    "drugInteractions": [
      "Warfarin â€” markedly increased INR (inhibits CYP2C9)",
      "Digoxin â€” increased digoxin toxicity (doubles levels)",
      "QT-prolonging drugs â€” additive torsades risk"
    ],
    "monitoring": [
      "TFT (every 6 months)",
      "LFT",
      "CXR + PFT (annual)",
      "ECG (QTc)",
      "Eye examination (annual)",
      "Thyroid"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (maintenance); loading: 600-800 mg/day for 1-4 weeks",
    "clinicalPearl": "Half-life of 40-55 days â€” toxicities persist for months after stopping; check TFT and LFT every 6 months."
  },
  {
    "rank": 427,
    "name": "Ticagrelor",
    "section": "Section 14: Cardiovascular Extended",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Brilinta / Ticardia / Ticagrelor Cipla",
    "formation": "Reversible direct-acting P2Y12 ADP receptor antagonist; faster and more consistent platelet inhibition than clopidogrel",
    "uses": "ACS (STEMI and NSTEMI) with PCI or medical management, prevention of recurrent MI/stroke/CV death (PLATO trial)",
    "adult": "Loading: 180 mg PO stat; maintenance: 90 mg BD for 12 months with aspirin; reduce to 60 mg BD after 1 year if continued",
    "child": "Not established",
    "avoid": "Active bleeding, history of ICH, severe hepatic impairment; causes dyspnoea (non-dose related) and bradycardia; avoid high-dose aspirin (>100 mg/day reduces efficacy)",
    "drug": "Ticagrelor",
    "sideEffects": [
      "Dyspnoea (15%)",
      "Bleeding",
      "Headache",
      "Bradycardia",
      "Nausea"
    ],
    "seriousRisks": [
      "Major bleeding including intracranial haemorrhage",
      "Dyspnoea (adenosine-mediated â€” not cardiac)",
      "Ventricular pauses",
      "TIA/stroke risk if stopped prematurely"
    ],
    "renalAdj": "No â€” standard dosing in renal impairment",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” insufficient data; avoid in pregnancy",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Aspirin >100 mg/day â€” reduces ticagrelor efficacy (paradoxical)",
      "Strong CYP3A4 inhibitors (ketoconazole) â€” increased ticagrelor levels",
      "Strong CYP3A4 inducers (rifampicin) â€” decreased ticagrelor levels"
    ],
    "monitoring": [
      "CBC (Hb)",
      "Renal function",
      "Dyspnoea assessment",
      "Bleeding signs",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "180 mg loading; 90 mg BD (first year ACS); then 60 mg BD",
    "clinicalPearl": "Dyspnoea in 15% of patients â€” not cardiac; due to adenosine accumulation; usually mild and self-limiting."
  },
  {
    "rank": 428,
    "name": "Prasugrel",
    "section": "Section 14: Cardiovascular Extended",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Effient / Prasugrel Aurobindo",
    "formation": "Thienopyridine pro-drug; irreversible P2Y12 ADP receptor antagonist; more potent than clopidogrel (TRITON-TIMI 38)",
    "uses": "ACS managed with PCI (STEMI preferred); reduces MI and stent thrombosis vs clopidogrel",
    "adult": "Loading: 60 mg PO stat; maintenance: 10 mg OD with aspirin Ã— 12 months; 5 mg OD if <60 kg or â‰¥75y (use not recommended)",
    "child": "Not established",
    "avoid": "Prior stroke/TIA (net harm), active bleeding; avoid in â‰¥75y (excess bleeding risk unless high-risk patient); weight <60 kg â€“ use 5 mg dose",
    "drug": "Prasugrel",
    "sideEffects": [
      "Bleeding",
      "Hypertension",
      "Hyperlipidaemia",
      "Headache",
      "Back pain"
    ],
    "seriousRisks": [
      "Major bleeding (higher than clopidogrel)",
      "TTP (rare)",
      "Intracranial haemorrhage (especially >75 years, <60 kg, prior stroke/TIA)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category B â€” insufficient human data; avoid if possible",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Strong CYP3A4/2B6 inhibitors â€” reduced activation (less concern than clopidogrel)",
      "Anticoagulants â€” major bleeding risk",
      "NSAIDs â€” additive GI bleeding"
    ],
    "monitoring": [
      "CBC (Hb)",
      "Bleeding signs",
      "Platelet count",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "60 mg loading; 10 mg/day maintenance (5 mg/day if <60 kg or >75 years)",
    "clinicalPearl": "Absolutely contraindicated in prior stroke/TIA â€” net clinical harm; preferred over clopidogrel in PCI/stent."
  },
  {
    "rank": 429,
    "name": "Ranolazine",
    "section": "Section 14: Cardiovascular Extended",
    "category": "Cardiovascular",
    "schedule": "H",
    "brand": "Ranexa / Ranolazine ER / Ranolaz",
    "formation": "Late sodium current (I-Na late) inhibitor; reduces sodium-calcium overload in ischaemic myocardium; anti-anginal without haemodynamic effects",
    "uses": "Chronic stable angina (add-on when Î²-blockers/CCBs insufficient), also anti-arrhythmic property in AF",
    "adult": "500 mg BD ER, titrate to 1000 mg BD as tolerated; swallow whole",
    "child": "Not established",
    "avoid": "Severe hepatic/renal impairment, QTc prolongation; inhibits CYP3A4 and P-gp â€“ check interactions (simvastatin, digoxin levels increase)",
    "drug": "Ranolazine",
    "sideEffects": [
      "Dizziness",
      "Headache",
      "Constipation",
      "Nausea",
      "QT prolongation"
    ],
    "seriousRisks": [
      "QT prolongation/arrhythmia",
      "Acute renal failure (rare)",
      "Severe hypersensitivity"
    ],
    "renalAdj": "Yes â€” use with caution in moderate-severe renal impairment; avoid if CrCl <30 mL/min",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment (Child-Pugh B/C)",
    "pregnancy": "Category C â€” insufficient data; avoid",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "CYP3A4 inhibitors (azoles, diltiazem) â€” increased ranolazine levels",
      "CYP3A4 inducers (rifampicin) â€” markedly reduced ranolazine levels",
      "P-gp substrates (digoxin, simvastatin) â€” increased substrate levels"
    ],
    "monitoring": [
      "ECG (QTc)",
      "Renal function",
      "Angina frequency",
      "BP"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2000 mg/day (1000 mg BD)",
    "clinicalPearl": "Unique MOA â€” inhibits late INa current; reduces angina without lowering BP or HR â€” ideal add-on therapy."
  },
  {
    "rank": 430,
    "name": "Cotrimoxazole (TMP-SMX)",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Bactrim / Septran / Cotrim",
    "formation": "Fixed combination: Trimethoprim 80mg + Sulfamethoxazole 400mg; sequential blockade of folate synthesis",
    "uses": "UTI, Pneumocystis jirovecii pneumonia (PCP) treatment and prophylaxis, nocardiosis, toxoplasmosis, MRSA skin infections, Stenotrophomonas",
    "adult": "UTI: 1 DS tab (160/800 mg) BD Ã— 3â€“7 days; PCP treatment: 15â€“20 mg/kg/day TMP IV/PO in 3â€“4 doses Ã— 21 days",
    "child": "6â€“12 mg/kg/day TMP component BD; neonates avoid in first 6 weeks (risk of kernicterus)",
    "avoid": "Sulfonamide allergy, severe hepatic/renal impairment, G6PD deficiency (haemolysis), pregnancy near term and neonates; can cause hyperkalaemia with ACEi/ARB/potassium-sparing diuretics",
    "drug": "Cotrimoxazole (TMP-SMX)",
    "sideEffects": [
      "Nausea/vomiting",
      "Rash",
      "Hyperkalaemia",
      "Crystalluria",
      "Photosensitivity"
    ],
    "seriousRisks": [
      "Stevens-Johnson syndrome/TEN",
      "Agranulocytosis/aplastic anaemia",
      "Severe hyperkalaemia (renal tubular effect)",
      "Severe hepatotoxicity",
      "Megaloblastic anaemia"
    ],
    "renalAdj": "Yes â€” reduce dose by 50% if CrCl 15-30 mL/min; avoid if CrCl <15 mL/min",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category C â€” avoid in 1st trimester (folate antagonist) and near term (kernicterus risk)",
    "lactation": "Caution â€” avoid in neonates/G6PD-deficient infants; kernicterus risk",
    "drugInteractions": [
      "Warfarin â€” markedly increased INR",
      "Methotrexate â€” increased bone marrow toxicity",
      "ACE inhibitors/ARBs â€” severe hyperkalaemia"
    ],
    "monitoring": [
      "CBC (bone marrow toxicity)",
      "Renal function",
      "Electrolytes (K+)",
      "LFT",
      "Rash monitoring"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "960 mg BD (standard dose); 960 mg TDS (PCP treatment)",
    "clinicalPearl": "Drug of choice for PCP prophylaxis in HIV/immunocompromised â€” also first-line for UTI, nocardia, and toxoplasma."
  },
  {
    "rank": 431,
    "name": "Ampicillin + Cloxacillin",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Ampiclox / Clonapen / Ampicloxin",
    "formation": "Aminopenicillin (Ampicillin) + Isoxazolyl penicillin (Cloxacillin); broad-spectrum with MSSA coverage",
    "uses": "Respiratory tract infections, skin and soft tissue infections, septicaemia, biliary infections; widely used in Indian hospitals",
    "adult": "250â€“500 mg each component QID PO; IV: 500 mgâ€“1 g each BD-QID; 30 min before food",
    "child": "25â€“50 mg/kg/day of each component divided QID",
    "avoid": "Penicillin/Î²-lactam hypersensitivity, infectious mononucleosis (ampicillin rash); no MRSA coverage â€“ check local antibiogram",
    "drug": "Ampicillin + Cloxacillin",
    "sideEffects": [
      "Diarrhoea",
      "Rash",
      "Nausea",
      "Hypersensitivity reactions",
      "Elevated transaminases"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "C. difficile colitis",
      "Steven-Johnson syndrome",
      "Cholestatic jaundice (cloxacillin)"
    ],
    "renalAdj": "Yes â€” reduce ampicillin dose in severe renal impairment; cloxacillin: standard dosing",
    "hepaticAdj": "Yes â€” cloxacillin causes cholestatic hepatitis; avoid in hepatic impairment",
    "pregnancy": "Category B â€” generally safe; widely used for perinatal infections",
    "lactation": "Safe â€” compatible with breastfeeding; monitor infant for GI effects",
    "drugInteractions": [
      "Oral contraceptives â€” reduced OCP efficacy",
      "Methotrexate â€” reduced methotrexate excretion",
      "Warfarin â€” possible increased anticoagulant effect"
    ],
    "monitoring": [
      "Renal function",
      "LFT",
      "CBC",
      "Signs of hypersensitivity"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "Ampicillin 3g/day + Cloxacillin 2g/day oral; IV: up to ampicillin 12g/day",
    "clinicalPearl": "Combination covers gram-negative (ampicillin) + penicillinase-producing Staphylococci (cloxacillin) â€” logical synergy."
  },
  {
    "rank": 432,
    "name": "Cefoperazone + Sulbactam",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Sulperazone / Cefoperazone-SB / Magnex",
    "formation": "3rd-gen cephalosporin + Î²-lactamase inhibitor; extended spectrum covering ESBL and some Acinetobacter",
    "uses": "Severe nosocomial infections, intra-abdominal infections, MDR gram-negative coverage, Acinetobacter baumannii (in combination)",
    "adult": "1â€“2 g IV every 12h (sulbactam 1:1 ratio); up to 4 g/day sulbactam component (max 8 g/day total)",
    "child": "40â€“80 mg/kg/day IV divided BD-TID",
    "avoid": "Cephalosporin allergy; adjust dose in severe hepatic impairment (biliary excretion); can cause disulfiram-like reaction with alcohol (N-methylthiotetrazole side chain)",
    "drug": "Cefoperazone + Sulbactam",
    "sideEffects": [
      "Diarrhoea",
      "Rash",
      "Elevated LFT",
      "Phlebitis (IV)",
      "Nausea"
    ],
    "seriousRisks": [
      "Hypoprothrombnaemia/bleeding (cefoperazone contains MTT side chain)",
      "C. difficile colitis",
      "Anaphylaxis",
      "Severe hepatotoxicity"
    ],
    "renalAdj": "Yes â€” sulbactam: reduce dose if CrCl <30 mL/min; cefoperazone: standard (biliary excretion)",
    "hepaticAdj": "Yes â€” reduce cefoperazone dose in hepatic impairment (biliary excretion); use combined 1:1 ratio max 4g/day in liver disease",
    "pregnancy": "Category B â€” limited data; use with caution",
    "lactation": "Caution â€” cephalosporins excreted in small amounts; generally considered acceptable",
    "drugInteractions": [
      "Alcohol â€” disulfiram-like reaction (MTT side chain; avoid alcohol during and 5 days after)",
      "Anticoagulants â€” increased hypoprothrombnaemia risk",
      "Aminoglycosides â€” synergistic (but separate infusion lines)"
    ],
    "monitoring": [
      "PT/INR (vitamin K)",
      "LFT",
      "Renal function",
      "CBC",
      "Culture sensitivities"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "8g/day (cefoperazone component); sulbactam 4g/day",
    "clinicalPearl": "MTT side chain causes disulfiram-like reaction â€” strictly avoid alcohol; supplement vitamin K to prevent bleeding."
  },
  {
    "rank": 433,
    "name": "Cefazolin",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Cefazolin IP / Ancef / Reflin",
    "formation": "1st-generation cephalosporin; gram-positive coverage (MSSA), limited gram-negative; most commonly used for surgical prophylaxis",
    "uses": "Surgical prophylaxis (preferred agent â€“ 1 g IV 30â€“60 min pre-incision), skin/soft tissue infections, MSSA bacteraemia (step-down), UTI",
    "adult": "Prophylaxis: 1â€“2 g IV single dose; treatment: 1â€“2 g IV every 8h",
    "child": "Prophylaxis: 25â€“30 mg/kg IV single dose (max 2 g); treatment: 25â€“50 mg/kg/day divided every 8h",
    "avoid": "Cephalosporin/penicillin allergy; adjust for renal impairment; not adequate for gram-negative coverage or MRSA",
    "drug": "Cefazolin",
    "sideEffects": [
      "Diarrhoea",
      "Rash",
      "Phlebitis (IV)",
      "Nausea",
      "Elevated LFT"
    ],
    "seriousRisks": [
      "Anaphylaxis",
      "C. difficile colitis",
      "Severe skin reactions (rare)",
      "Encephalopathy (high dose in renal impairment)"
    ],
    "renalAdj": "Yes â€” reduce dose/increase interval: CrCl 10-35 mL/min: 50% dose reduction; CrCl <10: 25% dose",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” preferred 1st-gen cephalosporin for surgical prophylaxis in pregnancy",
    "lactation": "Safe â€” compatible with breastfeeding",
    "drugInteractions": [
      "Probenecid â€” increased cefazolin levels (reduced tubular secretion)",
      "Aminoglycosides â€” potential synergy (compatible in clinical use)",
      "Loop diuretics â€” potential nephrotoxicity (additive)"
    ],
    "monitoring": [
      "Renal function",
      "CBC",
      "Signs of infection resolution"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "6000 mg/day (2g TDS); 12g/day in life-threatening infections",
    "clinicalPearl": "Preferred antibiotic for surgical prophylaxis â€” give within 60 minutes before incision for maximum tissue levels."
  },
  {
    "rank": 434,
    "name": "Valacyclovir",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Valcivir / Valtrex / Valcy",
    "formation": "L-valyl ester pro-drug of acyclovir; 3â€“5Ã— higher oral bioavailability than acyclovir; inhibits herpes DNA polymerase",
    "uses": "Herpes zoster (shingles), genital herpes (treatment and suppression), herpes labialis (cold sores), CMV prophylaxis in transplant",
    "adult": "Zoster: 1000 mg TDS Ã— 7 days; genital herpes (1st episode): 1000 mg BD Ã— 10 days; suppression: 500 mg OD; CMV: 2 g QID",
    "child": "Chickenpox â‰¥2y: 20 mg/kg TDS Ã— 5 days (max 1 g/dose); herpes labialis: 2 g BD Ã— 1 day (â‰¥12y)",
    "avoid": "TTP/HUS (especially at high CMV-prophylaxis doses in transplant patients), severe renal impairment (reduce dose); agitation/hallucinations at high doses â€“ CNS toxicity",
    "drug": "Valacyclovir",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Diarrhoea",
      "Abdominal pain",
      "Dizziness"
    ],
    "seriousRisks": [
      "TTP/HUS (in severely immunocompromised â€” high dose)",
      "Acute renal failure (dehydration + high dose)",
      "Neurological toxicity (tremor, confusion â€” renal impairment)",
      "Severe hypersensitivity"
    ],
    "renalAdj": "Yes â€” significant adjustment: CrCl 10-25 mL/min: 50% dose reduction; CrCl <10: 500 mg OD (herpes zoster)",
    "hepaticAdj": "No â€” standard dosing (prodrug converted renally)",
    "pregnancy": "Category B â€” considered safe; used in neonatal HSV prophylaxis",
    "lactation": "Safe â€” compatible with breastfeeding",
    "drugInteractions": [
      "Probenecid â€” increased acyclovir levels (reduced renal excretion)",
      "Nephrotoxic drugs â€” additive renal toxicity",
      "Cimetidine â€” increased acyclovir AUC"
    ],
    "monitoring": [
      "Renal function (especially high-dose)",
      "CBC (immunocompromised)",
      "Hydration status",
      "Neurological status"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3000 mg/day (1g TDS â€” herpes zoster); 1000 mg BD (genital herpes first episode)",
    "clinicalPearl": "Prodrug of acyclovir â€” 3-5x better oral bioavailability than acyclovir; ensure adequate hydration to prevent crystalluria."
  },
  {
    "rank": 435,
    "name": "Tigecycline",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Tygacil / Tigyke",
    "formation": "Glycylcycline tetracycline derivative; inhibits 30S ribosomal translation; avoids tetracycline efflux and ribosomal protection resistance",
    "uses": "Complicated skin/soft tissue infections, intra-abdominal infections, community-acquired pneumonia (CAP), MDR Acinetobacter (combination)",
    "adult": "100 mg IV loading, then 50 mg IV BD (infuse over 30â€“60 min); MDR Acinetobacter: higher dose 100 mg BD considered",
    "child": "8â€“11y: 1.2 mg/kg BD (max 50 mg); 12â€“17y: 50 mg BD; avoid <8y (bone/teeth effects as per tetracycline)",
    "avoid": "Pregnancy (foetal bone and teeth damage), <8y; black-box warning: all-cause mortality higher vs comparators in meta-analysis â€“ use only when no alternatives",
    "drug": "Tigecycline",
    "sideEffects": [
      "Nausea (30-35%)",
      "Vomiting",
      "Diarrhoea",
      "Abdominal pain",
      "Elevated LFT"
    ],
    "seriousRisks": [
      "Increased all-cause mortality vs comparators",
      "C. difficile colitis",
      "Acute pancreatitis",
      "Severe hepatotoxicity",
      "Photosensitivity (tetracycline class)"
    ],
    "renalAdj": "No â€” standard dosing (primarily biliary excretion)",
    "hepaticAdj": "Yes â€” reduce maintenance dose to 25 mg Q12h in Child-Pugh C",
    "pregnancy": "Category D â€” tetracycline class; causes fetal tooth discoloration/bone growth inhibition; avoid",
    "lactation": "Avoid â€” tetracycline class; excreted in breast milk",
    "drugInteractions": [
      "Warfarin â€” increased anticoagulant effect (reduced coagulation factor synthesis)",
      "Oral contraceptives â€” reduced OCP efficacy",
      "Antacids â€” adsorption (less concern with IV form)"
    ],
    "monitoring": [
      "LFT",
      "CBC",
      "Renal function",
      "Clinical response/procalcitonin",
      "Signs of Clostridium difficile"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg loading; then 50 mg Q12h (200 mg/day total infusion dose is non-approved high dose)",
    "clinicalPearl": "Reserve for truly MDR infections â€” associated with higher mortality than comparators in ventilator-associated pneumonia."
  },
  {
    "rank": 436,
    "name": "Fosfomycin",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Fosfocin / Monurol / Fosfomycin IP",
    "formation": "Phosphonic acid antibiotic; inhibits MurA enzyme (UDP-N-acetylglucosamine enolpyruvyl transferase) of bacterial cell wall synthesis",
    "uses": "Uncomplicated UTI (single-dose oral â€“ ESBL E.coli), complicated UTI and pyelonephritis (IV fosfomycin), carbapenem-resistant Enterobacteriaceae (combination)",
    "adult": "Oral (UTI): 3 g granules single sachet; IV (severe): 12â€“24 g/day in 3â€“4 divided doses",
    "child": "Oral: 2 g single dose (â‰¥12y); IV: 200â€“400 mg/kg/day divided BD-TID",
    "avoid": "Severe renal failure (dose adjustment); IV formulation causes sodium load â€“ caution in heart failure; developing resistance when used as monotherapy in serious infections",
    "drug": "Fosfomycin",
    "sideEffects": [
      "Diarrhoea",
      "Nausea",
      "Headache",
      "Vaginitis",
      "Rash"
    ],
    "seriousRisks": [
      "C. difficile colitis (rare)",
      "Severe hypersensitivity",
      "Hypernatraemia (parenteral formulation â€” sodium salt)"
    ],
    "renalAdj": "Yes â€” single oral dose for uncomplicated UTI: standard; IV: reduce dose if CrCl <50 mL/min",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” single-dose oral fosfomycin is preferred for uncomplicated UTI in pregnancy",
    "lactation": "Caution â€” excreted in breast milk; single dose generally acceptable",
    "drugInteractions": [
      "Metoclopramide â€” reduces fosfomycin serum and urine levels",
      "Other nephrotoxic drugs â€” additive risk (IV use)",
      "Calcium supplements â€” may reduce oral absorption"
    ],
    "monitoring": [
      "Urine culture clearance",
      "Renal function (IV use)",
      "Sodium levels (IV use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3g single dose (oral UTI); IV: 16-24g/day (severe systemic infections)",
    "clinicalPearl": "Single 3g oral sachet â€” preferred for uncomplicated cystitis in pregnancy; excellent urine concentration."
  },
  {
    "rank": 437,
    "name": "Oseltamivir",
    "section": "Section 15: Anti-Infective & Antiviral Extended",
    "category": "Anti-Infective",
    "schedule": "H",
    "brand": "Tamiflu / Fluvir / Antiflu",
    "formation": "Pro-drug ethyl ester; active carboxylate inhibits influenza neuraminidase; prevents viral release from infected cells",
    "uses": "Influenza A and B treatment (within 48h of symptom onset, reduces duration ~1 day), prophylaxis post-exposure, avian influenza H5N1/H1N1",
    "adult": "Treatment: 75 mg BD Ã— 5 days; prophylaxis: 75 mg OD Ã— 10 days (post-exposure) or Ã— 6 weeks (seasonal)",
    "child": ">1y: weight-based (â‰¤15 kg: 30 mg; 15â€“23 kg: 45 mg; 23â€“40 kg: 60 mg; >40 kg: 75 mg) BD Ã— 5 days",
    "avoid": "Severe renal failure (reduce dose); neuropsychiatric events (hallucinations, delirium, self-injury â€“ monitor in children); not effective against other respiratory viruses",
    "drug": "Oseltamivir",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Headache",
      "Abdominal pain",
      "Insomnia"
    ],
    "seriousRisks": [
      "Neuropsychiatric events (especially children â€” Japan data)",
      "Severe skin reactions (rare)",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” CrCl 10-30 mL/min: 75 mg OD treatment (75 mg BD standard); CrCl <10: 75 mg/48h",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” benefits outweigh risks in influenza; WHO endorses use in pregnancy",
    "lactation": "Safe â€” low levels in breast milk; WHO recommends continuing breastfeeding",
    "drugInteractions": [
      "Live influenza vaccine â€” avoid concomitant use (antiviral may reduce vaccine immunogenicity)",
      "Probenecid â€” doubles oseltamivir levels",
      "Cimetidine â€” mild increase in levels"
    ],
    "monitoring": [
      "Symptom resolution",
      "O2 saturation (severe influenza)",
      "Neuropsychiatric behaviour (children)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "150 mg/day (75 mg BD for 5 days treatment); prophylaxis: 75 mg OD for 10 days",
    "clinicalPearl": "Must start within 48 hours of symptom onset for maximum benefit â€” high-dose 150 mg BD for severe/hospitalised influenza."
  },
  {
    "rank": 438,
    "name": "Entecavir",
    "section": "Section 16: Hepatology, Antiviral & Thyroid",
    "category": "Hepatology",
    "schedule": "H",
    "brand": "Baraclude / Entaliv / Entehep",
    "formation": "Guanosine nucleoside analogue; inhibits HBV polymerase (priming, reverse transcription, DNA synthesis); minimal HIV cross-resistance",
    "uses": "Chronic hepatitis B (HBeAg-positive and -negative), compensated and decompensated cirrhosis, post-transplant HBV prophylaxis",
    "adult": "Treatment-naÃ¯ve: 0.5 mg OD fasting; lamivudine-refractory: 1 mg OD fasting; decompensated cirrhosis: 1 mg OD",
    "child": "2â€“<18y: weight-banded oral solution 0.015â€“0.015 mg/kg OD (max 0.5 mg OD); >30 kg: 0.5 mg tab OD",
    "avoid": "Lactic acidosis and severe hepatomegaly with steatosis (black-box); do NOT stop abruptly (risk of hepatitis flare); renal dose adjustment; not first-line in HIV co-infection (use TDF/TAF)",
    "drug": "Entecavir",
    "sideEffects": [
      "Headache",
      "Fatigue",
      "Dizziness",
      "Nausea",
      "Elevated LFT"
    ],
    "seriousRisks": [
      "Lactic acidosis (rare, especially with decompensated liver disease)",
      "Severe hepatitis exacerbation on discontinuation",
      "HBV resistance (higher with prior lamivudine failure)"
    ],
    "renalAdj": "Yes â€” significant: CrCl 10-50 mL/min: reduce dose to 0.5 mg OD; CrCl <10/dialysis: 0.05 mg OD",
    "hepaticAdj": "No â€” standard dosing in hepatic impairment (renal elimination)",
    "pregnancy": "Category C â€” use only if clearly needed; tenofovir preferred for PMTCT",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Nephrotoxic drugs â€” additive renal toxicity (affecting entecavir clearance)",
      "Lamivudine/adefovir-resistant HBV â€” entecavir less effective",
      "Drugs causing lactic acidosis â€” additive risk"
    ],
    "monitoring": [
      "HBV DNA (every 3-6 months)",
      "LFT",
      "Renal function",
      "Hepatitis B e-antigen/surface antigen"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "0.5 mg/day (HBV-naive); 1 mg/day (lamivudine-refractory)",
    "clinicalPearl": "High genetic barrier to resistance â€” do not stop abruptly; severe hepatitis flare can occur within months of discontinuation."
  },
  {
    "rank": 439,
    "name": "Tenofovir Disoproxil Fumarate (TDF)",
    "section": "Section 16: Hepatology, Antiviral & Thyroid",
    "category": "Hepatology",
    "schedule": "H",
    "brand": "Viread / Tenvir / Ricovir",
    "formation": "Nucleotide reverse transcriptase inhibitor (NtRTI); inhibits HIV-1 and HBV reverse transcriptase; incorporated as chain terminator",
    "uses": "HIV-1 infection (backbone of preferred ART regimens), chronic hepatitis B, PrEP (HIV pre-exposure prophylaxis)",
    "adult": "300 mg PO OD with food; HIV: part of combination ART; HBV: 300 mg OD (preferred in HIV-HBV co-infection)",
    "child": "â‰¥2y: 8 mg/kg OD (max 300 mg) with food",
    "avoid": "Renal impairment (Fanconi syndrome/renal tubular acidosis â€“ monitor creatinine, phosphate); bone density loss with long-term use â€“ supplement calcium/vit D; avoid with didanosine (pancreatitis)",
    "drug": "Tenofovir Disoproxil Fumarate (TDF)",
    "sideEffects": [
      "Nausea",
      "Diarrhoea",
      "Nephrotoxicity",
      "Bone mineral density loss",
      "Headache"
    ],
    "seriousRisks": [
      "Fanconi syndrome/proximal tubulopathy",
      "Lactic acidosis",
      "Severe HBV exacerbation on discontinuation",
      "Acute renal failure",
      "Osteomalacia"
    ],
    "renalAdj": "Yes â€” CrCl 30-49: 300 mg every 48h; CrCl 10-29: 300 mg every 72-96h; dialysis: 300 mg every 7 days",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” preferred PMTCT agent; widely used in HIV/HBV in pregnancy",
    "lactation": "Caution â€” present in breast milk; in HIV: WHO recommends ART continuation with breastfeeding under guidance",
    "drugInteractions": [
      "Didanosine â€” increased didanosine toxicity (pancreatitis)",
      "Atazanavir â€” must be boosted with ritonavir when combined",
      "NSAIDs â€” additive nephrotoxicity"
    ],
    "monitoring": [
      "Renal function (SCr, eGFR â€” baseline + every 3 months)",
      "Phosphate (Fanconi syndrome)",
      "Bone density (long-term)",
      "HBV DNA/viral load"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day",
    "clinicalPearl": "Monitor renal function and phosphate â€” Fanconi syndrome presents as hypophosphataemia + glycosuria with normal glucose."
  },
  {
    "rank": 440,
    "name": "Sofosbuvir + Velpatasvir",
    "section": "Section 16: Hepatology, Antiviral & Thyroid",
    "category": "Hepatology",
    "schedule": "H",
    "brand": "Velpanat / Sofosvel / Epclusa",
    "formation": "Pan-genotypic HCV DAA: Sofosbuvir (NS5B polymerase inhibitor) + Velpatasvir (NS5A inhibitor); 400/100 mg fixed-dose tablet",
    "uses": "Chronic HCV infection all genotypes (1â€“6) â€“ SVR rates >95%; compensated and decompensated cirrhosis (add ribavirin)",
    "adult": "1 tablet OD Ã— 12 weeks (no cirrhosis or compensated cirrhosis); decompensated: + ribavirin 12 weeks",
    "child": "â‰¥6y or â‰¥17 kg: 200/50 mg OD (oral pellets); â‰¥30 kg: 400/100 mg tablet OD",
    "avoid": "Severe renal impairment (sofosbuvir accumulation â€“ use sofosbuvir-free regimen if eGFR <30); potent P-gp inducers (rifampicin, St John's wort) dramatically reduce levels â€“ avoid; moderate-severe hepatic impairment (decompensated Child-Pugh C â€“ use with ribavirin only)",
    "drug": "Sofosbuvir + Velpatasvir",
    "sideEffects": [
      "Headache",
      "Fatigue",
      "Nausea",
      "Insomnia",
      "Anaemia (with ribavirin)"
    ],
    "seriousRisks": [
      "Hepatitis B reactivation (in HBV co-infected patients)",
      "Bradycardia (with amiodarone â€” potentially fatal)",
      "Symptomatic bradycardia/cardiac arrest"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30 mL/min (sofosbuvir metabolite accumulates); no dose adjustment for mild-moderate",
    "hepaticAdj": "No â€” standard dosing for Child-Pugh A/B; limited data for Child-Pugh C",
    "pregnancy": "Category â€” avoid; insufficient human data; ribavirin co-administration is Category X",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Amiodarone â€” severe bradycardia/cardiac arrest (absolute contraindication)",
      "P-gp/CYP inducers (rifampicin, carbamazepine) â€” significantly reduced DAA levels",
      "Proton pump inhibitors â€” reduce velpatasvir levels (separate timing or avoid)"
    ],
    "monitoring": [
      "HCV RNA (week 4, 12, 24 post-treatment)",
      "LFT",
      "HBsAg (screen before starting)",
      "ECG (if amiodarone used)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg sofosbuvir + 100 mg velpatasvir OD (single tablet)",
    "clinicalPearl": "Pan-genotypic HCV regimen â€” screen for HBV before starting; amiodarone co-use is absolutely contraindicated."
  },
  {
    "rank": 441,
    "name": "Sofosbuvir + Ledipasvir",
    "section": "Section 16: Hepatology, Antiviral & Thyroid",
    "category": "Hepatology",
    "schedule": "H",
    "brand": "Harvoni / Ledifos / Hepcinat-LP",
    "formation": "HCV genotype 1 and 4 DAA: Sofosbuvir 400mg (NS5B inhibitor) + Ledipasvir 90mg (NS5A inhibitor); first approved pan-oral HCV regimen",
    "uses": "HCV genotype 1 (most common in India), genotype 4; treatment-naÃ¯ve and treatment-experienced; with/without cirrhosis",
    "adult": "1 tablet OD Ã— 8 weeks (treatment-naÃ¯ve, no cirrhosis, HCV RNA <6M IU/mL) or 12 weeks (standard); 24 weeks for decompensated cirrhosis",
    "child": "â‰¥3y: weight-based pellets; â‰¥17 kg: tab OD",
    "avoid": "Same as sofosbuvir+velpatasvir; avoid proton pump inhibitors (reduce ledipasvir absorption â€“ separate or avoid omeprazole >20 mg); P-gp inducers contraindicated",
    "drug": "Sofosbuvir + Ledipasvir",
    "sideEffects": [
      "Fatigue",
      "Headache",
      "Nausea",
      "Diarrhoea",
      "Insomnia"
    ],
    "seriousRisks": [
      "Hepatitis B reactivation (HBV co-infection)",
      "Severe bradycardia/cardiac arrest (with amiodarone)",
      "Symptomatic bradycardia"
    ],
    "renalAdj": "Yes â€” avoid if eGFR <30 mL/min (sofosbuvir metabolite accumulation)",
    "hepaticAdj": "No â€” standard dosing (Child-Pugh A/B); not recommended in decompensated cirrhosis without specialist input",
    "pregnancy": "Category â€” avoid; insufficient safety data",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Amiodarone â€” fatal bradycardia (absolute contraindication)",
      "Antacids â€” reduce ledipasvir absorption (separate by 4 hours)",
      "P-gp inducers (rifampicin, St John's Wort) â€” reduced drug levels"
    ],
    "monitoring": [
      "HCV RNA (SVR12 at 12 weeks post-treatment)",
      "LFT",
      "HBsAg (pre-treatment screening)",
      "Cardiac monitoring if transitioning from amiodarone"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "400 mg sofosbuvir + 90 mg ledipasvir OD (single tablet)",
    "clinicalPearl": "Effective for HCV genotypes 1, 4, 5, 6 â€” 8 weeks sufficient for treatment-naive non-cirrhotic genotype 1 patients."
  },
  {
    "rank": 442,
    "name": "Carbimazole",
    "section": "Section 16: Hepatology, Antiviral & Thyroid",
    "category": "Endocrine",
    "schedule": "H",
    "brand": "Neomercazole / Thyrocab / Carbimazole IP",
    "formation": "Thionamide; pro-drug of methimazole; inhibits thyroid peroxidase preventing organification of iodide and thyroid hormone synthesis",
    "uses": "Hyperthyroidism (Graves' disease, toxic nodular goitre), preparation for thyroidectomy/radioiodine, thyroid storm (high-dose)",
    "adult": "Initial: 15â€“40 mg/day in 1â€“3 divided doses; maintenance 5â€“15 mg OD once euthyroid; thyroid storm: 20â€“30 mg every 4h",
    "child": "0.25â€“0.5 mg/kg/day in 3 divided doses; monitor TFTs monthly",
    "avoid": "Agranulocytosis (warn patient to report sore throat/fever â€“ check WBC immediately); aplastic anaemia; crosses placenta (use lowest effective dose); avoid in lactation (use PTU preferred if breastfeeding)",
    "drug": "Carbimazole",
    "sideEffects": [
      "Rash/urticaria",
      "Nausea",
      "Headache",
      "Arthralgia",
      "Taste disturbance"
    ],
    "seriousRisks": [
      "Agranulocytosis (0.2-0.5% â€” potentially fatal)",
      "Aplastic anaemia",
      "Hepatotoxicity",
      "Hypoprothrominaemia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category D â€” aplasia cutis risk; prefer PTU in first trimester; carbimazole in 2nd/3rd trimester",
    "lactation": "Caution â€” both carbimazole and PTU excreted in milk; PTU preferred in lactation at lowest effective dose",
    "drugInteractions": [
      "Warfarin â€” increased anticoagulant effect (thyroid state changes)",
      "Digoxin â€” as hyperthyroidism resolves, digoxin levels rise",
      "Beta-blockers â€” thyroid status affects beta-blocker requirement"
    ],
    "monitoring": [
      "TFT (T3, T4, TSH â€” every 4-6 weeks)",
      "CBC (agranulocytosis â€” if fever/sore throat)",
      "LFT"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60 mg/day (initial); maintenance 5-20 mg/day",
    "clinicalPearl": "Warn all patients to stop immediately and check CBC if sore throat or fever develops â€” agranulocytosis is the key risk."
  },
  {
    "rank": 443,
    "name": "Propylthiouracil (PTU)",
    "section": "Section 16: Hepatology, Antiviral & Thyroid",
    "category": "Endocrine",
    "schedule": "H",
    "brand": "Propycil / PTU / Propylthiouracil IP",
    "formation": "Thionamide; inhibits thyroid peroxidase AND peripheral conversion of T4â†’T3 (inhibits deiodinase); preferred in pregnancy/thyroid storm",
    "uses": "Hyperthyroidism (Graves' disease), thyroid storm (first-choice with Î²-blocker), 1st-trimester pregnancy (preferred over carbimazole)",
    "adult": "Initial: 100â€“150 mg TDS; maintenance: 50 mg TDSâ€“BD; thyroid storm: 200â€“400 mg every 4h",
    "child": "5â€“7 mg/kg/day TDS (max 300 mg/day)",
    "avoid": "Hepatotoxicity (potentially fatal â€“ black-box; avoid for routine use except pregnancy/thyroid storm); agranulocytosis; ANCA-associated vasculitis with long-term use",
    "drug": "Propylthiouracil (PTU)",
    "sideEffects": [
      "Rash",
      "Nausea",
      "Arthralgia",
      "Taste disturbance",
      "Headache"
    ],
    "seriousRisks": [
      "Agranulocytosis",
      "Severe hepatotoxicity (fulminant â€” PTU > carbimazole)",
      "ANCA-positive vasculitis",
      "Aplastic anaemia"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment; PTU causes more hepatotoxicity than carbimazole",
    "pregnancy": "Category D â€” preferred over carbimazole in FIRST trimester (aplasia cutis risk lower); switch to carbimazole in 2nd trimester",
    "lactation": "Caution â€” PTU preferred over carbimazole in lactation; use lowest effective dose",
    "drugInteractions": [
      "Warfarin â€” increased INR effect",
      "Digoxin â€” dose adjustment as euthyroid state is achieved",
      "Vitamin K-dependent clotting factors â€” inhibited (additional anticoagulant effect)"
    ],
    "monitoring": [
      "TFT (every 4-6 weeks)",
      "CBC (agranulocytosis)",
      "LFT (baseline + if symptomatic)",
      "ANCA (if vasculitis suspected)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "600 mg/day (TDS); thyroid storm: 1000-1200 mg/day",
    "clinicalPearl": "PTU also blocks peripheral T4 to T3 conversion â€” preferred in thyroid storm and first-trimester pregnancy."
  },
  {
    "rank": 444,
    "name": "Levosulpiride",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "GI",
    "schedule": "H",
    "brand": "Levosulpride / Nexpro / Levbid",
    "formation": "Left-enantiomer of sulpiride; selective D2/D3 receptor antagonist; prokinetic at gut level, antidopaminergic at CNS level",
    "uses": "Functional dyspepsia, gastroparesis, GERD (prokinetic), depression (off-label antidepressant in South Asia)",
    "adult": "25â€“75 mg TDS before meals (GI); 150â€“300 mg/day in divided doses (psychiatric)",
    "child": "Not well established; used cautiously in older children by specialists",
    "avoid": "Phaeochromocytoma, prolactin-dependent tumours, Parkinson's disease; can cause extrapyramidal symptoms (akathisia, tardive dyskinesia with long-term use); avoid with other antidopaminergics",
    "drug": "Levosulpiride",
    "sideEffects": [
      "Somnolence",
      "Galactorrhoea",
      "Extrapyramidal symptoms",
      "Amenorrhoea",
      "Weight gain"
    ],
    "seriousRisks": [
      "Tardive dyskinesia",
      "Neuroleptic malignant syndrome",
      "QT prolongation",
      "Hyperprolactinaemia-related tumours"
    ],
    "renalAdj": "Yes â€” reduce dose in renal impairment (renally cleared); avoid in severe",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” insufficient data; avoid if possible",
    "lactation": "Avoid â€” galactorrhoea inducer; increases prolactin; may affect infant",
    "drugInteractions": [
      "Dopamine agonists (levodopa) â€” opposing effects",
      "Antihypertensives â€” additive hypotension",
      "QT-prolonging drugs â€” additive risk"
    ],
    "monitoring": [
      "Prolactin levels",
      "ECG (QTc)",
      "Extrapyramidal assessment",
      "Menstrual pattern"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "75 mg/day (25 mg TDS â€” GI use); higher doses for psychiatric use",
    "clinicalPearl": "Used for functional dyspepsia in India â€” D2 blockade at GI level increases motility; also increases prolactin."
  },
  {
    "rank": 445,
    "name": "Itopride",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "GI",
    "schedule": "H",
    "brand": "Ganaton / Itopride IP / Domstal-IT",
    "formation": "D2 receptor antagonist + acetylcholinesterase inhibitor (dual mechanism); enhances gastric motility without crossing BBB significantly",
    "uses": "Functional dyspepsia, gastroparesis, post-prandial bloating, nausea associated with gastric stasis",
    "adult": "50 mg TDS before meals",
    "child": "Safety not established for routine use",
    "avoid": "GI haemorrhage/obstruction/perforation; less QT prolongation risk than domperidone (no significant CYP3A4 metabolism); avoid with anticholinergic drugs (opposing effects)",
    "drug": "Itopride",
    "sideEffects": [
      "Diarrhoea",
      "Headache",
      "Abdominal pain",
      "Nausea",
      "Elevated prolactin (mild)"
    ],
    "seriousRisks": [
      "Galactorrhoea (rare)",
      "QT prolongation (less than domperidone)",
      "Hypersensitivity reactions"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” insufficient data; avoid unless necessary",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Anticholinergics â€” opposing prokinetic effects",
      "Drugs metabolised by CYP2D6 â€” potential interaction",
      "QT-prolonging drugs â€” monitor ECG"
    ],
    "monitoring": [
      "Prolactin (long-term)",
      "GI symptom response",
      "ECG (if cardiac risk)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "150 mg/day (50 mg TDS)",
    "clinicalPearl": "Dual mechanism â€” D2 blockade + acetylcholinesterase inhibition; fewer cardiac side effects than domperidone."
  },
  {
    "rank": 446,
    "name": "Racecadotril",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "GI",
    "schedule": "H",
    "brand": "Redotil / Racecadotril IP / Hidrasec",
    "formation": "Enkephalinase inhibitor (pro-drug of thiorphan); reduces hypersecretion of water and electrolytes in intestinal lumen; antisecretory (not antimotility)",
    "uses": "Acute secretory diarrhoea in children (add-on to ORS), travellers' diarrhoea",
    "adult": "100 mg TDS before meals Ã— 3 days",
    "child": "1.5 mg/kg TDS (max 100 mg/dose); available as granule/sachet for paediatric use",
    "avoid": "Do not use as sole treatment â€“ ORS is primary; hepatic/renal impairment (limited data); avoid with ACE inhibitors (increased angioedema risk â€“ neprilysin pathway)",
    "drug": "Racecadotril",
    "sideEffects": [
      "Headache",
      "Nausea",
      "Constipation",
      "Drowsiness",
      "Rash"
    ],
    "seriousRisks": [
      "Severe hypersensitivity (rare)",
      "SJS (rare)",
      "Angioedema"
    ],
    "renalAdj": "Yes â€” use with caution in renal impairment",
    "hepaticAdj": "Yes â€” use with caution in hepatic impairment",
    "pregnancy": "Category C â€” insufficient data; avoid in pregnancy",
    "lactation": "Caution â€” insufficient data; avoid if possible",
    "drugInteractions": [
      "ACE inhibitors â€” additive enkephalinase inhibition; increased bradykinin (angioedema risk)",
      "Other antidiarrhoeals â€” additive effect",
      "CNS depressants â€” potential mild additive effect"
    ],
    "monitoring": [
      "Stool frequency/consistency",
      "Hydration status",
      "Signs of angioedema"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "300 mg/day (100 mg TDS)",
    "clinicalPearl": "Antisecretory (not antimotility) antidiarrheal â€” reduces intestinal hypersecretion without affecting gut motility or causing constipation."
  },
  {
    "rank": 447,
    "name": "Pancreatin (Pancreatic Enzyme Replacement)",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "GI",
    "schedule": "H",
    "brand": "Creon / Panzytrat / Pancreatin IP",
    "formation": "Porcine pancreatic extract containing lipase, amylase, protease (enteric-coated microspheres); replaces exocrine pancreatic function",
    "uses": "Exocrine pancreatic insufficiency (EPI) from chronic pancreatitis, cystic fibrosis, post-pancreatectomy, pancreatic cancer",
    "adult": "25,000â€“75,000 IU lipase with each main meal; 10,000â€“25,000 IU with snacks; titrate to stool normalisation",
    "child": "CF: 500â€“1000 IU lipase/kg/meal (max 10,000 IU/kg/day); titrate carefully to avoid fibrosing colonopathy",
    "avoid": "Pork allergy; fibrosing colonopathy with excess doses (>10,000 IU lipase/kg/day) â€“ especially in CF children; take with food â€“ NOT on empty stomach",
    "drug": "Pancreatin",
    "sideEffects": [
      "Nausea",
      "Abdominal cramps",
      "Diarrhoea",
      "Constipation",
      "Oral irritation (high-dose)"
    ],
    "seriousRisks": [
      "Fibrosing colonopathy (extremely high doses in cystic fibrosis)",
      "Hyperuricaemia (high dose)",
      "Allergic reactions"
    ],
    "renalAdj": "No â€” standard dosing (not systemically absorbed)",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” generally considered safe; exocrine pancreatic insufficiency management essential",
    "lactation": "Safe â€” not systemically absorbed; compatible",
    "drugInteractions": [
      "Acarbose â€” reduced acarbose efficacy (pancreatin provides exogenous amylase)",
      "Iron/folic acid â€” reduced absorption",
      "Antacids (calcium/magnesium) â€” reduce pancreatin activity"
    ],
    "monitoring": [
      "Nutritional status",
      "Weight",
      "Stool consistency (coefficient of fat absorption)",
      "Blood glucose (EPI-related diabetes)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "10,000 IU lipase/kg/day (cystic fibrosis); per meal dosing: 25,000-80,000 IU lipase/meal",
    "clinicalPearl": "Take with every meal and snack â€” dose based on fat content of meal; enteric-coated microspheres preferred."
  },
  {
    "rank": 448,
    "name": "Erythropoietin (EPO / Darbepoetin)",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "Nephrology",
    "schedule": "H",
    "brand": "Eprex / Wepox / Zyrop / Mircera",
    "formation": "Recombinant human erythropoietin; stimulates erythroid precursor differentiation via EPOR; EPO alfa/beta and long-acting darbepoetin available",
    "uses": "Anaemia of chronic kidney disease (CKD/ESRD on dialysis and pre-dialysis), chemotherapy-related anaemia, myelodysplastic syndrome",
    "adult": "EPO: 50â€“100 IU/kg SC/IV TIW; target Hb 10â€“12 g/dL; darbepoetin: 0.45 mcg/kg once weekly SC/IV",
    "child": "EPO: 50 IU/kg TIW SC/IV; titrate to target Hb; always ensure adequate iron stores before starting",
    "avoid": "Uncontrolled hypertension (check BP before each dose), pure red cell aplasia (anti-EPO antibodies â€“ rare but serious), haemoglobin >12 g/dL target (increased CV events, stroke risk)",
    "drug": "Erythropoietin (EPO/Darbepoetin)",
    "sideEffects": [
      "Hypertension",
      "Headache",
      "Injection site reaction",
      "Nausea",
      "Arthralgia"
    ],
    "seriousRisks": [
      "Thromboembolic events (DVT, stroke, MI)",
      "Pure red cell aplasia (anti-EPO antibodies)",
      "Severe hypertension/hypertensive encephalopathy",
      "Tumour progression (oncology use above Hb 12 g/dL)"
    ],
    "renalAdj": "No â€” used specifically for CKD anaemia; dose adjusted to Hb response",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” limited data; used in severe CKD anaemia if benefit outweighs risk",
    "lactation": "Caution â€” insufficient data",
    "drugInteractions": [
      "Iron supplements â€” required concomitantly for adequate response",
      "ACE inhibitors â€” may blunt erythropoietic response",
      "Androgens â€” synergistic erythropoietic effect"
    ],
    "monitoring": [
      "Haemoglobin (target 10-12 g/dL; do not exceed 12)",
      "Iron stores (ferritin, TSAT)",
      "BP",
      "Reticulocyte count",
      "Anti-EPO antibodies if response lost"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "EPO: 300 IU/kg/week SC; Darbepoetin: 0.75 mcg/kg/2 weeks (titrated to Hb)",
    "clinicalPearl": "Target Hb 10-12 g/dL â€” exceeding 12 g/dL increases cardiovascular mortality and stroke risk in CKD."
  },
  {
    "rank": 449,
    "name": "Calcitriol",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "Nephrology",
    "schedule": "H",
    "brand": "Rocaltrol / Calcirol / Decostriol",
    "formation": "Active vitamin D3 (1,25-dihydroxycholecalciferol); VDR agonist; requires no renal hydroxylation unlike cholecalciferol",
    "uses": "Renal osteodystrophy in CKD/dialysis, hypoparathyroidism, vitamin D-dependent rickets type I, hypocalcaemia management",
    "adult": "CKD dialysis: 0.25â€“0.5 mcg OD PO initially; adjust by 0.25 mcg every 2â€“4 weeks targeting PTH; hypoparathyroidism: 0.25â€“2 mcg OD",
    "child": "0.01â€“0.05 mcg/kg/day OD; neonatal hypocalcaemia: 0.25 mcg OD; monitor Ca/P weekly initially",
    "avoid": "Hypercalcaemia, hyperphosphataemia (correct phosphate first with sevelamer); vitamin D toxicity â€“ monitor serum calcium and phosphate regularly; no value in vitamin D deficiency without renal failure (use cholecalciferol instead)",
    "drug": "Calcitriol",
    "sideEffects": [
      "Hypercalcaemia",
      "Hypercalciuria",
      "Nausea",
      "Weakness",
      "Headache"
    ],
    "seriousRisks": [
      "Severe hypercalcaemia (cardiac arrhythmia, renal stones)",
      "Metastatic calcification (vascular/soft tissue)",
      "Adynamic bone disease"
    ],
    "renalAdj": "Yes â€” used specifically in CKD; start low (0.25 mcg/day); monitor calcium and phosphate closely",
    "hepaticAdj": "No â€” active form; no hepatic activation required (unlike cholecalciferol)",
    "pregnancy": "Category C â€” hypercalcaemia risk; use with caution; supplement only if deficient",
    "lactation": "Caution â€” present in breast milk; hypercalcaemia risk in infant",
    "drugInteractions": [
      "Thiazide diuretics â€” additive hypercalcaemia",
      "Calcium supplements â€” additive hypercalcaemia",
      "Digoxin â€” hypercalcaemia increases digoxin toxicity risk"
    ],
    "monitoring": [
      "Serum calcium (weekly initially)",
      "Serum phosphate",
      "PTH (every 3 months CKD)",
      "Urine calcium",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "2 mcg/day (CKD/hypoparathyroidism); titrated to PTH response",
    "clinicalPearl": "Active vitamin D â€” no hydroxylation needed; ideal for CKD and hypoparathyroidism where renal/hepatic activation is impaired."
  },
  {
    "rank": 450,
    "name": "Sevelamer",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "Nephrology",
    "schedule": "H",
    "brand": "Renvela / Sevelamer IP / Fosrenol alternative",
    "formation": "Non-absorbable cationic polymer; binds dietary phosphate in GI tract preventing absorption; calcium-free, aluminium-free",
    "uses": "Hyperphosphataemia in CKD dialysis patients, also reduces LDL cholesterol (secondary benefit)",
    "adult": "800 mg TDS with meals initially; adjust by 1â€“2 tablets per meal every 2 weeks to achieve serum phosphate <1.78 mmol/L",
    "child": "Adolescents â‰¥18 kg: 400â€“800 mg TDS with meals; limited paediatric data",
    "avoid": "Bowel obstruction; can cause dysphagia/GI upset â€“ take with food; reduces absorption of ciprofloxacin, mycophenolate, levothyroxine â€“ space 2h apart; take with, not before or after meals strictly",
    "drug": "Sevelamer",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Constipation",
      "Abdominal pain"
    ],
    "seriousRisks": [
      "GI obstruction/ileus (rare)",
      "Severe constipation",
      "Metabolic acidosis (sevelamer HCl formulation)",
      "GI perforation (rare)"
    ],
    "renalAdj": "No â€” used specifically in CKD dialysis (not absorbed; acts locally in gut)",
    "hepaticAdj": "No â€” not absorbed",
    "pregnancy": "Category C â€” not absorbed; theoretically safe but avoid due to fat-soluble vitamin malabsorption",
    "lactation": "Safe â€” not absorbed",
    "drugInteractions": [
      "Ciprofloxacin â€” reduced fluoroquinolone absorption (separate by 2 hours)",
      "Mycophenolate â€” reduced levels (separate by 2 hours)",
      "Levothyroxine â€” reduced absorption (separate by 2 hours)"
    ],
    "monitoring": [
      "Serum phosphate (target 3.5-5.5 mg/dL in dialysis)",
      "Serum calcium",
      "Bicarbonate (sevelamer HCl)",
      "Fat-soluble vitamin levels (long-term)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "14g/day (based on serum phosphate level at initiation)",
    "clinicalPearl": "Non-calcium phosphate binder â€” preferred over calcium carbonate to avoid hypercalcaemia and vascular calcification in CKD-MBD."
  },
  {
    "rank": 451,
    "name": "Cinacalcet",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "Nephrology",
    "schedule": "H",
    "brand": "Sensipar / Cinacal / Mimpara",
    "formation": "Calcimimetic; positive allosteric modulator of calcium-sensing receptor (CaSR) on parathyroid; reduces PTH secretion",
    "uses": "Secondary hyperparathyroidism (HPT) in CKD dialysis patients, primary HPT in non-surgical candidates, parathyroid carcinoma",
    "adult": "Start 30 mg OD; titrate every 2â€“4 weeks to 60 mg, 90 mg, 120 mg, 180 mg OD targeting PTH; take with food",
    "child": "Not routinely recommended <18y; trials ongoing",
    "avoid": "Hypocalcaemia (<7.5 mg/dL â€“ hold dose); nausea/vomiting (food reduces); strong CYP3A4 inhibitors increase levels (ketoconazole); do NOT crush â€“ modified release",
    "drug": "Cinacalcet",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Hypocalcaemia",
      "Muscle cramps",
      "Diarrhoea"
    ],
    "seriousRisks": [
      "Severe hypocalcaemia (tetany, seizures, QT prolongation)",
      "Adynamic bone disease",
      "Upper GI bleeding"
    ],
    "renalAdj": "No â€” standard dosing (used specifically in CKD/dialysis)",
    "hepaticAdj": "Yes â€” use with caution in moderate-severe hepatic impairment (CYP3A4 metabolism)",
    "pregnancy": "Category C â€” may reduce calcium delivery to fetus; avoid",
    "lactation": "Avoid â€” excreted in animal milk; insufficient human data",
    "drugInteractions": [
      "Strong CYP3A4 inhibitors (ketoconazole) â€” increased cinacalcet levels",
      "CYP2D6 substrates (tricyclics, flecainide) â€” cinacalcet inhibits CYP2D6",
      "Calcium supplements/vitamin D â€” may reduce cinacalcet efficacy requirement"
    ],
    "monitoring": [
      "Serum calcium (within 1 week of dose change)",
      "PTH (every 1-3 months)",
      "Serum phosphate",
      "ECG (if hypocalcaemia suspected)"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "180 mg/day (30-180 mg OD, titrated)",
    "clinicalPearl": "Calcimimetic â€” activates CaSR on parathyroid gland; lowers PTH without raising calcium (unlike vitamin D analogues)."
  },
  {
    "rank": 452,
    "name": "Natamycin (Ophthalmic)",
    "section": "Section 17: GI, Nephrology & Ophthalmology Ext",
    "category": "Ophthalmology",
    "schedule": "H",
    "brand": "Natacyn / Pimaricin / Natamycin Eye Drop",
    "formation": "Polyene macrolide antifungal; binds ergosterol in fungal cell membrane causing increased permeability and cell death",
    "uses": "Fungal keratitis (filamentous fungi â€“ Fusarium, Aspergillus; most common cause of corneal ulcer in Indian farmers), fungal blepharitis, conjunctivitis",
    "adult": "5% ophthalmic suspension: 1 drop every 1â€“2h for 3â€“4 days then QID for 14â€“21 days",
    "child": "Same dosing as adult; very limited systemic absorption from eye drops",
    "avoid": "Bacterial/viral keratitis (ineffective); poor penetration into anterior chamber (intrastromal/intracameral voriconazole may be needed for deep stromal disease); co-use with contact lenses contraindicated",
    "drug": "Natamycin Ophthalmic",
    "sideEffects": [
      "Ocular irritation/burning",
      "Redness",
      "Blurred vision (transient)",
      "Conjunctival oedema",
      "Eye discomfort"
    ],
    "seriousRisks": [
      "Severe allergic conjunctivitis",
      "Treatment failure with deep keratitis",
      "Secondary bacterial superinfection"
    ],
    "renalAdj": "No â€” topical use; negligible systemic absorption",
    "hepaticAdj": "No â€” topical use",
    "pregnancy": "Category C â€” topical; systemic absorption negligible; use with caution",
    "lactation": "Safe â€” topical; negligible systemic absorption",
    "drugInteractions": [
      "Other topical ocular medications â€” administer 10-15 minutes apart",
      "Contact lenses â€” avoid during treatment"
    ],
    "monitoring": [
      "Slit-lamp examination (response to treatment)",
      "Visual acuity",
      "Corneal healing"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5% suspension â€” 1 drop every 1-2 hours initially (severe keratitis), tapering to 6 times/day",
    "clinicalPearl": "Only topical antifungal approved for ophthalmic use in India â€” first-line for filamentous fungal keratitis (Fusarium, Aspergillus)."
  },
  {
    "rank": 453,
    "name": "Trihexyphenidyl (Benzhexol)",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Neurology",
    "schedule": "H",
    "brand": "Pacitane / Parkin / Trihex",
    "formation": "Synthetic anticholinergic; muscarinic M1 antagonist; restores dopamineâ€“acetylcholine balance in striatum in Parkinsonism",
    "uses": "Drug-induced parkinsonism (antipsychotic-induced EPS), idiopathic Parkinson's disease (adjunct for tremor), dystonia",
    "adult": "Start 1 mg OD; titrate by 2 mg every 3â€“5 days to 6â€“10 mg/day in 3â€“4 divided doses",
    "child": "Dystonia: 1â€“2 mg/day, titrate up as tolerated; dystonia doses up to 50 mg/day in children (high-dose dystonia trihexyphenidyl)",
    "avoid": "Angle-closure glaucoma, prostatic hypertrophy, tardive dyskinesia (worsens), dementia/delirium; elderly â€“ anticholinergic cognitive impairment; may cause dry mouth, constipation, urinary retention",
    "drug": "Trihexyphenidyl (Benzhexol)",
    "sideEffects": [
      "Dry mouth",
      "Constipation",
      "Urinary retention",
      "Blurred vision",
      "Cognitive impairment"
    ],
    "seriousRisks": [
      "Acute angle-closure glaucoma",
      "Toxic psychosis/hallucinations",
      "Hyperthermia",
      "Paralytic ileus",
      "Dependency/abuse potential"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” limited data; avoid in pregnancy",
    "lactation": "Avoid â€” anticholinergic effects in infant; suppresses lactation",
    "drugInteractions": [
      "Antipsychotics â€” reduces antipsychotic-induced EPS but may worsen psychosis",
      "Other anticholinergics â€” additive toxicity (TCAs, antihistamines)",
      "Levodopa â€” possible additive benefit in Parkinson's"
    ],
    "monitoring": [
      "IOP (glaucoma screening)",
      "Urinary retention",
      "Cognitive assessment",
      "CNS effects in elderly"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "15 mg/day",
    "clinicalPearl": "Avoid in elderly â€” high anticholinergic burden causes cognitive impairment; Beers Criteria drug â€” high fall risk."
  },
  {
    "rank": 454,
    "name": "Amantadine",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Neurology",
    "schedule": "H",
    "brand": "Symmetrel / Amantrel / Amanta",
    "formation": "Adamantane derivative; NMDA receptor antagonist and dopamine-releasing agent; also antiviral (influenza A â€“ largely historical)",
    "uses": "Parkinson's disease (adjunct, motor fluctuations, levodopa-induced dyskinesia), drug-induced parkinsonism, TBI-related disorders of consciousness",
    "adult": "Parkinson's: 100 mg BD initially; max 400 mg/day; reduce by 100 mg every 2 weeks if discontinuing (avoid abrupt stop)",
    "child": "TBI/DOC specialist use only; influenza: 5 mg/kg/day in 2 divided doses (â‰¥12y: 100 mg BD)",
    "avoid": "Renal impairment (dose reduce â€“ renally cleared), seizure disorder, psychiatric history (psychosis/hallucinations), angle-closure glaucoma; livedo reticularis and ankle oedema (cosmetic â€“ usually benign)",
    "drug": "Amantadine",
    "sideEffects": [
      "Livedo reticularis",
      "Ankle oedema",
      "Insomnia",
      "Confusion/hallucinations",
      "Nausea"
    ],
    "seriousRisks": [
      "Neuroleptic malignant syndrome (on abrupt withdrawal)",
      "Psychosis",
      "QT prolongation",
      "Severe confusion in elderly",
      "Suicidal ideation"
    ],
    "renalAdj": "Yes â€” significant adjustment: CrCl 15-29 mL/min: 100 mg OD; CrCl <15: 200 mg every 7 days",
    "hepaticAdj": "No â€” standard dosing (renally cleared)",
    "pregnancy": "Category C â€” cardiovascular malformations in animal studies; avoid",
    "lactation": "Avoid â€” excreted in breast milk; may suppress lactation",
    "drugInteractions": [
      "Anticholinergics â€” additive anticholinergic effects",
      "CNS stimulants â€” increased CNS toxicity",
      "Alcohol â€” worsens CNS effects"
    ],
    "monitoring": [
      "Renal function",
      "Mental status",
      "BP",
      "Livedo reticularis skin assessment"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "400 mg/day (100 mg BD â€” Parkinson's); 200 mg/day (influenza prophylaxis)",
    "clinicalPearl": "Livedo reticularis (mottled skin) is a characteristic side effect â€” reassure patients; resolves on drug discontinuation."
  },
  {
    "rank": 455,
    "name": "Baclofen",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Neurology",
    "schedule": "H",
    "brand": "Lioresal / Baclof / Lyflex",
    "formation": "GABA-B receptor agonist at spinal level; inhibits mono- and polysynaptic spinal reflexes; reduces muscle tone and spasm",
    "uses": "Spasticity from MS, spinal cord injury, cerebral palsy; intrathecal baclofen pump for severe spasticity; alcohol use disorder (off-label)",
    "adult": "Start 5 mg TDS; titrate by 5 mg per dose every 3 days; max 80â€“120 mg/day in divided doses",
    "child": "CP spasticity: start 2.5 mg TDS (>10y: 5 mg TDS); max 60 mg/day in children; adjust for weight",
    "avoid": "Abrupt withdrawal (life-threatening withdrawal seizures, hyperthermia, rhabdomyolysis â€“ taper slowly); epilepsy (lower seizure threshold); drowsiness; renal impairment (dose reduce)",
    "drug": "Baclofen",
    "sideEffects": [
      "Sedation/drowsiness",
      "Muscle weakness",
      "Dizziness",
      "Nausea",
      "Confusion"
    ],
    "seriousRisks": [
      "Seizures on abrupt withdrawal",
      "Severe respiratory depression",
      "Coma (overdose)",
      "Intrathecal pump failure (catastrophic withdrawal)",
      "Hallucinations"
    ],
    "renalAdj": "Yes â€” significant: reduce dose in renal impairment; cleared by dialysis; start with 5 mg BD",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” neonatal withdrawal seizures; avoid prolonged use near term",
    "lactation": "Caution â€” present in breast milk at low levels; monitor infant for sedation",
    "drugInteractions": [
      "CNS depressants/alcohol â€” profound sedation/respiratory depression",
      "Antihypertensives â€” additive hypotension",
      "TCAs â€” increased baclofen CNS effects"
    ],
    "monitoring": [
      "Spasticity assessment (Ashworth scale)",
      "Renal function",
      "Respiratory function",
      "Sedation level"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "80 mg/day (20 mg QDS); intrathecal: 300-800 mcg/day",
    "clinicalPearl": "Never stop abruptly â€” baclofen withdrawal causes life-threatening seizures and hyperthermia; taper slowly over 2 weeks."
  },
  {
    "rank": 456,
    "name": "Tizanidine",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Neurology",
    "schedule": "H",
    "brand": "Sirdalud / Tizan / Tizamel",
    "formation": "Central Î±2-adrenergic agonist; inhibits polysynaptic spinal pathways; shorter-acting antispastic than baclofen",
    "uses": "Spasticity in MS, spinal cord injury, stroke; muscle spasms, tension headache (off-label)",
    "adult": "2â€“4 mg TDS/QID; max 36 mg/day; take at consistent times (food significantly alters absorption)",
    "child": "Limited data; 0.05 mg/kg TDSâ€“QID under neurologist guidance",
    "avoid": "Hepatotoxicity (monitor LFTs for first 6 months); hypotension (especially with antihypertensives and caffeine withdrawal); drowsiness; CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) dramatically increase levels â€“ contraindicated combination",
    "drug": "Tizanidine",
    "sideEffects": [
      "Somnolence",
      "Dry mouth",
      "Dizziness",
      "Weakness",
      "Elevated LFT"
    ],
    "seriousRisks": [
      "Severe hypotension (especially with antihypertensives)",
      "Hepatotoxicity",
      "Hallucinations/psychosis",
      "Rebound hypertension on withdrawal"
    ],
    "renalAdj": "Yes â€” start with lowest dose; reduce in renal impairment; extended interval recommended",
    "hepaticAdj": "Yes â€” avoid in hepatic impairment; hepatotoxic",
    "pregnancy": "Category C â€” insufficient data; avoid",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "Fluvoxamine/ciprofloxacin â€” markedly increased tizanidine levels (CYP1A2 inhibitors â€” contraindicated)",
      "Antihypertensives â€” severe additive hypotension",
      "Alcohol â€” additive CNS depression"
    ],
    "monitoring": [
      "LFT (baseline, 1, 3, 6 months)",
      "BP (especially with antihypertensives)",
      "Spasticity assessment"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "36 mg/day (8-12 mg TDS); start with 2-4 mg",
    "clinicalPearl": "Ciprofloxacin and fluvoxamine are absolute contraindications â€” both are strong CYP1A2 inhibitors that increase tizanidine 10-fold."
  },
  {
    "rank": 457,
    "name": "Rivastigmine",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Neurology",
    "schedule": "H",
    "brand": "Exelon / Rivamer / Reminyl (not confused with galantamine)",
    "formation": "Pseudo-irreversible carbamate cholinesterase inhibitor; inhibits both AChE and BuChE; CNS-selective via slow dissociation",
    "uses": "Alzheimer's dementia (mild-moderate), Parkinson's disease dementia (preferred agent), Lewy body dementia",
    "adult": "Oral: start 1.5 mg BD with food; titrate by 1.5 mg/dose every 4 weeks to max 6 mg BD; transdermal patch: 4.6 mg/24h start, titrate to 9.5â€“13.3 mg/24h",
    "child": "Not indicated",
    "avoid": "Sick sinus syndrome, bradycardia, active GI ulcer (increases acid secretion), obstructive uropathy, seizures; GI adverse effects (nausea/vomiting) are the main tolerability issue â€“ take with food; patch preferred for GI tolerability",
    "drug": "Rivastigmine",
    "sideEffects": [
      "Nausea",
      "Vomiting",
      "Diarrhoea",
      "Anorexia",
      "Weight loss"
    ],
    "seriousRisks": [
      "Severe GI haemorrhage (peptic ulcer activation)",
      "Bradycardia/syncope",
      "Seizures",
      "Severe skin reactions (patch â€” localized)",
      "Respiratory complications (in asthma/COPD)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” use with caution in mild-moderate hepatic impairment; limit to 3 mg BD in severe",
    "pregnancy": "Category B â€” insufficient data; not indicated in childbearing women",
    "lactation": "Avoid â€” excreted in animal milk; no human data",
    "drugInteractions": [
      "Anticholinergic drugs â€” opposing effects (avoid combination)",
      "Beta-blockers (bradycardia) â€” additive bradycardia risk",
      "NSAIDs â€” increased GI ulcer risk"
    ],
    "monitoring": [
      "Cognitive assessment (MMSE/MOCA)",
      "Body weight",
      "GI tolerability",
      "Heart rate",
      "Caregiver-reported function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "12 mg/day oral (6 mg BD); patch: 13.3 mg/24h",
    "clinicalPearl": "GI side effects are dose-related â€” always titrate slowly; transdermal patch has better tolerability than oral capsules."
  },
  {
    "rank": 458,
    "name": "Buspirone",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Psychiatry",
    "schedule": "H",
    "brand": "Buspar / Buspimen / Anxipar",
    "formation": "Azapirone; 5-HT1A partial agonist; does NOT bind GABA-BZD receptor â€“ non-sedating, non-addictive anxiolytic",
    "uses": "Generalised anxiety disorder (GAD), adjunct in OCD and depression (as augmentation), social anxiety (off-label)",
    "adult": "Start 5 mg TDS; titrate by 5 mg every 2â€“3 days to 20â€“30 mg/day in divided doses; max 60 mg/day; onset 2â€“4 weeks",
    "child": "6â€“17y (GAD): 7.5 mg BD; titrate to max 30 mg/day in divided doses; limited data in very young children",
    "avoid": "Not effective for acute anxiety (slow onset); MAOIs (serotonin syndrome); hepatic/renal impairment (reduce dose); does not treat BZD withdrawal â€“ cross-taper slowly",
    "drug": "Buspirone",
    "sideEffects": [
      "Dizziness",
      "Headache",
      "Nausea",
      "Nervousness",
      "Insomnia"
    ],
    "seriousRisks": [
      "Serotonin syndrome (with MAOIs)",
      "Rare hypersensitivity reactions",
      "Worsening of hepatic encephalopathy"
    ],
    "renalAdj": "Yes â€” avoid in severe renal impairment (CrCl <20 mL/min)",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment",
    "pregnancy": "Category B â€” limited human data; use with caution",
    "lactation": "Caution â€” excreted in animal milk; avoid if possible",
    "drugInteractions": [
      "MAOIs â€” serotonin syndrome (contraindicated; 14-day washout needed)",
      "CYP3A4 inhibitors (itraconazole, erythromycin) â€” increased buspirone levels",
      "Rifampicin â€” reduced buspirone efficacy"
    ],
    "monitoring": [
      "Anxiety symptom assessment (GAD-7)",
      "LFT",
      "Renal function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "60 mg/day (20 mg TDS)",
    "clinicalPearl": "Non-addictive anxiolytic â€” onset delayed 2-4 weeks; no cross-tolerance with benzodiazepines; does not treat acute panic attacks."
  },
  {
    "rank": 459,
    "name": "Atomoxetine",
    "section": "Section 18: CNS & Neurology Extended",
    "category": "Psychiatry",
    "schedule": "H1",
    "brand": "Strattera / Attentrol / Axepta",
    "formation": "Selective noradrenaline reuptake inhibitor (NRI); increases synaptic NE in prefrontal cortex; non-stimulant ADHD medication",
    "uses": "ADHD (Attention Deficit Hyperactivity Disorder) in children and adults, especially when stimulants are not preferred (tics, abuse potential, anxiety co-morbidity)",
    "adult": ">70 kg: 40 mg OD Ã— 4 weeks, then 80 mg OD (max 100 mg OD); <70 kg: 0.5 mg/kg OD Ã— 4 weeks, then 1.2 mg/kg OD (max 1.8 mg/kg or 100 mg/day)",
    "child": ">6y, <70 kg: 0.5 mg/kg OD Ã— 4 weeks then 1.2 mg/kg OD; full effect takes 4â€“8 weeks",
    "avoid": "Narrow-angle glaucoma, MAOIs (14-day washout), pheochromocytoma; black-box: suicidality in paediatric patients â€“ monitor closely; hepatotoxicity (rare but monitor); QTc prolongation risk",
    "drug": "Atomoxetine",
    "sideEffects": [
      "Decreased appetite",
      "Insomnia",
      "Nausea",
      "Dry mouth",
      "Increased BP/HR"
    ],
    "seriousRisks": [
      "Suicidal ideation (children/adolescents)",
      "Severe hepatotoxicity (rare)",
      "Sudden cardiac death (in underlying cardiac disease)",
      "Psychiatric events (mania, aggression)",
      "Priapism (rare)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce by 75%",
    "pregnancy": "Category C â€” limited data; insufficient safety; avoid",
    "lactation": "Avoid â€” insufficient data",
    "drugInteractions": [
      "MAOIs â€” severe toxicity (contraindicated; 14-day washout)",
      "CYP2D6 inhibitors (fluoxetine, paroxetine) â€” markedly increased atomoxetine levels",
      "Salbutamol/sympathomimetics â€” increased cardiovascular effects"
    ],
    "monitoring": [
      "BP",
      "Heart rate",
      "Weight/height (children)",
      "LFT (if hepatic symptoms)",
      "Psychiatric symptoms",
      "Suicidality assessment"
    ],
    "therapyLine": "Second-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "100 mg/day or 1.4 mg/kg/day (whichever is lower)",
    "clinicalPearl": "Non-stimulant ADHD drug â€” no abuse potential; full effect takes 4-8 weeks; check cardiac history before starting."
  },
  {
    "rank": 460,
    "name": "Cisplatin",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Cisplatin IP / Platinex / Kemoplat",
    "formation": "Platinum coordination complex; forms intra- and inter-strand DNA crosslinks via alkylation of N7 guanine; cell-cycle non-specific",
    "uses": "Testicular cancer (curative â€“ BEP regimen), ovarian cancer, cervical cancer, head and neck cancers, NSCLC, bladder cancer, oesophageal cancer",
    "adult": "Varies by protocol: testicular: 20 mg/mÂ² IV days 1â€“5 per cycle; H&N: 100 mg/mÂ² every 3 weeks; always with aggressive hydration (1â€“2 L NS pre/post)",
    "child": "60â€“100 mg/mÂ² every 3â€“4 weeks (medulloblastoma, neuroblastoma, hepatoblastoma protocols)",
    "avoid": "Pre-existing renal impairment (major nephrotoxicity â€“ monitor creatinine, hold if creatinine clearance <60 mL/min), sensorineural hearing loss (audiometry baseline), severe neuropathy; hydrate aggressively; pre-medicate with antiemetics (granisetron/ondansetron + dexamethasone + aprepitant)",
    "drug": "Cisplatin",
    "sideEffects": [
      "Severe nausea/vomiting",
      "Nephrotoxicity",
      "Ototoxicity",
      "Peripheral neuropathy",
      "Myelosuppression"
    ],
    "seriousRisks": [
      "Acute renal failure (dose-limiting)",
      "Irreversible sensorineural hearing loss",
      "Severe electrolyte imbalance (Mg2+, K+, Ca2+)",
      "Severe peripheral neuropathy",
      "Anaphylaxis"
    ],
    "renalAdj": "Yes â€” CrCl 10-50 mL/min: 75% of dose; CrCl <10: avoid; adequate pre/post-hydration mandatory",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category D â€” teratogenic and fetotoxic; contraindicated; discuss fertility preservation",
    "lactation": "Avoid â€” excreted in breast milk; highly toxic",
    "drugInteractions": [
      "Aminoglycosides â€” additive nephrotoxicity and ototoxicity (avoid)",
      "Loop diuretics â€” additive ototoxicity (furosemide)",
      "Phenytoin â€” reduced phenytoin levels"
    ],
    "monitoring": [
      "Renal function (SCr, BUN â€” before each cycle)",
      "Electrolytes (Mg2+, K+, Na+)",
      "Audiometry (ototoxicity)",
      "CBC",
      "Neurotoxicity assessment"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "100 mg/m2/cycle (30-day cycle); cumulative dose limits apply",
    "clinicalPearl": "Aggressive pre-hydration with 1-2L NS before and after cisplatin is mandatory to prevent nephrotoxicity â€” most dose-limiting toxicity."
  },
  {
    "rank": 461,
    "name": "5-Fluorouracil (5-FU)",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "5-FU IP / Fudara / Fluorouracil",
    "formation": "Pyrimidine antimetabolite; inhibits thymidylate synthase (TS) disrupting DNA synthesis; also incorporated into RNA causing cytotoxicity",
    "uses": "Colorectal cancer (FOLFOX/FOLFIRI), gastric cancer, pancreatic cancer, breast cancer, head and neck cancer, oesophageal cancer, hepatocellular carcinoma (HAIC)",
    "adult": "500â€“1000 mg/mÂ² IV bolus or 2400â€“4800 mg/mÂ² by continuous 46h infusion (FOLFOX protocol); topical 5% cream for actinic keratosis",
    "child": "Oncology protocols: typically 300â€“600 mg/mÂ²/day Ã— 5 days; specialist guided",
    "avoid": "DPD (dihydropyrimidine dehydrogenase) deficiency â€“ severe toxicity risk (test DPYD before treatment), severe bone marrow suppression, hand-foot syndrome; palmar-plantar erythrodysaesthesia with infusional 5-FU; mucositis (oral cryotherapy reduces risk)",
    "drug": "5-Fluorouracil (5-FU)",
    "sideEffects": [
      "Mucositis/stomatitis",
      "Myelosuppression",
      "Diarrhoea",
      "Hand-foot syndrome (capecitabine)",
      "Nausea"
    ],
    "seriousRisks": [
      "DPD deficiency â€” life-threatening toxicity (5-FU accumulation)",
      "Cardiotoxicity (coronary vasospasm/MI)",
      "Severe mucositis/GI haemorrhage",
      "Severe bone marrow suppression",
      "Neurotoxicity (cerebellar)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose in significant hepatic impairment",
    "pregnancy": "Category D â€” teratogenic; contraindicated",
    "lactation": "Avoid â€” cytotoxic; excreted in breast milk",
    "drugInteractions": [
      "Leucovorin â€” synergistically increases 5-FU toxicity and efficacy",
      "Warfarin â€” markedly increased INR (monitor closely)",
      "Metronidazole â€” increased 5-FU toxicity (inhibits metabolism)"
    ],
    "monitoring": [
      "CBC (nadir at 9-14 days)",
      "LFT",
      "Renal function",
      "Mucositis assessment",
      "ECG (cardiac symptoms)",
      "DPD enzyme screening ideally"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Protocol-dependent: 400-1000 mg/m2/day (infusion); bolus: 500-600 mg/m2/dose",
    "clinicalPearl": "DPD enzyme deficiency causes 5-FU accumulation and life-threatening toxicity â€” screen or test DPD activity before starting."
  },
  {
    "rank": 462,
    "name": "Doxorubicin",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Adriamycin / Doxorubicin IP / Adrim",
    "formation": "Anthracycline topoisomerase II inhibitor; intercalates DNA strands and stabilises topoisomerase IIâ€“DNA cleavage complex; generates free radicals",
    "uses": "Breast cancer (AC/FAC regimen), Hodgkin's and non-Hodgkin's lymphoma (CHOP/ABVD), acute leukaemia, sarcomas, ovarian cancer, bladder cancer",
    "adult": "60â€“75 mg/mÂ² IV every 3 weeks (single agent) or 40â€“60 mg/mÂ² in combination; cumulative lifetime dose limit: 450â€“550 mg/mÂ² (cardiotoxicity risk)",
    "child": "25â€“75 mg/mÂ² every 3â€“4 weeks; lifetime dose limit applies equally; MUGA/echo before and during treatment",
    "avoid": "Cumulative dose limit exceeded (dilated cardiomyopathy â€“ LVEF monitoring mandatory), severe hepatic impairment (reduce dose), prior mediastinal radiotherapy (additive cardiotoxicity); extravasation causes severe tissue necrosis â€“ use central line",
    "drug": "Doxorubicin",
    "sideEffects": [
      "Myelosuppression",
      "Nausea/vomiting",
      "Alopecia",
      "Mucositis",
      "Red urine (harmless)"
    ],
    "seriousRisks": [
      "Cumulative dose-dependent cardiotoxicity (dilated cardiomyopathy)",
      "Congestive heart failure (at >400-550 mg/m2 cumulative)",
      "Severe extravasation necrosis",
      "Secondary leukaemia (AML)",
      "Severe myelosuppression"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose: bilirubin 1.2-3 mg/dL: 50% dose; bilirubin >3 mg/dL: 25% dose",
    "pregnancy": "Category D â€” teratogenic; contraindicated",
    "lactation": "Avoid â€” cytotoxic; excreted in breast milk",
    "drugInteractions": [
      "Trastuzumab â€” additive severe cardiotoxicity (avoid concurrent use)",
      "Dexrazoxane â€” cardioprotective (used preventively)",
      "Cyclosporine â€” increased doxorubicin AUC"
    ],
    "monitoring": [
      "LVEF/ECHO (baseline + every 3 cycles)",
      "CBC (nadir day 10-14)",
      "LFT",
      "Cumulative dose tracking",
      "ECG"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "Cumulative lifetime dose: 400-550 mg/m2 (doxorubicin); per cycle: 60-75 mg/m2",
    "clinicalPearl": "Lifetime cumulative dose limit of 550 mg/m2 â€” track total dose across all cycles to prevent irreversible cardiomyopathy."
  },
  {
    "rank": 463,
    "name": "Vincristine",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Oncovin / Vincristine IP / Cytocristin",
    "formation": "Vinca alkaloid; binds Î²-tubulin preventing polymerisation; arrests mitosis at metaphase by disrupting mitotic spindle (M-phase specific)",
    "uses": "ALL (backbone of VAMP/hyper-CVAD regimen), Hodgkin's and NHL (CHOP), Wilms' tumour, rhabdomyosarcoma, Ewing sarcoma, medulloblastoma",
    "adult": "1.4 mg/mÂ² IV weekly (max 2 mg cap per dose to limit neurotoxicity); given as IV bolus",
    "child": "1.5 mg/mÂ² IV weekly (no maximum cap in paediatric protocols typically, or 2 mg); slow push via patency-confirmed IV",
    "avoid": "FATAL if given intrathecally (mandatory black-box â€“ all vincristine must be labelled and given IV only); peripheral neuropathy (dose-limiting â€“ CIPN); ileus, jaw pain, SIADH; never store with intrathecal medications",
    "drug": "Vincristine",
    "sideEffects": [
      "Peripheral neuropathy (dose-limiting)",
      "Constipation",
      "Alopecia",
      "Jaw pain",
      "Nausea (mild)"
    ],
    "seriousRisks": [
      "Severe peripheral neuropathy (irreversible)",
      "Paralytic ileus (autonomic neuropathy)",
      "SIADH/severe hyponatraemia",
      "Fatal if given intrathecally (absolute error)",
      "CNS toxicity"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” reduce dose by 50% if bilirubin >3 mg/dL",
    "pregnancy": "Category D â€” teratogenic; contraindicated",
    "lactation": "Avoid â€” cytotoxic",
    "drugInteractions": [
      "Itraconazole/azoles â€” increased vincristine neurotoxicity (CYP3A4 inhibition â€” contraindicated)",
      "L-asparaginase â€” increased neurotoxicity (give vincristine 12-24h before)",
      "Phenytoin â€” reduced phenytoin levels"
    ],
    "monitoring": [
      "Neurological assessment (deep tendon reflexes, sensory)",
      "CBC (mild myelosuppression)",
      "Serum sodium (SIADH)",
      "Bowel function"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "2 mg per dose (single dose cap â€” regardless of BSA); weekly administration",
    "clinicalPearl": "NEVER administer intrathecally â€” invariably fatal; syringes must be labeled 'FOR IV USE ONLY â€” FATAL IF GIVEN INTRATHECALLY'."
  },
  {
    "rank": 464,
    "name": "Etoposide",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "VP-16 / Etoposide IP / Vepesid",
    "formation": "Semisynthetic epipodophyllotoxin; stabilises topoisomerase IIâ€“DNA complex at DNA strand break; S/G2 phase specific",
    "uses": "Testicular cancer (BEP regimen â€“ curative), small cell lung cancer (EP regimen), lymphoma (ESHAP/GDP), leukaemia, HSCT conditioning (high-dose)",
    "adult": "50â€“100 mg/mÂ²/day IV Ã— 5 days every 3â€“4 weeks (IV); 50 mg/mÂ²/day PO (oral bioavailability ~50%); infuse slowly >30 min (hypotension with rapid infusion)",
    "child": "100â€“150 mg/mÂ²/day IV Ã— 3â€“5 days; oral formulation available for maintenance",
    "avoid": "Severe bone marrow suppression, secondary AML risk with long-term use (treatment-related MDS/AML â€“ topoisomerase II-related); hypotension on rapid infusion; reduce dose in renal/hepatic impairment",
    "drug": "Etoposide",
    "sideEffects": [
      "Myelosuppression (dose-limiting)",
      "Alopecia",
      "Nausea/vomiting",
      "Mucositis",
      "Hypotension (rapid infusion)"
    ],
    "seriousRisks": [
      "Severe myelosuppression",
      "Secondary leukaemia (AML â€” topoisomerase II related)",
      "Severe hypotension (rapid IV infusion)",
      "Anaphylaxis (cremophor vehicle)",
      "Severe infections (neutropenia)"
    ],
    "renalAdj": "Yes â€” CrCl 15-50 mL/min: 75% of dose; CrCl <15: 50% of dose",
    "hepaticAdj": "Yes â€” reduce dose in significant hepatic impairment",
    "pregnancy": "Category D â€” teratogenic; contraindicated",
    "lactation": "Avoid â€” cytotoxic",
    "drugInteractions": [
      "Cyclosporine â€” increased etoposide AUC (toxicity)",
      "Warfarin â€” increased anticoagulant effect",
      "CYP3A4 inhibitors â€” increased etoposide levels"
    ],
    "monitoring": [
      "CBC (nadir day 7-14)",
      "LFT",
      "Renal function",
      "BP during infusion",
      "Secondary malignancy screening"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Absolute",
    "maxDose": "500 mg/m2/day (protocol-dependent; higher cumulative doses acceptable in some regimens)",
    "clinicalPearl": "Infuse slowly over 30-60 minutes â€” rapid infusion causes severe hypotension due to the cremophor vehicle."
  },
  {
    "rank": 465,
    "name": "Filgrastim (G-CSF)",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Neupogen / Grafeel / Zymofil",
    "formation": "Recombinant G-CSF; stimulates granulocyte-committed progenitor proliferation and differentiation; reduces neutropenia duration",
    "uses": "Chemotherapy-induced febrile neutropenia prophylaxis and treatment, bone marrow/stem cell transplantation support, severe chronic neutropenia, HSCT mobilisation",
    "adult": "5 mcg/kg/day SC (start 24â€“72h post-chemo; continue until ANC >10,000/ÂµL or by protocol); mobilisation: 10 mcg/kg/day Ã— 4â€“5 days before apheresis",
    "child": "5 mcg/kg/day SC/IV; same principles as adults; available as biosimilars in India at reduced cost",
    "avoid": "Sickle cell anaemia (increased crisis risk), myeloid malignancies from myeloid blasts (AML/CML â€“ do not use during induction for AML without specialist guidance); bone pain (manage with paracetamol/antihistamines); splenic rupture (rare â€“ educate patient)",
    "drug": "Filgrastim (G-CSF)",
    "sideEffects": [
      "Bone pain (most common)",
      "Injection site reactions",
      "Headache",
      "Fatigue",
      "Splenomegaly"
    ],
    "seriousRisks": [
      "Splenic rupture (rare â€” especially in donors)",
      "ARDS (sickle cell/severe infection)",
      "Allergic reactions/anaphylaxis",
      "Aortitis (rare)",
      "Transformation to AML in MDS"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category C â€” used in chemotherapy-induced neutropenia; potential fetal harm; use only if clearly needed",
    "lactation": "Caution â€” insufficient data; consider risk-benefit",
    "drugInteractions": [
      "Chemotherapy agents â€” do not give within 24 hours of cytotoxic chemotherapy (stem cell mobilisation)",
      "Lithium â€” may potentiate neutrophil release (additive)",
      "Bleomycin â€” possible pulmonary toxicity interaction"
    ],
    "monitoring": [
      "CBC with differential (every 2 days during chemo use)",
      "Spleen size (long-term use)",
      "Bone pain assessment",
      "LFT",
      "LDH/uric acid (high cell turnover)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "5 mcg/kg/day SC (prophylaxis); 10 mcg/kg/day (stem cell mobilisation)",
    "clinicalPearl": "Start filgrastim 24-72 hours after last chemotherapy dose â€” do not give same day as or before chemotherapy."
  },
  {
    "rank": 466,
    "name": "Granisetron",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Kytril / Granisetron IP / Emeset-G",
    "formation": "Selective 5-HT3 receptor antagonist; blocks serotonin-mediated vagal afferent activation of vomiting centre; high potency, long duration",
    "uses": "Chemotherapy-induced nausea and vomiting (CINV) â€“ prevention and treatment, post-operative nausea and vomiting (PONV), radiation-induced nausea",
    "adult": "CINV: 1â€“3 mg IV over 5 min or 1â€“2 mg PO 60 min before chemotherapy; 2 mg OD PO ongoing; 5-HT3 antagonist patch available",
    "child": "10â€“40 mcg/kg IV (max 3 mg/dose) before chemotherapy; oral: 20â€“40 mcg/kg/dose BD",
    "avoid": "QTc prolongation (less than ondansetron but monitor in combination with other QT-prolonging drugs); constipation; headache; class effect â€“ similar cautions as ondansetron; no advantage over ondansetron for mild emetogenicity",
    "drug": "Granisetron",
    "sideEffects": [
      "Headache",
      "Constipation",
      "Fatigue",
      "Dizziness",
      "Elevated LFT"
    ],
    "seriousRisks": [
      "QT prolongation",
      "Serotonin syndrome (rare)",
      "Severe constipation/ileus",
      "Anaphylaxis"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "No â€” standard dosing",
    "pregnancy": "Category B â€” widely used for chemotherapy CINV; safer than metoclopramide",
    "lactation": "Caution â€” insufficient data; avoid if possible",
    "drugInteractions": [
      "QT-prolonging drugs â€” additive QTc prolongation risk",
      "Serotonergic drugs (SSRIs, tramadol) â€” serotonin syndrome risk",
      "Ondansetron â€” additive 5-HT3 antagonism (no additional benefit)"
    ],
    "monitoring": [
      "ECG (QTc)",
      "Bowel habits (constipation)",
      "LFT (prolonged use)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "3 mg IV (single dose); oral: 2 mg/day; transdermal patch: 3.1 mg/24h",
    "clinicalPearl": "5-HT3 antagonist â€” highly effective for acute CINV; less effective for delayed CINV; combine with dexamethasone and aprepitant."
  },
  {
    "rank": 467,
    "name": "Aprepitant",
    "section": "Section 19: Oncology Support",
    "category": "Oncology",
    "schedule": "H",
    "brand": "Emend / Aprecap / Aprepitant IP",
    "formation": "Neurokinin-1 (NK1) receptor antagonist; blocks substance P-mediated delayed emesis at CNS level; IV fosaprepitant is pro-drug",
    "uses": "Highly and moderately emetogenic chemotherapy (CINV) â€“ delayed phase (24â€“120h post-chemo); combined with 5-HT3 antagonist + dexamethasone (triple antiemetic therapy)",
    "adult": "Day 1: 125 mg PO 60 min before chemo; Days 2â€“3: 80 mg OD morning; IV fosaprepitant: 150 mg single dose Day 1",
    "child": "â‰¥6 months: 3 mg/kg (max 125 mg) Day 1; 2 mg/kg (max 80 mg) Days 2â€“3; oral suspension available",
    "avoid": "CYP3A4 substrate AND moderate inhibitor â€“ check drug interactions (warfarin, dexamethasone dose adjustment needed); pimozide, cisapride contraindicated; reduces OCP efficacy â€“ advise barrier contraception for 1 month after course",
    "drug": "Aprepitant",
    "sideEffects": [
      "Fatigue",
      "Nausea (paradoxical, mild)",
      "Constipation",
      "Hiccups",
      "Dizziness"
    ],
    "seriousRisks": [
      "Severe drug interactions (CYP3A4 inhibition)",
      "Stevens-Johnson syndrome (rare)",
      "Severe hypersensitivity",
      "Infusion-related reactions (fosaprepitant IV)"
    ],
    "renalAdj": "No â€” standard dosing",
    "hepaticAdj": "Yes â€” avoid in severe hepatic impairment (Child-Pugh C)",
    "pregnancy": "Category B â€” limited data; use with caution; theoretical fetal risk from CYP interactions",
    "lactation": "Avoid â€” excreted in animal milk; insufficient human data",
    "drugInteractions": [
      "Dexamethasone â€” reduces dexamethasone dose by 50% (CYP3A4 inhibition â€” standard CINV protocol)",
      "Oral contraceptives â€” reduced OCP efficacy during and 28 days after aprepitant",
      "Warfarin â€” reduced INR (CYP2C9 induction â€” monitor closely)"
    ],
    "monitoring": [
      "INR (if on warfarin â€” monitor at 7-10 days post-cycle)",
      "OCP efficacy (use barrier contraception)",
      "Nausea/vomiting control (complete response rate)"
    ],
    "therapyLine": "First-line",
    "contraindicationSeverity": "Use With Caution",
    "maxDose": "125 mg day 1; 80 mg days 2 and 3 (3-day regimen for highly emetogenic chemotherapy)",
    "clinicalPearl": "NK1 antagonist â€” superior for delayed CINV (24-120h post-chemo); always reduce dexamethasone dose by 50% when co-prescribed."
  }
];

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  SCHEDULE META
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
const SCHED_META = {
  "OTC": { label:"OTC",     desc:"No Rx Required",       cls:"sch-OTC" },
  "C":   { label:"Sch. C",  desc:"Biological Product",   cls:"sch-C"   },
  "H":   { label:"Sch. H",  desc:"Prescription Only",    cls:"sch-H"   },
  "H1":  { label:"Sch. H1", desc:"Red Box Rx",           cls:"sch-H1"  },
  "X":   { label:"Sch. X",  desc:"Strict Control",       cls:"sch-X"   },
};

const SECTION_CLS = {
  "Section 1: Foundational Molecules":        "sec-1",
  "Section 2: Cardiovascular":                "sec-2",
  "Section 3: Metabolic & Endocrine":         "sec-3",
  "Section 4: Anti-Infective":                "sec-4",
  "Section 5: GI & Pain":                     "sec-5",
  "Section 6: Neuro-Psychiatry & CNS":        "sec-6",
  "Section 7: Dermatology & Ophthalmology":   "sec-7",
  "Section 8: Oncology & Immunology":         "sec-8",
  "Section 9: Respiratory, Allergy & ENT":    "sec-9",
  "Section 10: Specialty & Emerging":         "sec-10",
  "Section 11: Anti-Tuberculosis & Leprosy":        "sec-11",
  "Section 12: Emergency, Critical Care & Haematology": "sec-12",
  "Section 13: Obstetrics & Gynaecology":           "sec-13",
  "Section 14: Cardiovascular Extended":            "sec-14",
  "Section 15: Anti-Infective & Antiviral Extended":"sec-15",
  "Section 16: Hepatology, Antiviral & Thyroid":    "sec-16",
  "Section 17: GI, Nephrology & Ophthalmology Ext": "sec-17",
  "Section 18: CNS & Neurology Extended":           "sec-18",
  "Section 19: Oncology Support":                   "sec-19",
};

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  DRUG CLASS Â· SUFFIX MAP
//  Order matters: more specific suffixes first
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
// preg = FDA pregnancy category Â· moa = mechanism of action (class-level)
const SUFFIX_MAP = [
  // â”€â”€ RAAS â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"sartan",    label:"ARB",                    preg:"D", bg:"#F3E8FF", text:"#6B21A8", border:"#C084FC",
    moa:"Selectively blocks ATâ‚ angiotensin II receptors â†’ â†“ vasoconstriction & aldosterone secretion" },
  { suffix:"pril",      label:"ACE Inhibitor",          preg:"D", bg:"#CCFBF1", text:"#0F766E", border:"#5EEAD4",
    moa:"Inhibits ACE, preventing angiotensin Iâ†’II conversion â†’ â†“ BP, â†“ aldosterone & â†‘ bradykinin" },
  // â”€â”€ Lipid â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"statin",    label:"Statin",                 preg:"X", bg:"#DBEAFE", text:"#1D4ED8", border:"#93C5FD",
    moa:"Competitively inhibits HMG-CoA reductase â†’ â†“ hepatic cholesterol synthesis & â†‘ LDL receptor upregulation" },
  // â”€â”€ GI â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"prazole",   label:"PPI",                    preg:"B", bg:"#FEF3C7", text:"#B45309", border:"#FCD34D",
    moa:"Irreversibly inhibits Hâº/Kâº-ATPase proton pump in gastric parietal cells â†’ profound acid suppression" },
  // â”€â”€ Cardiovascular â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"dipine",    label:"CCB",                    preg:"C", bg:"#DCFCE7", text:"#15803D", border:"#86EFAC",
    moa:"Blocks L-type voltage-gated CaÂ²âº channels in vascular smooth muscle â†’ vasodilation & â†“ afterload" },
  { suffix:"olol",      label:"Beta-Blocker",           preg:"C", bg:"#F0F9FF", text:"#0369A1", border:"#7DD3FC",
    moa:"Competitively blocks Î²1 (Â± Î²2) adrenergic receptors â†’ â†“ HR, BP & myocardial Oâ‚‚ demand" },
  { suffix:"grelor",    label:"Antiplatelet",           preg:"C", bg:"#FFF1F2", text:"#881337", border:"#FECDD3",
    moa:"Reversibly inhibits P2Y12 ADP receptor on platelets â†’ â†“ ADP-induced platelet aggregation" },
  { suffix:"grel",      label:"Antiplatelet",           preg:"B", bg:"#FFF1F2", text:"#881337", border:"#FECDD3",
    moa:"Prodrug; active metabolite irreversibly blocks P2Y12 ADP receptor â†’ â†“ platelet aggregation" },
  { suffix:"xaban",     label:"Factor Xa Inhibitor",    preg:"C", bg:"#FEE2E2", text:"#7F1D1D", border:"#F87171",
    moa:"Directly & selectively inhibits Factor Xa â†’ â†“ thrombin generation & fibrin clot formation" },
  { suffix:"afil",      label:"PDE5 Inhibitor",         preg:"B", bg:"#F5F3FF", text:"#5B21B6", border:"#C4B5FD",
    moa:"Inhibits phosphodiesterase-5 â†’ â†‘ cGMP â†’ smooth muscle relaxation & vasodilation" },
  { suffix:"semide",    label:"Loop Diuretic",          preg:"C", bg:"#E6FFFA", text:"#285E61", border:"#81E6D6",
    moa:"Inhibits Naâº/Kâº/2Clâ» cotransporter (NKCC2) in thick ascending loop of Henle â†’ â†‘ diuresis" },
  { suffix:"zosin",     label:"Alpha-1 Blocker",        preg:"C", bg:"#F0FDFA", text:"#065F46", border:"#34D399",
    moa:"Selectively blocks Î±1-adrenergic receptors â†’ â†“ smooth muscle tone in prostate & blood vessels" },
  { suffix:"dronate",   label:"Bisphosphonate",         preg:"D", bg:"#F1F5F9", text:"#475569", border:"#94A3B8",
    moa:"Inhibits farnesyl diphosphate synthase in osteoclasts â†’ â†“ bone resorption & â†‘ bone density" },
  // â”€â”€ Antidiabetic â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"gliptin",   label:"DPP-4 Inhibitor",        preg:"B", bg:"#FFF7ED", text:"#9A3412", border:"#FDBA74",
    moa:"Inhibits DPP-4 enzyme â†’ â†‘ GLP-1 & GIP levels â†’ glucose-dependent insulin release & â†“ glucagon" },
  { suffix:"flozin",    label:"SGLT2 Inhibitor",        preg:"C", bg:"#ECFEFF", text:"#155E75", border:"#67E8F9",
    moa:"Inhibits SGLT2 in renal proximal tubule â†’ â†‘ urinary glucose excretion, insulin-independent" },
  { suffix:"glutide",   label:"GLP-1 Agonist",          preg:"C", bg:"#F7FEE7", text:"#3F6212", border:"#A3E635",
    moa:"GLP-1 receptor agonist â†’ â†‘ glucose-dependent insulin, â†“ glucagon, â†“ gastric emptying & appetite" },
  { suffix:"glitazone", label:"Thiazolidinedione",      preg:"C", bg:"#FEFCE8", text:"#854D0E", border:"#FDE047",
    moa:"Activates PPARÎ³ nuclear receptor â†’ â†‘ insulin sensitivity in adipose, muscle & hepatic tissue" },
  // â”€â”€ Antibiotics â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"floxacin",  label:"Fluoroquinolone",        preg:"C", bg:"#FEE2E2", text:"#B91C1C", border:"#FCA5A5",
    moa:"Inhibits bacterial DNA gyrase (topoisomerase II) & topoisomerase IV â†’ â†“ DNA replication" },
  { suffix:"thromycin", label:"Macrolide",              preg:"B", bg:"#FED7AA", text:"#9A3412", border:"#F97316",
    moa:"Binds 50S ribosomal subunit â†’ inhibits translocation & bacterial protein synthesis" },
  { suffix:"mycin",     label:"Antibiotic",             preg:"C", bg:"#FFF7ED", text:"#C2410C", border:"#FDBA74",
    moa:"Binds bacterial ribosome or disrupts cell wall/membrane â†’ inhibits protein synthesis or structural integrity" },
  { suffix:"cillin",    label:"Penicillin",             preg:"B", bg:"#ECFDF5", text:"#047857", border:"#6EE7B7",
    moa:"Inhibits transpeptidase (penicillin-binding proteins) â†’ â†“ bacterial cell wall cross-linking â†’ lysis" },
  { suffix:"cycline",   label:"Tetracycline",           preg:"D", bg:"#FDF4FF", text:"#86198F", border:"#E879F9",
    moa:"Binds 30S ribosomal subunit â†’ blocks aminoacyl-tRNA binding â†’ bacteriostatic inhibition" },
  // â”€â”€ Antifungal / Antiprotozoal â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"conazole",  label:"Azole Antifungal",       preg:"C", bg:"#D1FAE5", text:"#064E3B", border:"#34D399",
    moa:"Inhibits fungal CYP51 (lanosterol 14Î±-demethylase) â†’ â†“ ergosterol synthesis â†’ membrane disruption" },
  { suffix:"dazole",    label:"Nitroimidazole",         preg:"B", bg:"#F3F4F6", text:"#374151", border:"#9CA3AF",
    moa:"Reduced to cytotoxic free radicals in anaerobic organisms â†’ DNA strand breaks & cell death" },
  // â”€â”€ Antiviral (specific before general) â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"tegravir",  label:"Integrase Inhibitor",    preg:"B", bg:"#EFF6FF", text:"#1E3A8A", border:"#93C5FD",
    moa:"Inhibits HIV integrase strand transfer reaction â†’ prevents viral DNA integration into host genome" },
  { suffix:"fovir",     label:"NtRTI",                  preg:"B", bg:"#E0F2FE", text:"#0C4A6E", border:"#38BDF8",
    moa:"Nucleotide analogue; incorporated into viral DNA â†’ competes with dATP â†’ chain termination" },
  { suffix:"vir",       label:"Antiviral",              preg:"B", bg:"#CFFAFE", text:"#0E7490", border:"#22D3EE",
    moa:"Nucleoside/nucleotide analogue or enzyme inhibitor that blocks viral polymerase or neuraminidase" },
  // â”€â”€ CNS â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"azolam",    label:"Benzodiazepine",         preg:"D", bg:"#E0E7FF", text:"#3730A3", border:"#A5B4FC",
    moa:"Positive allosteric modulator of GABA-A receptor â†’ â†‘ Clâ» influx frequency â†’ CNS depression" },
  { suffix:"azepam",    label:"Benzodiazepine",         preg:"D", bg:"#E0E7FF", text:"#3730A3", border:"#A5B4FC",
    moa:"Positive allosteric modulator of GABA-A receptor â†’ â†‘ Clâ» influx frequency â†’ CNS depression" },
  { suffix:"azam",      label:"Benzodiazepine",         preg:"D", bg:"#E0E7FF", text:"#3730A3", border:"#A5B4FC",
    moa:"Positive allosteric modulator of GABA-A receptor â†’ â†‘ Clâ» influx frequency â†’ CNS depression" },
  { suffix:"apine",     label:"Atypical Antipsychotic", preg:"C", bg:"#EDE9FE", text:"#4C1D95", border:"#8B5CF6",
    moa:"Blocks D2 & 5-HT2A receptors (multi-receptor antagonism) â†’ â†“ positive & negative psychotic symptoms" },
  { suffix:"peridone",  label:"Atypical Antipsychotic", preg:"C", bg:"#EDE9FE", text:"#4C1D95", border:"#8B5CF6",
    moa:"Blocks D2 & 5-HT2A receptors (multi-receptor antagonism) â†’ â†“ positive & negative psychotic symptoms" },
  // â”€â”€ Biologics â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"mab",       label:"Monoclonal Ab",          preg:"C", bg:"#F8FAFC", text:"#334155", border:"#CBD5E1",
    moa:"Highly specific antibody binds target antigen â†’ neutralization, receptor blockade or immune effector activation" },
  { suffix:"cept",      label:"Fusion Protein",         preg:"C", bg:"#F1F5F9", text:"#1E293B", border:"#94A3B8",
    moa:"Soluble receptor fusion protein competitively binds cytokine or ligand â†’ prevents receptor activation" },
  { suffix:"limus",     label:"Immunosuppressant",      preg:"C", bg:"#FFF8F1", text:"#7C2D12", border:"#FB923C",
    moa:"Binds FKBP-12 â†’ inhibits mTOR (or calcineurin) â†’ â†“ IL-2 & T-cell proliferation" },
  // â”€â”€ NSAIDs â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"coxib",     label:"COX-2 Inhibitor",        preg:"C", bg:"#FFF0F0", text:"#9F1239", border:"#FB7185",
    moa:"Selectively inhibits COX-2 isoenzyme â†’ â†“ prostaglandin Eâ‚‚ synthesis with â†“ GI mucosal risk" },
  { suffix:"fenac",     label:"NSAID",                  preg:"C", bg:"#FFF1F2", text:"#881337", border:"#FDA4AF",
    moa:"Non-selectively inhibits COX-1 & COX-2 â†’ â†“ prostaglandin & thromboxane synthesis â†’ analgesia & â†“ inflammation" },
  { suffix:"profen",    label:"NSAID",                  preg:"C", bg:"#FFF1F2", text:"#881337", border:"#FDA4AF",
    moa:"Non-selectively inhibits COX-1 & COX-2 â†’ â†“ prostaglandin & thromboxane synthesis â†’ analgesia & â†“ inflammation" },
  { suffix:"oxicam",    label:"NSAID",                  preg:"C", bg:"#FFF1F2", text:"#881337", border:"#FDA4AF",
    moa:"Non-selectively inhibits COX-1 & COX-2 â†’ â†“ prostaglandin & thromboxane synthesis â†’ analgesia & â†“ inflammation" },
  { suffix:"sulide",    label:"NSAID",                  preg:"C", bg:"#FFF1F2", text:"#881337", border:"#FDA4AF",
    moa:"Non-selectively inhibits COX-1 & COX-2 â†’ â†“ prostaglandin & thromboxane synthesis â†’ analgesia & â†“ inflammation" },
  // â”€â”€ Corticosteroids â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"olone",     label:"Corticosteroid",         preg:"C", bg:"#FEFCE8", text:"#713F12", border:"#FDE68A",
    moa:"Binds glucocorticoid receptor â†’ â†‘ anti-inflammatory lipocortin, â†“ NF-ÎºB & immune cell activity" },
  { suffix:"sone",      label:"Corticosteroid",         preg:"C", bg:"#FEFCE8", text:"#713F12", border:"#FDE68A",
    moa:"Binds glucocorticoid receptor â†’ â†‘ anti-inflammatory lipocortin, â†“ NF-ÎºB & immune cell activity" },
  // â”€â”€ Misc â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
  { suffix:"triptan",   label:"Triptan",                preg:"C", bg:"#FEF2F2", text:"#C0392B", border:"#F87171",
    moa:"Selective 5-HT1B/1D agonist â†’ cerebral vasoconstriction & â†“ trigeminal neuropeptide release" },
  { suffix:"lukast",    label:"Leukotriene Antagonist", preg:"B", bg:"#F0F9FF", text:"#075985", border:"#38BDF8",
    moa:"Blocks CysLT1 leukotriene receptor â†’ â†“ bronchoconstriction, mucus secretion & airway inflammation" },
  { suffix:"setron",    label:"5-HT3 Antagonist",       preg:"B", bg:"#FAF5FF", text:"#6D28D9", border:"#A78BFA",
    moa:"Selective 5-HT3 receptor antagonist in gut & CTZ â†’ â†“ vagal afferent stimulation & nausea signalling" },
  { suffix:"gepant",    label:"CGRP Antagonist",        preg:"?", bg:"#FFF0EB", text:"#9A3412", border:"#FB923C",
    moa:"Blocks CGRP receptor â†’ â†“ vasodilation & neurogenic inflammation in trigeminovascular system" },
];

// Pregnancy category badge colours
const PREG_COLORS = {
  "A": { bg:"#DCFCE7", text:"#14532D", border:"#86EFAC" },
  "B": { bg:"#DBEAFE", text:"#1E3A8A", border:"#93C5FD" },
  "C": { bg:"#FEF3C7", text:"#78350F", border:"#FCD34D" },
  "D": { bg:"#FED7AA", text:"#7C2D12", border:"#FB923C" },
  "X": { bg:"#FEE2E2", text:"#7F1D1D", border:"#FCA5A5" },
  "?": { bg:"#F3F4F6", text:"#374151", border:"#9CA3AF" },
};

function getSuffixInfo(name, manualCls){
  // Manual class override takes priority (for drugs without recognisable suffix)
  if(manualCls){
    const item = SUFFIX_MAP.find(m=>m.label===manualCls);
    if(item) return { ...item, detected:"(manual)" };
  }
  // First component (before " + "), first word only â€” handles "Pantoprazole Sodium", "Doxycycline HCl", etc.
  const raw = name.split(/\s*\+\s*/)[0].trim();
  const firstWord = raw.split(/[\s(]/)[0].toLowerCase();
  for(const item of SUFFIX_MAP){
    if(firstWord.endsWith(item.suffix)){
      return { ...item, detected:"-"+item.suffix };
    }
  }
  return null;
}

// Derive pregnancy category for a salt (data override > class lookup)
function getPreg(s){
  if(s.preg) return s.preg;
  const info = getSuffixInfo(s.name, s.cls);
  return info ? info.preg : null;
}

// Detect renal caution from avoid text
function isRenalCaution(avoid){
  return /renal|egfr|kidney|creatinine|ckd|dialysis/i.test(avoid);
}
// Detect hepatic caution from avoid text
function isHepaticCaution(avoid){
  return /hepatic|liver/i.test(avoid);
}

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  STATE
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
let state = { category:"All", section:"All", schedule:"All", drugClass:"All", pregnancy:"All", search:"", sort:"rank", liver:false, renal:false, ped:false };

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  FILTER
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
function filterData(){
  let d = saltsData.filter(s=>{
    const q = state.search.toLowerCase();
    const matchSearch = !q || s.name.toLowerCase().includes(q)
      || s.brand.toLowerCase().includes(q)
      || s.uses.toLowerCase().includes(q)
      || s.formation.toLowerCase().includes(q)
      || s.category.toLowerCase().includes(q);
    const matchCat  = state.category==="All" || s.category===state.category;
    const matchSec  = state.section ==="All" || s.section ===state.section;
    const matchSch  = state.schedule==="All" || s.schedule===state.schedule;
    const matchDC   = state.drugClass==="All" || (()=>{ const info=getSuffixInfo(s.name,s.cls); return info && info.label===state.drugClass; })();
    const matchPreg = state.pregnancy==="All" || getPreg(s)===state.pregnancy;
    let ok = true;
    if(state.liver){ if(isHepaticCaution(s.avoid)) ok=false; }
    if(state.renal){ if(isRenalCaution(s.avoid)) ok=false; }
    if(state.ped){
      const bad=["not recommended","avoid","contraindicated","safety not established","not indicated","not approved"];
      if(bad.some(w=>s.child.toLowerCase().includes(w))) ok=false;
    }
    return matchSearch&&matchCat&&matchSec&&matchSch&&matchDC&&matchPreg&&ok;
  });
  if(state.sort==="rank")  d.sort((a,b)=>a.rank-b.rank);
  if(state.sort==="alpha") d.sort((a,b)=>a.name.localeCompare(b.name));
  return d;
}

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  RENDER CARDS
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
function renderGrid(){
  const data = filterData();
  document.getElementById("count-badge").textContent = data.length+" salts";
  const grid = document.getElementById("saltGrid");
  const empty= document.getElementById("emptyState");
  if(!data.length){ grid.classList.add("hidden"); empty.classList.remove("hidden"); return; }
  grid.classList.remove("hidden"); empty.classList.add("hidden");

  grid.innerHTML = data.map(s=>{
    const sm = SCHED_META[s.schedule]||SCHED_META["H"];
    const sc = SECTION_CLS[s.section]||"sec-1";
    const seFx  = (s.sideEffects||[]).map(e=>'<span class="text-[10px] bg-orange-100 text-orange-700 px-2 py-0.5 rounded-full">'+e+'</span>').join('');
    const risks = (s.seriousRisks||[]).map(r=>'<li class="text-[11px] text-red-700 leading-snug">&bull; '+r+'</li>').join('');
    const inter = (s.drugInteractions||[]).map(i=>'<li class="text-[11px] text-yellow-800 leading-snug">&bull; '+i+'</li>').join('');
    const monit = (s.monitoring||[]).map(m=>'<span class="text-[10px] bg-blue-100 text-blue-700 px-2 py-0.5 rounded-full">'+m+'</span>').join('');
    const ciSev = s.contraindicationSeverity||"";
    const ciColor = ciSev==="Absolute" ? "text-red-600" : "text-amber-600";
    const ciIcon  = ciSev==="Absolute" ? "ğŸš«" : "âš ï¸";
    const therapyBadge = s.therapyLine
      ? '<span class="text-[10px] font-semibold px-2 py-0.5 rounded-full '+(s.therapyLine==='First-line'?'bg-green-100 text-green-700':'bg-slate-100 text-slate-600')+'">'+s.therapyLine+'</span>'
      : '';
    const classBadgesHtml = (()=>{
      const info    = getSuffixInfo(s.name, s.cls);
      const renal   = isRenalCaution(s.avoid);
      const hepatic = isHepaticCaution(s.avoid);
      const pregKey = s.preg || (info ? info.preg : null);
      const pc      = pregKey ? (PREG_COLORS[pregKey]||PREG_COLORS["?"]) : null;
      let h = "";
      if(info || renal || hepatic || pc){
        h += '<div class="flex items-center gap-1 mt-1.5 flex-wrap">';
        if(info){
          h += '<span style="background:'+info.bg+';color:'+info.text+';border:1px solid '+info.border+'" class="text-[10px] font-bold px-2 py-0.5 rounded-full">'+info.label+'</span>';
          h += '<span class="text-slate-400 text-[10px] font-mono font-semibold">'+info.detected+'</span>';
        }
        if(pc) h += '<span style="background:'+pc.bg+';color:'+pc.text+';border:1px solid '+pc.border+'" class="text-[10px] font-bold px-1.5 py-0.5 rounded-full" title="FDA Pregnancy Category '+pregKey+'">Preg '+pregKey+'</span>';
        if(renal)   h += '<span class="text-[10px] bg-amber-50 text-amber-700 border border-amber-200 px-1.5 py-0.5 rounded-full font-semibold" title="Renal caution">ğŸ¦³ Renal</span>';
        if(hepatic) h += '<span class="text-[10px] bg-rose-50 text-rose-600 border border-rose-200 px-1.5 py-0.5 rounded-full font-semibold" title="Hepatic caution">ğŸ«€ Hepatic</span>';
        h += '</div>';
      }
      if(info && info.moa){
        h += '<p class="text-[10px] text-slate-500 italic leading-snug mt-1 pl-0.5">'+info.moa+'</p>';
      }
      return h;
    })();
    const clinicalPanel = s.sideEffects ? (`
      <div class="border-t border-slate-100">
        <button onclick="toggleClinical(this)" class="w-full px-4 py-2.5 flex items-center justify-between text-[11px] font-semibold text-teal-600 hover:bg-teal-50 transition group">
          <span>ğŸ”¬ Clinical Details</span>
          <svg class="w-3.5 h-3.5 text-teal-400 transition-transform duration-200" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7"/></svg>
        </button>
        <div class="clinical-panel hidden px-5 pb-5 pt-1 flex flex-col gap-3">

          <!-- Row 1: Side Effects + Serious Risks -->
          <div class="grid grid-cols-2 gap-3">
            <div class="bg-orange-50 rounded-xl p-3 border border-orange-100">
              <span class="text-[10px] font-bold text-orange-500 uppercase tracking-wide block mb-2">Common Side Effects</span>
              <div class="flex flex-wrap gap-1.5">` + seFx + `</div>
            </div>
            <div class="bg-red-50 rounded-xl p-3 border border-red-100">
              <span class="text-[10px] font-bold text-red-500 uppercase tracking-wide block mb-2">âš ï¸ Serious / Red Flag Risks</span>
              <ul class="space-y-1">` + risks + `</ul>
            </div>
          </div>

          <!-- Row 2: Renal | Hepatic | Pregnancy | Lactation -->
          <div class="grid grid-cols-4 gap-3">
            <div class="bg-amber-50 rounded-xl p-3 border border-amber-100">
              <span class="text-[10px] font-bold text-amber-500 uppercase tracking-wide block mb-1">ğŸ¦³ Renal</span>
              <p class="text-xs text-amber-800 leading-snug">` + (s.renalAdj||'â€”') + `</p>
            </div>
            <div class="bg-rose-50 rounded-xl p-3 border border-rose-100">
              <span class="text-[10px] font-bold text-rose-500 uppercase tracking-wide block mb-1">ğŸ«€ Hepatic</span>
              <p class="text-xs text-rose-700 leading-snug">` + (s.hepaticAdj||'â€”') + `</p>
            </div>
            <div class="bg-purple-50 rounded-xl p-3 border border-purple-100">
              <span class="text-[10px] font-bold text-purple-500 uppercase tracking-wide block mb-1">ğŸ¤° Pregnancy</span>
              <p class="text-xs text-purple-800 leading-snug">` + (s.pregnancy||'â€”') + `</p>
            </div>
            <div class="bg-pink-50 rounded-xl p-3 border border-pink-100">
              <span class="text-[10px] font-bold text-pink-500 uppercase tracking-wide block mb-1">ğŸ¤± Lactation</span>
              <p class="text-xs text-pink-700 leading-snug">` + (s.lactation||'â€”') + `</p>
            </div>
          </div>

          <!-- Row 3: Drug Interactions + Monitoring -->
          <div class="grid grid-cols-2 gap-3">
            <div class="bg-yellow-50 rounded-xl p-3 border border-yellow-100">
              <span class="text-[10px] font-bold text-yellow-600 uppercase tracking-wide block mb-2">âš¡ Drug Interactions</span>
              <ul class="space-y-1">` + inter + `</ul>
            </div>
            <div class="bg-blue-50 rounded-xl p-3 border border-blue-100">
              <span class="text-[10px] font-bold text-blue-500 uppercase tracking-wide block mb-2">ğŸ“Š Monitoring Parameters</span>
              <div class="flex flex-wrap gap-1.5">` + monit + `</div>
            </div>
          </div>

          <!-- Row 4: CI Severity + Clinical Pearl -->
          <div class="flex gap-3 items-stretch">
            ` + (ciSev ? '<div class="flex-none bg-slate-50 rounded-xl p-3 border border-slate-200 flex flex-col justify-center min-w-[148px]"><span class="text-[10px] font-bold text-slate-400 uppercase tracking-wide block mb-1">Contraindication</span><span class="text-sm font-bold '+ciColor+'">'+ciIcon+' '+ciSev+'</span></div>' : '') + `
            ` + (s.clinicalPearl ? '<div class="flex-1 bg-teal-600 rounded-xl p-3"><span class="text-[10px] font-bold text-teal-200 uppercase tracking-wide block mb-1">ğŸ’¡ Clinical Pearl</span><p class="text-sm text-white font-medium leading-snug">'+s.clinicalPearl+'</p></div>' : '') + `
          </div>

        </div>
      </div>`) : '';
    return `
    <div class="bg-white rounded-2xl border border-slate-200 card-hover flex flex-col overflow-hidden shadow-sm">
      <div class="px-4 pt-4 pb-3 border-b border-slate-100">
        <div class="flex items-start justify-between gap-2 mb-2">
          <span class="text-slate-400 text-xs font-bold bg-slate-100 px-2 py-0.5 rounded">#${s.rank}</span>
          <div class="flex flex-wrap gap-1 justify-end">
            <span class="${sm.cls} text-[10px] font-bold px-2 py-0.5 rounded-full" title="${sm.desc}">${sm.label}</span>
            <span class="${sc} text-[10px] font-semibold px-2 py-0.5 rounded-full">${s.section.replace("Section ","S")}</span>
            <span class="bg-teal-50 text-teal-700 text-[10px] font-semibold px-2 py-0.5 rounded-full uppercase tracking-wide">${s.category}</span>
            ${therapyBadge}
          </div>
        </div>
        <h3 class="text-lg font-bold text-slate-800 leading-tight">${s.name}</h3>
        <p class="text-[11px] text-slate-500 italic mt-0.5 leading-snug">${s.formation}</p>
        ${classBadgesHtml}
        <div class="flex items-start gap-1 mt-1.5">
          <span class="text-[10px] font-bold text-amber-600 whitespace-nowrap mt-0.5">ğŸ· Brand:</span>
          <span class="text-[11px] text-amber-700 font-medium leading-snug">${s.brand}</span>
        </div>
      </div>
      <div class="px-4 py-3 flex flex-col gap-2.5 flex-grow">
        <div>
          <span class="text-[10px] font-bold text-slate-400 uppercase block mb-0.5">Indications</span>
          <p class="text-xs text-slate-700 leading-snug">${s.uses}</p>
        </div>
        <div class="grid grid-cols-2 gap-2">
          <div class="bg-slate-50 rounded-lg p-2 border border-slate-100">
            <span class="text-[9px] font-bold text-slate-400 uppercase block">Adult Dose</span>
            <p class="text-[11px] text-slate-700 font-medium leading-snug mt-0.5">${s.adult}</p>
          </div>
          <div class="bg-slate-50 rounded-lg p-2 border border-slate-100">
            <span class="text-[9px] font-bold text-slate-400 uppercase block">Child Dose</span>
            <p class="text-[11px] text-slate-700 font-medium leading-snug mt-0.5">${s.child}</p>
          </div>
        </div>
        <div class="bg-rose-50 rounded-lg p-2 border border-rose-100">
          <span class="text-[9px] font-bold text-rose-400 uppercase block mb-0.5">â›” Avoid In</span>
          <p class="text-[11px] text-rose-700 font-medium leading-snug">${s.avoid}</p>
        </div>
        ${s.maxDose ? '<div class="bg-teal-50 rounded-lg p-2 border border-teal-100 flex items-start gap-1.5"><span class="text-[9px] font-bold text-teal-500 uppercase whitespace-nowrap mt-0.5">ğŸ’Š Max Dose</span><p class="text-[11px] text-teal-700 font-semibold leading-snug">'+s.maxDose+'</p></div>' : ''}
      </div>
      ${clinicalPanel}
    </div>`;
  }).join("");
}

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  RENDER FILTER PILLS
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
function pill(label, active, onclick, extraCls=""){
  return `<button onclick="${onclick}" class="px-2.5 py-1 rounded-full text-xs font-medium transition border
    ${active ? "bg-teal-600 text-white border-teal-600 shadow" : "bg-slate-100 text-slate-600 border-slate-200 hover:bg-slate-200"}
    ${extraCls}">${label}</button>`;
}

function renderPills(){
  // Categories
  const cats = ["All", ...new Set(saltsData.map(s=>s.category))].sort((a,b)=>a==="All"?-1:a.localeCompare(b));
  document.getElementById("category-pills").innerHTML =
    cats.map(c=>pill(c, state.category===c, `setFilter('category','${c}')`)).join("");

  // Sections
  const secs = ["All", ...new Set(saltsData.map(s=>s.section))];
  document.getElementById("section-pills").innerHTML =
    secs.map(s=>pill(s.replace("Section ","S"), state.section===s, `setFilter('section','${s}')`)).join("");

  // Schedules
  const schs = ["All","OTC","C","H","H1","X"];
  document.getElementById("schedule-pills").innerHTML =
    schs.map(s=>{
      const meta = s==="All"?{label:"All",cls:""}:SCHED_META[s];
      const activeCls = state.schedule===s ? "bg-teal-600 text-white border-teal-600 shadow" : "bg-slate-100 text-slate-600 border-slate-200 hover:bg-slate-200";
      return `<button onclick="setFilter('schedule','${s}')"
        class="px-2.5 py-1 rounded-full text-xs font-medium transition border ${activeCls}">${meta.label}</button>`;
    }).join("");

  // Drug Classes
  const presentClasses = new Set(saltsData.map(s=>{ const i=getSuffixInfo(s.name,s.cls); return i?i.label:null; }).filter(Boolean));
  const dcItems = [null, ...SUFFIX_MAP.filter(m=>presentClasses.has(m.label))];
  document.getElementById("drugclass-pills").innerHTML =
    dcItems.map(m=>{
      if(!m){
        const active = state.drugClass==="All";
        return `<button onclick="setFilter('drugClass','All')"
          class="px-2.5 py-1 rounded-full text-xs font-medium transition border
          ${active ? "bg-teal-600 text-white border-teal-600 shadow" : "bg-slate-100 text-slate-600 border-slate-200 hover:bg-slate-200"}">All</button>`;
      }
      const active = state.drugClass===m.label;
      const style = active
        ? `background:${m.bg};color:${m.text};border:1px solid ${m.border};box-shadow:0 1px 4px rgba(0,0,0,.12)`
        : "";
      const baseCls = active
        ? "font-bold"
        : "bg-slate-100 text-slate-600 border border-slate-200 hover:bg-slate-200";
      return `<button onclick="setFilter('drugClass','${m.label}')"
        style="${style}"
        class="px-2.5 py-1 rounded-full text-xs font-medium transition ${baseCls}">
        ${m.label} <span class="font-mono opacity-60">${m.detected||("-"+m.suffix)}</span>
      </button>`;
    }).join("");

  // Pregnancy categories
  const pregOrder = ["All","A","B","C","D","X","?"];
  const presentPregs = new Set(saltsData.map(s=>getPreg(s)).filter(Boolean));
  document.getElementById("pregnancy-pills").innerHTML =
    pregOrder.filter(p=>p==="All"||presentPregs.has(p)).map(p=>{
      if(p==="All") return pill("All", state.pregnancy==="All", "setFilter('pregnancy','All')");
      const pc = PREG_COLORS[p]||PREG_COLORS["?"];
      const active = state.pregnancy===p;
      const labels = {A:"A â€“ Safe",B:"B â€“ Probably Safe",C:"C â€“ Caution",D:"D â€“ Risk Evidence",X:"X â€“ Contraindicated","?":"Unknown"};
      const style = active ? `background:${pc.bg};color:${pc.text};border:1px solid ${pc.border};box-shadow:0 1px 4px rgba(0,0,0,.1)` : "";
      const baseCls = active ? "font-bold" : "bg-slate-100 text-slate-600 border border-slate-200 hover:bg-slate-200";
      return `<button onclick="setFilter('pregnancy','${p}')" style="${style}"
        class="px-2.5 py-1 rounded-full text-xs font-medium transition ${baseCls}">${labels[p]}</button>`;
    }).join("");
}


// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  CLINICAL PANEL TOGGLE
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
window.toggleClinical = function(btn){
  const panel = btn.nextElementSibling;
  const arrow = btn.querySelector('svg');
  panel.classList.toggle('hidden');
  if(arrow) arrow.style.transform = panel.classList.contains('hidden') ? '' : 'rotate(180deg)';
};

window.setFilter = (key, val) => { state[key]=val; renderPills(); renderGrid(); };

window.resetFilters = () => {
  state = { category:"All", section:"All", schedule:"All", drugClass:"All", pregnancy:"All", search:"", sort:state.sort, liver:false, renal:false, ped:false };
  document.getElementById("searchInput").value = "";
  document.getElementById("btn-liver").classList.remove("bg-rose-100","ring-2","ring-rose-400");
  document.getElementById("btn-renal").classList.remove("bg-amber-100","ring-2","ring-amber-400");
  document.getElementById("btn-pediatric").classList.remove("bg-blue-100","ring-2","ring-blue-400");
  renderPills(); renderGrid();
};

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  EVENTS
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
document.getElementById("searchInput").addEventListener("input", e=>{
  state.search = e.target.value; renderGrid();
});
document.getElementById("sortSelect").addEventListener("change", e=>{
  state.sort = e.target.value; renderGrid();
});
document.getElementById("btn-liver").addEventListener("click", function(){
  state.liver = !state.liver;
  this.classList.toggle("bg-rose-100"); this.classList.toggle("ring-2"); this.classList.toggle("ring-rose-400");
  renderGrid();
});
document.getElementById("btn-renal").addEventListener("click", function(){
  state.renal = !state.renal;
  this.classList.toggle("bg-amber-100"); this.classList.toggle("ring-2"); this.classList.toggle("ring-amber-400");
  renderGrid();
});
document.getElementById("btn-pediatric").addEventListener("click", function(){
  state.ped = !state.ped;
  this.classList.toggle("bg-blue-100"); this.classList.toggle("ring-2"); this.classList.toggle("ring-blue-400");
  renderGrid();
});

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  CHART
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
function initChart(){
  const counts = {};
  saltsData.forEach(s=>{ counts[s.category]=(counts[s.category]||0)+1; });
  const sorted = Object.entries(counts).sort((a,b)=>b[1]-a[1]);
  const labels = sorted.map(e=>e[0]);
  const data   = sorted.map(e=>e[1]);
  const palette = [
    "#0D9488","#2DD4BF","#3B82F6","#8B5CF6","#EC4899",
    "#F59E0B","#10B981","#EF4444","#6366F1","#F97316",
    "#06B6D4","#84CC16","#A855F7","#14B8A6","#FBBF24"
  ];
  new Chart(document.getElementById("categoryChart").getContext("2d"),{
    type:"doughnut",
    data:{ labels, datasets:[{ data, backgroundColor:palette, borderWidth:0, hoverOffset:6 }] },
    options:{
      responsive:true, maintainAspectRatio:false,
      plugins:{
        legend:{ position:"bottom", labels:{ boxWidth:10, font:{size:10}, padding:8 } },
        tooltip:{ callbacks:{ label: ctx=>`${ctx.label}: ${ctx.raw} salts` } }
      }
    }
  });
}

// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
//  INIT
// â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
document.addEventListener("DOMContentLoaded", ()=>{
  renderPills();
  renderGrid();
  initChart();
});
</script>
</body>
</html>